Gene Gene synonym Ensembl Gene description Chromosome Position Protein class Evidence Antibody Reliability (IH) Reliability (Mouse Brain) Reliability (IF) Subcellular location Prognostic p-value RNA cancer category RNA tissue category RNA TS RNA TS TPM TPM max in non-specific A4GALT A14GALT, Gb3S, P(k) ENSG00000128274 Alpha 1,4-galactosyltransferase 22 42692121-42721298 Enzymes, Predicted membrane proteins Evidence at protein level HPA001141, HPA076542 Supported Mitochondria Cervical cancer:2.48e-4 (favourable) Expressed in all Mixed seminal vesicle: 30.1 AAAS ENSG00000094914 Achalasia, adrenocortical insufficiency, alacrimia 12 53307456-53324864 Disease related genes, Potential drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA040086 Approved Approved Nuclear membrane
Centrosome
Cytosol Renal cancer:2.93e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 44.9 AACS ACSF1, FLJ12389, SUR-5 ENSG00000081760 Acetoacetyl-CoA synthetase 12 125065379-125143333 Enzymes, Predicted membrane proteins Evidence at protein level HPA058815 Approved Approved Vesicles Expressed in all Expressed in all breast: 54.1 AADAC CES5A1, DAC ENSG00000114771 Arylacetamide deacetylase 3 151814037-151828488 Enzymes, Predicted intracellular proteins Evidence at protein level HPA002911 Approved Ovarian cancer:5.58e-6 (favourable), Stomach cancer:2.19e-4 (unfavourable), Pancreatic cancer:5.02e-4 (unfavourable) Tissue enriched Group enriched 5 adrenal gland: 151.1;duodenum: 187.8;liver: 385.8;small intestine: 220.5 stomach: 43.9 AADACL4 ENSG00000204518 Arylacetamide deacetylase-like 4 1 12644547-12667086 Predicted membrane proteins Evidence at protein level HPA043588 Uncertain Not detected Not detected epididymis: 0.7 AASDH ACSF4, LYS2, NRPS998 ENSG00000157426 Aminoadipate-semialdehyde dehydrogenase 4 56338287-56387508 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036472, HPA036473 Approved Expressed in all Mixed parathyroid gland: 14.9 AATK AATYK, AATYK1, KIAA0641, LMR1, LMTK1, PPP1R77 ENSG00000181409 Apoptosis-associated tyrosine kinase 17 81117295-81166077 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009073 Supported Uncertain Mitochondria Mixed Tissue enhanced cerebral cortex: 36.5;duodenum: 24.0 small intestine: 18.7 ABC7-42404400C24.1 ENSG00000277758 10 47750864-47763592 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA036971, HPA036972, HPA064559 Approved Approved Golgi apparatus Not detected Tissue enhanced cerebral cortex: 13.8;lung: 19.5 skin: 5.7 ABCA1 ABC1, HDLDT1, TGD ENSG00000165029 ATP-binding cassette, sub-family A (ABC1), member 1 9 104781002-104928237 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057283, CAB069889 Approved Approved Nucleoplasm
Vesicles Expressed in all Mixed adrenal gland: 38.1 ABCA10 EST698739 ENSG00000154263 ATP-binding cassette, sub-family A (ABC1), member 10 17 69147214-69244846 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014535 Uncertain Mixed Mixed ovary: 13.7 ABCA13 FLJ33876, FLJ33951 ENSG00000179869 ATP-binding cassette, sub-family A (ABC1), member 13 7 48171458-48647496 Predicted membrane proteins Evidence at transcript level HPA063601 Approved Vesicles
Centrosome
Cytosol Mixed Tissue enriched 10 bone marrow: 29.4 testis: 3.0 ABCA2 ABC2 ENSG00000107331 ATP-binding cassette, sub-family A (ABC1), member 2 9 137007227-137028922 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA042886 Approved Expressed in all Tissue enriched 6 cerebral cortex: 98.2 thyroid gland: 17.0 ABCA3 ABC-C, ABC3, EST111653, LBM180 ENSG00000167972 ATP-binding cassette, sub-family A (ABC1), member 3 16 2275881-2340746 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA007884 Approved Approved Nucleoplasm
Cytosol Expressed in all Tissue enhanced lung: 135.8 cerebral cortex: 51.7 ABCA5 EST90625 ENSG00000154265 ATP-binding cassette, sub-family A (ABC1), member 5 17 69244311-69327244 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA022032 Approved Pancreatic cancer:9.97e-5 (favourable) Expressed in all Expressed in all skin: 28.0 ABCA6 EST155051 ENSG00000154262 ATP-binding cassette, sub-family A (ABC1), member 6 17 69078702-69141888 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA064878, HPA067180 Approved Nucleoplasm Liver cancer:3.29e-4 (favourable) Tissue enriched Tissue enhanced liver: 41.4 ovary: 37.2 ABCA7 ABCX ENSG00000064687 ATP-binding cassette, sub-family A (ABC1), member 7 19 1040101-1065572 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041564 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:1.12e-4 (favourable), Colorectal cancer:7.26e-4 (unfavourable) Expressed in all Mixed spleen: 25.8 ABCA8 KIAA0822 ENSG00000141338 ATP-binding cassette, sub-family A (ABC1), member 8 17 68867292-68955392 Predicted membrane proteins, Transporters Evidence at protein level HPA044914 Approved Approved Nucleoplasm
Cytosol Mixed Mixed ovary: 67.2 ABCA9 EST640918 ENSG00000154258 ATP-binding cassette, sub-family A (ABC1), member 9 17 68974488-69061064 Predicted membrane proteins, Transporters Evidence at protein level HPA054823 Uncertain Mixed Mixed ovary: 33.3 ABCB1 ABC20, CD243, CLCS, GP170, MDR1, P-gp, PGY1 ENSG00000085563 ATP-binding cassette, sub-family B (MDR/TAP), member 1 7 87503633-87713323 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001716, HPA002199 Approved Approved Nucleoplasm
Focal adhesion sites
Cytosol Renal cancer:2.95e-4 (favourable), Pancreatic cancer:3.33e-4 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 138.6;small intestine: 83.9 kidney: 37.0 ABCB10 EST20237, M-ABC2, MTABC2 ENSG00000135776 ATP-binding cassette, sub-family B (MDR/TAP), member 10 1 229516582-229558695 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB044063, CAB044065, HPA055175 Uncertain Expressed in all Expressed in all bone marrow: 36.6 ABCB11 ABC16, BSEP, PFIC-2, PFIC2, PGY4, SPGP ENSG00000073734 ATP-binding cassette, sub-family B (MDR/TAP), member 11 2 168922938-169031322 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019035 Supported Uncertain Nucleoplasm
Plasma membrane
Cytosol Tissue enriched Tissue enriched 13 liver: 19.1 testis: 1.4 ABCB4 ABCB4, GBD1, MDR2, MDR3 , PFIC-3, PGY3 ENSG00000005471 ATP-binding cassette, sub-family B (MDR/TAP), member 4 7 87401697-87480435 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA049395, HPA053288 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments
Focal adhesion sites Tissue enriched Tissue enriched 6 liver: 69.2 adrenal gland: 10.7 ABCB5 ABCB5alpha, ABCB5beta, EST422562 ENSG00000004846 ATP-binding cassette, sub-family B (MDR/TAP), member 5 7 20615207-20777038 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026975 Uncertain Tissue enriched Tissue enriched 7 epididymis: 31.7 gallbladder: 4.3 ABCB6 EST45597, MTABC3, umat ENSG00000115657 ATP-binding cassette, sub-family B (MDR/TAP), member 6 (Langereis blood group) 2 219209768-219218990 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046723, HPA058011 Approved Validated Nucleoplasm
Golgi apparatus
Plasma membrane
Mitochondria
Cytosol Renal cancer:1.52e-7 (unfavourable), Liver cancer:9.45e-7 (unfavourable) Expressed in all Expressed in all testis: 32.5 ABCB7 ABC7, ASAT, Atm1p, EST140535 ENSG00000131269 ATP-binding cassette, sub-family B (MDR/TAP), member 7 X 75053172-75156732 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034982 Approved Supported Mitochondria Renal cancer:5.31e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 21.3 ABCB8 EST328128, M-ABC1, MABC1 ENSG00000197150 ATP-binding cassette, sub-family B (MDR/TAP), member 8 7 151028422-151047782 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA045187 Approved Supported Nucleus
Mitochondria Pancreatic cancer:3.34e-4 (favourable), Renal cancer:5.88e-4 (favourable), Head and neck cancer:5.91e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.0 ABCB9 EST122234 ENSG00000150967 ATP-binding cassette, sub-family B (MDR/TAP), member 9 12 122920951-122981649 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB033052, HPA035113, HPA035114 Approved Supported Vesicles Glioma:4.62e-4 (unfavourable) Mixed Tissue enhanced testis: 23.9 cerebral cortex: 12.1 ABCC1 GS-X, MRP, MRP1 ENSG00000103222 ATP-binding cassette, sub-family C (CFTR/MRP), member 1 16 15949577-16143074 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002380 Uncertain Supported Plasma membrane Renal cancer:1.55e-6 (unfavourable), Liver cancer:5.42e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 18.1 ABCC10 EST182763, MRP7, SIMRP7 ENSG00000124574 ATP-binding cassette, sub-family C (CFTR/MRP), member 10 6 43427366-43450430 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041607, HPA045464 Approved Renal cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 12.4 ABCC11 MRP8 ENSG00000121270 ATP-binding cassette, sub-family C (CFTR/MRP), member 11 16 48166910-48247568 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031980, HPA031981, HPA031982, CAB032513 Uncertain Group enriched Tissue enriched 11 breast: 63.2 prostate: 5.5 ABCC12 MRP9 ENSG00000140798 ATP-binding cassette, sub-family C (CFTR/MRP), member 12 16 48082973-48156018 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043100 Uncertain Tissue enhanced Tissue enhanced testis: 2.9 breast,cerebral cortex: 0.5 ABCC2 CMOAT, cMRP, DJS, MRP2 ENSG00000023839 ATP-binding cassette, sub-family C (CFTR/MRP), member 2 10 99782732-99852192 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004860, CAB037271 Approved Renal cancer:1.93e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 44.7;gallbladder: 42.8;kidney: 20.8;liver: 67.6;small intestine: 50.5 breast: 4.3 ABCC3 cMOAT2, EST90757, MLP2, MOAT-D, MRP3 ENSG00000108846 ATP-binding cassette, sub-family C (CFTR/MRP), member 3 17 50634777-50692252 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037136, HPA048483 Approved Approved Plasma membrane Renal cancer:4.68e-6 (unfavourable), Pancreatic cancer:9.57e-4 (unfavourable) Mixed Mixed adrenal gland: 20.8 ABCC4 EST170205, MOAT-B, MOATB, MRP4 ENSG00000125257 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 13 95019829-95301446 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002476 Supported Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:2.25e-10 (favourable), Endometrial cancer:9.89e-4 (unfavourable) Tissue enriched Tissue enhanced prostate: 68.5 epididymis: 23.3 ABCC5 EST277145, MOAT-C, MRP5, SMRP ENSG00000114770 ATP-binding cassette, sub-family C (CFTR/MRP), member 5 3 183919934-184018015 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA044067, HPA052295 Uncertain Supported Nucleus
Plasma membrane
Cell Junctions Liver cancer:6.78e-8 (unfavourable), Prostate cancer:3.40e-4 (unfavourable) Expressed in all Expressed in all stomach: 72.0 ABCC6 ARA, EST349056, MLP1, MRP6, PXE, URG7 ENSG00000091262 ATP-binding cassette, sub-family C (CFTR/MRP), member 6 16 16148928-16223522 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038105 Supported Plasma membrane Liver cancer:3.82e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 15.2;liver: 19.1 duodenum: 11.6 ABCC8 ABC36, HHF1, HI, HRINS, MRP8, PHHI, SUR, SUR1, TNDM2 ENSG00000006071 ATP-binding cassette, sub-family C (CFTR/MRP), member 8 11 17392885-17476845 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB011451, HPA042318 Approved Approved Nucleoli
Golgi apparatus
Cytosol Tissue enriched Tissue enhanced cerebral cortex: 11.7 adrenal gland: 7.6 ABCC9 CMD1O, SUR2 ENSG00000069431 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 12 21797401-21941402 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA007279 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:1.85e-5 (unfavourable) Mixed Mixed smooth muscle: 34.9 ABCD3 PMP70, PXMP1, ZWS2 ENSG00000117528 ATP-binding cassette, sub-family D (ALD), member 3 1 94418455-94518666 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA032026, HPA032027, CAB032516, CAB075749 Supported Validated Peroxisomes Colorectal cancer:1.16e-5 (favourable), Renal cancer:4.84e-5 (favourable) Expressed in all Expressed in all liver: 66.4 ABCD4 EST352188, P70R, PMP69, PXMP1L ENSG00000119688 ATP-binding cassette, sub-family D (ALD), member 4 14 74285423-74303056 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003396 Approved Expressed in all Expressed in all fallopian tube: 13.6 ABCG1 ABC8 ENSG00000160179 ATP-binding cassette, sub-family G (WHITE), member 1 21 42199689-42297244 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA031470, HPA031471 Approved Supported Golgi apparatus
Vesicles Renal cancer:7.16e-6 (favourable) Expressed in all Expressed in all spleen: 43.7 ABCG2 ABCP, BCRP, CD338, EST157481, MXR ENSG00000118777 ATP-binding cassette, sub-family G (WHITE), member 2 (Junior blood group) 4 88090264-88231322 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037299, HPA054719 Supported Validated Nucleus
Plasma membrane Mixed Tissue enhanced small intestine: 116.1 seminal vesicle: 55.4 ABCG4 WHITE2 ENSG00000172350 ATP-binding cassette, sub-family G (WHITE), member 4 11 119149012-119162653 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA040312 Uncertain Not detected Group enriched 6 cerebral cortex: 6.6;parathyroid gland: 4.0;testis: 5.1 seminal vesicle: 0.8 ABCG5 STSL ENSG00000138075 ATP-binding cassette, sub-family G (WHITE), member 5 2 43812472-43838865 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA016514 Approved Approved Nucleus Liver cancer:2.60e-5 (favourable) Tissue enriched Group enriched 32 duodenum: 58.0;liver: 28.3;small intestine: 57.4 gallbladder: 1.4 ABCG8 GBD4 ENSG00000143921 ATP-binding cassette, sub-family G (WHITE), member 8 2 43838964-43878466 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019556 Uncertain Uncertain Vesicles Tissue enriched Group enriched 25 duodenum: 51.4;liver: 34.1;small intestine: 56.7 gallbladder: 1.8 ABHD1 FLJ36128, LABH1 ENSG00000143994 Abhydrolase domain containing 1 2 27123789-27130812 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044390 Uncertain Mixed Tissue enriched 17 testis: 29.9 liver: 1.7 ABHD12 ABHD12A, BEM46L2, C20orf22, dJ965G21.2, DKFZP434P106 ENSG00000100997 Abhydrolase domain containing 12 20 25294743-25390983 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026866 Uncertain Cervical cancer:1.30e-5 (favourable), Breast cancer:3.81e-5 (unfavourable), Liver cancer:7.18e-4 (unfavourable) Expressed in all Expressed in all epididymis: 135.4 ABHD13 bA153I24.2, BEM46L1, C13orf6, FLJ14906 ENSG00000139826 Abhydrolase domain containing 13 13 108218379-108234255 Predicted membrane proteins Evidence at protein level HPA032143, HPA032144 Approved Approved Cytosol Expressed in all Mixed thyroid gland: 12.6 ABHD14A DKFZP564O243, DORZ1 ENSG00000248487 Abhydrolase domain containing 14A 3 51971426-51981199 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA038153, HPA038154, HPA056913 Approved Supported Vesicles Lung cancer:4.72e-4 (favourable) Expressed in all Expressed in all thyroid gland: 50.8 ABHD14A-ACY1 ENSG00000114786 ABHD14A-ACY1 readthrough 3 51975050-51989183 Predicted intracellular proteins Evidence at protein level HPA036174, HPA036175, HPA038153 Uncertain Uncertain Vesicles Not detected Not detected cervix, uterine,thyroid gland: 0.2 ABHD16A BAT5, D6S82E, NG26 ENSG00000204427 Abhydrolase domain containing 16A 6 31686949-31703444 Predicted membrane proteins Evidence at protein level HPA058606 Approved Endometrial cancer:2.63e-4 (unfavourable) Expressed in all Tissue enhanced gallbladder: 1.7;testis: 1.3;thyroid gland: 1.3 esophagus: 0.9 ABHD18 C4orf29, FLJ21106 ENSG00000164074 Abhydrolase domain containing 18 4 127965306-128039711 Predicted intracellular proteins Evidence at protein level HPA050168, HPA051676 Approved Approved Nuclear membrane Colorectal cancer:5.35e-4 (favourable), Urothelial cancer:9.13e-4 (favourable) Expressed in all Expressed in all heart muscle: 9.5 ABHD2 LABH2 ENSG00000140526 Abhydrolase domain containing 2 15 89087459-89202360 Predicted membrane proteins Evidence at protein level HPA005999 Approved Approved Nucleoplasm
Cytosol Renal cancer:2.18e-7 (favourable) Expressed in all Expressed in all testis: 99.6 ABHD3 LABH3 ENSG00000158201 Abhydrolase domain containing 3 18 21650897-21704805 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010729 Approved Approved Nucleus
Vesicles
Plasma membrane Melanoma:8.52e-4 (unfavourable) Expressed in all Expressed in all rectum: 72.4 ABHD6 ENSG00000163686 Abhydrolase domain containing 6 3 58237506-58295693 Enzymes, Predicted membrane proteins Evidence at protein level HPA017283, HPA073225 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.11e-11 (favourable), Colorectal cancer:1.13e-4 (favourable) Expressed in all Mixed small intestine: 52.0 AC004754.3 ENSG00000269881 16 249547-269943 Predicted membrane proteins Evidence at transcript level HPA011651 Uncertain Nucleoplasm
Mitochondria Not detected Group enriched 5 duodenum: 14.6;small intestine: 8.1 testis: 2.0 AC006538.4 ENSG00000267001 19 2717769-2740048 Predicted membrane proteins Evidence at protein level HPA058526 Uncertain Not detected Mixed testis: 3.9 AC018755.18 ENSG00000268500 19 51612091-51646889 Predicted membrane proteins Evidence at transcript level HPA009085 Approved Not detected Group enriched 5 appendix: 7.3;bone marrow: 14.2;lymph node: 3.6;spleen: 5.0 urinary bladder: 1.4 AC138969.4 ENSG00000183889 16 16317444-16350590 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Uncertain Nucleoplasm Not detected Expressed in all skin: 115.8 AC171558.1 ENSG00000274792 Unmapped 386278-387620 Predicted membrane proteins Evidence at transcript level HPA057442 Uncertain Uncertain Centrosome Tissue enriched 11 testis: 4.3 cerebral cortex: 0.4 AC171558.2 ENSG00000275249 Unmapped 372322-373405 Predicted membrane proteins Evidence at transcript level HPA058889 Uncertain Tissue enriched 26 testis: 2.5 all non-specific tissues: 0.0 ACAA1 ENSG00000060971 Acetyl-CoA acyltransferase 1 3 38103129-38137242 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA006764, HPA007244 Supported Validated Peroxisomes Renal cancer:6.99e-9 (favourable), Head and neck cancer:1.23e-4 (favourable), Breast cancer:3.00e-4 (favourable), Endometrial cancer:7.53e-4 (favourable) Expressed in all Expressed in all liver: 327.6 ACAD10 MGC5601 ENSG00000111271 Acyl-CoA dehydrogenase family, member 10 12 111686056-111757107 Predicted intracellular proteins Evidence at protein level HPA067222 Uncertain Renal cancer:3.71e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 33.5 ACBD4 FLJ13322 ENSG00000181513 Acyl-CoA binding domain containing 4 17 45132600-45144181 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051772 Approved Approved Nucleus
Vesicles Pancreatic cancer:4.64e-4 (favourable), Liver cancer:4.76e-4 (favourable), Urothelial cancer:6.53e-4 (favourable) Expressed in all Expressed in all duodenum: 31.2 ACBD5 DKFZp434A2417, KIAA1996 ENSG00000107897 Acyl-CoA binding domain containing 5 10 27195214-27242130 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011861, HPA012145 Supported Validated Peroxisomes Renal cancer:4.68e-5 (favourable), Breast cancer:3.33e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 57.3 ACE ACE1, CD143, DCP1 ENSG00000159640 Angiotensin I converting enzyme 17 63477061-63498380 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002426, CAB002921, HPA029298, HPA069790 Supported Approved Vesicles Expressed in all Tissue enhanced duodenum: 183.8;small intestine: 297.5 testis: 83.7 ACE2 ENSG00000130234 Angiotensin I converting enzyme 2 X 15561033-15602148 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000288, CAB026174 Supported Renal cancer:2.12e-5 (favourable), Liver cancer:4.21e-4 (favourable) Tissue enhanced Group enriched 6 duodenum: 186.1;gallbladder: 100.6;kidney: 93.3;small intestine: 266.6;testis: 92.6 heart muscle: 23.1 ACHE YT ENSG00000087085 Acetylcholinesterase (Yt blood group) 7 100889994-100896974 Blood group antigen proteins, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019704, HPA027098 Approved Golgi apparatus
Vesicles Renal cancer:3.88e-5 (unfavourable), Glioma:7.16e-4 (unfavourable) Mixed Tissue enhanced skeletal muscle: 58.5 cerebral cortex: 14.1 ACKR1 CCBP1, CD234, DARC, Dfy, FY, GPD ENSG00000213088 Atypical chemokine receptor 1 (Duffy blood group) 1 159203307-159206500 Blood group antigen proteins, CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA016421, HPA017672 Supported Cervical cancer:2.52e-5 (favourable), Liver cancer:1.48e-4 (favourable), Thyroid cancer:9.76e-4 (unfavourable) Expressed in all Mixed adipose tissue: 111.8 ACKR2 CCBP2, CCR10, CCR9, CMKBR9, D6 ENSG00000144648 Atypical chemokine receptor 2 3 42804752-42887974 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013819, HPA073493 Supported Supported Nucleoplasm
Vesicles
Cytosol Mixed Tissue enhanced placenta: 22.8 adipose tissue: 5.2 ACKR3 CMKOR1, CXCR7, GPR159, RDC1 ENSG00000144476 Atypical chemokine receptor 3 2 236567787-236582358 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA032003, HPA049718 Approved Supported Vesicles
Plasma membrane Renal cancer:1.76e-6 (unfavourable), Stomach cancer:2.01e-4 (unfavourable), Urothelial cancer:2.93e-4 (unfavourable), Cervical cancer:4.64e-4 (unfavourable) Expressed in all Expressed in all placenta: 175.2 ACKR4 CCBP2, CCR11, CCRL1, CCX-CKR, PPR1, VSHK1 ENSG00000129048 Atypical chemokine receptor 4 3 132597237-132618967 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA027595 Uncertain Cytosol Mixed Mixed duodenum: 19.7 ACMSD ENSG00000153086 Aminocarboxymuconate semialdehyde decarboxylase 2 134838547-134902034 Enzymes, Predicted intracellular proteins Evidence at protein level HPA010533, HPA011179 Supported Uncertain Cytosol Renal cancer:2.39e-4 (favourable) Group enriched Group enriched 10 kidney: 136.5;liver: 80.0 gallbladder: 10.9 ACP1 HAAP, LMW-PTP ENSG00000143727 Acid phosphatase 1, soluble 2 264140-278283 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA016754 Approved Approved Nucleus
Cytosol Liver cancer:6.67e-6 (unfavourable), Melanoma:3.04e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 129.4 ACPP ACP-3, ACP3, PAP ENSG00000014257 Acid phosphatase, prostate 3 132317367-132368298 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000071, HPA004335, HPA063916 Supported Tissue enriched Tissue enriched 153 prostate: 6368.2 esophagus: 41.6 ACSBG2 BGR, DKFZp434K1635, PRTD-NY3 ENSG00000130377 Acyl-CoA synthetase bubblegum family member 2 19 6135247-6193094 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043421, HPA051013 Supported Uncertain Cytosol Not detected Tissue enriched 709 testis: 291.8 breast,cerebral cortex: 0.4 ACSF2 ACSMW, FLJ20920 ENSG00000167107 Acyl-CoA synthetase family member 2 17 50426158-50474845 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA024693 Approved Approved Nucleoplasm
Microtubules
Cytosol Renal cancer:2.17e-4 (unfavourable), Urothelial cancer:2.41e-4 (favourable) Expressed in all Tissue enhanced kidney: 136.1 thyroid gland: 68.3 ACSL1 ACS1, FACL1, FACL2, LACS, LACS1, LACS2 ENSG00000151726 Acyl-CoA synthetase long-chain family member 1 4 184755595-184826818 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011316, HPA011964 Supported Supported Nucleus
Mitochondria Renal cancer:1.25e-5 (favourable) Expressed in all Expressed in all adipose tissue: 820.6 ACSL3 ACS3, FACL3, PRO2194 ENSG00000123983 Acyl-CoA synthetase long-chain family member 3 2 222860934-222944639 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011315, HPA071021 Uncertain Approved Nucleoli
Lipid droplets Liver cancer:2.75e-4 (unfavourable), Lung cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 670.1 ACSL4 ACS4, FACL4, LACS4, MRX63, MRX68 ENSG00000068366 Acyl-CoA synthetase long-chain family member 4 X 109624244-109733403 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000286, HPA005552 Supported Approved Golgi apparatus
Mitochondria Urothelial cancer:5.73e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 70.3 ACSL5 ACS2, ACS5, FACL5 ENSG00000197142 Acyl-CoA synthetase long-chain family member 5 10 112374018-112428380 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007162, CAB062546 Supported Supported Nucleus
Mitochondria Endometrial cancer:1.13e-4 (favourable) Expressed in all Expressed in all small intestine: 469.9 ACSL6 ACS2, FACL6, KIAA0837, LACS2, LACS5 ENSG00000164398 Acyl-CoA synthetase long-chain family member 6 5 131949973-132012243 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040470 Uncertain Group enriched Group enriched 6 bone marrow: 18.0;cerebral cortex: 62.1;parathyroid gland: 22.1;seminal vesicle: 28.7;testis: 51.2 adrenal gland: 6.5 ACSM1 BUCS1, MACS1 ENSG00000166743 Acyl-CoA synthetase medium-chain family member 1 16 20623237-20698890 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046291 Uncertain Group enriched Tissue enriched 55 breast: 293.3 prostate: 5.2 ACSM2A A-923A4.1, ACSM2, MGC150530 ENSG00000183747 Acyl-CoA synthetase medium-chain family member 2A 16 20451461-20487667 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057699 Supported Liver cancer:1.41e-5 (favourable) Group enriched Group enriched 578 kidney: 284.3;liver: 185.7 cerebral cortex: 0.4 ACSM2B ACSM2, HXMA, HYST1046 ENSG00000066813 Acyl-CoA synthetase medium-chain family member 2B 16 20536226-20576427 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057699 Supported Liver cancer:3.31e-4 (favourable) Group enriched Group enriched 85 kidney: 423.8;liver: 261.6 thyroid gland: 4.0 ACSS1 ACAS2L, AceCS2L, dJ568C11.3, MGC33843 ENSG00000154930 Acyl-CoA synthetase short-chain family member 1 20 25006230-25058980 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041014, HPA043228 Approved Lung cancer:8.33e-5 (favourable), Cervical cancer:9.37e-4 (favourable) Expressed in all Expressed in all placenta: 165.1 ACSS2 ACAS2, AceCS, ACS, ACSA, dJ1161H23.1 ENSG00000131069 Acyl-CoA synthetase short-chain family member 2 20 34872146-34927962 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004141 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:2.04e-4 (favourable) Expressed in all Mixed adipose tissue: 55.9 ACTR3C ARP11 ENSG00000106526 ARP3 actin-related protein 3 homolog C (yeast) 7 150243916-150323725 Predicted intracellular proteins Evidence at transcript level HPA055957 Uncertain Mixed Tissue enriched 5 parathyroid gland: 85.6 adrenal gland: 15.9 ACVR1 ACVR1A, ACVRLK2, ALK2, SKR1 ENSG00000115170 Activin A receptor, type I 2 157736444-157875862 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007505 Approved Urothelial cancer:5.17e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 73.9 ACVR1B ActRIB, ACVRLK4, ALK4, SKR2 ENSG00000135503 Activin A receptor, type IB 12 51951667-51997078 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026126, HPA063761 Approved Validated Cytosol Expressed in all Expressed in all parathyroid gland: 53.7 ACVR1C ACVRLK7, ALK7 ENSG00000123612 Activin A receptor, type IC 2 157526767-157629005 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007982, HPA011933 Approved Mixed Tissue enriched 8 adipose tissue: 33.9 ovary: 4.3 ACVR2A ACTRII, ACVR2 ENSG00000121989 Activin A receptor, type IIA 2 147844517-147930826 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA046997 Approved Approved Cytosol Renal cancer:1.62e-4 (favourable) Expressed in all Mixed skin: 22.5 ACVR2B ActR-IIB ENSG00000114739 Activin A receptor, type IIB 3 38453851-38493142 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007398, CAB025115 Approved Approved Nucleus
Nuclear bodies
Cytosol Expressed in all Mixed parathyroid gland: 6.3 ACVRL1 ACVRLK1, ALK1, HHT, HHT2, ORW2 ENSG00000139567 Activin A receptor type II-like 1 12 51906908-51923361 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007041 Approved Expressed in all Tissue enhanced placenta: 125.5 lung: 76.6 ADAM10 CD156c, HsT18717, kuz, MADM ENSG00000137845 ADAM metallopeptidase domain 10 15 58588807-58749978 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001709, HPA050670 Approved Supported Vesicles
Plasma membrane Lung cancer:8.46e-5 (unfavourable), Pancreatic cancer:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 47.8 ADAM12 MCMPMltna, MLTN ENSG00000148848 ADAM metallopeptidase domain 12 10 126012381-126388455 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030866, HPA030867, HPA030868 Supported Supported Plasma membrane Renal cancer:2.39e-14 (unfavourable) Mixed Tissue enriched 8 placenta: 236.1 cervix, uterine: 29.5 ADAM15 MDC15 ENSG00000143537 ADAM metallopeptidase domain 15 1 155050566-155062775 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011633, HPA072878 Uncertain Uncertain Vesicles Renal cancer:5.64e-9 (unfavourable), Glioma:3.49e-5 (unfavourable), Liver cancer:3.49e-4 (unfavourable) Expressed in all Expressed in all skin: 72.8 ADAM17 CD156B, cSVP, TACE ENSG00000151694 ADAM metallopeptidase domain 17 2 9488486-9555792 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010738, CAB025906, HPA051575 Approved Supported Cytosol Urothelial cancer:4.23e-5 (unfavourable) Expressed in all Expressed in all placenta: 33.9 ADAM19 MLTNB ENSG00000135074 ADAM metallopeptidase domain 19 5 157395534-157575775 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA055537 Approved Vesicles Renal cancer:3.90e-12 (unfavourable) Expressed in all Mixed lymph node: 34.9 ADAM2 CT15, FTNB, PH-30b, PH30 ENSG00000104755 ADAM metallopeptidase domain 2 8 39743735-39838289 Enzymes, Predicted membrane proteins Evidence at protein level CAB022390, HPA024621, HPA026581 Supported Tissue enhanced Tissue enriched 288 testis: 41.7 breast: 0.1 ADAM20 ENSG00000134007 ADAM metallopeptidase domain 20 14 70522358-70535015 Enzymes, Predicted membrane proteins Evidence at protein level HPA059377 Supported Not detected Tissue enriched 76 testis: 9.2 cerebral cortex,endometrium,skin: 0.1 ADAM21 ADAM31 ENSG00000139985 ADAM metallopeptidase domain 21 14 70452157-70459899 Enzymes, Predicted membrane proteins Evidence at protein level HPA059016 Uncertain Not detected Tissue enriched 31 testis: 15.4 cerebral cortex: 0.5 ADAM22 MDC2 ENSG00000008277 ADAM metallopeptidase domain 22 7 87934143-88202889 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050325 Approved Cell Junctions Mixed Tissue enhanced cerebral cortex: 47.7 prostate: 17.5 ADAM23 MDC3 ENSG00000114948 ADAM metallopeptidase domain 23 2 206443539-206621130 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012130, CAB033276 Uncertain Mixed Group enriched 6 cerebral cortex: 55.7;parathyroid gland: 132.9 heart muscle: 16.4 ADAM28 ADAM23, eMDCII, MDC-Lm, MDC-Ls ENSG00000042980 ADAM metallopeptidase domain 28 8 24294040-24359018 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074034 Approved Plasma membrane
Mitochondria Endometrial cancer:3.17e-4 (favourable) Mixed Tissue enhanced epididymis: 428.3 stomach: 104.5 ADAM30 svph4 ENSG00000134249 ADAM metallopeptidase domain 30 1 119893533-119896495 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA026080 Uncertain Not detected Tissue enriched 468 testis: 46.8 all non-specific tissues: 0.0 ADAM32 ENSG00000197140 ADAM metallopeptidase domain 32 8 39106990-39284911 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044156, HPA062151 Approved Approved Nucleus
Vesicles Not detected Tissue enriched 31 testis: 28.7 epididymis: 0.9 ADAM33 C20orf153, dJ964F7.1, DKFZp434K0521 ENSG00000149451 ADAM metallopeptidase domain 33 20 3667965-3682246 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA067152, HPA071758 Approved Uncertain Nuclear speckles
Plasma membrane Mixed Mixed endometrium: 102.9 ADAM7 EAPI, GP-83 ENSG00000069206 ADAM metallopeptidase domain 7 8 24440930-24526970 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008879 Supported Group enriched Tissue enriched 198 epididymis: 4461.2 seminal vesicle: 22.5 ADAM8 CD156, CD156a, MS2 ENSG00000151651 ADAM metallopeptidase domain 8 10 133262403-133276868 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064637 Approved Renal cancer:3.99e-10 (unfavourable) Expressed in all Tissue enhanced bone marrow: 43.9;spleen: 33.5 appendix: 30.9 ADAM9 CORD9, KIAA0021, MCMP, MDC9, Mltng ENSG00000168615 ADAM metallopeptidase domain 9 8 38996869-39105144 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004000 Approved Endoplasmic reticulum
Vesicles Liver cancer:7.21e-6 (unfavourable), Pancreatic cancer:2.52e-5 (unfavourable), Breast cancer:1.14e-4 (unfavourable), Cervical cancer:2.25e-4 (unfavourable), Renal cancer:3.99e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 116.7 ADAMTS1 C3-C5, KIAA1346, METH1 ENSG00000154734 ADAM metallopeptidase with thrombospondin type 1 motif, 1 21 26835747-26845409 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016394, HPA031498, HPA031499 Uncertain Validated Cytosol Head and neck cancer:5.13e-4 (unfavourable) Expressed in all Tissue enhanced ovary: 410.9 adipose tissue: 276.6 ADAMTS4 ADAMTS-2, ADMP-1, KIAA0688 ENSG00000158859 ADAM metallopeptidase with thrombospondin type 1 motif, 4 1 161184308-161199056 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level CAB025876, HPA051296, HPA068374 Uncertain Approved Nuclear speckles Renal cancer:7.27e-7 (unfavourable), Lung cancer:5.00e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 62.7 appendix: 23.4 ADAP1 CENTA1, GCS1L ENSG00000105963 ArfGAP with dual PH domains 1 7 897901-955407 Predicted intracellular proteins Evidence at protein level HPA007033, HPA012049 Supported Supported Plasma membrane
Cytosol Renal cancer:4.13e-5 (favourable), Colorectal cancer:5.25e-4 (unfavourable), Head and neck cancer:9.13e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 80.5 colon: 38.9 ADCK2 MGC20727 ENSG00000133597 AarF domain containing kinase 2 7 140673153-140696261 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036036 Approved Uncertain Centrosome
Cytosol Renal cancer:9.75e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 26.7 ADCK4 COQ8, FLJ12229 ENSG00000123815 AarF domain containing kinase 4 19 40691529-40718207 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA027229, HPA027277, HPA027279, HPA028303 Supported Validated Mitochondria Expressed in all Expressed in all fallopian tube: 40.7 ADCK5 FLJ35454 ENSG00000173137 AarF domain containing kinase 5 8 144373101-144393242 Enzymes, Predicted membrane proteins Evidence at protein level HPA025692, HPA028679 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed duodenum: 9.9 ADCY1 AC1 ENSG00000164742 Adenylate cyclase 1 (brain) 7 45574140-45723116 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018364, HPA068274 Uncertain Approved Mitochondria Mixed Tissue enhanced cerebral cortex: 35.1 cervix, uterine: 8.2 ADCY10 HCA2, RP1-313L4.2, SAC, SACI, Sacy ENSG00000143199 Adenylate cyclase 10 (soluble) 1 167809388-167914215 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015243, HPA017749 Approved Tissue enhanced Tissue enriched 11 testis: 32.9 liver: 3.1 ADCY2 AC2, HBAC2, KIAA1060 ENSG00000078295 Adenylate cyclase 2 (brain) 5 7396208-7830081 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB031482, HPA038015, HPA038483 Approved Tissue enhanced Tissue enhanced cerebral cortex: 71.8;skeletal muscle: 35.8 prostate: 13.6 ADCY3 AC3 ENSG00000138031 Adenylate cyclase 3 2 24819169-24919839 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB010223 Approved Renal cancer:1.32e-9 (unfavourable) Expressed in all Expressed in all placenta: 121.3 ADCY4 AC4 ENSG00000129467 Adenylate cyclase 4 14 24318349-24335093 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB005070, HPA048344 Approved Renal cancer:7.01e-4 (unfavourable), Endometrial cancer:8.20e-4 (favourable) Expressed in all Tissue enhanced placenta: 20.9 lung: 11.6 ADCY5 AC5 ENSG00000173175 Adenylate cyclase 5 3 123282296-123449758 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017730, HPA077682 Uncertain Uncertain Intermediate filaments Renal cancer:7.46e-6 (favourable) Mixed Tissue enhanced heart muscle: 72.9 seminal vesicle: 29.7 ADCY6 AC6 ENSG00000174233 Adenylate cyclase 6 12 48766194-48789037 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018365 Approved Approved Golgi apparatus Liver cancer:8.23e-4 (unfavourable) Expressed in all Mixed adipose tissue: 44.5 ADCY7 AC7, KIAA0037 ENSG00000121281 Adenylate cyclase 7 16 50246137-50318135 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041218, HPA048241 Uncertain Approved Cytosol Cervical cancer:5.31e-4 (unfavourable) Mixed Mixed spleen: 42.9 ADCY8 AC8, ADCY3, HBAC1 ENSG00000155897 Adenylate cyclase 8 (brain) 8 130780301-131042426 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018652, HPA024291 Supported Group enriched Group enriched 8 cerebral cortex: 12.9;epididymis: 27.3;fallopian tube: 6.2 lung,seminal vesicle: 1.9 ADCY9 AC9 ENSG00000162104 Adenylate cyclase 9 16 3953387-4116185 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041328, HPA044225 Approved Approved Cytosol Renal cancer:5.24e-8 (favourable), Endometrial cancer:2.55e-5 (unfavourable) Expressed in all Mixed thyroid gland: 31.8 ADCYAP1R1 PAC1, PAC1R, PACAPR ENSG00000078549 Adenylate cyclase activating polypeptide 1 (pituitary) receptor type I 7 31052461-31111479 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA049877 Approved Uncertain Vesicles Endometrial cancer:5.78e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 137.5;fallopian tube: 46.5 cervix, uterine: 20.6 ADGRA1 GPR123, KIAA1828 ENSG00000197177 Adhesion G protein-coupled receptor A1 10 133070929-133131675 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA042773 Approved Tissue enriched Tissue enhanced adrenal gland: 4.9;cerebral cortex: 22.5 fallopian tube: 3.1 ADGRA2 DKFZp434C211, DKFZp434J0911, FLJ14390, GPR124, KIAA1531, TEM5 ENSG00000020181 Adhesion G protein-coupled receptor A2 8 37784191-37844896 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012393 Uncertain Renal cancer:3.18e-7 (unfavourable) Expressed in all Expressed in all seminal vesicle: 86.1 ADGRA3 FLJ38547, GPR125, PGR21 ENSG00000152990 Adhesion G protein-coupled receptor A3 4 22345071-22516054 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008904 Uncertain Expressed in all Expressed in all thyroid gland: 42.3 ADGRB2 BAI2 ENSG00000121753 Adhesion G protein-coupled receptor B2 1 31727117-31764893 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052612, HPA054617 Supported Centrosome Lung cancer:4.02e-5 (unfavourable), Breast cancer:6.46e-4 (favourable) Tissue enhanced Tissue enriched 14 cerebral cortex: 72.5 adrenal gland: 5.1 ADGRD1 DKFZp434B1272, GPR133, PGR25 ENSG00000111452 Adhesion G protein-coupled receptor D1 12 130953907-131141469 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042395 Uncertain Approved Nucleus
Cytosol Liver cancer:9.27e-4 (unfavourable) Mixed Tissue enhanced placenta: 44.3 lung: 32.7 ADGRE1 EMR1, TM7LN3 ENSG00000174837 Adhesion G protein-coupled receptor E1 19 6887566-6940459 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA052809 Uncertain Mixed Tissue enhanced appendix: 10.2;spleen: 20.1 lung: 6.8 ADGRE2 CD312, EMR2 ENSG00000127507 Adhesion G protein-coupled receptor E2 19 14732393-14778541 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA055200 Uncertain Vesicles Renal cancer:4.35e-6 (unfavourable) Mixed Tissue enhanced appendix: 27.6;spleen: 15.7 adipose tissue: 5.9 ADGRE3 EMR3 ENSG00000131355 Adhesion G protein-coupled receptor E3 19 14619117-14690027 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA015638 Uncertain Not detected Tissue enhanced appendix: 8.9;spleen: 8.8 lung: 3.9 ADGRE5 CD97, TM7LN1 ENSG00000123146 Adhesion G protein-coupled receptor E5 19 14380501-14408725 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA013707 Supported Approved Cytosol Renal cancer:1.87e-6 (unfavourable), Liver cancer:3.73e-5 (unfavourable) Expressed in all Expressed in all spleen: 142.8 ADGRF1 GPR110, hGPCR36, PGR19 ENSG00000153292 Adhesion G protein-coupled receptor F1 6 46997703-47042363 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA038438 Approved Renal cancer:1.35e-5 (favourable) Mixed Tissue enhanced esophagus: 14.7;kidney: 17.6;urinary bladder: 19.6 gallbladder: 9.5 ADGRF2 GPR111, hGPCR35, PGR20 ENSG00000164393 Adhesion G protein-coupled receptor F2 6 47656436-47697797 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA035507 Uncertain Not detected Tissue enhanced fallopian tube: 1.5;skin: 1.4 esophagus: 0.3 ADGRF3 GPR113, hGPCR37, PGR23 ENSG00000173567 Adhesion G protein-coupled receptor F3 2 26308173-26346817 G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA044500 Uncertain Not detected Not detected kidney: 0.9 ADGRF4 FLJ38076, GPR115, PGR18 ENSG00000153294 Adhesion G protein-coupled receptor F4 6 47685864-47722021 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA007131, HPA007158 Supported Uncertain Mitochondria Pancreatic cancer:5.52e-4 (unfavourable) Mixed Group enriched 7 esophagus: 12.1;skin: 45.9 tonsil: 3.9 ADGRG1 GPR56, TM7LN4, TM7XN1 ENSG00000205336 Adhesion G protein-coupled receptor G1 16 57610652-57665580 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046065 Uncertain Renal cancer:5.52e-7 (favourable), Head and neck cancer:2.53e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 348.2 ADGRG2 EDDM6, GPR64, HE6, TM7LN2 ENSG00000173698 Adhesion G protein-coupled receptor G2 X 18989309-19122637 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001478, HPA050029 Supported Approved Plasma membrane
Cytosol Tissue enhanced Tissue enriched 6 epididymis: 1469.4 parathyroid gland: 235.5 ADGRG3 GPR97, Pb99, PGR26 ENSG00000182885 Adhesion G protein-coupled receptor G3 16 57668187-57689378 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA040469 Uncertain Mixed Group enriched 5 appendix: 19.4;bone marrow: 86.7 adipose tissue: 9.6 ADGRG4 GPR112, PGR17, RP1-299I16 ENSG00000156920 Adhesion G protein-coupled receptor G4 X 136300963-136416888 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035324 Uncertain Not detected Tissue enhanced duodenum: 2.6;small intestine: 1.7 fallopian tube: 0.5 ADGRG5 GPR114, PGR27 ENSG00000159618 Adhesion G protein-coupled receptor G5 16 57542421-57591681 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007133 Supported Approved Nucleoplasm
Nuclear membrane
Vesicles Cervical cancer:4.25e-4 (favourable) Mixed Tissue enhanced lymph node: 11.3;tonsil: 8.9 appendix: 6.2 ADGRG6 FLJ14937, GPR126 ENSG00000112414 Adhesion G protein-coupled receptor G6 6 142301854-142446266 G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017346 Approved Pancreatic cancer:2.78e-5 (unfavourable), Lung cancer:8.78e-4 (unfavourable) Mixed Tissue enhanced placenta: 66.6 liver: 36.9 ADGRL1 CIRL1, KIAA0821, LEC2, LPHN1 ENSG00000072071 Adhesion G protein-coupled receptor L1 19 14147743-14206187 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037974 Uncertain Pancreatic cancer:1.14e-4 (favourable), Renal cancer:4.45e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 60.3 parathyroid gland: 24.2 ADGRL2 KIAA0786, LEC1, LPHH1, LPHN2 ENSG00000117114 Adhesion G protein-coupled receptor L2 1 81306160-81992436 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043447 Approved Plasma membrane
Cell Junctions Endometrial cancer:1.33e-4 (unfavourable), Stomach cancer:3.00e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Mixed thyroid gland: 72.8 ADGRL3 KIAA0768, LEC3, LPHN3 ENSG00000150471 Adhesion G protein-coupled receptor L3 4 61201258-62078335 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA015027, HPA015762, CAB022698 Uncertain Tissue enriched Tissue enhanced cerebral cortex: 42.1;parathyroid gland: 30.1 cervix, uterine: 8.5 ADGRL4 ELTD1, ETL ENSG00000162618 Adhesion G protein-coupled receptor L4 1 78889764-79006718 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA025229 Supported Renal cancer:1.60e-4 (unfavourable) Expressed in all Mixed adipose tissue: 67.6 ADGRV1 DKFZp761P0710, FEB4, GPR98, KIAA0686, MASS1, USH2C, VLGR1 ENSG00000164199 Adhesion G protein-coupled receptor V1 5 90529344-91164221 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA067503 Approved Mixed Group enriched 6 adrenal gland: 56.5;cerebral cortex: 29.1 thyroid gland: 6.6 ADIG MGC39724, RP5-1100H13.2, SMAF1 ENSG00000182035 Adipogenin 20 38581195-38588463 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA041124 Uncertain Tissue enhanced Group enriched 10 epididymis: 5.0;testis: 16.0;thyroid gland: 3.4 seminal vesicle: 0.8 ADIPOR2 ACDCR2, PAQR2 ENSG00000006831 Adiponectin receptor 2 12 1688574-1788678 Predicted membrane proteins Evidence at protein level HPA043737 Approved Expressed in all Expressed in all adipose tissue: 76.9 ADORA1 RDC7 ENSG00000163485 Adenosine A1 receptor 1 203090654-203167405 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA044383 Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 46.5;testis: 23.4 parathyroid gland: 17.5 ADORA2B ENSG00000170425 Adenosine A2b receptor 17 15944917-15975746 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA073747 Uncertain Cytosol Mixed Mixed colon: 8.3 ADPRM C17orf48, MDS006 ENSG00000170222 ADP-ribose/CDP-alcohol diphosphatase, manganese-dependent 17 10697594-10711233 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023265, HPA023820 Approved Endometrial cancer:2.38e-5 (favourable), Cervical cancer:1.69e-4 (favourable) Expressed in all Expressed in all prostate: 18.1 ADRA1A ADRA1C, ADRA1L1 ENSG00000120907 Adrenoceptor alpha 1A 8 26748150-26867273 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029678, HPA029679 Approved Tissue enhanced Tissue enhanced adipose tissue: 22.6;liver: 32.0 seminal vesicle: 19.5 ADRA1B ENSG00000170214 Adrenoceptor alpha 1B 5 159916783-159972544 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074416 Supported Plasma membrane Renal cancer:1.40e-6 (unfavourable), Thyroid cancer:3.19e-5 (favourable), Endometrial cancer:6.00e-5 (unfavourable), Ovarian cancer:2.67e-4 (favourable), Glioma:6.07e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.8;spleen: 17.3 ovary: 4.8 ADRA1D ADRA1, ADRA1A, ADRA1R ENSG00000171873 Adrenoceptor alpha 1D 20 4220631-4249074 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA038789 Uncertain Mixed Tissue enhanced cervix, uterine: 4.3;prostate: 4.2 seminal vesicle: 2.5 ADRA2B ADRA2L1, ADRA2RL1, ADRARL1 ENSG00000274286 Adrenoceptor alpha 2B 2 96112875-96116245 Predicted membrane proteins Evidence at transcript level HPA066029 Approved Mixed Mixed epididymis: 5.0 ADRA2C ADRA2L2, ADRA2RL2, ADRARL2 ENSG00000184160 Adrenoceptor alpha 2C 4 3766348-3768526 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057688 Uncertain Mixed Tissue enhanced cervix, uterine: 21.0;endometrium: 26.0;seminal vesicle: 26.7 fallopian tube: 7.9 ADRB1 ADRB1R ENSG00000043591 Adrenoceptor beta 1 10 114044056-114046908 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA067972 Supported Tissue enriched Tissue enhanced placenta: 45.2 heart muscle: 11.9 ADRB2 ADRB2R, ADRBR, B2AR, BAR ENSG00000169252 Adrenoceptor beta 2, surface 5 148825245-148828687 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003431, HPA075322 Uncertain Uncertain Cytosol Renal cancer:3.15e-9 (favourable) Mixed Mixed lung: 16.3 ADTRP AIG1L, C6orf105, dJ413H6.1 ENSG00000111863 Androgen-dependent TFPI-regulating protein 6 11712054-11807046 Predicted membrane proteins Evidence at transcript level HPA048113 Uncertain Uncertain Nucleoli Renal cancer:1.13e-5 (unfavourable) Mixed Tissue enhanced small intestine: 81.0 duodenum: 62.8 AFG3L2 SCA28, SPAX5 ENSG00000141385 AFG3-like AAA ATPase 2 18 12328944-12377314 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA004479, HPA004480 Supported Validated Mitochondria Renal cancer:6.05e-14 (favourable), Endometrial cancer:8.68e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 121.6 AGER RAGE ENSG00000204305 Advanced glycosylation end product-specific receptor 6 32180968-32184324 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB011682, HPA064436 Approved Approved Nucleoli fibrillar center
Plasma membrane
Cell Junctions Renal cancer:9.01e-7 (unfavourable), Urothelial cancer:2.74e-6 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enriched 181 lung: 891.2 thyroid gland: 4.9 AGMO FLJ16237, TMEM195 ENSG00000187546 Alkylglycerol monooxygenase 7 15200318-15562015 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057900 Uncertain Vesicles Tissue enriched Tissue enhanced liver: 63.6 epididymis: 17.5 AGPAT1 LPAAT-alpha ENSG00000204310 1-acylglycerol-3-phosphate O-acyltransferase 1 6 32168212-32178096 Enzymes, Predicted membrane proteins Evidence at protein level HPA048478, HPA073355 Approved Supported Endoplasmic reticulum
Rods & Rings Breast cancer:1.93e-4 (unfavourable), Endometrial cancer:5.21e-4 (unfavourable) Expressed in all Mixed epididymis: 51.4 AGPAT2 BSCL, LPAAT-beta ENSG00000169692 1-acylglycerol-3-phosphate O-acyltransferase 2 9 136673143-136687423 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA019544 Uncertain Approved Centrosome Expressed in all Expressed in all adipose tissue: 299.8 AGPAT4 dJ473J16.2, LPAAT-delta ENSG00000026652 1-acylglycerol-3-phosphate O-acyltransferase 4 6 161129979-161274061 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053287, HPA060525 Approved Approved Nucleoli
Golgi apparatus
Vesicles Cervical cancer:1.45e-4 (unfavourable), Renal cancer:4.08e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 24.8 placenta: 12.2 AGPAT5 FLJ11210, LPAAT-e, LPAAT-epsilon ENSG00000155189 1-acylglycerol-3-phosphate O-acyltransferase 5 8 6708357-6759666 Enzymes, Predicted membrane proteins Evidence at protein level HPA010644, HPA010950 Approved Liver cancer:4.57e-4 (unfavourable), Colorectal cancer:8.82e-4 (favourable) Expressed in all Expressed in all testis: 46.7 AGTR1 AG2S, AGTR1A, AGTR1B, AT1, AT1B, AT2R1, AT2R1A, AT2R1B, HAT1R ENSG00000144891 Angiotensin II receptor, type 1 3 148697784-148743008 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003596 Supported Uncertain Vesicles Group enriched Tissue enhanced placenta: 212.0 liver: 50.8 AGTRAP ATRAP ENSG00000177674 Angiotensin II receptor-associated protein 1 11736084-11754802 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA044120 Approved Supported Vesicles Liver cancer:6.57e-7 (unfavourable) Expressed in all Expressed in all prostate: 88.0 AIFM1 AIF, CMTX4, NAMSD, PDCD8 ENSG00000156709 Apoptosis-inducing factor, mitochondrion-associated, 1 X 130129362-130165887 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB003764, HPA030611 Supported Renal cancer:4.42e-10 (favourable) Expressed in all Expressed in all kidney: 156.9 AIG1 AIG-1, dJ95L4.1, FLJ10485 ENSG00000146416 Androgen-induced 1 6 143060496-143340304 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060766 Approved Approved Golgi apparatus Head and neck cancer:3.25e-7 (unfavourable), Cervical cancer:3.26e-6 (unfavourable), Endometrial cancer:3.06e-4 (unfavourable) Expressed in all Expressed in all liver: 153.9 AKAP1 AKAP121, AKAP149, AKAP84, D-AKAP1, PPP1R43, PRKA1, S-AKAP84, SAKAP84, TDRD17 ENSG00000121057 A kinase (PRKA) anchor protein 1 17 57085092-57121349 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008620, HPA008691, CAB019286 Supported Supported Mitochondria Renal cancer:7.86e-9 (favourable) Expressed in all Expressed in all testis: 149.4 AKAP6 ADAP6, AKAP100, KIAA0311, mAKAP, PRKA6 ENSG00000151320 A kinase (PRKA) anchor protein 6 14 32329273-32837681 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001983, HPA048741 Supported Mixed Tissue enhanced cerebral cortex: 49.1;heart muscle: 37.3 skeletal muscle: 16.6 AKAP9 AKAP350, AKAP450, CG-NAP, HYPERION, KIAA0803, LQT11, MU-RMS-40.16A, PPP1R45, PRKA9, YOTIAO ENSG00000127914 A kinase (PRKA) anchor protein 9 7 91940867-92110673 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008548, CAB012909, HPA026109 Supported Validated Golgi apparatus
Vesicles
Centrosome Renal cancer:2.10e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 37.2 AL021546.6 ENSG00000111780 12 120438198-120460006 Predicted intracellular proteins Evidence at protein level HPA062394 Uncertain Approved Mitochondria Not detected Tissue enhanced colon: 1.0 cerebral cortex,spleen: 0.6 ALCAM CD166, MEMD ENSG00000170017 Activated leukocyte cell adhesion molecule 3 105366909-105576900 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002148, HPA010926 Approved Renal cancer:3.15e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 462.8 lung: 111.3 ALDH3A2 ALDH10, ALDH3A2, FALDH , SLS ENSG00000072210 Aldehyde dehydrogenase 3 family, member A2 17 19648136-19677598 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014769, CAB020692 Approved Renal cancer:3.85e-8 (favourable) Expressed in all Expressed in all adrenal gland: 179.9 ALDH3B2 ALDH8 ENSG00000132746 Aldehyde dehydrogenase 3 family, member B2 11 67662162-67681200 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045132 Approved Mixed Group enriched 5 breast: 88.2;esophagus: 103.8;skin: 122.4 tonsil: 19.7 ALG1 HMAT1, HMT-1 ENSG00000033011 ALG1, chitobiosyldiphosphodolichol beta-mannosyltransferase 16 5033960-5087379 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060392 Approved Approved Nucleoli fibrillar center
Endoplasmic reticulum Colorectal cancer:5.79e-4 (favourable), Testis cancer:6.93e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 32.8 ALG10 ALG10A, DIE2, FLJ14751 ENSG00000139133 ALG10, alpha-1,2-glucosyltransferase 12 34022281-34029694 Enzymes, Predicted membrane proteins Evidence at protein level HPA043329, HPA063387 Approved Approved Endoplasmic reticulum Mixed Mixed parathyroid gland: 4.6 ALG10B KCR1 ENSG00000175548 ALG10B, alpha-1,2-glucosyltransferase 12 38316578-38329728 Enzymes, Predicted membrane proteins Evidence at protein level HPA043329, HPA063387 Approved Approved Endoplasmic reticulum Mixed Mixed parathyroid gland: 7.6 ALG11 KIAA0266 ENSG00000253710 ALG11, alpha-1,2-mannosyltransferase 13 52012398-52029664 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047214 Approved Mixed Expressed in all thyroid gland: 23.4 ALG12 ECM39 ENSG00000182858 ALG12, alpha-1,6-mannosyltransferase 22 49900229-49918458 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003076, HPA051665 Approved Approved Endoplasmic reticulum Renal cancer:3.60e-5 (favourable), Endometrial cancer:6.09e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.1 ALG2 CDGIi, FLJ14511, hALPG2, NET38 ENSG00000119523 ALG2, alpha-1,3/1,6-mannosyltransferase 9 99216426-99221956 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041512, HPA041601 Approved Validated Actin filaments
Cytosol Renal cancer:2.28e-7 (favourable), Endometrial cancer:8.44e-5 (favourable), Head and neck cancer:1.56e-4 (unfavourable) Expressed in all Expressed in all epididymis: 75.8 ALG3 CDGS4, D16Ertd36e, Not56, NOT56L ENSG00000214160 ALG3, alpha-1,3- mannosyltransferase 3 184242301-184249548 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA045103 Approved Liver cancer:1.58e-5 (unfavourable), Lung cancer:8.67e-5 (unfavourable), Renal cancer:1.25e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 32.7 ALG6 ENSG00000088035 ALG6, alpha-1,3-glucosyltransferase 1 63367590-63438562 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA062536 Supported Endoplasmic reticulum Renal cancer:2.63e-6 (unfavourable), Colorectal cancer:4.86e-4 (favourable), Liver cancer:9.46e-4 (unfavourable) Expressed in all Mixed placenta: 11.8 ALG8 MGC2840 ENSG00000159063 ALG8, alpha-1,3-glucosyltransferase 11 78100936-78139660 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA051898 Approved Approved Nucleoplasm Expressed in all Expressed in all testis: 85.6 ALG9 DIBD1 ENSG00000086848 ALG9, alpha-1,2-mannosyltransferase 11 111782195-111871581 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA038575 Approved Approved Endoplasmic reticulum Renal cancer:7.29e-5 (unfavourable) Expressed in all Expressed in all testis: 25.3 ALK CD246 ENSG00000171094 Anaplastic lymphoma receptor tyrosine kinase 2 29192774-29921566 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010694 Approved Supported Plasma membrane Group enriched Tissue enhanced cerebral cortex: 3.5;testis: 2.3 adrenal gland: 0.9 ALOX5AP FLAP ENSG00000132965 Arachidonate 5-lipoxygenase-activating protein 13 30713478-30764426 Disease related genes, Predicted membrane proteins Evidence at protein level HPA026592 Supported Renal cancer:5.68e-4 (unfavourable), Ovarian cancer:6.44e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 302.3 ALPK1 FLJ22670, KIAA1527, Lak ENSG00000073331 Alpha-kinase 1 4 112285509-112442620 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA027435, HPA027443 Approved Approved Centrosome Renal cancer:5.82e-7 (unfavourable), Urothelial cancer:1.17e-4 (favourable) Expressed in all Mixed parathyroid gland: 9.2 ALS2CL DKFZp686I0110, FLJ36525, RN49018 ENSG00000178038 ALS2 C-terminal like 3 46668997-46693704 Predicted intracellular proteins Evidence at protein level CAB046465, HPA048301 Uncertain Endometrial cancer:8.10e-4 (unfavourable) Expressed in all Tissue enhanced skin: 51.4 esophagus: 23.9 AMACR RACE ENSG00000242110 Alpha-methylacyl-CoA racemase 5 33986178-34008108 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB001809, HPA019527, HPA020912 Supported Supported Vesicles
Plasma membrane Colorectal cancer:7.11e-4 (favourable) Expressed in all Expressed in all kidney: 134.0 AMDHD1 MGC35366 ENSG00000139344 Amidohydrolase domain containing 1 12 95943293-95968716 Enzymes, Predicted intracellular proteins Evidence at protein level HPA039720 Approved Approved Plasma membrane
Actin filaments
Focal adhesion sites Tissue enriched Tissue enhanced testis: 27.1 liver: 22.4 AMFR gp78, RNF45 ENSG00000159461 Autocrine motility factor receptor, E3 ubiquitin protein ligase 16 56361452-56425538 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026381, HPA029018, HPA077835 Approved Supported Endoplasmic reticulum
Golgi apparatus Expressed in all Expressed in all testis: 154.3 AMHR2 MISR2, MISRII ENSG00000135409 Anti-Mullerian hormone receptor, type II 12 53423855-53431534 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060228, HPA069636 Approved Vesicles Tissue enhanced Tissue enhanced adrenal gland: 32.2;ovary: 40.8 testis: 10.1 AMICA1 AMICA, Gm638 ENSG00000160593 Adhesion molecule, interacts with CXADR antigen 1 11 118193740-118225094 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047919 Approved Head and neck cancer:3.11e-4 (favourable), Lung cancer:3.92e-4 (favourable) Mixed Tissue enhanced appendix: 84.3 spleen: 68.0 AMIGO1 AMIGO, KIAA1163 ENSG00000181754 Adhesion molecule with Ig-like domain 1 1 109504175-109509738 Predicted membrane proteins Evidence at protein level HPA046152 Approved Approved Nucleoplasm
Nuclear bodies Liver cancer:1.21e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 24.1 AMIGO2 ALI1, DEGA ENSG00000139211 Adhesion molecule with Ig-like domain 2 12 47075707-47079951 Predicted membrane proteins Evidence at protein level HPA054004, HPA059601 Uncertain Approved Golgi apparatus
Plasma membrane
Cytosol Pancreatic cancer:1.80e-4 (unfavourable) Expressed in all Mixed smooth muscle: 54.4 AMIGO3 ENSG00000176020 Adhesion molecule with Ig-like domain 3 3 49716834-49719695 Predicted membrane proteins Evidence at transcript level HPA026673 Uncertain Not detected Mixed skeletal muscle: 1.0 AMN amnionless ENSG00000166126 Amnion associated transmembrane protein 14 102922656-102933596 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000817 Approved Renal cancer:9.62e-5 (favourable) Mixed Group enriched 6 colon: 20.4;duodenum: 35.1;kidney: 29.0;small intestine: 72.0 liver,stomach: 6.8 ANAPC1 APC1, MCPR, TSG24 ENSG00000153107 Anaphase promoting complex subunit 1 2 111766271-111884690 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036329, HPA036330, HPA042998 Approved Approved Vesicles Endometrial cancer:1.34e-4 (unfavourable) Expressed in all Expressed in all testis: 20.3 ANKAR FLJ25415 ENSG00000151687 Ankyrin and armadillo repeat containing 2 189674290-189761193 Predicted intracellular proteins Evidence at transcript level HPA036168 Uncertain Approved Nucleus
Microtubule organizing center Mixed Tissue enriched 7 testis: 10.2 parathyroid gland: 1.4 ANKH ANK, CCAL2, CMDJ, CPPDD, HANK ENSG00000154122 ANKH inorganic pyrophosphate transport regulator 5 14704804-14871778 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA068104 Approved Cytosol Glioma:7.64e-4 (unfavourable) Expressed in all Expressed in all prostate: 49.5 ANKLE1 ANKRD41, FLJ39369, LEMD6 ENSG00000160117 Ankyrin repeat and LEM domain containing 1 19 17281645-17287646 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026789, HPA073498 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:4.86e-5 (unfavourable) Mixed Tissue enhanced bone marrow: 13.8 lymph node: 3.7 ANKLE2 KIAA0692, Lem4, LEMD7 ENSG00000176915 Ankyrin repeat and LEM domain containing 2 12 132725503-132761888 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003602, HPA074838 Uncertain Supported Endoplasmic reticulum
Plasma membrane Renal cancer:1.90e-8 (unfavourable), Liver cancer:3.97e-6 (unfavourable) Expressed in all Expressed in all testis: 80.1 ANKRD22 MGC22805 ENSG00000152766 Ankyrin repeat domain 22 10 88822132-88851818 Predicted intracellular proteins Evidence at protein level HPA012922 Approved Approved Nucleus Endometrial cancer:8.73e-6 (favourable), Pancreatic cancer:6.15e-4 (unfavourable) Expressed in all Tissue enhanced skin: 38.6;stomach: 48.9 esophagus: 27.1 ANKRD29 FLJ25053 ENSG00000154065 Ankyrin repeat domain 29 18 23598926-23662885 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041272, HPA049419 Uncertain Approved Nucleoplasm
Nuclear bodies Head and neck cancer:1.92e-5 (favourable), Lung cancer:5.98e-5 (favourable), Renal cancer:7.20e-5 (favourable) Mixed Mixed lung: 47.5 ANKRD42 FLJ37874, PPP1R79, SARP ENSG00000137494 Ankyrin repeat domain 42 11 83193739-83260694 Predicted intracellular proteins Evidence at protein level HPA039917 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Expressed in all Tissue enhanced testis: 71.7 epididymis: 28.4 ANKRD46 ENSG00000186106 Ankyrin repeat domain 46 8 100509752-100559784 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013758 Approved Approved Cytosol Expressed in all Expressed in all cerebral cortex: 70.6 ANO1 DOG1, FLJ10261, ORAOV2, TAOS2, TMEM16A ENSG00000131620 Anoctamin 1, calcium activated chloride channel 11 70078302-70189528 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032148 Supported Renal cancer:4.09e-6 (unfavourable), Endometrial cancer:4.58e-6 (favourable), Head and neck cancer:7.28e-5 (unfavourable), Pancreatic cancer:1.70e-4 (unfavourable), Lung cancer:2.40e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 217.7;seminal vesicle: 295.7 skin: 116.0 ANO10 FLJ10375, MGC47890, SCAR10, TMEM16K ENSG00000160746 Anoctamin 10 3 43354859-43691594 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051569 Approved Renal cancer:6.41e-6 (favourable), Endometrial cancer:1.11e-4 (favourable), Liver cancer:3.19e-4 (unfavourable), Colorectal cancer:6.70e-4 (favourable) Expressed in all Expressed in all duodenum: 64.3 ANO2 C12orf3, TMEM16B ENSG00000047617 Anoctamin 2, calcium activated chloride channel 12 5531869-5946232 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036276 Supported Nucleoplasm
Plasma membrane Tissue enhanced Tissue enhanced testis: 17.7 placenta: 5.9 ANO3 C11orf25, DYT23, GENX-3947, TMEM16C ENSG00000134343 Anoctamin 3 11 26309599-26663288 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041629 Uncertain Not detected Tissue enriched 6 epididymis: 61.3 cerebral cortex: 10.6 ANO4 FLJ34221, FLJ34272, FLJ35277, TMEM16D ENSG00000151572 Anoctamin 4 12 100717526-101128641 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA053412 Uncertain Renal cancer:5.48e-5 (favourable) Mixed Group enriched 6 adrenal gland: 17.6;cerebral cortex: 10.0;cervix, uterine: 12.5;endometrium: 8.3;ovary: 10.9;prostate: 10.9;seminal vesicle: 11.3 testis: 2.0 ANO5 GDD1, LGMD2L, TMEM16E ENSG00000171714 Anoctamin 5 11 22193176-22283357 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA058857 Uncertain Renal cancer:2.50e-7 (favourable) Mixed Tissue enhanced parathyroid gland: 55.2 skeletal muscle: 23.6 ANO6 DKFZp313M0720, TMEM16F ENSG00000177119 Anoctamin 6 12 45215987-45440404 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038958 Approved Approved Plasma membrane
Cytosol Breast cancer:7.56e-5 (unfavourable), Cervical cancer:3.82e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 90.8 ANO7 IPCA-5, NGEP, PCANAP5, PCANAP5L, TMEM16G ENSG00000146205 Anoctamin 7 2 241188509-241225377 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035730 Uncertain Tissue enriched Tissue enhanced prostate: 86.9;stomach: 26.2 small intestine: 15.7 ANO8 KIAA1623, TMEM16H ENSG00000074855 Anoctamin 8 19 17323223-17334829 Predicted membrane proteins Evidence at protein level HPA031787, HPA049206 Uncertain Uncertain Nucleoplasm
Nucleoli fibrillar center Expressed in all Tissue enhanced cerebral cortex: 34.6 skin: 20.0 ANO9 PIG5, TMEM16J, TP53I5 ENSG00000185101 Anoctamin 9 11 417933-442011 Predicted membrane proteins, Transporters Evidence at protein level HPA039948, HPA040112 Approved Uncertain Golgi apparatus Urothelial cancer:8.81e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 32.4;small intestine: 31.6 skin: 21.6 ANPEP CD13, gp150, LAP1, p150, PEPN ENSG00000166825 Alanyl (membrane) aminopeptidase 15 89784889-89815401 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002417, HPA004625 Supported Supported Nucleus
Plasma membrane Expressed in all Group enriched 9 duodenum: 2451.4;small intestine: 2177.9 colon: 263.9 ANTXR1 ATR, FLJ10601, FLJ21776, TEM8 ENSG00000169604 Anthrax toxin receptor 1 2 69013178-69249327 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA052046, HPA054785 Uncertain Uncertain Vesicles Thyroid cancer:1.22e-5 (unfavourable), Cervical cancer:5.76e-4 (unfavourable) Expressed in all Mixed gallbladder: 180.9 AP000322.53 ENSG00000243627 21 34418715-34423966 Predicted membrane proteins Evidence at transcript level HPA029085 Uncertain Not detected Group enriched 6 breast: 3.3;fallopian tube: 3.2;kidney: 8.7 epididymis: 0.9 AP000350.10 ENSG00000251357 22 23862188-23895223 Predicted membrane proteins Evidence at transcript level HPA042960 Uncertain Not detected Not detected adrenal gland: 0.5 AP1M1 AP47, CLAPM2 ENSG00000072958 Adaptor-related protein complex 1, mu 1 subunit 19 16197578-16245907 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA045256 Uncertain Renal cancer:1.75e-4 (unfavourable) Expressed in all Expressed in all testis: 96.4 APCDD1L FLJ90166 ENSG00000198768 Adenomatosis polyposis coli down-regulated 1-like 20 58459101-58515131 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067015 Uncertain Uncertain Mitochondria Mixed Tissue enhanced breast: 6.5;salivary gland: 11.7 kidney: 2.9 APEH D3F15S2, D3S48E, DNF15S2 ENSG00000164062 Acylaminoacyl-peptide hydrolase 3 49674002-49683963 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA029700, HPA029701, HPA029702, HPA029703 Supported Validated Cytosol Renal cancer:3.32e-10 (favourable) Expressed in all Expressed in all parathyroid gland: 99.6 APH1A APH-1A, CGI-78 ENSG00000117362 APH1A gamma secretase subunit 1 150265399-150269580 Predicted membrane proteins Evidence at protein level CAB037272 Approved Expressed in all Expressed in all thyroid gland: 160.6 APLF C2orf13, MGC47799, Xip1, ZCCHH1 ENSG00000169621 Aprataxin and PNKP like factor 2 68467561-68655862 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029396, HPA034642, HPA034643 Approved Supported Nucleoplasm Mixed Mixed skin: 3.3 APLNR AGTRL1, APJ, APJR, FLJ90771 ENSG00000134817 Apelin receptor 11 57233577-57237314 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB025842 Approved Expressed in all Group enriched 5 cerebral cortex: 82.9;placenta: 145.6;spleen: 164.2 adipose tissue: 24.9 APLP1 APLP ENSG00000105290 Amyloid beta (A4) precursor-like protein 1 19 35867899-35879791 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028970, HPA028971 Supported Urothelial cancer:2.65e-5 (unfavourable), Endometrial cancer:3.87e-4 (unfavourable) Tissue enhanced Tissue enriched 13 cerebral cortex: 441.8 adrenal gland: 34.6 APLP2 APPH, APPL2 ENSG00000084234 Amyloid beta (A4) precursor-like protein 2 11 130069837-130144811 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039319 Approved Approved Vesicles Renal cancer:1.33e-9 (favourable), Thyroid cancer:2.90e-4 (favourable), Liver cancer:3.37e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 1052.3 APMAP BSCv, C20orf3 ENSG00000101474 Adipocyte plasma membrane associated protein 20 24962925-24992979 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012863, HPA064700 Uncertain Approved Plasma membrane Expressed in all Expressed in all thyroid gland: 322.5 APOA2 ENSG00000158874 Apolipoprotein A-II 1 161222292-161223631 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025885 Supported Tissue enriched Tissue enriched 1053 liver: 18141.3 bone marrow: 17.2 APOC4-APOC2 ENSG00000224916 APOC4-APOC2 readthrough (NMD candidate) 19 44942238-44949565 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055877 Supported Tissue enriched Tissue enriched 61 liver: 4036.7 small intestine: 66.2 APOL1 APOL ENSG00000100342 Apolipoprotein L, 1 22 36253010-36267530 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018885, CAB056156 Supported Renal cancer:7.43e-6 (unfavourable), Urothelial cancer:2.01e-5 (favourable), Lung cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all liver: 116.0 APOL2 APOL-II ENSG00000128335 Apolipoprotein L, 2 22 36226203-36239954 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001078 Uncertain Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:1.22e-7 (unfavourable), Urothelial cancer:5.06e-6 (favourable) Expressed in all Expressed in all gallbladder: 65.0 APOL4 APOLIV ENSG00000100336 Apolipoprotein L, 4 22 36189124-36204840 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049797, HPA055435 Approved Supported Vesicles Urothelial cancer:2.40e-6 (favourable), Renal cancer:2.00e-5 (unfavourable), Ovarian cancer:3.45e-4 (favourable) Expressed in all Tissue enhanced prostate: 27.8 lung: 19.8 APOL6 APOL-VI, APOLVI ENSG00000221963 Apolipoprotein L, 6 22 35648395-35668409 Predicted membrane proteins Evidence at protein level CAB028574, HPA029165, HPA029167 Approved Supported Nucleoplasm
Nuclear bodies
Cytosol Urothelial cancer:6.61e-4 (favourable) Expressed in all Mixed spleen: 25.5 APOLD1 DKFZP434F0318, FLJ25138 ENSG00000178878 Apolipoprotein L domain containing 1 12 12725917-12829975 Predicted membrane proteins Evidence at protein level HPA052462, HPA058882 Approved Validated Nucleoplasm
Cytosol Expressed in all Tissue enhanced adipose tissue: 142.0 placenta: 121.8 APOO FAM121B, MGC4825, Mic23, MIC26, My025 ENSG00000184831 Apolipoprotein O X 23833353-23907934 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003187 Supported Approved Mitochondria
Cytosol Renal cancer:2.56e-6 (favourable), Cervical cancer:3.77e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 50.9 APP AD1 ENSG00000142192 Amyloid beta (A4) precursor protein 21 25880550-26171128 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000157, HPA001462 Supported Approved Golgi apparatus
Vesicles Renal cancer:2.79e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 1206.8 AQP1 CHIP28, CO ENSG00000240583 Aquaporin 1 (Colton blood group) 7 30911855-30925516 Blood group antigen proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001707, HPA019206 Supported Supported Plasma membrane Renal cancer:1.32e-8 (favourable), Head and neck cancer:6.52e-4 (favourable) Expressed in all Expressed in all kidney: 801.2 AQP10 ENSG00000143595 Aquaporin 10 1 154321090-154325325 Predicted membrane proteins, Transporters Evidence at protein level HPA065947 Supported Not detected Group enriched 8 duodenum: 70.3;small intestine: 50.1 fallopian tube: 7.1 AQP11 ENSG00000178301 Aquaporin 11 11 77589391-77610355 Predicted membrane proteins, Transporters Evidence at protein level HPA042879 Approved Approved Nucleoplasm
Vesicles Ovarian cancer:9.89e-4 (favourable) Mixed Tissue enhanced duodenum: 24.8;small intestine: 23.6 adrenal gland: 10.1 AQP12A AQP12 ENSG00000184945 Aquaporin 12A 2 240691845-240698483 Predicted membrane proteins, Transporters Evidence at protein level HPA042216 Supported Not detected Tissue enriched 67 pancreas: 27.7 duodenum,small intestine: 0.4 AQP12B INSSA3 ENSG00000185176 Aquaporin 12B 2 240676418-240682906 Predicted membrane proteins Evidence at protein level HPA042216 Supported Not detected Tissue enriched 56 pancreas: 35.7 duodenum: 0.6 AQP2 ENSG00000167580 Aquaporin 2 (collecting duct) 12 49950741-49958881 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046834 Supported Group enriched Group enriched 93 kidney: 432.9;seminal vesicle: 299.3 prostate: 3.9 AQP3 GIL ENSG00000165272 Aquaporin 3 (Gill blood group) 9 33441154-33447611 Blood group antigen proteins, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014924 Supported Supported Nucleus
Plasma membrane Cervical cancer:5.31e-4 (favourable) Expressed in all Expressed in all esophagus: 975.2 AQP4 MIWC ENSG00000171885 Aquaporin 4 18 26852038-26865818 Predicted membrane proteins, Transporters Evidence at protein level CAB005079, HPA014784, CAB058689 Supported Supported Supported Plasma membrane
Cell Junctions Tissue enriched Group enriched 17 cerebral cortex: 631.8;lung: 172.2 thyroid gland: 24.3 AQP5 ENSG00000161798 Aquaporin 5 12 49961870-49965681 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA065008 Supported Approved Plasma membrane Head and neck cancer:1.75e-5 (favourable) Tissue enhanced Group enriched 8 salivary gland: 257.1;stomach: 54.0;testis: 176.5 breast: 21.0 AQP6 AQP2L ENSG00000086159 Aquaporin 6, kidney specific 12 49967194-49977139 Predicted membrane proteins, Transporters Evidence at protein level HPA015278 Supported Tissue enriched Tissue enriched 9 kidney: 20.8 cerebral cortex: 2.3 AQP8 ENSG00000103375 Aquaporin 8 16 25215731-25228940 Predicted membrane proteins, Transporters Evidence at protein level HPA046259 Approved Group enriched Group enriched 132 colon: 325.1;pancreas: 269.4;rectum: 169.2 smooth muscle: 1.9 AQR fSAP164, IBP160, KIAA0560 ENSG00000021776 Aquarius intron-binding spliceosomal factor 15 34851782-34969839 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040624, HPA055647 Validated Nucleoplasm Renal cancer:4.83e-4 (favourable) Expressed in all Mixed testis: 10.1 AR AIS, DHTR, HUMARA, NR3C4, SBMA, SMAX1 ENSG00000169083 Androgen receptor X 67544032-67730619 Cancer-related genes, Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000001, HPA065701, CAB065764 Supported Approved Mitochondria Renal cancer:1.03e-8 (favourable), Liver cancer:8.77e-4 (favourable) Mixed Mixed fallopian tube: 42.6 AREG AREGB, SDGF ENSG00000109321 Amphiregulin 4 74445134-74455009 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA008720, CAB023519 Approved Approved Mitochondria Lung cancer:1.05e-5 (unfavourable), Head and neck cancer:2.61e-5 (unfavourable), Pancreatic cancer:8.32e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 461.0 gallbladder: 120.0 AREL1 KIAA0317 ENSG00000119682 Apoptosis resistant E3 ubiquitin protein ligase 1 14 74653437-74713115 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051306 Uncertain Renal cancer:4.67e-6 (favourable) Expressed in all Expressed in all testis: 33.7 ARFGEF3 BIG3, C6orf92, dJ171N11.1, KIAA1244, PPP1R33 ENSG00000112379 ARFGEF family member 3 6 138161921-138344663 Predicted intracellular proteins Evidence at protein level HPA036350 Uncertain Breast cancer:8.20e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 23.7;parathyroid gland: 29.2 prostate: 19.3 ARHGAP1 CDC42GAP, p50rhoGAP, RhoGAP ENSG00000175220 Rho GTPase activating protein 1 11 46677080-46700615 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004689, HPA008285 Approved Approved Supported Vesicles Liver cancer:2.14e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 114.7 ARHGAP26 GRAF, KIAA0621, OPHN1L, OPHN1L1 ENSG00000145819 Rho GTPase activating protein 26 5 142770384-143229011 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035106, HPA035107 Approved Approved Cytosol Urothelial cancer:2.88e-6 (favourable), Endometrial cancer:5.93e-6 (favourable), Cervical cancer:1.36e-4 (favourable), Breast cancer:2.05e-4 (favourable), Colorectal cancer:6.95e-4 (favourable) Expressed in all Mixed cerebral cortex: 30.9 ARHGAP35 GRF-1, GRLF1, KIAA1722, P190A, p190ARhoGAP, p190RhoGAP ENSG00000160007 Rho GTPase activating protein 35 19 46918676-47005077 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB037311, HPA055184, HPA056470 Approved Supported Nuclear bodies
Aggresome Renal cancer:5.55e-8 (favourable) Expressed in all Expressed in all testis: 96.5 ARHGAP4 C1, KIAA0131, p115, RhoGAP4, SrGAP4 ENSG00000089820 Rho GTPase activating protein 4 X 153907367-153934999 Predicted intracellular proteins Evidence at protein level HPA001012, HPA001083 Supported Approved Nucleoplasm
Focal adhesion sites Colorectal cancer:1.97e-5 (unfavourable), Cervical cancer:3.94e-5 (favourable), Renal cancer:2.49e-4 (unfavourable), Head and neck cancer:3.31e-4 (favourable) Expressed in all Tissue enhanced spleen: 96.8 lymph node: 88.6 ARHGEF1 LBCL2, P115-RHOGEF, SUB1.5 ENSG00000076928 Rho guanine nucleotide exchange factor (GEF) 1 19 41883161-41930150 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009502, HPA012924, HPA060784 Supported Validated Plasma membrane
Cytosol Renal cancer:3.36e-8 (unfavourable), Breast cancer:5.92e-4 (favourable) Expressed in all Expressed in all lymph node: 147.0 ARHGEF10 Gef10, KIAA0294 ENSG00000104728 Rho guanine nucleotide exchange factor (GEF) 10 8 1823976-1958641 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024649 Approved Approved Nucleoplasm Mixed Mixed testis: 16.5 ARL10 ARL10A ENSG00000175414 ADP-ribosylation factor-like 10 5 176365468-176401865 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047044 Approved Mixed Mixed skin: 17.0 ARL6IP1 AIP1, ARL6IP, ARMER, KIAA0069, SPG61 ENSG00000170540 ADP-ribosylation factor-like 6 interacting protein 1 16 18791667-18801678 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045307 Uncertain Approved Endoplasmic reticulum Expressed in all Expressed in all cerebral cortex: 388.0 ARL6IP5 DERP11, GTRAP3-18, HSPC127, JWA, PRAF3 ENSG00000144746 ADP-ribosylation factor-like 6 interacting protein 5 3 69084944-69106066 Predicted membrane proteins Evidence at protein level HPA015540, CAB019321 Supported Approved Endoplasmic reticulum Expressed in all Expressed in all prostate: 217.5 ARL6IP6 MGC33864 ENSG00000177917 ADP-ribosylation factor-like 6 interacting protein 6 2 152717893-152761253 Predicted membrane proteins Evidence at protein level HPA014743 Approved Approved Nuclear membrane
Cytosol Liver cancer:1.73e-4 (unfavourable), Renal cancer:2.14e-4 (unfavourable) Expressed in all Mixed placenta: 7.5 ARMC10 MGC3195, SVH ENSG00000170632 Armadillo repeat containing 10 7 103074881-103099764 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011036, HPA011057 Supported Supported Mitochondria Pancreatic cancer:2.49e-6 (unfavourable), Glioma:6.98e-6 (unfavourable), Liver cancer:3.58e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 25.5 ARMCX2 ALEX2, GASP9, KIAA0512 ENSG00000184867 Armadillo repeat containing, X-linked 2 X 101655281-101659891 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA005761 Supported Approved Nucleus
Mitochondria Pancreatic cancer:3.45e-5 (favourable), Stomach cancer:2.69e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 199.2 thyroid gland: 107.0 ARMCX3 ALEX3, GASP6 ENSG00000102401 Armadillo repeat containing, X-linked 3 X 101622797-101627843 Predicted membrane proteins Evidence at protein level HPA000325, HPA000967, HPA001530 Uncertain Approved Nucleoplasm
Golgi apparatus
Cytosol Renal cancer:1.55e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 165.0 ARMCX4 CXorf35, GASP4, MGC40053 ENSG00000196440 Armadillo repeat containing, X-linked 4 X 101418287-101533459 Predicted intracellular proteins Evidence at protein level HPA000429, HPA051930 Uncertain Approved Nucleoplasm
Vesicles Pancreatic cancer:8.20e-5 (favourable) Mixed Mixed parathyroid gland: 14.1 ARMCX6 FLJ20811, GASP10 ENSG00000198960 Armadillo repeat containing, X-linked 6 X 101615118-101618001 Predicted membrane proteins Evidence at protein level HPA043030, HPA048125 Approved Supported Nucleus
Nuclear membrane
Cytosol Expressed in all Expressed in all parathyroid gland: 33.6 ARSD ENSG00000006756 Arylsulfatase D X 2903970-2929351 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004694, HPA063835 Supported Approved Vesicles
Lipid droplets Renal cancer:1.97e-5 (favourable), Endometrial cancer:5.21e-4 (favourable) Expressed in all Mixed fallopian tube: 44.7 ARSE CDPX, CDPX1 ENSG00000157399 Arylsulfatase E (chondrodysplasia punctata 1) X 2934632-2968310 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA060518 Supported Golgi apparatus Colorectal cancer:8.95e-4 (favourable) Mixed Tissue enhanced kidney: 41.1;liver: 49.1 pancreas: 23.9 ARSF ENSG00000062096 Arylsulfatase F X 3041471-3112726 Predicted membrane proteins Evidence at protein level HPA000549 Uncertain Cytosol Tissue enhanced Group enriched 6 adrenal gland: 4.0;cerebral cortex: 2.1;epididymis: 2.1;esophagus: 2.3;kidney: 8.0;skin: 6.7 liver,urinary bladder: 0.6 ARSJ FLJ23548 ENSG00000180801 Arylsulfatase family, member J 4 113900284-113979727 Predicted intracellular proteins Evidence at protein level HPA036481, HPA036482 Uncertain Supported Nucleoli
Actin filaments Renal cancer:2.97e-6 (favourable), Head and neck cancer:6.08e-4 (unfavourable) Mixed Mixed parathyroid gland: 12.5 ART1 ART2, CD296 ENSG00000129744 ADP-ribosyltransferase 1 11 3645128-3664416 CD markers, Enzymes, Predicted membrane proteins Evidence at transcript level HPA051148 Uncertain Not detected Tissue enriched 21 skeletal muscle: 16.4 esophagus: 0.7 ART3 ENSG00000156219 ADP-ribosyltransferase 3 4 76011184-76112802 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011268 Supported Tissue enhanced Tissue enhanced skeletal muscle: 77.0;testis: 173.4 heart muscle: 33.4 ART4 CD297, DO, DOK1 ENSG00000111339 ADP-ribosyltransferase 4 (Dombrock blood group) 12 14825569-14843495 Blood group antigen proteins, CD markers, Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA075664 Uncertain Rods & Rings Tissue enhanced Tissue enhanced liver: 27.1;spleen: 27.3 gallbladder: 15.2 ARTN ENOVIN, EVN, NBN ENSG00000117407 Artemin 1 43933320-43937241 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA060012 Uncertain Mitochondria Ovarian cancer:8.18e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 21.3 seminal vesicle: 12.0 ARV1 ENSG00000173409 ARV1 homolog, fatty acid homeostasis modulator 1 230978981-231000595 Predicted membrane proteins, Transporters Evidence at protein level HPA035709 Approved Approved Vesicles Lung cancer:3.27e-5 (favourable), Colorectal cancer:1.33e-4 (favourable) Expressed in all Expressed in all testis: 61.6 ASAH2 ENSG00000188611 N-acylsphingosine amidohydrolase (non-lysosomal ceramidase) 2 10 50182778-50248610 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA061171 Supported Approved Focal adhesion sites Mixed Group enriched 18 duodenum: 85.8;small intestine: 72.9 stomach: 4.4 ASB11 DKFZp779E2460 ENSG00000165192 Ankyrin repeat and SOCS box containing 11, E3 ubiquitin protein ligase X 15281697-15315656 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000238 Uncertain Tissue enriched Group enriched 6 heart muscle: 27.2;skeletal muscle: 42.1 stomach: 5.6 ASB18 ENSG00000182177 Ankyrin repeat and SOCS box containing 18 2 236194872-236264409 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA068447 Approved Not detected Group enriched 7 heart muscle: 3.9;skeletal muscle: 3.6;testis: 1.0 cerebral cortex: 0.4 ASB5 ENSG00000164122 Ankyrin repeat and SOCS box containing 5 4 176213673-176277571 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA028870 Uncertain Plasma membrane Head and neck cancer:5.67e-4 (unfavourable) Tissue enhanced Tissue enhanced skeletal muscle: 75.7 prostate: 18.1 ASGR1 CLEC4H1 ENSG00000141505 Asialoglycoprotein receptor 1 17 7173431-7179564 Predicted intracellular proteins Evidence at protein level HPA011954, HPA012852 Supported Supported Vesicles
Cell Junctions Tissue enriched Tissue enriched 13 liver: 236.1 testis: 17.7 ASGR2 CLEC4H2 ENSG00000161944 Asialoglycoprotein receptor 2 17 7101322-7115700 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014899, HPA015998 Supported Supported Endoplasmic reticulum
Plasma membrane Tissue enriched Tissue enriched 11 liver: 317.4 gallbladder: 28.1 ASIC1 ACCN2, BNaC2, hBNaC2 ENSG00000110881 Acid sensing (proton gated) ion channel 1 12 50057548-50083611 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA058870 Approved Golgi apparatus
Plasma membrane Tissue enhanced Tissue enriched 10 cerebral cortex: 57.0 parathyroid gland: 5.5 ASIC2 ACCN, ACCN1, ASIC2a, BNaC1, BNC1, hBNaC1, MDEG ENSG00000108684 Acid sensing (proton gated) ion channel 2 17 33013087-34174964 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA052112 Approved Tissue enhanced Group enriched 6 cerebral cortex: 8.7;cervix, uterine: 3.9;endometrium: 6.4;smooth muscle: 2.1 adrenal gland: 0.8 ASIC3 ACCN3, DRASIC, TNaC1 ENSG00000213199 Acid sensing (proton gated) ion channel 3 7 151048292-151052756 Predicted membrane proteins Evidence at protein level HPA049155 Approved Approved Nucleoplasm
Cytosol Tissue enhanced Tissue enhanced testis: 8.1 cerebral cortex: 5.8 ASIC4 ACCN4, BNAC4 ENSG00000072182 Acid sensing (proton gated) ion channel family member 4 2 219514170-219538772 Predicted membrane proteins Evidence at protein level HPA036042 Approved Golgi apparatus Tissue enriched Tissue enriched 8 cerebral cortex: 10.6 adrenal gland: 1.3 ASIC5 ACCN5, HINAC, INAC ENSG00000256394 Acid sensing (proton gated) ion channel family member 5 4 155829729-155866273 Predicted membrane proteins Evidence at protein level HPA014903, HPA029444 Approved Not detected Group enriched 19 duodenum: 2.4;small intestine: 1.3 all non-specific tissues: 0.0 ASPH BAH, CASQ2BP1, HAAH, JCTN ENSG00000198363 Aspartate beta-hydroxylase 8 61500556-61714640 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055161, HPA059303 Uncertain Supported Endoplasmic reticulum Renal cancer:1.57e-5 (unfavourable), Cervical cancer:8.07e-5 (unfavourable), Pancreatic cancer:1.75e-4 (unfavourable), Lung cancer:3.61e-4 (unfavourable), Thyroid cancer:4.24e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 394.0 ASPHD1 ENSG00000174939 Aspartate beta-hydroxylase domain containing 1 16 29900375-29919864 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045175 Uncertain Pancreatic cancer:7.38e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 53.7 gallbladder: 11.9 ASPHD2 FLJ39838 ENSG00000128203 Aspartate beta-hydroxylase domain containing 2 22 26429273-26445015 Predicted membrane proteins Evidence at protein level HPA000820 Uncertain Renal cancer:4.06e-5 (unfavourable) Mixed Tissue enhanced cerebral cortex: 12.9 stomach: 7.9 ASPRV1 FLJ25084, SASPase, Taps ENSG00000244617 Aspartic peptidase, retroviral-like 1 2 69960089-69962265 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA034809, HPA034810 Supported Group enriched Tissue enriched 13 skin: 286.7 breast: 22.3 ASTN1 ASTN ENSG00000152092 Astrotactin 1 1 176857302-177164973 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074112 Approved Golgi apparatus
Vesicles Tissue enriched Group enriched 6 adrenal gland: 19.7;cerebral cortex: 67.0 ovary: 7.4 ASTN2 KIAA0634 ENSG00000148219 Astrotactin 2 9 116425225-117415070 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027035 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:6.66e-16 (favourable) Expressed in all Expressed in all prostate: 42.3 ASZ1 ALP1, ANKL1, C7orf7, CT1.19, GASZ, Orf3 ENSG00000154438 Ankyrin repeat, SAM and basic leucine zipper domain containing 1 7 117363222-117428123 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020558 Supported Approved Nucleoplasm
Cytosol Not detected Tissue enriched 195 testis: 19.5 all non-specific tissues: 0.0 ATAD1 FLJ14600 ENSG00000138138 ATPase family, AAA domain containing 1 10 87751512-87841343 Enzymes, Predicted membrane proteins Evidence at protein level HPA037569 Uncertain Approved Nucleus
Nucleoli
Mitochondria Renal cancer:3.98e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 28.5 ATCAY BNIP-H ENSG00000167654 Ataxia, cerebellar, Cayman type 19 3879864-3928079 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA017755 Supported Tissue enriched Tissue enriched 12 cerebral cortex: 109.9 adrenal gland: 8.9 ATF6 ATF6A ENSG00000118217 Activating transcription factor 6 1 161766294-161964070 Plasma proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA005935 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 40.6 ATF6B CREBL1, G13 ENSG00000213676 Activating transcription factor 6 beta 6 32098176-32128253 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA046871 Uncertain Supported Nucleus
Nucleoli Expressed in all Expressed in all parathyroid gland: 55.8 ATF7 ATFA ENSG00000170653 Activating transcription factor 7 12 53507856-53626410 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA003384 Approved Approved Nucleus
Cytosol Stomach cancer:2.10e-4 (unfavourable) Expressed in all Expressed in all endometrium: 40.1 ATG9A APG9L1, FLJ22169 ENSG00000198925 Autophagy related 9A 2 219209772-219229717 Predicted membrane proteins Evidence at protein level HPA059551 Uncertain Supported Vesicles Liver cancer:2.18e-5 (unfavourable) Expressed in all Expressed in all testis: 112.6 ATL1 AD-FSP, FSP1, SPG3, SPG3A ENSG00000198513 Atlastin GTPase 1 14 50532509-50633068 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027550 Approved Mixed Tissue enhanced cerebral cortex: 97.2 smooth muscle: 22.1 ATL2 ARL6IP2 ENSG00000119787 Atlastin GTPase 2 2 38294880-38377285 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029108 Approved Endometrial cancer:4.51e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 100.9 ATL3 DKFZP564J0863 ENSG00000184743 Atlastin GTPase 3 11 63624087-63671921 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065702 Supported Endoplasmic reticulum Pancreatic cancer:1.04e-4 (unfavourable) Expressed in all Expressed in all testis: 66.0 ATP10A ATP10C, ATPVA, ATPVC, KIAA0566 ENSG00000206190 ATPase, class V, type 10A 15 25677273-25865172 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA041496, HPA042509 Uncertain Renal cancer:6.60e-5 (unfavourable) Expressed in all Mixed lung: 10.5 ATP10B ATPVB, FLJ21477, KIAA0715 ENSG00000118322 ATPase, class V, type 10B 5 160563120-160852214 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034574 Uncertain Group enriched Tissue enhanced colon: 36.7;rectum: 40.8 gallbladder: 21.5 ATP10D ATPVD, KIAA1487 ENSG00000145246 ATPase, class V, type 10D 4 47485288-47593486 Enzymes, Predicted membrane proteins Evidence at protein level HPA050808 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:5.00e-8 (favourable) Expressed in all Mixed parathyroid gland: 22.1 ATP11A ATPIH, ATPIS, KIAA1021 ENSG00000068650 ATPase, class VI, type 11A 13 112690329-112887168 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035583, HPA035584 Approved Validated Vesicles Renal cancer:7.44e-4 (favourable) Expressed in all Expressed in all lung: 59.2 ATP11B ATPIF, ATPIR, KIAA0956 ENSG00000058063 ATPase, class VI, type 11B 3 182793500-182921635 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA036237, HPA036238 Uncertain Approved Microtubule organizing center
Cytosol Pancreatic cancer:1.09e-4 (unfavourable), Endometrial cancer:3.44e-4 (unfavourable) Expressed in all Expressed in all testis: 57.7 ATP11C ATPIG, ATPIQ ENSG00000101974 ATPase, class VI, type 11C X 139726346-139945276 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030830 Approved Expressed in all Mixed liver: 25.6 ATP12A ATP1AL1 ENSG00000075673 ATPase, H+/K+ transporting, nongastric, alpha polypeptide 13 24680411-24712493 Enzymes, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039526 Approved Tissue enhanced Tissue enhanced esophagus: 12.8;placenta: 8.1;tonsil: 14.6 skin: 7.1 ATP13A1 ATP13A, CGI-152, FLJ31858, KIAA1825 ENSG00000105726 ATPase type 13A1 19 19645198-19663693 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA031798, HPA049717 Approved Approved Vesicles Renal cancer:6.51e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 51.5 ATP13A2 CLN12, HSA9947, PARK9 ENSG00000159363 ATPase type 13A2 1 16985958-17011928 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB037038, CAB037111, HPA050910, HPA054717 Approved Liver cancer:3.33e-7 (unfavourable) Expressed in all Expressed in all cerebral cortex: 75.0 ATP13A3 AFURS1 ENSG00000133657 ATPase type 13A3 3 194402672-194498364 Predicted membrane proteins Evidence at protein level HPA029471 Approved Approved Nucleoli
Plasma membrane
Cytosol Pancreatic cancer:1.60e-4 (unfavourable), Renal cancer:1.63e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 146.4 ATP13A4 DKFZp761I1011, FLJ37958 ENSG00000127249 ATPase type 13A4 3 193402077-193593111 Disease related genes, Predicted membrane proteins Evidence at protein level HPA051932 Approved Nucleoplasm Head and neck cancer:3.91e-4 (favourable) Tissue enhanced Tissue enhanced epididymis: 89.1;parathyroid gland: 129.5;thyroid gland: 68.2 lung: 56.5 ATP13A5 FLJ16025 ENSG00000187527 ATPase type 13A5 3 193274790-193378843 Predicted membrane proteins Evidence at transcript level HPA031771, HPA031774 Uncertain Tissue enhanced Tissue enhanced breast: 17.8 salivary gland: 4.0 ATP1A1 ENSG00000163399 ATPase, Na+/K+ transporting, alpha 1 polypeptide 1 116372668-116410261 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB018702, CAB069993 Supported Renal cancer:8.98e-8 (favourable), Liver cancer:1.42e-4 (unfavourable), Urothelial cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 2441.5 ATP1A2 FHM2, MHP2 ENSG00000018625 ATPase, Na+/K+ transporting, alpha 2 polypeptide 1 160115759-160143591 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022230 Approved Tissue enriched Group enriched 6 cerebral cortex: 435.6;skeletal muscle: 307.1 heart muscle: 59.1 ATP1A3 DYT12 ENSG00000105409 ATPase, Na+/K+ transporting, alpha 3 polypeptide 19 41966582-41997497 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB033630, HPA045367, HPA056446 Supported Renal cancer:3.02e-6 (unfavourable), Pancreatic cancer:6.15e-5 (favourable), Ovarian cancer:3.44e-4 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 376.4;heart muscle: 94.2 testis: 54.1 ATP1B1 ATP1B ENSG00000143153 ATPase, Na+/K+ transporting, beta 1 polypeptide 1 169105697-169132722 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA012911 Supported Renal cancer:7.08e-7 (favourable) Expressed in all Expressed in all kidney: 1327.1 ATP1B2 AMOG ENSG00000129244 ATPase, Na+/K+ transporting, beta 2 polypeptide 17 7646627-7657768 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010698 Supported Pancreatic cancer:1.05e-4 (favourable), Renal cancer:4.17e-4 (unfavourable) Tissue enriched Tissue enriched 9 cerebral cortex: 340.3 ovary: 36.6 ATP1B3 CD298, FLJ29027 ENSG00000069849 ATPase, Na+/K+ transporting, beta 3 polypeptide 3 141876124-141926514 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB020697, HPA048963 Supported Supported Plasma membrane Liver cancer:6.32e-6 (unfavourable), Renal cancer:1.29e-5 (unfavourable), Endometrial cancer:5.19e-5 (favourable) Expressed in all Expressed in all skin: 310.5 ATP2A1 ATP2A, SERCA1 ENSG00000196296 ATPase, Ca++ transporting, cardiac muscle, fast twitch 1 16 28878405-28904509 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002310, CAB032706 Supported Approved Endoplasmic reticulum Tissue enhanced Tissue enriched 95 skeletal muscle: 2782.7 esophagus: 29.2 ATP2A2 ATP2B, DAR, SERCA2 ENSG00000174437 ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 12 110280756-110351093 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA062605, HPA067892 Supported Supported Nucleoplasm Expressed in all Expressed in all skeletal muscle: 1006.6 ATP2A3 SERCA3 ENSG00000074370 ATPase, Ca++ transporting, ubiquitous 17 3923870-3964464 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007180, CAB010882 Approved Cervical cancer:4.69e-5 (favourable), Head and neck cancer:2.51e-4 (favourable) Expressed in all Expressed in all lymph node: 119.9 ATP2B1 PMCA1 ENSG00000070961 ATPase, Ca++ transporting, plasma membrane 1 12 89588049-89709300 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB005605, HPA011166, HPA012945 Supported Supported Plasma membrane Liver cancer:7.74e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 144.0 ATP2B2 PMCA2 ENSG00000157087 ATPase, Ca++ transporting, plasma membrane 2 3 10324023-10708031 Enzymes, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB005606 Supported Tissue enhanced Tissue enriched 7 cerebral cortex: 63.0 salivary gland: 9.2 ATP2B3 CFAP39, CLA2, PMCA3, SCAX1 ENSG00000067842 ATPase, Ca++ transporting, plasma membrane 3 X 153517676-153582939 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA001583 Supported Uncertain Golgi apparatus
Plasma membrane Not detected Group enriched 8 adrenal gland: 12.2;cerebral cortex: 19.1 fallopian tube: 2.0 ATP2B4 ATP2B2, MXRA1, PMCA4 ENSG00000058668 ATPase, Ca++ transporting, plasma membrane 4 1 203626561-203744081 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB016118, HPA040431 Supported Supported Plasma membrane Renal cancer:1.21e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 251.3 ATP2C1 ATP2C1A, BCPM, KIAA1347, PMR1, SPCA1 ENSG00000017260 ATPase, Ca++ transporting, type 2C, member 1 3 130850595-131016712 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010207, HPA035116, HPA069684 Supported Validated Golgi apparatus Liver cancer:5.06e-6 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Renal cancer:1.55e-4 (favourable) Expressed in all Expressed in all prostate: 136.8 ATP2C2 KIAA0703, SPCA2 ENSG00000064270 ATPase, Ca++ transporting, type 2C, member 2 16 84368527-84464187 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA052262, HPA075812 Approved Approved Plasma membrane
Focal adhesion sites Endometrial cancer:6.20e-6 (favourable) Mixed Tissue enhanced rectum: 39.0 skin: 30.1 ATP4A ATP6A ENSG00000105675 ATPase, H+/K+ exchanging, alpha polypeptide 19 35550043-35563658 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039154 Supported Tissue enriched Tissue enriched 250 stomach: 537.7 pancreas: 2.1 ATP4B ATP6B ENSG00000186009 ATPase, H+/K+ exchanging, beta polypeptide 13 113648804-113658186 Predicted membrane proteins, Transporters Evidence at protein level HPA045400, HPA052649 Supported Tissue enriched Tissue enriched 85 stomach: 919.0 fallopian tube: 10.8 ATP5F1 ENSG00000116459 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit B1 1 111448864-111462773 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046067, HPA057347 Supported Supported Nucleoplasm
Mitochondria Renal cancer:3.26e-9 (favourable), Stomach cancer:8.07e-4 (favourable) Expressed in all Expressed in all heart muscle: 51.1 ATP5G2 ENSG00000135390 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C2 (subunit 9) 12 53632726-53677408 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051469 Approved Expressed in all Expressed in all fallopian tube: 769.8 ATP5I ENSG00000169020 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit E 4 672436-674338 Predicted intracellular proteins Evidence at protein level HPA035010 Supported Validated Mitochondria Expressed in all Expressed in all skeletal muscle: 541.6 ATP5J2 ATP5JL, F1Fo-ATPase ENSG00000241468 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit F2 7 99448475-99466331 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067267, HPA070412 Approved Supported Nucleoplasm
Mitochondria Head and neck cancer:2.58e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 463.2 ATP6AP1 16A, Ac45, ATP6IP1, ATP6S1, CF2, ORF, VATPS1, XAP-3, XAP3 ENSG00000071553 ATPase, H+ transporting, lysosomal accessory protein 1 X 154428632-154436516 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015218 Uncertain Approved Plasma membrane
Microtubules
Cytosol Renal cancer:5.26e-8 (favourable), Breast cancer:2.40e-4 (unfavourable), Glioma:7.82e-4 (unfavourable), Pancreatic cancer:7.83e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 205.5 ATP6AP1L ENSG00000205464 ATPase, H+ transporting, lysosomal accessory protein 1-like 5 82279462-82386977 Predicted membrane proteins Evidence at transcript level HPA053771 Approved Approved Nucleoli
Cytosol Mixed Mixed testis: 10.3 ATP6AP2 APT6M8-9, ATP6IP2, ATP6M8-9, M8-9, PRR, RENR ENSG00000182220 ATPase, H+ transporting, lysosomal accessory protein 2 X 40580908-40606637 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003156 Approved Renal cancer:2.01e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 899.3 ATP6V0A1 a1, ATP6N1, ATP6N1A, Stv1, Vph1, VPP1 ENSG00000033627 ATPase, H+ transporting, lysosomal V0 subunit a1 17 42458844-42522611 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA022144 Supported Approved Nuclear speckles
Golgi apparatus
Vesicles
Cytosol Renal cancer:1.28e-4 (favourable), Pancreatic cancer:2.05e-4 (favourable), Urothelial cancer:6.90e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 201.5 ATP6V0A2 a2, ATP6a2, ATP6N1D, J6B7, Stv1, TJ6, TJ6M, TJ6s, Vph1 ENSG00000185344 ATPase, H+ transporting, lysosomal V0 subunit a2 12 123712318-123761755 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044279 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all skin: 15.2 ATP6V0A4 a4, ATP6N1B, ATP6N2, RDRTA2, RTA1C, RTADR, Stv1, Vph1, VPP2 ENSG00000105929 ATPase, H+ transporting, lysosomal V0 subunit a4 7 138706295-138799560 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA018029, HPA064555 Supported Approved Cytosol Renal cancer:1.32e-6 (favourable) Tissue enriched Group enriched 9 kidney: 69.1;salivary gland: 31.8 breast: 5.5 ATP6V0B ATP6F, HATPL, VMA16 ENSG00000117410 ATPase, H+ transporting, lysosomal 21kDa, V0 subunit b 1 43974487-43978295 Predicted membrane proteins Evidence at transcript level HPA044281 Approved Cytosol Renal cancer:3.62e-6 (favourable), Pancreatic cancer:3.24e-4 (favourable), Liver cancer:4.79e-4 (unfavourable), Urothelial cancer:8.87e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 181.8 ATP6V0C ATP6C, ATP6L, ATPL, VATL, Vma3 ENSG00000185883 ATPase, H+ transporting, lysosomal 16kDa, V0 subunit c 16 2513870-2520218 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065100 Approved Cytosol Renal cancer:1.07e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 424.2 ATP7A MNK ENSG00000165240 ATPase, Cu++ transporting, alpha polypeptide X 77910656-78050395 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA012887, HPA048107 Approved Supported Golgi apparatus
Vesicles Renal cancer:8.38e-4 (favourable) Expressed in all Mixed parathyroid gland: 15.0 ATP7B WND ENSG00000123191 ATPase, Cu++ transporting, beta polypeptide 13 51930436-52012125 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA009137, HPA013187 Supported Supported Golgi apparatus Endometrial cancer:5.01e-4 (unfavourable) Mixed Mixed testis: 14.0 ATP8A1 ATPIA ENSG00000124406 ATPase, aminophospholipid transporter (APLT), class I, type 8A, member 1 4 42408373-42657105 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA049948, HPA052935 Approved Supported Vesicles Renal cancer:5.54e-10 (favourable) Mixed Tissue enhanced parathyroid gland: 67.5;thyroid gland: 66.3 cerebral cortex: 58.4 ATP8A2 ATPIB, ML-1 ENSG00000132932 ATPase, aminophospholipid transporter, class I, type 8A, member 2 13 25372071-26025851 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA039926, HPA040033 Approved Supported Nucleoplasm
Plasma membrane Mixed Group enriched 6 cerebral cortex: 26.5;testis: 10.6 adrenal gland: 2.9 ATP8B1 ATPIC, BRIC, FIC1, PFIC, PFIC1 ENSG00000081923 ATPase, aminophospholipid transporter, class I, type 8B, member 1 18 57646426-57803101 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018673, HPA018674 Supported Colorectal cancer:2.60e-4 (favourable), Renal cancer:6.35e-4 (favourable) Expressed in all Expressed in all colon: 96.9 ATP8B2 ATPID, KIAA1137 ENSG00000143515 ATPase, aminophospholipid transporter, class I, type 8B, member 2 1 154325553-154351307 Enzymes, Predicted membrane proteins Evidence at protein level HPA046680 Approved Approved Golgi apparatus
Vesicles
Cytosol Urothelial cancer:5.29e-5 (unfavourable), Pancreatic cancer:1.60e-4 (favourable) Expressed in all Mixed smooth muscle: 60.2 ATP8B4 ATPIM, KIAA1939 ENSG00000104043 ATPase, class I, type 8B, member 4 15 49858238-50182817 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040254 Approved Approved Nucleoplasm
Vesicles Mixed Tissue enhanced bone marrow: 23.1 endometrium: 9.2 ATP9A ATPIIA, KIAA0611 ENSG00000054793 ATPase, class II, type 9A 20 51596514-51768634 Enzymes, Predicted membrane proteins Evidence at protein level CAB020699, HPA035630 Approved Renal cancer:5.67e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 156.2 ATP9B ATPIIB ENSG00000166377 ATPase, class II, type 9B 18 79069285-79378283 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029364 Approved Expressed in all Expressed in all testis: 39.0 ATR FRP1, MEC1, SCKL, SCKL1 ENSG00000175054 ATR serine/threonine kinase 3 142449235-142578826 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054320 Supported Nucleoplasm
Golgi apparatus Pancreatic cancer:1.23e-5 (unfavourable), Liver cancer:8.39e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 15.2 ATRAID APR3, C2orf28, HSPC013, p18 ENSG00000138085 All-trans retinoic acid-induced differentiation factor 2 27212027-27217178 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051353 Uncertain Expressed in all Expressed in all epididymis: 511.9 ATRIP ENSG00000282827 ATR interacting protein 3 48446710-48467645 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035437, HPA047590 Approved Approved Nucleus Mixed testis: 6.2 ATRN DPPT-L, MGCA ENSG00000088812 Attractin 20 3471040-3651122 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008853 Uncertain Approved Cytosol Renal cancer:2.19e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 83.4 ATRNL1 ALP, FLJ45344, KIAA0534 ENSG00000107518 Attractin-like 1 10 115093365-115948992 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038070 Uncertain Approved Nucleus
Mitochondria Mixed Tissue enhanced cerebral cortex: 34.0 testis: 22.6 ATXN3 ATX3, JOS, MJD, SCA3 ENSG00000066427 Ataxin 3 14 92038652-92106621 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB021976, HPA024123, HPA069338 Uncertain Supported Nucleus
Nucleoli
Plasma membrane Mixed Mixed testis: 18.5 AUP1 ENSG00000115307 Ancient ubiquitous protein 1 2 74526645-74529939 Predicted membrane proteins Evidence at protein level HPA007674 Approved Approved Nucleoplasm
Vesicles Renal cancer:2.97e-9 (unfavourable), Liver cancer:2.29e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 57.1 AVL9 KIAA0241 ENSG00000105778 AVL9 homolog (S. cerevisiase) 7 32495426-32588721 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050957 Approved Approved Endoplasmic reticulum Expressed in all Expressed in all cerebral cortex: 25.6 AVPR2 DIR, DIR3, V2R ENSG00000126895 Arginine vasopressin receptor 2 X 153902531-153907166 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA046678 Approved Mixed Tissue enhanced adipose tissue: 5.8 heart muscle,kidney: 2.8 AWAT1 DGAT2L3 ENSG00000204195 Acyl-CoA wax alcohol acyltransferase 1 X 70234655-70240627 Enzymes, Predicted membrane proteins Evidence at protein level HPA063412 Supported Not detected Not detected breast: 0.8 AWAT2 DGAT2L4, MFAT ENSG00000147160 Acyl-CoA wax alcohol acyltransferase 2 X 70040542-70049938 Enzymes, Predicted membrane proteins Evidence at protein level HPA062748 Approved Tissue enriched Tissue enhanced breast: 2.0;skin: 1.2 testis: 0.5 AXIN1 PPP1R49 ENSG00000103126 Axin 1 16 287440-352673 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012987 Approved Supported Nucleoli
Vesicles Liver cancer:3.38e-5 (unfavourable) Expressed in all Expressed in all spleen: 15.8 AXL ARK, JTK11, Tyro7, UFO ENSG00000167601 AXL receptor tyrosine kinase 19 41219203-41261766 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032501, HPA037422, HPA037423 Uncertain Approved Intermediate filaments Renal cancer:2.53e-7 (unfavourable) Expressed in all Expressed in all smooth muscle: 54.0 B3GALNT1 B3GALT3, beta3Gal-T3, galT3, GLOB, P1 ENSG00000169255 Beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) 3 161083883-161105384 Blood group antigen proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041204 Approved Vesicles Expressed in all Mixed thyroid gland: 47.6 B3GALT2 beta3Gal-T2 ENSG00000162630 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 2 1 193179045-193186654 Predicted membrane proteins Evidence at transcript level HPA078659 Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 29.0;gallbladder: 26.0 heart muscle: 16.2 B3GALT5 B3GalT-V, B3T5, beta3Gal-T5, GLCT5 ENSG00000183778 UDP-Gal:betaGlcNAc beta 1,3-galactosyltransferase, polypeptide 5 21 39556442-39673137 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054092, HPA054684 Approved Endometrial cancer:6.36e-4 (favourable) Mixed Group enriched 5 colon: 23.1;duodenum: 28.2;gallbladder: 8.6;rectum: 41.3;small intestine: 37.9 stomach: 5.1 B3GAT1 CD57, GlcAT-P, HNK-1, LEU7, NK-1 ENSG00000109956 Beta-1,3-glucuronyltransferase 1 11 134378504-134411918 Enzymes, Predicted intracellular proteins Evidence at protein level CAB002500, CAB010893, HPA069468 Supported Validated Vesicles Group enriched Tissue enriched 11 cerebral cortex: 115.7 thyroid gland: 10.3 B3GAT2 GlcAT-S ENSG00000112309 Beta-1,3-glucuronyltransferase 2 6 70856679-70957038 Enzymes, Predicted membrane proteins Evidence at protein level HPA012059 Uncertain Group enriched Tissue enriched 10 cerebral cortex: 19.6 testis: 1.9 B3GAT3 GlcAT-I ENSG00000149541 Beta-1,3-glucuronyltransferase 3 11 62615296-62622175 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA051328 Approved Liver cancer:5.11e-6 (unfavourable), Glioma:5.96e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 37.0 B3GNT2 B3GN-T1, B3GN-T2, B3GNT-2, B3GNT1, BETA3GNT ENSG00000170340 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 2 2 62196113-62224731 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA005997 Approved Approved Vesicles Pancreatic cancer:1.62e-4 (unfavourable) Expressed in all Expressed in all lung: 51.0 B3GNT4 B3GN-T4, beta3Gn-T4 ENSG00000176383 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 4 12 122203543-122208952 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA055261 Uncertain Approved Nucleoli
Mitochondria Renal cancer:3.52e-6 (unfavourable) Mixed Tissue enhanced cerebral cortex: 4.3;skin: 2.9 kidney: 1.9 B3GNT5 B3GN-T5, beta3Gn-T5 ENSG00000176597 UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 3 183253244-183298504 Enzymes, Predicted intracellular proteins Evidence at protein level HPA017292 Uncertain Approved Nucleoli Renal cancer:1.30e-7 (unfavourable), Pancreatic cancer:7.23e-6 (unfavourable), Liver cancer:5.09e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 49.2 B4GALNT2 Cad, GALGT2, Sda ENSG00000167080 Beta-1,4-N-acetyl-galactosaminyl transferase 2 17 49132460-49176840 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015721 Approved Renal cancer:1.29e-5 (favourable) Mixed Tissue enhanced colon: 33.9 rectum: 16.1 B4GALT1 beta4Gal-T1, GGTB2 ENSG00000086062 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 1 9 33104082-33167356 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA010806, HPA010807 Supported Validated Golgi apparatus Endometrial cancer:6.85e-7 (favourable), Lung cancer:1.25e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 138.8 B4GALT2 beta4Gal-T2 ENSG00000117411 UDP-Gal:betaGlcNAc beta 1,4- galactosyltransferase, polypeptide 2 1 43978943-43991170 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007620, HPA047739 Supported Supported Golgi apparatus
Vesicles Liver cancer:2.96e-5 (unfavourable), Renal cancer:3.62e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 49.6 B4GALT7 beta4Gal-T7, XGALT-1 ENSG00000027847 Xylosylprotein beta 1,4-galactosyltransferase, polypeptide 7 5 177600100-177610347 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA042330 Supported Glioma:1.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 27.2 BACE1 BACE ENSG00000186318 Beta-site APP-cleaving enzyme 1 11 117285207-117316259 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB016358 Approved Supported Plasma membrane Urothelial cancer:6.76e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex,pancreas: 100.6 BACE2 AEPLC, ALP56, CEAP1, DRAP ENSG00000182240 Beta-site APP-cleaving enzyme 2 21 41167801-41282518 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB008975 Uncertain Cervical cancer:1.11e-4 (unfavourable), Glioma:8.13e-4 (unfavourable) Expressed in all Mixed stomach: 31.1 BAK1 BAK, BCL2L7, CDN1 ENSG00000030110 BCL2-antagonist/killer 1 6 33572547-33580293 Predicted membrane proteins, Transporters Evidence at protein level CAB005029 Supported Renal cancer:1.64e-5 (unfavourable), Endometrial cancer:1.71e-4 (unfavourable), Liver cancer:4.52e-4 (unfavourable), Lung cancer:5.64e-4 (unfavourable) Expressed in all Expressed in all duodenum: 49.2 BAMBI NMA ENSG00000095739 BMP and activin membrane-bound inhibitor 10 28677342-28682939 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA010819, HPA010866 Approved Approved Nucleoli fibrillar center
Vesicles
Lipid droplets Liver cancer:9.42e-6 (unfavourable), Renal cancer:5.25e-4 (favourable) Expressed in all Tissue enhanced ovary: 87.4 adrenal gland: 50.1 BANP BEND1, DKFZp761H172, FLJ10177, FLJ20538, SMAR1, SMARBP1 ENSG00000172530 BTG3 associated nuclear protein 16 87949244-88118422 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047164 Approved Supported Nucleoplasm
Nuclear bodies Expressed in all Expressed in all testis: 14.1 BAX BCL2L4 ENSG00000087088 BCL2-associated X protein 19 48954815-48961798 Cancer-related genes, Predicted intracellular proteins, Transporters Evidence at protein level CAB004206, HPA027878 Approved Liver cancer:1.63e-5 (unfavourable) Expressed in all Expressed in all appendix: 83.2 BBS4 ENSG00000140463 Bardet-Biedl syndrome 4 15 72686179-72738476 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039418 Approved Supported Cytosol Endometrial cancer:2.57e-4 (favourable) Expressed in all Expressed in all testis: 37.3 BCAM CD239, LU ENSG00000187244 Basal cell adhesion molecule (Lutheran blood group) 19 44809059-44821420 Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005654 Uncertain Approved Nucleoli fibrillar center Renal cancer:5.94e-6 (favourable), Endometrial cancer:1.24e-5 (unfavourable), Colorectal cancer:2.31e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 172.9 BCAP29 BAP29, DKFZp686M2086 ENSG00000075790 B-cell receptor-associated protein 29 7 107579977-107629170 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029215, HPA049694 Supported Approved Cytosol Liver cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 185.4 BCAP31 6C6-Ag, BAP31, CDM, DXS1357E ENSG00000185825 B-cell receptor-associated protein 31 X 153700497-153724697 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003906, CAB015350, CAB015424 Supported Approved Validated Endoplasmic reticulum Head and neck cancer:9.87e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 272.6 BCL2 Bcl-2, PPP1R50 ENSG00000171791 B-cell CLL/lymphoma 2 18 63123346-63320128 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000003, HPA055295 Supported Supported Nucleoplasm
Nuclear membrane Renal cancer:1.29e-8 (favourable), Cervical cancer:5.13e-5 (favourable), Thyroid cancer:2.47e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 69.2 parathyroid gland: 34.6 BCL2L1 Bcl-X, bcl-xL, bcl-xS, BCL2L, BCLX, PPP1R52 ENSG00000171552 BCL2-like 1 20 31664452-31723989 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level HPA035734, CAB072801 Approved Approved Mitochondria Renal cancer:8.89e-5 (favourable), Pancreatic cancer:5.87e-4 (unfavourable), Endometrial cancer:9.10e-4 (unfavourable), Melanoma:9.57e-4 (favourable) Expressed in all Expressed in all gallbladder: 100.9 BCL2L10 BCL-B, Boo, Diva ENSG00000137875 BCL2-like 10 (apoptosis facilitator) 15 52109263-52112775 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042222 Approved Mixed Tissue enhanced skin: 6.1 kidney: 3.3 BCL2L13 BCL-RAMBO, MIL1 ENSG00000099968 BCL2-like 13 (apoptosis facilitator) 22 17628855-17730855 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002052, HPA030994, HPA050377 Uncertain Supported Mitochondria Renal cancer:1.96e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 45.9 BCL2L2 BCL-W, KIAA0271, PPP1R51 ENSG00000129473 BCL2-like 2 14 23298790-23311759 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB040539 Approved Renal cancer:1.99e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 89.1 BCR ALL, BCR1, CML, D22S11, D22S662, PHL ENSG00000186716 Breakpoint cluster region 22 23179704-23318037 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB010421, CAB018545, HPA038337 Approved Approved Nucleoplasm
Cytosol Renal cancer:9.15e-10 (favourable) Expressed in all Expressed in all cerebral cortex: 48.5 BCS1L BCS, BJS, h-BCS, Hs.6719 ENSG00000074582 BC1 (ubiquinol-cytochrome c reductase) synthesis-like 2 218658764-218663443 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037700, HPA037701 Supported Uncertain Vesicles Urothelial cancer:3.31e-4 (favourable) Expressed in all Expressed in all fallopian tube: 30.9 BDKRB1 B1BKR, BKR1, bradyb1 ENSG00000100739 Bradykinin receptor B1 14 96255824-96268967 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA002935 Approved Mixed Tissue enhanced gallbladder: 18.3;urinary bladder: 10.3 appendix: 7.0 BDKRB2 BK-2 ENSG00000168398 Bradykinin receptor B2 14 96204679-96244166 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050841 Approved Mixed Mixed gallbladder: 32.6 BDNF ENSG00000176697 Brain-derived neurotrophic factor 11 27654893-27722058 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009564, HPA031440, HPA056104 Supported Supported Nuclear speckles
Mitochondria Mixed Tissue enhanced cerebral cortex: 12.0 epididymis: 5.8 BEAN1 SCA31 ENSG00000166546 Brain expressed, associated with NEDD4, 1 16 66427297-66493529 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA053851 Uncertain Uncertain Nucleoplasm
Centrosome Mixed Mixed cerebral cortex: 2.2 BEST1 BEST, BMD, RP50, VMD2 ENSG00000167995 Bestrophin 1 11 61949821-61965515 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA057464 Supported Group enriched Mixed cerebral cortex: 17.0 BEST2 FLJ20132, VMD2L1 ENSG00000039987 Bestrophin 2 19 12751702-12758458 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA046229 Approved Tissue enhanced Tissue enhanced colon: 15.8;rectum: 15.4 tonsil: 4.9 BEST3 MGC13168, MGC40411, VMD2L3 ENSG00000127325 Bestrophin 3 12 69643360-69699476 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA054582 Approved Tissue enriched Tissue enhanced cerebral cortex: 16.4;skeletal muscle: 12.2 testis: 5.9 BEST4 VMD2L2 ENSG00000142959 Bestrophin 4 1 44783585-44787705 Predicted membrane proteins Evidence at protein level HPA058564 Uncertain Mixed Tissue enhanced colon: 26.7;rectum: 21.9 duodenum: 11.6 BET1L GOLIM3, GS15 ENSG00000177951 Bet1 golgi vesicular membrane trafficking protein-like 11 167784-207428 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039819 Approved Approved Nucleus
Golgi apparatus Liver cancer:2.20e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 74.3 BIK NBK ENSG00000100290 BCL2-interacting killer (apoptosis-inducing) 22 43110748-43129712 Predicted membrane proteins Evidence at protein level HPA051360 Approved Renal cancer:7.45e-5 (favourable) Mixed Mixed lymph node: 14.2 BLCAP BC10 ENSG00000166619 Bladder cancer associated protein 20 37492472-37527931 Predicted intracellular proteins Evidence at protein level HPA047390 Approved Nucleoli Urothelial cancer:7.28e-5 (favourable), Endometrial cancer:1.40e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 221.5 BMP2K BIKe, DKFZp434K0614 ENSG00000138756 BMP2 inducible kinase 4 78776342-78916372 Enzymes, Predicted intracellular proteins Evidence at protein level HPA026436, HPA026451, HPA026501 Approved Supported Nuclear speckles Colorectal cancer:1.74e-4 (favourable) Mixed Mixed testis: 32.3 BMPR1A ACVRLK3, ALK3, CD292 ENSG00000107779 Bone morphogenetic protein receptor, type IA 10 86756650-86932838 Cancer-related genes, CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019398 Approved Approved Cytosol Liver cancer:8.93e-4 (unfavourable), Glioma:9.38e-4 (favourable) Expressed in all Mixed thyroid gland: 33.8 BMPR1B ALK6, CDw293 ENSG00000138696 Bone morphogenetic protein receptor, type IB 4 94757968-95158448 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009634 Uncertain Endometrial cancer:2.84e-4 (favourable) Tissue enhanced Tissue enhanced cervix, uterine: 37.0;prostate: 36.4 seminal vesicle: 20.8 BMPR2 BMPR-II, BMPR3, BRK-3, PPH1, T-ALK ENSG00000204217 Bone morphogenetic protein receptor, type II (serine/threonine kinase) 2 202376936-202567751 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017385, HPA049014 Approved Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all cerebral cortex: 36.5 BNIP1 Nip1, SEC20 ENSG00000113734 BCL2/adenovirus E1B 19kDa interacting protein 1 5 173144442-173164387 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008009, HPA008149 Supported Supported Endoplasmic reticulum Expressed in all Expressed in all testis: 26.9 BNIP2 BNIP-2, Nip2 ENSG00000140299 BCL2/adenovirus E1B 19kDa interacting protein 2 15 59659146-59689534 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026843 Approved Renal cancer:2.19e-5 (unfavourable), Endometrial cancer:8.42e-4 (favourable) Expressed in all Expressed in all bone marrow: 84.4 BNIP3 Nip3 ENSG00000176171 BCL2/adenovirus E1B 19kDa interacting protein 3 10 131966455-131982013 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003015, CAB011676 Supported Uncertain Cytosol Renal cancer:4.55e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 84.4 BNIP3L BNIP3a, Nix ENSG00000104765 BCL2/adenovirus E1B 19kDa interacting protein 3-like 8 26382898-26505636 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA015652, CAB025371 Supported Approved Nuclear speckles
Mitochondria Renal cancer:5.92e-5 (unfavourable), Thyroid cancer:3.95e-4 (unfavourable) Expressed in all Expressed in all placenta: 150.7 BOC CDON2 ENSG00000144857 BOC cell adhesion associated, oncogene regulated 3 113211003-113287459 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025806, HPA060778, HPA061787 Uncertain Supported Nucleoplasm
Plasma membrane Urothelial cancer:1.18e-5 (unfavourable), Head and neck cancer:4.89e-4 (favourable) Mixed Mixed fallopian tube: 56.6 BPI BPIFD1 ENSG00000101425 Bactericidal/permeability-increasing protein 20 38260149-38337505 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA061284 Supported Not detected Tissue enriched 36 bone marrow: 963.1 testis: 27.0 BRCA1 BRCC1, FANCS, PPP1R53, RNF53 ENSG00000012048 Breast cancer 1, early onset 17 43044295-43170245 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB001946, HPA034966 Approved Expressed in all Mixed testis: 23.9 BRI3 ENSG00000164713 Brain protein I3 7 98252379-98310441 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042215 Uncertain Head and neck cancer:3.35e-4 (unfavourable) Expressed in all Expressed in all lung: 119.5 BRI3BP BNAS1, HCCR-2, KG19 ENSG00000184992 BRI3 binding protein 12 124993700-125031231 Predicted membrane proteins, Transporters Evidence at protein level HPA014957 Approved Approved Nucleoplasm
Mitochondria Liver cancer:6.87e-4 (unfavourable) Expressed in all Mixed duodenum: 21.1 BRICD5 C16orf79, MGC21830 ENSG00000182685 BRICHOS domain containing 5 16 2209253-2211950 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019197, HPA063522 Uncertain Approved Nucleoplasm
Actin filaments Urothelial cancer:8.06e-5 (favourable), Pancreatic cancer:7.01e-4 (favourable), Breast cancer:9.74e-4 (favourable) Expressed in all Mixed testis: 10.6 BRINP3 DBCCR1L, DBCCR1L1, FAM5C ENSG00000162670 Bone morphogenetic protein/retinoic acid inducible neural-specific 3 1 190097662-190478404 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054693 Uncertain Group enriched Tissue enhanced cerebral cortex: 44.6;small intestine: 20.0 prostate: 10.5 BRIP1 BACH1, FANCJ, OF ENSG00000136492 BRCA1 interacting protein C-terminal helicase 1 17 61681266-61863521 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA005474 Approved Supported Nucleus
Nuclear membrane Colorectal cancer:3.45e-5 (favourable), Head and neck cancer:3.62e-4 (favourable) Mixed Tissue enhanced testis: 14.4 bone marrow: 5.0 BRSK1 KIAA1811 ENSG00000160469 BR serine/threonine kinase 1 19 55282072-55312533 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021212, HPA061719 Supported Supported Nucleoplasm Renal cancer:7.98e-6 (unfavourable), Pancreatic cancer:1.02e-4 (favourable) Expressed in all Tissue enriched 6 cerebral cortex: 138.2 parathyroid gland: 23.8 BRSK2 C11orf7, PEN11B, STK29 ENSG00000174672 BR serine/threonine kinase 2 11 1389899-1462689 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA073690 Approved Golgi apparatus Tissue enhanced Tissue enhanced cerebral cortex: 61.8;pancreas: 19.2 testis: 9.5 BSCL2 GNG3LG, SPG17 ENSG00000168000 Berardinelli-Seip congenital lipodystrophy 2 (seipin) 11 62690275-62709845 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042394 Approved Renal cancer:7.55e-5 (favourable) Expressed in all Expressed in all testis: 249.9 BSG CD147, EMMPRIN, OK ENSG00000172270 Basigin (Ok blood group) 19 571277-583493 Blood group antigen proteins, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB002427, HPA036048, HPA074870 Supported Approved Vesicles Renal cancer:1.95e-6 (favourable), Liver cancer:5.48e-6 (unfavourable), Endometrial cancer:2.59e-4 (favourable) Expressed in all Expressed in all heart muscle: 585.9 BSND BART, DFNB73 ENSG00000162399 Barttin CLCNK-type chloride channel accessory beta subunit 1 54998933-55010883 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA053836 Supported Tissue enriched Tissue enriched 6 kidney: 10.2 salivary gland: 1.5 BST2 CD317, tetherin ENSG00000130303 Bone marrow stromal cell antigen 2 19 17402939-17405648 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA017060 Approved Supported Golgi apparatus
Plasma membrane
Cytosol Renal cancer:3.56e-9 (unfavourable), Testis cancer:4.22e-4 (unfavourable), Breast cancer:6.69e-4 (favourable) Expressed in all Expressed in all ovary: 585.6 BTBD10 GMRP-1, GMRP1, MGC13007 ENSG00000148925 BTB (POZ) domain containing 10 11 13388001-13463297 Predicted intracellular proteins Evidence at protein level HPA046777 Approved Supported Nucleus
Nucleoli fibrillar center Liver cancer:1.37e-4 (unfavourable) Expressed in all Expressed in all testis: 67.5 BTBD11 ABTB2B, FLJ33957 ENSG00000151136 BTB (POZ) domain containing 11 12 107318413-107659642 Predicted intracellular proteins Evidence at protein level HPA055898 Approved Nucleoplasm Mixed Tissue enhanced parathyroid gland: 128.0 thyroid gland: 31.6 BTBD7 FLJ10648, FUP1 ENSG00000011114 BTB (POZ) domain containing 7 14 93237550-93333092 Predicted intracellular proteins Evidence at protein level HPA049926, HPA053406 Uncertain Approved Focal adhesion sites Renal cancer:1.69e-6 (favourable) Expressed in all Mixed parathyroid gland: 18.3 BTLA BTLA1, CD272 ENSG00000186265 B and T lymphocyte associated 3 112463968-112499561 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047211, HPA062029 Supported Mixed Group enriched 7 appendix: 14.7;lymph node: 29.6;spleen: 14.8;tonsil: 25.7 urinary bladder: 3.1 BTN1A1 BT, BTN, BTN1 ENSG00000124557 Butyrophilin, subfamily 1, member A1 6 26501221-26510422 Predicted membrane proteins Evidence at protein level HPA011126 Supported Tissue enhanced Tissue enriched 45 breast: 37.0 tonsil: 0.8 BTN2A1 BT2.1, BTF1, BTN2.1 ENSG00000112763 Butyrophilin, subfamily 2, member A1 6 26457904-26476621 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019208 Approved Approved Plasma membrane Urothelial cancer:4.52e-5 (favourable), Renal cancer:5.90e-5 (unfavourable) Expressed in all Expressed in all placenta: 26.1 BTN2A2 BT2.2, BTF2, BTN2.2 ENSG00000124508 Butyrophilin, subfamily 2, member A2 6 26383096-26394874 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051504 Uncertain Supported Mitochondria Breast cancer:1.01e-4 (favourable) Expressed in all Mixed lymph node: 38.1 BTN3A1 BT3.1, BTF5, BTN3.1, CD277 ENSG00000026950 Butyrophilin, subfamily 3, member A1 6 26402237-26415216 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012565 Approved Uncertain Vesicles Renal cancer:4.15e-5 (unfavourable), Urothelial cancer:4.81e-4 (favourable) Expressed in all Expressed in all spleen: 114.2 BTN3A2 BTN3.2 ENSG00000186470 Butyrophilin, subfamily 3, member A2 6 26365159-26378320 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB019392 Uncertain Renal cancer:4.24e-4 (unfavourable) Expressed in all Expressed in all spleen: 131.4 BTN3A3 BTF3, BTN3.3 ENSG00000111801 Butyrophilin, subfamily 3, member A3 6 26440472-26453415 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007904, HPA011871 Supported Renal cancer:2.42e-5 (unfavourable), Ovarian cancer:1.80e-4 (favourable) Expressed in all Mixed spleen: 65.0 BTNL8 BTN9.2, FLJ21458 ENSG00000113303 Butyrophilin-like 8 5 180899077-180950906 Predicted membrane proteins Evidence at protein level HPA039738 Approved Group enriched Group enriched 6 colon: 26.5;duodenum: 120.7;rectum: 28.2;small intestine: 96.1 gallbladder: 10.5 BTNL9 BTN8, FLJ32535 ENSG00000165810 Butyrophilin-like 9 5 181040225-181061523 Predicted membrane proteins Evidence at protein level HPA043429 Approved Nuclear membrane
Vesicles Liver cancer:1.55e-9 (favourable), Endometrial cancer:7.51e-4 (unfavourable) Mixed Tissue enhanced adipose tissue: 166.7 lung: 56.0 BVES HBVES, POP1, POPDC1 ENSG00000112276 Blood vessel epicardial substance 6 105096822-105137174 Predicted membrane proteins Evidence at protein level HPA014788, HPA018176 Supported Supported Cell Junctions Mixed Tissue enhanced smooth muscle: 24.7 testis: 20.7 C10orf128 Em:AC084727.5 ENSG00000204161 Chromosome 10 open reading frame 128 10 49154725-49188585 Predicted membrane proteins Evidence at transcript level HPA058166 Approved Renal cancer:2.86e-5 (unfavourable) Expressed in all Mixed lung: 40.5 C10orf35 ENSG00000171224 Chromosome 10 open reading frame 35 10 69630251-69633599 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034591 Approved Approved Nucleus
Centrosome
Cytosol Liver cancer:1.03e-4 (unfavourable), Head and neck cancer:8.64e-4 (unfavourable), Urothelial cancer:9.72e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 27.7 testis: 20.2 C10orf54 B7-H5, B7H5, GI24, SISP1, VISTA ENSG00000107738 Chromosome 10 open reading frame 54 10 71747559-71773498 Predicted membrane proteins Evidence at protein level HPA007968 Uncertain Approved Nucleoplasm Testis cancer:6.93e-4 (unfavourable) Expressed in all Expressed in all spleen: 188.4 C10orf76 FLJ13114 ENSG00000120029 Chromosome 10 open reading frame 76 10 101845599-102056193 Predicted intracellular proteins Evidence at protein level HPA050913, HPA053580 Approved Approved Vesicles Expressed in all Expressed in all parathyroid gland: 25.9 C11orf24 DM4E3 ENSG00000171067 Chromosome 11 open reading frame 24 11 68261335-68272001 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012748 Uncertain Uncertain Nucleoplasm
Vesicles Renal cancer:1.60e-9 (unfavourable), Lung cancer:6.05e-4 (unfavourable), Glioma:9.83e-4 (unfavourable) Expressed in all Expressed in all small intestine: 67.2 C11orf80 FLJ22531 ENSG00000173715 Chromosome 11 open reading frame 80 11 66744451-66843328 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038932, HPA038933 Approved Approved Centrosome Expressed in all Mixed skin: 48.3 C11orf87 LOC399947, LOH11CR1A, NEURIM1 ENSG00000185742 Chromosome 11 open reading frame 87 11 109422120-109429114 Predicted membrane proteins Evidence at protein level HPA034656 Approved Tissue enhanced Tissue enriched 21 cerebral cortex: 30.9 endometrium: 1.5 C11orf96 AG2 ENSG00000187479 Chromosome 11 open reading frame 96 11 43925342-43944338 Predicted intracellular proteins Evidence at protein level HPA038843 Uncertain Approved Nucleus
Focal adhesion sites
Cytosol Renal cancer:2.34e-5 (unfavourable) Expressed in all Tissue enhanced adrenal gland: 164.1 adipose tissue: 126.9 C12orf56 ENSG00000185306 Chromosome 12 open reading frame 56 12 64264762-64391192 Predicted intracellular proteins Evidence at protein level HPA056986 Supported Mixed Tissue enriched 21 testis: 15.2 skin: 0.7 C12orf76 FLJ40142 ENSG00000174456 Chromosome 12 open reading frame 76 12 110027028-110073686 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA039713, HPA042013 Uncertain Approved Plasma membrane
Actin filaments Renal cancer:5.74e-5 (unfavourable), Lung cancer:6.44e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 106.1 C14orf1 ERG28, NET51 ENSG00000133935 Chromosome 14 open reading frame 1 14 75649791-75661189 Predicted membrane proteins Evidence at protein level HPA043172, HPA063568 Approved Approved Nucleoplasm
Cytosol Renal cancer:4.30e-5 (favourable) Expressed in all Expressed in all testis: 77.0 C14orf2 MP68 ENSG00000156411 Chromosome 14 open reading frame 2 14 103912288-103928269 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058978, HPA060520 Supported Supported Nucleoli fibrillar center
Mitochondria Ovarian cancer:6.80e-4 (favourable) Expressed in all Expressed in all heart muscle: 206.9 C14orf37 ENSG00000139971 Chromosome 14 open reading frame 37 14 57999735-58298139 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001580, HPA001789 Approved Approved Plasma membrane Mixed Mixed kidney: 8.8 C15orf48 NMES1 ENSG00000166920 Chromosome 15 open reading frame 48 15 45430529-45448761 Predicted intracellular proteins Evidence at protein level HPA012677, HPA012943 Approved Uncertain Mitochondria Expressed in all Tissue enhanced colon: 728.9;rectum: 845.4 small intestine: 336.3 C16orf54 FLJ35681 ENSG00000185905 Chromosome 16 open reading frame 54 16 29742463-29746006 Predicted membrane proteins Evidence at protein level HPA060546 Uncertain Expressed in all Tissue enhanced bone marrow: 26.0 lymph node: 24.3 C16orf58 FLJ13868 ENSG00000140688 Chromosome 16 open reading frame 58 16 31489471-31509309 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024406 Uncertain Approved Nucleoplasm
Nucleoli
Golgi apparatus
Vesicles
Cytosol Expressed in all Expressed in all parathyroid gland: 81.3 C16orf62 MGC16824 ENSG00000103544 Chromosome 16 open reading frame 62 16 19555240-19706793 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042969, HPA053547 Uncertain Approved Mitochondria Renal cancer:1.31e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 68.5 C17orf62 FLJ90469, MGC4368 ENSG00000178927 Chromosome 17 open reading frame 62 17 82442589-82450829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045696 Uncertain Approved Plasma membrane
Cell Junctions Renal cancer:6.83e-11 (unfavourable) Expressed in all Expressed in all lymph node: 129.5 C17orf74 ENSG00000184560 Chromosome 17 open reading frame 74 17 7425615-7427568 Predicted membrane proteins Evidence at transcript level HPA023649 Uncertain Not detected Tissue enriched 618 testis: 61.7 all non-specific tissues: 0.0 C17orf80 FLJ20721, HLC-8, MIG3, SPEP1 ENSG00000141219 Chromosome 17 open reading frame 80 17 73232233-73248947 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012896 Uncertain Approved Nucleoplasm
Vesicles Liver cancer:9.02e-6 (unfavourable), Colorectal cancer:1.43e-4 (favourable) Expressed in all Expressed in all testis: 71.6 C19orf18 MGC41906 ENSG00000177025 Chromosome 19 open reading frame 18 19 57958437-57974534 Predicted membrane proteins Evidence at transcript level HPA014527 Uncertain Approved Golgi apparatus Endometrial cancer:5.07e-4 (favourable) Mixed Tissue enhanced testis: 16.9 epididymis: 4.8 C19orf24 FLJ20640 ENSG00000228300 Chromosome 19 open reading frame 24 19 1275438-1279249 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043279, HPA047026 Uncertain Approved Nuclear speckles
Golgi apparatus Expressed in all Expressed in all appendix: 37.5 C19orf38 HIDE1 ENSG00000214212 Chromosome 19 open reading frame 38 19 10836575-10869790 Predicted membrane proteins Evidence at protein level HPA012150, HPA055027 Uncertain Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.75e-7 (unfavourable), Cervical cancer:2.43e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 62.9 spleen: 17.8 C1GALT1C1 C1GALT2, COSMC ENSG00000171155 C1GALT1-specific chaperone 1 X 120625793-120630150 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA015632 Approved Approved Cytosol Breast cancer:5.66e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 43.9 C1orf159 FLJ20584 ENSG00000131591 Chromosome 1 open reading frame 159 1 1081818-1116361 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010019 Approved Approved Nucleoli fibrillar center
Cytosol Renal cancer:1.77e-6 (unfavourable), Liver cancer:9.58e-6 (unfavourable), Urothelial cancer:1.62e-4 (favourable) Expressed in all Mixed skin: 15.2 C1orf162 MGC24133 ENSG00000143110 Chromosome 1 open reading frame 162 1 111473792-111478512 Predicted membrane proteins Evidence at protein level HPA026988 Approved Renal cancer:3.14e-6 (unfavourable) Expressed in all Expressed in all spleen: 131.2 C1orf210 MGC52423 ENSG00000253313 Chromosome 1 open reading frame 210 1 43281883-43285617 Predicted membrane proteins Evidence at protein level HPA013788 Uncertain Uncertain Nucleoli Renal cancer:0.00e+0 (favourable) Mixed Mixed duodenum: 45.5 C1orf27 FLJ20505, odr-4, TTG1 ENSG00000157181 Chromosome 1 open reading frame 27 1 186375838-186421378 Predicted membrane proteins Evidence at protein level HPA015988, HPA031352 Uncertain Approved Nucleoplasm
Plasma membrane Ovarian cancer:9.92e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 75.0 C1orf43 DKFZp586G1722, NICE-3 ENSG00000143612 Chromosome 1 open reading frame 43 1 154206706-154220628 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010725 Approved Liver cancer:6.57e-4 (unfavourable) Expressed in all Expressed in all kidney: 194.2 C1QTNF2 CTRP2 ENSG00000145861 C1q and tumor necrosis factor related protein 2 5 160347751-160370641 Predicted secreted proteins Evidence at protein level HPA061290 Approved Approved Golgi apparatus
Centrosome Mixed Mixed cervix, uterine: 4.5 C1QTNF6 CTRP6, ZACRP6 ENSG00000133466 C1q and tumor necrosis factor related protein 6 22 37180167-37199385 Predicted intracellular proteins Evidence at protein level HPA002042 Supported Approved Nucleus Renal cancer:0.00e+0 (unfavourable), Lung cancer:9.60e-6 (unfavourable) Expressed in all Tissue enhanced endometrium: 52.2;placenta: 41.1 gallbladder: 13.5 C20orf24 PNAS-11, RIP5 ENSG00000101084 Chromosome 20 open reading frame 24 20 36605734-36612557 Predicted membrane proteins Evidence at protein level HPA057387 Uncertain Approved Cytosol Liver cancer:4.56e-6 (unfavourable), Renal cancer:2.46e-4 (unfavourable) Expressed in all Expressed in all esophagus: 83.3 C2CD2L KIAA0285, TMEM24 ENSG00000172375 C2CD2-like 11 119102198-119118544 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011044 Approved Approved Nucleus
Nuclear membrane
Nucleoli
Cytosol Renal cancer:1.75e-4 (unfavourable), Endometrial cancer:4.92e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 29.7 C2orf74 LOC339804 ENSG00000237651 Chromosome 2 open reading frame 74 2 61145068-61164829 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA026826 Approved Approved Centrosome Mixed Expressed in all testis: 80.2 C2orf82 ASCL830, UNQ830 ENSG00000182600 Chromosome 2 open reading frame 82 2 232857270-232878708 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA052824 Uncertain Approved Nucleus
Nucleoli Endometrial cancer:3.56e-4 (unfavourable) Mixed Tissue enhanced breast: 5.2;testis: 4.1 cerebral cortex: 2.6 C3AR1 AZ3B, C3AR ENSG00000171860 Complement component 3a receptor 1 12 8058302-8066471 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB009405 Supported Expressed in all Tissue enhanced appendix: 88.4 placenta: 49.2 C3orf17 DKFZP434F2021, NET17 ENSG00000163608 Chromosome 3 open reading frame 17 3 113002440-113019861 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069654 Supported Nucleus
Nucleoli Endometrial cancer:1.13e-4 (unfavourable), Liver cancer:4.25e-4 (unfavourable) Expressed in all Expressed in all testis: 21.7 C3orf18 G20 ENSG00000088543 Chromosome 3 open reading frame 18 3 50558025-50571027 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA012105 Approved Approved Cytosol Renal cancer:2.80e-9 (favourable) Expressed in all Mixed parathyroid gland: 27.8 C3orf33 AC3-33, FLJ31139 ENSG00000174928 Chromosome 3 open reading frame 33 3 155762617-155806351 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA037663 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:6.48e-7 (favourable) Expressed in all Mixed thyroid gland: 14.4 C3orf52 FLJ23186, TTMP ENSG00000114529 Chromosome 3 open reading frame 52 3 112086335-112131004 Predicted membrane proteins Evidence at protein level HPA008119, HPA011968 Uncertain Pancreatic cancer:3.85e-4 (unfavourable) Mixed Tissue enhanced skin: 23.2 stomach: 16.7 C3orf80 ENSG00000180044 Chromosome 3 open reading frame 80 3 160225636-160228213 Predicted membrane proteins Evidence at transcript level HPA047439 Uncertain Mixed Tissue enhanced cerebral cortex: 1.9 duodenum: 0.5 C4orf3 ENSG00000164096 Chromosome 4 open reading frame 3 4 119296419-119304445 Predicted membrane proteins Evidence at protein level HPA026907 Approved Approved Cytosol Renal cancer:3.46e-4 (favourable) Expressed in all Expressed in all esophagus: 151.2 C4orf32 FLJ39370 ENSG00000174749 Chromosome 4 open reading frame 32 4 112145397-112195256 Predicted membrane proteins Evidence at protein level HPA062443, HPA069294 Approved Approved Golgi apparatus Stomach cancer:8.87e-4 (unfavourable) Mixed Mixed adipose tissue: 19.3 C5AR1 C5A, C5AR, C5R1, CD88 ENSG00000197405 Complement component 5a receptor 1 19 47290023-47322066 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002720, HPA014520 Approved Renal cancer:1.16e-4 (unfavourable), Cervical cancer:4.71e-4 (favourable), Testis cancer:7.99e-4 (unfavourable), Ovarian cancer:9.55e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 123.6 adipose tissue: 90.1 C5AR2 C5L2, GPR77 ENSG00000134830 Complement component 5a receptor 2 19 47332147-47347327 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA016629 Uncertain Tissue enhanced Tissue enhanced spleen: 9.9 appendix: 6.1 C5orf15 HTGN29, KCT2 ENSG00000113583 Chromosome 5 open reading frame 15 5 133955502-133968787 Predicted membrane proteins Evidence at protein level HPA011951, HPA039165 Uncertain Approved Golgi apparatus Expressed in all Expressed in all thyroid gland: 81.4 C5orf28 FLJ21657 ENSG00000151881 Chromosome 5 open reading frame 28 5 43444252-43483893 Predicted membrane proteins Evidence at protein level HPA059946 Approved Nucleoplasm Liver cancer:1.59e-4 (unfavourable), Renal cancer:2.85e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 64.8 C5orf42 FLJ13231, JBTS17 ENSG00000197603 Chromosome 5 open reading frame 42 5 37106228-37249428 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036775, HPA036776 Approved Approved Cytosol Mixed Mixed thyroid gland: 13.7 C6orf136 Em:AB023049.8 ENSG00000204564 Chromosome 6 open reading frame 136 6 30647039-30653210 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046804 Uncertain Renal cancer:9.16e-8 (favourable), Urothelial cancer:7.51e-4 (favourable) Expressed in all Mixed parathyroid gland: 8.0 C6orf25 G6b, NG31 ENSG00000204420 Chromosome 6 open reading frame 25 6 31718594-31726714 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA073017 Uncertain Golgi apparatus Mixed Not detected skin: 0.8 C6orf47 D6S53E, G4 ENSG00000204439 Chromosome 6 open reading frame 47 6 31658298-31660772 Predicted membrane proteins Evidence at protein level HPA045281, HPA053373 Uncertain Approved Cytosol Expressed in all Mixed skin: 5.4 C6orf89 BRAP, FLJ25357 ENSG00000198663 Chromosome 6 open reading frame 89 6 36871870-36928964 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012548 Uncertain Renal cancer:5.77e-5 (favourable) Expressed in all Expressed in all thyroid gland: 96.8 C7orf60 DKFZp762M126, FLJ31818 ENSG00000164603 Chromosome 7 open reading frame 60 7 112819147-112939916 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044405, HPA050733 Uncertain Approved Cytosol Expressed in all Mixed testis: 14.8 C8orf58 FLJ34715 ENSG00000241852 Chromosome 8 open reading frame 58 8 22599601-22604150 Predicted intracellular proteins Evidence at transcript level HPA024667, HPA028286 Uncertain Approved Nuclear bodies Renal cancer:3.58e-6 (unfavourable) Expressed in all Mixed testis: 28.1 C9orf69 bA83N9.1 ENSG00000238227 Chromosome 9 open reading frame 69 9 136114581-136118863 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066070 Supported Supported Nucleoplasm Endometrial cancer:1.09e-4 (favourable) Expressed in all Expressed in all skin: 23.8 C9orf84 FLJ32779 ENSG00000165181 Chromosome 9 open reading frame 84 9 111686173-111795008 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA032108 Approved Vesicles
Cytosol Mixed Tissue enriched 10 testis: 30.9 adrenal gland: 3.1 C9orf91 DKFZp547P234, FLJ38045 ENSG00000157693 Chromosome 9 open reading frame 91 9 114611206-114646422 Predicted membrane proteins Evidence at transcript level HPA017199 Approved Approved Plasma membrane
Cytosol Endometrial cancer:3.61e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 22.4 CA12 HsT18816 ENSG00000074410 Carbonic anhydrase XII 15 63321378-63382161 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA008773, CAB025181, CAB062549, CAB068179, HPA073203 Supported Approved Nucleus
Vesicles Pancreatic cancer:3.80e-6 (unfavourable) Expressed in all Tissue enhanced kidney: 307.3;skin: 168.7 rectum: 105.5 CA14 ENSG00000118298 Carbonic anhydrase XIV 1 150257159-150265078 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008482 Approved Approved Plasma membrane Group enriched Tissue enhanced cerebral cortex: 10.6;seminal vesicle: 21.1 skeletal muscle: 9.4 CA4 CAIV, Car4, RP17 ENSG00000167434 Carbonic anhydrase IV 17 60149936-60170899 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011089, HPA017258 Approved Supported Vesicles Mixed Tissue enhanced colon: 258.2;rectum: 183.7 adipose tissue: 88.6 CA9 CAIX, MN ENSG00000107159 Carbonic anhydrase IX 9 35673856-35681159 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB005100, CAB017107, HPA055207 Supported Validated Plasma membrane
Cytosol Renal cancer:2.22e-7 (unfavourable), Liver cancer:1.71e-5 (unfavourable), Testis cancer:9.50e-4 (favourable) Mixed Tissue enhanced gallbladder: 36.1;stomach: 92.4 small intestine: 14.8 CABLES2 C20orf150, dJ908M14.2, ik3-2 ENSG00000149679 Cdk5 and Abl enzyme substrate 2 20 62388632-62407285 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052138 Approved Nuclear bodies
Cell Junctions Renal cancer:1.24e-6 (unfavourable), Endometrial cancer:5.26e-5 (unfavourable) Expressed in all Tissue enriched 6 testis: 58.3 cerebral cortex: 9.0 CABP7 MGC57793 ENSG00000100314 Calcium binding protein 7 22 29720084-29731839 Predicted membrane proteins Evidence at protein level HPA016439 Uncertain Tissue enhanced Tissue enhanced adrenal gland: 2.5;cerebral cortex: 3.4 small intestine: 1.4 CACFD1 C9orf7, D9S2135, flower ENSG00000160325 Calcium channel flower domain containing 1 9 133459965-133470848 Predicted membrane proteins, Transporters Evidence at protein level HPA015280 Approved Nucleoplasm Renal cancer:2.83e-8 (favourable) Expressed in all Expressed in all thyroid gland: 16.6 CACHD1 KIAA1573, VWCD1 ENSG00000158966 Cache domain containing 1 1 64470792-64693058 Predicted membrane proteins Evidence at protein level HPA017202 Uncertain Uncertain Nucleus
Nucleoli Expressed in all Mixed ovary: 28.0 CACNA1A APCA, CACNL1A4, Cav2.1, EA2, FHM, HPCA, MHP, MHP1, SCA6 ENSG00000141837 Calcium channel, voltage-dependent, P/Q type, alpha 1A subunit 19 13206442-13623990 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064258 Supported Approved Nucleoplasm
Golgi apparatus
Vesicles Pancreatic cancer:4.32e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 18.1 stomach: 6.4 CACNA1B CACNL1A5, CACNN, Cav2.2 ENSG00000148408 Calcium channel, voltage-dependent, N type, alpha 1B subunit 9 137877789-138124624 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA044347 Uncertain Tissue enhanced Group enriched 8 adrenal gland: 3.7;cerebral cortex: 14.9;fallopian tube: 4.8;testis: 7.6 prostate: 1.0 CACNA1C CACH2, CACN2, CACNL1A1, Cav1.2, CCHL1A1, LQT8, TS ENSG00000151067 Calcium channel, voltage-dependent, L type, alpha 1C subunit 12 1970786-2697950 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039796 Supported Mixed Tissue enhanced smooth muscle: 30.9 endometrium: 26.2 CACNA1D CACH3, CACN4, CACNL1A2, Cav1.3, CCHL1A2 ENSG00000157388 Calcium channel, voltage-dependent, L type, alpha 1D subunit 3 53494656-53813733 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA020215 Uncertain Approved Nuclear membrane Renal cancer:8.34e-8 (favourable) Mixed Mixed fallopian tube: 13.7 CACNA1E BII, CACH6, CACNL1A6, Cav2.3 ENSG00000198216 Calcium channel, voltage-dependent, R type, alpha 1E subunit 1 181413102-181808084 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA042515 Approved Plasma membrane
Actin filaments
Cytosol Mixed Tissue enriched 7 cerebral cortex: 10.3 adrenal gland: 1.3 CACNA1G Cav3.1, NBR13 ENSG00000006283 Calcium channel, voltage-dependent, T type, alpha 1G subunit 17 50561068-50627474 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA004714 Uncertain Mixed Tissue enhanced cerebral cortex: 10.6;cervix, uterine: 8.5 endometrium: 5.2 CACNA1H Cav3.2 ENSG00000196557 Calcium channel, voltage-dependent, T type, alpha 1H subunit 16 1153241-1221771 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039125 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.78e-5 (unfavourable), Pancreatic cancer:3.12e-5 (favourable) Expressed in all Tissue enhanced ovary: 50.6 seminal vesicle: 46.9 CACNA1S CACNL1A3, Cav1.1, HOKPP, hypoPP, MHS5 ENSG00000081248 Calcium channel, voltage-dependent, L type, alpha 1S subunit 1 201039512-201112566 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB009507, HPA048892, HPA056815 Supported Tissue enhanced Tissue enriched 34 skeletal muscle: 103.0 esophagus: 3.0 CACNA2D1 CACNA2, CACNL2A, LINC01112, lncRNA-N3, MHS3 ENSG00000153956 Calcium channel, voltage-dependent, alpha 2/delta subunit 1 7 81946444-82443798 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA008213, HPA008621 Supported Renal cancer:1.16e-4 (unfavourable) Mixed Mixed cerebral cortex: 35.5 CACNA2D2 KIAA0558 ENSG00000007402 Calcium channel, voltage-dependent, alpha 2/delta subunit 2 3 50362799-50504244 FDA approved drug targets, Predicted intracellular proteins, Transporters Evidence at protein level HPA034771, HPA071829 Approved Approved Vesicles Endometrial cancer:7.62e-5 (unfavourable), Pancreatic cancer:1.21e-4 (favourable) Tissue enhanced Tissue enriched 6 lung: 73.0 testis: 12.4 CACNA2D3 HSA272268 ENSG00000157445 Calcium channel, voltage-dependent, alpha 2/delta subunit 3 3 54122547-55074557 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030849, HPA030850 Uncertain Nucleus
Cytosol Mixed Tissue enhanced cerebral cortex: 16.3 adrenal gland: 5.4 CACNG3 ENSG00000006116 Calcium channel, voltage-dependent, gamma subunit 3 16 24255553-24362801 Predicted membrane proteins, Transporters Evidence at protein level HPA059010 Approved Tissue enriched Tissue enriched 28 cerebral cortex: 42.6 adrenal gland: 1.5 CACNG4 MGC11138, MGC24983 ENSG00000075461 Calcium channel, voltage-dependent, gamma subunit 4 17 66964910-67033398 Predicted membrane proteins, Transporters Evidence at transcript level HPA005803, HPA065370 Approved Approved Cytosol Mixed Tissue enhanced cerebral cortex: 48.7;prostate: 18.8 lung: 9.3 CACNG5 ENSG00000075429 Calcium channel, voltage-dependent, gamma subunit 5 17 66835117-66885486 Predicted membrane proteins Evidence at protein level HPA050115 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 1.2 lymph node: 0.6 CACNG6 ENSG00000130433 Calcium channel, voltage-dependent, gamma subunit 6 19 53992288-54012669 Predicted membrane proteins, Transporters Evidence at transcript level HPA056615 Approved Nucleoli fibrillar center
Cytosol Mixed Group enriched 11 fallopian tube: 17.8;skeletal muscle: 33.9 lung: 2.3 CACNG8 ENSG00000142408 Calcium channel, voltage-dependent, gamma subunit 8 19 53963040-53990215 Predicted membrane proteins, Transporters Evidence at protein level HPA041351 Supported Tissue enriched Tissue enriched 32 cerebral cortex: 23.8 testis: 0.7 CADM1 BL2, IGSF4, IGSF4A, Necl-2, NECL2, RA175, ST17, SYNCAM, SYNCAM1, TSLC1 ENSG00000182985 Cell adhesion molecule 1 11 115169218-115504957 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037266 Supported Supported Cell Junctions Endometrial cancer:1.32e-4 (favourable) Expressed in all Mixed parathyroid gland: 119.5 CADM2 IGSF4D, Necl-3, NECL3, SynCAM2 ENSG00000175161 Cell adhesion molecule 2 3 84958981-86074429 Predicted membrane proteins Evidence at protein level HPA010024 Supported Tissue enriched Tissue enriched 14 cerebral cortex: 86.4 seminal vesicle: 6.2 CADM3 BIgR, FLJ10698, IGSF4B, Necl-1, NECL1, SynCAM3, TSLL1 ENSG00000162706 Cell adhesion molecule 3 1 159171609-159203313 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002981, CAB025746 Supported Renal cancer:1.03e-5 (unfavourable), Urothelial cancer:5.75e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 279.4;placenta: 113.9 cervix, uterine: 48.6 CADM4 IGSF4C, Necl-4, SynCAM4, TSLL2 ENSG00000105767 Cell adhesion molecule 4 19 43622368-43639839 Predicted membrane proteins Evidence at protein level HPA012612 Supported Approved Nucleus
Nuclear membrane Renal cancer:2.28e-6 (favourable) Expressed in all Tissue enhanced cerebral cortex: 164.1 parathyroid gland: 58.8 CALCR CTR ENSG00000004948 Calcitonin receptor 7 93424487-93574730 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA028962 Uncertain Tissue enriched Tissue enhanced kidney: 2.1;testis: 1.4 placenta: 0.9 CALCRL CGRPR, CRLR ENSG00000064989 Calcitonin receptor-like 2 187343129-187448460 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA008070, HPA046515 Uncertain Supported Plasma membrane Expressed in all Tissue enhanced lung: 114.4 adipose tissue: 76.3 CALHM1 FAM26C ENSG00000185933 Calcium homeostasis modulator 1 10 103453387-103458888 Predicted membrane proteins, Transporters Evidence at protein level HPA018317 Uncertain Not detected Tissue enhanced cerebral cortex: 1.8 kidney: 0.6 CALHM2 FAM26B ENSG00000138172 Calcium homeostasis modulator 2 10 103446786-103452402 Predicted membrane proteins, Transporters Evidence at protein level HPA014706 Approved Approved Nucleoplasm
Mitochondria
Cytosol Renal cancer:3.03e-6 (unfavourable) Expressed in all Mixed ovary: 44.9 CALHM3 bA225H22.7, FAM26A ENSG00000183128 Calcium homeostasis modulator 3 10 103472804-103479240 Predicted membrane proteins, Transporters Evidence at transcript level HPA018205 Uncertain Approved Nucleoplasm Tissue enhanced Not detected testis: 0.4 CALN1 ENSG00000183166 Calneuron 1 7 71779491-72447151 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036278, HPA036708 Approved Uncertain Vesicles
Plasma membrane Mixed Group enriched 5 adrenal gland: 14.8;cerebral cortex: 46.5 testis: 6.0 CALY CALCYON, DRD1IP, NSG3 ENSG00000130643 Calcyon neuron-specific vesicular protein 10 133324072-133336935 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042283 Uncertain Pancreatic cancer:3.54e-4 (favourable) Group enriched Group enriched 13 adrenal gland: 23.6;cerebral cortex: 77.3 testis: 3.8 CAMK2A CAMKA, CaMKIINalpha, KIAA0968 ENSG00000070808 Calcium/calmodulin-dependent protein kinase II alpha 5 150219491-150290291 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004330, HPA051783, HPA051785, HPA053973 Supported Supported Plasma membrane
Cell Junctions Tissue enriched Tissue enriched 9 cerebral cortex: 284.4 skeletal muscle: 33.3 CAMK2B CAM2, CAMK2, CAMKB ENSG00000058404 Calcium/calmodulin-dependent protein kinase II beta 7 44217150-44334577 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006849, HPA026307, HPA051783, HPA051785, HPA053973 Supported Supported Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 214.7 skeletal muscle: 46.1 CAMK2D CAMKD ENSG00000145349 Calcium/calmodulin-dependent protein kinase II delta 4 113451032-113761927 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026281, HPA051783, HPA051785, HPA053973 Approved Supported Plasma membrane
Cell Junctions Expressed in all Expressed in all parathyroid gland: 106.2 CAMK2G CAMKG ENSG00000148660 Calcium/calmodulin-dependent protein kinase II gamma 10 73812501-73874591 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040656, HPA051783, HPA051785, HPA053973 Approved Approved Plasma membrane
Cell Junctions
Cytosol Expressed in all Expressed in all cerebral cortex: 119.4 CAMLG CAML, GET2 ENSG00000164615 Calcium modulating ligand 5 134738501-134752160 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052636, HPA056472 Approved Approved Nucleus
Nucleoli
Vesicles Renal cancer:1.09e-5 (unfavourable) Expressed in all Expressed in all testis: 99.0 CANT1 SCAN-1, SHAPY ENSG00000171302 Calcium activated nucleotidase 1 17 78991717-79009867 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019627, HPA019639, HPA022818 Supported Liver cancer:1.41e-4 (unfavourable), Lung cancer:2.90e-4 (unfavourable), Renal cancer:6.21e-4 (unfavourable) Expressed in all Expressed in all prostate: 110.0 CANX CNX, IP90, P90 ENSG00000127022 Calnexin 5 179678628-179730925 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004738, HPA009433, HPA009696 Supported Validated Endoplasmic reticulum Colorectal cancer:1.38e-4 (favourable), Thyroid cancer:3.17e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 871.4 CAPZA2 CAPPA2, CAPZ ENSG00000198898 Capping protein (actin filament) muscle Z-line, alpha 2 7 116811070-116922049 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA007470, HPA007643 Uncertain Approved Endoplasmic reticulum
Cytosol Renal cancer:3.65e-6 (favourable), Liver cancer:9.34e-5 (unfavourable) Expressed in all Expressed in all smooth muscle: 41.9 CARD19 bA370F5.1, BinCARD, C9orf89, MGC11115 ENSG00000165233 Caspase recruitment domain family, member 19 9 93096218-93113283 Predicted membrane proteins Evidence at protein level HPA010921, HPA010990, HPA038297 Approved Supported Mitochondria Liver cancer:1.32e-5 (unfavourable), Glioma:6.41e-5 (unfavourable) Expressed in all Mixed testis: 11.2 CARNS1 ATPGD1, KIAA1394 ENSG00000172508 Carnosine synthase 1 11 67414968-67425607 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA038569 Approved Group enriched Group enriched 9 cerebral cortex: 37.2;skeletal muscle: 25.9 heart muscle: 3.4 CASC4 DKFZp459F1927, H63 ENSG00000166734 Cancer susceptibility candidate 4 15 44288729-44415758 Predicted intracellular proteins Evidence at protein level HPA043015, HPA049488 Approved Supported Golgi apparatus Renal cancer:1.45e-5 (favourable) Expressed in all Expressed in all thyroid gland: 141.1 CASD1 C7orf12, FLJ21213, FLJ21879 ENSG00000127995 CAS1 domain containing 1 7 94509219-94557019 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044404 Uncertain Approved Nucleoplasm Expressed in all Expressed in all cerebral cortex: 38.9 CASK CAGH39, FGS4, LIN2, TNRC8 ENSG00000147044 Calcium/calmodulin-dependent serine protein kinase (MAGUK family) X 41514934-41923463 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001949, HPA023857 Supported Approved Nucleoplasm
Cytosol Pancreatic cancer:6.11e-5 (unfavourable) Expressed in all Expressed in all small intestine: 35.2 CASR FHH, GPRC2A, HHC, HHC1, NSHPT ENSG00000036828 Calcium-sensing receptor 3 122183683-122286503 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039686, HPA050335 Supported Tissue enriched Tissue enriched 60 parathyroid gland: 1627.2 kidney: 27.0 CATSPER4 ENSG00000188782 Cation channel, sperm associated 4 1 26190561-26202968 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA045257 Supported Not detected Tissue enriched 63 testis: 9.7 skin: 0.1 CATSPERB C14orf161, FLJ14298 ENSG00000133962 Catsper channel auxiliary subunit beta 14 91580696-91780707 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035134 Uncertain Uncertain Vesicles Mixed Mixed skin: 2.7 CATSPERD MGC39581, TMEM146 ENSG00000174898 Catsper channel auxiliary subunit delta 19 5720677-5778734 Predicted membrane proteins, Transporters Evidence at protein level HPA024056 Supported Tissue enhanced Tissue enriched 160 testis: 15.9 all non-specific tissues: 0.0 CATSPERG C19orf15, DKFZp434A1022, FLJ46353 ENSG00000099338 Catsper channel auxiliary subunit gamma 19 38335775-38370943 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052777 Approved Nucleus
Nucleoli
Cytosol Mixed Tissue enriched 41 testis: 48.5 skin: 1.1 CAV1 CAV ENSG00000105974 Caveolin 1, caveolae protein, 22kDa 7 116524785-116561184 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB003791, HPA049326 Supported Supported Golgi apparatus Lung cancer:7.17e-5 (unfavourable), Renal cancer:1.29e-4 (unfavourable) Expressed in all Tissue enhanced lung: 860.5 adipose tissue: 638.7 CAV2 CAV ENSG00000105971 Caveolin 2 7 116287380-116508541 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013488, HPA044810 Supported Approved Vesicles Head and neck cancer:5.80e-5 (unfavourable), Pancreatic cancer:1.21e-4 (unfavourable) Expressed in all Mixed adipose tissue: 233.3 CAV3 LGMD1C, LQT9, VIP-21, VIP21 ENSG00000182533 Caveolin 3 3 8733800-8841808 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB017518, CAB018557, HPA054488 Supported Supported Vesicles
Plasma membrane Tissue enhanced Group enriched 6 heart muscle: 13.0;skeletal muscle: 63.3 esophagus: 6.0 CBARP BARP, C19orf26, DOS, MGC40084 ENSG00000099625 Calcium channel, voltage-dependent, beta subunit associated regulatory protein 19 1228287-1238027 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012777 Uncertain Approved Nucleoplasm Tissue enhanced Tissue enhanced adrenal gland: 2.4;cerebral cortex: 7.0 skin,testis: 1.1 CCDC108 DKFZp434O0527, MGC35338 ENSG00000181378 Coiled-coil domain containing 108 2 219002846-219041527 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA055156 Uncertain Endometrial cancer:6.08e-5 (favourable) Tissue enhanced Group enriched 7 fallopian tube: 40.7;testis: 17.7 lung: 4.0 CCDC109B FLJ20647 ENSG00000005059 Coiled-coil domain containing 109B 4 109560205-109688726 Predicted membrane proteins, Transporters Evidence at protein level HPA048776 Approved Approved Nucleoplasm
Cytosol Renal cancer:7.35e-6 (unfavourable) Expressed in all Mixed lymph node: 36.7 CCDC127 FLJ25701 ENSG00000164366 Coiled-coil domain containing 127 5 196871-218215 Predicted intracellular proteins Evidence at protein level HPA045052 Approved Supported Nucleus
Nucleoli fibrillar center Liver cancer:4.04e-6 (unfavourable), Renal cancer:5.95e-5 (unfavourable), Breast cancer:7.01e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 25.8 CCDC136 DKFZP434G156, KIAA1793, NAG6 ENSG00000128596 Coiled-coil domain containing 136 7 128790757-128822132 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010647, HPA071015 Supported Approved Nucleoli Mixed Tissue enriched 7 testis: 307.5 cerebral cortex: 44.3 CCDC141 CAMDI, FLJ39502 ENSG00000163492 Coiled-coil domain containing 141 2 178829757-179050086 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012718 Approved Nucleoplasm Not detected Tissue enriched 9 heart muscle: 48.7 skeletal muscle: 5.7 CCDC144A FLJ43983, KIAA0565 ENSG00000170160 Coiled-coil domain containing 144A 17 16689537-16777881 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022996, HPA047220, HPA047851 Approved Approved Nucleoplasm
Vesicles Not detected Tissue enhanced testis: 16.7 endometrium: 6.3 CCDC15 FLJ13215 ENSG00000149548 Coiled-coil domain containing 15 11 124954121-125041489 Predicted intracellular proteins Evidence at transcript level HPA040450, HPA041738 Uncertain Approved Plasma membrane
Cytosol Mixed Tissue enriched 5 testis: 18.8 breast: 3.5 CCDC155 FLJ32658, KASH5 ENSG00000161609 Coiled-coil domain containing 155 19 49388218-49417994 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019937, HPA019940 Approved Tissue enhanced Tissue enriched 135 testis: 56.9 pancreas: 0.4 CCDC167 C6orf129, dJ153P14.2 ENSG00000198937 Coiled-coil domain containing 167 6 37482920-37499922 Predicted membrane proteins Evidence at protein level HPA045215 Uncertain Approved Cytosol Renal cancer:1.71e-7 (unfavourable), Liver cancer:2.94e-4 (unfavourable), Cervical cancer:7.59e-4 (favourable) Expressed in all Expressed in all tonsil: 57.5 CCDC168 C13orf40, FLJ40176 ENSG00000175820 Coiled-coil domain containing 168 13 102729369-102759070 Predicted membrane proteins Evidence at protein level HPA048184, HPA058793 Uncertain Not detected Tissue enriched 12 testis: 7.5 epididymis: 0.6 CCDC171 bA536D16.1, bA778P13.1, C9orf93, Em:AL513423.1, FLJ39267, FLJ46740 ENSG00000164989 Coiled-coil domain containing 171 9 15552897-16061663 Predicted intracellular proteins Evidence at protein level HPA019803, HPA019806, HPA024133 Uncertain Approved Nucleus Mixed Tissue enhanced testis: 21.3 endometrium: 9.7 CCDC188 ENSG00000234409 Coiled-coil domain containing 188 22 20148427-20151065 Predicted membrane proteins Evidence at transcript level HPA049901 Approved Nucleoplasm
Nuclear bodies Mixed Tissue enriched 10 testis: 18.2 spleen: 1.9 CCDC47 GK001 ENSG00000108588 Coiled-coil domain containing 47 17 63745250-63776351 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029674, HPA072573 Approved Validated Endoplasmic reticulum Colorectal cancer:2.17e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 159.7 CCDC51 FLJ12436 ENSG00000164051 Coiled-coil domain containing 51 3 48432164-48440456 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010980, HPA011408 Supported Supported Nucleoplasm
Centrosome
Mitochondria Expressed in all Mixed thyroid gland: 17.2 CCDC67 FLJ25393 ENSG00000165325 Coiled-coil domain containing 67 11 93329971-93438487 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010986 Uncertain Not detected Group enriched 11 fallopian tube: 7.6;testis: 29.8 prostate,thyroid gland: 1.6 CCDC80 DRO1, SSG1, URB ENSG00000091986 Coiled-coil domain containing 80 3 112596794-112649530 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002266 Approved Renal cancer:2.86e-5 (unfavourable), Urothelial cancer:1.26e-4 (unfavourable) Expressed in all Mixed smooth muscle: 526.0 CCDC90B MDS011, MDS025 ENSG00000137500 Coiled-coil domain containing 90B 11 83259097-83286407 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011130, HPA011931 Supported Validated Mitochondria Expressed in all Expressed in all testis: 96.2 CCNC CycC ENSG00000112237 Cyclin C 6 99542380-99568973 Predicted intracellular proteins Evidence at protein level CAB010499, HPA069322 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:8.12e-4 (favourable) Expressed in all Expressed in all thyroid gland: 99.7 CCND3 ENSG00000112576 Cyclin D3 6 41934933-42050357 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB000116, HPA055107 Approved Supported Plasma membrane
Focal adhesion sites
Cytosol Thyroid cancer:8.08e-6 (favourable) Expressed in all Expressed in all lymph node: 161.4 CCNF FBX1, FBXO1 ENSG00000162063 Cyclin F 16 2429394-2458854 Predicted intracellular proteins Evidence at protein level HPA060596, HPA070495, HPA071600 Supported Supported Centrosome Liver cancer:7.46e-7 (unfavourable) Expressed in all Mixed tonsil: 9.1 CCNJL FLJ14166 ENSG00000135083 Cyclin J-like 5 160251652-160345396 Predicted intracellular proteins Evidence at protein level HPA049970 Approved Approved Nuclear speckles Thyroid cancer:7.10e-4 (favourable), Colorectal cancer:7.31e-4 (favourable), Urothelial cancer:8.02e-4 (favourable) Mixed Tissue enhanced testis: 19.4 lung: 10.3 CCPG1 CPR8, KIAA1254 ENSG00000260916 Cell cycle progression 1 15 55340032-55408510 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009432, HPA026861 Approved Approved Endoplasmic reticulum
Golgi apparatus Stomach cancer:5.02e-5 (unfavourable), Renal cancer:5.07e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 139.9 CCR10 GPR2 ENSG00000184451 Chemokine (C-C motif) receptor 10 17 42678889-42683917 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011684, HPA048007, HPA069188 Uncertain Supported Endoplasmic reticulum Mixed Mixed adipose tissue: 4.5 CCR2 CC-CKR-2, CD192, CKR2, CMKBR2, FLJ78302, MCP-1-R ENSG00000121807 Chemokine (C-C motif) receptor 2 3 46353734-46360928 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB003793 Approved Lung cancer:5.87e-4 (favourable) Mixed Tissue enhanced appendix: 53.0 spleen: 20.8 CCR3 CC-CKR-3, CD193, CKR3, CMKBR3 ENSG00000183625 Chemokine (C-C motif) receptor 3 3 46163604-46266706 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB003795 Uncertain Not detected Mixed small intestine: 3.0 CCR4 CC-CKR-4, CD194, ChemR13, CKR4, CMKBR4, k5-5 ENSG00000183813 Chemokine (C-C motif) receptor 4 3 32951574-32956349 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031613 Approved Mixed Tissue enhanced appendix: 11.8 urinary bladder: 9.2 CCR6 BN-1, CD196, CKR-L3, CMKBR6, DCR2, DRY-6, GPR-CY4, GPR29, STRL22 ENSG00000112486 Chemokine (C-C motif) receptor 6 6 167111807-167139696 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB006820, HPA014488 Approved Not detected Tissue enhanced lymph node: 20.6;tonsil: 33.8 spleen: 17.3 CCR7 BLR2, CD197, CDw197, CMKBR7, EBI1 ENSG00000126353 Chemokine (C-C motif) receptor 7 17 40553769-40565472 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB003796, HPA031383, HPA074467 Supported Supported Mitochondria Head and neck cancer:7.61e-7 (favourable), Cervical cancer:8.03e-6 (favourable), Breast cancer:3.84e-4 (favourable), Testis cancer:7.72e-4 (unfavourable) Mixed Group enriched 6 appendix: 91.9;lymph node: 98.3;spleen: 39.9;tonsil: 80.2 urinary bladder: 12.9 CCR9 CDw199, GPR-9-6, GPR28 ENSG00000173585 Chemokine (C-C motif) receptor 9 3 45886504-45903177 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006839 Uncertain Not detected Group enriched 6 appendix: 1.5;duodenum: 3.9;small intestine: 5.8;spleen: 1.2 lymph node: 0.5 CCRL2 ACKR5, CKRX, CRAM-A, CRAM-B, HCR ENSG00000121797 Chemokine (C-C motif) receptor-like 2 3 46407163-46412997 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA043238 Approved Colorectal cancer:3.72e-5 (favourable), Urothelial cancer:9.67e-5 (favourable) Mixed Mixed lung: 17.7 CD101 IGSF2, V7 ENSG00000134256 CD101 molecule 1 117001750-117036476 CD markers, Predicted membrane proteins Evidence at protein level HPA057763 Approved Mixed Tissue enhanced lung: 9.6 small intestine: 7.0 CD151 PETA-3, RAPH, SFA-1, TSPAN24 ENSG00000177697 CD151 molecule (Raph blood group) 11 832843-839831 Blood group antigen proteins, CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002428, HPA011906 Supported Liver cancer:5.58e-4 (unfavourable), Thyroid cancer:6.92e-4 (favourable), Lung cancer:9.46e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 356.5 CD163 M130, MM130 ENSG00000177575 CD163 molecule 12 7470813-7503893 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002432, HPA046404, HPA051974 Supported Approved Plasma membrane Ovarian cancer:7.27e-4 (unfavourable) Expressed in all Mixed appendix: 224.6 CD163L1 CD163B, M160 ENSG00000177675 CD163 molecule-like 1 12 7346685-7479897 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015663 Supported Approved Nucleoplasm
Centrosome
Cytosol Mixed Tissue enhanced spleen: 43.9 rectum: 24.5 CD164 DFNA66, MGC-24, MUC-24 ENSG00000135535 CD164 molecule, sialomucin 6 109366514-109382559 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010636 Uncertain Expressed in all Expressed in all thyroid gland: 608.3 CD164L2 ENSG00000174950 CD164 sialomucin-like 2 1 27379176-27383380 Predicted membrane proteins Evidence at protein level HPA062915 Approved Head and neck cancer:1.64e-5 (favourable) Mixed Tissue enhanced fallopian tube: 45.7 skin: 10.7 CD180 LY64, Ly78, RP105 ENSG00000134061 CD180 molecule 5 67179613-67196799 CD markers, Predicted membrane proteins Evidence at protein level HPA003740 Supported Mixed Tissue enhanced lymph node: 27.8;tonsil: 22.2 spleen: 18.0 CD19 ENSG00000177455 CD19 molecule 16 28931939-28939346 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB016110 Supported Mixed Group enriched 11 appendix: 38.8;lymph node: 85.0;spleen: 48.2;tonsil: 70.8 urinary bladder: 5.7 CD1A CD1 ENSG00000158477 CD1a molecule 1 158254137-158258269 CD markers, Predicted membrane proteins Evidence at protein level CAB000009, HPA010734 Supported Cervical cancer:6.37e-4 (favourable) Mixed Group enriched 6 esophagus: 9.5;skin: 27.1 tonsil: 3.1 CD1B CD1 ENSG00000158485 CD1b molecule 1 158327951-158331531 CD markers, Predicted membrane proteins Evidence at protein level HPA021824 Approved Mixed Tissue enhanced rectum: 3.2;skin: 3.9 lymph node: 2.8 CD1D ENSG00000158473 CD1d molecule 1 158179947-158184896 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB016107, HPA072662 Uncertain Supported Endoplasmic reticulum Renal cancer:2.12e-5 (unfavourable) Mixed Mixed spleen: 20.9 CD1E ENSG00000158488 CD1e molecule 1 158353696-158357553 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA057769 Uncertain Mixed Tissue enhanced skin: 18.3 tonsil: 10.8 CD2 SRBC ENSG00000116824 CD2 molecule 1 116754385-116769228 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002430, HPA003883 Supported Renal cancer:4.82e-6 (unfavourable), Endometrial cancer:1.69e-5 (favourable), Melanoma:3.97e-5 (favourable), Head and neck cancer:7.46e-5 (favourable), Cervical cancer:1.47e-4 (favourable), Breast cancer:4.36e-4 (favourable), Ovarian cancer:7.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 132.9 tonsil: 73.5 CD200 MOX1, MOX2, MRC, OX-2 ENSG00000091972 CD200 molecule 3 112332347-112362812 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA031149 Approved Expressed in all Mixed cerebral cortex: 78.8 CD207 CLEC4K, Langerin ENSG00000116031 CD207 molecule, langerin 2 70830214-70835822 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB002222, HPA011216 Supported Uncertain Cytosol Mixed Tissue enriched 5 skin: 104.2 esophagus: 19.4 CD209 CDSIGN, CLEC4L, DC-SIGN, DC-SIGN1 ENSG00000090659 CD209 molecule 19 7739994-7747564 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB032436, CAB033831 Supported Renal cancer:1.15e-5 (unfavourable) Mixed Tissue enhanced adipose tissue: 43.4 placenta: 32.8 CD22 SIGLEC-2, SIGLEC2 ENSG00000012124 CD22 molecule 19 35319261-35347355 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002418, HPA024353 Supported Mixed Tissue enhanced lymph node: 269.3;ovary: 163.3;spleen: 155.4;tonsil: 219.0 appendix: 102.4 CD226 DNAM-1, DNAM1, PTA1, TLiSA1 ENSG00000150637 CD226 molecule 18 69831158-69961803 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015715 Supported Not detected Tissue enriched 11 parathyroid gland: 312.4 spleen: 28.8 CD247 CD3H, CD3Q, CD3Z ENSG00000198821 CD247 molecule 1 167430640-167518610 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004651, HPA008750 Supported Endometrial cancer:8.63e-6 (favourable), Renal cancer:9.94e-6 (unfavourable), Head and neck cancer:3.98e-4 (favourable), Breast cancer:9.12e-4 (favourable) Mixed Tissue enhanced lymph node: 66.0;spleen: 49.4 tonsil: 34.9 CD248 CD164L1, TEM1 ENSG00000174807 CD248 molecule, endosialin 11 66314487-66317044 CD markers, Predicted membrane proteins Evidence at protein level HPA051856 Uncertain Approved Nucleoplasm
Plasma membrane Renal cancer:2.69e-7 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 136.1 placenta: 96.3 CD27 S152, TNFRSF7, Tp55 ENSG00000139193 CD27 molecule 12 6444867-6451718 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002420, HPA038936 Supported Head and neck cancer:6.65e-7 (favourable), Renal cancer:1.19e-6 (unfavourable), Cervical cancer:3.77e-5 (favourable), Endometrial cancer:2.90e-4 (favourable), Melanoma:5.50e-4 (favourable) Expressed in all Tissue enhanced lymph node: 142.5;tonsil: 90.3 spleen: 69.5 CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1 ENSG00000120217 CD274 molecule 9 5450503-5470566 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB030018 Approved Cytosol Colorectal cancer:1.64e-5 (favourable), Breast cancer:8.89e-4 (favourable) Mixed Mixed appendix: 14.4 CD276 B7-H3, B7H3, B7RP-2 ENSG00000103855 CD276 molecule 15 73683966-73714518 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009285, HPA017139, CAB017826 Approved Approved Vesicles Renal cancer:6.31e-5 (unfavourable), Liver cancer:9.81e-4 (unfavourable) Expressed in all Mixed placenta: 30.1 CD28 ENSG00000178562 CD28 molecule 2 203706475-203738912 CD markers, Predicted membrane proteins Evidence at protein level HPA070003 Supported Mixed Tissue enhanced lymph node: 32.9;placenta: 20.8 appendix: 19.2 CD300A CMRF-35-H9, CMRF35H, IGSF12, IRC1, IRC2, Irp60 ENSG00000167851 CD300a molecule 17 74466416-74484796 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011645 Approved Renal cancer:1.91e-5 (unfavourable) Expressed in all Tissue enhanced spleen: 87.2 appendix: 41.1 CD300C CMRF-35A, CMRF35, CMRF35A, IGSF16, LIR ENSG00000167850 CD300c molecule 17 74541108-74546143 CD markers, Predicted membrane proteins Evidence at transcript level HPA014523 Approved Testis cancer:8.53e-5 (unfavourable) Mixed Tissue enhanced lung: 12.5 appendix: 9.7 CD300E CD300LE, CLM2, IREM2 ENSG00000186407 CD300e molecule 17 74609887-74623738 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015570 Uncertain Mixed Tissue enhanced appendix: 53.9;bone marrow: 29.0 adipose tissue: 17.9 CD300LD CD300D, CMRF35A4 ENSG00000204345 CD300 molecule-like family member d 17 74579365-74592283 CD markers, Predicted membrane proteins Evidence at protein level HPA027756 Uncertain Not detected Mixed appendix,breast: 1.0 CD300LF CD300f, CLM1, IGSF13, IREM1, NKIR ENSG00000186074 CD300 molecule-like family member f 17 74694311-74712978 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013712 Supported Expressed in all Tissue enhanced lung: 25.6;spleen: 28.6 appendix: 18.8 CD320 8D6, 8D6A ENSG00000167775 CD320 molecule 19 8302127-8308356 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA014500, HPA073489 Uncertain Approved Cytosol Liver cancer:4.02e-4 (unfavourable) Expressed in all Expressed in all epididymis: 75.7 CD33 FLJ00391, p67, SIGLEC-3, SIGLEC3 ENSG00000105383 CD33 molecule 19 51225064-51243860 CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011442, HPA035832, HPA064807 Approved Supported Nucleus
Plasma membrane Mixed Tissue enhanced spleen: 33.6 bone marrow: 20.9 CD34 ENSG00000174059 CD34 molecule 1 207880972-207911402 CD markers, Predicted membrane proteins Evidence at protein level CAB000018, HPA036722, HPA036723 Supported Approved Nucleus
Plasma membrane
Cell Junctions Head and neck cancer:5.93e-5 (favourable), Renal cancer:8.47e-4 (unfavourable) Expressed in all Expressed in all placenta: 313.8 CD36 FAT, GP3B, GP4, GPIV, SCARB3 ENSG00000135218 CD36 molecule (thrombospondin receptor) 7 80369575-80679277 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA002018, CAB025866 Supported Stomach cancer:4.47e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 1614.0 CD37 TSPAN26 ENSG00000104894 CD37 molecule 19 49335171-49343335 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002492, HPA032120, HPA032121 Supported Endometrial cancer:4.51e-4 (favourable) Expressed in all Tissue enhanced lymph node: 244.2;spleen: 212.9 appendix: 133.5 CD38 ENSG00000004468 CD38 molecule 4 15778275-15853230 Cancer-related genes, CD markers, Enzymes, Predicted intracellular proteins Evidence at protein level CAB002493, HPA022132, CAB025255, HPA052381 Supported Approved Plasma membrane Endometrial cancer:9.68e-4 (favourable) Expressed in all Mixed lymph node,seminal vesicle: 27.3 CD3D T3D ENSG00000167286 CD3d molecule, delta (CD3-TCR complex) 11 118338954-118342744 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013055 Supported Endometrial cancer:1.73e-7 (favourable), Renal cancer:3.07e-5 (unfavourable), Cervical cancer:8.46e-5 (favourable), Head and neck cancer:1.70e-4 (favourable), Breast cancer:3.00e-4 (favourable), Urothelial cancer:6.16e-4 (favourable) Expressed in all Tissue enhanced lymph node: 202.6;tonsil: 124.1 appendix: 90.4 CD3E ENSG00000198851 CD3e molecule, epsilon (CD3-TCR complex) 11 118304545-118316175 CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000010, HPA040957, HPA043955, CAB072863, CAB072864 Supported Endometrial cancer:2.30e-6 (favourable), Renal cancer:1.12e-5 (unfavourable), Melanoma:1.18e-4 (favourable), Head and neck cancer:1.32e-4 (favourable), Cervical cancer:1.62e-4 (favourable), Breast cancer:1.72e-4 (favourable) Expressed in all Tissue enhanced lymph node: 203.4;tonsil: 118.2 appendix: 97.3 CD3G ENSG00000160654 CD3g molecule, gamma (CD3-TCR complex) 11 118344344-118355161 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017520, HPA038494 Supported Renal cancer:9.33e-5 (unfavourable), Cervical cancer:2.61e-4 (favourable), Head and neck cancer:3.00e-4 (favourable), Breast cancer:6.33e-4 (favourable) Mixed Tissue enhanced lymph node: 31.8;tonsil: 19.7 spleen: 16.3 CD4 ENSG00000010610 CD4 molecule 12 6786858-6820808 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000011, HPA004252, HPA004472, CAB068180 Supported Supported Plasma membrane Endometrial cancer:2.16e-4 (favourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 538.7 spleen: 224.0 CD40 Bp50, p50, TNFRSF5 ENSG00000101017 CD40 molecule, TNF receptor superfamily member 5 20 46118272-46129863 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002495, HPA031567, HPA031568, CAB072868 Supported Renal cancer:4.48e-4 (unfavourable) Expressed in all Expressed in all lymph node: 65.6 CD40LG CD154, CD40L, gp39, hCD40L, HIGM1, IMD3, TNFSF5, TRAP ENSG00000102245 CD40 ligand X 136648193-136660390 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA045827 Supported Mixed Tissue enhanced lymph node: 19.0;tonsil: 14.7 appendix: 10.9 CD44 CD44R, CSPG8, HCELL, IN, MC56, MDU2, MDU3, MIC4, Pgp1 ENSG00000026508 CD44 molecule (Indian blood group) 11 35138870-35232402 Blood group antigen proteins, Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000112, CAB000316, HPA005785 Supported Validated Golgi apparatus
Plasma membrane Renal cancer:1.78e-8 (unfavourable) Expressed in all Expressed in all skin: 505.8 CD46 MCP, MGC26544, MIC10, TLX, TRA2.10 ENSG00000117335 CD46 molecule, complement regulatory protein 1 207752057-207795513 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB010401, HPA016903 Supported Approved Plasma membrane Cervical cancer:8.54e-5 (unfavourable), Stomach cancer:2.38e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 483.7 CD47 IAP, MER6, OA3 ENSG00000196776 CD47 molecule 3 108043298-108091025 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016055, HPA044659 Approved Supported Golgi apparatus
Vesicles
Plasma membrane Thyroid cancer:7.29e-5 (favourable), Renal cancer:1.69e-4 (unfavourable), Endometrial cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all lung: 204.9 CD48 BCM1, BLAST, hCD48, mCD48, SLAMF2 ENSG00000117091 CD48 molecule 1 160678746-160711851 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002497, HPA055146 Supported Supported Nucleoli fibrillar center
Plasma membrane
Cytosol Renal cancer:3.36e-4 (unfavourable), Breast cancer:3.91e-4 (favourable), Colorectal cancer:4.17e-4 (favourable) Expressed in all Tissue enhanced lymph node: 315.8;spleen: 216.7;tonsil: 235.9 appendix: 153.7 CD5 LEU1, T1 ENSG00000110448 CD5 molecule 11 61102395-61127852 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015392, CAB020308, HPA043416, HPA060839 Supported Head and neck cancer:7.41e-6 (favourable), Renal cancer:8.94e-5 (unfavourable), Endometrial cancer:9.00e-5 (favourable), Cervical cancer:9.16e-5 (favourable), Melanoma:3.93e-4 (favourable), Breast cancer:4.05e-4 (favourable) Mixed Tissue enhanced appendix: 31.0;lymph node: 43.6 tonsil: 21.1 CD53 MOX44, TSPAN25 ENSG00000143119 CD53 molecule 1 110873154-110899928 CD markers, Predicted membrane proteins Evidence at protein level HPA047216 Approved Renal cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all lymph node: 468.7 CD6 Tp120 ENSG00000013725 CD6 molecule 11 60971680-61020377 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002489, CAB016252 Supported Head and neck cancer:5.10e-6 (favourable), Cervical cancer:1.57e-5 (favourable), Renal cancer:1.82e-4 (unfavourable), Breast cancer:1.95e-4 (favourable), Endometrial cancer:2.41e-4 (favourable) Mixed Tissue enhanced appendix: 29.5;lymph node: 49.8 tonsil: 27.7 CD63 ME491, MLA1, TSPAN30 ENSG00000135404 CD63 molecule 12 55725323-55729707 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA010088, CAB026356 Supported Supported Vesicles Liver cancer:1.37e-4 (unfavourable) Expressed in all Expressed in all epididymis: 1712.6 CD68 DKFZp686M18236, GP110, LAMP4, macrosialin, SCARD1 ENSG00000129226 CD68 molecule 17 7579467-7582113 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000051, CAB000066, HPA048982, CAB072861, CAB072862 Supported Supported Golgi apparatus
Vesicles Renal cancer:1.14e-5 (unfavourable) Mixed Expressed in all lung: 534.2 CD69 CLEC2C ENSG00000110848 CD69 molecule 12 9752486-9760901 CD markers, Predicted membrane proteins Evidence at protein level CAB002503, HPA050525 Supported Breast cancer:3.31e-5 (favourable), Renal cancer:7.87e-5 (unfavourable) Mixed Tissue enhanced bone marrow: 106.2;lymph node: 110.6 appendix: 66.2 CD7 GP40, LEU-9, Tp40, TP41 ENSG00000173762 CD7 molecule 17 82314868-82317602 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002594, HPA039079 Supported Renal cancer:7.75e-11 (unfavourable), Endometrial cancer:2.03e-5 (favourable), Melanoma:2.69e-4 (favourable), Cervical cancer:5.51e-4 (favourable) Expressed in all Tissue enhanced appendix: 44.8;lymph node: 42.1;spleen: 44.0 small intestine: 17.4 CD70 CD27L, CD27LG, TNFSF7 ENSG00000125726 CD70 molecule 19 6583183-6604103 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046582 Uncertain Nucleoplasm Renal cancer:3.22e-4 (unfavourable), Lung cancer:6.29e-4 (unfavourable) Tissue enhanced Tissue enhanced appendix: 4.5 lymph node: 3.9 CD72 CD72b, LYB2 ENSG00000137101 CD72 molecule 9 35609533-35646810 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002505, HPA044658 Supported Approved Nucleus
Mitochondria Renal cancer:2.49e-8 (unfavourable) Expressed in all Group enriched 8 appendix: 26.2;lymph node: 72.0;spleen: 65.9;tonsil: 44.3 gallbladder,urinary bladder: 6.2 CD74 DHLAG ENSG00000019582 CD74 molecule, major histocompatibility complex, class II invariant chain 5 150401637-150412929 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB002506, HPA010592 Supported Supported Golgi apparatus Endometrial cancer:6.53e-6 (favourable), Breast cancer:1.06e-4 (favourable) Expressed in all Expressed in all spleen: 6665.5 CD79A IGA, MB-1 ENSG00000105369 CD79a molecule, immunoglobulin-associated alpha 19 41877120-41881372 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000019 Supported Head and neck cancer:1.18e-5 (favourable), Renal cancer:2.15e-5 (unfavourable), Breast cancer:8.45e-5 (favourable) Mixed Group enriched 6 appendix: 275.4;lymph node: 522.9;spleen: 324.4;tonsil: 440.3 stomach: 62.7 CD79B B29, IGB ENSG00000007312 CD79b molecule, immunoglobulin-associated beta 17 63928740-63932354 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA009178, CAB009751 Approved Uncertain Nucleoplasm
Plasma membrane
Cytosol Head and neck cancer:2.35e-4 (favourable) Expressed in all Group enriched 5 appendix: 94.7;lymph node: 315.6;spleen: 160.3;tonsil: 196.1 bone marrow: 36.2 CD80 B7-1, B7.1, CD28LG, CD28LG1 ENSG00000121594 CD80 molecule 3 119524293-119559602 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025368, HPA050092 Supported Mixed Tissue enhanced appendix: 7.4;lymph node: 6.8;tonsil: 6.1 spleen: 4.6 CD81 TAPA-1, TAPA1, TSPAN28 ENSG00000110651 CD81 molecule 11 2376177-2397419 CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002507, HPA007234 Supported Supported Plasma membrane Glioma:5.12e-5 (unfavourable), Pancreatic cancer:3.86e-4 (favourable), Colorectal cancer:7.56e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 2246.2 CD82 IA4, KAI1, R2, ST6, TSPAN27 ENSG00000085117 CD82 molecule 11 44564427-44620363 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002508, HPA028900, HPA061418 Supported Approved Vesicles Expressed in all Expressed in all esophagus: 132.1 CD83 BL11, HB15 ENSG00000112149 CD83 molecule 6 14117256-14136918 CD markers, Predicted membrane proteins Evidence at protein level CAB002509, HPA041454 Supported Approved Vesicles Renal cancer:3.49e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 131.1 tonsil: 66.5 CD84 hCD84, mCD84, SLAMF5 ENSG00000066294 CD84 molecule 1 160541095-160579516 CD markers, Predicted membrane proteins Evidence at protein level HPA070502 Supported Expressed in all Tissue enhanced lymph node: 28.8 appendix: 27.5 CD86 B7-2, B7.2, CD28LG2 ENSG00000114013 CD86 molecule 3 122055366-122121139 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004319 Uncertain Renal cancer:9.83e-5 (unfavourable) Expressed in all Tissue enhanced appendix: 49.1 spleen: 32.9 CD8A CD8 ENSG00000153563 CD8a molecule 2 86784610-86808396 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000012, HPA037756, CAB075722 Supported Endometrial cancer:6.15e-6 (favourable), Renal cancer:1.91e-5 (unfavourable), Cervical cancer:4.54e-4 (favourable) Expressed in all Tissue enhanced spleen: 164.7 lymph node: 47.7 CD8B CD8B1 ENSG00000172116 CD8b molecule 2 86815339-86861924 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004353, HPA029164 Approved Supported Plasma membrane Endometrial cancer:7.88e-7 (favourable), Renal cancer:7.11e-6 (unfavourable) Mixed Tissue enhanced cervix, uterine: 60.5;lymph node: 40.2 parathyroid gland: 22.4 CD9 BA2, MIC3, MRP-1, P24, TSPAN29 ENSG00000010278 CD9 molecule 12 6199715-6238271 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002490 Supported Supported Plasma membrane Renal cancer:6.49e-5 (favourable), Thyroid cancer:8.93e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all esophagus: 1009.8 CD93 C1qR(P), C1QR1, C1qRP, CDw93, dJ737E23.1, ECSM3, MXRA4 ENSG00000125810 CD93 molecule 20 23079349-23086340 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA009300, HPA012368 Supported Approved Vesicles
Plasma membrane Renal cancer:2.74e-4 (unfavourable) Expressed in all Expressed in all placenta: 195.4 CD96 TACTILE ENSG00000153283 CD96 molecule 3 111292719-111665750 CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066754 Supported Renal cancer:2.02e-6 (unfavourable), Urothelial cancer:5.23e-5 (favourable), Head and neck cancer:5.52e-4 (favourable) Mixed Tissue enhanced lymph node: 28.4 urinary bladder: 17.4 CD99 MIC2 ENSG00000002586 CD99 molecule X 2691179-2741309 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000020, HPA035304 Supported Approved Golgi apparatus Renal cancer:5.87e-7 (unfavourable) Expressed in all Expressed in all gallbladder: 376.9 CD99L2 CD99B, MIC2L1 ENSG00000102181 CD99 molecule-like 2 X 150766337-150898816 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038782, HPA038783 Supported Uncertain Golgi apparatus
Plasma membrane
Intermediate filaments Pancreatic cancer:2.74e-5 (favourable), Lung cancer:4.96e-4 (favourable), Urothelial cancer:8.74e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 143.9 CDAN1 CDA-I, CDAI ENSG00000140326 Codanin 1 15 42723559-42737126 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039404, HPA040787 Supported Validated Plasma membrane
Cytosol Liver cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all ovary: 15.1 CDC14B Cdc14B1, Cdc14B2, CDC14B3, hCDC14B ENSG00000081377 Cell division cycle 14B 9 96490241-96619830 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013312 Approved Supported Nuclear membrane Renal cancer:2.97e-10 (favourable), Thyroid cancer:2.82e-4 (unfavourable) Expressed in all Mixed testis: 18.5 CDCA7L JPO2, R1, RAM2 ENSG00000164649 Cell division cycle associated 7-like 7 21900900-21946084 Predicted intracellular proteins Evidence at protein level HPA027169 Approved Supported Nucleus
Nucleoli
Cytosol Liver cancer:4.36e-6 (unfavourable), Renal cancer:1.98e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 45.8 CDCP1 CD318, SIMA135 ENSG00000163814 CUB domain containing protein 1 3 45082278-45146422 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010978, HPA010979, CAB025637 Supported Lung cancer:1.41e-5 (unfavourable), Pancreatic cancer:1.48e-4 (unfavourable) Expressed in all Mixed skin: 27.8 CDH1 CD324, UVO, uvomorulin ENSG00000039068 Cadherin 1, type 1 16 68737225-68835548 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000087, HPA004812, CAB028364, CAB072855, CAB072856, CAB072857 Supported Supported Golgi apparatus
Plasma membrane
Cell Junctions Renal cancer:2.06e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 467.0 thyroid gland: 264.7 CDH10 ENSG00000040731 Cadherin 10, type 2 (T2-cadherin) 5 24487100-24644978 Predicted membrane proteins Evidence at protein level HPA010651 Approved Group enriched Group enriched 19 cerebral cortex: 32.7;prostate: 6.8 adrenal gland: 1.0 CDH11 CAD11, OB ENSG00000140937 Cadherin 11, type 2, OB-cadherin (osteoblast) 16 64943753-65126112 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013072 Approved Renal cancer:2.48e-9 (unfavourable) Expressed in all Tissue enhanced ovary: 223.0 placenta: 172.7 CDH12 Br-cadherin, CDHB ENSG00000154162 Cadherin 12, type 2 (N-cadherin 2) 5 21750673-22853622 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA029325 Uncertain Approved Vesicles Mixed Group enriched 5 adrenal gland: 2.5;cerebral cortex: 3.8;cervix, uterine: 5.3;fallopian tube: 4.0;skin: 1.1;testis: 2.7 breast,urinary bladder: 0.6 CDH15 CDH14, CDH3 ENSG00000129910 Cadherin 15, type 1, M-cadherin (myotubule) 16 89171767-89195492 Disease related genes, Predicted membrane proteins Evidence at protein level HPA009139, HPA070961 Supported Supported Golgi apparatus
Cytosol Mixed Tissue enriched 11 skeletal muscle: 13.0 placenta: 1.1 CDH16 ENSG00000166589 Cadherin 16, KSP-cadherin 16 66908122-66918984 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013526, HPA036260 Supported Renal cancer:1.02e-7 (favourable) Tissue enriched Group enriched 8 kidney: 230.2;thyroid gland: 57.6 fallopian tube: 16.9 CDH17 cadherin, HPT-1 ENSG00000079112 Cadherin 17, LI cadherin (liver-intestine) 8 94127171-94217303 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023614, HPA023616, CAB025143, HPA026556 Supported Supported Cell Junctions Group enriched Group enriched 7 colon: 261.7;duodenum: 323.0;rectum: 272.5;small intestine: 300.5 appendix: 39.2 CDH18 CDH14, EY-CADHERIN ENSG00000145526 Cadherin 18, type 2 5 19472951-20575873 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014416 Uncertain Mixed Tissue enhanced adrenal gland: 5.9;cerebral cortex: 19.1 testis: 3.2 CDH19 CDH7 ENSG00000071991 Cadherin 19, type 2 18 66501083-66604138 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA056332 Uncertain Tissue enriched Mixed heart muscle: 9.6 CDH2 CD325, CDHN, NCAD ENSG00000170558 Cadherin 2, type 1, N-cadherin (neuronal) 18 27950966-28177446 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000141, CAB018580, HPA058574 Supported Supported Plasma membrane
Cell Junctions Expressed in all Tissue enhanced heart muscle: 125.8;parathyroid gland: 124.0 adrenal gland: 87.7 CDH20 Cdh7, CDH7L3 ENSG00000101542 Cadherin 20, type 2 18 61333582-61555773 Predicted membrane proteins Evidence at protein level HPA015490 Uncertain Tissue enriched Tissue enriched 5 cerebral cortex: 26.9 adipose tissue: 4.9 CDH22 C20orf25, dJ998H6.1 ENSG00000149654 Cadherin 22, type 2 20 46173733-46308498 Predicted membrane proteins Evidence at transcript level HPA012164 Uncertain Mixed Group enriched 6 adrenal gland: 2.0;cerebral cortex: 10.3;fallopian tube: 2.3;skin: 5.2 testis: 0.8 CDH23 CDHR23, DFNB12, USH1D ENSG00000107736 Cadherin-related 23 10 71396934-71815947 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017232 Approved Urothelial cancer:3.40e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 29.7 ovary: 19.4 CDH24 CDH11L ENSG00000139880 Cadherin 24, type 2 14 23047062-23057538 Predicted membrane proteins Evidence at protein level HPA054135 Approved Nucleoplasm Renal cancer:1.15e-4 (unfavourable) Expressed in all Mixed endometrium: 8.4 CDH26 VR20 ENSG00000124215 Cadherin 26 20 59958427-60034011 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015722, HPA047578 Uncertain Approved Plasma membrane
Microtubules Lung cancer:3.75e-4 (favourable), Cervical cancer:7.62e-4 (favourable) Group enriched Tissue enhanced prostate: 19.8 urinary bladder: 6.3 CDH3 CDHP, PCAD ENSG00000062038 Cadherin 3, type 1, P-cadherin (placental) 16 68636189-68722616 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001767, CAB002487 Supported Uncertain Cell Junctions
Cytosol Pancreatic cancer:8.43e-4 (unfavourable), Lung cancer:8.53e-4 (unfavourable) Mixed Tissue enhanced skin: 32.0 ovary: 26.9 CDH4 ENSG00000179242 Cadherin 4, type 1, R-cadherin (retinal) 20 61252426-61940617 Predicted membrane proteins Evidence at protein level HPA015613 Validated Plasma membrane Group enriched Tissue enhanced cerebral cortex: 6.0;spleen: 4.9 seminal vesicle: 1.3 CDH5 7B4, CD144 ENSG00000179776 Cadherin 5, type 2 (vascular endothelium) 16 66366622-66404786 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB028366 Approved Renal cancer:5.14e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 332.2 lung: 120.6 CDH6 ENSG00000113361 Cadherin 6, type 2, K-cadherin (fetal kidney) 5 31193750-31329146 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007047, HPA007456, CAB025274 Approved Group enriched Mixed kidney: 15.9 CDH7 ENSG00000081138 Cadherin 7, type 2 18 65750252-65890341 Predicted membrane proteins Evidence at protein level HPA061419 Approved Tissue enhanced Tissue enhanced cerebral cortex: 2.8;prostate: 1.2 testis: 0.7 CDH8 ENSG00000150394 Cadherin 8, type 2 16 61647242-62037035 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014908, HPA058444 Approved Supported Plasma membrane Tissue enhanced Group enriched 8 cerebral cortex: 27.9;seminal vesicle: 6.9 ovary: 2.1 CDH9 ENSG00000113100 Cadherin 9, type 2 (T1-cadherin) 5 26880600-27121150 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007167 Uncertain Not detected Tissue enhanced breast: 16.7;cerebral cortex: 11.4 testis: 6.6 CDHR1 CORD15, KIAA1775, PCDH21, RP65 ENSG00000148600 Cadherin-related family member 1 10 84194635-84219621 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA036819 Supported Tissue enhanced Group enriched 5 rectum: 58.7;skin: 252.8 colon: 29.7 CDHR2 FLJ20124, FLJ20383, PC-LKC, PCDH24, PCLKC ENSG00000074276 Cadherin-related family member 2 5 176542511-176595974 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012569, HPA017053 Supported Renal cancer:9.29e-4 (favourable) Group enriched Group enriched 12 duodenum: 284.1;small intestine: 265.8 colon: 23.1 CDHR3 CDH28, FLJ23834, FLJ44366 ENSG00000128536 Cadherin-related family member 3 7 105876796-106033773 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011218 Uncertain Approved Nucleoli fibrillar center Mixed Tissue enriched 8 fallopian tube: 145.5 lung: 19.2 CDHR5 FLJ20219, MU-PCDH, MUCDHL, MUPCDH ENSG00000099834 Cadherin-related family member 5 11 616565-626078 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009081, HPA009173, CAB025004 Supported Group enriched Group enriched 9 colon: 42.5;duodenum: 85.2;kidney: 23.4;liver: 20.6;rectum: 55.1;small intestine: 65.8 gallbladder: 5.3 CDIPT PIS, PIS1 ENSG00000103502 CDP-diacylglycerol--inositol 3-phosphatidyltransferase 16 29858357-29863736 Enzymes, Predicted membrane proteins Evidence at protein level HPA056597 Approved Approved Nucleoplasm
Nuclear membrane
Plasma membrane Cervical cancer:9.40e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 110.5 CDKAL1 FLJ20342 ENSG00000145996 CDK5 regulatory subunit associated protein 1-like 1 6 20534457-21232404 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057474 Uncertain Vesicles Endometrial cancer:1.03e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 15.9 CDKN2A ARF, CDK4I, CDKN2, CMM2, INK4, INK4a, MLM, MTS1, p14, p14ARF, p16, p16INK4a, p19, p19Arf ENSG00000147889 Cyclin-dependent kinase inhibitor 2A 9 21967753-21995301 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000093, CAB000445, CAB018232, HPA047838 Uncertain Validated Nucleoli Endometrial cancer:1.82e-7 (unfavourable), Renal cancer:5.76e-7 (unfavourable), Liver cancer:2.17e-4 (unfavourable), Head and neck cancer:5.19e-4 (favourable) Expressed in all Mixed parathyroid gland: 7.5 CDON CDO, CDON1, ORCAM ENSG00000064309 Cell adhesion associated, oncogene regulated 11 125955796-126063335 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB012422, HPA017377 Uncertain Renal cancer:1.78e-7 (unfavourable), Breast cancer:1.35e-4 (favourable) Mixed Tissue enhanced thyroid gland: 75.1 ovary: 53.3 CDS1 ENSG00000163624 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 1 4 84582979-84651338 Enzymes, Predicted membrane proteins Evidence at protein level HPA036187 Uncertain Approved Nucleus
Nuclear membrane Renal cancer:0.00e+0 (favourable), Colorectal cancer:5.22e-4 (favourable) Expressed in all Mixed fallopian tube: 49.0 CDS2 ENSG00000101290 CDP-diacylglycerol synthase (phosphatidate cytidylyltransferase) 2 20 5126786-5197887 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA019698 Approved Approved Endoplasmic reticulum
Cytosol Renal cancer:3.53e-9 (favourable) Expressed in all Expressed in all cerebral cortex: 49.1 CDYL CDYL1, DKFZP586C1622 ENSG00000153046 Chromodomain protein, Y-like 6 4706159-4955551 Enzymes, Predicted intracellular proteins Evidence at protein level CAB012249, HPA035577, HPA035578 Supported Validated Nucleoplasm
Nuclear speckles Glioma:2.10e-4 (favourable), Liver cancer:2.20e-4 (unfavourable), Melanoma:7.52e-4 (unfavourable) Expressed in all Expressed in all placenta: 27.5 CDYL2 FLJ38866 ENSG00000166446 Chromodomain protein, Y-like 2 16 80597906-80804329 Predicted intracellular proteins Evidence at protein level HPA041016 Approved Endometrial cancer:6.13e-4 (favourable) Expressed in all Mixed testis: 21.3 CEACAM1 BGP, BGP1, CD66a ENSG00000079385 Carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein) 19 42507304-42561234 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002146, HPA011041 Supported Endometrial cancer:6.32e-7 (favourable) Mixed Tissue enhanced colon: 205.9;rectum: 132.8 esophagus: 46.7 CEACAM19 CEAL1 ENSG00000186567 Carcinoembryonic antigen-related cell adhesion molecule 19 19 44662278-44684359 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014462, HPA052865 Uncertain Approved Nucleus
Nucleoli
Mitochondria Expressed in all Mixed skin: 12.7 CEACAM21 FLJ13540, R29124_1 ENSG00000007129 Carcinoembryonic antigen-related cell adhesion molecule 21 19 41549518-41586844 Predicted membrane proteins Evidence at transcript level HPA043411 Uncertain Endometrial cancer:1.89e-5 (favourable) Mixed Tissue enhanced bone marrow: 11.0 spleen: 6.6 CEACAM3 CD66d, CGM1 ENSG00000170956 Carcinoembryonic antigen-related cell adhesion molecule 3 19 41796437-41811553 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011041 Approved Not detected Tissue enriched 5 bone marrow: 28.5 appendix: 5.4 CEACAM5 CD66e, CEA ENSG00000105388 Carcinoembryonic antigen-related cell adhesion molecule 5 19 41708585-41729798 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB000021, CAB000022, HPA011041, HPA019758 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced colon: 1030.9;rectum: 1100.3 appendix: 268.1 CEACAM6 CD66c, NCA ENSG00000086548 Carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) 19 41750977-41772208 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB008370, HPA011041 Supported Mixed Group enriched 6 bone marrow: 110.9;colon: 184.1;esophagus: 174.2;gallbladder: 190.2;lung: 406.1;rectum: 236.9 appendix: 38.9 CEACAM7 CEA, CGM2 ENSG00000007306 Carcinoembryonic antigen-related cell adhesion molecule 7 19 41673307-41706976 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA069621 Supported Tissue enhanced Group enriched 7 colon: 592.8;rectum: 701.8 appendix: 95.9 CEACAM8 CD66b, CGM6 ENSG00000124469 Carcinoembryonic antigen-related cell adhesion molecule 8 19 42580241-42740384 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB033676 Approved Not detected Tissue enriched 88 bone marrow: 150.9 lung: 1.7 CEBPZOS CEBPZ-AS1 ENSG00000218739 CEBPZ opposite strand 2 37196488-37216193 Predicted membrane proteins Evidence at protein level HPA053866 Uncertain Approved Nucleoplasm Renal cancer:3.46e-7 (unfavourable), Liver cancer:1.72e-6 (unfavourable) Expressed in all Expressed in all epididymis: 48.4 CECR6 ENSG00000183307 Cat eye syndrome chromosome region, candidate 6 22 17116299-17121367 Predicted membrane proteins Evidence at protein level HPA068790 Approved Nucleoplasm
Vesicles
Plasma membrane Tissue enhanced Group enriched 7 cerebral cortex: 15.0;prostate: 10.9 testis: 1.9 CELSR1 ADGRC1, CDHF9, FMI2, HFMI2, ME2 ENSG00000075275 Cadherin, EGF LAG seven-pass G-type receptor 1 22 46360834-46537170 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052976, HPA060521, HPA067269 Uncertain Supported Plasma membrane Expressed in all Mixed fallopian tube: 15.4 CELSR2 ADGRC2, CDHF10, EGFL2, Flamingo1, KIAA0279, MEGF3 ENSG00000143126 Cadherin, EGF LAG seven-pass G-type receptor 2 1 109250019-109275750 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013952 Uncertain Approved Cytosol Expressed in all Tissue enhanced cerebral cortex: 45.2 skin: 31.1 CELSR3 ADGRC3, CDHF11, EGFL1, FMI1, HFMI1, MEGF2 ENSG00000008300 Cadherin, EGF LAG seven-pass G-type receptor 3 3 48636469-48662915 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA062866 Approved Mixed Group enriched 6 adrenal gland: 1.6;cerebral cortex: 6.0;testis: 3.6 parathyroid gland,stomach: 0.6 CEND1 BM88, FLJ90066 ENSG00000184524 Cell cycle exit and neuronal differentiation 1 11 787104-790123 Predicted membrane proteins Evidence at protein level HPA042527 Supported Approved Mitochondria Glioma:6.10e-5 (unfavourable) Tissue enriched Tissue enriched 16 cerebral cortex: 114.3 adrenal gland: 7.1 CENPM C22orf18, CENP-M, MGC861, Pane1 ENSG00000100162 Centromere protein M 22 41938721-41947164 Predicted intracellular proteins Evidence at protein level HPA042404, HPA056500 Supported Validated Cytosol Renal cancer:5.99e-7 (unfavourable), Cervical cancer:3.40e-5 (favourable), Liver cancer:5.50e-5 (unfavourable) Expressed in all Tissue enhanced lymph node: 28.9 bone marrow: 17.6 CEP170 FAM68A, KAB, KIAA0470 ENSG00000143702 Centrosomal protein 170kDa 1 243124428-243255348 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042151, HPA045787 Uncertain Validated Centrosome
Cytosol Renal cancer:1.30e-9 (unfavourable) Expressed in all Tissue enhanced testis: 106.3 cerebral cortex: 44.9 CEP95 CCDC45, DKFZp667E1824 ENSG00000258890 Centrosomal protein 95kDa 17 64506588-64542461 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023654, HPA052426, HPA052428, HPA061371 Approved Approved Nucleoplasm
Centrosome
Cytosol Liver cancer:2.52e-5 (unfavourable), Renal cancer:5.76e-5 (unfavourable), Head and neck cancer:5.78e-4 (favourable) Expressed in all Expressed in all endometrium: 27.7 CERS1 LAG1, LASS1, UOG1 ENSG00000223802 Ceramide synthase 1 19 18868545-18896727 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045724 Approved Approved Endoplasmic reticulum Tissue enhanced Group enriched 13 cerebral cortex: 136.6;testis: 28.0 skeletal muscle: 6.5 CERS2 FLJ10243, LASS2, SP260 ENSG00000143418 Ceramide synthase 2 1 150960583-150975004 Predicted membrane proteins Evidence at protein level HPA027262 Approved Supported Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all liver: 408.6 CERS3 LASS3, MGC27091 ENSG00000154227 Ceramide synthase 3 15 100400395-100544995 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006092, HPA024356 Uncertain Tissue enhanced Group enriched 9 esophagus: 48.3;skin: 60.7;testis: 32.1;tonsil: 14.9 breast: 4.2 CERS4 FLJ12089, LASS4, Trh1 ENSG00000090661 Ceramide synthase 4 19 8206736-8262421 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033734, HPA054729 Uncertain Approved Nucleus
Vesicles Lung cancer:3.45e-5 (favourable), Renal cancer:9.63e-5 (favourable), Cervical cancer:2.71e-4 (favourable), Head and neck cancer:7.83e-4 (favourable), Pancreatic cancer:8.05e-4 (favourable) Expressed in all Mixed thyroid gland: 80.7 CERS5 FLJ25304, LASS5, MGC45411, Trh4 ENSG00000139624 Ceramide synthase 5 12 50129306-50167533 Enzymes, Predicted membrane proteins Evidence at protein level HPA026589 Approved Approved Nucleus
Nucleoli Renal cancer:9.33e-11 (unfavourable), Liver cancer:4.63e-5 (unfavourable), Thyroid cancer:5.76e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 37.9 CERS6 LASS6 ENSG00000172292 Ceramide synthase 6 2 168455862-168775137 Predicted membrane proteins Evidence at protein level HPA044683, HPA063527 Approved Supported Nucleus Liver cancer:1.10e-4 (unfavourable), Endometrial cancer:7.31e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 43.4 CES5A CAUXIN, CES4C1, CES5, CES7, FLJ31547 ENSG00000159398 Carboxylesterase 5A 16 55846154-55956031 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA047635 Uncertain Tissue enhanced Tissue enriched 40 epididymis: 78.9 liver: 1.9 CFAP47 CHDC2, CXorf22, CXorf30, CXorf59, FLJ36601, MGC34831, RP13-11B7.1 ENSG00000165164 Cilia and flagella associated protein 47 X 35919734-36385319 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA044633, HPA054859 Uncertain Tissue enhanced Tissue enriched 6 fallopian tube: 9.1 testis: 1.6 CFAP54 C12orf55, C12orf63, FLJ31514, FLJ44112 ENSG00000188596 Cilia and flagella associated 54 12 96489571-96875555 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039897 Supported Approved Microtubules
Cytosol Not detected Mixed testis: 10.6 CFAP57 FLJ32000, WDR65 ENSG00000243710 Cilia and flagella associated protein 57 1 43172149-43254358 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002736, HPA028623 Supported Uncertain Cytosol Endometrial cancer:6.02e-4 (favourable) Mixed Group enriched 8 fallopian tube: 35.3;testis: 27.6 liver: 3.8 CFAP61 C20orf26, CaM-IP3, dJ1002M8.3, DKFZP434K156 ENSG00000089101 Cilia and flagella associated protein 61 20 20052514-20360702 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA009079 Uncertain Mixed Group enriched 6 fallopian tube: 20.0;heart muscle: 6.9;testis: 30.1 skeletal muscle: 3.3 CFTR ABC35, ABCC7, CF, CFTR/MRP, dJ760C5.1, MRP7, TNR-CFTR ENSG00000001626 Cystic fibrosis transmembrane conductance regulator (ATP-binding cassette sub-family C, member 7) 7 117465784-117715971 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB001951, HPA021939 Supported Liver cancer:9.44e-4 (unfavourable) Tissue enhanced Tissue enhanced gallbladder: 89.6;rectum: 50.1 colon: 47.0 CGRRF1 CGR19, RNF197 ENSG00000100532 Cell growth regulator with ring finger domain 1 14 54509812-54539309 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002930 Uncertain Supported Nucleoplasm
Vesicles Renal cancer:2.57e-8 (favourable), Liver cancer:6.84e-4 (unfavourable) Expressed in all Expressed in all testis: 33.6 CHIC1 BRX ENSG00000204116 Cysteine-rich hydrophobic domain 1 X 73563200-73687102 Predicted membrane proteins Evidence at protein level HPA026782, HPA052062 Uncertain Approved Nuclear speckles
Vesicles
Cytosol Renal cancer:2.75e-4 (favourable) Mixed Mixed cerebral cortex: 14.2 CHIC2 BTL ENSG00000109220 Cysteine-rich hydrophobic domain 2 4 54009789-54064690 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026782 Uncertain Renal cancer:1.56e-4 (unfavourable) Expressed in all Expressed in all testis: 62.9 CHL1 CALL, FLJ44930, L1CAM2, MGC132578 ENSG00000134121 Cell adhesion molecule L1-like 3 196596-409417 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003345, CAB026120 Supported Renal cancer:1.21e-6 (favourable) Tissue enhanced Tissue enriched 5 cerebral cortex: 112.2 ovary: 20.9 CHODL C21orf68, FLJ12627, MT75, PRED12 ENSG00000154645 Chondrolectin 21 17901263-18267373 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017282 Approved Supported Endometrial cancer:1.18e-6 (unfavourable) Mixed Tissue enhanced spleen: 19.7;testis: 57.3 prostate: 8.2 CHPT1 CPT1 ENSG00000111666 Choline phosphotransferase 1 12 101696947-101744140 Enzymes, Predicted membrane proteins Evidence at protein level HPA067643 Approved Approved Vesicles Thyroid cancer:7.41e-4 (favourable) Expressed in all Expressed in all breast: 124.5 CHRM1 ENSG00000168539 Cholinergic receptor, muscarinic 1 11 62908679-62921807 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014101, CAB022366 Supported Approved Nucleus
Cytosol Tissue enriched Group enriched 6 cerebral cortex: 40.0;prostate: 40.1;salivary gland: 11.1 breast: 4.7 CHRM2 ENSG00000181072 Cholinergic receptor, muscarinic 2 7 136868669-137020255 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022338, HPA029795 Approved Tissue enhanced Tissue enhanced gallbladder: 18.4;heart muscle: 26.7;smooth muscle: 13.6 urinary bladder: 6.1 CHRM3 ENSG00000133019 Cholinergic receptor, muscarinic 3 1 239386565-239915452 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA024106, HPA048036 Approved Supported Plasma membrane Mixed Tissue enhanced cerebral cortex: 15.7 esophagus: 8.5 CHRM4 ENSG00000180720 Cholinergic receptor, muscarinic 4 11 46385098-46386608 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022444, HPA072083 Uncertain Uncertain Nucleus
Golgi apparatus Mixed Tissue enhanced cerebral cortex: 8.1;small intestine: 7.9;spleen: 21.9 testis: 6.9 CHRM5 ENSG00000184984 Cholinergic receptor, muscarinic 5 15 33968720-34067457 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA013172 Uncertain Not detected Tissue enhanced cerebral cortex: 3.1;testis: 4.1 placenta: 2.5 CHRNA1 CHRNA ENSG00000138435 Cholinergic receptor, nicotinic, alpha 1 (muscle) 2 174747592-174764472 Disease related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA071554 Supported Plasma membrane Tissue enhanced Tissue enhanced skeletal muscle: 7.2 prostate: 2.6 CHRNA3 ENSG00000080644 Cholinergic receptor, nicotinic, alpha 3 (neuronal) 15 78593052-78621295 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029430 Approved Mixed Tissue enriched 7 adrenal gland: 48.2 appendix: 6.5 CHRNA4 BFNC, EBN, EBN1 ENSG00000101204 Cholinergic receptor, nicotinic, alpha 4 (neuronal) 20 63343223-63378401 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB034064 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 6.8;parathyroid gland: 16.9 liver: 3.7 CHRNA5 ENSG00000169684 Cholinergic receptor, nicotinic, alpha 5 (neuronal) 15 78565520-78595269 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054381 Approved Approved Plasma membrane
Focal adhesion sites Lung cancer:3.64e-5 (unfavourable) Mixed Mixed gallbladder: 6.9 CHRNA7 ENSG00000175344 Cholinergic receptor, nicotinic, alpha 7 (neuronal) 15 32030488-32172521 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029422, CAB033624 Supported Mixed Tissue enhanced adrenal gland: 6.0;small intestine: 6.0 stomach: 3.6 CHRNB1 CHRNB ENSG00000170175 Cholinergic receptor, nicotinic, beta 1 (muscle) 17 7445061-7457707 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005822, CAB011200 Approved Expressed in all Expressed in all skeletal muscle: 43.9 CHRNB3 ENSG00000147432 Cholinergic receptor, nicotinic, beta 3 (neuronal) 8 42697376-42737407 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA045555 Uncertain Tissue enriched Tissue enriched 6 testis: 3.7 cerebral cortex: 0.6 CHST10 HNK-1ST ENSG00000115526 Carbohydrate sulfotransferase 10 2 100391860-100417656 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012884, HPA051545 Approved Approved Cytosol Pancreatic cancer:4.05e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 46.6 endometrium: 19.3 CHST11 C4ST, C4St-1, C4ST1, HSA269537 ENSG00000171310 Carbohydrate (chondroitin 4) sulfotransferase 11 12 104455295-104762014 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA052828 Approved Approved Golgi apparatus Renal cancer:7.59e-11 (unfavourable), Urothelial cancer:8.42e-4 (unfavourable) Expressed in all Mixed appendix: 28.4 CHST12 C4S-2, C4ST2 ENSG00000136213 Carbohydrate (chondroitin 4) sulfotransferase 12 7 2403560-2448483 Enzymes, Predicted membrane proteins Evidence at protein level HPA041680 Approved Approved Golgi apparatus Pancreatic cancer:1.32e-5 (favourable) Expressed in all Expressed in all spleen: 16.4 CHST14 D4ST-1, D4ST1, HD4ST ENSG00000169105 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 14 15 40470998-40474571 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA057697, HPA071601 Approved Approved Vesicles Expressed in all Expressed in all placenta: 38.5 CHST15 BRAG, GALNAC4S-6ST, KIAA0598 ENSG00000182022 Carbohydrate (N-acetylgalactosamine 4-sulfate 6-O) sulfotransferase 15 10 124007666-124093607 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017584 Approved Approved Centrosome
Cytosol Renal cancer:2.22e-7 (unfavourable) Expressed in all Expressed in all ovary: 45.4 CHST2 C6ST ENSG00000175040 Carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 2 3 143119331-143124014 Predicted membrane proteins Evidence at protein level HPA013620 Supported Golgi apparatus Expressed in all Mixed spleen: 15.5 CHST3 C6ST, C6ST1 ENSG00000122863 Carbohydrate (chondroitin 6) sulfotransferase 3 10 71964365-72013564 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA047523, HPA055704 Approved Approved Golgi apparatus
Cytosol Expressed in all Mixed testis: 30.7 CHST5 FLJ22167, I-GLCNAC-6-ST ENSG00000135702 Carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 16 75528535-75535247 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043804 Approved Group enriched Group enriched 14 colon: 46.8;duodenum: 88.4;rectum: 60.8;small intestine: 85.3 stomach: 4.9 CHST9 GALNAC-4-ST2, GALNAC4ST-2 ENSG00000154080 Carbohydrate (N-acetylgalactosamine 4-0) sulfotransferase 9 18 26906481-27185317 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011393 Uncertain Mixed Tissue enhanced fallopian tube: 16.5;testis: 12.7 spleen: 8.0 CIITA C2TA, MHC2TA, NLRA ENSG00000179583 Class II, major histocompatibility complex, transactivator 16 10877198-10932281 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB016084 Approved Approved Nucleoplasm Expressed in all Mixed spleen: 53.8 CISD1 C10orf70, MDS029, mitoNEET, ZCD1 ENSG00000122873 CDGSH iron sulfur domain 1 10 58269058-58289586 Predicted membrane proteins Evidence at protein level CAB045965, HPA074383 Uncertain Supported Mitochondria Breast cancer:1.11e-4 (unfavourable), Liver cancer:4.15e-4 (unfavourable), Urothelial cancer:6.69e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 116.1 cerebral cortex: 27.3 CISD2 ERIS, Miner1, NAF-1, WFS2, ZCD2 ENSG00000145354 CDGSH iron sulfur domain 2 4 102868978-102889242 Disease related genes, Predicted membrane proteins Evidence at protein level HPA015914 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all thyroid gland: 61.7 CKAP4 CLIMP-63, ERGIC-63, P63 ENSG00000136026 Cytoskeleton-associated protein 4 12 106237877-106304279 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000278, HPA000792, HPA001225 Supported Uncertain Nuclear speckles
Cytosol
Cytoplasmic bodies Renal cancer:0.00e+0 (unfavourable), Liver cancer:6.61e-5 (unfavourable), Lung cancer:5.61e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 78.2 CKLF C32, CKLF1, CKLF3, CKLF4, HSPC224, UCK-1 ENSG00000217555 Chemokine-like factor 16 66552563-66566251 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA062779 Approved Vesicles Renal cancer:1.06e-9 (unfavourable), Liver cancer:5.67e-5 (unfavourable), Thyroid cancer:2.22e-4 (favourable) Expressed in all Expressed in all testis: 91.2 CKLF-CMTM1 ENSG00000254788 CKLF-CMTM1 readthrough 16 66552587-66579135 Predicted membrane proteins Evidence at transcript level HPA017136 Approved Mixed Mixed testis: 4.1 CKMT2 SMTCK ENSG00000131730 Creatine kinase, mitochondrial 2 (sarcomeric) 5 81233285-81266397 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051880 Approved Mixed Group enriched 21 heart muscle: 672.7;skeletal muscle: 505.4 adrenal gland: 28.1 CLCA2 CLCRG2 ENSG00000137975 Chloride channel accessory 2 1 86424086-86456558 Predicted membrane proteins Evidence at protein level HPA047192 Supported Supported Nucleus
Cell Junctions Group enriched Tissue enhanced esophagus: 126.9;skin: 102.9 tonsil: 23.5 CLCA4 CaCC2 ENSG00000016602 Chloride channel accessory 4 1 86547078-86580754 Predicted membrane proteins Evidence at protein level HPA017045 Uncertain Colorectal cancer:7.47e-4 (favourable), Head and neck cancer:8.63e-4 (favourable) Tissue enhanced Group enriched 6 colon: 253.7;esophagus: 366.8;rectum: 160.8 urinary bladder: 42.4 CLCC1 MCLC ENSG00000121940 Chloride channel CLIC-like 1 1 108929508-108963457 Predicted membrane proteins, Transporters Evidence at protein level HPA009087, HPA013210 Supported Validated Endoplasmic reticulum Colorectal cancer:1.33e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 38.0 CLCN2 ClC-2, CLC2, EJM6 ENSG00000114859 Chloride channel, voltage-sensitive 2 3 184346185-184361651 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009397, HPA014545, HPA024108 Approved Approved Cytosol Liver cancer:4.67e-8 (unfavourable) Expressed in all Mixed testis: 22.0 CLCN3 ClC-3, CLC3 ENSG00000109572 Chloride channel, voltage-sensitive 3 4 169612633-169723673 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044723 Approved Approved Cytosol Renal cancer:1.10e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 104.4 CLCN4 ClC-4, CLC4 ENSG00000073464 Chloride channel, voltage-sensitive 4 X 10156945-10237660 Predicted membrane proteins, Transporters Evidence at protein level HPA031313, HPA063637 Supported Approved Vesicles Endometrial cancer:2.13e-5 (unfavourable), Pancreatic cancer:9.55e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 49.2;epididymis: 27.6 skeletal muscle: 14.6 CLCN5 ClC-5, CLC5, DENTS, hCIC-K2, hClC-K2, NPHL1, NPHL2, XLRH, XRN ENSG00000171365 Chloride channel, voltage-sensitive 5 X 49922615-50099235 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000401, HPA003213 Uncertain Supported Golgi apparatus
Plasma membrane
Cytosol Renal cancer:2.05e-8 (favourable), Pancreatic cancer:5.20e-4 (favourable) Expressed in all Tissue enhanced epididymis: 33.2;kidney: 51.6 placenta: 9.5 CLCN6 CLC-6, KIAA0046 ENSG00000011021 Chloride channel, voltage-sensitive 6 1 11806096-11843144 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA032097 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed cerebral cortex: 31.2 CLCN7 CLC-7, CLC7, OPTA2, PPP1R63 ENSG00000103249 Chloride channel, voltage-sensitive 7 16 1444934-1475580 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043019, HPA043586 Supported Supported Nucleoplasm Testis cancer:3.21e-4 (unfavourable), Head and neck cancer:5.23e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 40.4 CLCNKA hClC-Ka ENSG00000186510 Chloride channel, voltage-sensitive Ka 1 16018875-16034050 Disease related genes, Predicted membrane proteins Evidence at protein level HPA057717 Approved Group enriched Group enriched 9 kidney: 63.9;parathyroid gland: 39.6 thyroid gland: 5.5 CLCNKB hClC-Kb ENSG00000184908 Chloride channel, voltage-sensitive Kb 1 16043736-16057308 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057717 Approved Renal cancer:1.27e-7 (favourable) Tissue enriched Tissue enhanced kidney: 107.5 salivary gland: 22.1 CLDN1 ILVASC, SEMP1 ENSG00000163347 Claudin 1 3 190305701-190322475 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002602, HPA048319 Supported Endometrial cancer:2.00e-4 (unfavourable), Pancreatic cancer:5.23e-4 (unfavourable) Expressed in all Tissue enhanced skin: 306.9;smooth muscle: 183.5 liver: 158.3 CLDN10 CPETRL3, OSP-L ENSG00000134873 Claudin 10 13 95433604-95579759 Predicted membrane proteins Evidence at protein level CAB012969, HPA042348 Supported Renal cancer:7.46e-5 (favourable), Thyroid cancer:2.13e-4 (favourable) Mixed Tissue enhanced kidney: 161.8 gallbladder: 111.0 CLDN11 OSP, OTM ENSG00000013297 Claudin 11 3 170418865-170860380 Predicted membrane proteins Evidence at protein level CAB009789, HPA013166 Supported Breast cancer:6.31e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 89.2;testis: 184.3 ovary: 61.8 CLDN12 ENSG00000157224 Claudin 12 7 90383721-90513402 Predicted membrane proteins Evidence at protein level HPA026945 Approved Cervical cancer:6.36e-4 (unfavourable) Expressed in all Expressed in all prostate: 40.8 CLDN16 HOMG3, PCLN1 ENSG00000113946 Claudin 16 3 190322541-190412143 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA056020 Supported Endometrial cancer:1.99e-5 (unfavourable) Group enriched Tissue enriched 6 kidney: 51.3 thyroid gland: 8.7 CLDN17 MGC126552, MGC126554 ENSG00000156282 Claudin 17 21 30165564-30166756 Predicted membrane proteins, Transporters Evidence at protein level HPA045903 Supported Tissue enhanced Tissue enriched 5 esophagus: 6.6 tonsil: 1.3 CLDN18 SFTPJ ENSG00000066405 Claudin 18 3 137998735-138033655 Predicted membrane proteins Evidence at protein level CAB013010, CAB013243, HPA018446 Supported Group enriched Group enriched 99 lung: 362.1;stomach: 695.3 gallbladder: 5.3 CLDN2 ENSG00000165376 Claudin 2 X 106900164-106930861 Predicted membrane proteins Evidence at protein level CAB002609, HPA051548 Supported Supported Nucleoplasm
Cell Junctions Thyroid cancer:1.70e-4 (favourable) Group enriched Tissue enhanced gallbladder: 159.7;kidney: 170.5;seminal vesicle: 128.0 epididymis: 40.4 CLDN23 CLDNL ENSG00000253958 Claudin 23 8 8701938-8704106 Predicted membrane proteins, Transporters Evidence at protein level HPA070578 Uncertain Nucleus
Plasma membrane Renal cancer:9.65e-8 (favourable), Colorectal cancer:3.46e-4 (favourable) Expressed in all Tissue enhanced colon: 24.1;stomach: 24.9 small intestine: 16.9 CLDN25 ENSG00000228607 Claudin 25 11 113779747-113780500 Predicted membrane proteins No evidence HPA053555 Uncertain Not detected Not detected epididymis: 0.1 CLDN3 C7orf1, CPE-R2, CPETR2, HRVP1, RVP1 ENSG00000165215 Claudin 3 7 73768997-73770270 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002702, HPA014361 Supported Supported Cell Junctions Renal cancer:3.39e-5 (favourable) Mixed Tissue enhanced colon: 89.6;small intestine: 121.9 duodenum: 56.5 CLDN4 CPE-R, CPETR, CPETR1, hCPE-R, WBSCR8 ENSG00000189143 Claudin 4 7 73799542-73832693 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002610 Supported Supported Plasma membrane Renal cancer:3.46e-10 (favourable), Ovarian cancer:3.28e-4 (unfavourable) Mixed Mixed colon: 212.3 CLDN5 AWAL, BEC1, CPETRL1, TMVCF ENSG00000184113 Claudin 5 22 19523024-19527545 Predicted membrane proteins, Transporters Evidence at protein level CAB002607 Approved Expressed in all Tissue enhanced adipose tissue: 128.2 lung: 53.8 CLDN7 CEPTRL2, CPETRL2, Hs.84359 ENSG00000181885 Claudin 7 17 7259903-7263983 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013063, HPA014703, HPA073662 Supported Approved Vesicles
Cell Junctions Renal cancer:8.96e-11 (favourable), Thyroid cancer:1.85e-4 (favourable), Stomach cancer:4.09e-4 (favourable) Expressed in all Mixed small intestine: 357.1 CLDN8 ENSG00000156284 Claudin 8 21 30214006-30216073 Predicted membrane proteins, Transporters Evidence at protein level HPA060605 Approved Renal cancer:3.32e-4 (favourable) Tissue enhanced Tissue enhanced breast: 84.5;kidney: 75.5;rectum: 56.8 thyroid gland: 37.2 CLDN9 ENSG00000213937 Claudin 9 16 3012456-3014505 Predicted membrane proteins Evidence at protein level HPA076613 Supported Vesicles
Cell Junctions Endometrial cancer:2.24e-6 (unfavourable), Stomach cancer:4.67e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 3.1 bone marrow: 1.7 CLDND1 C3orf4 ENSG00000080822 Claudin domain containing 1 3 98497912-98523066 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029841 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:5.84e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 400.9 CLDND2 MGC33839 ENSG00000160318 Claudin domain containing 2 19 51367098-51369003 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA056971 Uncertain Approved Nucleoplasm Mixed Tissue enhanced testis: 22.3 spleen: 6.4 CLEC10A CD301, CLECSF13, CLECSF14, HML, HML2 ENSG00000132514 C-type lectin domain family 10, member A 17 7074537-7080307 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA021937 Approved Head and neck cancer:1.26e-5 (favourable), Testis cancer:4.22e-4 (unfavourable), Lung cancer:9.24e-4 (favourable) Expressed in all Mixed appendix: 40.3 CLEC12A CD371, CLL-1, DCAL-2, MICL ENSG00000172322 C-type lectin domain family 12, member A 12 9951316-9995694 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048515 Supported Urothelial cancer:9.33e-4 (favourable) Mixed Tissue enhanced bone marrow: 51.4 spleen: 27.1 CLEC12B ENSG00000256660 C-type lectin domain family 12, member B 12 10010627-10018619 Predicted membrane proteins Evidence at protein level HPA026973 Uncertain Not detected Tissue enhanced testis: 27.2 skin: 5.5 CLEC14A C14orf27 ENSG00000176435 C-type lectin domain family 14, member A 14 38254103-38256369 Predicted membrane proteins Evidence at protein level HPA039468, HPA048119 Uncertain Supported Endoplasmic reticulum
Golgi apparatus Head and neck cancer:4.13e-6 (favourable) Expressed in all Tissue enhanced lung: 76.4 adipose tissue: 40.9 CLEC16A Gop-1, KIAA0350 ENSG00000038532 C-type lectin domain family 16, member A 16 10944488-11182189 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035814, HPA035815, HPA061385 Approved Approved Nucleus
Vesicles Renal cancer:2.92e-6 (favourable) Expressed in all Expressed in all testis: 60.2 CLEC2A INPE5792, KACL, PILAR, UNQ5792 ENSG00000188393 C-type lectin domain family 2, member A 12 9898673-9932381 Predicted membrane proteins Evidence at protein level HPA048530, HPA072407 Approved Uncertain Plasma membrane Tissue enhanced Tissue enriched 14 skin: 67.7 breast: 4.7 CLEC2D CLAX, LLT1, OCIL ENSG00000069493 C-type lectin domain family 2, member D 12 9664969-9699555 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017649, HPA047584 Uncertain Approved Nucleoplasm
Golgi apparatus Renal cancer:5.85e-11 (unfavourable), Urothelial cancer:1.68e-7 (favourable), Cervical cancer:1.37e-4 (favourable) Expressed in all Tissue enhanced lymph node: 64.2 tonsil: 39.5 CLEC2L FLJ32986 ENSG00000236279 C-type lectin domain family 2, member L 7 139523856-139544984 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045050 Supported Mixed Group enriched 9 cerebral cortex: 21.0;parathyroid gland: 13.4 endometrium: 1.9 CLEC4A CD367, CLECSF6, DCIR, DDB27 ENSG00000111729 C-type lectin domain family 4, member A 12 8123632-8138607 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007842 Uncertain Expressed in all Tissue enhanced appendix: 38.2 spleen: 21.4 CLEC4C BDCA2, CD303, CLECSF11, CLECSF7, DLEC, HECL ENSG00000198178 C-type lectin domain family 4, member C 12 7729415-7751605 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029432 Approved Not detected Tissue enhanced lymph node: 6.1;spleen: 4.7;tonsil: 4.7 appendix,breast: 1.8 CLEC4D CD368, CLECSF8, Mpcl ENSG00000166527 C-type lectin domain family 4, member D 12 8509475-8522366 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004906 Approved Tissue enriched Group enriched 6 appendix: 10.7;bone marrow: 42.9 cervix, uterine: 4.8 CLEC4E CLECSF9, mincle ENSG00000166523 C-type lectin domain family 4, member E 12 8533305-8540963 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004935 Uncertain Uncertain Cytosol Mixed Tissue enhanced appendix: 55.1;bone marrow: 49.8;spleen: 44.9 gallbladder: 19.0 CLEC4G LSECtin, UNQ431 ENSG00000182566 C-type lectin domain family 4, member G 19 7728957-7733906 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB003789, HPA014044 Supported Mixed Group enriched 6 adipose tissue: 18.5;liver: 27.6;lymph node: 17.0 urinary bladder: 3.5 CLEC4M CD209L, CD299, DC-SIGN2, DC-SIGNR, DCSIGNR, HP10347, LSIGN ENSG00000104938 C-type lectin domain family 4, member M 19 7763149-7769605 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033689, CAB033691, HPA042661 Supported Not detected Group enriched 7 liver: 34.7;lymph node: 20.6;placenta: 12.4 testis: 3.3 CLEC7A CD369, CLECSF12, dectin-1, hDectin-1 ENSG00000172243 C-type lectin domain family 7, member A 12 10116777-10130258 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043244, HPA050229 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:1.31e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 67.3 bone marrow: 53.5 CLGN ENSG00000153132 Calmegin 4 140388455-140427968 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB020709, HPA048761, HPA058627 Supported Validated Endoplasmic reticulum Tissue enhanced Tissue enhanced testis: 185.4 heart muscle: 39.1 CLMN FLJ12383, KIAA0500, KIAA1188 ENSG00000165959 Calmin (calponin-like, transmembrane) 14 95181940-95319906 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012634 Approved Approved Nuclear bodies
Cytosol Renal cancer:2.68e-7 (favourable) Expressed in all Tissue enhanced testis: 48.6 kidney: 14.8 CLN3 BTS, JNCL ENSG00000188603 Ceroid-lipofuscinosis, neuronal 3 16 28477279-28495575 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063280 Uncertain Expressed in all Expressed in all placenta: 54.9 CLN5 ENSG00000102805 Ceroid-lipofuscinosis, neuronal 5 13 76990660-77002517 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041788 Approved Renal cancer:1.52e-9 (favourable) Expressed in all Expressed in all thyroid gland: 141.2 CLN6 FLJ20561, HsT18960, nclf ENSG00000128973 Ceroid-lipofuscinosis, neuronal 6, late infantile, variant 15 68206992-68257211 Disease related genes, Predicted membrane proteins Evidence at protein level HPA066046, HPA074162 Approved Approved Vesicles Renal cancer:4.87e-4 (favourable) Expressed in all Expressed in all appendix: 23.0 CLPTM1 ENSG00000104853 Cleft lip and palate associated transmembrane protein 1 19 44954585-44993341 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA068702 Approved Nuclear membrane
Microtubule organizing center Expressed in all Expressed in all parathyroid gland: 127.5 CLPTM1L CRR9, FLJ14400 ENSG00000049656 CLPTM1-like 5 1317744-1345099 Predicted membrane proteins Evidence at protein level HPA014791 Approved Approved Endoplasmic reticulum Liver cancer:3.75e-4 (unfavourable) Expressed in all Expressed in all testis: 54.1 CLRN1 RP61, USH3, USH3A ENSG00000163646 Clarin 1 3 150926163-150972999 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054636 Uncertain Not detected Tissue enhanced adrenal gland: 6.8;duodenum: 1.6 testis: 0.8 CLRN2 ENSG00000249581 Clarin 2 4 17515165-17527104 Predicted membrane proteins, Transporters Evidence at transcript level HPA042407 Uncertain Not detected Not detected testis: 0.3 CLRN3 MGC32871, TMEM12, USH3AL1 ENSG00000180745 Clarin 3 10 127877841-127892947 Predicted membrane proteins, Transporters Evidence at protein level HPA014482 Approved Stomach cancer:8.98e-4 (favourable) Group enriched Group enriched 8 colon: 71.2;duodenum: 75.4;gallbladder: 23.7;kidney: 43.9;liver: 40.2;rectum: 77.5;small intestine: 99.5 appendix: 7.5 CLSTN1 CDHR12, CSTN1, KIAA0911 ENSG00000171603 Calsyntenin 1 1 9729026-9824526 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012412 Approved Renal cancer:4.10e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 382.9 CLSTN2 CDHR13, CS2, CSTN2, FLJ39113 ENSG00000158258 Calsyntenin 2 3 139935185-140577397 Predicted membrane proteins Evidence at protein level HPA031342, HPA061800 Approved Approved Vesicles Tissue enriched Tissue enhanced cerebral cortex: 35.3;ovary: 95.1 adipose tissue: 19.8 CLUH CLU1, KIAA0664 ENSG00000132361 Clustered mitochondria (cluA/CLU1) homolog 17 2689386-2712663 Predicted intracellular proteins Evidence at protein level HPA031505, HPA044346 Uncertain Supported Nuclear bodies
Vesicles Renal cancer:1.92e-5 (favourable) Expressed in all Expressed in all esophagus: 50.9 CLYBL CLB ENSG00000125246 Citrate lyase beta like 13 99606669-99897134 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039959, HPA040691 Supported Approved Cytosol Renal cancer:6.66e-16 (favourable) Expressed in all Expressed in all kidney: 66.9 CMKLR1 RVER1 ENSG00000174600 Chemerin chemokine-like receptor 1 12 108288044-108339341 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA047865 Uncertain Expressed in all Tissue enhanced spleen: 49.3 placenta: 40.0 CMSS1 C3orf26, MGC4308 ENSG00000184220 Cms1 ribosomal small subunit homolog (yeast) 3 99817834-100178603 Predicted intracellular proteins Evidence at protein level HPA042820 Uncertain Approved Nucleus
Nuclear membrane
Nucleoli
Mitochondria Liver cancer:5.92e-10 (unfavourable), Endometrial cancer:3.15e-6 (unfavourable), Prostate cancer:3.10e-4 (unfavourable) Expressed in all Expressed in all testis: 56.0 CMTM1 CKLFH, CKLFH1a, CKLFSF1 ENSG00000089505 CKLF-like MARVEL transmembrane domain containing 1 16 66566393-66579137 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013801, HPA017136 Uncertain Approved Nucleoplasm Pancreatic cancer:5.68e-5 (unfavourable) Mixed Tissue enriched 6 testis: 28.8 spleen: 4.5 CMTM3 BNAS2, CKLFSF3, FLJ31762 ENSG00000140931 CKLF-like MARVEL transmembrane domain containing 3 16 66603874-66613892 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013870 Approved Nucleoplasm Renal cancer:4.42e-6 (unfavourable), Stomach cancer:1.85e-4 (unfavourable) Expressed in all Expressed in all testis: 69.3 CMTM4 CKLFSF4 ENSG00000183723 CKLF-like MARVEL transmembrane domain containing 4 16 66614750-66696707 Predicted membrane proteins Evidence at protein level HPA014704, HPA023890 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:4.72e-9 (favourable) Expressed in all Tissue enhanced thyroid gland: 63.9 parathyroid gland: 47.2 CMTM5 CKLFSF5, FLJ37521 ENSG00000166091 CKLF-like MARVEL transmembrane domain containing 5 14 23376808-23379772 Predicted membrane proteins Evidence at protein level HPA052338 Supported Group enriched Tissue enriched 20 cerebral cortex: 81.5 bone marrow,seminal vesicle: 4.0 CMTM6 CKLFSF6, FLJ20396 ENSG00000091317 CKLF-like MARVEL transmembrane domain containing 6 3 32481312-32503408 Predicted membrane proteins Evidence at protein level HPA026980 Approved Approved Intermediate filaments
Cytosol Expressed in all Expressed in all fallopian tube: 236.7 CMTM7 CKLFSF7, FLJ30992 ENSG00000153551 CKLF-like MARVEL transmembrane domain containing 7 3 32391671-32483067 Predicted membrane proteins, Transporters Evidence at protein level HPA077409 Approved Plasma membrane Renal cancer:1.00e-6 (unfavourable), Liver cancer:3.21e-4 (unfavourable) Expressed in all Mixed fallopian tube: 60.9 CMTM8 CKLFSF8 ENSG00000170293 CKLF-like MARVEL transmembrane domain containing 8 3 32238679-32370325 Predicted membrane proteins Evidence at protein level HPA055077, HPA073258 Approved Approved Nucleoplasm Renal cancer:2.80e-4 (favourable) Expressed in all Mixed placenta: 24.7 CMTR2 AFT, FLJ11171, FTSJD1, MTr2 ENSG00000180917 Cap methyltransferase 2 16 71281389-71289715 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041700, HPA048265 Uncertain Approved Nuclear speckles
Cell Junctions Renal cancer:4.97e-5 (favourable) Expressed in all Mixed testis: 16.2 CNBD2 C20orf152, CNMPD1, dJ954P9.1 ENSG00000149646 Cyclic nucleotide binding domain containing 2 20 35954564-36030700 Predicted intracellular proteins Evidence at protein level HPA043182 Uncertain Not detected Tissue enhanced testis: 37.8 epididymis: 14.8 CNEP1R1 C16orf69, FLJ38101, NEP1-R1, TMEM188 ENSG00000205423 CTD nuclear envelope phosphatase 1 regulatory subunit 1 16 50024410-50037088 Predicted membrane proteins Evidence at protein level HPA042815, HPA077906 Uncertain Supported Cytosol Expressed in all Mixed testis: 32.7 CNGA1 CNCG, CNCG1, CNG1, RCNC1, RCNCa, RP49 ENSG00000198515 Cyclic nucleotide gated channel alpha 1 4 47935977-48016672 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA076168 Approved Vesicles
Plasma membrane Mixed Mixed liver: 14.2 CNGA2 CNCA, CNCA1, CNG2, FLJ46312, OCNC1, OCNCa, OCNCALPHA ENSG00000183862 Cyclic nucleotide gated channel alpha 2 X 151738451-151745304 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA015065 Uncertain Not detected Not detected testis: 0.4 CNGB1 CNCG2, CNCG3L, CNGB1B, GAR1, GARP, RCNC2, RCNCb, RP45 ENSG00000070729 Cyclic nucleotide gated channel beta 1 16 57882340-57971116 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039159, HPA060355 Uncertain Approved Vesicles
Cytosol Tissue enriched Mixed adrenal gland,appendix: 1.6 CNGB3 ACHM1, ACHM3, RMCH ENSG00000170289 Cyclic nucleotide gated channel beta 3 8 86553977-86743675 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA057244 Approved Not detected Tissue enhanced testis: 4.0 bone marrow: 2.7 CNIH1 CNIH, CNIL, TGAM77 ENSG00000100528 Cornichon family AMPA receptor auxiliary protein 1 14 54423560-54441431 Predicted membrane proteins, Transporters Evidence at protein level HPA002544 Approved Approved Vesicles Urothelial cancer:8.95e-4 (unfavourable) Expressed in all Expressed in all liver: 118.5 CNIH4 HSPC163 ENSG00000143771 Cornichon family AMPA receptor auxiliary protein 4 1 224356850-224379459 Predicted membrane proteins Evidence at protein level HPA044268 Approved Renal cancer:4.27e-6 (unfavourable), Head and neck cancer:1.72e-4 (unfavourable), Pancreatic cancer:4.61e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 27.1 CNNM1 ACDP1 ENSG00000119946 Cyclin and CBS domain divalent metal cation transport mediator 1 10 99329099-99394330 Predicted membrane proteins Evidence at protein level HPA040408 Approved Uncertain Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 10.2;testis: 16.7 ovary: 3.0 CNNM2 ACDP2 ENSG00000148842 Cyclin and CBS domain divalent metal cation transport mediator 2 10 102918293-103090221 Disease related genes, Predicted membrane proteins Evidence at protein level HPA059954, HPA071631 Validated Vesicles Renal cancer:2.39e-8 (favourable) Expressed in all Tissue enhanced parathyroid gland: 33.5 placenta: 12.4 CNNM3 ACDP3 ENSG00000168763 Cyclin and CBS domain divalent metal cation transport mediator 3 2 96816245-96833911 Predicted membrane proteins, Transporters Evidence at protein level HPA016711 Supported Approved Cytosol Expressed in all Expressed in all parathyroid gland: 42.9 CNNM4 ACDP4, KIAA1592 ENSG00000158158 Cyclin and CBS domain divalent metal cation transport mediator 4 2 96760902-96811891 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017732 Supported Uncertain Plasma membrane
Actin filaments Ovarian cancer:8.75e-4 (unfavourable), Endometrial cancer:9.14e-4 (unfavourable) Expressed in all Expressed in all rectum: 37.5 CNOT1 AD-005, CDC39, KIAA1007, NOT1, NOT1H ENSG00000125107 CCR4-NOT transcription complex, subunit 1 16 58519951-58629886 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046577, HPA049664 Approved Supported Cytosol Expressed in all Expressed in all testis: 206.0 CNOT2 CDC36, NOT2, NOT2H ENSG00000111596 CCR4-NOT transcription complex, subunit 2 12 70242994-70354993 Predicted intracellular proteins Evidence at protein level HPA067711 Approved Approved Nucleus
Cytosol Renal cancer:8.63e-5 (unfavourable), Liver cancer:2.21e-4 (unfavourable), Melanoma:6.86e-4 (unfavourable) Expressed in all Expressed in all skin: 54.3 CNPPD1 C2orf24, CGI-57 ENSG00000115649 Cyclin Pas1/PHO80 domain containing 1 2 219171897-219178106 Predicted membrane proteins Evidence at transcript level HPA049303 Uncertain Renal cancer:1.62e-10 (favourable), Liver cancer:2.04e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 86.9 CNR1 CANN6, CB-R, CB1, CB1A, CB1K5, CNR ENSG00000118432 Cannabinoid receptor 1 (brain) 6 88139864-88166359 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB005603, HPA042256 Approved Approved Plasma membrane
Actin filaments Tissue enriched Tissue enhanced cerebral cortex: 32.2 adipose tissue: 12.1 CNR2 CB2 ENSG00000188822 Cannabinoid receptor 2 (macrophage) 1 23870526-23913362 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB009719 Uncertain Tissue enriched Group enriched 7 appendix: 3.2;lymph node: 8.8;spleen: 8.1;tonsil: 7.2 bone marrow: 1.0 CNST C1orf71, FLJ32001, PPP1R64 ENSG00000162852 Consortin, connexin sorting protein 1 246566444-246668584 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007225, HPA007226 Approved Supported Vesicles Expressed in all Expressed in all cerebral cortex: 26.4 CNTFR ENSG00000122756 Ciliary neurotrophic factor receptor 9 34551432-34590140 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025310, HPA036635 Approved Approved Golgi apparatus Tissue enhanced Tissue enhanced adipose tissue: 62.5;cerebral cortex: 53.6 spleen: 28.0 CNTN1 F3, GP135 ENSG00000018236 Contactin 1 12 40692442-41072418 Disease related genes, Plasma proteins, Predicted secreted proteins Evidence at protein level CAB025200, HPA041060 Approved Urothelial cancer:3.75e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 226.1 ovary: 65.4 CNTN3 BIG-1, PANG ENSG00000113805 Contactin 3 (plasmacytoma associated) 3 74262568-74521140 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA003341 Approved Mixed Tissue enhanced cerebral cortex: 12.4 fallopian tube: 11.9 CNTNAP1 Caspr, CNTNAP, NRXN4, p190 ENSG00000108797 Contactin associated protein 1 17 42682613-42699814 Disease related genes, Predicted membrane proteins Evidence at protein level HPA011772 Approved Approved Nucleoplasm Renal cancer:4.16e-14 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 62.0;smooth muscle: 38.6 endometrium: 19.2 CNTNAP2 Caspr2, KIAA0868, NRXN4 ENSG00000174469 Contactin associated protein-like 2 7 146116002-148420998 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002739 Supported Tissue enhanced Group enriched 11 cerebral cortex: 20.2;prostate: 5.7 breast,fallopian tube: 1.2 CNTNAP3 CASPR3, CNTNAP3A, FLJ14195, KIAA1714 ENSG00000106714 Contactin associated protein-like 3 9 39072767-39288315 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA015604, HPA047731 Approved Mixed Mixed esophagus: 8.3 CNTNAP3B ENSG00000154529 Contactin associated protein-like 3B 9 41890314-42129510 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA015604, HPA047731 Uncertain Not detected Mixed esophagus,skin: 10.4 CNTNAP4 CASPR4, KIAA1763 ENSG00000152910 Contactin associated protein-like 4 16 76277278-76559238 Predicted membrane proteins Evidence at protein level HPA031859, HPA057342 Supported Tissue enriched Tissue enriched 21 cerebral cortex: 36.0 testis: 1.6 CNTNAP5 caspr5, FLJ31966 ENSG00000155052 Contactin associated protein-like 5 2 124025287-124915287 Predicted membrane proteins Evidence at protein level HPA069095, HPA069356 Supported Nucleus
Nucleoli fibrillar center
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 5.8;gallbladder: 1.6 adrenal gland: 0.7 COA1 C7orf44, FLJ10803, MITRAC15 ENSG00000106603 Cytochrome c oxidase assembly factor 1 homolog 7 43608456-43729717 Predicted membrane proteins Evidence at protein level HPA011944 Approved Supported Mitochondria Liver cancer:7.84e-5 (unfavourable) Expressed in all Expressed in all lymph node: 36.9 COA3 CCDC56, HSPC009, MITRAC12 ENSG00000183978 Cytochrome c oxidase assembly factor 3 17 42795147-42798704 Predicted membrane proteins Evidence at protein level HPA031966 Approved Supported Mitochondria Cervical cancer:3.40e-4 (favourable), Renal cancer:6.62e-4 (favourable), Endometrial cancer:8.93e-4 (favourable) Expressed in all Expressed in all epididymis: 210.1 COL13A1 ENSG00000197467 Collagen, type XIII, alpha 1 10 69801931-69964275 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050392 Approved Mixed Tissue enhanced epididymis: 32.5 prostate: 17.8 COL17A1 BP180, BPAG2 ENSG00000065618 Collagen, type XVII, alpha 1 10 104031286-104086002 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043673, HPA052963 Supported Breast cancer:1.38e-4 (favourable), Pancreatic cancer:1.86e-4 (unfavourable) Tissue enhanced Tissue enriched 15 skin: 770.5 placenta: 52.8 COL23A1 DKFZp434K0621 ENSG00000050767 Collagen, type XXIII, alpha 1 5 178237618-178590555 Predicted intracellular proteins Evidence at protein level HPA067824 Uncertain Endometrial cancer:6.46e-5 (unfavourable) Tissue enhanced Tissue enhanced thyroid gland: 57.5 seminal vesicle: 16.1 COL25A1 ENSG00000188517 Collagen, type XXV, alpha 1 4 108810721-109302657 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029107 Approved Endoplasmic reticulum
Vesicles
Cytosol Mixed Tissue enhanced testis: 20.4 adipose tissue: 7.5 COLEC12 CL-P1, SCARA4, SRCL ENSG00000158270 Collectin sub-family member 12 18 316740-500722 Predicted membrane proteins Evidence at protein level HPA047917, HPA071056 Supported Approved Golgi apparatus
Vesicles
Cell Junctions Thyroid cancer:8.10e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 28.2 lung: 16.7 COMT ENSG00000093010 Catechol-O-methyltransferase 22 19941607-19969975 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001169, CAB011233 Supported Approved Endoplasmic reticulum
Vesicles Endometrial cancer:3.68e-4 (favourable), Prostate cancer:5.67e-4 (favourable), Renal cancer:9.76e-4 (unfavourable) Expressed in all Expressed in all placenta: 172.0 COMTD1 FLJ23841 ENSG00000165644 Catechol-O-methyltransferase domain containing 1 10 75233969-75236030 Predicted intracellular proteins Evidence at protein level HPA042165 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.88e-4 (favourable) Expressed in all Mixed duodenum: 14.0 COPS4 CSN4 ENSG00000138663 COP9 signalosome subunit 4 4 83034447-83075818 Predicted intracellular proteins Evidence at protein level HPA036894, HPA042828 Uncertain Supported Nuclear speckles Renal cancer:5.21e-6 (favourable), Colorectal cancer:4.14e-4 (favourable) Expressed in all Expressed in all testis: 78.6 COPS6 CSN6, MOV34-34KD ENSG00000168090 COP9 signalosome subunit 6 7 100088954-100092200 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044315 Approved Supported Nucleoplasm Renal cancer:6.72e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 127.1 COPZ2 MGC23008 ENSG00000005243 Coatomer protein complex, subunit zeta 2 17 48026167-48038030 Predicted intracellular proteins Evidence at protein level HPA055999 Uncertain Renal cancer:3.45e-9 (unfavourable), Thyroid cancer:2.89e-6 (unfavourable), Urothelial cancer:4.66e-4 (unfavourable) Expressed in all Mixed adipose tissue: 73.0 COQ2 CL640, FLJ26072 ENSG00000173085 Coenzyme Q2 4-hydroxybenzoate polyprenyltransferase 4 83261536-83284914 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA056599, HPA068727 Approved Approved Cytosol Expressed in all Expressed in all adrenal gland: 18.5 CORIN ATC2, CRN, Lrp4, PRSC, TMPRSS10 ENSG00000145244 Corin, serine peptidase 4 47593998-47838106 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070941 Approved Nuclear bodies
Plasma membrane
Actin filaments Mixed Tissue enhanced heart muscle: 45.0 skin: 9.5 COX10 ENSG00000006695 COX10 heme A:farnesyltransferase cytochrome c oxidase assembly factor 17 14069496-14208677 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA032005, HPA032006 Supported Supported Nucleoli
Mitochondria
Cytosol Renal cancer:4.32e-6 (favourable), Stomach cancer:8.73e-4 (favourable) Expressed in all Expressed in all testis: 43.0 COX11 COX11P ENSG00000166260 COX11 cytochrome c oxidase copper chaperone 17 54951902-54968785 Predicted membrane proteins Evidence at protein level HPA044020 Approved Colorectal cancer:4.30e-4 (favourable) Expressed in all Expressed in all duodenum: 62.9 COX14 C12orf62, MGC14288 ENSG00000178449 COX14 cytochrome c oxidase assembly factor 12 50111979-50120457 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044618, HPA062014 Approved Supported Mitochondria Melanoma:7.90e-4 (unfavourable) Expressed in all Expressed in all kidney: 86.0 COX15 CEMCOX2 ENSG00000014919 Cytochrome c oxidase assembly homolog 15 (yeast) 10 99711844-99732100 Disease related genes, Predicted membrane proteins Evidence at protein level HPA037727, HPA037728, HPA066096 Uncertain Supported Mitochondria Renal cancer:9.21e-6 (favourable) Expressed in all Expressed in all thyroid gland: 36.2 COX18 FLJ38991 ENSG00000163626 COX18 cytochrome c oxidase assembly factor 4 73052362-73069755 Predicted membrane proteins Evidence at protein level HPA046772, HPA049489 Approved Renal cancer:8.22e-7 (favourable), Colorectal cancer:6.31e-4 (favourable) Expressed in all Mixed thyroid gland: 5.5 COX20 FAM36A, FLJ43269 ENSG00000203667 COX20 cytochrome c oxidase assembly factor 1 244835322-244845057 Predicted membrane proteins Evidence at protein level HPA043617, HPA045490 Approved Validated Mitochondria Ovarian cancer:3.13e-4 (favourable) Expressed in all Expressed in all adrenal gland: 46.7 COX4I1 COX4, COX4-1 ENSG00000131143 Cytochrome c oxidase subunit IV isoform 1 16 85798633-85807044 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA002485, CAB004080 Supported Supported Mitochondria Renal cancer:2.56e-8 (favourable) Expressed in all Expressed in all heart muscle: 1070.8 COX6A1 COX6A ENSG00000111775 Cytochrome c oxidase subunit VIa polypeptide 1 12 120438090-120440742 Disease related genes, Predicted membrane proteins Evidence at protein level HPA062394 Approved Supported Mitochondria Renal cancer:6.50e-7 (favourable) Expressed in all Expressed in all duodenum: 589.3 COX6C ENSG00000164919 Cytochrome c oxidase subunit VIc 8 99873200-99894062 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA014295, CAB016244 Supported Validated Mitochondria Expressed in all Expressed in all duodenum: 349.0 COX7A2L COX7AR, COX7RP, EB1, SIG81 ENSG00000115944 Cytochrome c oxidase subunit VIIa polypeptide 2 like 2 42333546-42425088 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059124, CAB073545 Validated Nucleoli
Mitochondria Liver cancer:4.13e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 255.6 COX7C ENSG00000127184 Cytochrome c oxidase subunit VIIc 5 86617904-86620962 Predicted membrane proteins, Transporters Evidence at protein level HPA046647 Approved Renal cancer:1.23e-5 (favourable) Expressed in all Expressed in all skeletal muscle: 822.1 COX8A COX, COX8, COX8-2, COX8L, VIII, VIII-L ENSG00000176340 Cytochrome c oxidase subunit VIIIA (ubiquitous) 11 63974607-63976543 Predicted membrane proteins, Transporters Evidence at protein level HPA055942 Supported Renal cancer:2.51e-6 (favourable) Expressed in all Expressed in all skeletal muscle: 512.5 COX8C COX8-3 ENSG00000187581 Cytochrome c oxidase subunit VIIIC 14 93347191-93348356 Predicted membrane proteins, Transporters Evidence at transcript level HPA003127 Approved Group enriched Tissue enriched 52 testis: 29.6 fallopian tube: 0.5 CP ENSG00000047457 Ceruloplasmin (ferroxidase) 3 149162410-149222055 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001834, CAB008591 Supported Renal cancer:1.14e-7 (unfavourable) Tissue enhanced Tissue enriched 10 liver: 916.4 cervix, uterine: 95.6 CPA5 ENSG00000158525 Carboxypeptidase A5 7 130344816-130368730 Enzymes, Predicted intracellular proteins Evidence at protein level HPA020322 Approved Nucleus Not detected Tissue enriched 11 testis: 47.1 spleen: 4.2 CPD GP180 ENSG00000108582 Carboxypeptidase D 17 30378905-30469989 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052796, HPA055465 Approved Approved Nucleoplasm
Nuclear membrane
Nuclear speckles Expressed in all Expressed in all thyroid gland: 94.6 CPEB1 CPEB, FLJ13203 ENSG00000214575 Cytoplasmic polyadenylation element binding protein 1 15 82543201-82648861 Predicted intracellular proteins Evidence at protein level HPA040396 Approved Nucleoplasm
Vesicles Tissue enriched Tissue enhanced testis: 61.1 cerebral cortex: 22.4 CPM ENSG00000135678 Carboxypeptidase M 12 68842197-68971570 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002657, HPA077243 Uncertain Uncertain Vesicles Endometrial cancer:1.00e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 163.6 placenta: 100.2 CPOX CPO, CPX, HCP ENSG00000080819 Coproporphyrinogen oxidase 3 98521132-98593723 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA015736, HPA054448 Validated Mitochondria Renal cancer:1.04e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 25.5 CPT1A CPT1, CPT1-L, L-CPT1 ENSG00000110090 Carnitine palmitoyltransferase 1A (liver) 11 68754620-68844410 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008835 Supported Supported Mitochondria Renal cancer:2.67e-7 (favourable), Breast cancer:3.84e-4 (unfavourable) Expressed in all Expressed in all small intestine: 80.5 CPT1B CPT1-M, M-CPT1 ENSG00000205560 Carnitine palmitoyltransferase 1B (muscle) 22 50568861-50578465 Enzymes, Predicted membrane proteins Evidence at protein level HPA029583 Approved Mixed Expressed in all heart muscle: 110.6 CPT1C CPT1P, CPTIC, FLJ23809 ENSG00000169169 Carnitine palmitoyltransferase 1C 19 49690898-49713731 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014529 Supported Approved Centrosome Pancreatic cancer:1.84e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 34.3 adrenal gland: 7.0 CPTP GLTPD1, MGC10334 ENSG00000224051 Ceramide-1-phosphate transfer protein 1 1324756-1328897 Predicted intracellular proteins Evidence at protein level HPA056832 Approved Approved Cytosol Renal cancer:1.75e-4 (favourable) Expressed in all Expressed in all testis: 47.0 CR1 CD35, KN ENSG00000203710 Complement component (3b/4b) receptor 1 (Knops blood group) 1 207496147-207640647 Blood group antigen proteins, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002491, CAB016271, HPA042455, HPA043579, HPA049348 Supported Mixed Tissue enhanced appendix: 38.5;spleen: 34.2 lymph node: 23.7 CR2 CD21 ENSG00000117322 Complement component (3d/Epstein Barr virus) receptor 2 1 207454230-207489895 CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002659, HPA052942, HPA060715 Supported Breast cancer:6.90e-4 (favourable) Mixed Group enriched 22 appendix: 70.8;lymph node: 207.6;spleen: 101.3;tonsil: 159.4 kidney: 6.1 CRB1 LCA8, RP12 ENSG00000134376 Crumbs family member 1, photoreceptor morphogenesis associated 1 197268204-197478455 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA061250, HPA063127 Approved Uncertain Vesicles Tissue enriched Group enriched 10 cerebral cortex: 12.1;testis: 4.9 ovary: 0.8 CRB2 FLJ16786, FLJ38464 ENSG00000148204 Crumbs family member 2 9 123356170-123380324 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043674 Uncertain Group enriched Tissue enhanced cerebral cortex: 9.4 kidney: 2.1 CRB3 MGC17303 ENSG00000130545 Crumbs family member 3 19 6463777-6467221 Predicted membrane proteins Evidence at protein level HPA013835 Approved Supported Cell Junctions Renal cancer:0.00e+0 (favourable), Urothelial cancer:8.06e-5 (favourable), Endometrial cancer:4.54e-4 (favourable) Mixed Mixed duodenum: 38.4 CREB3 Luman, LZIP, sLZIP ENSG00000107175 CAMP responsive element binding protein 3 9 35732320-35737007 Predicted membrane proteins, Transcription factors Evidence at protein level HPA030978 Supported Cytosol Renal cancer:3.77e-5 (favourable), Ovarian cancer:5.40e-4 (favourable), Liver cancer:5.57e-4 (unfavourable) Expressed in all Expressed in all prostate: 54.5 CREB3L1 OASIS ENSG00000157613 CAMP responsive element binding protein 3-like 1 11 46277661-46321422 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA024069, CAB026151 Supported Uncertain Plasma membrane
Cytosol Renal cancer:2.97e-4 (unfavourable), Endometrial cancer:3.92e-4 (favourable), Thyroid cancer:8.59e-4 (unfavourable) Expressed in all Mixed stomach: 66.1 CREB3L2 BBF2H7, TCAG_1951439 ENSG00000182158 CAMP responsive element binding protein 3-like 2 7 137874979-138002067 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA015068, HPA015534 Uncertain Supported Nucleoplasm
Endoplasmic reticulum Expressed in all Expressed in all thyroid gland: 109.9 CREB3L3 CREB-H ENSG00000060566 CAMP responsive element binding protein 3-like 3 19 4153601-4173054 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA040671, HPA056228 Supported Renal cancer:3.53e-6 (unfavourable) Tissue enriched Group enriched 104 duodenum: 248.3;liver: 61.3;small intestine: 284.6 colon: 1.9 CREB3L4 AIbZIP, ATCE1, CREB3, CREB4, hJAL ENSG00000143578 CAMP responsive element binding protein 3-like 4 1 153967534-153974363 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA038122 Supported Approved Nucleoplasm
Nuclear membrane
Mitochondria Endometrial cancer:7.21e-4 (favourable) Group enriched Expressed in all prostate: 171.5 CRELD1 AVSD2 ENSG00000163703 Cysteine-rich with EGF-like domains 1 3 9933822-9945413 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026964 Uncertain Approved Nucleoli
Cytosol Glioma:6.05e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 65.6 CRHR2 CRF-RB, CRF2, HM-CRF ENSG00000106113 Corticotropin releasing hormone receptor 2 7 30651943-30700129 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046683 Uncertain Not detected Tissue enhanced seminal vesicle: 1.8 cerebral cortex: 1.2 CRIM1 S52 ENSG00000150938 Cysteine rich transmembrane BMP regulator 1 (chordin-like) 2 36355926-36551135 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000556 Approved Renal cancer:9.51e-4 (favourable) Expressed in all Expressed in all placenta: 238.1 CRISP3 Aeg2, CRISP-3, CRS3, dJ442L6.3, SGP28 ENSG00000096006 Cysteine-rich secretory protein 3 6 49727384-49744437 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA054392 Supported Group enriched Tissue enhanced fallopian tube: 1867.9;salivary gland: 923.6 esophagus: 289.4 CRTAM CD355 ENSG00000109943 Cytotoxic and regulatory T cell molecule 11 122838500-122872639 CD markers, Predicted membrane proteins Evidence at protein level HPA054595 Uncertain Mixed Tissue enhanced lymph node: 10.0 spleen: 5.0 CRYAB CRYA2, HSPB5 ENSG00000109846 Crystallin, alpha B 11 111908565-111923722 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002053, CAB040560, HPA057100 Supported Validated Plasma membrane
Cytosol Urothelial cancer:1.70e-5 (unfavourable), Colorectal cancer:4.90e-5 (unfavourable) Group enriched Tissue enhanced heart muscle: 3940.2 cerebral cortex: 1892.7 CS ENSG00000062485 Citrate synthase 12 56271699-56300392 Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038460, HPA038461, CAB075750, CAB075751, CAB075752, CAB075753, CAB075754 Supported Validated Mitochondria Renal cancer:1.17e-4 (favourable) Expressed in all Expressed in all heart muscle: 203.7 CSF1 M-CSF, MCSF, MGC31930 ENSG00000184371 Colony stimulating factor 1 (macrophage) 1 109910242-109930992 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA076624 Supported Plasma membrane Renal cancer:1.00e-11 (unfavourable), Liver cancer:4.25e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 66.1 CSF1R C-FMS, CD115, CSFR, FMS ENSG00000182578 Colony stimulating factor 1 receptor 5 150053291-150113372 Cancer-related genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB008970, HPA012323 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.08e-4 (unfavourable), Testis cancer:4.92e-4 (unfavourable) Expressed in all Mixed spleen: 150.2 CSF2RA CD116, CSF2R ENSG00000198223 Colony stimulating factor 2 receptor, alpha, low-affinity (granulocyte-macrophage) X 1268800-1310381 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016148 Uncertain Cervical cancer:2.38e-5 (favourable), Head and neck cancer:2.81e-4 (favourable), Testis cancer:5.53e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 93.5 appendix: 36.4 CSF2RB CD131, IL3RB, IL5RB ENSG00000100368 Colony stimulating factor 2 receptor, beta, low-affinity (granulocyte-macrophage) 22 36913628-36940449 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA078677 Uncertain Golgi apparatus Head and neck cancer:7.47e-5 (favourable) Expressed in all Tissue enhanced appendix: 92.0 tonsil: 59.3 CSF3R CD114, GCSFR ENSG00000119535 Colony stimulating factor 3 receptor (granulocyte) 1 36466043-36483278 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017116, HPA048086 Supported Testis cancer:3.79e-4 (unfavourable), Renal cancer:5.72e-4 (unfavourable) Mixed Tissue enhanced appendix: 215.2;bone marrow: 243.8;placenta: 147.0 spleen: 98.2 CSGALNACT2 GALNACT-2, GALNACT2, MGC40204, PRO0082 ENSG00000169826 Chondroitin sulfate N-acetylgalactosaminyltransferase 2 10 43138486-43185308 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031540 Approved Approved Endoplasmic reticulum Renal cancer:3.53e-7 (unfavourable) Expressed in all Expressed in all bone marrow: 87.4 CSMD1 KIAA1890, PPP1R24 ENSG00000183117 CUB and Sushi multiple domains 1 8 2935353-4994972 Predicted membrane proteins Evidence at protein level HPA074707 Approved Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 6.2;testis: 4.7 fallopian tube: 1.1 CSMD2 KIAA1884 ENSG00000121904 CUB and Sushi multiple domains 2 1 33513999-34165842 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008622 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 2.6;gallbladder: 1.8 testis: 1.0 CSMD3 ENSG00000164796 CUB and Sushi multiple domains 3 8 112222928-113437099 Predicted membrane proteins Evidence at transcript level HPA029007 Uncertain Not detected Group enriched 7 cerebral cortex: 4.9;testis: 1.8 fallopian tube,prostate,spleen: 0.4 CSNK1A1 CK1, CK1a, CK1alpha, CKIa, CKIalpha ENSG00000113712 Casein kinase 1, alpha 1 5 149492197-149551552 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016680, HPA051334 Uncertain Approved Cytosol Colorectal cancer:1.15e-4 (favourable), Pancreatic cancer:5.79e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 230.2 CSNK1G1 CK1gamma1 ENSG00000169118 Casein kinase 1, gamma 1 15 64165517-64356259 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018209 Supported Cytosol Expressed in all Tissue enhanced testis: 63.5 thyroid gland: 14.1 CSPG4 HMW-MAA, MCSP, MCSPG, MEL-CSPG, MSK16, NG2 ENSG00000173546 Chondroitin sulfate proteoglycan 4 15 75674322-75712848 Predicted membrane proteins Evidence at protein level HPA002951, CAB016189, HPA042785, HPA050008 Approved Approved Nucleus
Plasma membrane Renal cancer:7.60e-6 (unfavourable), Urothelial cancer:4.93e-5 (unfavourable) Expressed in all Mixed adipose tissue: 31.9 CSPG5 NGC ENSG00000114646 Chondroitin sulfate proteoglycan 5 (neuroglycan C) 3 47562239-47580792 Predicted membrane proteins Evidence at protein level HPA049529, HPA067818, HPA071779 Supported Approved Nucleoplasm
Mitochondria Ovarian cancer:2.14e-4 (favourable) Tissue enriched Tissue enriched 56 cerebral cortex: 157.1 testis: 2.8 CTAG1A ESO1, LAGE2A ENSG00000268651 Cancer/testis antigen 1A X 154585143-154586821 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB013061 Supported Not detected Tissue enriched 39 testis: 4.6 spleen: 0.1 CTAG1B CT6.1, CTAG, CTAG1, ESO1, LAGE2A, LAGE2B, NY-ESO-1 ENSG00000184033 Cancer/testis antigen 1B X 154617604-154619282 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB015453 Supported Not detected Tissue enriched 46 testis: 5.5 spleen: 0.1 CTAG2 CAMEL, CT6.2a, CT6.2b, ESO2, LAGE-1, LAGE-1a, LAGE-1b, LAGE1, MGC138724, MGC3803 ENSG00000126890 Cancer/testis antigen 2 X 154651972-154653579 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA071467 Supported Liver cancer:2.35e-4 (unfavourable) Mixed Group enriched 7 fallopian tube: 2.5;heart muscle: 2.5;placenta: 3.6;skeletal muscle: 1.2;testis: 6.0 pancreas: 0.4 CTAGE1 CT21.1, CT21.2, CTAGE, cTAGE-1, cTAGE-2 ENSG00000212710 Cutaneous T-cell lymphoma-associated antigen 1 18 22413601-22417915 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922, CAB016204 Uncertain Not detected Tissue enriched 50 testis: 5.0 all non-specific tissues: 0.0 CTAGE15 CTAGE15P ENSG00000271079 CTAGE family, member 15 7 143571801-143574387 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922 Uncertain Not detected Tissue enhanced testis: 7.2 thyroid gland: 1.9 CTAGE4 cTAGE-4, FLJ43692 ENSG00000225932 CTAGE family, member 4 7 144183466-144186053 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922 Uncertain Not detected Mixed thyroid gland: 16.7 CTAGE5 cTAGE-5A, cTAGE-5B, cTAGE-5C, cTAGE-5D, MEA6, MGEA, MGEA11, MGEA6 ENSG00000150527 CTAGE family, member 5 14 39265284-39388513 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000387, HPA000922 Uncertain Renal cancer:2.81e-4 (favourable) Mixed Expressed in all thyroid gland: 77.3 CTAGE6 CTAGE6P, MGC41943 ENSG00000271321 CTAGE family, member 6 7 143755089-143757696 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922 Uncertain Not detected Tissue enriched 38 testis: 9.9 skin: 0.2 CTAGE8 ENSG00000244693 CTAGE family, member 8 7 144266701-144269288 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922 Uncertain Not detected Mixed thyroid gland: 12.5 CTAGE9 ENSG00000236761 CTAGE family, member 9 6 131708684-131711017 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922 Uncertain Not detected Tissue enriched 40 testis: 7.6 duodenum,seminal vesicle,small intestine: 0.1 CTB-133G6.1 ENSG00000263264 19 7348943-7383385 Predicted membrane proteins Evidence at protein level HPA049151 Uncertain Mixed Tissue enhanced lymph node: 22.6;spleen: 16.8 appendix: 16.0 CTCFL BORIS, CT27, dJ579F20.2 ENSG00000124092 CCCTC-binding factor (zinc finger protein)-like 20 57495966-57525652 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA001472 Supported Tissue enhanced Tissue enriched 19 testis: 20.6 epididymis: 1.1 CTD-2370N5.3 ENSG00000265118 17 31305213-31318831 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA045033 Uncertain Not detected Tissue enhanced appendix: 5.3 tonsil: 3.2 CTD-2521M24.10 ENSG00000269035 19 17436611-17460804 Predicted membrane proteins No evidence HPA041580, HPA042010 Uncertain Uncertain Nuclear membrane Not detected Not detected all non-specific tissues: 0.0 CTDNEP1 DULLARD, HSA011916, NET56 ENSG00000175826 CTD nuclear envelope phosphatase 1 17 7243591-7252491 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037439 Uncertain Pancreatic cancer:1.81e-4 (favourable), Endometrial cancer:6.45e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 190.2 CTNS CTNS-LSB, PQLC4 ENSG00000040531 Cystinosin, lysosomal cystine transporter 17 3636468-3661542 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA046947 Supported Vesicles
Intermediate filaments Pancreatic cancer:6.39e-5 (favourable), Head and neck cancer:7.33e-4 (favourable) Expressed in all Expressed in all testis: 43.3 CTSC DPP1, PALS, PLS ENSG00000109861 Cathepsin C 11 88293592-88337787 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025364, HPA066610, HPA068434 Supported Supported Vesicles Liver cancer:9.30e-5 (unfavourable), Renal cancer:4.80e-4 (favourable) Expressed in all Expressed in all lung: 390.6 CTSK CTSO, CTSO2, PKND, PYCD ENSG00000143387 Cathepsin K 1 150796208-150808323 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050346 Supported Vesicles Renal cancer:7.12e-5 (unfavourable) Expressed in all Expressed in all cervix, uterine: 571.4 CTXN1 FLJ25968 ENSG00000178531 Cortexin 1 19 7924485-7926166 Predicted membrane proteins Evidence at transcript level HPA016669 Uncertain Approved Nucleoplasm
Plasma membrane
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 100.8 endometrium: 22.7 CTXN2 ENSG00000233932 Cortexin 2 15 48191539-48203756 Predicted membrane proteins Evidence at transcript level HPA053168 Uncertain Not detected Group enriched 8 cerebral cortex: 1.9;testis: 1.5 fallopian tube: 0.2 CUTA ACHAP, C6orf82 ENSG00000112514 CutA divalent cation tolerance homolog (E. coli) 6 33416442-33418317 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB016787, HPA064369 Uncertain Approved Plasma membrane
Focal adhesion sites Lung cancer:8.50e-4 (favourable) Expressed in all Expressed in all thyroid gland: 292.6 CUX1 CASP, CDP, CDP/Cut, CDP/Cux, CDP1, Clox, CUT, CUTL1, CUX, Cux/CDP, GOLIM6 ENSG00000257923 Cut-like homeobox 1 7 101815904-102283957 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA003277, HPA003317 Approved Supported Nucleoplasm
Golgi apparatus Renal cancer:5.72e-7 (favourable), Glioma:9.90e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 82.3 CUX2 CDP2, CUTL2, KIAA0293 ENSG00000111249 Cut-like homeobox 2 12 111034024-111350554 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA044772 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 12.2;liver: 9.6;prostate: 17.1 thyroid gland: 6.8 CUZD1 ERG-1, UO-44 ENSG00000138161 CUB and zona pellucida-like domains 1 10 122832149-122850793 Predicted membrane proteins Evidence at protein level HPA068479, HPA068660, HPA074117 Supported Approved Nucleoli
Vesicles Tissue enriched Tissue enriched 170 pancreas: 380.4 testis: 2.2 CWH43 CWH43-C, FLJ21511 ENSG00000109182 Cell wall biogenesis 43 C-terminal homolog 4 48986247-49062081 Predicted membrane proteins Evidence at protein level HPA042814, HPA048140 Uncertain Renal cancer:2.29e-11 (favourable), Endometrial cancer:1.32e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 69.1 skin: 29.7 CX3CL1 ABCD-3, C3Xkine, CXC3, CXC3C, fractalkine, neurotactin, NTN, SCYD1 ENSG00000006210 Chemokine (C-X3-C motif) ligand 1 16 57372458-57385048 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026192, HPA040361 Approved Supported Plasma membrane Renal cancer:8.52e-7 (favourable), Cervical cancer:9.46e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 100.4 lung: 69.4 CX3CR1 CCRL1, CMKBRL1, CMKDR1, GPR13, V28 ENSG00000168329 Chemokine (C-X3-C motif) receptor 1 3 39263494-39281735 Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032478, HPA046587 Approved Tissue enhanced Tissue enhanced cerebral cortex: 59.4 spleen: 16.8 CXADR CAR ENSG00000154639 Coxsackie virus and adenovirus receptor 21 17512382-17593579 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003342, CAB005103, HPA030411, HPA030412 Supported Validated Plasma membrane
Cell Junctions Head and neck cancer:3.50e-4 (favourable) Expressed in all Mixed skin: 59.6 CXCL16 CXCLG16, SR-PSOX, SRPSOX ENSG00000161921 Chemokine (C-X-C motif) ligand 16 17 4733526-4739922 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA053253, HPA066315 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed lung: 106.3 CXCR1 CD181, CDw128a, CKR-1, CMKAR1, IL8RA ENSG00000163464 Chemokine (C-X-C motif) receptor 1 2 218162845-218166995 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031991 Uncertain Mixed Tissue enhanced appendix: 35.7;spleen: 25.4 adipose tissue: 15.5 CXCR2 CD182, CMKAR2, IL8RB ENSG00000180871 Chemokine (C-X-C motif) receptor 2 2 218125289-218137253 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016268, HPA031999, HPA032017 Supported Mixed Tissue enhanced appendix: 56.9;spleen: 37.2 esophagus: 30.0 CXCR3 CD183, CKR-L2, CMKAR3, GPR9, IP10-R, MigR ENSG00000186810 Chemokine (C-X-C motif) receptor 3 X 71615916-71618517 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA045942 Supported Renal cancer:1.67e-6 (unfavourable), Endometrial cancer:3.44e-6 (favourable), Melanoma:2.90e-4 (favourable), Head and neck cancer:3.35e-4 (favourable) Mixed Tissue enhanced lymph node: 18.1 spleen: 8.9 CXCR5 BLR1, CD185, MDR15 ENSG00000160683 Chemokine (C-X-C motif) receptor 5 11 118883766-118897799 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB026149, HPA042432 Supported Not detected Tissue enhanced lymph node: 32.9;spleen: 21.7;tonsil: 16.2 appendix: 15.1 CXCR6 BONZO, CD186, STRL33, TYMSTR ENSG00000172215 Chemokine (C-X-C motif) receptor 6 3 45940933-45948353 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA047591 Uncertain Endometrial cancer:6.74e-6 (favourable), Renal cancer:2.42e-5 (unfavourable), Head and neck cancer:2.16e-4 (favourable), Cervical cancer:4.92e-4 (favourable) Mixed Mixed lymph node: 17.6 CXorf65 ENSG00000204165 Chromosome X open reading frame 65 X 71103889-71106788 Predicted intracellular proteins Evidence at protein level HPA047396 Uncertain Mixed Tissue enriched 9 testis: 19.5 lymph node: 2.0 CXorf66 RP11-35F15.2, SGPX ENSG00000203933 Chromosome X open reading frame 66 X 139955725-139965520 Predicted membrane proteins Evidence at protein level HPA048517 Approved Not detected Tissue enriched 76 testis: 24.1 liver: 0.3 CYB561 CYB561A1, FRRS2 ENSG00000008283 Cytochrome b561 17 63432304-63446378 Predicted membrane proteins, Transporters Evidence at protein level HPA014753 Approved Endometrial cancer:2.95e-5 (favourable), Breast cancer:8.89e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 164.3 CYB561A3 CYBASC3 ENSG00000162144 Cytochrome b561 family, member A3 11 61348745-61362299 Predicted membrane proteins Evidence at protein level HPA052548 Uncertain Expressed in all Expressed in all adrenal gland: 188.0 CYB561D1 FLJ39035, FLJ44753 ENSG00000174151 Cytochrome b561 family, member D1 1 109494052-109502932 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027028 Uncertain Pancreatic cancer:5.16e-6 (favourable), Renal cancer:2.22e-4 (favourable), Head and neck cancer:4.68e-4 (favourable) Expressed in all Mixed skin: 21.4 CYB561D2 101F6, TSP10 ENSG00000114395 Cytochrome b561 family, member D2 3 50350695-50358460 Predicted membrane proteins Evidence at protein level HPA042817 Uncertain Renal cancer:6.16e-5 (favourable), Pancreatic cancer:1.86e-4 (favourable) Expressed in all Expressed in all epididymis: 28.3 CYB5A CYB5 ENSG00000166347 Cytochrome b5 type A (microsomal) 18 74250847-74292016 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006333, HPA047548, HPA058547 Supported Approved Vesicles
Cytosol Liver cancer:4.15e-4 (favourable), Colorectal cancer:5.23e-4 (favourable) Expressed in all Expressed in all liver: 1254.1 CYB5B CYB5-M ENSG00000103018 Cytochrome b5 type B (outer mitochondrial membrane) 16 69424525-69466266 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007893 Approved Approved Endoplasmic reticulum
Microtubule organizing center
Cytosol Renal cancer:6.38e-5 (favourable), Head and neck cancer:2.51e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 399.7 CYB5R2 ENSG00000166394 Cytochrome b5 reductase 2 11 7665100-7677222 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038962 Approved Approved Nucleoplasm
Golgi apparatus Mixed Tissue enhanced testis: 226.8 parathyroid gland: 78.3 CYB5R3 DIA1 ENSG00000100243 Cytochrome b5 reductase 3 22 42617840-42649568 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001566 Approved Validated Endoplasmic reticulum Liver cancer:2.13e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 336.2 CYBA p22-PHOX ENSG00000051523 Cytochrome b-245, alpha polypeptide 16 88643283-88651152 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009492 Supported Endometrial cancer:4.75e-5 (favourable), Renal cancer:1.83e-4 (unfavourable), Breast cancer:8.19e-4 (favourable) Expressed in all Expressed in all spleen: 476.3 CYBB CGD, GP91-PHOX, NOX2 ENSG00000165168 Cytochrome b-245, beta polypeptide X 37780011-37813461 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA051227 Supported Expressed in all Tissue enhanced appendix: 221.1 lung: 132.4 CYBRD1 CYB561A2, DCYTB, FLJ23462, FRRS3 ENSG00000071967 Cytochrome b reductase 1 2 171522247-171558133 Predicted membrane proteins Evidence at protein level HPA014757, HPA056736 Approved Approved Golgi apparatus
Cytosol Expressed in all Expressed in all thyroid gland: 379.4 CYC1 UQCR4 ENSG00000179091 Cytochrome c-1 8 144095027-144097525 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA001247 Supported Supported Mitochondria Renal cancer:5.89e-6 (favourable) Expressed in all Expressed in all skeletal muscle: 242.3 CYHR1 CHRP, KIAA0496, MGC13010 ENSG00000187954 Cysteine/histidine-rich 1 8 144449582-144465677 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA053653, HPA059543 Approved Validated Nucleoplasm Colorectal cancer:1.05e-4 (unfavourable), Liver cancer:3.90e-4 (unfavourable) Expressed in all Expressed in all testis: 51.5 CYP19A1 ARO, ARO1, aromatase, CPV1, CYAR, CYP19, P-450AROM ENSG00000137869 Cytochrome P450, family 19, subfamily A, polypeptide 1 15 51208057-51338610 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000355, HPA051194 Supported Approved Vesicles Mixed Tissue enriched 14 placenta: 173.9 testis: 12.4 CYP1A2 CP12, P3-450 ENSG00000140505 Cytochrome P450, family 1, subfamily A, polypeptide 2 15 74748844-74756202 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level CAB016531 Supported Group enriched Tissue enriched 168 liver: 268.7 thyroid gland: 1.5 CYP1B1 CP1B, GLC3A ENSG00000138061 Cytochrome P450, family 1, subfamily B, polypeptide 1 2 38066973-38109902 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011705, HPA026863 Approved Uncertain Mitochondria Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:2.76e-4 (unfavourable) Expressed in all Mixed fallopian tube: 75.4 CYP2D6 CPD6, CYP2D, CYP2D7AP, CYP2D7BP, CYP2D7P2, CYP2D8P2, CYP2DL1, P450-DB1, P450C2D ENSG00000100197 Cytochrome P450, family 2, subfamily D, polypeptide 6 22 42126499-42130906 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045223 Supported Uncertain Golgi apparatus Tissue enriched Tissue enhanced liver: 11.4;small intestine: 13.2 duodenum: 3.9 CYP2S1 ENSG00000167600 Cytochrome P450, family 2, subfamily S, polypeptide 1 19 41193049-41207539 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049227 Approved Endoplasmic reticulum Renal cancer:1.60e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 99.4;small intestine: 70.0;stomach: 113.4 colon: 26.4 CYP2U1 SPG49 ENSG00000155016 Cytochrome P450, family 2, subfamily U, polypeptide 1 4 107931369-107953457 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA041622, HPA046754, HPA064827 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:2.75e-5 (favourable), Stomach cancer:6.97e-4 (unfavourable) Expressed in all Mixed prostate: 15.7 CYP2W1 FLJ20359, MGC34287 ENSG00000073067 Cytochrome P450, family 2, subfamily W, polypeptide 1 7 983199-989640 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012753 Uncertain Urothelial cancer:5.85e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 5.6;duodenum: 6.3;skin: 9.7 placenta: 1.4 CYP3A4 CYP3A3 ENSG00000160868 Cytochrome P450, family 3, subfamily A, polypeptide 4 7 99756960-99784265 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033671, HPA072245 Supported Uncertain Cytosol Tissue enriched Group enriched 200 duodenum: 849.6;liver: 2446.6;small intestine: 990.4 adrenal gland: 7.1 CYP3A43 ENSG00000021461 Cytochrome P450, family 3, subfamily A, polypeptide 43 7 99828013-99866102 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066463, HPA072245 Supported Uncertain Cytosol Liver cancer:3.41e-4 (favourable) Tissue enriched Tissue enriched 14 liver: 22.4 testis: 1.5 CYP3A5 CP35, P450PCN3, PCN3 ENSG00000106258 Cytochrome P450, family 3, subfamily A, polypeptide 5 7 99648194-99679998 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Liver cancer:3.72e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 117.9;liver: 93.1;small intestine: 191.3 stomach: 79.3 CYP3A7 CP37, P450-HFLA ENSG00000160870 Cytochrome P450, family 3, subfamily A, polypeptide 7 7 99705037-99735196 Enzymes, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Tissue enriched Tissue enriched 14 liver: 143.0 gallbladder,kidney: 9.8 CYP3A7-CYP3A51P ENSG00000282301 CYP3A7-CYP3A51P readthrough 7 99684957-99735102 Enzymes, Predicted membrane proteins Evidence at protein level HPA072245 Uncertain Cytosol Tissue enhanced liver: 7.4 gallbladder: 1.9 CYP4B1 ENSG00000142973 Cytochrome P450, family 4, subfamily B, polypeptide 1 1 46757838-46819413 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004331 Approved Supported Vesicles Cervical cancer:5.99e-4 (favourable) Tissue enhanced Tissue enriched 5 lung: 371.8 fallopian tube: 71.5 CYP4F12 ENSG00000186204 Cytochrome P450, family 4, subfamily F, polypeptide 12 19 15672757-15697174 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Cervical cancer:1.21e-4 (favourable), Urothelial cancer:2.33e-4 (favourable) Group enriched Tissue enhanced duodenum: 37.1;small intestine: 43.1 skin: 22.4 CYP4F2 ENSG00000186115 Cytochrome P450, family 4, subfamily F, polypeptide 2 19 15878023-15898120 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014048, HPA017265, HPA058960 Supported Tissue enriched Group enriched 6 duodenum: 80.4;epididymis: 27.5;kidney: 39.1;liver: 84.6;small intestine: 86.1 prostate: 10.6 CYP4F22 FLJ39501 ENSG00000171954 Cytochrome P450, family 4, subfamily F, polypeptide 22 19 15508493-15552317 Disease related genes, Predicted membrane proteins Evidence at protein level HPA058960 Uncertain Group enriched Tissue enhanced esophagus: 14.1;skin: 34.3 seminal vesicle: 9.0 CYP4F3 CYP4F, LTB4H ENSG00000186529 Cytochrome P450, family 4, subfamily F, polypeptide 3 19 15615617-15662825 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Tissue enhanced Tissue enhanced bone marrow: 53.2;liver: 98.0 kidney: 29.2 CYP4F8 ENSG00000186526 Cytochrome P450, family 4, subfamily F, polypeptide 8 19 15615218-15630638 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058960 Approved Group enriched Tissue enriched 51 seminal vesicle: 145.8 prostate: 2.8 CYP4V2 CYP4AH1 ENSG00000145476 Cytochrome P450, family 4, subfamily V, polypeptide 2 4 186191520-186213456 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA029122 Approved Approved Nuclear speckles Renal cancer:1.49e-7 (favourable), Liver cancer:1.85e-4 (favourable), Endometrial cancer:5.86e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 63.8 liver: 47.3 CYP4X1 MGC40051 ENSG00000186377 Cytochrome P450, family 4, subfamily X, polypeptide 1 1 47023568-47050751 Enzymes, Predicted membrane proteins Evidence at protein level HPA017661 Approved Mixed Tissue enhanced cervix, uterine: 52.7 breast: 18.6 CYP51A1 CP51, CYP51, CYPL1, LDM, P450-14DM, P450L1 ENSG00000001630 Cytochrome P450, family 51, subfamily A, polypeptide 1 7 92112151-92142952 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041325, HPA043508 Approved Validated Endoplasmic reticulum Cervical cancer:6.12e-4 (unfavourable) Expressed in all Expressed in all testis: 175.2 CYP7B1 SPG5A ENSG00000172817 Cytochrome P450, family 7, subfamily B, polypeptide 1 8 64587763-64798761 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017761 Uncertain Mixed Tissue enhanced parathyroid gland: 39.6 thyroid gland: 22.3 CYSLTR1 CysLT(1), CysLT1, CYSLT1R ENSG00000173198 Cysteinyl leukotriene receptor 1 X 78271464-78327691 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA010546 Approved Mixed Mixed spleen: 15.1 CYSLTR2 CysLT(2), CYSLT2R ENSG00000152207 Cysteinyl leukotriene receptor 2 13 48653711-48711226 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046528 Uncertain Group enriched Tissue enhanced placenta: 36.4;seminal vesicle: 24.8 spleen: 11.6 CYYR1 C21orf95 ENSG00000166265 Cysteine/tyrosine-rich 1 21 26466209-26573284 Predicted membrane proteins Evidence at transcript level CAB034921, HPA067685 Uncertain Approved Nucleoplasm Expressed in all Expressed in all adrenal gland: 60.4 DAD1 OST2 ENSG00000129562 Defender against cell death 1 14 22564905-22589269 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA028882 Uncertain Approved Cytosol Liver cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all epididymis: 507.2 DAG1 156DAG, A3a, AGRNR, DAG ENSG00000173402 Dystroglycan 1 (dystrophin-associated glycoprotein 1) 3 49468703-49535618 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB001960, CAB016353 Supported Approved Vesicles Renal cancer:2.59e-4 (favourable) Expressed in all Expressed in all placenta: 108.6 DAGLA C11orf11, DAGLALPHA, KIAA0659, NSDDR ENSG00000134780 Diacylglycerol lipase, alpha 11 61680433-61747001 Disease related genes, Predicted membrane proteins Evidence at protein level HPA062497 Approved Endometrial cancer:1.13e-7 (unfavourable) Expressed in all Tissue enriched 6 cerebral cortex: 18.6 colon: 3.1 DAGLB DAGLBETA, KCCR13L ENSG00000164535 Diacylglycerol lipase, beta 7 6409126-6484190 Predicted membrane proteins Evidence at protein level HPA069377 Supported Plasma membrane Ovarian cancer:7.18e-5 (unfavourable), Renal cancer:1.54e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 20.6 DAPL1 ENSG00000163331 Death associated protein-like 1 2 158795317-158862958 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046937 Approved Nucleoplasm
Mitochondria Cervical cancer:8.43e-4 (favourable) Group enriched Tissue enhanced epididymis: 236.1;esophagus: 245.6;skin: 219.1 fallopian tube: 128.2 DBH DBM ENSG00000123454 Dopamine beta-hydroxylase (dopamine beta-monooxygenase) 9 133636360-133659344 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002130, HPA005960, HPA070789 Supported Supported Vesicles Mixed Tissue enriched 12 adrenal gland: 358.5 epididymis: 30.6 DCAF11 GL014, PRO2389, WDR23 ENSG00000100897 DDB1 and CUL4 associated factor 11 14 24114195-24125242 Predicted intracellular proteins Evidence at protein level HPA003583, HPA031157 Approved Validated Nucleoplasm Renal cancer:3.50e-13 (favourable) Expressed in all Expressed in all parathyroid gland: 73.0 DCAF17 C2orf37, FLJ13096 ENSG00000115827 DDB1 and CUL4 associated factor 17 2 171434217-171485052 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053339, HPA055040 Uncertain Supported Nucleoplasm Thyroid cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 17.0 DCAKD FLJ22955 ENSG00000172992 Dephospho-CoA kinase domain containing 17 45023340-45061109 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060997 Approved Nucleus Endometrial cancer:7.16e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 47.2 DCBLD1 dJ94G16.1, MGC46341 ENSG00000164465 Discoidin, CUB and LCCL domain containing 1 6 117453817-117569858 Predicted membrane proteins Evidence at protein level HPA059667 Approved Approved Cytosol Renal cancer:8.57e-8 (unfavourable), Cervical cancer:6.44e-5 (unfavourable) Expressed in all Mixed gallbladder: 14.4 DCBLD2 CLCP1, ESDN ENSG00000057019 Discoidin, CUB and LCCL domain containing 2 3 98795941-98901689 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016909 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:3.32e-5 (unfavourable), Pancreatic cancer:1.52e-4 (unfavourable), Stomach cancer:2.87e-4 (unfavourable) Expressed in all Mixed testis: 44.8 DCC IGDCC1, NTN1R1 ENSG00000187323 DCC netrin 1 receptor 18 52340172-53535903 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055376, HPA069552 Supported Approved Golgi apparatus Tissue enhanced Tissue enhanced cerebral cortex: 3.7;testis: 13.4 lung: 2.2 DCHS1 CDH25, CDHR6, FIB1, FLJ11790, KIAA1773, PCDH16 ENSG00000166341 Dachsous cadherin-related 1 11 6621323-6655854 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA017970, HPA050246 Approved Approved Plasma membrane Renal cancer:9.32e-4 (unfavourable) Expressed in all Mixed endometrium: 29.5 DCHS2 CDH27, CDHJ, CDHR7, FLJ20047, PCDH23, PCDHJ ENSG00000197410 Dachsous cadherin-related 2 4 154232037-154491716 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA064159 Uncertain Approved Vesicles
Plasma membrane Not detected Mixed endometrium: 4.0 DCLK3 DCAMKL3, DCDC3C, KIAA1765 ENSG00000163673 Doublecortin-like kinase 3 3 36712422-36739861 Enzymes, Predicted membrane proteins Evidence at protein level CAB015207 Uncertain Tissue enhanced Tissue enhanced testis: 4.9 cerebral cortex: 1.1 DCST1 FLJ32785 ENSG00000163357 DC-STAMP domain containing 1 1 155033824-155050930 Predicted membrane proteins Evidence at protein level HPA060314 Uncertain Not detected Group enriched 5 skin: 3.7;testis: 6.2 small intestine: 0.9 DCT TYRP2 ENSG00000080166 Dopachrome tautomerase 13 94436808-94479682 Enzymes, Predicted membrane proteins Evidence at protein level HPA010743, HPA010800, CAB017634 Supported Tissue enriched Tissue enriched 32 skin: 127.2 breast: 4.0 DCUN1D5 FLJ32431, MGC2714 ENSG00000137692 DCN1, defective in cullin neddylation 1, domain containing 5 11 103062076-103092215 Predicted intracellular proteins Evidence at protein level HPA050863 Approved Approved Nucleus
Nucleoli Liver cancer:2.01e-7 (unfavourable), Ovarian cancer:9.52e-5 (favourable), Prostate cancer:4.12e-4 (unfavourable), Head and neck cancer:4.62e-4 (unfavourable) Expressed in all Expressed in all testis: 34.4 DDO ENSG00000203797 D-aspartate oxidase 6 110391771-110415562 Enzymes, Predicted membrane proteins Evidence at protein level HPA037525, HPA037526 Supported Supported Cytosol Renal cancer:8.69e-5 (favourable) Mixed Tissue enhanced parathyroid gland: 24.0 heart muscle: 11.7 DDOST KIAA0115, OST, OST48, WBP1 ENSG00000244038 Dolichyl-diphosphooligosaccharide--protein glycosyltransferase subunit (non-catalytic) 1 20651767-20661544 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009746, HPA046841, HPA052867 Supported Supported Endoplasmic reticulum Renal cancer:9.05e-7 (unfavourable), Liver cancer:2.64e-5 (unfavourable), Head and neck cancer:4.88e-4 (unfavourable), Endometrial cancer:5.99e-4 (favourable) Expressed in all Expressed in all thyroid gland: 307.5 DDR1 CAK, CD167, EDDR1, NEP, NTRK4, PTK3A, RTK6 ENSG00000204580 Discoidin domain receptor tyrosine kinase 1 6 30876421-30900156 CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010162, CAB025656, HPA057194 Approved Approved Nucleoplasm
Cell Junctions Renal cancer:3.31e-10 (favourable) Expressed in all Mixed cerebral cortex: 51.7 DDR2 NTRKR3, TKT, TYRO10 ENSG00000162733 Discoidin domain receptor tyrosine kinase 2 1 162631373-162787400 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA070112 Supported Plasma membrane
Actin filaments Renal cancer:1.73e-7 (unfavourable) Expressed in all Mixed adrenal gland: 94.0 DDX59 DKFZP564B1023, ZNHIT5 ENSG00000118197 DEAD (Asp-Glu-Ala-Asp) box polypeptide 59 1 200623896-200669969 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA047166 Approved Approved Nucleus
Actin filaments Renal cancer:9.02e-4 (unfavourable) Expressed in all Expressed in all breast: 33.2 DEGS1 DEGS-1, Des-1, DES1, FADS7, MLD ENSG00000143753 Delta(4)-desaturase, sphingolipid 1 1 224175756-224193441 Enzymes, Predicted membrane proteins Evidence at protein level HPA076422 Supported Mitochondria Renal cancer:6.83e-7 (unfavourable), Liver cancer:4.29e-5 (unfavourable), Endometrial cancer:7.74e-5 (unfavourable), Urothelial cancer:2.53e-4 (unfavourable) Expressed in all Expressed in all skin: 617.7 DEGS2 C14orf66, DES2, FADS8 ENSG00000168350 Delta(4)-desaturase, sphingolipid 2 14 100143957-100160163 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046644 Approved Nucleus
Nucleoli Renal cancer:7.94e-7 (favourable), Urothelial cancer:1.66e-4 (favourable) Mixed Tissue enhanced skin: 31.3;small intestine: 39.5 duodenum: 25.5 DENND1A FAM31A, FLJ21129, KIAA1608 ENSG00000119522 DENN/MADD domain containing 1A 9 123379654-123930152 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020481 Supported Nucleoplasm
Vesicles
Cytosol Renal cancer:4.11e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 21.5 DENND3 KIAA0870 ENSG00000105339 DENN/MADD domain containing 3 8 141117278-141195808 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024491 Approved Vesicles
Cytosol Expressed in all Mixed bone marrow: 68.7 DENND4C bA513M16.3, C9orf55, C9orf55B, FLJ20686 ENSG00000137145 DENN/MADD domain containing 4C 9 19230435-19373545 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014917, HPA015096 Approved Supported Golgi apparatus
Vesicles
Cytosol Renal cancer:3.51e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 47.3 DENND5B MGC24039 ENSG00000170456 DENN/MADD domain containing 5B 12 31382223-31591097 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038865 Approved Approved Nucleoli
Microtubules Expressed in all Mixed testis: 29.1 DERL1 DER-1, DER1, derlin-1, FLJ13784, MGC3067, PRO2577 ENSG00000136986 Derlin 1 8 123013164-123042423 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016562, CAB037269 Supported Validated Endoplasmic reticulum Endometrial cancer:5.66e-5 (unfavourable), Renal cancer:1.58e-4 (unfavourable), Breast cancer:2.43e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 76.6 DERL2 CGI-101, derlin-2, F-LAN-1, F-LANa, FLANa ENSG00000072849 Derlin 2 17 5471251-5486811 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037287, HPA048957, HPA056551 Supported Supported Endoplasmic reticulum Renal cancer:6.49e-4 (unfavourable), Endometrial cancer:7.26e-4 (favourable) Expressed in all Expressed in all thyroid gland: 41.3 DERL3 C22orf14, derlin-3, FLJ43842, IZP6, MGC71803 ENSG00000099958 Derlin 3 22 23834503-23839128 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037234, HPA049306 Uncertain Uncertain Vesicles Renal cancer:7.76e-13 (unfavourable), Cervical cancer:8.70e-5 (favourable), Head and neck cancer:8.01e-4 (favourable) Expressed in all Mixed stomach: 39.0 DESI2 C1orf121, CGI-146, FAM152A, FLJ21998, PNAS-4, PPPDE1 ENSG00000121644 Desumoylating isopeptidase 2 1 244652935-244709033 Predicted intracellular proteins Evidence at protein level HPA049950 Approved Vesicles Renal cancer:4.25e-5 (unfavourable) Expressed in all Expressed in all testis: 94.5 DEXI MYLE ENSG00000182108 Dexi homolog (mouse) 16 10928891-10942460 Predicted membrane proteins Evidence at transcript level HPA041511 Approved Approved Nuclear speckles
Cytosol Pancreatic cancer:4.23e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 45.0 DGAT1 ARGP1, DGAT ENSG00000185000 Diacylglycerol O-acyltransferase 1 8 144314584-144326910 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032853 Supported Approved Nucleoli
Endoplasmic reticulum Expressed in all Tissue enhanced duodenum: 73.2;small intestine: 76.7 adipose tissue: 20.0 DGCR2 DGS-C, IDD, KIAA0163, LAN, SEZ-12 ENSG00000070413 DiGeorge syndrome critical region gene 2 22 19036282-19122454 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA000873, HPA075929 Uncertain Approved Nucleoplasm
Nuclear bodies Renal cancer:8.72e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 58.4 DGKE DAGK6, DGK ENSG00000153933 Diacylglycerol kinase, epsilon 64kDa 17 56834099-56869567 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017167 Approved Approved Nucleus
Cytosol Endometrial cancer:3.92e-5 (favourable) Mixed Mixed testis: 12.1 DHCR24 DCE, KIAA0018, seladin-1 ENSG00000116133 24-dehydrocholesterol reductase 1 54849633-54887218 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037247, HPA063005 Approved Endometrial cancer:1.05e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 1100.8 DHCR7 SLOS ENSG00000172893 7-dehydrocholesterol reductase 11 71428193-71452868 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA044280 Approved Supported Endoplasmic reticulum
Cytosol Renal cancer:6.93e-7 (favourable), Urothelial cancer:5.67e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 116.0 DHODH ENSG00000102967 Dihydroorotate dehydrogenase (quinone) 16 72008588-72027664 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010123, HPA011942 Approved Supported Nucleoplasm
Mitochondria Expressed in all Mixed liver: 23.7 DHRS12 FLJ13639, SDR40C1 ENSG00000102796 Dehydrogenase/reductase (SDR family) member 12 13 51767993-51804157 Predicted intracellular proteins Evidence at protein level CAB034238, HPA057028, HPA058315 Uncertain Supported Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:2.22e-16 (favourable), Breast cancer:1.41e-4 (favourable) Expressed in all Expressed in all epididymis: 22.6 DHRS3 RDH17, retSDR1, Rsdr1, SDR1, SDR16C1 ENSG00000162496 Dehydrogenase/reductase (SDR family) member 3 1 12567910-12617731 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010844 Supported Approved Nucleoli
Mitochondria Thyroid cancer:2.65e-4 (favourable) Expressed in all Expressed in all adipose tissue: 99.6 DHRS7B CGI-93, DKFZp566O084, MGC8916, SDR32C1 ENSG00000109016 Dehydrogenase/reductase (SDR family) member 7B 17 21123364-21193265 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012132, HPA016873 Uncertain Approved Plasma membrane
Cell Junctions
Cytosol Endometrial cancer:1.98e-8 (favourable), Renal cancer:3.95e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.4 DHRS9 3alpha-HSD, RDH15, RDHL, RETSDR8, SDR9C4 ENSG00000073737 Dehydrogenase/reductase (SDR family) member 9 2 169064789-169096167 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA036491, HPA036667 Approved Pancreatic cancer:2.73e-4 (unfavourable) Tissue enhanced Tissue enhanced colon: 67.6;rectum: 48.8 esophagus: 30.3 DHX36 DDX36, KIAA1488, MLEL1 ENSG00000174953 DEAH (Asp-Glu-Ala-His) box polypeptide 36 3 154272546-154324497 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035399 Approved Supported Nucleus
Cytosol Expressed in all Expressed in all testis: 63.0 DIABLO DFNA64, DIABLO-S, FLJ10537, FLJ25049, SMAC ENSG00000184047 Diablo, IAP-binding mitochondrial protein 12 122207662-122227534 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001825, CAB003857, CAB016688 Supported Validated Mitochondria Renal cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all testis: 94.5 DIEXF C1orf107, DEF, MGC29875, UTP25 ENSG00000117597 Digestive organ expansion factor homolog (zebrafish) 1 209828007-209857565 Predicted intracellular proteins Evidence at protein level HPA026640, HPA061682 Approved Approved Nucleoplasm
Golgi apparatus Expressed in all Mixed ovary: 8.8 DIO2 SelY, TXDI2 ENSG00000211448 Deiodinase, iodothyronine, type II 14 80197527-80387757 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029544, HPA048002 Supported Nucleoplasm
Cytosol Endometrial cancer:4.62e-6 (favourable), Colorectal cancer:1.67e-4 (favourable) Tissue enhanced Group enriched 6 cervix, uterine: 268.3;thyroid gland: 599.1 esophagus: 70.6 DIP2C KIAA0934 ENSG00000151240 Disco-interacting protein 2 homolog C 10 274190-689668 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030264, HPA059325 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:2.46e-6 (favourable), Endometrial cancer:8.92e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 23.5 DIRC2 FLJ14784, RCC4 ENSG00000138463 Disrupted in renal carcinoma 2 3 122794795-122881139 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA072579 Supported Vesicles Renal cancer:8.81e-11 (favourable), Pancreatic cancer:5.81e-5 (unfavourable), Liver cancer:7.48e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 15.9 DISP1 DISPA, DKFZP434I0428, MGC13130, MGC16796 ENSG00000154309 Dispatched homolog 1 (Drosophila) 1 222872271-223005995 Predicted membrane proteins Evidence at protein level HPA051411 Uncertain Approved Nuclear bodies Renal cancer:3.86e-5 (favourable), Thyroid cancer:4.16e-4 (favourable), Pancreatic cancer:5.00e-4 (favourable) Expressed in all Mixed lung: 15.8 DISP2 DISPB, HsT16908, KIAA1742 ENSG00000140323 Dispatched homolog 2 (Drosophila) 15 40358235-40378639 Predicted membrane proteins Evidence at protein level HPA059903 Uncertain Approved Nucleoplasm
Vesicles Mixed Tissue enhanced cerebral cortex: 7.5 thyroid gland: 1.9 DKC1 DKC, dyskerin, NAP57, NOLA4, XAP101 ENSG00000130826 Dyskeratosis congenita 1, dyskerin X 154762742-154777689 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA000166, HPA000447, HPA001022, CAB033086 Supported Supported Nucleus
Nucleoli fibrillar center Renal cancer:1.46e-9 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Endometrial cancer:2.66e-5 (unfavourable), Head and neck cancer:2.94e-4 (unfavourable), Melanoma:9.13e-4 (unfavourable) Expressed in all Expressed in all lymph node: 45.7 DLK1 Delta1, FA1, pG2, Pref-1, ZOG ENSG00000185559 Delta-like 1 homolog (Drosophila) 14 100725705-100738224 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB005872, HPA053879, HPA062262 Supported Approved Golgi apparatus Endometrial cancer:2.31e-4 (unfavourable) Tissue enhanced Group enriched 20 adrenal gland: 1598.8;placenta: 2319.0 ovary: 99.9 DLK2 EGFL9, MGC2487 ENSG00000171462 Delta-like 2 homolog (Drosophila) 6 43450352-43456632 Predicted membrane proteins Evidence at transcript level HPA061223, HPA068672 Uncertain Approved Nucleus Mixed Tissue enhanced skin: 14.5 prostate: 8.1 DLL3 SCDO1 ENSG00000090932 Delta-like 3 (Drosophila) 19 39498895-39508481 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA056533 Approved Nucleoplasm
Cytosol Endometrial cancer:2.94e-4 (unfavourable) Group enriched Tissue enriched 49 cerebral cortex: 51.5 testis: 1.0 DLL4 ENSG00000128917 Delta-like 4 (Drosophila) 15 40929340-40939072 Predicted membrane proteins Evidence at protein level HPA023392 Uncertain Cervical cancer:3.97e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 28.4 lung: 16.4 DMPK DM, DM1, DM1PK, DMK, MDPK, MT-PK ENSG00000104936 Dystrophia myotonica-protein kinase 19 45769717-45782552 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007164, HPA008905 Supported Approved Vesicles
Cytosol Pancreatic cancer:9.39e-5 (favourable) Expressed in all Expressed in all smooth muscle: 96.5 DMRT2 ENSG00000173253 Doublesex and mab-3 related transcription factor 2 9 1049858-1057552 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at transcript level HPA029297 Uncertain Tissue enhanced Tissue enriched 7 parathyroid gland: 106.9 kidney: 16.0 DMXL2 KIAA0856, RC3 ENSG00000104093 Dmx-like 2 15 51447711-51622833 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039375 Approved Renal cancer:7.50e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 26.2 DNAH10 FLJ43808 ENSG00000197653 Dynein, axonemal, heavy chain 10 12 123762188-123936206 Predicted intracellular proteins Evidence at protein level HPA039065, HPA039066 Approved Tissue enhanced Group enriched 6 fallopian tube: 5.5;testis: 5.5 lung: 0.9 DNAH14 C1orf67, DKFZp781B1548, Dnahc14, HL-18, HL18, MGC27277 ENSG00000185842 Dynein, axonemal, heavy chain 14 1 224896262-225399292 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027718, HPA028545, HPA031379 Uncertain Approved Centrosome Mixed Tissue enhanced testis: 21.5 thyroid gland: 7.3 DNAH2 DNHD3, FLJ46675, KIAA1503 ENSG00000183914 Dynein, axonemal, heavy chain 2 17 7717354-7833744 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067103 Supported Approved Microtubules Mixed Group enriched 8 fallopian tube: 20.7;parathyroid gland: 28.1;testis: 11.0 placenta: 2.5 DNAH9 DNAH17L, Dnahc9, DNAL1, DYH9, HL-20, HL20, KIAA0357 ENSG00000007174 Dynein, axonemal, heavy chain 9 17 11598431-11969748 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA052641 Supported Endometrial cancer:6.79e-5 (favourable) Tissue enhanced Tissue enriched 5 fallopian tube: 55.6 testis: 11.1 DNAJB11 EDJ, ERdj3, HEDJ ENSG00000090520 DnaJ (Hsp40) homolog, subfamily B, member 11 3 186567403-186597203 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA010814, HPA017051 Supported Supported Endoplasmic reticulum Renal cancer:3.44e-9 (unfavourable) Expressed in all Expressed in all thyroid gland: 111.3 DNAJB12 DJ10, FLJ20027 ENSG00000148719 DnaJ (Hsp40) homolog, subfamily B, member 12 10 72332830-72355230 Predicted membrane proteins Evidence at protein level HPA010642 Approved Supported Endoplasmic reticulum Colorectal cancer:4.79e-4 (unfavourable), Head and neck cancer:8.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 47.2 DNAJB14 FLJ14281 ENSG00000164031 DnaJ (Hsp40) homolog, subfamily B, member 14 4 99896248-99946726 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036016 Approved Renal cancer:2.12e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 34.8 DNAJC1 DNAJL1, ERdj1, MTJ1 ENSG00000136770 DnaJ (Hsp40) homolog, subfamily C, member 1 10 21756537-22003769 Predicted membrane proteins, Transcription factors Evidence at protein level HPA013432 Approved Approved Endoplasmic reticulum Liver cancer:1.96e-5 (unfavourable), Renal cancer:2.33e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 56.8 DNAJC10 ERdj5, PDIA19 ENSG00000077232 DnaJ (Hsp40) homolog, subfamily C, member 10 2 182716041-182794464 Predicted membrane proteins Evidence at protein level HPA031111 Approved Renal cancer:2.19e-7 (unfavourable), Endometrial cancer:6.42e-5 (favourable), Thyroid cancer:7.27e-4 (unfavourable) Expressed in all Expressed in all epididymis: 152.2 DNAJC11 FLJ10737 ENSG00000007923 DnaJ (Hsp40) homolog, subfamily C, member 11 1 6634168-6701924 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028705 Uncertain Approved Cytosol Renal cancer:2.63e-5 (favourable) Expressed in all Expressed in all kidney: 38.2 DNAJC13 KIAA0678, RME8 ENSG00000138246 DnaJ (Hsp40) homolog, subfamily C, member 13 3 132417526-132539032 Disease related genes, Predicted membrane proteins Evidence at protein level HPA036923, HPA036924 Approved Supported Vesicles
Cytosol Liver cancer:7.49e-4 (unfavourable), Pancreatic cancer:8.36e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 28.8 DNAJC14 DNAJ, DRIP78, FLJ32792, HDJ3, LIP6 ENSG00000135392 DnaJ (Hsp40) homolog, subfamily C, member 14 12 55820960-55830824 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017653 Approved Expressed in all Expressed in all parathyroid gland: 49.6 DNAJC16 KIAA0962 ENSG00000116138 DnaJ (Hsp40) homolog, subfamily C, member 16 1 15526813-15592379 Predicted membrane proteins Evidence at protein level HPA043643 Approved Approved Vesicles Colorectal cancer:6.77e-4 (favourable), Renal cancer:7.24e-4 (favourable) Expressed in all Expressed in all kidney: 20.8 DNAJC18 MGC29463 ENSG00000170464 DnaJ (Hsp40) homolog, subfamily C, member 18 5 139408588-139444491 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036538, HPA060154 Approved Supported Cell Junctions Pancreatic cancer:5.89e-4 (favourable) Mixed Group enriched 5 cerebral cortex: 30.2;testis: 115.2 ovary: 13.8 DNAJC22 FLJ13236, wus ENSG00000178401 DnaJ (Hsp40) homolog, subfamily C, member 22 12 49346917-49357546 Predicted membrane proteins Evidence at protein level HPA039953 Approved Vesicles Endometrial cancer:4.56e-5 (favourable), Melanoma:7.54e-4 (unfavourable) Mixed Mixed thyroid gland: 17.9 DNAJC25 bA16L21.2.1 ENSG00000059769 DnaJ (Hsp40) homolog, subfamily C , member 25 9 111631352-111654351 Predicted membrane proteins Evidence at protein level HPA019122 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:3.73e-4 (favourable) Expressed in all Tissue enhanced liver: 16.7 parathyroid gland: 7.8 DNAJC30 WBSCR18 ENSG00000176410 DnaJ (Hsp40) homolog, subfamily C, member 30 7 73680969-73683453 Predicted membrane proteins Evidence at protein level HPA017318 Uncertain Supported Renal cancer:4.91e-8 (favourable), Glioma:6.59e-5 (unfavourable) Expressed in all Expressed in all testis: 11.3 DNAJC4 HSPF2, MCG18 ENSG00000110011 DnaJ (Hsp40) homolog, subfamily C, member 4 11 64230278-64234286 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011947 Uncertain Colorectal cancer:3.12e-4 (unfavourable), Renal cancer:6.21e-4 (favourable) Expressed in all Expressed in all testis: 136.3 DNAJC5G CSP-gamma, FLJ40417 ENSG00000163793 DnaJ (Hsp40) homolog, subfamily C, member 5 gamma 2 27275421-27281499 Predicted membrane proteins Evidence at transcript level HPA041445 Approved Not detected Group enriched 40 epididymis: 63.9;testis: 42.6 cerebral cortex: 1.3 DNER bet, UNQ26 ENSG00000187957 Delta/notch-like EGF repeat containing 2 229357629-229714558 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA017320 Approved Liver cancer:1.05e-4 (unfavourable), Renal cancer:3.42e-4 (unfavourable) Tissue enriched Group enriched 7 adrenal gland: 74.9;cerebral cortex: 176.5 salivary gland: 17.4 DOCK11 ACG, FLJ32122, FLJ43653, ZIZ2 ENSG00000147251 Dedicator of cytokinesis 11 X 118495898-118686163 Predicted intracellular proteins Evidence at protein level HPA059695 Uncertain Approved Nuclear membrane
Nucleoli Head and neck cancer:4.87e-4 (favourable) Expressed in all Mixed adipose tissue: 33.9 DOCK3 KIAA0299, MOCA, PBP ENSG00000088538 Dedicator of cytokinesis 3 3 50675241-51384198 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA037543, HPA037544 Approved Validated Cytosol Tissue enhanced Group enriched 6 cerebral cortex: 33.8;parathyroid gland: 12.5;testis: 8.5;thyroid gland: 15.1 adrenal gland: 3.0 DOCK4 FLJ34238, KIAA0716 ENSG00000128512 Dedicator of cytokinesis 4 7 111726110-112206411 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA071516 Supported Nucleoli
Golgi apparatus
Plasma membrane
Cytosol Expressed in all Tissue enhanced cerebral cortex: 31.8 lung: 27.6 DOCK6 KIAA1395, ZIR1 ENSG00000130158 Dedicator of cytokinesis 6 19 11199295-11262481 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA049423, HPA049424 Approved Supported Cytosol Head and neck cancer:9.09e-4 (favourable) Expressed in all Mixed skin: 29.4 DOCK9 KIAA1058, ZIZ1 ENSG00000088387 Dedicator of cytokinesis 9 13 98793487-99086625 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034061, CAB034065, HPA043940 Uncertain Expressed in all Expressed in all placenta: 157.4 DOLK DK1, KIAA1094, TMEM15 ENSG00000175283 Dolichol kinase 9 128945530-128947619 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA054813 Uncertain Nucleus
Cytosol Thyroid cancer:6.88e-5 (favourable), Renal cancer:5.53e-4 (favourable) Expressed in all Mixed parathyroid gland: 24.3 DOLPP1 LSFR2 ENSG00000167130 Dolichyldiphosphatase 1 9 129081100-129090438 Enzymes, Predicted membrane proteins Evidence at protein level HPA019179 Approved Approved Vesicles
Intermediate filaments Expressed in all Expressed in all duodenum: 26.5 DONSON B17, C21orf60, C2TA, DKFZP434M035 ENSG00000159147 Downstream neighbor of SON 21 33559542-33588708 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039558, HPA049033 Uncertain Approved Nucleoplasm
Cell Junctions
Cytosol Renal cancer:0.00e+0 (unfavourable), Ovarian cancer:2.17e-4 (favourable), Liver cancer:8.22e-4 (unfavourable) Expressed in all Tissue enhanced testis: 40.2 parathyroid gland: 15.4 DOPEY1 dJ202D23.2, KIAA1117 ENSG00000083097 Dopey family member 1 6 83067666-83171350 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027902, HPA027904 Approved Approved Nucleus Pancreatic cancer:7.36e-4 (favourable) Expressed in all Mixed parathyroid gland: 25.0 DOPEY2 C21orf5, KIAA0933 ENSG00000142197 Dopey family member 2 21 36156782-36294274 Predicted intracellular proteins Evidence at protein level CAB034922, HPA072065 Approved Approved Nucleoplasm
Mitochondria Breast cancer:7.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 83.9 DPAGT1 ALG7, CDG-Ij, D11S366, DGPT, DPAGT, DPAGT2, GPT ENSG00000172269 Dolichyl-phosphate (UDP-N-acetylglucosamine) N-acetylglucosaminephosphotransferase 1 (GlcNAc-1-P transferase) 11 119096503-119108331 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA053878 Approved Liver cancer:2.03e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 30.3 DPCR1 bCX105N19.6, PBLT ENSG00000168631 Diffuse panbronchiolitis critical region 1 6 30940972-30954221 Predicted membrane proteins Evidence at transcript level HPA014036 Approved Pancreatic cancer:6.58e-4 (unfavourable) Group enriched Tissue enriched 12 stomach: 191.9 gallbladder: 16.1 DPEP1 ENSG00000015413 Dipeptidase 1 (renal) 16 89613308-89638456 Enzymes, FDA approved drug targets, Predicted secreted proteins Evidence at protein level HPA009426, HPA012783 Supported Approved Nucleus
Cell Junctions Renal cancer:6.84e-4 (favourable) Tissue enriched Tissue enhanced kidney: 262.3;small intestine: 426.5 pancreas: 92.8 DPEP2 ENSG00000167261 Dipeptidase 2 16 67987394-68000586 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035644 Approved Testis cancer:8.47e-4 (unfavourable) Mixed Tissue enhanced spleen: 39.4 lung: 28.2 DPH7 C9orf112, FLJ90634, RRT2, WDR85 ENSG00000148399 Diphthamide biosynthesis 7 9 137554904-137578935 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022911 Uncertain Approved Nuclear bodies Renal cancer:1.52e-5 (unfavourable), Urothelial cancer:3.23e-4 (favourable), Pancreatic cancer:6.52e-4 (favourable) Expressed in all Expressed in all fallopian tube: 23.0 DPM2 MGC111193, MGC21559 ENSG00000136908 Dolichyl-phosphate mannosyltransferase polypeptide 2, regulatory subunit 9 127935099-127938484 Disease related genes, Predicted membrane proteins Evidence at protein level HPA064623 Approved Endometrial cancer:2.20e-4 (favourable), Liver cancer:7.08e-4 (unfavourable) Expressed in all Mixed stomach: 25.0 DPM3 MGC125904, MGC125905, MGC34275 ENSG00000179085 Dolichyl-phosphate mannosyltransferase polypeptide 3 1 155139891-155140595 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014667 Approved Endometrial cancer:7.09e-5 (favourable), Ovarian cancer:8.97e-5 (favourable), Urothelial cancer:8.64e-4 (favourable) Expressed in all Expressed in all adrenal gland: 78.8 DPP10 DPRP3 ENSG00000175497 Dipeptidyl-peptidase 10 (non-functional) 2 114442299-115845752 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048767 Uncertain Approved Nucleus
Vesicles
Cytosol Mixed Group enriched 7 adrenal gland: 14.2;cerebral cortex: 34.8 pancreas: 3.6 DPP4 ADCP2, CD26, DPPIV ENSG00000197635 Dipeptidyl-peptidase 4 2 161992241-162074542 CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB045970 Supported Renal cancer:1.35e-6 (favourable), Prostate cancer:1.98e-4 (unfavourable), Thyroid cancer:4.99e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 542.0 placenta: 167.8 DPP6 DPPX ENSG00000130226 Dipeptidyl-peptidase 6 7 153887097-154894285 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA050509 Supported Supported Tissue enriched Tissue enhanced cerebral cortex: 51.2;endometrium: 27.4 smooth muscle: 15.2 DPP8 DP8, DPRP1, FLJ14920, FLJ20283, MGC26191, MSTP141 ENSG00000074603 Dipeptidyl-peptidase 8 15 65442463-65517704 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA008706 Approved Supported Cytosol Expressed in all Expressed in all testis: 47.9 DPY19L1 KIAA0877 ENSG00000173852 Dpy-19-like 1 (C. elegans) 7 34928876-35038271 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059139 Uncertain Approved Vesicles Pancreatic cancer:2.99e-4 (unfavourable) Expressed in all Expressed in all testis: 69.2 DPY19L2 FLJ32949, SPATA34 ENSG00000177990 Dpy-19-like 2 (C. elegans) 12 63558913-63668939 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071264 Approved Nucleus
Mitochondria Mixed Tissue enriched 8 testis: 111.5 parathyroid gland: 14.6 DPY19L3 ENSG00000178904 Dpy-19-like 3 (C. elegans) 19 32405543-32485895 Predicted membrane proteins Evidence at protein level HPA008325 Approved Approved Microtubules Pancreatic cancer:1.70e-4 (favourable), Head and neck cancer:5.55e-4 (favourable) Expressed in all Mixed cerebral cortex: 20.4 DPY19L4 ENSG00000156162 Dpy-19-like 4 (C. elegans) 8 94719703-94793836 Predicted membrane proteins Evidence at protein level HPA024780 Approved Approved Vesicles Endometrial cancer:3.73e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 36.2 DRAM2 MGC54289, PRO180, RP5-1180E21.1, TMEM77, WWFQ154 ENSG00000156171 DNA-damage regulated autophagy modulator 2 1 111117333-111140216 Predicted membrane proteins Evidence at protein level HPA018036, HPA061701 Supported Validated Golgi apparatus
Vesicles Liver cancer:3.45e-5 (unfavourable), Melanoma:6.43e-4 (unfavourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Mixed spleen: 19.8 DRD1 ENSG00000184845 Dopamine receptor D1 5 175440039-175444208 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013393 Uncertain Mixed Tissue enhanced cerebral cortex: 8.0 prostate: 1.6 DRD2 ENSG00000149295 Dopamine receptor D2 11 113409615-113475691 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015691 Supported Mixed Tissue enriched 5 adrenal gland: 11.3 smooth muscle: 2.2 DRD5 DRD1B, DRD1L2 ENSG00000169676 Dopamine receptor D5 4 9781680-9784009 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA048930 Supported Not detected Tissue enhanced appendix: 1.8;cerebral cortex: 2.0;stomach: 3.7 testis: 0.8 DSC1 CDHF1 ENSG00000134765 Desmocollin 1 18 31129236-31162856 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012891 Uncertain Group enriched Tissue enriched 15 skin: 273.7 heart muscle: 18.7 DSC2 CDHF2, DSC3 ENSG00000134755 Desmocollin 2 18 31058840-31102415 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011911, HPA012615 Supported Urothelial cancer:3.01e-4 (unfavourable), Lung cancer:5.80e-4 (unfavourable) Tissue enhanced Tissue enhanced esophagus: 187.4 parathyroid gland: 60.8 DSC3 CDHF3, DSC, DSC1, DSC2, DSC4 ENSG00000134762 Desmocollin 3 18 30990008-31042815 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037328, HPA049265, HPA073937 Supported Validated Plasma membrane
Cell Junctions Urothelial cancer:1.04e-5 (unfavourable) Tissue enhanced Group enriched 11 esophagus: 119.5;skin: 455.7 tonsil: 25.9 DSCAM CHD2-42, CHD2-52 ENSG00000171587 Down syndrome cell adhesion molecule 21 40010999-40847139 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA019324 Supported Approved Nucleoplasm
Cytosol Tissue enriched Tissue enriched 11 cerebral cortex: 12.5 spleen: 1.1 DSCAML1 KIAA1132 ENSG00000177103 Down syndrome cell adhesion molecule like 1 11 117427773-117817525 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035230 Uncertain Renal cancer:8.37e-4 (favourable) Group enriched Tissue enhanced cerebral cortex: 12.1 ovary: 4.4 DSE DSEPI, SART2 ENSG00000111817 Dermatan sulfate epimerase 6 116254173-116444860 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014764, HPA052151 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:1.50e-4 (unfavourable), Cervical cancer:3.36e-4 (unfavourable), Ovarian cancer:6.34e-4 (unfavourable) Mixed Mixed appendix: 37.1 DSEL C18orf4, FLJ11477, NCAG1 ENSG00000171451 Dermatan sulfate epimerase-like 18 67506582-67516980 Predicted membrane proteins Evidence at protein level HPA060942 Approved Nucleoplasm
Plasma membrane Tissue enhanced Mixed cerebral cortex: 5.3 DSG1 CDHF4, DSG ENSG00000134760 Desmoglein 1 18 31318089-31357029 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009394, HPA022128 Supported Urothelial cancer:2.99e-4 (unfavourable) Group enriched Tissue enriched 20 skin: 727.4 esophagus: 36.5 DSG2 CDHF5 ENSG00000046604 Desmoglein 2 18 31498043-31549008 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004896, CAB025122 Supported Supported Cell Junctions Renal cancer:3.14e-10 (favourable), Pancreatic cancer:4.94e-5 (unfavourable), Lung cancer:2.43e-4 (unfavourable), Head and neck cancer:5.63e-4 (unfavourable), Colorectal cancer:7.81e-4 (favourable), Cervical cancer:8.22e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 246.8 rectum: 108.5 DSG3 CDHF6 ENSG00000134757 Desmoglein 3 18 31447795-31478702 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA046864, HPA056863, CAB069880 Supported Pancreatic cancer:1.43e-5 (unfavourable), Urothelial cancer:9.90e-4 (unfavourable) Group enriched Tissue enriched 5 esophagus: 350.9 tonsil: 68.5 DSG4 CDHF13, LAH ENSG00000175065 Desmoglein 4 18 31376777-31414912 Disease related genes, Predicted membrane proteins Evidence at protein level HPA059456 Supported Not detected Not detected testis: 0.8 DST BP240, BPA, BPAG1, CATX-15, FLJ13425, FLJ21489, FLJ30627, FLJ32235, KIAA0728, MACF2 ENSG00000151914 Dystonin 6 56457987-56954628 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA030200 Uncertain Approved Nucleus
Microtubules
Cytosol Expressed in all Expressed in all skin: 192.5 DTD1 bA379J5.3, bA555E18.1, C20orf88, DUEB, HARS2, MGC119131, MGC41905, pqn-68 ENSG00000125821 D-tyrosyl-tRNA deacylase 1 20 18567453-18763917 Predicted intracellular proteins Evidence at protein level HPA040981, HPA042653 Uncertain Uncertain Nucleoli
Cytosol Expressed in all Expressed in all cerebral cortex: 55.9 DTNA D18S892E, DRP3, DTN, DTN-1, DTN-2, DTN-3 ENSG00000134769 Dystrobrevin, alpha 18 34493290-34891844 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB015196, HPA071177 Supported Approved Nucleoplasm
Cell Junctions
Intermediate filaments Renal cancer:2.64e-7 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 197.7 heart muscle: 100.9 DUOX1 LNOX1, NOXEF1, THOX1 ENSG00000137857 Dual oxidase 1 15 45129933-45165576 Enzymes, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA023544 Approved Cervical cancer:4.31e-6 (favourable) Tissue enhanced Tissue enhanced skin: 96.8;thyroid gland: 92.3 esophagus: 73.4 DUOXA1 FLJ32334, mol, NIP, NUMBIP ENSG00000140254 Dual oxidase maturation factor 1 15 45117367-45129938 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041578 Approved Tissue enhanced Tissue enhanced esophagus: 122.6;skin: 107.8;thyroid gland: 111.5 epididymis: 59.7 DUOXA2 ENSG00000140274 Dual oxidase maturation factor 2 15 45114321-45118421 Disease related genes, Predicted membrane proteins Evidence at protein level HPA063548 Supported Group enriched Tissue enhanced gallbladder: 97.7;urinary bladder: 25.6 thyroid gland: 13.6 DUSP27 ENSG00000198842 Dual specificity phosphatase 27 (putative) 1 167094045-167129165 Predicted intracellular proteins Evidence at protein level HPA012608, HPA012912 Uncertain Approved Nucleoplasm Group enriched Group enriched 15 heart muscle: 39.9;skeletal muscle: 39.7 placenta: 2.6 DYM DMC, FLJ20071, SMC ENSG00000141627 Dymeclin 18 49041474-49461347 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043551, HPA049187 Approved Supported Golgi apparatus Renal cancer:2.76e-5 (favourable), Urothelial cancer:5.26e-5 (unfavourable) Expressed in all Expressed in all testis: 79.7 DYNAP C18orf26, FLJ39106 ENSG00000178690 Dynactin associated protein 18 54587757-54599493 Predicted membrane proteins Evidence at protein level HPA011148 Uncertain Tissue enhanced Tissue enriched 7 esophagus: 32.3 spleen: 4.4 DYRK2 ENSG00000127334 Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 12 67648338-67665406 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027230, HPA056902 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all small intestine: 31.7 DYSF FER1L1, LGMD2B ENSG00000135636 Dysferlin 2 71453722-71686768 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002510, HPA017071, HPA021945 Supported Supported Plasma membrane
Microtubule organizing center Expressed in all Mixed skeletal muscle: 32.8 E2F5 ENSG00000133740 E2F transcription factor 5, p130-binding 8 85177225-85217158 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA055723 Supported Nucleus
Nucleoli Renal cancer:1.89e-6 (unfavourable) Expressed in all Mixed lymph node: 31.3 EBP CDPX2, CHO2, CPX, CPXD ENSG00000147155 Emopamil binding protein (sterol isomerase) X 48521158-48528716 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003130 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all liver: 91.1 EBPL EBRP ENSG00000123179 Emopamil binding protein-like 13 49660723-49691475 Predicted membrane proteins Evidence at protein level HPA049891 Approved Supported Endoplasmic reticulum Renal cancer:7.18e-8 (unfavourable), Ovarian cancer:1.38e-4 (unfavourable) Expressed in all Expressed in all liver: 61.3 ECE1 ECE ENSG00000117298 Endothelin converting enzyme 1 1 21217247-21345504 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001490, HPA013616 Approved Expressed in all Expressed in all parathyroid gland: 428.4 ECE2 KIAA0604, MGC2408 ENSG00000145194 Endothelin converting enzyme 2 3 184249650-184293031 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043346, HPA062215 Approved Approved Nucleus
Cytosol Endometrial cancer:8.41e-5 (unfavourable), Liver cancer:5.80e-4 (unfavourable) Expressed in all Mixed adrenal gland: 15.5 ECEL1 DINE, XCE ENSG00000171551 Endothelin converting enzyme-like 1 2 232479827-232487828 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067560 Approved Nucleoplasm
Nuclear membrane
Nucleoli Tissue enhanced Tissue enriched 24 ovary: 111.9 spleen: 4.6 ECHDC1 dJ351K20.2 ENSG00000093144 Ethylmalonyl-CoA decarboxylase 1 6 127288710-127343609 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035445 Uncertain Expressed in all Expressed in all adipose tissue: 98.7 EDA ED1, ED1-A1, ED1-A2, EDA-A1, EDA-A2, EDA1, EDA2, HED, ODT1, XHED, XLHED ENSG00000158813 Ectodysplasin A X 69616067-70039469 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037972, HPA037973 Supported Vesicles
Lipid droplets Renal cancer:1.04e-9 (favourable) Mixed Tissue enhanced parathyroid gland: 19.0 thyroid gland: 10.0 EDA2R EDA-A2R, EDAA2R, TNFRSF27, XEDAR ENSG00000131080 Ectodysplasin A2 receptor X 66595637-66639298 Predicted membrane proteins Evidence at protein level HPA054522 Approved Cell Junctions Mixed Mixed thyroid gland: 9.5 EDAR DL, ED1R, ED3, ED5, EDA1R, EDA3, Edar ENSG00000135960 Ectodysplasin A receptor 2 108894471-108989372 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA042292 Approved Mixed Mixed esophagus: 2.8 EDNRA ENSG00000151617 Endothelin receptor type A 4 147480917-147544954 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013774, CAB018957 Uncertain Renal cancer:1.50e-7 (unfavourable), Stomach cancer:3.93e-4 (unfavourable) Expressed in all Tissue enhanced seminal vesicle: 145.4 cervix, uterine: 82.6 EDNRB ETB, HSCR, HSCR2 ENSG00000136160 Endothelin receptor type B 13 77895481-77919768 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB017842, HPA027546 Approved Approved Plasma membrane
Cytosol Renal cancer:7.20e-5 (favourable) Group enriched Tissue enhanced placenta: 178.8 cerebral cortex: 89.1 EDRF1 C10orf137, DKFZp586F1019, FLJ21617 ENSG00000107938 Erythroid differentiation regulatory factor 1 10 125719515-125764143 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031820 Approved Nucleoplasm
Centrosome
Cytosol Renal cancer:3.16e-5 (unfavourable) Expressed in all Expressed in all testis: 27.5 EEF1E1 AIMP3, P18 ENSG00000124802 Eukaryotic translation elongation factor 1 epsilon 1 6 8073360-8102578 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027901, HPA057866 Approved Supported Nucleus
Cytosol Liver cancer:1.55e-7 (unfavourable), Cervical cancer:3.16e-4 (favourable), Ovarian cancer:3.24e-4 (favourable) Expressed in all Expressed in all testis: 101.7 EFCAB14 KIAA0494 ENSG00000159658 EF-hand calcium binding domain 14 1 46675159-46719064 Predicted membrane proteins Evidence at protein level HPA011224, HPA011938 Supported Approved Nucleoli
Golgi apparatus
Cytosol Expressed in all Expressed in all parathyroid gland: 299.7 EFNA3 Ehk1-L, EPLG3, LERK3 ENSG00000143590 Ephrin-A3 1 155078872-155087538 Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB010494 Uncertain Renal cancer:9.66e-10 (unfavourable), Liver cancer:2.46e-4 (unfavourable) Expressed in all Tissue enhanced skin: 51.5 cerebral cortex: 17.1 EFNA4 EPLG4, LERK4 ENSG00000243364 Ephrin-A4 1 155063731-155069553 Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB021350, HPA064952 Approved Uncertain Nucleus
Vesicles Liver cancer:1.00e-5 (unfavourable), Stomach cancer:3.60e-5 (favourable), Renal cancer:3.14e-4 (unfavourable) Expressed in all Mixed skin: 24.5 EFNA5 AF1, EPLG7, LERK7 ENSG00000184349 Ephrin-A5 5 107376889-107670895 Cancer-related genes, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB013282, HPA054047 Approved Approved Vesicles
Cytosol Renal cancer:1.92e-7 (unfavourable), Stomach cancer:3.77e-4 (unfavourable) Mixed Mixed cervix, uterine: 17.1 EFNB1 CFNS, Elk-L, EPLG2, LERK2 ENSG00000090776 Ephrin-B1 X 68828997-68842147 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB031489, HPA067188 Uncertain Supported Plasma membrane Endometrial cancer:3.32e-5 (unfavourable), Pancreatic cancer:4.29e-4 (unfavourable), Melanoma:8.68e-4 (unfavourable) Expressed in all Mixed adipose tissue: 37.7 EFNB2 EPLG5, Htk-L, HTKL, LERK5, MGC126226, MGC126227, MGC126228 ENSG00000125266 Ephrin-B2 13 106489731-106535114 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008999, CAB009368 Supported Supported Nucleoplasm
Cytosol Head and neck cancer:3.11e-6 (unfavourable), Pancreatic cancer:8.70e-5 (unfavourable), Lung cancer:8.43e-4 (unfavourable) Expressed in all Mixed placenta: 48.1 EFNB3 EPLG8, LERK-8 ENSG00000108947 Ephrin-B3 17 7705202-7711378 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA001623 Approved Approved Nucleoplasm Endometrial cancer:5.52e-4 (unfavourable), Pancreatic cancer:8.21e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 48.8 endometrium: 17.3 EGFR ERBB, ERBB1 ENSG00000146648 Epidermal growth factor receptor 7 55019021-55256620 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000035, HPA001200, HPA018530, CAB068186, CAB073534 Supported Validated Plasma membrane Urothelial cancer:2.04e-5 (unfavourable) Expressed in all Tissue enhanced placenta: 97.3 skin: 58.9 EHBP1 KIAA0903, NACSIN ENSG00000115504 EH domain binding protein 1 2 62673851-63046487 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA035468, HPA035469 Supported Supported Plasma membrane
Cytosol Urothelial cancer:1.95e-8 (unfavourable), Lung cancer:9.03e-4 (unfavourable) Expressed in all Expressed in all testis: 67.5 EI24 EPG4, PIG8, TP53I8 ENSG00000149547 Etoposide induced 2.4 11 125569216-125584687 Cancer-related genes, Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047165, HPA051029 Uncertain Supported Endoplasmic reticulum
Golgi apparatus
Cytosol Pancreatic cancer:9.28e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 1098.6 liver: 124.7 EID3 FLJ25832, NSE4B, NSMCE4B ENSG00000255150 EP300 interacting inhibitor of differentiation 3 12 104303739-104305202 Predicted intracellular proteins Evidence at protein level HPA059367 Uncertain Supported Nucleus
Nucleoli Renal cancer:5.96e-5 (unfavourable), Glioma:9.70e-5 (unfavourable) Mixed Tissue enriched 14 testis: 111.7 seminal vesicle: 7.7 EIF2AK3 PEK, PERK ENSG00000172071 Eukaryotic translation initiation factor 2-alpha kinase 3 2 88556741-88627576 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB009204, HPA015737 Approved Expressed in all Mixed parathyroid gland: 36.7 EIF5A EIF-5A, EIF5A1, MGC104255, MGC99547 ENSG00000132507 Eukaryotic translation initiation factor 5A 17 7306999-7312463 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level CAB005042, HPA061298 Approved Validated Nucleoplasm
Cytosol Renal cancer:1.63e-5 (unfavourable), Lung cancer:9.04e-4 (unfavourable) Expressed in all Expressed in all esophagus: 437.6 ELFN2 dJ63G5.3, KIAA1904, LRRC62, PPP1R29 ENSG00000166897 Extracellular leucine-rich repeat and fibronectin type III domain containing 2 22 37367960-37427470 Predicted membrane proteins Evidence at protein level HPA000781 Approved Approved Nucleoplasm
Vesicles Renal cancer:7.21e-4 (unfavourable) Mixed Tissue enriched 7 cerebral cortex: 24.3 testis: 3.7 ELK4 SAP1 ENSG00000158711 ELK4, ETS-domain protein (SRF accessory protein 1) 1 205597556-205631962 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA028863 Uncertain Supported Nucleoplasm Renal cancer:2.94e-6 (unfavourable), Head and neck cancer:4.65e-4 (favourable) Expressed in all Expressed in all prostate: 41.5 ELMOD1 DKFZp547C176 ENSG00000110675 ELMO/CED-12 domain containing 1 11 107591091-107666779 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038434, HPA038435 Supported Nucleoplasm
Cytosol Tissue enriched Group enriched 15 cerebral cortex: 71.6;skin: 36.8 adrenal gland,fallopian tube: 3.5 ELOVL1 Ssc1 ENSG00000066322 ELOVL fatty acid elongase 1 1 43363397-43368074 Enzymes, Predicted membrane proteins Evidence at protein level CAB033426, HPA056557 Approved Approved Endoplasmic reticulum Liver cancer:2.79e-7 (unfavourable), Cervical cancer:3.63e-5 (unfavourable), Pancreatic cancer:8.51e-4 (unfavourable) Expressed in all Expressed in all skin: 157.0 ELOVL3 CIG-30 ENSG00000119915 ELOVL fatty acid elongase 3 10 102226328-102229589 Enzymes, Predicted membrane proteins Evidence at protein level HPA036236 Supported Approved Vesicles
Cytosol Endometrial cancer:6.25e-5 (unfavourable) Tissue enhanced Tissue enhanced adipose tissue: 3.6;breast: 4.4;skin: 3.4 testis: 2.3 ELOVL5 dJ483K16.1, HELO1, SCA38 ENSG00000012660 ELOVL fatty acid elongase 5 6 53267398-53349179 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017042, HPA047752, HPA054197 Supported Validated Endoplasmic reticulum Renal cancer:1.94e-6 (unfavourable), Thyroid cancer:6.80e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 256.1 ELOVL6 FLJ23378, LCE, MGC5487 ENSG00000170522 ELOVL fatty acid elongase 6 4 110045846-110199199 Enzymes, Predicted membrane proteins Evidence at protein level HPA042355 Uncertain Colorectal cancer:6.74e-4 (favourable) Expressed in all Mixed liver: 27.9 ELOVL7 FLJ23563 ENSG00000164181 ELOVL fatty acid elongase 7 5 60751791-60844389 Enzymes, Predicted membrane proteins Evidence at protein level HPA036337 Approved Renal cancer:1.54e-9 (favourable), Endometrial cancer:3.87e-5 (unfavourable) Expressed in all Mixed prostate: 36.3 ELP6 C3orf75, FLJ20211, TMEM103 ENSG00000163832 Elongator acetyltransferase complex subunit 6 3 47495640-47513761 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046358, HPA064545 Uncertain Approved Nucleus
Centrosome
Cytosol Renal cancer:3.42e-6 (favourable) Expressed in all Expressed in all testis: 32.0 EMC1 KIAA0090 ENSG00000127463 ER membrane protein complex subunit 1 1 19215664-19251552 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048904 Approved Approved Microtubules
Cytokinetic bridge Liver cancer:8.56e-6 (unfavourable), Urothelial cancer:1.43e-4 (unfavourable) Expressed in all Expressed in all placenta: 34.3 EMC3 TMEM111 ENSG00000125037 ER membrane protein complex subunit 3 3 9962537-10011116 Predicted membrane proteins Evidence at protein level HPA042372 Approved Approved Microtubules
Cytosol Renal cancer:2.81e-6 (favourable) Expressed in all Expressed in all testis: 90.7 EMC4 FLJ90746, MGC24415, PIG17, TMEM85 ENSG00000128463 ER membrane protein complex subunit 4 15 34224999-34230156 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026868, HPA053440 Approved Approved Cell Junctions
Focal adhesion sites Expressed in all Expressed in all epididymis: 120.7 EMC6 MGC2963, TMEM93 ENSG00000127774 ER membrane protein complex subunit 6 17 3668815-3669668 Predicted membrane proteins Evidence at protein level HPA062681 Uncertain Approved Nucleus
Centrosome Lung cancer:9.39e-5 (unfavourable), Cervical cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 49.2 EMC7 C11orf3, C15orf24 ENSG00000134153 ER membrane protein complex subunit 7 15 34084017-34101948 Predicted membrane proteins Evidence at protein level HPA010029, HPA047572 Approved Approved Nucleoplasm Endometrial cancer:4.68e-5 (favourable), Head and neck cancer:9.25e-5 (unfavourable) Expressed in all Expressed in all testis: 129.1 EMCN MUC14 ENSG00000164035 Endomucin 4 100395341-100880126 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005928 Approved Liver cancer:1.03e-4 (favourable), Renal cancer:2.25e-4 (favourable) Expressed in all Mixed kidney: 82.9 EMD LEMD5, STA ENSG00000102119 Emerin X 154379197-154381523 Disease related genes, Predicted membrane proteins Evidence at protein level HPA000609, CAB001545, CAB002029, CAB062552 Supported Validated Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all fallopian tube: 32.3 EML2 ELP70, EMAP-2, EMAP2 ENSG00000125746 Echinoderm microtubule associated protein like 2 19 45606994-45645629 Predicted intracellular proteins Evidence at protein level HPA012757 Approved Approved Vesicles Expressed in all Expressed in all parathyroid gland: 98.7 EMP1 CL-20, TMP ENSG00000134531 Epithelial membrane protein 1 12 13196716-13219939 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051931, HPA056250 Approved Nucleoplasm Ovarian cancer:2.26e-8 (unfavourable), Urothelial cancer:9.69e-8 (unfavourable), Pancreatic cancer:7.46e-4 (unfavourable) Expressed in all Expressed in all esophagus: 2208.3 EMP2 XMP ENSG00000213853 Epithelial membrane protein 2 16 10528422-10580698 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014711 Approved Approved Nucleoplasm
Cytosol Renal cancer:2.85e-8 (unfavourable), Glioma:1.93e-4 (unfavourable) Expressed in all Tissue enhanced lung: 344.5 skin: 166.7 EMP3 YMP ENSG00000142227 Epithelial membrane protein 3 19 48321509-48330553 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051163 Approved Nuclear bodies Renal cancer:2.31e-7 (unfavourable), Stomach cancer:3.13e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 199.1 ENDOD1 KIAA0830 ENSG00000149218 Endonuclease domain containing 1 11 95089810-95132645 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008932, HPA010517 Supported Approved Nuclear membrane Renal cancer:6.64e-7 (favourable), Urothelial cancer:3.27e-4 (unfavourable), Pancreatic cancer:8.86e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 97.8 ENG CD105, END, HHT1, ORW, ORW1 ENSG00000106991 Endoglin 9 127815012-127854756 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB000096, HPA011862, HPA067440, CAB072873 Supported Liver cancer:5.62e-6 (favourable), Renal cancer:4.26e-4 (unfavourable), Head and neck cancer:6.61e-4 (favourable) Expressed in all Expressed in all spleen: 170.7 ENHO C9orf165, UNQ470 ENSG00000168913 Energy homeostasis associated 9 34521040-34523041 Predicted secreted proteins Evidence at transcript level HPA042575 Approved Endometrial cancer:3.71e-4 (unfavourable) Tissue enhanced Tissue enriched 12 cerebral cortex: 140.7 testis: 11.6 ENPEP CD249, gp160 ENSG00000138792 Glutamyl aminopeptidase (aminopeptidase A) 4 110365733-110565285 CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA005128 Approved Tissue enriched Group enriched 5 duodenum: 37.5;kidney: 93.6;parathyroid gland: 157.9;small intestine: 183.8 placenta: 21.5 ENPP1 M6S1, NPPS, PC-1, PCA1, PDNP1 ENSG00000197594 Ectonucleotide pyrophosphatase/phosphodiesterase 1 6 131808016-131895155 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB032904, HPA062066 Supported Expressed in all Tissue enhanced parathyroid gland: 53.4;placenta: 62.4 thyroid gland: 33.9 ENPP2 ATX, PD-IALPHA, PDNP2 ENSG00000136960 Ectonucleotide pyrophosphatase/phosphodiesterase 2 8 119557086-119673453 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023700, HPA053652 Approved Approved Nucleus
Golgi apparatus
Actin filaments Pancreatic cancer:2.07e-5 (favourable) Expressed in all Expressed in all placenta: 372.6 ENPP3 B10, CD203c, gp130RB13-6, PD-IBETA, PDNP3 ENSG00000154269 Ectonucleotide pyrophosphatase/phosphodiesterase 3 6 131628442-131747418 CD markers, Enzymes, Predicted intracellular proteins Evidence at protein level HPA043772 Supported Renal cancer:1.96e-4 (unfavourable) Tissue enriched Tissue enhanced cervix, uterine: 45.1;small intestine: 51.0 seminal vesicle: 21.8 ENPP4 KIAA0879, NPP4 ENSG00000001561 Ectonucleotide pyrophosphatase/phosphodiesterase 4 (putative) 6 46129993-46146699 Enzymes, Predicted membrane proteins Evidence at protein level HPA016594 Approved Renal cancer:6.95e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 37.8 ENPP5 ENSG00000112796 Ectonucleotide pyrophosphatase/phosphodiesterase 5 (putative) 6 46159187-46170971 Predicted membrane proteins Evidence at protein level HPA016902 Approved Renal cancer:4.44e-13 (favourable), Pancreatic cancer:4.04e-4 (favourable), Lung cancer:4.57e-4 (favourable) Expressed in all Tissue enhanced epididymis: 291.6 thyroid gland: 85.2 ENTHD2 C17orf56, FLJ31528 ENSG00000167302 ENTH domain containing 2 17 81228277-81239091 Predicted intracellular proteins Evidence at protein level HPA063410 Supported Nuclear membrane
Nuclear speckles
Golgi apparatus Renal cancer:7.31e-8 (unfavourable), Pancreatic cancer:6.95e-4 (favourable), Head and neck cancer:9.96e-4 (favourable) Expressed in all Expressed in all spleen: 15.1 ENTPD1 ATPDase, CD39, NTPDase-1, SPG64 ENSG00000138185 Ectonucleoside triphosphate diphosphohydrolase 1 10 95711779-95869695 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB002494, HPA014067 Supported Uncertain Microtubules Renal cancer:5.33e-5 (unfavourable), Thyroid cancer:7.89e-4 (favourable) Expressed in all Mixed smooth muscle: 89.5 ENTPD2 CD39L1, NTPDase-2 ENSG00000054179 Ectonucleoside triphosphate diphosphohydrolase 2 9 137048098-137054045 Predicted membrane proteins Evidence at protein level HPA017676 Approved Renal cancer:3.51e-6 (favourable), Liver cancer:2.48e-5 (unfavourable), Stomach cancer:1.38e-4 (favourable) Expressed in all Mixed duodenum: 12.6 ENTPD3 CD39L3, HB6, NTPDase-3 ENSG00000168032 Ectonucleoside triphosphate diphosphohydrolase 3 3 40387156-40428619 Enzymes, Predicted membrane proteins Evidence at protein level HPA071802 Approved Cytosol Mixed Tissue enhanced cervix, uterine: 33.4 urinary bladder: 15.2 ENTPD4 KIAA0392, LALP70, LAP70, LYSAL1, NTPDase-4, UDPase ENSG00000197217 Ectonucleoside triphosphate diphosphohydrolase 4 8 23385783-23457695 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017655 Supported Supported Vesicles Expressed in all Expressed in all parathyroid gland: 46.4 ENTPD6 CD39L2, dJ738P15.3, IL6ST2, NTPDase-6 ENSG00000197586 Ectonucleoside triphosphate diphosphohydrolase 6 (putative) 20 25195693-25226729 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015491, HPA069555 Approved Supported Golgi apparatus Expressed in all Expressed in all cerebral cortex: 106.0 ENTPD7 FLJ30978, LALP1 ENSG00000198018 Ectonucleoside triphosphate diphosphohydrolase 7 10 99659506-99706240 Predicted membrane proteins Evidence at protein level HPA014351 Uncertain Approved Nucleoplasm Expressed in all Mixed small intestine: 24.2 ENTPD8 NTPDase-8, UNQ2492 ENSG00000188833 Ectonucleoside triphosphate diphosphohydrolase 8 9 137434364-137441816 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA021509 Supported Approved Nucleoplasm
Vesicles
Cytosol Stomach cancer:7.17e-4 (favourable) Mixed Tissue enhanced colon: 22.2;duodenum: 29.5;small intestine: 32.1 rectum: 12.7 EOGT AER61, C3orf64, FLJ33770 ENSG00000163378 EGF domain-specific O-linked N-acetylglucosamine (GlcNAc) transferase 3 68975214-69013961 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019460 Approved Approved Nucleoplasm
Nuclear membrane
Cytosol Renal cancer:8.97e-5 (unfavourable) Expressed in all Expressed in all seminal vesicle: 49.6 EPB41L3 4.1B, DAL1, KIAA0987 ENSG00000082397 Erythrocyte membrane protein band 4.1-like 3 18 5392381-5630700 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028605 Approved Validated Plasma membrane Mixed Expressed in all testis: 121.4 EPCAM 17-1A, 323/A3, CD326, CO-17A, EGP-2, EGP34, EGP40, Ep-CAM, ESA, GA733-2, HEA125, KS1/4, KSA, Ly74, M4S1, MH99, MIC18, MK-1, MOC31, TACST-1, TACSTD1, TROP1 ENSG00000119888 Epithelial cell adhesion molecule 2 47345158-47387601 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB003809, HPA026761, CAB030012, CAB055098, HPA067463 Supported Supported Plasma membrane Renal cancer:1.04e-6 (favourable), Ovarian cancer:3.30e-4 (favourable) Mixed Tissue enhanced rectum: 691.1;small intestine: 728.8 colon: 672.2 EPGN ALGV3072, EPG, epigen, PRO9904 ENSG00000182585 Epithelial mitogen 4 74308473-74315307 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014369 Approved Nucleus
Nuclear membrane
Cytosol Urothelial cancer:2.40e-4 (unfavourable) Tissue enhanced Tissue enriched 12 esophagus: 63.9 seminal vesicle: 5.3 EPHA1 EPH, EPHT, EPHT1 ENSG00000146904 EPH receptor A1 7 143390289-143408892 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB026144 Approved Renal cancer:1.14e-6 (favourable) Mixed Tissue enriched 24 parathyroid gland: 861.4 esophagus: 36.4 EPHA10 FLJ16103, FLJ33655 ENSG00000183317 EPH receptor A10 1 37713880-37765133 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027497 Uncertain Mixed Tissue enhanced testis: 20.4 colon: 8.1 EPHA2 ECK ENSG00000142627 EPH receptor A2 1 16124337-16156087 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA066055 Uncertain Vesicles Expressed in all Tissue enhanced esophagus: 87.1 gallbladder: 44.7 EPHA3 ETK, ETK1, HEK, HEK4, TYRO4 ENSG00000044524 EPH receptor A3 3 89107524-89482134 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010462 Approved Uncertain Nucleoplasm
Golgi apparatus
Cytosol Renal cancer:3.28e-7 (unfavourable) Mixed Tissue enhanced prostate: 49.0 gallbladder: 29.9 EPHA4 Hek8, TYRO1 ENSG00000116106 EPH receptor A4 2 221418027-221574202 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB028368 Supported Renal cancer:5.67e-4 (favourable), Ovarian cancer:9.56e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 41.8 testis: 22.3 EPHA6 FLJ35246 ENSG00000080224 EPH receptor A6 3 96814581-97752460 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007397, HPA058047 Uncertain Validated Nucleoplasm Mixed Tissue enhanced ovary: 7.7;testis: 15.1 cerebral cortex: 3.6 EPHA7 Hek11 ENSG00000135333 EPH receptor A7 6 93240020-93419547 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010496 Uncertain Tissue enhanced Tissue enriched 13 parathyroid gland: 250.5 prostate: 19.4 EPHA8 EEK, Hek3 ENSG00000070886 EPH receptor A8 1 22563564-22603594 Cancer-related genes, Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009660, HPA031433 Uncertain Mixed Tissue enhanced adrenal gland: 4.9;spleen: 2.7;testis: 1.9 cerebral cortex: 1.3 EPHB1 EPHT2, Hek6 ENSG00000154928 EPH receptor B1 3 134597801-135260467 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067740 Approved Approved Endoplasmic reticulum
Plasma membrane
Cytosol Tissue enriched Tissue enhanced cerebral cortex: 23.7;testis: 22.9 thyroid gland: 12.0 EPHB2 DRT, EPHT3, ERK, Hek5, Tyro5 ENSG00000133216 EPH receptor B2 1 22710839-22921500 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013647, HPA071200 Approved Supported Nucleus
Plasma membrane Endometrial cancer:1.05e-5 (unfavourable), Colorectal cancer:4.98e-4 (favourable) Tissue enhanced Mixed rectum: 27.8 EPHB3 ETK2, Hek2, Tyro6 ENSG00000182580 EPH receptor B3 3 184561784-184582409 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA007698, HPA008184, CAB034350 Approved Renal cancer:7.88e-5 (unfavourable) Expressed in all Tissue enhanced skin: 45.4 stomach: 17.9 EPHB4 HTK, Tyro11 ENSG00000196411 EPH receptor B4 7 100802565-100827521 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB013537 Uncertain Colorectal cancer:4.33e-4 (unfavourable), Breast cancer:8.56e-4 (unfavourable), Urothelial cancer:8.84e-4 (unfavourable) Expressed in all Expressed in all placenta: 50.3 EPHB6 HEP ENSG00000106123 EPH receptor B6 7 142855061-142871094 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035784 Approved Nuclear speckles Urothelial cancer:4.68e-5 (favourable), Cervical cancer:1.80e-4 (favourable), Glioma:6.96e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 22.6;skin: 25.0 cervix, uterine: 7.5 EPHX3 ABHD9, FLJ22408 ENSG00000105131 Epoxide hydrolase 3 19 15226919-15233435 Predicted secreted proteins Evidence at transcript level HPA012842 Uncertain Head and neck cancer:2.27e-5 (favourable) Tissue enhanced Group enriched 7 esophagus: 35.3;skin: 62.9;tonsil: 25.2 urinary bladder: 5.5 EPHX4 ABHD7, EPHXRP, FLJ90341 ENSG00000172031 Epoxide hydrolase 4 1 92029982-92063536 Predicted intracellular proteins Evidence at protein level HPA035067 Uncertain Approved Vesicles Pancreatic cancer:2.00e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.6 thyroid gland: 3.0 EPOR ENSG00000187266 Erythropoietin receptor 19 11377205-11384342 Cancer-related genes, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA077613 Uncertain Vesicles Pancreatic cancer:3.17e-5 (favourable) Expressed in all Tissue enhanced parathyroid gland: 52.9 thyroid gland: 18.1 EPSTI1 BRESI1, MGC29634 ENSG00000133106 Epithelial stromal interaction 1 (breast) 13 42886388-42992271 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017362 Approved Approved Cytosol Renal cancer:1.02e-5 (unfavourable), Pancreatic cancer:1.66e-4 (unfavourable) Expressed in all Mixed appendix: 44.1 EQTN AFAF, C9orf11, equatorin, SPACA8 ENSG00000120160 Equatorin, sperm acrosome associated 9 27284659-27297139 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015089, HPA015504 Supported Not detected Tissue enriched 86 testis: 67.2 ovary: 0.7 ERBB2 CD340, HER-2, HER2, NEU, NGL ENSG00000141736 Erb-b2 receptor tyrosine kinase 2 17 39687914-39730426 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000043, HPA001060, HPA001338, HPA001383, CAB020416, CAB062555 Approved Supported Plasma membrane
Cytosol Renal cancer:2.41e-14 (favourable), Endometrial cancer:8.99e-8 (unfavourable), Pancreatic cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 122.9 ERBB3 HER3, LCCS2 ENSG00000065361 Erb-b2 receptor tyrosine kinase 3 12 56079857-56103505 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025331, HPA045396 Uncertain Approved Plasma membrane
Actin filaments Expressed in all Mixed small intestine: 88.5 ERBB4 ALS19, HER4 ENSG00000178568 Erb-b2 receptor tyrosine kinase 4 2 211375717-212538841 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000276, HPA012016, CAB025522 Approved Tissue enhanced Tissue enhanced fallopian tube: 17.6 cerebral cortex: 7.6 EREG ER ENSG00000124882 Epiregulin 4 74365143-74388751 Predicted membrane proteins Evidence at protein level HPA054373 Approved Vesicles Cervical cancer:1.67e-7 (unfavourable), Lung cancer:1.45e-5 (unfavourable), Pancreatic cancer:6.57e-5 (unfavourable) Tissue enhanced Tissue enriched 6 bone marrow: 82.5 appendix: 14.7 ERGIC1 ERGIC-32, ERGIC32, KIAA1181, NET24 ENSG00000113719 Endoplasmic reticulum-golgi intermediate compartment 1 5 172834275-172952685 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018666, HPA018900 Supported Validated Nucleoplasm
Vesicles Expressed in all Expressed in all prostate: 238.4 ERGIC3 C20orf47, CGI-54, Erv46, NY-BR-84, PRO0989, SDBCAG84 ENSG00000125991 ERGIC and golgi 3 20 35542021-35557634 Predicted membrane proteins Evidence at protein level HPA015242, HPA015968 Approved Supported Nucleoplasm Liver cancer:2.20e-7 (unfavourable), Renal cancer:9.81e-5 (unfavourable) Expressed in all Expressed in all epididymis: 520.8 ERMAP BTN5, RD, SC ENSG00000164010 Erythroblast membrane-associated protein (Scianna blood group) 1 42817124-42844989 Blood group antigen proteins, Predicted membrane proteins Evidence at protein level HPA042573 Uncertain Expressed in all Mixed thyroid gland: 18.8 ERMARD C6orf70, dJ266L20.3, FLJ11152 ENSG00000130023 ER membrane-associated RNA degradation 6 169751622-169781584 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041741 Approved Approved Cytosol Expressed in all Expressed in all testis: 33.0 ERMP1 FLJ23309, FXNA, KIAA1815 ENSG00000099219 Endoplasmic reticulum metallopeptidase 1 9 5765076-5833117 Enzymes, Predicted membrane proteins Evidence at protein level HPA020584 Approved Approved Nucleus
Nucleoli Renal cancer:5.83e-10 (favourable) Expressed in all Tissue enhanced parathyroid gland: 122.3 thyroid gland: 43.8 ERN1 IRE1, IRE1P ENSG00000178607 Endoplasmic reticulum to nucleus signaling 1 17 64039142-64130819 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009495, HPA027730 Supported Renal cancer:1.68e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 53.7 ERN2 IRE1b ENSG00000134398 Endoplasmic reticulum to nucleus signaling 2 16 23690309-23713500 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016558 Uncertain Mixed Group enriched 6 cervix, uterine: 26.7;colon: 27.8;duodenum: 12.7;gallbladder: 25.2;rectum: 23.4;small intestine: 10.1;stomach: 49.9 appendix: 3.9 ERVMER34-1 ENSG00000226887 Endogenous retrovirus group MER34, member 1 4 52722618-52751640 Predicted membrane proteins Evidence at protein level HPA011423, HPA024053 Uncertain Approved Nucleus
Cytosol Head and neck cancer:3.55e-4 (unfavourable) Mixed Group enriched 8 parathyroid gland: 47.3;placenta: 15.5 kidney: 3.7 ESAM W117m ENSG00000149564 Endothelial cell adhesion molecule 11 124752583-124762290 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA051043, HPA056293 Uncertain Approved Microtubules Expressed in all Expressed in all placenta: 156.5 ESPL1 ESP1, KIAA0165, SEPA ENSG00000135476 Extra spindle pole bodies like 1, separase 12 53268299-53293643 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB012185 Uncertain Supported Nucleoplasm
Vesicles Liver cancer:2.01e-5 (unfavourable), Endometrial cancer:5.32e-5 (unfavourable), Stomach cancer:7.10e-4 (favourable), Lung cancer:7.14e-4 (unfavourable) Mixed Tissue enhanced esophagus: 11.4;testis: 10.6 lymph node: 4.9 ESYT1 FAM62A, KIAA0747, MBC2 ENSG00000139641 Extended synaptotagmin-like protein 1 12 56118250-56144671 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016858, HPA076926 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:3.86e-4 (favourable) Expressed in all Expressed in all adipose tissue: 114.2 ESYT2 CHR2SYT, FAM62B, KIAA1228 ENSG00000117868 Extended synaptotagmin-like protein 2 7 158730995-158830253 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002132 Approved Uncertain Cytosol Urothelial cancer:2.81e-5 (unfavourable), Pancreatic cancer:5.73e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 79.8 ESYT3 CHR3SYT, FAM62C ENSG00000158220 Extended synaptotagmin-like protein 3 3 138434586-138481686 Predicted membrane proteins Evidence at protein level HPA039200 Approved Lung cancer:8.30e-4 (favourable) Tissue enhanced Tissue enhanced lung: 8.4;skin: 7.5;thyroid gland: 8.4 endometrium: 3.6 ETFDH ETFQO ENSG00000171503 Electron-transferring-flavoprotein dehydrogenase 4 158672125-158709623 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041978 Supported Renal cancer:5.76e-10 (favourable) Expressed in all Expressed in all liver: 99.6 ETNK1 EKI, EKI1 ENSG00000139163 Ethanolamine kinase 1 12 22625075-22690665 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010712, HPA029407 Approved Supported Nucleoplasm
Plasma membrane
Cytosol Urothelial cancer:1.75e-4 (favourable), Liver cancer:5.85e-4 (unfavourable) Expressed in all Expressed in all stomach: 45.8 ETV6 TEL ENSG00000139083 Ets variant 6 12 11649854-11895402 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA000264 Supported Validated Nucleoli
Cytosol Renal cancer:4.66e-8 (unfavourable), Urothelial cancer:1.54e-5 (favourable), Pancreatic cancer:9.38e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 26.5 ETV7 TEL-2, TEL2 ENSG00000010030 Ets variant 7 6 36354091-36387800 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA029033 Uncertain Supported Nucleoplasm Urothelial cancer:2.95e-6 (favourable), Cervical cancer:5.16e-4 (favourable), Ovarian cancer:5.32e-4 (favourable) Expressed in all Mixed skin: 19.9 EVA1A FAM176A, FLJ13391, TMEM166 ENSG00000115363 Eva-1 homolog A (C. elegans) 2 75469302-75569722 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008055 Approved Supported Vesicles
Plasma membrane Ovarian cancer:5.67e-4 (favourable), Renal cancer:5.80e-4 (favourable) Mixed Tissue enhanced liver: 98.5 lung: 31.1 EVA1B C1orf78, FAM176B, FLJ10647 ENSG00000142694 Eva-1 homolog B (C. elegans) 1 36322031-36324154 Predicted intracellular proteins Evidence at protein level HPA041928, HPA043537 Approved Approved Cytosol Renal cancer:4.79e-5 (unfavourable), Breast cancer:4.58e-4 (favourable), Liver cancer:4.82e-4 (unfavourable) Expressed in all Mixed placenta: 14.7 EVA1C B18, B19, C21orf63, C21orf64, FAM176C, PRED34 ENSG00000166979 Eva-1 homolog C (C. elegans) 21 32412006-32515397 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015720, HPA029944, CAB034174 Approved Head and neck cancer:5.06e-4 (favourable) Expressed in all Mixed fallopian tube: 24.9 EVC DWF-1 ENSG00000072840 Ellis van Creveld protein 4 5711197-5814305 Disease related genes, Predicted membrane proteins Evidence at protein level HPA008703, HPA016046 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:5.60e-9 (favourable), Urothelial cancer:9.47e-5 (unfavourable) Expressed in all Mixed ovary: 41.3 EVC2 LBN ENSG00000173040 Ellis van Creveld syndrome 2 4 5542772-5709548 Disease related genes, Predicted membrane proteins Evidence at protein level HPA040910, HPA048122 Uncertain Approved Mitochondria Renal cancer:1.58e-4 (favourable) Mixed Mixed ovary: 8.8 EVI2A EVDA, EVI2 ENSG00000126860 Ecotropic viral integration site 2A 17 31317560-31321884 Predicted membrane proteins Evidence at protein level HPA045033, HPA057051 Uncertain Approved Nucleoplasm
Nuclear bodies Renal cancer:2.63e-6 (unfavourable), Melanoma:7.55e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 83.2 EVI2B CD361, D17S376, EVDB ENSG00000185862 Ecotropic viral integration site 2B 17 31303766-31314112 CD markers, Predicted membrane proteins Evidence at protein level HPA007436 Approved Renal cancer:2.05e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 216.7 lymph node: 177.3 EVI5L ENSG00000142459 Ecotropic viral integration site 5-like 19 7830233-7864976 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043099, HPA043563 Approved Approved Nuclear bodies Renal cancer:2.18e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 41.7 EXD2 C14orf114, EXDL2, FLJ10738 ENSG00000081177 Exonuclease 3'-5' domain containing 2 14 69191511-69244020 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002906, HPA005848 Uncertain Approved Intermediate filaments
Mitochondria Renal cancer:2.08e-9 (favourable), Liver cancer:8.47e-4 (unfavourable) Expressed in all Expressed in all testis: 36.4 EXT1 LGCR, LGS, ttv ENSG00000182197 Exostosin glycosyltransferase 1 8 117794490-118111853 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044394 Uncertain Lung cancer:1.20e-5 (unfavourable), Thyroid cancer:4.64e-4 (unfavourable), Cervical cancer:7.04e-4 (unfavourable) Expressed in all Expressed in all duodenum: 32.5 EXT2 SOTV ENSG00000151348 Exostosin glycosyltransferase 2 11 44095549-44245429 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA078409 Supported Golgi apparatus Renal cancer:5.36e-6 (unfavourable), Head and neck cancer:2.50e-4 (unfavourable) Expressed in all Expressed in all placenta: 89.9 EXTL2 ENSG00000162694 Exostosin-like glycosyltransferase 2 1 100872372-100895998 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB020716, HPA068921 Approved Approved Nucleus
Cytosol Liver cancer:1.64e-5 (unfavourable) Expressed in all Expressed in all placenta: 33.9 EXTL3 botv, REGR ENSG00000012232 Exostosin-like glycosyltransferase 3 8 28600469-28755599 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025387 Approved Liver cancer:1.14e-5 (unfavourable), Renal cancer:2.47e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 36.0 F11R CD321, JAM-1, JAM-A, JAM1, JAMA, JCAM, PAM-1 ENSG00000158769 F11 receptor 1 160995211-161021348 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB004671, HPA043616, HPA061700 Supported Approved Cell Junctions
Microtubules Expressed in all Expressed in all lung: 95.1 F2R CF2R, PAR-1, PAR1, TR ENSG00000181104 Coagulation factor II (thrombin) receptor 5 76716043-76735781 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB008973, CAB012962 Approved Renal cancer:2.21e-7 (unfavourable) Expressed in all Expressed in all spleen: 95.4 F2RL1 GPR11, PAR2 ENSG00000164251 Coagulation factor II (thrombin) receptor-like 1 5 76818933-76835315 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB012989, HPA014091 Approved Approved Plasma membrane Renal cancer:5.86e-7 (favourable), Colorectal cancer:3.88e-4 (favourable), Head and neck cancer:5.88e-4 (unfavourable), Lung cancer:8.92e-4 (unfavourable) Expressed in all Mixed colon: 59.9 F3 CD142 ENSG00000117525 Coagulation factor III (thromboplastin, tissue factor) 1 94529225-94541800 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009438, HPA049292, HPA069132 Approved Validated Vesicles Renal cancer:2.02e-8 (unfavourable), Pancreatic cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all placenta: 189.7 FA2H FAAH, FAXDC1, FLJ25287, SPG35 ENSG00000103089 Fatty acid 2-hydroxylase 16 74712955-74774831 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056614, HPA077840 Approved Approved Nuclear membrane Renal cancer:5.01e-6 (favourable), Pancreatic cancer:3.74e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 51.7;stomach: 57.9 gallbladder: 28.7 FAAH FAAH-1 ENSG00000117480 Fatty acid amide hydrolase 1 46394265-46413848 Enzymes, Predicted membrane proteins Evidence at protein level HPA007425 Approved Uncertain Cytosol Stomach cancer:3.63e-5 (favourable), Renal cancer:4.25e-5 (favourable), Endometrial cancer:1.51e-4 (favourable) Expressed in all Expressed in all prostate: 56.6 FADS1 D5D, FADS6, FADSD5, LLCDL1, TU12 ENSG00000149485 Fatty acid desaturase 1 11 61799625-61829318 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042705 Approved Renal cancer:1.95e-9 (unfavourable), Urothelial cancer:1.33e-4 (unfavourable), Thyroid cancer:2.79e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 89.6 FADS2 D6D, DES6, FADSD6, LLCDL2, SLL0262, TU13 ENSG00000134824 Fatty acid desaturase 2 11 61792980-61867354 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006741 Approved Renal cancer:1.00e-7 (unfavourable), Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 416.6 FADS3 CYB5RP, LLCDL3 ENSG00000221968 Fatty acid desaturase 3 11 61873519-61892051 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045224 Approved Renal cancer:1.50e-9 (unfavourable), Head and neck cancer:9.54e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 98.7 FADS6 ENSG00000172782 Fatty acid desaturase 6 17 74877299-74893781 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA016802 Uncertain Tissue enhanced Tissue enhanced epididymis: 22.6 small intestine: 10.3 FAF2 ETEA, KIAA0887, UBXD8, UBXN3B ENSG00000113194 Fas associated factor family member 2 5 176447628-176510074 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065968, HPA073828 Validated Endoplasmic reticulum
Lipid droplets Lung cancer:1.38e-4 (unfavourable), Liver cancer:1.79e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 41.2 FAIM2 KIAA0950, LFG, LFG2, LIFEGUARD, NMP35, TMBIM2 ENSG00000135472 Fas apoptotic inhibitory molecule 2 12 49866896-49904217 Predicted membrane proteins Evidence at protein level HPA018790, HPA048800 Supported Approved Intermediate filaments Tissue enriched Tissue enriched 7 cerebral cortex: 370.8 adrenal gland: 56.0 FAM105A FLJ11127, NET20 ENSG00000145569 Family with sequence similarity 105, member A 5 14581775-14615007 Enzymes, Predicted membrane proteins Evidence at protein level HPA046638 Uncertain Approved Nucleoli
Cytosol Pancreatic cancer:1.02e-4 (favourable), Testis cancer:7.62e-4 (unfavourable) Expressed in all Mixed bone marrow: 35.6 FAM118A bK268H5.C22.4, C22orf8, FLJ20635 ENSG00000100376 Family with sequence similarity 118, member A 22 45308968-45341955 Predicted intracellular proteins Evidence at protein level HPA003902 Uncertain Approved Intermediate filaments
Cytosol Renal cancer:1.87e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 75.3 FAM122C RP3-473B4.1 ENSG00000156500 Family with sequence similarity 122C X 134796789-134854610 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA059961 Approved Uncertain Nucleoplasm Mixed Mixed testis: 7.8 FAM134A C2orf17, MGC3035 ENSG00000144567 Family with sequence similarity 134, member A 2 219176225-219185479 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011170, HPA011844 Approved Approved Cytosol Liver cancer:1.49e-4 (unfavourable), Colorectal cancer:7.95e-4 (unfavourable) Expressed in all Expressed in all testis: 142.9 FAM134B FLJ20152, JK1 ENSG00000154153 Family with sequence similarity 134, member B 5 16473038-16617058 Disease related genes, Predicted membrane proteins Evidence at protein level HPA012077 Supported Nuclear bodies
Endoplasmic reticulum Renal cancer:5.25e-10 (favourable) Expressed in all Expressed in all heart muscle: 64.0 FAM134C DKFZp686B1036, FLJ33806 ENSG00000141699 Family with sequence similarity 134, member C 17 42579513-42610623 Predicted membrane proteins Evidence at protein level HPA016492 Uncertain Approved Nucleoplasm
Nuclear membrane
Cytosol Endometrial cancer:1.61e-4 (favourable), Renal cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all testis: 48.6 FAM151A C1orf179, MGC27169 ENSG00000162391 Family with sequence similarity 151, member A 1 54609182-54623556 Predicted intracellular proteins Evidence at protein level HPA016840 Approved Uncertain Nucleoplasm Renal cancer:4.09e-5 (favourable) Group enriched Group enriched 14 kidney: 175.6;small intestine: 68.0 liver: 8.5 FAM155A ENSG00000204442 Family with sequence similarity 155, member A 13 107163510-107866735 Predicted membrane proteins Evidence at protein level HPA039453, HPA058768 Supported Approved Nucleus
Vesicles
Centrosome Mixed Tissue enriched 6 cerebral cortex: 15.6 seminal vesicle: 2.4 FAM155B CXorf63, TED, TMEM28 ENSG00000130054 Family with sequence similarity 155, member B X 69505241-69532508 Predicted membrane proteins Evidence at transcript level HPA036093 Uncertain Breast cancer:4.61e-5 (unfavourable), Prostate cancer:1.83e-4 (unfavourable), Renal cancer:6.63e-4 (favourable) Mixed Tissue enhanced heart muscle: 12.9;seminal vesicle: 8.5;thyroid gland: 16.6 cerebral cortex: 2.5 FAM159A MGC52498 ENSG00000182183 Family with sequence similarity 159, member A 1 52633344-52669683 Predicted membrane proteins Evidence at transcript level HPA030744 Uncertain Mixed Tissue enhanced lymph node: 8.9;tonsil: 6.9 spleen: 4.6 FAM159B ENSG00000145642 Family with sequence similarity 159, member B 5 64690308-64718090 Predicted membrane proteins Evidence at protein level HPA011778 Supported Tissue enriched Group enriched 8 pancreas: 1.0;stomach: 3.5 cerebral cortex,duodenum: 0.2 FAM162A C3orf28, E2IG5 ENSG00000114023 Family with sequence similarity 162, member A 3 122384176-122412334 Predicted membrane proteins Evidence at protein level HPA035856, HPA058113 Approved Validated Mitochondria
Cytosol Urothelial cancer:3.93e-4 (favourable) Expressed in all Expressed in all rectum: 165.0 FAM162B bA86F4.2, C6orf189 ENSG00000183807 Family with sequence similarity 162, member B 6 116752197-116765723 Predicted membrane proteins Evidence at protein level HPA036112, HPA060342 Uncertain Renal cancer:2.48e-4 (unfavourable) Tissue enriched Tissue enhanced placenta: 93.2 lung: 27.0 FAM163A C1orf76, MGC16664 ENSG00000143340 Family with sequence similarity 163, member A 1 179743163-179816198 Predicted membrane proteins Evidence at transcript level HPA010778 Uncertain Mixed Tissue enhanced adrenal gland: 7.7;testis: 9.7 appendix,gallbladder: 1.8 FAM163B C9orf166 ENSG00000196990 Family with sequence similarity 163, member B 9 133578415-133586197 Predicted membrane proteins Evidence at transcript level HPA067336 Approved Approved Nuclear bodies
Plasma membrane
Cytosol Tissue enriched Tissue enriched 6 cerebral cortex: 103.9 adrenal gland: 16.5 FAM171A1 C10orf38, FLJ12884 ENSG00000148468 Family with sequence similarity 171, member A1 10 15211643-15371062 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051345 Approved Approved Nucleoplasm
Plasma membrane Thyroid cancer:4.90e-6 (unfavourable), Renal cancer:2.71e-5 (favourable) Expressed in all Mixed cerebral cortex: 73.4 FAM171A2 MGC34829 ENSG00000161682 Family with sequence similarity 171, member A2 17 44353215-44363875 Predicted membrane proteins Evidence at protein level HPA019770 Uncertain Mixed Tissue enhanced cerebral cortex: 13.4 epididymis: 3.3 FAM171B FLJ34104, KIAA1946 ENSG00000144369 Family with sequence similarity 171, member B 2 186693971-186765965 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010639, HPA013434 Approved Approved Nucleus
Mitochondria Renal cancer:9.51e-7 (unfavourable), Urothelial cancer:5.03e-4 (unfavourable) Tissue enriched Tissue enriched 6 cerebral cortex: 114.9 parathyroid gland: 19.0 FAM173A C16orf24, MGC2494 ENSG00000103254 Family with sequence similarity 173, member A 16 720581-722601 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046262 Approved Approved Cytosol Renal cancer:4.24e-5 (favourable), Head and neck cancer:8.88e-4 (favourable) Expressed in all Mixed spleen: 9.5 FAM173B ENSG00000150756 Family with sequence similarity 173, member B 5 10226330-10249897 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA074513 Approved Nucleus
Vesicles Breast cancer:1.32e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.7 FAM174A TMEM157, UNQ1912 ENSG00000174132 Family with sequence similarity 174, member A 5 100535305-100586741 Predicted membrane proteins Evidence at protein level HPA019539 Approved Approved Golgi apparatus
Cytosol Glioma:3.85e-6 (unfavourable), Renal cancer:5.48e-4 (favourable) Expressed in all Expressed in all fallopian tube: 51.2 FAM174B LOC400451, MGC102891 ENSG00000185442 Family with sequence similarity 174, member B 15 92617443-92809884 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015306 Approved Approved Intermediate filaments Endometrial cancer:9.03e-5 (favourable) Expressed in all Mixed thyroid gland: 61.6 FAM180B LOC399888 ENSG00000196666 Family with sequence similarity 180, member B 11 47586693-47589194 Predicted intracellular proteins Evidence at transcript level HPA029408 Uncertain Tissue enhanced Tissue enhanced breast: 6.9 skin: 4.4 FAM187A ENSG00000214447 Family with sequence similarity 187, member A 17 44899712-44905390 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022794, HPA043131 Approved Approved Cytosol Not detected Tissue enhanced fallopian tube: 24.3;testis: 17.2 thyroid gland: 5.3 FAM188A C10orf97, CARP, DERP5, FLJ13397, my042 ENSG00000148481 Family with sequence similarity 188, member A 10 15778170-15860520 Predicted intracellular proteins Evidence at protein level HPA038400, HPA038406 Uncertain Supported Nucleoplasm
Nuclear membrane Expressed in all Expressed in all testis: 39.0 FAM189A1 KIAA0574, TMEM228 ENSG00000104059 Family with sequence similarity 189, member A1 15 29120254-29570723 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009410, HPA010637 Uncertain Supported Nucleus Mixed Tissue enhanced cerebral cortex: 2.2;parathyroid gland: 2.0 colon,testis: 0.8 FAM189A2 C9orf61, X123 ENSG00000135063 Family with sequence similarity 189, member A2 9 69324572-69392455 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029411, HPA057207 Approved Endometrial cancer:1.16e-6 (favourable), Renal cancer:1.75e-5 (favourable) Tissue enhanced Tissue enhanced thyroid gland: 100.5 cervix, uterine: 64.0 FAM189B C1orf2, cote1 ENSG00000160767 Family with sequence similarity 189, member B 1 155247205-155255483 Predicted membrane proteins Evidence at protein level HPA006659, HPA050674 Uncertain Supported Nucleoplasm Renal cancer:3.43e-7 (unfavourable), Endometrial cancer:9.59e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Cervical cancer:4.98e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 6.7 FAM198B C4orf18, DKFZp434L142, FLJ38155 ENSG00000164125 Family with sequence similarity 198, member B 4 158124474-158173318 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007227 Uncertain Approved Nucleoplasm
Nucleoli fibrillar center
Golgi apparatus Expressed in all Expressed in all adrenal gland: 272.9 FAM19A5 TAFA-5 ENSG00000219438 Family with sequence similarity 19 (chemokine (C-C motif)-like), member A5 22 48489460-48850912 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level CAB025629 Approved Expressed in all Tissue enhanced cerebral cortex: 50.1 cervix, uterine: 12.9 FAM200A C7orf38, DKFZp727G131, FLJ36794 ENSG00000221909 Family with sequence similarity 200, member A 7 99546308-99558536 Predicted intracellular proteins Evidence at protein level HPA017855 Uncertain Renal cancer:2.17e-7 (favourable), Liver cancer:9.24e-4 (unfavourable) Expressed in all Mixed testis: 15.2 FAM205A C9orf144B ENSG00000205108 Family with sequence similarity 205, member A 9 34723055-34729467 Predicted membrane proteins Evidence at protein level HPA071267 Supported Not detected Tissue enriched 319 testis: 39.3 parathyroid gland,skin: 0.1 FAM209B C20orf107, dJ1153D9.4 ENSG00000213714 Family with sequence similarity 209, member B 20 56533246-56536520 Predicted membrane proteins Evidence at protein level HPA042144 Supported Mixed Tissue enriched 22 testis: 111.9 bone marrow: 5.0 FAM210A C18orf19, HsT2329, MGC24180 ENSG00000177150 Family with sequence similarity 210, member A 18 13663347-13726663 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014324, HPA051564 Uncertain Approved Nucleus
Golgi apparatus
Mitochondria Head and neck cancer:8.14e-4 (unfavourable) Expressed in all Mixed testis: 15.7 FAM210B C20orf108, dJ1167H4.1, DKFZP434A1114 ENSG00000124098 Family with sequence similarity 210, member B 20 56358915-56368663 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042652 Approved Approved Plasma membrane
Cytosol Renal cancer:1.44e-10 (favourable), Lung cancer:4.26e-4 (favourable), Cervical cancer:5.44e-4 (favourable) Expressed in all Expressed in all ovary: 131.1 FAM213A C10orf58, MGC4248, PAMM ENSG00000122378 Family with sequence similarity 213, member A 10 80407829-80437115 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009025, HPA024565 Approved Urothelial cancer:6.11e-4 (favourable) Expressed in all Expressed in all adipose tissue: 424.6 FAM220A C7orf70, MGC12966, SIPAR ENSG00000178397 Family with sequence similarity 220, member A 7 6329409-6348981 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA055050 Approved Vesicles Liver cancer:5.17e-6 (unfavourable), Thyroid cancer:3.47e-4 (unfavourable) Expressed in all Expressed in all testis: 102.0 FAM234A C16orf9, DKFZP761D0211, FLJ32603, ITFG3 ENSG00000167930 Family with sequence similarity 234, member A 16 234546-268971 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011651 Uncertain Nucleoplasm
Mitochondria Expressed in all Expressed in all duodenum: 113.8 FAM234B KIAA1467 ENSG00000084444 Family with sequence similarity 234, member B 12 13044284-13142521 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010803 Approved Endoplasmic reticulum Expressed in all Tissue enhanced cerebral cortex: 32.5 breast: 20.5 FAM24A AC073585.4 ENSG00000203795 Family with sequence similarity 24, member A 10 122910701-122913111 Predicted intracellular proteins Evidence at transcript level HPA052490 Uncertain Not detected Tissue enriched 330 testis: 32.9 all non-specific tissues: 0.0 FAM24B AC073585.2, MGC45962 ENSG00000213185 Family with sequence similarity 24, member B 10 122849078-122879641 Predicted intracellular proteins Evidence at transcript level HPA052490 Uncertain Expressed in all Tissue enhanced kidney: 13.7 testis: 11.4 FAM26E C6orf188, dJ493F7.3, MGC45451 ENSG00000178033 Family with sequence similarity 26, member E 6 116511646-116524792 Predicted membrane proteins Evidence at protein level HPA034969, HPA034970 Uncertain Approved Golgi apparatus Mixed Mixed placenta: 6.4 FAM3A 2-19, DXS560S, XAP-7 ENSG00000071889 Family with sequence similarity 3, member A X 154506159-154516242 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025016, HPA056991 Uncertain Approved Nucleus
Nucleoli Colorectal cancer:1.76e-4 (unfavourable) Expressed in all Expressed in all small intestine: 28.9 FAM3B 2-21, C21orf11, C21orf76, D21M16SJHU19e, ORF9, PANDER, PRED44 ENSG00000183844 Family with sequence similarity 3, member B 21 41304212-41357431 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015885, HPA029777 Approved Approved Vesicles Tissue enhanced Tissue enhanced duodenum: 166.7;small intestine: 170.3 stomach: 124.7 FAM3D EF7, OIT1 ENSG00000198643 Family with sequence similarity 3, member D 3 58633946-58666848 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013844 Approved Head and neck cancer:1.89e-4 (favourable), Breast cancer:7.51e-4 (favourable) Tissue enhanced Tissue enhanced colon: 324.9;rectum: 492.0 salivary gland: 192.8 FAM57B DKFZP434I2117 ENSG00000149926 Family with sequence similarity 57, member B 16 30024427-30052978 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030837 Uncertain Tissue enriched Group enriched 12 cerebral cortex: 18.7;testis: 77.3 skeletal muscle: 3.9 FAM69A FLJ23493 ENSG00000154511 Family with sequence similarity 69, member A 1 92832737-92961522 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015718, HPA017281 Approved Approved Nucleus
Cytosol Renal cancer:1.45e-7 (unfavourable), Breast cancer:8.96e-4 (favourable) Expressed in all Mixed cerebral cortex: 44.8 FAM69B C9orf136, MGC20262 ENSG00000165716 Family with sequence similarity 69, member B 9 136712570-136724050 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046812, HPA054443 Uncertain Approved Nucleus
Nuclear bodies
Vesicles Colorectal cancer:1.77e-5 (unfavourable), Pancreatic cancer:9.48e-5 (favourable) Expressed in all Expressed in all placenta: 29.6 FAM73A FLJ35093 ENSG00000180488 Family with sequence similarity 73, member A 1 77779624-77879539 Predicted membrane proteins Evidence at protein level HPA017589 Approved Supported Mitochondria Expressed in all Expressed in all parathyroid gland: 32.2 FAM73B C9orf54, FLJ00199, FLJ14596 ENSG00000148343 Family with sequence similarity 73, member B 9 129036621-129072082 Predicted membrane proteins Evidence at protein level HPA041363 Approved Approved Cell Junctions
Cytosol Pancreatic cancer:3.04e-6 (favourable) Expressed in all Mixed small intestine: 15.8 FAM76B MGC33371 ENSG00000077458 Family with sequence similarity 76, member B 11 95768942-95790409 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036608 Approved Approved Nucleus
Nucleoli fibrillar center Renal cancer:7.17e-5 (unfavourable), Urothelial cancer:2.72e-4 (favourable) Expressed in all Expressed in all testis: 32.9 FAM83H FLJ46072 ENSG00000180921 Family with sequence similarity 83, member H 8 143723933-143733801 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024505, HPA024604 Approved Approved Cytosol Lung cancer:3.77e-4 (unfavourable), Stomach cancer:4.42e-4 (favourable) Expressed in all Tissue enhanced skin: 17.2 esophagus: 10.4 FAM8A1 AHCP ENSG00000137414 Family with sequence similarity 8, member A1 6 17600355-17611719 Predicted membrane proteins, Transporters Evidence at protein level HPA044698 Supported Golgi apparatus Expressed in all Expressed in all endometrium: 45.3 FAM98B FLJ38426 ENSG00000171262 Family with sequence similarity 98, member B 15 38454127-38487710 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008320, HPA008502 Approved Supported Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 31.6 FANCA FA-H, FAA, FACA, FAH, FANCH ENSG00000187741 Fanconi anemia, complementation group A 16 89737549-89816657 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063236 Supported Nucleus Mixed Mixed testis: 19.5 FANCD2 FA-D2, FACD, FAD, FANCD ENSG00000144554 Fanconi anemia, complementation group D2 3 10026414-10101930 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level CAB016117, HPA063742 Approved Supported Nucleus
Nuclear bodies
Cytosol Ovarian cancer:5.00e-5 (unfavourable) Expressed in all Mixed testis: 21.7 FAR1 FLJ22728, MLSTD2, SDR10E1 ENSG00000197601 Fatty acyl CoA reductase 1 11 13668670-13732346 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017322 Approved Validated Peroxisomes Colorectal cancer:2.27e-4 (favourable) Expressed in all Expressed in all stomach: 59.0 FAR2 FLJ10462, MLSTD1, SDR10E2 ENSG00000064763 Fatty acyl CoA reductase 2 12 29149103-29340980 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015884 Approved Approved Nucleoli
Golgi apparatus Renal cancer:4.93e-4 (unfavourable) Expressed in all Mixed epididymis: 52.9 FAS APO-1, APT1, CD95, FAS1, TNFRSF6 ENSG00000026103 Fas cell surface death receptor 10 88990531-89015785 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027444 Approved Approved Plasma membrane
Cytosol Expressed in all Mixed lung: 39.5 FASLG APT1LG1, CD178, FasL, TNFSF6 ENSG00000117560 Fas ligand (TNF superfamily, member 6) 1 172659018-172666874 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA054959 Approved Renal cancer:1.59e-6 (unfavourable) Mixed Tissue enhanced lymph node: 5.9 spleen: 5.2 FASTKD1 FLJ21901 ENSG00000138399 FAST kinase domains 1 2 169529749-169573875 Predicted intracellular proteins Evidence at protein level HPA043719 Approved Approved Nucleoplasm Expressed in all Expressed in all rectum: 27.1 FAT1 CDHF7, CDHR8, FAT ENSG00000083857 FAT atypical cadherin 1 4 186587783-186726722 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001869, HPA023882 Approved Lung cancer:4.22e-4 (unfavourable) Expressed in all Mixed gallbladder: 37.4 FAT2 CDHF8, CDHR9, HFAT2, MEGF1 ENSG00000086570 FAT atypical cadherin 2 5 151504093-151568944 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB033680 Supported Group enriched Tissue enhanced skin: 66.6 esophagus: 14.4 FAT3 CDHF15, CDHR10, KIAA1989 ENSG00000165323 FAT atypical cadherin 3 11 92352096-92896470 Predicted membrane proteins Evidence at protein level HPA026878 Uncertain Tissue enriched Tissue enhanced cerebral cortex: 3.9;seminal vesicle: 2.6 prostate: 1.6 FAT4 CDHF14, CDHR11, FAT-J ENSG00000196159 FAT atypical cadherin 4 4 125316399-125492932 Disease related genes, Predicted membrane proteins Evidence at protein level HPA052819 Approved Approved Cytosol Renal cancer:1.89e-4 (favourable) Mixed Mixed parathyroid gland: 9.4 FATE1 CT43, FATE ENSG00000147378 Fetal and adult testis expressed 1 X 151716035-151723194 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034604 Supported Renal cancer:2.88e-4 (unfavourable) Group enriched Tissue enriched 313 testis: 307.8 cerebral cortex: 0.9 FAXC C6orf168, dJ273F20, MGC2817 ENSG00000146267 Failed axon connections homolog 6 99271169-99350062 Predicted intracellular proteins Evidence at protein level HPA039106 Uncertain Approved Nucleoplasm Mixed Tissue enhanced cerebral cortex: 23.6 seminal vesicle: 14.7 FBXL17 DKFZP434C1715, Fbl17, Fbx13, FBXO13 ENSG00000145743 F-box and leucine-rich repeat protein 17 5 107859035-108382098 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036410, HPA036411 Uncertain Approved Nucleus Renal cancer:4.60e-8 (favourable), Thyroid cancer:3.27e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 43.5 FBXO18 FBH1, Fbx18, FLJ14590 ENSG00000134452 F-box protein, helicase, 18 10 5890203-5937594 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA002844 Supported Liver cancer:7.73e-7 (unfavourable) Expressed in all Expressed in all fallopian tube: 46.4 FBXO8 FBS, FBX8 ENSG00000164117 F-box protein 8 4 174236658-174284264 Predicted intracellular proteins Evidence at transcript level HPA002885 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:1.29e-7 (favourable) Expressed in all Expressed in all placenta: 44.1 FBXW12 Fbw12, FBXO35 ENSG00000164049 F-box and WD repeat domain containing 12 3 48372219-48401259 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037491, HPA037492 Uncertain Not detected Group enriched 5 pancreas: 1.2;testis: 1.1 cerebral cortex: 0.2 FBXW5 DKFZP434B205, Fbw5, MGC20962 ENSG00000159069 F-box and WD repeat domain containing 5 9 136940435-136944696 Predicted intracellular proteins Evidence at protein level HPA046615 Approved Approved Mitochondria Endometrial cancer:1.02e-4 (favourable), Renal cancer:4.74e-4 (favourable) Expressed in all Expressed in all testis: 163.4 FBXW7 AGO, CDC4, FBW7, FBX30, FBXW6, FLJ11071, SEL-10, SEL10 ENSG00000109670 F-box and WD repeat domain containing 7, E3 ubiquitin protein ligase 4 152321259-152536101 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB013793, CAB029987 Supported Supported Nucleoplasm
Vesicles Renal cancer:1.52e-4 (unfavourable) Expressed in all Expressed in all skin: 87.7 FCAR CD89 ENSG00000186431 Fc fragment of IgA receptor 19 54874248-54890472 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014050 Approved Supported Plasma membrane Not detected Tissue enriched 15 bone marrow: 20.8 appendix: 1.4 FCER1A FCE1A ENSG00000179639 Fc fragment of IgE, high affinity I, receptor for; alpha polypeptide 1 159289714-159308224 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB022102, HPA036051, CAB055526 Approved Renal cancer:1.20e-4 (favourable) Expressed in all Mixed skin: 39.9 FCER1G ENSG00000158869 Fc fragment of IgE, high affinity I, receptor for; gamma polypeptide 1 161215234-161220699 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB022108, HPA026872 Supported Renal cancer:1.83e-6 (unfavourable) Expressed in all Expressed in all spleen: 470.3 FCER2 CD23, CD23A, CLEC4J, FCE2 ENSG00000104921 Fc fragment of IgE, low affinity II, receptor for (CD23) 19 7688758-7702146 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002624, HPA008928 Approved Mixed Group enriched 7 appendix: 22.9;lymph node: 48.1;spleen: 53.7;tonsil: 39.4 adipose tissue: 5.7 FCGR2A CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1, IGFR2 ENSG00000143226 Fc fragment of IgG, low affinity IIa, receptor (CD32) 1 161505430-161524013 CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010718, HPA014730 Supported Renal cancer:6.49e-7 (unfavourable) Expressed in all Tissue enhanced appendix: 151.6;placenta: 159.2 lung: 118.4 FCGR2B CD32, CD32B, FCG2, FCGR2 ENSG00000072694 Fc fragment of IgG, low affinity IIb, receptor (CD32) 1 161663147-161678654 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB007796, HPA014730 Supported Renal cancer:8.82e-4 (unfavourable) Mixed Tissue enriched 16 placenta: 571.2 adipose tissue: 36.3 FCGR3A CD16, CD16a, FCG3, FCGR3 ENSG00000203747 Fc fragment of IgG, low affinity IIIa, receptor (CD16a) 1 161541759-161550737 CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB032435, HPA055431 Supported Renal cancer:3.22e-6 (unfavourable) Expressed in all Expressed in all spleen: 427.3 FCGRT alpha-chain, FCRN ENSG00000104870 Fc fragment of IgG, receptor, transporter, alpha 19 49506816-49526333 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012122, HPA015130 Approved Expressed in all Expressed in all small intestine: 318.5 FCMR FAIM3, TOSO ENSG00000162894 Fc fragment of IgM receptor 1 206904386-206923247 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003910 Approved Approved Nucleus
Focal adhesion sites
Cytosol Breast cancer:4.23e-4 (favourable) Expressed in all Tissue enhanced lymph node: 178.0;spleen: 150.5;tonsil: 152.4 appendix: 91.5 FCN1 FCNM ENSG00000085265 Ficolin (collagen/fibrinogen domain containing) 1 9 134905890-134917963 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA000685, HPA001295, CAB016760 Supported Renal cancer:3.98e-4 (unfavourable) Mixed Group enriched 5 appendix: 331.6;bone marrow: 635.8 spleen: 96.4 FCRL1 CD307a, FCRH1, IFGP1, IRTA5 ENSG00000163534 Fc receptor-like 1 1 157794403-157820105 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013323 Approved Mixed Tissue enhanced lymph node: 30.7;spleen: 23.9;tonsil: 20.7 appendix: 13.0 FCRL3 CD307c, FCRH3, IFGP3, IRTA3, SPAP2, SPAP2a, SPAP2b, SPAP2c, SPAP2d, SPAP2e ENSG00000160856 Fc receptor-like 3 1 157674321-157700857 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015508 Approved Mixed Group enriched 12 appendix: 18.8;lymph node: 56.6;spleen: 37.3;tonsil: 33.6 urinary bladder: 2.9 FCRL4 CD307d, FCRH4, IGFP2, IRTA1 ENSG00000163518 Fc receptor-like 4 1 157573749-157598080 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA054030 Approved Not detected Group enriched 5 appendix: 3.7;lymph node: 4.5;tonsil: 10.1 spleen: 1.2 FCRLA FCRL, FCRLa, FCRLb, FCRLc1, FCRLc2, FCRLd, FCRLe, FCRLM1, FCRLX, FREB, MGC4595 ENSG00000132185 Fc receptor-like A 1 161706972-161714352 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016545 Supported Tissue enriched Group enriched 10 appendix: 32.5;lymph node: 81.6;spleen: 57.4;tonsil: 90.1 urinary bladder: 6.5 FDFT1 ENSG00000079459 Farnesyl-diphosphate farnesyltransferase 1 8 11795573-11839309 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008874 Approved Supported Endoplasmic reticulum Renal cancer:6.59e-9 (favourable), Colorectal cancer:4.92e-5 (favourable) Expressed in all Expressed in all testis: 204.4 FDPS ENSG00000160752 Farnesyl diphosphate synthase 1 155308748-155320666 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA028200 Approved Approved Nucleoplasm
Cytosol Liver cancer:7.35e-4 (unfavourable) Expressed in all Expressed in all liver: 186.1 FER1L6 C8ORFK23 ENSG00000214814 Fer-1-like family member 6 8 123851987-124120061 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA054117 Uncertain Group enriched Group enriched 5 rectum: 12.6;stomach: 44.3 small intestine: 5.4 FFAR2 FFA2R, GPR43 ENSG00000126262 Free fatty acid receptor 2 19 35443907-35451767 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA023985 Approved Tissue enhanced Tissue enhanced appendix: 26.2;bone marrow: 13.4 spleen: 11.1 FFAR3 FFA3R, GPR41 ENSG00000185897 Free fatty acid receptor 3 19 35358460-35360485 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA044681 Uncertain Not detected Tissue enhanced adipose tissue: 2.5;appendix: 3.6;smooth muscle: 2.2 gallbladder: 0.8 FFAR4 GPR120, GPR129, O3FAR1, PGR4 ENSG00000186188 Free fatty acid receptor 4 10 93566665-93604480 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA042563 Uncertain Uncertain Plasma membrane Tissue enhanced Tissue enhanced colon: 8.6;rectum: 12.9 lung: 5.5 FGF3 HBGF-3, INT2 ENSG00000186895 Fibroblast growth factor 3 11 69810224-69819024 Cancer-related genes, Disease related genes, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA012692 Uncertain Approved Group enriched Not detected all non-specific tissues: 0.0 FGFR1 BFGFR, CD331, CEK, FLG, FLT2, H2, H3, H4, H5, KAL2, N-SAM ENSG00000077782 Fibroblast growth factor receptor 1 8 38411138-38468834 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB033614, HPA056402, HPA076274 Approved Approved Nucleoli Expressed in all Expressed in all gallbladder: 109.6 FGFR2 BEK, CD332, CEK3, CFD1, ECT1, JWS, K-SAM, KGFR, TK14, TK25 ENSG00000066468 Fibroblast growth factor receptor 2 10 121478334-121598458 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010886, HPA035305, HPA056562 Uncertain Approved Vesicles Cervical cancer:8.79e-4 (favourable), Head and neck cancer:9.32e-4 (favourable) Expressed in all Mixed skin: 97.5 FGFR3 ACH, CD333, CEK2, JTK4 ENSG00000068078 Fibroblast growth factor receptor 3 4 1793307-1808872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB004231, HPA067204 Supported Supported Endoplasmic reticulum Endometrial cancer:3.77e-4 (unfavourable) Expressed in all Tissue enriched 7 skin: 334.6 cerebral cortex: 49.7 FGFR4 CD334, JTK2 ENSG00000160867 Fibroblast growth factor receptor 4 5 177086886-177098144 Cancer-related genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005196, HPA027273, HPA027369, HPA028251 Approved Mixed Tissue enhanced lung: 39.1 duodenum: 22.0 FGFRL1 ENSG00000127418 Fibroblast growth factor receptor-like 1 4 1009936-1026897 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026019, HPA068828 Approved Approved Nucleoplasm
Vesicles
Cytosol Expressed in all Expressed in all thyroid gland: 67.5 FGL2 pT49, T49 ENSG00000127951 Fibrinogen-like 2 7 77193371-77199826 Plasma proteins, Predicted secreted proteins Evidence at protein level HPA021011, HPA026682 Supported Expressed in all Expressed in all spleen: 228.4 FIBCD1 FLJ14810 ENSG00000130720 Fibrinogen C domain containing 1 9 130902438-130939286 Predicted intracellular proteins Evidence at protein level HPA053898, HPA055353 Uncertain Supported Cell Junctions Mixed Tissue enhanced adrenal gland: 4.7;parathyroid gland: 8.5;testis: 5.3 cerebral cortex: 2.5 FIG4 ALS11, CMT4J, dJ249I4.1, hSac3, KIAA0274, SAC3 ENSG00000112367 FIG4 phosphoinositide 5-phosphatase 6 109691312-109825428 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017823, HPA068859 Approved Approved Vesicles
Lipid droplets Liver cancer:4.73e-4 (unfavourable), Breast cancer:5.91e-4 (unfavourable), Renal cancer:8.19e-4 (favourable), Colorectal cancer:8.42e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 32.6 FIS1 CGI-135, Fis1, H_NH0132A01.6, TTC11 ENSG00000214253 Fission, mitochondrial 1 7 101239458-101252316 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017430 Approved Validated Mitochondria Renal cancer:1.08e-7 (favourable) Expressed in all Expressed in all thyroid gland: 269.1 FITM1 FIT1 ENSG00000139914 Fat storage-inducing transmembrane protein 1 14 24131275-24132849 Predicted membrane proteins Evidence at protein level HPA019842 Uncertain Liver cancer:1.00e-3 (favourable) Mixed Group enriched 14 heart muscle: 45.3;skeletal muscle: 113.0 spleen: 5.5 FKBP11 FKBP19 ENSG00000134285 FK506 binding protein 11, 19 kDa 12 48921518-48926474 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041709 Approved Approved Centrosome Renal cancer:0.00e+0 (unfavourable), Endometrial cancer:7.09e-4 (favourable) Expressed in all Mixed pancreas: 60.7 FKBP1A FKBP-12, FKBP1, FKBP12, FKBP12C, PKC12, PPIASE ENSG00000088832 FK506 binding protein 1A, 12kDa 20 1368978-1393172 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004639, HPA051798, HPA057830 Uncertain Approved Microtubules Liver cancer:3.44e-7 (unfavourable), Renal cancer:6.69e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 368.4 FKBP8 FKBP38, FKBPr38 ENSG00000105701 FK506 binding protein 8, 38kDa 19 18531751-18544077 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025346, HPA045177 Supported Supported Endoplasmic reticulum
Mitochondria
Cytosol Colorectal cancer:1.24e-4 (unfavourable), Pancreatic cancer:7.76e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 355.7 FKRP LGMD2I, MDC1C ENSG00000181027 Fukutin related protein 19 46746046-46776988 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043115, HPA060454 Approved Approved Nucleus
Golgi apparatus
Cytosol Pancreatic cancer:8.98e-4 (favourable) Expressed in all Expressed in all placenta: 14.8 FLNA ABP-280, FLN, FLN1, OPD1, OPD2 ENSG00000196924 Filamin A, alpha X 154348524-154374638 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB000356, HPA000368, HPA001016, HPA001115, HPA002925 Supported Approved Validated Plasma membrane
Actin filaments
Cytosol Renal cancer:1.54e-6 (unfavourable), Urothelial cancer:3.88e-4 (unfavourable), Colorectal cancer:7.37e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1037.9 FLRT1 MGC21624, SPG68 ENSG00000126500 Fibronectin leucine rich transmembrane protein 1 11 64103188-64119173 Predicted membrane proteins Evidence at protein level HPA054589 Uncertain Mixed Tissue enhanced cerebral cortex: 12.5 adrenal gland: 5.9 FLRT3 ENSG00000125848 Fibronectin leucine rich transmembrane protein 3 20 14322988-14337616 Disease related genes, Predicted membrane proteins Evidence at protein level CAB026166, HPA056033 Supported Approved Plasma membrane
Microtubules
Cytosol Renal cancer:1.49e-7 (favourable), Lung cancer:9.85e-5 (unfavourable), Pancreatic cancer:1.54e-4 (unfavourable) Expressed in all Mixed lung: 32.3 FLT1 FLT, VEGFR1 ENSG00000102755 Fms-related tyrosine kinase 1 13 28300344-28495128 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA011740, HPA014290, CAB068189, CAB068190 Supported Supported Plasma membrane
Actin filaments Renal cancer:2.19e-4 (unfavourable) Expressed in all Tissue enriched 8 placenta: 617.5 thyroid gland: 81.7 FLT3 CD135, FLK2, STK1 ENSG00000122025 Fms-related tyrosine kinase 3 13 28003274-28100592 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA047539 Approved Endoplasmic reticulum Tissue enhanced Tissue enhanced lymph node: 7.1;spleen: 7.8 appendix: 4.0 FLT4 PCL, VEGFR3 ENSG00000037280 Fms-related tyrosine kinase 4 5 180601506-180649624 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB000099 Supported Nuclear speckles
Plasma membrane
Cell Junctions Expressed in all Mixed spleen: 18.6 FLVCR1 AXPC1, FLVCR, MFSD7B, PCA ENSG00000162769 Feline leukemia virus subgroup C cellular receptor 1 1 212858255-212899363 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046646 Approved Approved Cell Junctions Renal cancer:1.06e-5 (unfavourable), Liver cancer:2.52e-5 (unfavourable), Pancreatic cancer:3.50e-4 (favourable) Expressed in all Tissue enhanced small intestine: 21.9 duodenum: 10.0 FLVCR2 C14orf58, FLJ20371, MFSD7C ENSG00000119686 Feline leukemia virus subgroup C cellular receptor family, member 2 14 75578617-75663214 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA037984 Supported Renal cancer:2.53e-5 (favourable) Expressed in all Tissue enhanced testis: 38.5 small intestine: 27.4 FMNL1 C17orf1, C17orf1B, FMNL ENSG00000184922 Formin-like 1 17 45221444-45247320 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008129, HPA028288 Supported Approved Cytosol Renal cancer:4.23e-8 (unfavourable) Expressed in all Expressed in all bone marrow: 175.4 FMO1 ENSG00000010932 Flavin containing monooxygenase 1 1 171248471-171285978 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023680 Uncertain Renal cancer:2.81e-4 (favourable) Tissue enriched Tissue enriched 8 kidney: 218.3 small intestine: 25.7 FMO2 ENSG00000094963 Flavin containing monooxygenase 2 (non-functional) 1 171185208-171211230 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA028261 Approved Mixed Tissue enhanced adipose tissue: 98.1;esophagus: 103.4;lung: 158.2 breast: 56.2 FMO3 ENSG00000007933 Flavin containing monooxygenase 3 1 171090877-171117819 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013750 Supported Lung cancer:5.60e-5 (favourable), Renal cancer:1.13e-4 (unfavourable), Liver cancer:3.46e-4 (favourable) Tissue enriched Tissue enriched 25 liver: 555.8 fallopian tube: 22.5 FMO4 FMO2 ENSG00000076258 Flavin containing monooxygenase 4 1 171314208-171342084 Enzymes, Predicted membrane proteins Evidence at protein level HPA049100 Uncertain Liver cancer:1.09e-4 (favourable), Renal cancer:6.96e-4 (favourable), Lung cancer:7.45e-4 (favourable) Expressed in all Tissue enhanced kidney: 47.7;liver: 30.1 parathyroid gland: 10.7 FMO5 ENSG00000131781 Flavin containing monooxygenase 5 1 147175351-147243050 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012373 Supported Supported Endoplasmic reticulum
Cytosol Renal cancer:1.34e-6 (favourable) Tissue enriched Tissue enhanced liver: 324.2 small intestine: 77.0 FMR1NB CT37, FLJ25736, NY-SAR-35 ENSG00000176988 Fragile X mental retardation 1 neighbor X 147981329-148026667 Predicted membrane proteins Evidence at protein level HPA011284, CAB026403 Supported Tissue enhanced Tissue enriched 420 testis: 86.4 epididymis: 0.2 FNDC3A bA203I16.5, FNDC3, KIAA0970 ENSG00000102531 Fibronectin type III domain containing 3A 13 48975912-49209779 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008927, HPA012825 Approved Approved Endoplasmic reticulum Renal cancer:4.25e-4 (favourable) Expressed in all Expressed in all thyroid gland: 85.5 FNDC3B DKFZp762K137, FAD104, FLJ23399, PRO4979, YVTM2421 ENSG00000075420 Fibronectin type III domain containing 3B 3 172039628-172401665 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007859 Uncertain Approved Endoplasmic reticulum Renal cancer:5.65e-7 (unfavourable), Cervical cancer:2.41e-5 (unfavourable), Pancreatic cancer:9.06e-5 (unfavourable), Liver cancer:9.85e-4 (unfavourable) Expressed in all Expressed in all placenta: 76.8 FNDC4 FLJ22362, FRCP1 ENSG00000115226 Fibronectin type III domain containing 4 2 27491883-27495245 Predicted membrane proteins Evidence at transcript level HPA051804, HPA063581 Uncertain Approved Nucleoplasm
Aggresome
Cytosol Endometrial cancer:5.07e-4 (unfavourable), Urothelial cancer:6.11e-4 (unfavourable) Expressed in all Tissue enhanced adrenal gland: 72.9 cerebral cortex: 36.0 FNDC5 FRCP2 ENSG00000160097 Fibronectin type III domain containing 5 1 32862268-32872482 Predicted membrane proteins Evidence at protein level HPA051290 Approved Group enriched Tissue enhanced skeletal muscle: 109.1 heart muscle: 29.7 FNDC9 C5orf40, MGC27121 ENSG00000172568 Fibronectin type III domain containing 9 5 157341600-157345721 Predicted membrane proteins Evidence at transcript level HPA011115, HPA017291 Approved Tissue enriched Group enriched 17 adrenal gland: 6.3;cerebral cortex: 20.7 appendix: 0.7 FOCAD FLJ20375, KIAA1797 ENSG00000188352 Focadhesin 9 20658309-20995955 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055015 Uncertain Uncertain Mitochondria Renal cancer:3.09e-8 (favourable), Liver cancer:4.41e-5 (unfavourable), Colorectal cancer:3.25e-4 (favourable) Expressed in all Expressed in all thyroid gland: 34.0 FOLH1 FOLH, GCP2, GCPII, NAALAD1, NAALAdase, PSM, PSMA ENSG00000086205 Folate hydrolase (prostate-specific membrane antigen) 1 11 49146635-49208670 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB001451, HPA010593 Supported Renal cancer:1.30e-6 (unfavourable), Endometrial cancer:5.24e-5 (favourable), Liver cancer:4.25e-4 (favourable) Tissue enriched Group enriched 6 duodenum: 307.0;prostate: 128.9;small intestine: 93.5 cerebral cortex: 31.1 FOLR1 FOLR ENSG00000110195 Folate receptor 1 (adult) 11 72189558-72196301 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA077030 Approved Nuclear membrane Liver cancer:2.50e-4 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 176.8;fallopian tube: 289.8;lung: 284.9 kidney: 154.6 FOXRED1 H17 ENSG00000110074 FAD-dependent oxidoreductase domain containing 1 11 126269055-126278131 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA039620, HPA046192 Uncertain Supported Mitochondria Renal cancer:2.01e-6 (favourable), Breast cancer:7.36e-4 (unfavourable) Expressed in all Expressed in all liver: 19.0 FPR1 FMLP, FPR ENSG00000171051 Formyl peptide receptor 1 19 51745172-51804110 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA046550, HPA061744 Approved Approved Nucleus
Nucleoli
Golgi apparatus Renal cancer:2.21e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 181.6 bone marrow: 95.2 FPR2 ALXR, FMLP-R-II, FMLPX, FPR2A, FPRH2, FPRL1, HM63, LXA4R ENSG00000171049 Formyl peptide receptor 2 19 51752026-51770526 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029154 Approved Mixed Tissue enhanced appendix: 71.3 spleen: 20.0 FRAS1 FLJ14927, FLJ22031, KIAA1500 ENSG00000138759 Fraser extracellular matrix complex subunit 1 4 78057570-78544269 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011281, HPA051601 Approved Approved Nucleoli fibrillar center Renal cancer:4.69e-4 (favourable) Mixed Tissue enhanced thyroid gland: 20.2 kidney,placenta: 8.2 FREM2 DKFZp686J0811 ENSG00000150893 FRAS1 related extracellular matrix protein 2 13 38687129-38887131 Disease related genes, Predicted membrane proteins Evidence at protein level HPA028831 Uncertain Approved Cytosol Renal cancer:2.23e-7 (favourable) Mixed Tissue enhanced kidney: 8.2;thyroid gland: 8.2 lung: 3.3 FRMD3 EPB41L4O, MGC20553 ENSG00000172159 FERM domain containing 3 9 83242990-83538546 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017285 Approved Approved Nucleoplasm
Golgi apparatus
Plasma membrane Thyroid cancer:1.79e-4 (favourable), Renal cancer:7.24e-4 (favourable) Tissue enhanced Tissue enhanced heart muscle: 51.7 skeletal muscle: 28.6 FRMD5 MGC14161 ENSG00000171877 FERM domain containing 5 15 43870761-44195252 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011746, HPA013961 Uncertain Uncertain Golgi apparatus
Centrosome Pancreatic cancer:5.89e-4 (unfavourable) Tissue enhanced Group enriched 6 adrenal gland: 7.1;cerebral cortex: 20.1;heart muscle: 7.1;testis: 5.5 fallopian tube: 1.6 FRRS1 SDFR2, SDR2 ENSG00000156869 Ferric-chelate reductase 1 1 99708703-99766631 Predicted membrane proteins Evidence at protein level HPA017883 Approved Renal cancer:6.53e-4 (unfavourable) Expressed in all Mixed placenta: 15.7 FRRS1L C9orf4, CG-6 ENSG00000260230 Ferric-chelate reductase 1-like 9 109130293-109167291 Predicted membrane proteins Evidence at protein level HPA071086 Supported Mixed Tissue enhanced cerebral cortex: 47.9 ovary: 14.1 FRY 13CDNA73, bA37E23.1, C13orf14, CG003 ENSG00000073910 Furry homolog (Drosophila) 13 32031300-32299122 Predicted intracellular proteins Evidence at protein level HPA041635 Approved Renal cancer:9.60e-4 (favourable) Mixed Expressed in all heart muscle: 32.0 FSD1L CCDC10, CSDUFD1, FSD1CL, FSD1NL ENSG00000106701 Fibronectin type III and SPRY domain containing 1-like 9 105447796-105552433 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035138 Approved Approved Plasma membrane
Actin filaments Mixed Tissue enhanced cerebral cortex: 17.8 testis: 13.4 FTCD ENSG00000160282 Formimidoyltransferase cyclodeaminase 21 46136262-46155567 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA020073, HPA030928, HPA030929, HPA036114 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:6.78e-5 (favourable), Liver cancer:1.70e-4 (favourable), Renal cancer:5.78e-4 (favourable) Tissue enriched Group enriched 18 kidney: 100.1;liver: 184.7 testis: 7.7 FURIN FUR, PACE, PCSK3, SPC1 ENSG00000140564 Furin (paired basic amino acid cleaving enzyme) 15 90868592-90883458 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009499 Approved Supported Nucleoplasm
Golgi apparatus Lung cancer:1.58e-4 (unfavourable) Expressed in all Expressed in all salivary gland: 93.2 FUT2 SE, Se2, SEC2, sej ENSG00000176920 Fucosyltransferase 2 (secretor status included) 19 48695971-48705950 Blood group antigen proteins, Enzymes, Predicted membrane proteins Evidence at transcript level HPA014402 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:5.83e-4 (favourable) Mixed Tissue enhanced duodenum: 52.9 stomach: 32.5 FUT3 CD174, LE ENSG00000171124 Fucosyltransferase 3 (galactoside 3(4)-L-fucosyltransferase, Lewis blood group) 19 5842888-5851474 Blood group antigen proteins, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046966 Supported Renal cancer:8.22e-7 (favourable), Breast cancer:6.86e-4 (unfavourable) Tissue enhanced Tissue enhanced colon: 69.4;esophagus: 83.4;small intestine: 64.4 duodenum,rectum: 50.3 FUT4 CD15, ELFT, FCT3A, FUC-TIV ENSG00000196371 Fucosyltransferase 4 (alpha (1,3) fucosyltransferase, myeloid-specific) 11 94543840-94549898 Predicted membrane proteins Evidence at protein level CAB000014, CAB016129 Supported Validated Vesicles Lung cancer:3.64e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 63.0 duodenum: 12.7 FUT5 FUC-TV ENSG00000130383 Fucosyltransferase 5 (alpha (1,3) fucosyltransferase) 19 5865826-5870540 Enzymes, Predicted membrane proteins Evidence at transcript level HPA046966 Uncertain Not detected Not detected bone marrow,testis: 0.3 FUT6 FCT3A, FLJ40754, FT1A, FucT-VI ENSG00000156413 Fucosyltransferase 6 (alpha (1,3) fucosyltransferase) 19 5830610-5839731 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043707, HPA046966 Approved Supported Golgi apparatus Renal cancer:3.17e-8 (favourable), Head and neck cancer:2.12e-4 (favourable) Mixed Tissue enhanced esophagus: 50.0;kidney: 34.3 small intestine: 31.2 FUT7 ENSG00000180549 Fucosyltransferase 7 (alpha (1,3) fucosyltransferase) 9 137030174-137033010 Predicted intracellular proteins Evidence at protein level HPA042780 Approved Golgi apparatus Mixed Tissue enhanced lymph node: 3.7;spleen: 2.7 tonsil: 2.1 FUT8 ENSG00000033170 Fucosyltransferase 8 (alpha (1,6) fucosyltransferase) 14 65410592-65744121 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017129, HPA040863, HPA043410 Supported Validated Golgi apparatus
Cytosol Expressed in all Mixed cerebral cortex: 31.6 FUT9 Fuc-TIX ENSG00000172461 Fucosyltransferase 9 (alpha (1,3) fucosyltransferase) 6 96015984-96215612 Predicted membrane proteins Evidence at protein level HPA070923 Approved Nucleoplasm
Microtubules
Cytokinetic bridge
Cytosol Tissue enhanced Group enriched 12 cerebral cortex: 28.2;stomach: 22.2 duodenum: 2.1 FUZ FLJ22688, Fy ENSG00000010361 Fuzzy planar cell polarity protein 19 49806869-49817376 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041779, HPA042196 Uncertain Approved Cytosol Renal cancer:1.50e-5 (favourable) Expressed in all Expressed in all testis: 52.6 FXYD1 PLM ENSG00000266964 FXYD domain containing ion transport regulator 1 19 35138808-35143109 Predicted membrane proteins Evidence at protein level HPA026873 Approved Nucleus
Nucleoli
Cytosol Renal cancer:7.59e-8 (unfavourable), Glioma:9.67e-4 (unfavourable) Tissue enhanced Expressed in all skeletal muscle: 469.2 FXYD2 ATP1G1, HOMG2, MGC12372 ENSG00000137731 FXYD domain containing ion transport regulator 2 11 117800844-117828698 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA064218, HPA068838 Supported Approved Mitochondria Renal cancer:3.23e-9 (favourable) Tissue enriched Group enriched 6 gallbladder: 575.2;kidney: 1428.7;salivary gland: 383.4 pancreas: 134.6 FXYD3 MAT-8, PLML ENSG00000089356 FXYD domain containing ion transport regulator 3 19 35115879-35124324 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010856 Supported Supported Plasma membrane Renal cancer:1.15e-6 (unfavourable) Expressed in all Tissue enhanced colon: 1480.8;rectum: 1982.1 prostate: 686.5 FXYD4 CHIF ENSG00000150201 FXYD domain containing ion transport regulator 4 10 43371642-43376335 Predicted membrane proteins Evidence at protein level HPA058421 Supported Group enriched Tissue enriched 27 kidney: 126.8 stomach: 4.7 FXYD5 OIT2 ENSG00000089327 FXYD domain containing ion transport regulator 5 19 35154730-35169883 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA010817 Uncertain Approved Endoplasmic reticulum Renal cancer:3.71e-9 (unfavourable) Expressed in all Expressed in all spleen: 241.4 FXYD6 ENSG00000137726 FXYD domain containing ion transport regulator 6 11 117836976-117877486 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041334, HPA042284 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:1.05e-5 (unfavourable), Renal cancer:4.38e-5 (favourable), Urothelial cancer:1.60e-4 (unfavourable), Liver cancer:5.87e-4 (favourable), Pancreatic cancer:5.97e-4 (favourable) Tissue enriched Expressed in all cerebral cortex: 698.7 FXYD6-FXYD2 ENSG00000255245 FXYD6-FXYD2 readthrough 11 117820163-117876667 Predicted membrane proteins Evidence at transcript level HPA068838 Approved Not detected Tissue enhanced kidney: 5.5 salivary gland: 2.2 FXYD7 ENSG00000221946 FXYD domain containing ion transport regulator 7 19 35143250-35154301 Predicted membrane proteins Evidence at protein level HPA026916 Approved Tissue enhanced Tissue enriched 34 cerebral cortex: 106.1 lymph node: 3.1 FZD1 DKFZp564G072 ENSG00000157240 Frizzled class receptor 1 7 91264364-91271326 Cancer-related genes, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013008 Approved Supported Plasma membrane Renal cancer:8.87e-7 (favourable) Expressed in all Mixed thyroid gland: 32.3 FZD10 CD350 ENSG00000111432 Frizzled class receptor 10 12 130162459-130165740 CD markers, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014484, HPA014485 Uncertain Supported Nucleoplasm Endometrial cancer:5.05e-7 (favourable) Mixed Tissue enhanced cervix, uterine: 9.3;esophagus: 8.8 skin: 5.6 FZD2 ENSG00000180340 Frizzled class receptor 2 17 44557459-44559570 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA057667 Uncertain Approved Nuclear bodies
Cell Junctions Expressed in all Mixed placenta: 4.9 FZD3 ENSG00000104290 Frizzled class receptor 3 8 28494205-28574268 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB024995, HPA042320 Approved Approved Nucleoplasm
Vesicles Colorectal cancer:1.17e-4 (favourable), Ovarian cancer:3.71e-4 (favourable) Mixed Mixed cerebral cortex: 16.5 FZD4 CD344, EVR1 ENSG00000174804 Frizzled class receptor 4 11 86945679-86955391 CD markers, Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA042328, HPA074833 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.60e-5 (favourable) Expressed in all Tissue enhanced adipose tissue: 127.0 seminal vesicle: 42.1 FZD5 C2orf31, DKFZP434E2135, HFZ5 ENSG00000163251 Frizzled class receptor 5 2 207762586-207769563 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA052361 Approved Expressed in all Mixed duodenum: 20.1 FZD6 Hfz6 ENSG00000164930 Frizzled class receptor 6 8 103298433-103332866 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA017991 Approved Approved Plasma membrane Pancreatic cancer:1.20e-6 (unfavourable) Expressed in all Mixed parathyroid gland: 45.3 FZD7 FzE3 ENSG00000155760 Frizzled class receptor 7 2 202034587-202038445 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA069165 Approved Nucleoplasm Liver cancer:7.71e-5 (unfavourable) Expressed in all Mixed seminal vesicle: 38.7 FZD8 ENSG00000177283 Frizzled class receptor 8 10 35638249-35642278 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA045025, HPA071142 Approved Approved Endoplasmic reticulum Pancreatic cancer:8.21e-4 (favourable) Expressed in all Tissue enhanced spleen: 16.2 lung: 6.6 G6PC G6PT, GSD1a ENSG00000131482 Glucose-6-phosphatase, catalytic subunit 17 42900797-42913369 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA052324 Approved Renal cancer:3.79e-5 (favourable), Liver cancer:5.42e-5 (favourable) Tissue enriched Tissue enhanced kidney: 88.4;liver: 146.8 small intestine: 33.8 G6PC3 UGRP ENSG00000141349 Glucose 6 phosphatase, catalytic, 3 17 44070735-44076344 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067052 Supported Endoplasmic reticulum Endometrial cancer:1.11e-4 (favourable), Liver cancer:9.61e-4 (unfavourable) Expressed in all Expressed in all epididymis: 82.8 GAA ENSG00000171298 Glucosidase, alpha; acid 17 80101556-80119879 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA026970, HPA029126 Supported Colorectal cancer:7.66e-4 (unfavourable) Expressed in all Expressed in all placenta: 69.4 GABBR1 GPRC3A, hGB1a ENSG00000204681 Gamma-aminobutyric acid (GABA) B receptor, 1 6 29555629-29633976 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050483, HPA058459 Uncertain Uncertain Centrosome Renal cancer:3.77e-10 (unfavourable), Pancreatic cancer:2.54e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 20.9 spleen: 13.3 GABBR2 GABABR2, GPR51, GPRC3B, HG20 ENSG00000136928 Gamma-aminobutyric acid (GABA) B receptor, 2 9 98288082-98709197 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA013820, HPA031684 Supported Group enriched Tissue enriched 19 cerebral cortex: 88.4 adrenal gland: 4.6 GABRA1 EJM5 ENSG00000022355 Gamma-aminobutyric acid (GABA) A receptor, alpha 1 5 161847191-161899981 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022502, HPA055746 Supported Tissue enriched Tissue enriched 44 cerebral cortex: 109.1 adrenal gland: 2.4 GABRA3 ENSG00000011677 Gamma-aminobutyric acid (GABA) A receptor, alpha 3 X 152166234-152451358 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA000839 Approved Supported Tissue enriched Tissue enriched 7 cerebral cortex: 28.9 placenta: 4.1 GABRA5 ENSG00000186297 Gamma-aminobutyric acid (GABA) A receptor, alpha 5 15 26866363-26949207 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077031 Supported Cell Junctions Mixed Tissue enriched 43 cerebral cortex: 82.0 esophagus: 1.8 GABRA6 ENSG00000145863 Gamma-aminobutyric acid (GABA) A receptor, alpha 6 5 161547063-161702593 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA019188, CAB022462, HPA058329 Uncertain Not detected Tissue enhanced testis: 1.2 cerebral cortex: 0.3 GABRB1 ENSG00000163288 Gamma-aminobutyric acid (GABA) A receptor, beta 1 4 46993723-47426444 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051297 Uncertain Tissue enhanced Tissue enriched 15 cerebral cortex: 19.8 heart muscle: 1.3 GABRB2 ENSG00000145864 Gamma-aminobutyric acid (GABA) A receptor, beta 2 5 161288429-161549044 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB001964, HPA067632 Supported Tissue enriched Tissue enriched 11 cerebral cortex: 63.0 epididymis: 5.5 GABRD ENSG00000187730 Gamma-aminobutyric acid (GABA) A receptor, delta 1 2019324-2030751 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA044371 Supported Uncertain Golgi apparatus
Vesicles Renal cancer:4.12e-8 (unfavourable) Expressed in all Tissue enriched 10 cerebral cortex: 47.4 testis: 4.5 GABRE ENSG00000102287 Gamma-aminobutyric acid (GABA) A receptor, epsilon X 151953124-151974680 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA045918 Uncertain Renal cancer:4.05e-11 (unfavourable) Mixed Tissue enhanced adipose tissue: 10.1 heart muscle: 5.5 GABRG1 ENSG00000163285 Gamma-aminobutyric acid (GABA) A receptor, gamma 1 4 46035769-46124081 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA035622 Approved Tissue enriched Tissue enriched 17 cerebral cortex: 26.1 ovary: 1.5 GABRG3 ENSG00000182256 Gamma-aminobutyric acid (GABA) A receptor, gamma 3 15 26971282-27541991 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054010 Supported Tissue enhanced Tissue enhanced prostate: 10.6;testis: 16.4 cerebral cortex: 4.2 GABRP ENSG00000094755 Gamma-aminobutyric acid (GABA) A receptor, pi 5 170763350-170814047 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB014883 Uncertain Cervical cancer:3.37e-4 (favourable) Mixed Expressed in all breast: 186.6 GABRQ THETA ENSG00000268089 Gamma-aminobutyric acid (GABA) A receptor, theta X 152638183-152657534 FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA002063 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 6.6;cervix, uterine: 12.8 adrenal gland: 3.0 GAL3ST4 FLJ12116 ENSG00000197093 Galactose-3-O-sulfotransferase 4 7 100159244-100168750 Predicted membrane proteins Evidence at protein level HPA038137, HPA038138 Uncertain Approved Nucleoplasm
Cytosol Ovarian cancer:2.57e-4 (unfavourable), Renal cancer:4.14e-4 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable) Expressed in all Tissue enhanced skin: 32.6 smooth muscle: 14.6 GALNT1 GalNAc-T1 ENSG00000141429 Polypeptide N-acetylgalactosaminyltransferase 1 18 35581117-35711834 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012628 Uncertain Expressed in all Expressed in all urinary bladder: 88.7 GALNT11 GalNAc-T11 ENSG00000178234 Polypeptide N-acetylgalactosaminyltransferase 11 7 152025674-152122347 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA039330 Uncertain Renal cancer:2.24e-6 (favourable), Glioma:8.42e-4 (unfavourable) Expressed in all Expressed in all kidney: 241.1 GALNT13 GalNAc-T13, KIAA1918 ENSG00000144278 Polypeptide N-acetylgalactosaminyltransferase 13 2 153871913-154453849 Enzymes, Predicted intracellular proteins Evidence at protein level HPA060775 Approved Tissue enriched Group enriched 6 adrenal gland: 6.6;cerebral cortex: 32.8 lung: 3.2 GALNT14 FLJ12691, GalNac-T10, GalNac-T14 ENSG00000158089 Polypeptide N-acetylgalactosaminyltransferase 14 2 30910467-31155202 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030138 Approved Nucleus
Golgi apparatus Tissue enriched Tissue enhanced kidney: 40.0 parathyroid gland: 12.5 GALNT16 GalNAc-T16, GALNTL1, KIAA1130 ENSG00000100626 Polypeptide N-acetylgalactosaminyltransferase 16 14 69259277-69357033 Enzymes, Predicted intracellular proteins Evidence at protein level HPA059136 Approved Approved Nucleus Renal cancer:5.23e-6 (favourable) Mixed Mixed cerebral cortex: 28.6 GALNT18 GalNAc-T18, GALNT15, GALNTL4, MGC71806 ENSG00000110328 Polypeptide N-acetylgalactosaminyltransferase 18 11 11270876-11622005 Enzymes, Predicted membrane proteins Evidence at protein level HPA012955 Approved Approved Mitochondria Endometrial cancer:1.29e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 59.0 lung: 43.2 GALNT3 GalNAc-T3, HFTC, HHS ENSG00000115339 Polypeptide N-acetylgalactosaminyltransferase 3 2 165747591-165794682 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007613 Supported Supported Golgi apparatus Cervical cancer:2.08e-4 (unfavourable), Head and neck cancer:4.10e-4 (unfavourable) Expressed in all Mixed stomach: 86.2 GALNT7 GALNAC-T7 ENSG00000109586 Polypeptide N-acetylgalactosaminyltransferase 7 4 173168753-173323967 Predicted intracellular proteins Evidence at protein level HPA064243, HPA065317 Supported Validated Nucleus
Golgi apparatus Colorectal cancer:4.53e-4 (favourable), Pancreatic cancer:7.65e-4 (unfavourable) Expressed in all Mixed stomach: 63.1 GALNT8 GALNAC-T8 ENSG00000130035 Polypeptide N-acetylgalactosaminyltransferase 8 12 4720341-4851927 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012638, HPA014418, HPA073461 Approved Approved Vesicles Tissue enhanced Group enriched 7 cerebral cortex: 19.5;colon: 18.0;duodenum: 8.4;rectum: 41.3;small intestine: 19.3;testis: 26.3 appendix: 3.3 GALNT9 GALNAC-T9 ENSG00000182870 Polypeptide N-acetylgalactosaminyltransferase 9 12 132196372-132329349 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA075016 Approved Vesicles Mixed Group enriched 7 cerebral cortex: 29.5;epididymis: 7.8;thyroid gland: 6.4 kidney: 1.9 GALNTL5 GalNAc-T5L, GALNT15 ENSG00000106648 Polypeptide N-acetylgalactosaminyltransferase-like 5 7 151956379-152019934 Disease related genes, Predicted membrane proteins Evidence at protein level HPA011140 Supported Not detected Tissue enriched 14 testis: 11.1 cerebral cortex: 0.8 GALNTL6 GalNAc-T6L, GALNT17 ENSG00000174473 Polypeptide N-acetylgalactosaminyltransferase-like 6 4 171812254-173041559 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031019 Uncertain Not detected Tissue enhanced cerebral cortex: 5.5;testis: 4.8 spleen: 2.1 GALR2 GALNR2 ENSG00000182687 Galanin receptor 2 17 76074794-76077541 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA044513 Approved Mixed Tissue enhanced smooth muscle: 2.4 bone marrow: 0.6 GAPT C5orf29, FLJ33641 ENSG00000175857 GRB2-binding adaptor protein, transmembrane 5 58491435-58497090 Predicted intracellular proteins Evidence at protein level HPA011070 Uncertain Mixed Tissue enhanced appendix: 39.9;tonsil: 40.4 lymph node: 30.5 GBF1 ARF1GEF, KIAA0248 ENSG00000107862 Golgi brefeldin A resistant guanine nucleotide exchange factor 1 10 102245532-102382899 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA037759, HPA037760 Uncertain Supported Golgi apparatus Expressed in all Expressed in all parathyroid gland: 58.1 GBP1 ENSG00000117228 Guanylate binding protein 1, interferon-inducible 1 89052319-89065360 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB015450 Approved Renal cancer:5.12e-9 (unfavourable), Ovarian cancer:5.04e-4 (favourable), Colorectal cancer:8.32e-4 (favourable) Expressed in all Expressed in all appendix: 122.1 GBP2 ENSG00000162645 Guanylate binding protein 2, interferon-inducible 1 89106132-89150456 Predicted intracellular proteins Evidence at protein level HPA042682, CAB045975 Supported Supported Nucleoplasm
Actin filaments
Cytosol Renal cancer:2.14e-10 (unfavourable), Urothelial cancer:1.10e-5 (favourable), Pancreatic cancer:5.73e-5 (unfavourable), Breast cancer:7.57e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 192.3 GBP3 FLJ10961 ENSG00000117226 Guanylate binding protein 3 1 89006666-89022894 Predicted intracellular proteins Evidence at protein level HPA045657 Approved Expressed in all Mixed duodenum: 79.1 GBP5 ENSG00000154451 Guanylate binding protein 5 1 89258950-89272804 Predicted intracellular proteins Evidence at protein level HPA028656 Approved Approved Endoplasmic reticulum Renal cancer:5.53e-8 (unfavourable), Endometrial cancer:3.73e-6 (favourable), Ovarian cancer:1.24e-4 (favourable), Colorectal cancer:9.54e-4 (favourable) Expressed in all Tissue enhanced appendix: 103.3 lymph node: 61.2 GBP6 DKFZp686G0786 ENSG00000183347 Guanylate binding protein family, member 6 1 89364058-89386461 Predicted intracellular proteins Evidence at protein level HPA027744 Supported Group enriched Tissue enriched 7 esophagus: 450.3 tonsil: 68.6 GBP7 FLJ38822, GBP4L ENSG00000213512 Guanylate binding protein 7 1 89131751-89176040 Predicted intracellular proteins Evidence at protein level HPA051245 Uncertain Tissue enriched Tissue enriched 89 liver: 48.3 adrenal gland: 0.5 GCGR GGR ENSG00000215644 Glucagon receptor 17 81804132-81814013 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071228 Approved Golgi apparatus Tissue enhanced Group enriched 7 adrenal gland: 6.6;kidney: 8.5;liver: 20.9;parathyroid gland: 9.4 skin: 1.6 GCLC GCS, GLCL, GLCLC ENSG00000001084 Glutamate-cysteine ligase, catalytic subunit 6 53497341-53616970 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009569, HPA036359, HPA036360 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:3.83e-6 (favourable), Thyroid cancer:8.24e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 81.9 GCNT2 bA360O19.2, bA421M1.1, CCAT, GCNT5, IGNT, II, NACGT1, NAGCT1, ULG3 ENSG00000111846 Glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group) 6 10492223-10629368 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA026776 Approved Supported Golgi apparatus Mixed Tissue enhanced prostate: 49.8 breast: 14.2 GCNT3 C2/4GnT, C2GnT-M, C2GnT2 ENSG00000140297 Glucosaminyl (N-acetyl) transferase 3, mucin type 15 59594875-59640239 Enzymes, Predicted membrane proteins Evidence at protein level HPA011154 Approved Approved Golgi apparatus
Vesicles Liver cancer:6.49e-5 (unfavourable), Endometrial cancer:1.78e-4 (favourable) Tissue enhanced Tissue enhanced colon: 144.6;gallbladder: 118.5;rectum: 136.6;small intestine: 141.0 duodenum: 100.5 GDAP1 CMT2K, CMT4, CMT4A ENSG00000104381 Ganglioside induced differentiation associated protein 1 8 74321130-74488872 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014266, HPA024334 Supported Supported Mitochondria
Cytosol Endometrial cancer:1.82e-4 (unfavourable), Lung cancer:2.68e-4 (favourable), Thyroid cancer:4.54e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 77.0 parathyroid gland: 18.1 GDAP1L1 ENSG00000124194 Ganglioside induced differentiation associated protein 1-like 1 20 44247099-44280917 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054182, HPA063265 Approved Approved Endoplasmic reticulum Tissue enriched Tissue enriched 20 cerebral cortex: 55.7 adrenal gland: 2.8 GDPD3 MGC4171 ENSG00000102886 Glycerophosphodiester phosphodiesterase domain containing 3 16 30104810-30113856 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041148, HPA041470 Uncertain Approved Nucleoplasm
Cytokinetic bridge
Cytosol Renal cancer:5.89e-9 (unfavourable) Expressed in all Mixed esophagus: 23.2 GDPD5 GDE2, PP1665 ENSG00000158555 Glycerophosphodiester phosphodiesterase domain containing 5 11 75434640-75525903 Predicted membrane proteins Evidence at protein level HPA065257, HPA066762, HPA069281 Uncertain Approved Golgi apparatus Renal cancer:6.59e-9 (unfavourable), Endometrial cancer:1.29e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 68.0 testis: 31.2 GFRA1 GDNFR, GDNFRA, GFR-ALPHA-1, RET1L, RETL1, TRNR1 ENSG00000151892 GDNF family receptor alpha 1 10 116056925-116273467 Predicted membrane proteins Evidence at protein level HPA043829 Uncertain Approved Nucleoplasm
Golgi apparatus Tissue enriched Mixed breast: 30.1 GFRA3 GFRa-3 ENSG00000146013 GDNF family receptor alpha 3 5 138252379-138274671 Predicted membrane proteins Evidence at protein level HPA020731 Approved Uncertain Plasma membrane
Cytosol Mixed Mixed seminal vesicle: 8.0 GFRAL bA360D14.1, C6orf144, GRAL, UNQ9356 ENSG00000187871 GDNF family receptor alpha like 6 55327469-55402493 Predicted membrane proteins Evidence at protein level HPA047372 Uncertain Not detected Not detected testis: 0.2 GGCX VKCFD1 ENSG00000115486 Gamma-glutamyl carboxylase 2 85544723-85561547 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA018284 Approved Endometrial cancer:1.82e-6 (unfavourable) Expressed in all Expressed in all liver: 61.2 GGT1 CD224, D22S672, D22S732, GGT ENSG00000100031 Gamma-glutamyltransferase 1 22 24583750-24629005 Candidate cardiovascular disease genes, CD markers, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045635, HPA047534, HPA065444 Supported Approved Vesicles Renal cancer:4.83e-4 (favourable), Ovarian cancer:7.44e-4 (favourable) Expressed in all Tissue enhanced kidney: 160.6 small intestine: 97.9 GGT6 FLJ90165 ENSG00000167741 Gamma-glutamyltransferase 6 17 4556927-4560818 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023362, HPA027213 Approved Renal cancer:9.42e-7 (favourable), Lung cancer:4.35e-4 (favourable) Mixed Mixed colon: 55.8 GGT7 D20S101, dJ18C9.2, GGTL3, GGTL5 ENSG00000131067 Gamma-glutamyltransferase 7 20 34844720-34872860 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013204, HPA013339 Approved Approved Nucleus
Vesicles Endometrial cancer:1.26e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 50.1 GHITM DERP2, HSPC282, My021, PTD010, TMBIM5 ENSG00000165678 Growth hormone inducible transmembrane protein 10 84139440-84153555 Predicted membrane proteins Evidence at protein level HPA016464, HPA061664 Approved Supported Mitochondria Renal cancer:2.32e-10 (favourable), Head and neck cancer:1.76e-4 (unfavourable) Expressed in all Expressed in all kidney: 349.8 GHR GHBP ENSG00000112964 Growth hormone receptor 5 42423777-42721878 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA045339, HPA057705 Supported Supported Plasma membrane
Cytosol
Cytoplasmic bodies Liver cancer:2.73e-6 (favourable) Mixed Group enriched 5 adipose tissue: 91.1;liver: 110.5 prostate: 18.4 GHSR ENSG00000121853 Growth hormone secretagogue receptor 3 172445133-172448456 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB012451 Uncertain Not detected Not detected adrenal gland: 0.3 GIMAP1 HIMAP1, IAN2, IMAP1, IMAP38 ENSG00000213203 GTPase, IMAP family member 1 7 150716557-150724284 Predicted membrane proteins Evidence at protein level HPA044887, HPA053441 Uncertain Supported Endoplasmic reticulum Liver cancer:1.09e-4 (favourable), Testis cancer:6.12e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 33.3 lymph node: 21.6 GIMAP1-GIMAP5 ENSG00000281887 GIMAP1-GIMAP5 readthrough 7 150716668-150743646 Predicted membrane proteins Evidence at protein level HPA053441 Supported Endoplasmic reticulum Not detected Tissue enhanced spleen: 18.3 appendix: 15.4 GIMAP2 DKFZp586D0824, HIMAP2, IAN12, IMAP2 ENSG00000106560 GTPase, IMAP family member 2 7 150685697-150693641 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013589 Approved Renal cancer:1.29e-4 (unfavourable), Breast cancer:3.50e-4 (favourable) Expressed in all Mixed lymph node: 89.2 GIMAP4 FLJ11110, HIMAP4, IAN1, IMAP4 ENSG00000133574 GTPase, IMAP family member 4 7 150567277-150573955 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019135, HPA019137, HPA027198 Supported Renal cancer:1.13e-4 (unfavourable), Endometrial cancer:7.63e-4 (favourable) Expressed in all Expressed in all spleen: 150.0 GIMAP6 FLJ22690, IAN6 ENSG00000133561 GTPase, IMAP family member 6 7 150625375-150632648 Predicted intracellular proteins Evidence at protein level HPA026715, HPA050740 Uncertain Uncertain Nucleoplasm
Cytosol Liver cancer:1.56e-4 (favourable), Head and neck cancer:2.91e-4 (favourable), Endometrial cancer:3.12e-4 (favourable), Renal cancer:5.27e-4 (unfavourable) Expressed in all Mixed spleen: 89.4 GINM1 C6orf72, dJ12G14.2 ENSG00000055211 Glycoprotein integral membrane 1 6 149566294-149591748 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017210, HPA041679 Approved Approved Nucleoli fibrillar center
Plasma membrane Expressed in all Expressed in all thyroid gland: 118.1 GIPR ENSG00000010310 Gastric inhibitory polypeptide receptor 19 45668244-45683724 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB022710 Uncertain Tissue enriched Tissue enhanced stomach: 22.6 parathyroid gland: 12.2 GJA1 CX43, GJAL, ODD, ODDD, ODOD, SDTY3 ENSG00000152661 Gap junction protein, alpha 1, 43kDa 6 121435692-121449727 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level CAB010753, HPA035097 Supported Approved Stomach cancer:4.99e-5 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 639.4 skin: 470.1 GJA10 CX62 ENSG00000135355 Gap junction protein, alpha 10, 62kDa 6 89894469-89896120 Predicted membrane proteins Evidence at protein level HPA021145 Uncertain Tissue enriched Not detected testis: 0.3 GJA3 CX46, CZP3 ENSG00000121743 Gap junction protein, alpha 3, 46kDa 13 20138255-20161049 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014821 Supported Tissue enhanced Tissue enhanced heart muscle: 4.7;parathyroid gland: 5.8;placenta: 3.5 testis: 2.5 GJA4 CX37 ENSG00000187513 Gap junction protein, alpha 4, 37kDa 1 34792998-34795747 Predicted membrane proteins, Transporters Evidence at protein level HPA047981 Approved Liver cancer:3.28e-4 (favourable), Renal cancer:7.44e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 88.6 fallopian tube: 47.8 GJA5 CX40 ENSG00000265107 Gap junction protein, alpha 5, 40kDa 1 147756199-147773362 Disease related genes, Predicted membrane proteins Evidence at protein level CAB013080 Uncertain Expressed in all Tissue enhanced placenta: 122.1 lung: 39.9 GJA9 CX58, CX59, GJA10 ENSG00000131233 Gap junction protein, alpha 9, 59kDa 1 38874451-38881587 Predicted membrane proteins Evidence at transcript level HPA067850 Uncertain Not detected Tissue enhanced testis: 2.2 skin: 0.5 GJB1 CMTX, CMTX1, CX32 ENSG00000169562 Gap junction protein, beta 1, 32kDa X 71215194-71225516 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB012994 Uncertain Renal cancer:2.85e-6 (favourable) Tissue enhanced Tissue enhanced liver: 159.3 gallbladder: 59.5 GJB2 CX26, DFNA3, DFNB1, NSRD1 ENSG00000165474 Gap junction protein, beta 2, 26kDa 13 20187470-20192898 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB013093, HPA014362 Uncertain Approved Mitochondria Renal cancer:2.53e-6 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable), Glioma:5.98e-4 (unfavourable), Lung cancer:6.25e-4 (unfavourable) Expressed in all Tissue enriched 9 esophagus: 728.4 tonsil: 84.8 GJB3 CX31, DFNA2, EKV ENSG00000188910 Gap junction protein, beta 3, 31kDa 1 34781189-34786369 Disease related genes, Predicted membrane proteins Evidence at protein level HPA074472 Supported Vesicles
Cell Junctions Pancreatic cancer:7.56e-5 (unfavourable), Lung cancer:4.56e-4 (unfavourable) Mixed Tissue enhanced esophagus: 33.7;skin: 77.4 tonsil: 12.1 GJB4 CX30.3 ENSG00000189433 Gap junction protein, beta 4, 30.3kDa 1 34759741-34763724 Disease related genes, Predicted membrane proteins Evidence at protein level HPA055112 Supported Cell Junctions Pancreatic cancer:3.24e-5 (unfavourable), Cervical cancer:5.48e-4 (favourable) Group enriched Tissue enriched 5 skin: 27.8 epididymis: 5.0 GJB5 CX31.1 ENSG00000189280 Gap junction protein, beta 5, 31.1kDa 1 34755047-34758512 Cancer-related genes, Predicted membrane proteins Evidence at transcript level HPA038146 Uncertain Pancreatic cancer:1.54e-4 (unfavourable) Group enriched Group enriched 6 esophagus: 56.7;skin: 77.6 tonsil: 11.9 GJB6 CX30, DFNA3, ED2, EDH, HED ENSG00000121742 Gap junction protein, beta 6, 30kDa 13 20221971-20232395 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014846 Supported Cell Junctions Tissue enhanced Group enriched 5 bone marrow: 47.6;cerebral cortex: 39.6;esophagus: 150.3;skin: 32.0 tonsil: 12.7 GJC1 CX45, GJA7 ENSG00000182963 Gap junction protein, gamma 1, 45kDa 17 44798448-44830816 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA071788 Uncertain Nucleoli
Cell Junctions
Cytosol Renal cancer:3.55e-8 (unfavourable), Urothelial cancer:7.83e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 43.9;placenta: 50.9;smooth muscle: 48.2 seminal vesicle: 27.0 GJC3 CX30.2, GJE1 ENSG00000176402 Gap junction protein, gamma 3, 30.2kDa 7 99923269-99929620 Predicted membrane proteins, Transporters Evidence at protein level HPA015024 Uncertain Group enriched Tissue enhanced breast: 8.9;prostate: 5.6 testis: 3.2 GJD2 CX36, GJA9 ENSG00000159248 Gap junction protein, delta 2, 36kDa 15 34751032-34754965 Predicted membrane proteins Evidence at protein level HPA014355 Uncertain Tissue enriched Group enriched 6 adrenal gland: 8.0;cerebral cortex: 1.9 pancreas: 0.8 GJD4 CX40.1, FLJ90023 ENSG00000177291 Gap junction protein, delta 4, 40.1kDa 10 35605410-35608935 Predicted membrane proteins, Transporters Evidence at transcript level HPA038266 Approved Not detected Mixed cerebral cortex: 1.7 GJE1 CX23 ENSG00000203733 Gap junction protein, epsilon 1, 23kDa 6 142133090-142135151 Predicted membrane proteins No evidence HPA014916 Uncertain Not detected Not detected testis: 0.1 GK GK1, GKD ENSG00000198814 Glycerol kinase X 30653359-30731456 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060687 Approved Renal cancer:3.24e-9 (favourable) Expressed in all Tissue enhanced kidney: 110.2;small intestine: 100.8 duodenum: 89.7 GK2 GKP2, GKTA ENSG00000196475 Glycerol kinase 2 4 79406352-79408293 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA060687 Uncertain Not detected Tissue enriched 1517 testis: 151.7 all non-specific tissues: 0.0 GLB1L3 FLJ90231 ENSG00000166105 Galactosidase, beta 1-like 3 11 134274245-134319564 Predicted intracellular proteins Evidence at protein level HPA039916 Uncertain Lung cancer:1.97e-4 (favourable) Tissue enhanced Tissue enhanced prostate: 18.8;seminal vesicle: 10.7 cerebral cortex: 4.0 GLCCI1 FAM117C, GIG18, TSSN1 ENSG00000106415 Glucocorticoid induced 1 7 7968794-8094272 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001674, HPA005987 Approved Uncertain Nucleoli Expressed in all Mixed thyroid gland: 28.1 GLG1 CFR-1, ESL-1, MG-160 ENSG00000090863 Golgi glycoprotein 1 16 74447427-74607144 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010815 Supported Validated Golgi apparatus Renal cancer:1.56e-7 (favourable), Cervical cancer:1.99e-4 (unfavourable), Urothelial cancer:7.97e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 164.3 GLIPR1 GliPR, RTVP1 ENSG00000139278 GLI pathogenesis-related 1 12 75480680-75503853 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011014 Approved Renal cancer:8.69e-9 (unfavourable) Expressed in all Mixed appendix: 66.6 GLIPR1L2 MGC39497 ENSG00000180481 GLI pathogenesis-related 1 like 2 12 75391070-75432688 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039795, HPA039866 Supported Mixed Tissue enriched 8 testis: 84.5 parathyroid gland: 11.0 GLMP C1orf85, MGC31963, NCU-G1 ENSG00000198715 Glycosylated lysosomal membrane protein 1 156290089-156295689 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029121 Uncertain Liver cancer:6.35e-5 (unfavourable) Expressed in all Expressed in all prostate: 94.9 GLP2R ENSG00000065325 Glucagon-like peptide 2 receptor 17 9822206-9892102 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022690, HPA049244 Supported Supported Plasma membrane Tissue enhanced Tissue enhanced gallbladder: 19.4 duodenum: 10.4 GLRA1 STHE ENSG00000145888 Glycine receptor, alpha 1 5 151822513-151924842 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA016502 Uncertain Not detected Not detected adrenal gland: 0.4 GLRA2 GLR ENSG00000101958 Glycine receptor, alpha 2 X 14529298-14731812 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB070422 Approved Mixed Group enriched 10 cerebral cortex: 6.2;colon: 1.4;rectum: 4.3 testis: 0.3 GLRA4 ENSG00000188828 Glycine receptor, alpha 4 X 103707224-103728655 Predicted membrane proteins Evidence at transcript level HPA044759 Uncertain Not detected Tissue enhanced smooth muscle: 2.7 parathyroid gland: 1.0 GLRB ENSG00000109738 Glycine receptor, beta 4 157076057-157172090 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052363 Approved Renal cancer:4.89e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 62.2;parathyroid gland: 62.0 cervix, uterine: 14.0 GLT8D1 AD-017, FLJ14611 ENSG00000016864 Glycosyltransferase 8 domain containing 1 3 52694485-52706083 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010588 Approved Approved Mitochondria Endometrial cancer:2.76e-4 (favourable) Expressed in all Expressed in all testis: 116.6 GLT8D2 FLJ31494 ENSG00000120820 Glycosyltransferase 8 domain containing 2 12 103988984-104064183 Predicted intracellular proteins Evidence at protein level HPA026904 Approved Approved Cytosol Renal cancer:1.58e-6 (unfavourable), Cervical cancer:7.37e-4 (unfavourable), Stomach cancer:7.92e-4 (unfavourable) Expressed in all Mixed gallbladder: 57.3 GNA12 gep ENSG00000146535 Guanine nucleotide binding protein (G protein) alpha 12 7 2728112-2844324 Predicted intracellular proteins Evidence at protein level CAB010046 Approved Approved Cytosol Liver cancer:1.20e-6 (unfavourable), Renal cancer:4.71e-5 (unfavourable), Urothelial cancer:2.27e-4 (unfavourable) Expressed in all Expressed in all placenta: 34.4 GNA14 ENSG00000156049 Guanine nucleotide binding protein (G protein), alpha 14 9 77423079-77648307 Predicted intracellular proteins Evidence at protein level HPA048886 Approved Mixed Mixed thyroid gland: 29.7 GNAT1 CSNBAD3 ENSG00000114349 Guanine nucleotide binding protein (G protein), alpha transducing activity polypeptide 1 3 50191612-50196516 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA045393 Supported Not detected Tissue enhanced testis: 1.4 cerebral cortex: 0.3 GNL2 HUMAUANTIG, Ngp-1, Nog2, Nug2 ENSG00000134697 Guanine nucleotide binding protein-like 2 (nucleolar) 1 37566816-37595935 Predicted intracellular proteins Evidence at protein level HPA027163, HPA060026 Approved Validated Nucleoli Renal cancer:2.90e-11 (unfavourable), Liver cancer:5.86e-9 (unfavourable), Ovarian cancer:7.89e-4 (favourable) Expressed in all Expressed in all testis: 55.3 GNPTAB GNPTA, KIAA1208, MGC4170 ENSG00000111670 N-acetylglucosamine-1-phosphate transferase, alpha and beta subunits 12 101745497-101830938 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017754, HPA042343 Approved Approved Vesicles Endometrial cancer:8.48e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 64.0 GNRHR GRHR, LHRHR ENSG00000109163 Gonadotropin-releasing hormone receptor 4 67739328-67754360 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA013424 Supported Not detected Tissue enhanced parathyroid gland: 1.2 adrenal gland: 1.0 GOLGA5 golgin-84, GOLIM5, ret-II, rfg5 ENSG00000066455 Golgin A5 14 92794231-92839963 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000992, HPA063876 Supported Supported Supported Golgi apparatus Expressed in all Expressed in all epididymis: 64.2 GOLGB1 GCP, GCP372, giantin, GOLIM1 ENSG00000173230 Golgin B1 3 121663199-121749767 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011008, HPA011555 Supported Validated Golgi apparatus Expressed in all Expressed in all prostate: 42.4 GOLIM4 GIMPC, GOLPH4, GPP130, P138 ENSG00000173905 Golgi integral membrane protein 4 3 168008677-168095975 Predicted membrane proteins Evidence at protein level HPA001677, HPA002315 Supported Validated Golgi apparatus Expressed in all Expressed in all small intestine: 95.7 GOLT1B CGI-141, GOT1, YMR292W ENSG00000111711 Golgi transport 1B 12 21501781-21518408 Predicted membrane proteins Evidence at protein level HPA055909, HPA066383 Approved Approved Vesicles Renal cancer:4.83e-10 (unfavourable), Liver cancer:1.99e-8 (unfavourable), Pancreatic cancer:2.32e-4 (unfavourable) Expressed in all Expressed in all placenta: 42.1 GOSR1 GOLIM2, GOS-28, GOS28, GS28, P28 ENSG00000108587 Golgi SNAP receptor complex member 1 17 30477362-30527592 Predicted membrane proteins Evidence at protein level HPA020590 Uncertain Renal cancer:2.26e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 54.8 GOSR2 Bos1, GS27 ENSG00000108433 Golgi SNAP receptor complex member 2 17 46923117-46967019 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017456, HPA048956, HPA054472 Uncertain Supported Nucleoplasm
Golgi apparatus Liver cancer:3.80e-4 (unfavourable) Expressed in all Expressed in all testis: 132.2 GP1BA CD42b, GP1B ENSG00000185245 Glycoprotein Ib (platelet), alpha polypeptide 17 4932297-4935030 CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002496, HPA013316 Supported Mixed Tissue enhanced lymph node: 17.5 tonsil: 7.9 GP2 ENSG00000169347 Glycoprotein 2 (zymogen granule membrane) 16 20309572-20327808 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015739, HPA016668 Supported Tissue enriched Tissue enriched 200 pancreas: 7528.0 duodenum: 37.5 GP6 GPVI ENSG00000088053 Glycoprotein VI (platelet) 19 55013705-55038264 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA066482 Approved Approved Nucleoplasm Not detected Tissue enhanced testis: 1.3 skin: 0.7 GP9 CD42a, GPIX ENSG00000169704 Glycoprotein IX (platelet) 3 129060767-129062406 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA063182 Supported Not detected Tissue enhanced bone marrow: 2.9;spleen: 2.8 testis: 1.2 GPA33 A33 ENSG00000143167 Glycoprotein A33 (transmembrane) 1 167052836-167166479 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018858, CAB025943 Supported Tissue enriched Group enriched 8 colon: 186.8;duodenum: 134.3;rectum: 191.4;small intestine: 133.9 appendix: 19.9 GPAM GPAT1, KIAA1560, MGC26846 ENSG00000119927 Glycerol-3-phosphate acyltransferase, mitochondrial 10 112149864-112215377 Enzymes, Predicted membrane proteins Evidence at protein level HPA046339, HPA060090 Approved Approved Mitochondria Renal cancer:4.54e-6 (favourable) Tissue enriched Expressed in all adipose tissue: 315.5 GPAT2 CT123 ENSG00000186281 Glycerol-3-phosphate acyltransferase 2, mitochondrial 2 96021946-96039451 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036841 Uncertain Approved Mitochondria Mixed Mixed testis: 7.3 GPAT3 AGPAT10, AGPAT9, HMFN0839, LPAAT-theta, MAG1, MGC11324 ENSG00000138678 Glycerol-3-phosphate acyltransferase 3 4 83535914-83605875 Enzymes, Predicted membrane proteins Evidence at protein level HPA029414, CAB033749 Approved Uncertain Plasma membrane
Cytosol Renal cancer:2.71e-9 (favourable), Urothelial cancer:8.21e-4 (unfavourable) Mixed Tissue enhanced kidney: 89.3 duodenum: 41.9 GPAT4 AGPAT6, DKFZp586M1819, LPAAT-zeta, TSARG7 ENSG00000158669 Glycerol-3-phosphate acyltransferase 4 8 41577187-41625001 Enzymes, Predicted membrane proteins Evidence at protein level HPA016471 Approved Ovarian cancer:2.20e-4 (unfavourable), Prostate cancer:4.15e-4 (favourable), Urothelial cancer:5.65e-4 (favourable), Endometrial cancer:9.37e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 78.7 GPATCH2L C14orf118, FLJ10033, FLJ20689 ENSG00000089916 G patch domain containing 2-like 14 76151916-76254342 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018856 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all bone marrow: 39.9 GPBAR1 BG37, GPCR, GPCR19, GPR131, M-BAR, MGC40597, TGR5 ENSG00000179921 G protein-coupled bile acid receptor 1 2 218259496-218263859 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA062890 Approved Tissue enhanced Tissue enhanced gallbladder: 27.0;smooth muscle: 13.8 adipose tissue: 10.0 GPC1 glypican ENSG00000063660 Glypican 1 2 240435671-240468078 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030571 Approved Supported Plasma membrane
Cytosol Liver cancer:2.44e-6 (unfavourable), Colorectal cancer:5.78e-5 (unfavourable), Endometrial cancer:1.55e-4 (unfavourable) Expressed in all Tissue enhanced skin: 266.0 prostate: 57.7 GPC2 cerebroglycan, DKFZp547M109, FLJ38962 ENSG00000213420 Glypican 2 7 100169606-100177372 Predicted secreted proteins Evidence at protein level CAB025423, HPA053945 Uncertain Uncertain Nucleus
Nucleoli
Golgi apparatus Urothelial cancer:9.94e-4 (favourable) Mixed Tissue enhanced skin: 5.7;testis: 10.1 cerebral cortex: 3.4 GPC3 DGSX, OCI-5, SDYS, SGB, SGBS, SGBS1 ENSG00000147257 Glypican 3 X 133535745-133985895 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006316 Approved Plasma membrane Stomach cancer:4.83e-4 (unfavourable) Expressed in all Tissue enriched 6 placenta: 838.1 lung: 130.8 GPC4 K-glypican ENSG00000076716 Glypican 4 X 133300103-133415490 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA030836 Approved Approved Vesicles Renal cancer:1.25e-5 (favourable), Lung cancer:3.51e-4 (favourable) Expressed in all Mixed placenta: 41.4 GPER1 CEPR, CMKRL2, DRY12, FEG-1, GPCR-Br, GPER, GPR30, LERGU, LERGU2, LyGPR ENSG00000164850 G protein-coupled estrogen receptor 1 7 1082208-1093815 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027052 Approved Endometrial cancer:1.17e-4 (favourable) Expressed in all Mixed placenta: 9.1 GPM6A GPM6 ENSG00000150625 Glycoprotein M6A 4 175632934-176002664 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017338 Supported Tissue enriched Tissue enriched 36 cerebral cortex: 1107.6 lung: 30.7 GPM6B M6B, MGC17150, MGC54284 ENSG00000046653 Glycoprotein M6B X 13771031-13938638 Predicted membrane proteins Evidence at protein level HPA002913 Approved Ovarian cancer:2.67e-4 (favourable) Group enriched Tissue enriched 17 cerebral cortex: 838.3 seminal vesicle: 48.9 GPR1 ENSG00000183671 G protein-coupled receptor 1 2 206175316-206218047 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010525 Uncertain Supported Vesicles
Plasma membrane Mixed Tissue enhanced placenta: 11.2 esophagus: 5.5 GPR101 ENSG00000165370 G protein-coupled receptor 101 X 137030148-137031674 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA001084 Uncertain Not detected Not detected cerebral cortex: 0.1 GPR107 FLJ20998, KIAA1624, LUSTR1, RP11-88G17 ENSG00000148358 G protein-coupled receptor 107 9 130053426-130140169 Predicted membrane proteins Evidence at protein level HPA031704 Supported Approved Nucleoplasm
Golgi apparatus Renal cancer:1.87e-5 (favourable), Breast cancer:3.56e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 55.1 GPR108 LUSTR2 ENSG00000125734 G protein-coupled receptor 108 19 6729914-6737603 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041924, HPA041951, HPA063863 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.29e-9 (favourable), Endometrial cancer:1.04e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 73.7 GPR12 GPCR21, PPP1R84 ENSG00000132975 G protein-coupled receptor 12 13 26755200-26760785 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050972 Uncertain Group enriched Tissue enhanced cerebral cortex: 8.0 breast: 1.7 GPR132 G2A ENSG00000183484 G protein-coupled receptor 132 14 105049389-105065445 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029694, HPA029695 Supported Renal cancer:1.71e-5 (unfavourable), Cervical cancer:3.21e-4 (favourable), Head and neck cancer:6.44e-4 (favourable) Mixed Mixed appendix: 9.7 GPR135 HUMNPIIY20, PAFR ENSG00000181619 G protein-coupled receptor 135 14 59429022-59465342 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA045337 Uncertain Mixed Tissue enhanced testis: 9.1 fallopian tube: 5.0 GPR137 C11orf4, GPR137A, TM7SF1L1 ENSG00000173264 G protein-coupled receptor 137 11 64270062-64289500 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA062871 Uncertain Approved Nucleus
Nucleoli
Actin filaments Liver cancer:5.34e-4 (unfavourable), Pancreatic cancer:6.18e-4 (favourable) Expressed in all Expressed in all testis: 147.8 GPR137B TM7SF1 ENSG00000077585 G protein-coupled receptor 137B 1 236142505-236221865 Predicted membrane proteins, Transporters Evidence at protein level HPA026422 Approved Colorectal cancer:1.63e-4 (unfavourable) Expressed in all Mixed kidney: 70.2 GPR137C DKFZp762F0713, TM7SF1L2 ENSG00000180998 G protein-coupled receptor 137C 14 52553148-52637713 Predicted membrane proteins Evidence at transcript level HPA003640, HPA030763 Uncertain Approved Vesicles Mixed Tissue enhanced cerebral cortex: 18.0;epididymis: 10.5 testis: 8.2 GPR139 PGR3 ENSG00000180269 G protein-coupled receptor 139 16 20031485-20073917 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA046596 Uncertain Not detected Not detected endometrium: 0.3 GPR142 PGR2 ENSG00000257008 G protein-coupled receptor 142 17 74367407-74372622 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA031392 Uncertain Uncertain Plasma membrane
Cell Junctions
Cytosol Tissue enhanced Not detected appendix: 0.1 GPR143 OA1 ENSG00000101850 G protein-coupled receptor 143 X 9725346-9786297 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003648 Approved Renal cancer:2.45e-5 (favourable), Cervical cancer:8.73e-4 (favourable) Tissue enriched Mixed skin: 10.3 GPR148 PGR6 ENSG00000173302 G protein-coupled receptor 148 2 130729070-130730336 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA060527 Uncertain Not detected Not detected stomach: 0.4 GPR149 IEDA, PGR10 ENSG00000174948 G protein-coupled receptor 149 3 154337672-154429715 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA018020 Uncertain Not detected Tissue enriched 6 seminal vesicle: 2.9 testis: 0.4 GPR15 ENSG00000154165 G protein-coupled receptor 15 3 98531899-98533150 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA013775 Approved Mixed Tissue enhanced colon: 25.7;rectum: 47.8 urinary bladder: 19.1 GPR150 PGR11 ENSG00000178015 G protein-coupled receptor 150 5 95620078-95622142 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA026635 Uncertain Mixed Tissue enhanced cerebral cortex: 1.3;parathyroid gland: 2.0 pancreas: 1.0 GPR152 PGR5 ENSG00000175514 G protein-coupled receptor 152 11 67451301-67452729 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA035078 Uncertain Not detected Not detected parathyroid gland: 0.2 GPR153 PGR1 ENSG00000158292 G protein-coupled receptor 153 1 6247346-6260975 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA007159 Approved Endometrial cancer:3.07e-4 (unfavourable), Lung cancer:3.75e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 17.3 GPR155 DEP.7, DEPDC3, FLJ31819, PGR22 ENSG00000163328 G protein-coupled receptor 155 2 174431571-174487094 Predicted membrane proteins Evidence at protein level HPA036159, HPA057384 Approved Approved Nuclear bodies
Cytosol Expressed in all Expressed in all stomach: 44.0 GPR156 GABABL, PGR28 ENSG00000175697 G protein-coupled receptor 156 3 120164645-120285094 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028642, HPA028644 Uncertain Supported Plasma membrane Mixed Tissue enhanced testis: 5.1 fallopian tube: 1.8 GPR157 FLJ12132 ENSG00000180758 G protein-coupled receptor 157 1 9100305-9129170 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA028697 Uncertain Uncertain Nucleoli
Plasma membrane
Cell Junctions Expressed in all Mixed parathyroid gland: 23.9 GPR158 KIAA1136 ENSG00000151025 G protein-coupled receptor 158 10 25175062-25602226 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013185 Uncertain Approved Cytosol Mixed Tissue enriched 17 cerebral cortex: 17.9 testis: 1.0 GPR160 GPCR1, GPCR150 ENSG00000173890 G protein-coupled receptor 160 3 170037929-170085403 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006970 Approved Supported Plasma membrane Renal cancer:4.93e-7 (favourable), Lung cancer:1.21e-4 (favourable), Urothelial cancer:3.61e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 426.5 small intestine: 111.2 GPR161 RE2 ENSG00000143147 G protein-coupled receptor 161 1 168079543-168137667 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA015576, HPA072047 Uncertain Approved Nucleus
Nucleoli Mixed Tissue enhanced smooth muscle: 39.8 endometrium: 28.5 GPR162 A-2, GRCA ENSG00000250510 G protein-coupled receptor 162 12 6821545-6829972 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055135 Supported Approved Microtubule organizing center Renal cancer:1.37e-6 (unfavourable), Pancreatic cancer:4.29e-5 (favourable) Tissue enriched Group enriched 6 cerebral cortex: 84.5;fallopian tube: 29.1 lung: 9.6 GPR17 ENSG00000144230 G protein-coupled receptor 17 2 127645864-127652639 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA029766 Approved Approved Vesicles Tissue enriched Mixed spleen: 12.3 GPR171 H963 ENSG00000174946 G protein-coupled receptor 171 3 151197832-151203201 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA062429 Approved Mixed Tissue enhanced appendix: 30.7 lymph node: 21.8 GPR173 SREB3 ENSG00000184194 G protein-coupled receptor 173 X 53049091-53080615 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA003905 Approved Plasma membrane
Cytosol Endometrial cancer:2.88e-6 (unfavourable), Pancreatic cancer:2.33e-5 (favourable), Renal cancer:2.47e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 19.1 ovary: 9.0 GPR174 FKSG79 ENSG00000147138 G protein-coupled receptor 174 X 79170972-79172229 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA041025 Supported Uncertain Vesicles Mixed Tissue enhanced lymph node: 30.2;spleen: 16.9;tonsil: 17.8 appendix: 13.1 GPR176 Gm1012 ENSG00000166073 G protein-coupled receptor 176 15 39799023-39920892 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA039943, HPA039979 Approved Renal cancer:9.38e-7 (unfavourable), Stomach cancer:6.84e-5 (unfavourable) Expressed in all Mixed cerebral cortex: 19.1 GPR179 CSNB1E, GPR158L1 ENSG00000277399 G protein-coupled receptor 179 17 38325530-38343847 Predicted membrane proteins No evidence HPA017885 Uncertain Not detected Not detected epididymis: 0.1 GPR18 ENSG00000125245 G protein-coupled receptor 18 13 99254714-99261744 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013873 Supported Mixed Tissue enhanced lymph node: 52.2;testis: 25.1;tonsil: 32.9 appendix: 17.0 GPR180 ITR ENSG00000152749 G protein-coupled receptor 180 13 94601903-94634645 Predicted membrane proteins Evidence at protein level HPA047250 Approved Approved Vesicles Renal cancer:3.18e-5 (unfavourable) Expressed in all Mixed adipose tissue: 6.3 GPR182 ADMR, AM-R, G10D, hrhAMR ENSG00000166856 G protein-coupled receptor 182 12 56994446-56998441 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027037 Supported Not detected Tissue enhanced spleen: 12.4;testis: 6.6 liver: 2.0 GPR183 EBI2 ENSG00000169508 G protein-coupled receptor 183 13 99294530-99307405 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028847, CAB033690 Uncertain Approved Nuclear membrane
Vesicles Cervical cancer:9.77e-4 (favourable) Expressed in all Mixed appendix: 117.8 GPR19 ENSG00000183150 G protein-coupled receptor 19 12 12660891-12696207 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013955 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 8.5;testis: 7.7 appendix: 2.8 GPR21 ENSG00000188394 G protein-coupled receptor 21 9 123034527-123035696 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA041651 Uncertain Not detected Tissue enhanced cerebral cortex: 2.1 endometrium: 0.9 GPR26 ENSG00000154478 G protein-coupled receptor 26 10 123666355-123694607 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA062736 Supported Tissue enriched Tissue enriched 15 cerebral cortex: 4.3 testis: 0.2 GPR27 SREB1 ENSG00000170837 G protein-coupled receptor 27 3 71754050-71756496 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029395 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments
Cytosol Ovarian cancer:1.21e-6 (favourable), Breast cancer:5.63e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 45.7 cerebral cortex: 24.9 GPR3 ACCA ENSG00000181773 G protein-coupled receptor 3 1 27392644-27395814 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB006254 Uncertain Mixed Tissue enhanced cerebral cortex: 5.3 thyroid gland: 1.3 GPR31 12-HETER, HETER1 ENSG00000120436 G protein-coupled receptor 31 6 167156271-167158329 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA014014, HPA027108 Uncertain Not detected Tissue enhanced lymph node: 1.6 epididymis,spleen: 0.9 GPR32 RVDR1 ENSG00000142511 G protein-coupled receptor 32 19 50770464-50771732 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA030330 Approved Not detected Tissue enriched 98 parathyroid gland: 254.8 placenta: 2.5 GPR34 ENSG00000171659 G protein-coupled receptor 34 X 41688973-41697277 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA010668, CAB025490 Uncertain Uncertain Nucleus
Cytosol Expressed in all Mixed placenta: 60.4 GPR37 EDNRBL, hET(B)R-LP, PAELR ENSG00000170775 G protein-coupled receptor 37 (endothelin receptor type B-like) 7 124745997-124765627 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA042903, HPA068009 Approved Approved Nuclear membrane
Cytosol Lung cancer:6.00e-5 (unfavourable), Ovarian cancer:7.26e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 78.9;testis: 27.6 placenta: 12.7 GPR37L1 ETBR-LP-2 ENSG00000170075 G protein-coupled receptor 37 like 1 1 202122858-202133592 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA064454 Supported Tissue enriched Tissue enriched 61 cerebral cortex: 34.2 seminal vesicle: 0.5 GPR39 ENSG00000183840 G protein-coupled receptor 39 2 132416574-132646559 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA022111 Approved Pancreatic cancer:7.50e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 17.7 colon: 6.2 GPR4 ENSG00000177464 G protein-coupled receptor 4 19 45589764-45602208 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014278 Uncertain Renal cancer:2.07e-5 (unfavourable), Lung cancer:9.19e-4 (unfavourable) Expressed in all Mixed adipose tissue: 10.3 GPR42 FFAR3L, GPR41L, GPR42P ENSG00000126251 G protein-coupled receptor 42 (gene/pseudogene) 19 35370929-35372962 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA044681 Uncertain Not detected Not detected appendix,small intestine: 0.3 GPR45 PSP24, PSP24A ENSG00000135973 G protein-coupled receptor 45 2 105241743-105243049 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055940 Uncertain Not detected Tissue enhanced cerebral cortex: 1.8 testis: 0.5 GPR50 H9, Mel1c ENSG00000102195 G protein-coupled receptor 50 X 151176653-151181465 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA049862, HPA054678 Supported Supported Nucleoplasm
Plasma membrane Mixed Not detected placenta: 0.6 GPR52 ENSG00000203737 G protein-coupled receptor 52 1 174448111-174449198 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA028575 Uncertain Not detected Tissue enriched 7 cerebral cortex: 2.7 bone marrow: 0.3 GPR61 BALGR ENSG00000156097 G protein-coupled receptor 61 1 109539872-109548406 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA007326, HPA026088 Approved Not detected Tissue enhanced cerebral cortex: 3.4;thyroid gland: 1.2 adrenal gland: 1.0 GPR63 PSP24(beta), PSP24B ENSG00000112218 G protein-coupled receptor 63 6 96794126-96837463 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA039103 Approved Approved Nucleus
Plasma membrane
Cytosol Mixed Mixed testis: 4.6 GPR65 hTDAG8, TDAG8 ENSG00000140030 G protein-coupled receptor 65 14 88005124-88014811 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA054454 Approved Cytosol Renal cancer:4.99e-4 (unfavourable) Mixed Mixed spleen: 13.5 GPR78 ENSG00000155269 G protein-coupled receptor 78 4 8558725-8619761 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013209 Uncertain Tissue enhanced Not detected all non-specific tissues: 0.0 GPR82 ENSG00000171657 G protein-coupled receptor 82 X 41724155-41730135 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA035914 Approved Mixed Tissue enhanced tonsil: 6.7 lymph node: 3.7 GPR84 EX33 ENSG00000139572 G protein-coupled receptor 84 12 54362445-54364487 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA027603 Supported Mixed Tissue enhanced appendix: 11.9;bone marrow: 14.7 adipose tissue: 5.9 GPR87 GPR95 ENSG00000138271 G protein-coupled receptor 87 3 151294086-151316952 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA066313 Approved Nucleoplasm
Lipid droplets
Mitochondria Pancreatic cancer:4.62e-6 (unfavourable) Group enriched Tissue enhanced esophagus: 29.4;skin: 29.8 placenta: 11.9 GPR88 ENSG00000181656 G protein-coupled receptor 88 1 100538137-100542018 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA007488 Uncertain Approved Tissue enriched Group enriched 12 breast: 9.7;cerebral cortex: 3.1;liver: 5.1;ovary: 3.4;parathyroid gland: 7.9;spleen: 14.7 adipose tissue,prostate: 0.6 GPR89A UNQ192 ENSG00000117262 G protein-coupled receptor 89A 1 145607990-145670648 Predicted membrane proteins Evidence at protein level HPA076096 Approved Endoplasmic reticulum Mixed Mixed kidney: 20.8 GPR89B GPR89, GPR89C, SH120 ENSG00000188092 G protein-coupled receptor 89B 1 147928393-147993521 Predicted membrane proteins Evidence at protein level HPA076096 Approved Endoplasmic reticulum Mixed Expressed in all kidney: 30.9 GPRC5A PEIG-1, RAI3, RAIG1, TIG1 ENSG00000013588 G protein-coupled receptor, class C, group 5, member A 12 12890782-12917937 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007928, HPA046526 Approved Validated Vesicles
Plasma membrane Pancreatic cancer:4.63e-6 (unfavourable), Renal cancer:9.02e-5 (unfavourable) Mixed Tissue enhanced lung: 302.3 thyroid gland: 90.7 GPRC5B RAIG-2 ENSG00000167191 G protein-coupled receptor, class C, group 5, member B 16 19856691-19886167 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015247 Approved Supported Nucleus
Nucleoli
Vesicles Colorectal cancer:9.27e-5 (unfavourable), Renal cancer:6.30e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 309.2 testis: 66.5 GPRC5C RAIG-3 ENSG00000170412 G protein-coupled receptor, class C, group 5, member C 17 74424851-74451653 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029776 Supported Uncertain Nucleus
Microtubule organizing center
Cytosol Renal cancer:1.58e-5 (favourable) Expressed in all Mixed thyroid gland: 103.7 GPRC5D ENSG00000111291 G protein-coupled receptor, class C, group 5, member D 12 12940775-12952147 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA071909 Approved Head and neck cancer:5.09e-4 (favourable) Mixed Mixed testis: 5.2 GPX8 EPLA847, UNQ847 ENSG00000164294 Glutathione peroxidase 8 (putative) 5 55160118-55167071 Enzymes, Predicted intracellular proteins Evidence at protein level HPA036720, HPA036721 Supported Supported Actin filaments
Cytosol Renal cancer:5.13e-9 (unfavourable), Stomach cancer:7.96e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 47.7 GRAMD1A FLJ90346, KIAA1533 ENSG00000089351 GRAM domain containing 1A 19 34994784-35026471 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008852, HPA012570 Approved Approved Plasma membrane
Cytosol Renal cancer:7.95e-12 (unfavourable) Expressed in all Expressed in all appendix: 36.8 GRAMD1B KIAA1201 ENSG00000023171 GRAM domain containing 1B 11 123454398-123627774 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008557 Approved Approved Nucleus
Nucleoli
Intermediate filaments Renal cancer:4.30e-7 (unfavourable) Mixed Tissue enhanced adrenal gland: 87.8 cerebral cortex: 39.0 GRAMD1C DKFZp434C0328 ENSG00000178075 GRAM domain containing 1C 3 113828182-113947174 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012316 Approved Uncertain Plasma membrane
Cytosol Renal cancer:4.22e-15 (favourable) Mixed Mixed testis: 28.3 GRAMD2 ENSG00000175318 GRAM domain containing 2 15 72159807-72197785 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA029435 Uncertain Approved Nucleoli
Nuclear speckles
Cytosol Thyroid cancer:7.01e-4 (unfavourable) Mixed Tissue enhanced epididymis: 45.7;placenta: 69.4 lung: 23.6 GRAMD3 FLJ21313, NS3TP2 ENSG00000155324 GRAM domain containing 3 5 126360132-126496494 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009678, HPA010095 Supported Approved Nucleoplasm
Golgi apparatus
Cytosol Expressed in all Mixed thyroid gland: 68.7 GREB1 KIAA0575 ENSG00000196208 Growth regulation by estrogen in breast cancer 1 2 11482341-11642788 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024616, HPA027843, HPA028416 Uncertain Approved Mitochondria
Cytosol Endometrial cancer:1.05e-4 (favourable) Tissue enhanced Tissue enhanced ovary: 156.7 prostate: 54.3 GRHL1 LBP-32, MGR, TFCP2L2 ENSG00000134317 Grainyhead-like transcription factor 1 2 9951693-10002277 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA005798, HPA006420 Approved Validated Nucleus
Golgi apparatus
Vesicles Mixed Tissue enhanced esophagus: 111.9;skin: 106.8 parathyroid gland: 51.7 GRIA1 GluA1, GLUR1, GLURA ENSG00000155511 Glutamate receptor, ionotropic, AMPA 1 5 153489615-153813869 FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB001965, HPA035202 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 67.3 lung: 10.6 GRIA2 GluA2, GLUR2, GLURB ENSG00000120251 Glutamate receptor, ionotropic, AMPA 2 4 157204182-157366075 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB006830, CAB007812, HPA008441, CAB012981 Supported Group enriched Tissue enriched 8 cerebral cortex: 207.2 endometrium: 27.2 GRIA3 GluA3, GLUR3, GLURC, MRX94 ENSG00000125675 Glutamate receptor, ionotropic, AMPA 3 X 123184153-123490915 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA058659 Uncertain Tissue enriched Tissue enhanced cerebral cortex: 56.8 adrenal gland: 11.4 GRID2 GluD2, GluR-delta-2 ENSG00000152208 Glutamate receptor, ionotropic, delta 2 4 92303622-93774556 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056253, HPA058538 Approved Tissue enriched Tissue enriched 10 testis: 59.7 cerebral cortex: 5.9 GRIK1 GluK1, GLUR5 ENSG00000171189 Glutamate receptor, ionotropic, kainate 1 21 29536933-29940033 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA014623 Uncertain Glioma:9.12e-4 (unfavourable) Group enriched Tissue enhanced adrenal gland: 16.8;cerebral cortex: 9.1 prostate: 3.9 GRIK2 GluK2, GLUR6, MRT6 ENSG00000164418 Glutamate receptor, ionotropic, kainate 2 6 101398788-102070083 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014395, HPA014623, CAB022463 Approved Tissue enhanced Tissue enhanced cerebral cortex: 22.6 thyroid gland: 6.2 GRIN1 GluN1, NMDAR1 ENSG00000176884 Glutamate receptor, ionotropic, N-methyl D-aspartate 1 9 137138390-137168762 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins, Transporters Evidence at protein level CAB006831 Approved Mixed Tissue enriched 202 cerebral cortex: 152.3 prostate: 0.7 GRIN2A GluN2A, NMDAR2A ENSG00000183454 Glutamate receptor, ionotropic, N-methyl D-aspartate 2A 16 9753404-10182754 Cancer-related genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022725 Supported Mixed Tissue enriched 5 cerebral cortex: 25.0 testis: 4.7 GRIN2B GluN2B, NMDAR2B ENSG00000273079 Glutamate receptor, ionotropic, N-methyl D-aspartate 2B 12 13537337-13981957 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA069762 Approved Not detected Tissue enriched 25 cerebral cortex: 13.2 adipose tissue: 0.5 GRINA HNRGW, LFG1, NMDARA1, TMBIM3 ENSG00000178719 Glutamate receptor, ionotropic, N-methyl D-aspartate-associated protein 1 (glutamate binding) 8 143990058-143993415 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA036980, HPA036981 Approved Approved Nucleoli fibrillar center
Cytosol Expressed in all Expressed in all seminal vesicle: 261.5 GRM1 GPRC1A, mGlu1, MGLUR1, PPP1R85 ENSG00000152822 Glutamate receptor, metabotropic 1 6 146027646-146437598 Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA015701 Approved Approved Vesicles Not detected Tissue enhanced cerebral cortex: 7.1 heart muscle: 1.4 GRM2 GPRC1B, mGlu2, MGLUR2 ENSG00000164082 Glutamate receptor, metabotropic 2 3 51707070-51718613 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065166 Approved Tissue enhanced Tissue enriched 10 cerebral cortex: 4.4 testis: 0.4 GRM4 GPRC1D, mGlu4, MGLUR4 ENSG00000124493 Glutamate receptor, metabotropic 4 6 34018645-34155622 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB022096 Supported Tissue enhanced Tissue enhanced cerebral cortex: 2.9 testis: 0.7 GRM6 CSNB1B, GPRC1F, mGlu6, MGLUR6 ENSG00000113262 Glutamate receptor, metabotropic 6 5 178978327-178996206 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA014511 Supported Not detected Not detected testis: 0.8 GRM7 GLUR7, GPRC1G, mGlu7, MGLUR7, PPP1R87 ENSG00000196277 Glutamate receptor, metabotropic 7 3 6770001-7741533 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015964 Uncertain Cytosol Not detected Tissue enhanced cerebral cortex: 10.1;parathyroid gland: 7.0 smooth muscle: 3.4 GRM8 GLUR8, GPRC1H, mGlu8, MGLUR8 ENSG00000179603 Glutamate receptor, metabotropic 8 7 126438598-127253294 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051481 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 4.1 testis: 2.9 GRPR BB2 ENSG00000126010 Gastrin-releasing peptide receptor X 16123556-16153021 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA069604 Validated Plasma membrane Tissue enhanced Tissue enhanced pancreas: 4.2 breast: 2.6 GSG1L KTSR5831, MGC18079, PRO19651 ENSG00000169181 GSG1-like 16 27787535-28063509 Predicted membrane proteins, Transporters Evidence at protein level HPA014479 Approved Tissue enriched Tissue enhanced cerebral cortex: 11.7;heart muscle: 8.8 fallopian tube: 2.7 GSG1L2 ENSG00000214978 GSG1-like 2 17 9802386-9822071 Predicted membrane proteins Evidence at transcript level HPA059428 Uncertain Tissue enriched Group enriched 14 cerebral cortex: 1.5;testis: 1.1 all non-specific tissues: 0.0 GTF3C3 TFIIIC102, TFiiiC2-102 ENSG00000119041 General transcription factor IIIC, polypeptide 3, 102kDa 2 196763032-196799725 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069179 Supported Nucleus
Nuclear membrane Liver cancer:1.26e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 40.1 GUCY2C GUC2C, STAR ENSG00000070019 Guanylate cyclase 2C 12 14612632-14696585 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA037655, HPA073759 Uncertain Uncertain Vesicles Liver cancer:1.37e-5 (unfavourable) Group enriched Group enriched 13 colon: 38.4;duodenum: 70.6;rectum: 48.1;small intestine: 74.7 appendix: 4.5 GULP1 CED-6, CED6, GULP ENSG00000144366 GULP, engulfment adaptor PTB domain containing 1 2 188291669-188595931 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020587 Approved Approved Vesicles Renal cancer:4.25e-6 (favourable), Stomach cancer:6.17e-4 (unfavourable) Mixed Mixed epididymis: 98.7 GYPA CD235a, GPA, MN, MNS ENSG00000170180 Glycophorin A (MNS blood group) 4 144109303-144140751 Blood group antigen proteins, CD markers, Predicted membrane proteins Evidence at protein level CAB002658, HPA014811 Supported Not detected Tissue enriched 16 bone marrow: 84.8 placenta: 5.3 GYPC CD236, CD236R, Ge, GPC, GYPD ENSG00000136732 Glycophorin C (Gerbich blood group) 2 126655933-126696675 Blood group antigen proteins, CD markers, Predicted membrane proteins Evidence at protein level HPA008965, CAB009445 Supported Approved Vesicles
Cytosol Expressed in all Expressed in all bone marrow: 230.3 GYS1 GSY, GYS ENSG00000104812 Glycogen synthase 1 (muscle) 19 48968125-48993310 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB007793, HPA041598 Supported Approved Microtubules
Cytosol Renal cancer:3.46e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 109.8 H2AFV H2AV, MGC10170, MGC10831, MGC1947 ENSG00000105968 H2A histone family, member V 7 44826791-44848083 Predicted intracellular proteins Evidence at protein level HPA057236 Supported Cervical cancer:4.66e-4 (favourable), Renal cancer:8.04e-4 (favourable) Expressed in all Expressed in all bone marrow: 219.0 H2AFY2 macroH2A2 ENSG00000099284 H2A histone family, member Y2 10 70052796-70112280 Predicted intracellular proteins Evidence at protein level HPA035865, HPA041189 Supported Validated Nucleoplasm Expressed in all Expressed in all endometrium: 31.3 HACD2 PTPLB ENSG00000206527 3-hydroxyacyl-CoA dehydratase 2 3 123490820-123585185 Enzymes, Predicted membrane proteins Evidence at protein level CAB019282 Approved Pancreatic cancer:9.59e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 68.9 HACD3 B-ind1, HSPC121, PTPLAD1 ENSG00000074696 3-hydroxyacyl-CoA dehydratase 3 15 65530418-65578352 Enzymes, Predicted membrane proteins Evidence at protein level HPA014837, HPA060347 Approved Validated Nuclear membrane
Endoplasmic reticulum
Mitochondria
Cytosol Renal cancer:3.09e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 139.3 HACD4 Em:AL662879.1, PTPLAD2 ENSG00000188921 3-hydroxyacyl-CoA dehydratase 4 9 20999515-21031636 Enzymes, Predicted membrane proteins Evidence at protein level HPA058666 Uncertain Ovarian cancer:3.14e-4 (favourable), Renal cancer:6.77e-4 (unfavourable) Mixed Mixed lung: 12.6 HACL1 2-HPCL, HPCL, PHYH2 ENSG00000131373 2-hydroxyacyl-CoA lyase 1 3 15560704-15601852 Predicted intracellular proteins Evidence at protein level HPA035496, HPA035497, HPA073760 Approved Supported Vesicles Renal cancer:2.63e-5 (favourable) Expressed in all Expressed in all duodenum: 52.3 HAPLN3 EXLD1, HsT19883 ENSG00000140511 Hyaluronan and proteoglycan link protein 3 15 88877288-88895626 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039237 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.18e-13 (unfavourable) Expressed in all Tissue enhanced appendix: 14.3;lymph node: 11.0 spleen: 4.0 HAS1 HAS ENSG00000105509 Hyaluronan synthase 1 19 51713112-51723994 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA067602 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enhanced adipose tissue: 26.9 appendix: 9.1 HAS2 ENSG00000170961 Hyaluronan synthase 2 8 121612116-121641390 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA052060 Approved Nuclear speckles Mixed Tissue enhanced adipose tissue: 27.7 appendix: 12.9 HAS3 ENSG00000103044 Hyaluronan synthase 3 16 69105564-69118719 Enzymes, Predicted membrane proteins Evidence at protein level HPA031554, CAB033850 Supported Approved Microtubules Pancreatic cancer:5.36e-4 (unfavourable) Group enriched Tissue enhanced lung: 29.9;urinary bladder: 37.7 stomach: 12.1 HAVCR1 CD365, HAVCR, HAVCR-1, TIM-1, TIM1, TIMD1 ENSG00000113249 Hepatitis A virus cellular receptor 1 5 157029413-157059119 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007173 Approved Vesicles Urothelial cancer:1.32e-4 (favourable), Stomach cancer:7.81e-4 (unfavourable) Tissue enriched Group enriched 5 colon: 4.9;kidney: 8.2;rectum: 4.2;testis: 1.7 parathyroid gland: 0.9 HAVCR2 CD366, FLJ14428, Tim-3, TIM3, TIMD3 ENSG00000135077 Hepatitis A virus cellular receptor 2 5 157085832-157142869 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010505, CAB026003, HPA047581 Supported Supported Nucleoplasm Expressed in all Mixed lung,spleen: 24.0 HBD ENSG00000223609 Hemoglobin, delta 11 5232678-5235370 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037087, HPA043234 Supported Not detected Tissue enriched 65 bone marrow: 1224.5 placenta: 18.8 HBEGF DTR, DTS, HEGFL ENSG00000113070 Heparin-binding EGF-like growth factor 5 140332843-140346631 Predicted membrane proteins Evidence at protein level HPA053243 Uncertain Head and neck cancer:2.41e-4 (unfavourable), Prostate cancer:6.00e-4 (favourable), Pancreatic cancer:7.09e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 89.2 HBG2 HBG-T1 ENSG00000196565 Hemoglobin, gamma G 11 5248274-5645789 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016143, HPA043234 Approved Approved Vesicles Not detected Tissue enriched 126 placenta: 20295.9 bone marrow: 160.6 HBS1L DKFZp434g247, EF-1a, eRF3c, ERFS, HBS1, HSPC276, KIAA1038 ENSG00000112339 HBS1-like translational GTPase 6 134960378-135103056 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029728, HPA029729 Approved Approved Nuclear bodies
Cytosol Colorectal cancer:6.77e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 73.4 HCAR2 GPR109A, HCA2, HM74A, NIACR1, Puma-g, PUMAG ENSG00000182782 Hydroxycarboxylic acid receptor 2 12 122701293-122703343 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Group enriched Tissue enhanced spleen: 36.5 esophagus: 25.6 HCAR3 GPR109B, HCA3, HM74 ENSG00000255398 Hydroxycarboxylic acid receptor 3 12 122714756-122716892 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA028660 Approved Approved Cell Junctions Mixed Tissue enhanced bone marrow: 16.7;spleen: 22.1 appendix: 12.6 HCN1 BCNG-1, BCNG1, HAC-2 ENSG00000164588 Hyperpolarization activated cyclic nucleotide gated potassium channel 1 5 45254950-45696498 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019195 Supported Not detected Tissue enriched 7 cerebral cortex: 11.5 heart muscle: 1.7 HCN3 KIAA1535 ENSG00000143630 Hyperpolarization activated cyclic nucleotide gated potassium channel 3 1 155277583-155289848 Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA026584 Approved Urothelial cancer:6.93e-4 (favourable), Renal cancer:7.49e-4 (unfavourable) Expressed in all Mixed liver,skin: 3.0 HCRTR1 OX1R ENSG00000121764 Hypocretin (orexin) receptor 1 1 31617686-31632518 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA014018 Approved Not detected Mixed adrenal gland: 1.2 HCRTR2 OX2R ENSG00000137252 Hypocretin (orexin) receptor 2 6 55106460-55282620 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA054516 Supported Not detected Not detected kidney: 0.6 HCST DAP10, DKFZP586C1522, KAP10, PIK3AP ENSG00000126264 Hematopoietic cell signal transducer 19 35902480-35904377 Predicted membrane proteins Evidence at protein level CAB034435, HPA063026 Supported Uncertain Vesicles Renal cancer:1.59e-10 (unfavourable), Melanoma:6.70e-4 (favourable) Expressed in all Expressed in all bone marrow: 154.7 HDAC10 DKFZP761B039 ENSG00000100429 Histone deacetylase 10 22 50245183-50251405 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB045977, HPA056514 Supported Approved Nucleoli fibrillar center Renal cancer:4.74e-11 (unfavourable), Endometrial cancer:2.45e-5 (favourable), Cervical cancer:4.46e-4 (favourable), Pancreatic cancer:9.25e-4 (favourable) Expressed in all Mixed spleen: 9.9 HDAC2 RPD3, YAF1 ENSG00000196591 Histone deacetylase 2 6 113933028-114011308 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB005054, HPA011727 Supported Validated Nucleus Liver cancer:5.39e-10 (unfavourable), Breast cancer:7.07e-4 (unfavourable) Expressed in all Expressed in all testis: 142.0 HEATR5A C14orf125, DKFZP434I1735 ENSG00000129493 HEAT repeat containing 5A 14 31291791-31420582 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049539 Uncertain Renal cancer:1.11e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 17.9 HEG1 HEG, KIAA1237 ENSG00000173706 Heart development protein with EGF-like domains 1 3 124965710-125055958 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA010952, HPA011559 Approved Approved Vesicles Renal cancer:1.93e-5 (unfavourable), Urothelial cancer:1.16e-4 (unfavourable) Expressed in all Mixed thyroid gland: 64.8 HELZ DHRC, HUMORF5, KIAA0054 ENSG00000198265 Helicase with zinc finger 17 67070438-67245989 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028276 Approved Approved Nucleoli
Plasma membrane
Actin filaments Expressed in all Expressed in all parathyroid gland: 32.3 HEPACAM FLJ25530, GLIALCAM, hepaCAM ENSG00000165478 Hepatic and glial cell adhesion molecule 11 124919193-124936412 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017613, CAB025486 Supported Approved Vesicles Tissue enriched Tissue enriched 6 cerebral cortex: 80.9 adipose tissue: 14.4 HEPH CPL, KIAA0698 ENSG00000089472 Hephaestin X 66162549-66268867 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005824 Approved Renal cancer:7.00e-6 (unfavourable), Glioma:6.23e-4 (unfavourable) Expressed in all Mixed smooth muscle: 117.4 HEPHL1 DKFZp686F22190 ENSG00000181333 Hephaestin-like 1 11 94021361-94113751 Predicted membrane proteins Evidence at protein level HPA031517 Uncertain Cervical cancer:4.94e-4 (unfavourable) Tissue enriched Group enriched 11 esophagus: 3.2;tonsil: 9.8 testis: 0.6 HERC4 DKFZP564G092, KIAA1593 ENSG00000148634 HECT and RLD domain containing E3 ubiquitin protein ligase 4 10 67921899-68075348 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045453, HPA070301 Uncertain Supported Nucleoli fibrillar center
Cytosol Renal cancer:3.86e-5 (unfavourable) Expressed in all Expressed in all testis: 32.4 HERC5 CEB1 ENSG00000138646 HECT and RLD domain containing E3 ubiquitin protein ligase 5 4 88457117-88506163 Predicted membrane proteins Evidence at protein level HPA043929 Supported Endometrial cancer:4.46e-5 (unfavourable) Expressed in all Tissue enhanced testis: 106.1 endometrium: 25.8 HERC6 FLJ20637 ENSG00000138642 HECT and RLD domain containing E3 ubiquitin protein ligase family member 6 4 88378739-88443111 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035846 Uncertain Supported Nucleus
Cytosol Renal cancer:7.14e-5 (favourable) Expressed in all Expressed in all esophagus: 22.9 HERPUD1 HERP, KIAA0025, Mif1, SUP ENSG00000051108 Homocysteine-inducible, endoplasmic reticulum stress-inducible, ubiquitin-like domain member 1 16 56932048-56944863 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB037041, CAB037104, HPA040754, HPA041219 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.41e-9 (favourable) Expressed in all Expressed in all prostate: 379.0 HERPUD2 FLJ22313 ENSG00000122557 HERPUD family member 2 7 35632659-35695571 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015630, HPA076087 Approved Approved Nucleoli Expressed in all Expressed in all testis: 51.6 HFE HLA-H ENSG00000010704 Hemochromatosis 6 26087281-26098343 Disease related genes, Predicted membrane proteins Evidence at protein level HPA017276, HPA053470 Approved Approved Nuclear membrane
Mitochondria Expressed in all Mixed parathyroid gland: 27.3 HGSNAT FLJ32731, HGNAT, TMEM76 ENSG00000165102 Heparan-alpha-glucosaminide N-acetyltransferase 8 43140455-43202855 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA029578 Approved Ovarian cancer:6.33e-5 (favourable), Glioma:7.02e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 50.4 HHAT FLJ10724, GUP2, MART-2, MART2, rasp, sit, ski, Skn ENSG00000054392 Hedgehog acyltransferase 1 210328252-210676296 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016462 Approved Approved Golgi apparatus Renal cancer:8.47e-7 (favourable) Expressed in all Mixed thyroid gland: 7.8 HHATL C3orf3, GUP1, KIAA1173, MBOAT3, MSTP002, OACT3 ENSG00000010282 Hedgehog acyltransferase-like 3 42692663-42702827 Predicted membrane proteins Evidence at protein level HPA018174 Supported Tissue enhanced Tissue enhanced heart muscle: 333.2;skeletal muscle: 97.6 cerebral cortex: 53.4 HHIP FLJ20992, HIP ENSG00000164161 Hedgehog interacting protein 4 144646021-144745271 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012616 Uncertain Approved Nucleoplasm Mixed Tissue enhanced lung: 24.3 cerebral cortex: 10.8 HHLA2 B7-H5, B7H7, B7y ENSG00000114455 HERV-H LTR-associating 2 3 108296490-108378285 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055478 Approved Group enriched Group enriched 10 colon: 89.3;duodenum: 89.6;gallbladder: 46.3;rectum: 92.1;small intestine: 146.8 stomach: 9.3 HIAT1 DKFZP564L0864 ENSG00000156875 Hippocampus abundant transcript 1 1 100038097-100083377 Predicted membrane proteins Evidence at transcript level HPA073681 Approved Vesicles Liver cancer:2.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 197.2 HIATL1 FLJ14753 ENSG00000148110 Hippocampus abundant transcript-like 1 9 94374551-94461042 Predicted membrane proteins, Transporters Evidence at protein level HPA017978 Approved Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 251.1 HID1 C17orf28, DMC1, HID-1 ENSG00000167861 HID1 domain containing 17 74950743-74973166 Predicted intracellular proteins Evidence at protein level HPA023095, HPA031406 Approved Supported Golgi apparatus
Cytosol Renal cancer:3.13e-5 (favourable), Urothelial cancer:1.34e-4 (favourable) Expressed in all Expressed in all stomach: 54.0 HIGD1A DKFZP564K247, HIG1 ENSG00000181061 HIG1 hypoxia inducible domain family, member 1A 3 42784298-42804531 Predicted membrane proteins Evidence at protein level HPA043336 Approved Supported Nucleoplasm
Mitochondria Renal cancer:3.99e-8 (favourable), Colorectal cancer:2.12e-4 (favourable) Expressed in all Expressed in all rectum: 333.6 HIGD2A MGC2198 ENSG00000146066 HIG1 hypoxia inducible domain family, member 2A 5 176388747-176389771 Predicted membrane proteins Evidence at protein level HPA042715 Uncertain Supported Mitochondria
Cytosol Liver cancer:9.47e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 168.2 HIGD2B HIGD2BP ENSG00000175202 HIG1 hypoxia inducible domain family, member 2B 15 72675783-72686149 Predicted membrane proteins Evidence at protein level HPA019016, HPA042715 Uncertain Not detected Tissue enriched 14 testis: 6.7 epididymis,thyroid gland: 0.4 HILPDA C7orf68, FLJ21076, HIG-2, HIG2 ENSG00000135245 Hypoxia inducible lipid droplet-associated 7 128455849-128458418 Predicted membrane proteins Evidence at protein level HPA010515 Approved Supported Nucleoplasm
Lipid droplets Liver cancer:4.30e-11 (unfavourable), Renal cancer:2.05e-7 (unfavourable) Expressed in all Expressed in all esophagus: 108.2 HLA-A ENSG00000206503 Major histocompatibility complex, class I, A 6 29941260-29945884 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB078470 Supported Golgi apparatus
Plasma membrane Ovarian cancer:6.47e-4 (favourable), Endometrial cancer:9.59e-4 (favourable) Expressed in all Mixed gallbladder: 342.4 HLA-B AS ENSG00000234745 Major histocompatibility complex, class I, B 6 31353872-31357188 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB015418 Supported Melanoma:2.90e-4 (favourable) Expressed in all Mixed lung: 1245.1 HLA-DMA D6S222E, RING6 ENSG00000204257 Major histocompatibility complex, class II, DM alpha 6 32948613-32969094 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012750, HPA017295 Supported Approved Vesicles Endometrial cancer:4.64e-5 (favourable), Lung cancer:4.59e-4 (favourable) Expressed in all Tissue enhanced lung: 64.8 fallopian tube: 41.3 HLA-DMB D6S221E, RING7 ENSG00000242574 Major histocompatibility complex, class II, DM beta 6 32934629-32941070 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012298 Supported Endometrial cancer:3.89e-5 (favourable) Expressed in all Tissue enhanced thyroid gland: 29.3 spleen: 12.0 HLA-DOA HLA-D0-alpha, HLA-DNA, HLA-DZA ENSG00000204252 Major histocompatibility complex, class II, DO alpha 6 33004178-33009612 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045038 Supported Expressed in all Tissue enhanced spleen: 14.8 tonsil: 9.2 HLA-DOB ENSG00000241106 Major histocompatibility complex, class II, DO beta 6 32812763-32817048 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013846 Approved Renal cancer:3.15e-5 (unfavourable), Ovarian cancer:4.17e-5 (favourable), Breast cancer:4.29e-4 (favourable) Expressed in all Group enriched 5 lymph node: 19.9;spleen: 18.8;tonsil: 31.8;urinary bladder: 8.6 colon: 3.6 HLA-DPA1 HLA-DP1A ENSG00000231389 Major histocompatibility complex, class II, DP alpha 1 6 33064569-33080775 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017967 Supported Supported Vesicles Expressed in all Expressed in all lung: 122.4 HLA-DPB1 HLA-DP1B ENSG00000223865 Major histocompatibility complex, class II, DP beta 1 6 33075926-33087201 Predicted membrane proteins Evidence at protein level HPA011078, HPA058509 Approved Approved Nucleus
Cell Junctions Endometrial cancer:3.38e-4 (favourable) Expressed in all Expressed in all spleen: 174.2 HLA-DQA1 CELIAC1, HLA-DQA ENSG00000196735 Major histocompatibility complex, class II, DQ alpha 1 6 32628179-32647062 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012315 Supported Expressed in all Tissue enhanced lung: 505.9 lymph node: 346.2 HLA-DQB1 CELIAC1, HLA-DQB, IDDM1 ENSG00000179344 Major histocompatibility complex, class II, DQ beta 1 6 32659467-32668383 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013667 Uncertain Approved Golgi apparatus Expressed in all Tissue enhanced lymph node: 292.8 lung: 269.6 HLA-DRA HLA-DRA1 ENSG00000204287 Major histocompatibility complex, class II, DR alpha 6 32439842-32445046 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002798, CAB015402, HPA050162, HPA053176 Supported Colorectal cancer:5.30e-4 (favourable) Expressed in all Tissue enhanced lung: 729.2;lymph node: 906.6 tonsil: 492.4 HLA-DRB1 HLA-DR1B ENSG00000196126 Major histocompatibility complex, class II, DR beta 1 6 32552990-32589848 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB015400, CAB034021, HPA043151 Supported Expressed in all Tissue enhanced lung: 870.8 lymph node: 634.1 HLA-DRB5 ENSG00000198502 Major histocompatibility complex, class II, DR beta 5 6 32517343-32530287 Predicted membrane proteins Evidence at protein level HPA043151 Supported Endometrial cancer:7.89e-4 (favourable) Expressed in all Tissue enhanced lung: 532.0 lymph node: 405.2 HLA-E ENSG00000204592 Major histocompatibility complex, class I, E 6 30489467-30494205 Predicted membrane proteins Evidence at protein level CAB024589, HPA031454 Supported Approved Vesicles Renal cancer:3.86e-4 (unfavourable) Expressed in all Mixed skin: 153.8 HLA-G ENSG00000204632 Major histocompatibility complex, class I, G 6 29826967-29831125 Cancer-related genes, Predicted membrane proteins Evidence at protein level CAB016158 Supported Melanoma:3.91e-5 (favourable) Expressed in all Tissue enriched 23 placenta: 14.8 duodenum,testis: 0.6 HM13 dJ324O17.1, H13, IMP1, IMPAS, PSENL3, PSL3, SPP, SPPL1 ENSG00000101294 Histocompatibility (minor) 13 20 31514428-31577923 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA045089, HPA056062 Approved Supported Endoplasmic reticulum Renal cancer:4.64e-12 (unfavourable), Liver cancer:1.95e-5 (unfavourable) Expressed in all Expressed in all cervix, uterine: 153.3 HMGCR ENSG00000113161 3-hydroxy-3-methylglutaryl-CoA reductase 5 75336329-75362104 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008338, CAB016797 Approved Renal cancer:9.42e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 87.8 HMOX1 bK286B10, HO-1 ENSG00000100292 Heme oxygenase 1 22 35380361-35394214 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000635, CAB017444 Supported Uncertain Golgi apparatus
Plasma membrane Liver cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all spleen: 435.2 HMOX2 HO-2 ENSG00000103415 Heme oxygenase 2 16 4474690-4510347 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025464, HPA040611 Supported Approved Vesicles
Cytosol Renal cancer:8.98e-6 (favourable), Endometrial cancer:7.91e-4 (favourable) Expressed in all Expressed in all testis: 97.3 HMP19 ENSG00000170091 HMP19 protein 5 174045604-174243501 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056191 Supported Approved Golgi apparatus Tissue enriched Tissue enriched 7 cerebral cortex: 289.3 adrenal gland: 42.2 HOGA1 C10orf65, DHDPS2, DHDPSL, FLJ37472, NPL2 ENSG00000241935 4-hydroxy-2-oxoglutarate aldolase 1 10 97584323-97612802 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA039466 Approved Renal cancer:9.08e-4 (favourable) Group enriched Tissue enhanced kidney: 53.2;liver: 20.7 adrenal gland: 8.2 HPN TMPRSS1 ENSG00000105707 Hepsin 19 35040506-35066571 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006804 Approved Renal cancer:5.45e-5 (favourable) Tissue enhanced Tissue enhanced kidney: 99.4;liver: 155.0 prostate: 27.9 HPS3 BLOC2S1, SUTAL ENSG00000163755 Hermansky-Pudlak syndrome 3 3 149129584-149173732 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046281, HPA052778 Approved Approved Golgi apparatus
Plasma membrane Renal cancer:4.38e-4 (unfavourable), Liver cancer:6.04e-4 (unfavourable) Expressed in all Mixed spleen: 22.5 HRASLS H-REV107, HRASLS1 ENSG00000127252 HRAS-like suppressor 3 193241125-193277738 Predicted membrane proteins Evidence at transcript level HPA051179 Uncertain Approved Focal adhesion sites
Cytosol Testis cancer:4.36e-4 (favourable) Mixed Group enriched 6 skeletal muscle: 27.2;testis: 95.4 thyroid gland: 10.0 HRASLS2 FLJ20556 ENSG00000133328 HRAS-like suppressor 2 11 63552770-63563383 Predicted membrane proteins Evidence at protein level HPA058997 Approved Approved Mitochondria Pancreatic cancer:5.27e-5 (unfavourable), Cervical cancer:6.87e-4 (favourable) Mixed Tissue enhanced duodenum: 69.6;small intestine: 47.5 rectum: 14.7 HRCT1 LGLL338, PRO537, UNQ338 ENSG00000196196 Histidine rich carboxyl terminus 1 9 35906192-35907141 Predicted intracellular proteins Evidence at transcript level HPA067038 Approved Nucleoplasm Liver cancer:3.62e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 18.1 colon: 13.5 HRH1 ENSG00000196639 Histamine receptor H1 3 11137093-11263557 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029740 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 12.4 HRH2 ENSG00000113749 Histamine receptor H2 5 175658030-175686242 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013770 Approved Tissue enhanced Tissue enhanced bone marrow: 26.4 placenta: 17.9 HRH4 AXOR35, GPCR105, GPRv53, H4R, HH4R ENSG00000134489 Histamine receptor H4 18 24460629-24479957 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA035009 Uncertain Not detected Not detected skin: 0.7 HRK DP5 ENSG00000135116 Harakiri, BCL2 interacting protein 12 116856144-116881441 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025973 Uncertain Mixed Group enriched 9 cerebral cortex: 13.4;thyroid gland: 6.4 testis: 1.1 HS3ST2 3OST2 ENSG00000122254 Heparan sulfate (glucosamine) 3-O-sulfotransferase 2 16 22814177-22916338 Enzymes, Predicted intracellular proteins Evidence at protein level HPA017736 Approved Renal cancer:1.35e-4 (favourable), Glioma:2.22e-4 (unfavourable) Mixed Tissue enriched 30 cerebral cortex: 35.8 lung: 1.1 HS3ST3A1 30ST3A1, 3OST3A1 ENSG00000153976 Heparan sulfate (glucosamine) 3-O-sulfotransferase 3A1 17 13495689-13601927 Enzymes, Predicted intracellular proteins Evidence at protein level HPA062518, HPA071530 Uncertain Approved Microtubules Mixed Tissue enhanced spleen: 9.3 seminal vesicle: 6.7 HS3ST3B1 30ST3B1, 3OST3B1 ENSG00000125430 Heparan sulfate (glucosamine) 3-O-sulfotransferase 3B1 17 14301083-14349404 Enzymes, Predicted intracellular proteins Evidence at protein level HPA064126 Approved Vesicles Mixed Tissue enhanced liver: 14.7 lymph node: 7.2 HS6ST2 ENSG00000171004 Heparan sulfate 6-O-sulfotransferase 2 X 132626016-132961395 Predicted membrane proteins Evidence at protein level HPA034625, HPA034626 Uncertain Validated Nucleoplasm Urothelial cancer:6.03e-4 (favourable) Mixed Tissue enhanced kidney: 14.9;ovary: 17.6 placenta: 11.9 HS6ST3 ENSG00000185352 Heparan sulfate 6-O-sulfotransferase 3 13 96090839-96839562 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA051513 Approved Nucleus
Nucleoli fibrillar center Renal cancer:6.12e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 27.8 urinary bladder: 6.2 HSD11B1 HSD11, HSD11B, SDR26C1 ENSG00000117594 Hydroxysteroid (11-beta) dehydrogenase 1 1 209686178-209734950 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA047729 Supported Renal cancer:1.97e-10 (unfavourable) Tissue enriched Group enriched 9 liver: 491.1;placenta: 104.6 ovary: 31.5 HSD11B1L SCDR10, SDR26C2 ENSG00000167733 Hydroxysteroid (11-beta) dehydrogenase 1-like 19 5680604-5688523 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA049078 Approved Vesicles Head and neck cancer:4.38e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 25.7 fallopian tube: 8.0 HSD11B2 SDR9C3 ENSG00000176387 Hydroxysteroid (11-beta) dehydrogenase 2 16 67430652-67437553 Disease related genes, Predicted membrane proteins Evidence at protein level CAB032443, HPA042186, HPA056385 Supported Approved Vesicles Renal cancer:9.51e-5 (favourable) Expressed in all Tissue enhanced colon: 154.2;kidney: 172.7 salivary gland: 123.5 HSD17B12 KAR, SDR12C1 ENSG00000149084 Hydroxysteroid (17-beta) dehydrogenase 12 11 43556436-43856617 Enzymes, Predicted membrane proteins Evidence at protein level HPA016427 Approved Renal cancer:2.10e-8 (favourable), Liver cancer:2.76e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 205.0 HSD17B14 DHRS10, retSDR3, SDR47C1 ENSG00000087076 Hydroxysteroid (17-beta) dehydrogenase 14 19 48813017-48836678 Predicted intracellular proteins Evidence at protein level HPA021467 Approved Pancreatic cancer:2.87e-5 (favourable), Colorectal cancer:4.39e-5 (unfavourable) Expressed in all Mixed kidney: 53.1 HSD17B2 HSD17, SDR9C2 ENSG00000086696 Hydroxysteroid (17-beta) dehydrogenase 2 16 82035004-82098534 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021826, HPA050235 Supported Approved Endoplasmic reticulum Urothelial cancer:3.83e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 443.2;placenta: 548.0 small intestine: 204.1 HSD17B7 PRAP, SDR37C1 ENSG00000132196 Hydroxysteroid (17-beta) dehydrogenase 7 1 162790702-162812817 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047496 Approved Renal cancer:8.47e-5 (unfavourable) Expressed in all Mixed liver: 17.2 HSD3B1 HSD3B, HSDB3, SDR11E1 ENSG00000203857 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 1 1 119507198-119515054 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Urothelial cancer:4.59e-5 (favourable) Tissue enhanced Tissue enriched 12 placenta: 110.1 small intestine: 8.9 HSD3B2 SDR11E2 ENSG00000203859 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 2 1 119414931-119423035 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043261, HPA043264, HPA044028 Supported Tissue enhanced Tissue enriched 436 adrenal gland: 2394.6 testis: 5.4 HSD3B7 C(27)-3BETA-HSD, SDR11E3 ENSG00000099377 Hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 16 30985207-30989152 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050521, HPA060847 Uncertain Supported Lipid droplets Renal cancer:1.60e-6 (unfavourable), Colorectal cancer:5.95e-4 (unfavourable) Expressed in all Expressed in all liver: 21.9 HTATIP2 CC3, FLJ26963, SDR44U1, TIP30 ENSG00000109854 HIV-1 Tat interactive protein 2, 30kDa 11 20363685-20383783 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006417, HPA024321 Approved Supported Cytosol Liver cancer:2.86e-4 (unfavourable), Pancreatic cancer:6.18e-4 (unfavourable), Renal cancer:8.01e-4 (unfavourable) Expressed in all Expressed in all duodenum: 139.0 HTR1A 5-HT1A, ADRB2RL1, ADRBRL1 ENSG00000178394 5-hydroxytryptamine (serotonin) receptor 1A, G protein-coupled 5 63960356-63962507 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018073 Uncertain Not detected Group enriched 10 cerebral cortex: 1.9;ovary: 3.9 testis: 0.2 HTR1B 5-HT1B, 5-HT1DB, HTR1D2, S12 ENSG00000135312 5-hydroxytryptamine (serotonin) receptor 1B, G protein-coupled 6 77462205-77463464 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA028808 Approved Uncertain Plasma membrane Mixed Tissue enhanced placenta: 13.7;stomach: 5.8 cerebral cortex: 2.8 HTR1E 5-HT1E ENSG00000168830 5-hydroxytryptamine (serotonin) receptor 1E, G protein-coupled 6 86937306-87016683 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA004931 Approved Not detected Tissue enhanced endometrium: 2.4;ovary: 4.9 cerebral cortex: 1.9 HTR1F 5-HT1F, HTR1EL ENSG00000179097 5-hydroxytryptamine (serotonin) receptor 1F, G protein-coupled 3 87990696-87993835 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA005555 Uncertain Not detected Tissue enhanced placenta: 2.7 cerebral cortex: 1.0 HTR2A 5-HT2A, HTR2 ENSG00000102468 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled 13 46831550-46897076 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014011 Supported Not detected Tissue enriched 8 cerebral cortex: 32.3 smooth muscle: 3.8 HTR2B 5-HT(2B), 5-HT2B ENSG00000135914 5-hydroxytryptamine (serotonin) receptor 2B, G protein-coupled 2 231108230-231125118 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB011448, HPA012867, HPA063658 Approved Approved Nucleoplasm Mixed Tissue enhanced cervix, uterine: 31.1;endometrium: 30.0;smooth muscle: 23.0 adrenal gland: 19.1 HTR3B 5-HT3B ENSG00000149305 5-hydroxytryptamine (serotonin) receptor 3B, ionotropic 11 113904677-113946565 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039559 Approved Not detected Tissue enhanced cerebral cortex: 2.8 testis: 1.1 HTR3E ENSG00000186038 5-hydroxytryptamine (serotonin) receptor 3E, ionotropic 3 184097064-184106995 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049764 Supported Not detected Tissue enhanced duodenum: 1.0 small intestine: 0.8 HTR4 5-HT4 ENSG00000164270 5-hydroxytryptamine (serotonin) receptor 4, G protein-coupled 5 148451032-148677235 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040591 Approved Not detected Tissue enhanced duodenum: 5.0;small intestine: 10.2 heart muscle: 3.5 HTR5A 5-HT5A ENSG00000157219 5-hydroxytryptamine (serotonin) receptor 5A, G protein-coupled 7 155070324-155085749 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level CAB017467 Approved Not detected Tissue enriched 11 cerebral cortex: 8.6 testis: 0.7 HTR7 5-HT7 ENSG00000148680 5-hydroxytryptamine (serotonin) receptor 7, adenylate cyclase-coupled 10 90740823-90857698 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB022708 Uncertain Supported Nuclear speckles
Plasma membrane
Cytosol Group enriched Group enriched 8 parathyroid gland: 43.9;testis: 16.0 urinary bladder: 3.9 HTRA2 OMI, PARK13, PRSS25 ENSG00000115317 HtrA serine peptidase 2 2 74529377-74533348 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB004004, HPA006602, HPA027366 Uncertain Supported Mitochondria Liver cancer:7.77e-8 (unfavourable) Expressed in all Mixed spleen: 9.2 HTT HD, IT15 ENSG00000197386 Huntingtin 4 3074681-3243959 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002756, HPA026114 Supported Supported Nucleoplasm
Cytosol Renal cancer:2.41e-12 (favourable), Head and neck cancer:3.26e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 26.8 HUWE1 Ib772, KIAA0312, UREB1 ENSG00000086758 HECT, UBA and WWE domain containing 1, E3 ubiquitin protein ligase X 53532096-53686729 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002548, CAB022718 Approved Validated Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 94.8 HVCN1 Hv1, MGC15619, VSOP ENSG00000122986 Hydrogen voltage gated channel 1 12 110627841-110704950 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039329 Approved Expressed in all Mixed testis: 82.3 HYAL4 ENSG00000106302 Hyaluronoglucosaminidase 4 7 123828983-123877478 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029453 Uncertain Tissue enriched Tissue enhanced placenta: 5.9;testis: 4.0 epididymis: 2.1 ICA1 ICAp69 ENSG00000003147 Islet cell autoantigen 1, 69kDa 7 8113184-8262687 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017646, HPA061452 Approved Supported Vesicles
Cytosol Renal cancer:4.23e-8 (favourable) Expressed in all Mixed testis: 42.6 ICAM1 BB2, CD54 ENSG00000090339 Intercellular adhesion molecule 1 19 10270835-10286615 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA002126, CAB002142, HPA004877 Supported Uncertain Plasma membrane
Cytosol Renal cancer:1.32e-6 (unfavourable), Breast cancer:7.09e-4 (favourable) Expressed in all Expressed in all lung: 256.0 ICAM2 CD102 ENSG00000108622 Intercellular adhesion molecule 2 17 64002594-64020634 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071155 Uncertain Cytosol Expressed in all Expressed in all spleen: 203.8 ICAM3 CD50, CDW50, ICAM-R ENSG00000076662 Intercellular adhesion molecule 3 19 10333776-10339823 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002498, HPA049820 Supported Approved Nucleus
Nuclear membrane
Mitochondria Mixed Expressed in all bone marrow: 112.2 ICAM4 CD242, LW ENSG00000105371 Intercellular adhesion molecule 4 (Landsteiner-Wiener blood group) 19 10286967-10288522 Blood group antigen proteins, CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA067629 Approved Nuclear speckles Not detected Tissue enhanced epididymis: 10.3;lung: 14.6 bone marrow: 8.8 ICAM5 TLCN, TLN ENSG00000105376 Intercellular adhesion molecule 5, telencephalin 19 10289981-10296778 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008943, HPA009083, CAB025178 Supported Approved Nucleoplasm Tissue enhanced Tissue enriched 10 cerebral cortex: 21.6 lung: 2.0 ICMT HSTE14, PCCMT, PPMT ENSG00000116237 Isoprenylcysteine carboxyl methyltransferase 1 6221193-6235972 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA032024, HPA032025 Uncertain Liver cancer:1.79e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 45.0 ICOS AILIM, CD278 ENSG00000163600 Inducible T-cell co-stimulator 2 203936748-203961577 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB032575 Approved Head and neck cancer:1.80e-4 (favourable) Mixed Tissue enhanced lymph node: 17.1;tonsil: 15.4 bone marrow: 10.9 ICOSLG B7-H2, B7H2, B7RP-1, B7RP1, CD275, GL50, ICOS-L, ICOSL, KIAA0653 ENSG00000160223 Inducible T-cell co-stimulator ligand 21 44222991-44240966 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB026037 Uncertain Supported Mitochondria Not detected Mixed bone marrow: 10.3 IER3IP1 ENSG00000134049 Immediate early response 3 interacting protein 1 18 47152998-47176374 Disease related genes, Predicted membrane proteins Evidence at protein level HPA010027 Supported Supported Endoplasmic reticulum Liver cancer:6.47e-6 (unfavourable), Ovarian cancer:8.59e-4 (favourable) Expressed in all Expressed in all kidney: 33.8 IFI27 FAM14D, ISG12, P27 ENSG00000165949 Interferon, alpha-inducible protein 27 14 94104836-94116698 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028875 Uncertain Ovarian cancer:8.80e-4 (favourable) Expressed in all Expressed in all spleen: 743.8 IFI6 6-16, FAM14C, G1P3, IFI-6-16, IFI616 ENSG00000126709 Interferon, alpha-inducible protein 6 1 27666061-27672218 Predicted membrane proteins Evidence at transcript level HPA005543 Approved Approved Mitochondria Expressed in all Expressed in all placenta: 412.1 IFITM1 9-27, CD225, IFI17 ENSG00000185885 Interferon induced transmembrane protein 1 11 313506-315272 CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004810, CAB017615 Supported Supported Cytosol Renal cancer:5.77e-9 (unfavourable) Expressed in all Expressed in all epididymis: 904.7 IFITM2 1-8D ENSG00000185201 Interferon induced transmembrane protein 2 11 307631-315272 Predicted membrane proteins, Transporters Evidence at protein level HPA004337 Uncertain Renal cancer:2.37e-9 (unfavourable) Expressed in all Expressed in all appendix: 722.4 IFITM3 1-8U ENSG00000142089 Interferon induced transmembrane protein 3 11 319669-327537 Predicted membrane proteins, Transporters Evidence at protein level HPA004337 Uncertain Renal cancer:5.78e-7 (unfavourable) Expressed in all Expressed in all fallopian tube: 1027.4 IFITM5 BRIL, fragilis4, Hrmp1 ENSG00000206013 Interferon induced transmembrane protein 5 11 298200-299526 Disease related genes, Predicted membrane proteins Evidence at protein level HPA039258 Uncertain Mixed Tissue enhanced epididymis: 1.1 bone marrow: 0.5 IFNAR1 IFNAR, IFRC ENSG00000142166 Interferon (alpha, beta and omega) receptor 1 21 33324477-33359862 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018015, HPA029226 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 60.2 IFNAR2 IFNABR ENSG00000159110 Interferon (alpha, beta and omega) receptor 2 21 33229901-33265675 Cancer-related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025889 Approved Renal cancer:7.54e-7 (unfavourable) Expressed in all Expressed in all spleen: 59.7 IFNGR1 CD119, IFNGR ENSG00000027697 Interferon gamma receptor 1 6 137197484-137219449 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029213, HPA063871 Approved Supported Endoplasmic reticulum
Vesicles
Plasma membrane Renal cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all spleen: 225.2 IFNGR2 AF-1, IFNGT1 ENSG00000159128 Interferon gamma receptor 2 (interferon gamma transducer 1) 21 33402896-33479348 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA001535 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:1.13e-10 (unfavourable), Liver cancer:3.25e-4 (unfavourable) Expressed in all Mixed spleen: 10.3 IFNLR1 CRF2/12, IFNLR, IL-28R1, IL28RA ENSG00000185436 Interferon, lambda receptor 1 1 24154157-24187959 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017319 Uncertain Approved Cytosol Breast cancer:5.12e-4 (favourable) Expressed in all Mixed small intestine: 10.3 IFRD1 PC4, TIS7 ENSG00000006652 Interferon-related developmental regulator 1 7 112422968-112481017 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024122 Approved Approved Plasma membrane
Cytosol Ovarian cancer:5.45e-4 (favourable) Expressed in all Expressed in all bone marrow: 130.1 IGDCC3 HsT18880, PUNC ENSG00000174498 Immunoglobulin superfamily, DCC subclass, member 3 15 65327127-65378040 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA015246 Approved Tissue enhanced Group enriched 5 cerebral cortex: 3.3;parathyroid gland: 14.4;placenta: 8.5;testis: 5.2 thyroid gland: 1.5 IGDCC4 LOC57722, NOPE ENSG00000103742 Immunoglobulin superfamily, DCC subclass, member 4 15 65381464-65423072 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008510, HPA008576 Approved Approved Approved Nucleoplasm
Cytosol Tissue enhanced Mixed ovary: 8.9 IGF1R CD221, IGFIR, IGFR, JTK13, MGC18216 ENSG00000140443 Insulin-like growth factor 1 receptor 15 98648971-98964530 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB010268, HPA045563 Uncertain Uncertain Vesicles Renal cancer:3.75e-7 (favourable) Expressed in all Mixed prostate: 24.7 IGF2 C11orf43, FLJ44734, IGF-II ENSG00000167244 Insulin-like growth factor 2 11 2129112-2141238 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007556, HPA007993 Supported Approved Nucleoplasm
Vesicles Liver cancer:7.12e-4 (favourable) Group enriched Tissue enriched 18 placenta: 3974.6 fallopian tube: 220.1 IGF2R CD222, CIMPR, M6P-R, MPR1, MPRI ENSG00000197081 Insulin-like growth factor 2 receptor 6 159969099-160113507 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009661, HPA011332 Supported Validated Golgi apparatus
Vesicles Cervical cancer:2.92e-5 (unfavourable), Breast cancer:3.01e-4 (unfavourable), Urothelial cancer:6.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 49.5 IGFBP2 IBP2 ENSG00000115457 Insulin-like growth factor binding protein 2, 36kDa 2 216632828-216664436 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA077723 Approved Endoplasmic reticulum Renal cancer:2.22e-5 (unfavourable), Melanoma:2.43e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 276.7 IGFLR1 FLJ22573, TMEM149, U2AF1L4 ENSG00000126246 IGF-like family receptor 1 19 35738801-35742453 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012369 Uncertain Approved Focal adhesion sites Ovarian cancer:1.59e-5 (favourable), Cervical cancer:6.55e-4 (favourable) Expressed in all Mixed lymph node: 38.0 IGLL1 14.1, CD179B, IGL5, IGLL, IGVPB ENSG00000128322 Immunoglobulin lambda-like polypeptide 1 22 23573125-23580308 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA051134, HPA071406 Approved Approved Endoplasmic reticulum Tissue enhanced Group enriched 17 bone marrow: 44.3;testis: 16.1 tonsil: 1.7 IGSF1 IGCD1, IGDC1, INHBP, KIAA0364, MGC75490, PGSF2 ENSG00000147255 Immunoglobulin superfamily, member 1 X 131273506-131578899 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035582 Supported Approved Cytosol Endometrial cancer:4.25e-8 (unfavourable) Tissue enriched Tissue enhanced testis: 19.9 adrenal gland: 13.2 IGSF11 BT-IgSF, CT119, Igsf13, MGC35227, VSIG3 ENSG00000144847 Immunoglobulin superfamily, member 11 3 118900557-119146068 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046377 Uncertain Approved Nucleus
Cell Junctions
Cytosol Group enriched Tissue enhanced cerebral cortex: 31.1;testis: 64.7 ovary: 20.0 IGSF23 ENSG00000216588 Immunoglobulin superfamily, member 23 19 44613630-44636781 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051811, HPA054591 Uncertain Approved Nucleus
Cell Junctions Liver cancer:7.20e-6 (favourable) Tissue enriched Group enriched 7 duodenum: 15.6;liver: 13.1;small intestine: 17.8 testis: 2.3 IGSF3 EWI-3, MGC117164, V8 ENSG00000143061 Immunoglobulin superfamily, member 3 1 116574399-116667755 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036305, HPA036306 Approved Approved Nucleoplasm
Cytosol Renal cancer:2.87e-6 (favourable), Liver cancer:4.03e-6 (unfavourable), Endometrial cancer:1.98e-4 (unfavourable), Pancreatic cancer:2.03e-4 (unfavourable) Expressed in all Mixed skin: 21.6 IGSF6 DORA ENSG00000140749 Immunoglobulin superfamily, member 6 16 21639537-21652660 Predicted membrane proteins Evidence at protein level HPA041023, HPA041072 Uncertain Endometrial cancer:1.54e-5 (favourable), Cervical cancer:4.92e-4 (favourable) Expressed in all Tissue enhanced spleen: 64.7 appendix: 37.2 IGSF8 CD316, CD81P3, EWI2, PGRL ENSG00000162729 Immunoglobulin superfamily, member 8 1 160091340-160098943 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011917 Uncertain Cervical cancer:7.32e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 108.1 IGSF9 IGSF9A, KIAA1355, Nrt1 ENSG00000085552 Immunoglobulin superfamily, member 9 1 159927039-159945604 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA037753 Uncertain Endometrial cancer:5.16e-4 (unfavourable) Mixed Tissue enhanced skin: 28.2 stomach: 13.4 IGSF9B KIAA1030 ENSG00000080854 Immunoglobulin superfamily, member 9B 11 133908564-133956985 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA010744, HPA010802 Uncertain Approved Cytosol Mixed Mixed cerebral cortex: 9.0 IKBIP FLJ31051, IKIP ENSG00000166130 IKBKB interacting protein 12 98613405-98645113 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038677, HPA038678, HPA061541 Approved Validated Endoplasmic reticulum Renal cancer:4.60e-9 (unfavourable), Liver cancer:4.00e-5 (unfavourable) Expressed in all Mixed placenta: 36.3 IL10RB CDW210B, CRF2-4, CRFB4, D21S58, D21S66, IL-10R2 ENSG00000243646 Interleukin 10 receptor, beta 21 33266358-33297234 CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB020670, HPA047550 Approved Approved Cytosol Renal cancer:5.62e-9 (unfavourable) Expressed in all Expressed in all placenta: 89.0 IL11RA ENSG00000137070 Interleukin 11 receptor, alpha 9 34650702-34661892 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013162, CAB032830, HPA036652 Supported Renal cancer:6.56e-4 (unfavourable) Expressed in all Expressed in all skin: 72.6 IL12RB1 CD212, IL12RB ENSG00000096996 Interleukin 12 receptor, beta 1 19 18058995-18098944 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074414 Approved Plasma membrane Renal cancer:5.90e-5 (unfavourable), Cervical cancer:3.41e-4 (favourable) Mixed Tissue enhanced lymph node: 26.3 spleen: 21.1 IL12RB2 ENSG00000081985 Interleukin 12 receptor, beta 2 1 67307364-67396900 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA024168 Uncertain Uncertain Plasma membrane
Cytosol Tissue enhanced Tissue enhanced placenta: 11.7 cerebral cortex: 4.5 IL13RA1 CD213a1, IL-13Ra, NR4 ENSG00000131724 Interleukin 13 receptor, alpha 1 X 118727572-118794539 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA000293, HPA001795 Approved Nucleoplasm
Golgi apparatus Renal cancer:1.19e-8 (unfavourable) Expressed in all Expressed in all lung: 72.1 IL13RA2 CD213a2, CT19, IL-13R, IL13BP ENSG00000123496 Interleukin 13 receptor, alpha 2 X 115003975-115019977 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA055552 Approved Nucleus
Nucleoli Liver cancer:3.55e-4 (favourable) Tissue enhanced Tissue enriched 8 testis: 52.5 prostate: 6.5 IL15RA CD215, IL-15RA ENSG00000134470 Interleukin 15 receptor, alpha 10 5937569-5978187 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026215 Approved Uncertain Plasma membrane
Cytosol Renal cancer:1.27e-12 (unfavourable), Liver cancer:2.67e-6 (unfavourable), Pancreatic cancer:5.35e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.5 IL17RA CD217, CDw217, hIL-17R, IL-17RA, IL17R ENSG00000177663 Interleukin 17 receptor A 22 17084954-17115694 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB024996 Supported Approved Nucleoplasm
Cytosol Stomach cancer:8.35e-4 (favourable) Expressed in all Mixed bone marrow: 20.7 IL17RB CRL4, EVI27, IL17BR, IL17RH1 ENSG00000056736 Interleukin 17 receptor B 3 53846580-53865800 Predicted membrane proteins Evidence at protein level HPA005482 Supported Renal cancer:6.61e-4 (favourable) Expressed in all Tissue enhanced kidney: 62.4 cervix, uterine: 32.2 IL17RC IL17-RL ENSG00000163702 Interleukin 17 receptor C 3 9917074-9933630 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019885, CAB026255, HPA048514 Approved Uncertain Microtubules
Centrosome Endometrial cancer:1.38e-4 (favourable) Expressed in all Expressed in all prostate: 21.3 IL17RD FLJ35755, IL-17RD, IL17RLM, SEF ENSG00000144730 Interleukin 17 receptor D 3 57089982-57170306 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039577, HPA043550 Approved Supported Nucleoplasm
Golgi apparatus Renal cancer:2.92e-9 (favourable) Mixed Mixed parathyroid gland: 26.3 IL17RE FLJ23658 ENSG00000163701 Interleukin 17 receptor E 3 9902612-9916402 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019011 Uncertain Expressed in all Mixed small intestine: 23.1 IL18R1 CD218a, IL-1Rrp, IL1RRP ENSG00000115604 Interleukin 18 receptor 1 2 102311529-102398775 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007615 Approved Approved Mitochondria Renal cancer:4.52e-4 (unfavourable) Mixed Mixed placenta: 14.3 IL18RAP AcPL, CD218b ENSG00000115607 Interleukin 18 receptor accessory protein 2 102418689-102452565 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025270 Supported Mixed Tissue enhanced bone marrow: 71.0 appendix: 17.3 IL1R1 CD121A, D2S1473, IL1R, IL1RA ENSG00000115594 Interleukin 1 receptor, type I 2 102064544-102179874 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001237, HPA005823, CAB007779, HPA029560 Approved Validated Vesicles Renal cancer:6.92e-6 (unfavourable) Expressed in all Expressed in all cervix, uterine: 244.6 IL1R2 CD121b, IL1RB ENSG00000115590 Interleukin 1 receptor, type II 2 101991844-102028544 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027597, HPA027598 Approved Renal cancer:5.58e-12 (unfavourable) Mixed Mixed appendix: 51.2 IL1RAP C3orf13, IL-1RAcP, IL1R3 ENSG00000196083 Interleukin 1 receptor accessory protein 3 190514051-190659750 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035293 Uncertain Approved Vesicles
Cytosol Renal cancer:2.16e-7 (unfavourable), Pancreatic cancer:1.31e-4 (unfavourable), Urothelial cancer:6.29e-4 (unfavourable) Expressed in all Tissue enhanced liver: 112.5;placenta: 53.2 gallbladder: 19.9 IL1RAPL2 IL-1R9, IL1R9, IL1RAPL-2, TIGIRR-1 ENSG00000189108 Interleukin 1 receptor accessory protein-like 2 X 104566315-105767829 Predicted membrane proteins Evidence at protein level HPA036128, HPA036129 Uncertain Not detected Tissue enhanced parathyroid gland: 4.7 adrenal gland: 1.9 IL1RL1 DER4, FIT-1, IL33R, ST2, ST2L, ST2V, T1 ENSG00000115602 Interleukin 1 receptor-like 1 2 102311502-102352037 Candidate cardiovascular disease genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007406, HPA007917 Uncertain Approved Vesicles Tissue enhanced Tissue enriched 12 placenta: 286.6 gallbladder: 23.8 IL1RL2 IL1R-rp2, IL1RRP2 ENSG00000115598 Interleukin 1 receptor-like 2 2 102186973-102240002 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015485 Uncertain Mixed Tissue enhanced skin: 15.5 parathyroid gland: 8.3 IL20RA IL-20R1, ZCYTOR7 ENSG00000016402 Interleukin 20 receptor, alpha 6 136999971-137045180 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB024990, HPA042281 Approved Approved Cytosol Endometrial cancer:1.43e-6 (favourable), Head and neck cancer:2.29e-5 (favourable) Mixed Tissue enhanced skin: 45.1 breast: 33.2 IL21R CD360 ENSG00000103522 Interleukin 21 receptor 16 27402162-27452042 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA042296 Uncertain Uncertain Plasma membrane
Cytosol Head and neck cancer:7.29e-4 (favourable) Mixed Tissue enhanced appendix: 16.4;lymph node: 29.2;tonsil: 18.0 spleen: 7.7 IL22RA1 CRF2-9, IL22R ENSG00000142677 Interleukin 22 receptor, alpha 1 1 24119771-24143121 Predicted membrane proteins Evidence at protein level HPA042399 Approved Mixed Group enriched 5 colon: 11.5;duodenum: 20.8;esophagus: 10.2;pancreas: 26.0;rectum: 11.1;skin: 38.8;small intestine: 32.0 gallbladder: 4.0 IL23R IL-23R ENSG00000162594 Interleukin 23 receptor 1 67166400-67259979 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056427 Uncertain Not detected Tissue enhanced adrenal gland: 2.1;testis: 2.2 rectum: 0.9 IL27RA CRL1, IL-27R, TCCR, WSX-1, WSX1, zcytor1 ENSG00000104998 Interleukin 27 receptor, alpha 19 14031748-14053216 Predicted membrane proteins Evidence at protein level HPA047188 Approved Vesicles
Cytosol Renal cancer:2.58e-10 (unfavourable), Breast cancer:1.74e-6 (favourable) Expressed in all Mixed tonsil: 31.5 IL2RA CD25, IDDM10, IL2R ENSG00000134460 Interleukin 2 receptor, alpha 10 6010689-6062325 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002419, HPA054622 Supported Renal cancer:2.08e-9 (unfavourable) Mixed Tissue enhanced adipose tissue: 23.9;appendix: 20.4;lymph node: 20.7 tonsil: 12.5 IL2RB CD122, IL15RB ENSG00000100385 Interleukin 2 receptor, beta 22 37125838-37175054 Cancer-related genes, CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062657 Supported Renal cancer:3.50e-7 (unfavourable), Endometrial cancer:3.18e-5 (favourable), Colorectal cancer:6.76e-4 (favourable) Expressed in all Tissue enhanced spleen: 68.3 placenta: 52.4 IL2RG CD132, CIDX, IMD4, SCIDX1 ENSG00000147168 Interleukin 2 receptor, gamma X 71107404-71112108 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046641, HPA049691 Supported Approved Vesicles Renal cancer:2.28e-7 (unfavourable), Endometrial cancer:1.73e-4 (favourable) Expressed in all Tissue enhanced lymph node: 277.4;tonsil: 290.2 appendix: 188.7 IL31RA CRL, CRL3, GLM-R, Glmr, IL-31RA ENSG00000164509 Interleukin 31 receptor A 5 55851379-55922853 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051532 Approved Nucleoplasm
Vesicles Mixed Tissue enhanced testis: 3.7 bone marrow: 1.2 IL3RA CD123 ENSG00000185291 Interleukin 3 receptor, alpha (low affinity) X 1336616-1382689 CD markers, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003539, CAB018374 Approved Cervical cancer:4.27e-4 (favourable), Breast cancer:9.78e-4 (favourable) Expressed in all Expressed in all lung: 33.8 IL4R CD124 ENSG00000077238 Interleukin 4 receptor 16 27313668-27364778 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004451, HPA050124 Supported Approved Cytosol Renal cancer:1.23e-5 (unfavourable), Endometrial cancer:6.43e-4 (favourable) Expressed in all Expressed in all lymph node: 139.5 IL6ST CD130, GP130 ENSG00000134352 Interleukin 6 signal transducer 5 55935095-55994993 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010558, CAB025784 Uncertain Supported Golgi apparatus
Plasma membrane Renal cancer:5.05e-4 (unfavourable) Expressed in all Expressed in all placenta: 327.1 IL7R CD127 ENSG00000168685 Interleukin 7 receptor 5 35852695-35879603 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010215 Approved Supported Plasma membrane Expressed in all Expressed in all appendix: 188.9 IL9R CD129 ENSG00000124334 Interleukin 9 receptor X 155997581-156010817 CD markers, Predicted membrane proteins Evidence at protein level CAB010497 Uncertain Urothelial cancer:1.90e-7 (favourable) Tissue enhanced Tissue enhanced urinary bladder: 8.8 lymph node: 2.9 ILDR1 DFNB42, MGC50831 ENSG00000145103 Immunoglobulin-like domain containing receptor 1 3 121987323-122022204 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018207 Approved Renal cancer:5.79e-9 (favourable) Mixed Tissue enhanced parathyroid gland: 34.7 cervix, uterine: 20.0 ILDR2 C1orf32 ENSG00000143195 Immunoglobulin-like domain containing receptor 2 1 166895711-166975482 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012545 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 11.4;testis: 17.4 kidney: 3.0 ILVBL 209L8, AHAS, FLJ39061, ILV2H, MGC1269, MGC19535 ENSG00000105135 IlvB (bacterial acetolactate synthase)-like 19 15114984-15125785 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067682 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.91e-8 (favourable), Endometrial cancer:1.52e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 80.0 IMPAD1 FLJ20421, gPAPP, IMPA3 ENSG00000104331 Inositol monophosphatase domain containing 1 8 56957933-56993844 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009411 Supported Supported Nucleus
Golgi apparatus
Cytosol Expressed in all Expressed in all parathyroid gland: 51.8 IMPG2 IPM200, RP56 ENSG00000081148 Interphotoreceptor matrix proteoglycan 2 3 101222546-101320560 Disease related genes, Predicted membrane proteins Evidence at protein level HPA008779, HPA015907 Supported Tissue enriched Tissue enriched 44 fallopian tube: 15.5 appendix,lymph node,spleen: 0.3 INAFM1 PRR24 ENSG00000257704 InaF-motif containing 1 19 47274453-47275707 Predicted intracellular proteins Evidence at transcript level HPA064015 Uncertain Colorectal cancer:3.20e-5 (unfavourable), Renal cancer:3.04e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 23.4 INHBE activin, MGC4638 ENSG00000139269 Inhibin, beta E 12 57452323-57459280 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA016843, CAB034017 Supported Approved Vesicles Renal cancer:5.66e-8 (unfavourable) Tissue enriched Tissue enriched 28 liver: 68.1 thyroid gland: 2.4 INO80C C18orf37, FLJ38183, hIes6, IES6 ENSG00000153391 INO80 complex subunit C 18 35452230-35497991 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049060 Approved Supported Nucleoli fibrillar center Endometrial cancer:2.62e-5 (unfavourable), Cervical cancer:3.58e-4 (favourable) Expressed in all Expressed in all testis: 165.6 INPP4A INPP4 ENSG00000040933 Inositol polyphosphate-4-phosphatase type I A 2 98444854-98594390 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001628 Approved Approved Nucleus
Nuclear membrane Endometrial cancer:3.70e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 38.8 INPP4B ENSG00000109452 Inositol polyphosphate-4-phosphatase type II B 4 142023160-142847432 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037681, HPA037682 Approved Approved Centrosome Pancreatic cancer:1.03e-4 (unfavourable) Mixed Mixed testis: 33.1 INPP5J INPP5, PIB5PA ENSG00000185133 Inositol polyphosphate-5-phosphatase J 22 31122731-31134696 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034539 Approved Nucleoli
Cytosol Renal cancer:1.12e-7 (favourable), Lung cancer:1.47e-5 (favourable) Tissue enriched Group enriched 10 parathyroid gland: 211.5;thyroid gland: 241.2 small intestine: 22.8 INSIG1 CL-6, MGC1405 ENSG00000186480 Insulin induced gene 1 7 155297776-155310235 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA071524 Approved Vesicles Thyroid cancer:9.62e-4 (unfavourable) Expressed in all Expressed in all liver: 281.1 INSIG2 ENSG00000125629 Insulin induced gene 2 2 118088452-118110997 Predicted membrane proteins Evidence at protein level CAB033861 Uncertain Pancreatic cancer:2.19e-6 (unfavourable), Renal cancer:4.11e-6 (unfavourable), Head and neck cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 27.9 INSR CD220 ENSG00000171105 Insulin receptor 19 7112255-7294034 CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA036302, HPA036303 Uncertain Supported Vesicles Expressed in all Expressed in all ovary,spleen: 35.4 INSRR IRR ENSG00000027644 Insulin receptor-related receptor 1 156840063-156859018 Enzymes, Predicted membrane proteins Evidence at protein level HPA025285 Uncertain Not detected Tissue enhanced adrenal gland: 1.8;kidney: 1.4;testis: 2.2 prostate: 0.6 INTS1 DKFZp586J0619, INT1, KIAA1440, NET28 ENSG00000164880 Integrator complex subunit 1 7 1470277-1504367 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021658, HPA053009 Approved Approved Nucleoplasm Liver cancer:1.66e-4 (unfavourable), Pancreatic cancer:4.83e-4 (favourable) Expressed in all Expressed in all testis: 41.9 INTS2 INT2, KIAA1287 ENSG00000108506 Integrator complex subunit 2 17 61865367-61928016 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049524 Uncertain Approved Nucleoplasm Thyroid cancer:2.20e-4 (unfavourable), Liver cancer:4.37e-4 (unfavourable) Expressed in all Mixed parathyroid gland,testis: 11.4 INTS5 INT5, KIAA1698 ENSG00000185085 Integrator complex subunit 5 11 62646848-62653302 Predicted membrane proteins Evidence at protein level HPA056915 Uncertain Supported Nucleus Renal cancer:8.44e-5 (favourable) Expressed in all Expressed in all fallopian tube: 21.1 INTS7 C1orf73, DKFZP434B168, INT7 ENSG00000143493 Integrator complex subunit 7 1 211940399-212035542 Predicted intracellular proteins Evidence at protein level HPA048769 Supported Nucleus
Nuclear speckles Renal cancer:1.42e-5 (unfavourable) Expressed in all Tissue enhanced testis: 38.6 thyroid gland: 11.1 IPO8 IMP8, RANBP8 ENSG00000133704 Importin 8 12 30628988-30695986 Predicted intracellular proteins, Transporters Evidence at protein level HPA018439, HPA023765 Uncertain Supported Nucleus Renal cancer:8.62e-5 (favourable), Liver cancer:1.35e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 119.5 IQCH FLJ12476 ENSG00000103599 IQ motif containing H 15 67254800-67502260 Predicted intracellular proteins Evidence at protein level HPA040845 Uncertain Approved Cytosol Mixed Tissue enhanced fallopian tube: 10.7;testis: 21.0 thyroid gland: 6.9 IQSEC1 ARF-GEP100, BRAG2, GEP100, KIAA0763 ENSG00000144711 IQ motif and Sec7 domain 1 3 12897220-13073117 Predicted intracellular proteins Evidence at protein level HPA038143, HPA038144 Uncertain Approved Nucleoli
Vesicles Renal cancer:3.58e-6 (favourable), Breast cancer:3.03e-5 (unfavourable), Pancreatic cancer:9.07e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 83.6 IQSEC2 KIAA0522, MRX1 ENSG00000124313 IQ motif and Sec7 domain 2 X 53232876-53321324 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003973 Approved Vesicles Renal cancer:2.00e-4 (unfavourable), Urothelial cancer:2.38e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 30.6 parathyroid gland: 8.6 ISLR2 KIAA1465 ENSG00000167178 Immunoglobulin superfamily containing leucine-rich repeat 2 15 74100311-74138540 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012930, HPA067333 Uncertain Mixed Group enriched 5 cerebral cortex: 31.2;testis: 15.2 endometrium: 4.5 ITFG1 CDA08, LNKN-1, TIP ENSG00000129636 Integrin alpha FG-GAP repeat containing 1 16 47154387-47464149 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015590, HPA019728 Approved Approved Intermediate filaments
Aggresome Renal cancer:1.95e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 108.2 ITGA1 CD49a, VLA1 ENSG00000213949 Integrin, alpha 1 5 52787896-52959210 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA042555 Uncertain Approved Endoplasmic reticulum Renal cancer:2.24e-4 (unfavourable) Expressed in all Mixed spleen: 78.9 ITGA10 ENSG00000143127 Integrin, alpha 10 1 145891208-145910189 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA064008 Approved Endoplasmic reticulum Breast cancer:7.18e-4 (favourable) Tissue enhanced Mixed cervix, uterine: 8.1 ITGA11 HsT18964 ENSG00000137809 Integrin, alpha 11 15 68296533-68432162 Predicted membrane proteins Evidence at protein level HPA051813 Uncertain Renal cancer:3.22e-7 (unfavourable) Mixed Tissue enhanced cervix, uterine: 54.4;endometrium: 52.2;smooth muscle: 74.7 epididymis: 22.7 ITGA2 CD49B ENSG00000164171 Integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 receptor) 5 52989326-53094779 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB017690, HPA060991, HPA063556 Supported Approved Nucleus
Cytosol Pancreatic cancer:1.02e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 24.3 ITGA2B CD41, CD41B, GP2B, PPP1R93 ENSG00000005961 Integrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41) 17 44372180-44389505 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB018611, HPA031168, HPA031169, HPA031170, HPA031171 Supported Uncertain Nucleoplasm
Cell Junctions
Cytosol Mixed Tissue enhanced bone marrow: 11.2;epididymis: 28.6 testis: 4.4 ITGA3 CD49c, GAP-B3, MSK18, VCA-2, VLA3a ENSG00000005884 Integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) 17 50055968-50090481 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008572, CAB018594 Supported Supported Plasma membrane Pancreatic cancer:5.95e-5 (unfavourable), Head and neck cancer:1.36e-4 (unfavourable), Cervical cancer:6.75e-4 (unfavourable) Expressed in all Mixed lung: 99.1 ITGA4 CD49D ENSG00000115232 Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor) 2 181457202-181536187 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064041 Approved Golgi apparatus
Vesicles Renal cancer:3.08e-5 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Mixed Tissue enhanced spleen: 68.6 appendix: 51.2 ITGA5 CD49e, FNRA ENSG00000161638 Integrin, alpha 5 (fibronectin receptor, alpha polypeptide) 12 54395261-54419460 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002642, CAB009008 Supported Renal cancer:1.32e-8 (unfavourable), Cervical cancer:4.07e-6 (unfavourable), Liver cancer:2.23e-5 (unfavourable), Lung cancer:2.44e-4 (unfavourable), Head and neck cancer:2.91e-4 (unfavourable), Colorectal cancer:8.43e-4 (unfavourable), Thyroid cancer:8.89e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 482.6 ITGA6 CD49f ENSG00000091409 Integrin, alpha 6 2 172427354-172506282 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009009, HPA012696, HPA027582 Supported Renal cancer:2.35e-11 (favourable), Head and neck cancer:1.03e-4 (unfavourable) Expressed in all Expressed in all placenta: 114.3 ITGA7 ENSG00000135424 Integrin, alpha 7 12 55684568-55716043 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008427 Uncertain Approved Plasma membrane
Cytosol Urothelial cancer:9.59e-5 (unfavourable), Pancreatic cancer:1.75e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 154.2 smooth muscle: 135.5 ITGA8 ENSG00000077943 Integrin, alpha 8 10 15513949-15720125 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA003432 Approved Mixed Tissue enhanced prostate: 55.8 seminal vesicle: 40.0 ITGA9 ALPHA-RLC, ITGA4L, RLC ENSG00000144668 Integrin, alpha 9 3 37452115-37823514 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030609 Approved Approved Nucleus
Vesicles Expressed in all Mixed thyroid gland: 34.5 ITGAD ADB2, CD11d ENSG00000156886 Integrin, alpha D 16 31393312-31426505 CD markers, Predicted membrane proteins Evidence at protein level HPA026786 Uncertain Mixed Tissue enriched 5 spleen: 28.4 lymph node: 5.1 ITGAE CD103, HUMINAE ENSG00000083457 Integrin, alpha E (antigen CD103, human mucosal lymphocyte antigen 1; alpha polypeptide) 17 3714628-3801243 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026461, HPA036313 Approved Renal cancer:1.13e-8 (unfavourable), Endometrial cancer:1.04e-4 (favourable), Urothelial cancer:3.56e-4 (favourable), Pancreatic cancer:5.78e-4 (favourable) Expressed in all Tissue enhanced lung: 9.5 small intestine: 6.4 ITGAL CD11A, LFA-1 ENSG00000005844 Integrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide) 16 30472658-30523185 CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025011 Supported Renal cancer:2.69e-5 (unfavourable), Endometrial cancer:5.63e-5 (favourable), Head and neck cancer:3.34e-4 (favourable), Melanoma:5.57e-4 (favourable) Expressed in all Tissue enhanced lymph node: 80.1;spleen: 82.2 appendix: 54.3 ITGAM CD11B, CR3A, MAC-1 ENSG00000169896 Integrin, alpha M (complement component 3 receptor 3 subunit) 16 31259990-31332892 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002274, CAB025091, CAB072870 Supported Renal cancer:6.93e-5 (unfavourable), Liver cancer:3.43e-4 (unfavourable), Testis cancer:6.93e-4 (unfavourable) Expressed in all Tissue enhanced bone marrow: 130.4 appendix: 37.1 ITGAV CD51, MSK8, VNRA, VTNR ENSG00000138448 Integrin, alpha V 2 186590065-186680901 Cancer-related genes, CD markers, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002499, HPA004856 Supported Approved Focal adhesion sites
Cytosol Stomach cancer:1.05e-6 (unfavourable), Liver cancer:2.08e-4 (unfavourable), Pancreatic cancer:5.07e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 187.7 ITGAX CD11C ENSG00000140678 Integrin, alpha X (complement component 3 receptor 4 subunit) 16 31355134-31382997 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004458, HPA004723, CAB072871 Supported Renal cancer:1.37e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 59.8;spleen: 60.0 bone marrow: 30.4 ITGB1 CD29, FNRB, GPIIA, MDF2, MSK12 ENSG00000150093 Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) 10 32900319-33005792 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB003434 Approved Supported Endoplasmic reticulum
Plasma membrane
Focal adhesion sites Lung cancer:3.36e-6 (unfavourable), Cervical cancer:5.01e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 1058.2 ITGB2 CD18, LFA-1, MAC-1, MFI7 ENSG00000160255 Integrin, beta 2 (complement component 3 receptor 3 and 4 subunit) 21 44885953-44931989 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008877, HPA016894 Supported Approved Cytosol Expressed in all Expressed in all appendix: 246.8 ITGB3 CD61, GP3A, GPIIIa ENSG00000259207 Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61) 17 47253846-47311816 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027852 Supported Group enriched Tissue enhanced thyroid gland: 95.1 smooth muscle: 36.3 ITGB4 CD104 ENSG00000132470 Integrin, beta 4 17 75721328-75757818 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002422, CAB005258, HPA036348, HPA036349 Supported Supported Nucleus
Plasma membrane
Cell Junctions Pancreatic cancer:6.39e-4 (unfavourable), Lung cancer:7.18e-4 (unfavourable) Expressed in all Mixed skin: 84.4 ITGB5 ENSG00000082781 Integrin, beta 5 3 124761948-124901418 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001820, CAB022050 Approved Approved Plasma membrane
Mitochondria Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Expressed in all placenta: 116.8 ITGB6 ENSG00000115221 Integrin, beta 6 2 160099666-160271888 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023626, CAB073536 Approved Uncertain Nucleoplasm
Cell Junctions
Centrosome Pancreatic cancer:5.03e-6 (unfavourable) Mixed Tissue enhanced lung: 66.9 urinary bladder: 31.3 ITGB7 ENSG00000139626 Integrin, beta 7 12 53191318-53207307 Cancer-related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042277 Approved Plasma membrane
Cytosol Mixed Mixed spleen: 32.8 ITGB8 ENSG00000105855 Integrin, beta 8 7 20330702-20415754 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA027796, HPA027797 Approved Approved Plasma membrane
Cytosol Renal cancer:1.77e-4 (favourable) Mixed Mixed cerebral cortex: 30.9 ITM2A BRICD2A, E25A ENSG00000078596 Integral membrane protein 2A X 79360384-79367667 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002918 Uncertain Nucleoplasm Liver cancer:3.66e-6 (favourable) Expressed in all Expressed in all ovary: 219.0 ITM2B BRI, BRI2, BRICD2B, E25B, E3-16 ENSG00000136156 Integral membrane protein 2B 13 48233158-48270357 Disease related genes, Predicted membrane proteins Evidence at protein level HPA029292, HPA071992 Approved Validated Golgi apparatus
Vesicles Renal cancer:3.73e-5 (favourable) Expressed in all Expressed in all epididymis: 1826.9 ITPR1 ACV, Insp3r1, IP3R1, PPP1R94, SCA15, SCA16, SCA29 ENSG00000150995 Inositol 1,4,5-trisphosphate receptor, type 1 3 4493348-4847840 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014765, HPA016487 Approved Approved Vesicles Thyroid cancer:3.43e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 104.9 thyroid gland: 47.2 ITPR2 CFAP48, IP3R2 ENSG00000123104 Inositol 1,4,5-trisphosphate receptor, type 2 12 26336515-26833198 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059144, HPA062260 Uncertain Supported Nucleus
Endoplasmic reticulum Expressed in all Mixed parathyroid gland: 25.7 ITPR3 IP3R3 ENSG00000096433 Inositol 1,4,5-trisphosphate receptor, type 3 6 33620365-33696574 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA003915, HPA064704 Approved Uncertain Vesicles Expressed in all Mixed skin: 65.2 ITPRIPL1 KIAA1754L ENSG00000198885 Inositol 1,4,5-trisphosphate receptor interacting protein-like 1 2 96325331-96330517 Predicted membrane proteins Evidence at protein level HPA017985 Uncertain Mixed Tissue enriched 6 testis: 27.3 lymph node: 4.9 ITPRIPL2 FLJ22994, LOC162073, MGC126798, MGC126800 ENSG00000205730 Inositol 1,4,5-trisphosphate receptor interacting protein-like 2 16 19113932-19121629 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042011 Approved Centrosome Expressed in all Expressed in all skin: 27.9 ITSN1 ITSN, MGC134948, MGC134949, SH3D1A, SH3P17 ENSG00000205726 Intersectin 1 (SH3 domain protein) 21 33642400-33899861 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018007 Approved Supported Plasma membrane Expressed in all Expressed in all adipose tissue: 61.3 IYD C6orf71, DEHAL1, dJ422F24.1 ENSG00000009765 Iodotyrosine deiodinase 6 150368892-150405969 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA059627 Supported Supported Plasma membrane Liver cancer:6.22e-4 (favourable) Tissue enriched Tissue enriched 28 thyroid gland: 792.4 kidney: 27.9 IZUMO1 IZUMO, MGC34799, OBF ENSG00000182264 Izumo sperm-egg fusion 1 19 48740852-48746909 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA038104 Supported Not detected Tissue enriched 22 testis: 19.2 lung: 0.8 IZUMO2 C19orf41, MGC33947, SCRL ENSG00000161652 IZUMO family member 2 19 50152548-50163195 Predicted membrane proteins, Transporters Evidence at transcript level HPA042143 Uncertain Not detected Tissue enriched 255 testis: 55.9 skin,thyroid gland: 0.2 JAG1 AGS, AHD, AWS, CD339, HJ1, JAGL1 ENSG00000101384 Jagged 1 20 10637684-10674107 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB010343, HPA021555 Supported Supported Golgi apparatus
Plasma membrane Pancreatic cancer:4.10e-6 (unfavourable) Expressed in all Expressed in all placenta: 96.3 JAG2 ENSG00000184916 Jagged 2 14 105140981-105168824 Predicted membrane proteins Evidence at protein level CAB025481, HPA030636, HPA050567 Approved Supported Vesicles Expressed in all Tissue enhanced skin: 22.6 adipose tissue: 6.5 JAGN1 FLJ14602, GL009 ENSG00000171135 Jagunal homolog 1 3 9890554-9894349 Disease related genes, Predicted membrane proteins Evidence at protein level HPA067610 Approved Vesicles Expressed in all Expressed in all epididymis: 37.2 JAKMIP1 FLJ31564, Gababrbp, JAMIP1, MARLIN1 ENSG00000152969 Janus kinase and microtubule interacting protein 1 4 6026199-6200591 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044570 Uncertain Mixed Tissue enriched 5 cerebral cortex: 38.5 prostate: 7.4 JAKMIP2 JAMIP2, KIAA0555 ENSG00000176049 Janus kinase and microtubule interacting protein 2 5 147585439-147782848 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046929, HPA065023 Approved Supported Golgi apparatus Tissue enriched Tissue enriched 6 cerebral cortex: 32.8 testis: 5.2 JAKMIP3 bA140A10.5, C10orf14, C10orf39, FLJ37857, KIAA4091, NECC2 ENSG00000188385 Janus kinase and microtubule interacting protein 3 10 132104671-132184809 Predicted membrane proteins Evidence at protein level HPA022872 Uncertain Mixed Tissue enhanced cerebral cortex: 5.8 prostate: 2.0 JAM2 C21orf43, CD322, JAM-B, JAMB, VE-JAM ENSG00000154721 Junctional adhesion molecule 2 21 25639272-25717562 CD markers, Predicted membrane proteins Evidence at protein level HPA046547 Approved Cytosol Tissue enriched Tissue enhanced placenta: 92.1 cerebral cortex: 34.3 JAM3 JAM-C, JAMC ENSG00000166086 Junctional adhesion molecule 3 11 134068925-134152001 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003417, HPA050434 Uncertain Validated Golgi apparatus Urothelial cancer:2.68e-4 (unfavourable), Renal cancer:3.73e-4 (unfavourable) Expressed in all Expressed in all placenta: 143.3 JKAMP C14orf100, CDA06, HSPC213, HSPC327, JAMP ENSG00000050130 JNK1/MAPK8-associated membrane protein 14 59484443-59505410 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031172, HPA071650 Supported Approved Nucleoplasm
Vesicles Liver cancer:3.09e-6 (unfavourable), Renal cancer:1.36e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 74.7 JPH1 JP-1 ENSG00000104369 Junctophilin 1 8 74234700-74321328 Predicted membrane proteins Evidence at protein level HPA008996, HPA009413, CAB013461 Supported Supported Nucleus Lung cancer:5.77e-5 (favourable) Mixed Tissue enriched 10 skeletal muscle: 88.0 cerebral cortex: 8.6 JPH2 JP-2 ENSG00000149596 Junctophilin 2 20 44111695-44187578 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052646 Approved Mixed Tissue enhanced skeletal muscle: 72.1;smooth muscle: 55.4 seminal vesicle: 47.3 JPH3 CAGL237, HDL2, JP-3, JP3, TNRC22 ENSG00000154118 Junctophilin 3 16 87601835-87698156 Disease related genes, Predicted membrane proteins Evidence at protein level HPA076304 Approved Nucleoplasm
Cytosol Mixed Tissue enriched 22 cerebral cortex: 43.4 adrenal gland: 2.0 JPH4 JPHL1, KIAA1831 ENSG00000092051 Junctophilin 4 14 23568035-23578800 Predicted membrane proteins Evidence at transcript level CAB013492, HPA054232 Approved Nucleoplasm
Golgi apparatus Tissue enhanced Tissue enhanced cerebral cortex: 107.4;seminal vesicle: 51.4 endometrium: 28.0 JTB hJT ENSG00000143543 Jumping translocation breakpoint 1 153974269-153977688 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006514 Approved Approved Vesicles
Actin filaments Renal cancer:6.65e-9 (unfavourable), Ovarian cancer:7.87e-4 (favourable) Expressed in all Expressed in all epididymis: 114.3 KANSL1L C2orf67, FLJ23861, FLJ32349, KIAA1267L, MSL1v2 ENSG00000144445 KAT8 regulatory NSL complex subunit 1-like 2 210021423-210171383 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043102, HPA046790 Uncertain Approved Cytosol Expressed in all Tissue enriched 12 parathyroid gland: 575.5 testis: 46.2 KCNA1 AEMK, HUK1, Kv1.1, MBK1, RBK1 ENSG00000111262 Potassium channel, voltage gated shaker related subfamily A, member 1 12 4909905-4931361 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB022365 Uncertain Not detected Tissue enriched 6 cerebral cortex: 13.5 parathyroid gland: 2.0 KCNA10 Kv1.8 ENSG00000143105 Potassium channel, voltage gated shaker related subfamily A, member 10 1 110517251-110518838 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA015061, CAB022564 Uncertain Uncertain Nucleoplasm
Cytosol Not detected Tissue enhanced testis: 1.0 spleen: 0.2 KCNA2 HK4, Kv1.2 ENSG00000177301 Potassium channel, voltage gated shaker related subfamily A, member 2 1 110593580-110631474 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001976 Supported Tissue enhanced Tissue enriched 5 cerebral cortex: 20.7 thyroid gland: 3.8 KCNA3 HLK3, HPCN3, Kv1.3, MK3 ENSG00000177272 Potassium channel, voltage gated shaker related subfamily A, member 3 1 110672465-110675033 FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016625 Approved Mixed Mixed lymph node: 10.7 KCNA4 HK1, HPCN2, KCNA4L, Kv1.4 ENSG00000182255 Potassium channel, voltage gated shaker related subfamily A, member 4 11 30009741-30017023 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB001977, HPA016422 Approved Not detected Tissue enhanced adrenal gland: 7.9;cerebral cortex: 4.3 heart muscle: 1.2 KCNA5 HK2, HPCN1, Kv1.5 ENSG00000130037 Potassium channel, voltage gated shaker related subfamily A, member 5 12 5043989-5046788 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA021516, CAB022562 Approved Mixed Tissue enhanced heart muscle: 20.8 esophagus: 5.6 KCNA6 ENSG00000151079 Potassium voltage-gated channel subfamily A member 6 12 4809176-4813412 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level CAB011539, HPA014418 Approved Not detected Not detected appendix,duodenum,lymph node: 0.1 KCNB1 Kv2.1 ENSG00000158445 Potassium channel, voltage gated Shab related subfamily B, member 1 20 49363877-49484297 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB001979, HPA042434 Supported Mixed Tissue enhanced adipose tissue: 11.0;cerebral cortex: 21.0 fallopian tube: 7.5 KCNB2 Kv2.2 ENSG00000182674 Potassium channel, voltage gated Shab related subfamily B, member 2 8 72537391-72938349 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA065970 Approved Nucleoli
Plasma membrane
Midbody Not detected Tissue enhanced cerebral cortex: 3.2;spleen: 3.4 fallopian tube,testis: 0.7 KCNC1 Kv3.1 ENSG00000129159 Potassium channel, voltage gated Shaw related subfamily C, member 1 11 17734812-17783055 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA047634, HPA048249 Supported Approved Nucleus
Nuclear membrane
Vesicles
Cytosol Tissue enhanced Tissue enriched 8 cerebral cortex: 16.5 testis: 1.9 KCNC2 Kv3.2 ENSG00000166006 Potassium channel, voltage gated Shaw related subfamily C, member 2 12 75040077-75209868 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA019664, CAB022571 Uncertain Supported Plasma membrane
Cytosol Group enriched Tissue enriched 11 cerebral cortex: 46.5 prostate: 4.2 KCNC3 Kv3.3, SCA13 ENSG00000131398 Potassium channel, voltage gated Shaw related subfamily C, member 3 19 50311937-50333515 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA018041 Uncertain Renal cancer:1.23e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 39.3 cerebral cortex: 19.9 KCNC4 C1orf30, HKSHIIIC, Kv3.4 ENSG00000116396 Potassium channel, voltage gated Shaw related subfamily C, member 4 1 110211343-110283100 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA014740 Approved Approved Nucleoli
Cytosol Mixed Mixed cerebral cortex: 6.3 KCND1 Kv4.1 ENSG00000102057 Potassium channel, voltage gated Shal related subfamily D, member 1 X 48961378-48971569 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA000524, HPA001066 Approved Approved Nucleus Pancreatic cancer:2.66e-6 (favourable) Mixed Mixed gallbladder: 4.0 KCND2 KIAA1044, Kv4.2, RK5 ENSG00000184408 Potassium channel, voltage gated Shal related subfamily D, member 2 7 120273668-120750331 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029068 Approved Tissue enhanced Tissue enhanced cerebral cortex: 20.8 gallbladder: 6.9 KCND3 KSHIVB, Kv4.3, SCA19, SCA22 ENSG00000171385 Potassium channel, voltage gated Shal related subfamily D, member 3 1 111770662-111989155 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029452 Approved Mixed Mixed cerebral cortex: 26.8 KCNE2 LQT6, MiRP1 ENSG00000159197 Potassium channel, voltage gated subfamily E regulatory beta subunit 2 21 34364024-34371389 Disease related genes, Predicted membrane proteins Evidence at protein level HPA029706, HPA051553 Supported Tissue enriched Tissue enriched 23 stomach: 170.2 testis: 7.3 KCNE3 HOKPP, MiRP2 ENSG00000175538 Potassium channel, voltage gated subfamily E regulatory beta subunit 3 11 74454841-74467729 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014849 Approved Liver cancer:2.28e-4 (unfavourable) Expressed in all Mixed duodenum: 72.1 KCNE4 MiRP3 ENSG00000152049 Potassium channel, voltage gated subfamily E regulatory beta subunit 4 2 223051814-223198399 Predicted membrane proteins Evidence at protein level HPA011420 Approved Approved Nuclear bodies
Microtubules Renal cancer:2.02e-7 (unfavourable), Colorectal cancer:9.42e-5 (unfavourable) Expressed in all Tissue enhanced smooth muscle: 53.5 endometrium: 33.4 KCNE5 KCNE1L ENSG00000176076 Potassium channel, voltage gated subfamily E regulatory beta subunit 5 X 109623700-109625172 Disease related genes, Predicted membrane proteins Evidence at protein level HPA042316 Uncertain Uncertain Cytosol Group enriched Tissue enhanced cerebral cortex: 2.1 adipose tissue: 1.1 KCNF1 IK8, KCNF, kH1, Kv5.1 ENSG00000162975 Potassium channel, voltage gated modifier subfamily F, member 1 2 10911937-10914225 Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB004678, HPA014738 Supported Approved Golgi apparatus Tissue enriched Tissue enriched 32 cerebral cortex: 37.6 endometrium: 1.1 KCNG1 K13, KCNG, kH2, Kv6.1 ENSG00000026559 Potassium channel, voltage gated modifier subfamily G, member 1 20 51003656-51023129 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA039530, HPA040024 Approved Validated Vesicles Tissue enhanced Tissue enhanced endometrium: 23.4;seminal vesicle: 17.9 placenta: 10.8 KCNG2 KCNF2, Kv6.2 ENSG00000178342 Potassium channel, voltage gated modifier subfamily G, member 2 18 79863668-79900184 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA048628 Approved Not detected Not detected cerebral cortex: 0.4 KCNG3 Kv6.3 ENSG00000171126 Potassium channel, voltage gated modifier subfamily G, member 3 2 42442017-42494097 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA041625 Approved Cytoplasmic bodies Mixed Tissue enhanced adrenal gland: 1.2;cerebral cortex: 1.3;testis: 1.1 colon,endometrium: 0.4 KCNG4 Kv6.4 ENSG00000168418 Potassium channel, voltage gated modifier subfamily G, member 4 16 84218667-84239750 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA039161 Uncertain Not detected Not detected adrenal gland: 0.6 KCNH1 eag, eag1, h-eag, Kv10.1 ENSG00000143473 Potassium channel, voltage gated eag related subfamily H, member 1 1 210678315-211134115 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA014551, HPA019445 Supported Approved Vesicles Not detected Tissue enriched 12 cerebral cortex: 11.5 adrenal gland,testis: 0.9 KCNH3 BEC1, elk2, Kv12.2 ENSG00000135519 Potassium channel, voltage gated eag related subfamily H, member 3 12 49539157-49558308 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA051088 Uncertain Approved Nucleus
Mitochondria Tissue enhanced Group enriched 5 cerebral cortex: 24.3;fallopian tube: 7.1;parathyroid gland: 4.9 adrenal gland: 2.2 KCNH5 eag2, H-EAG2, Kv10.2 ENSG00000140015 Potassium channel, voltage gated eag related subfamily H, member 5 14 62699454-63102037 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA030487 Uncertain Uncertain Microtubules
Mitotic spindle Not detected Tissue enhanced adrenal gland: 1.4;cerebral cortex: 3.6 testis: 0.7 KCNH7 erg3, HERG3, Kv11.3 ENSG00000184611 Potassium channel, voltage gated eag related subfamily H, member 7 2 162371407-162838730 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA018039 Uncertain Not detected Tissue enriched 6 cerebral cortex: 4.7 testis: 0.7 KCNIP4 CALP, KCHIP4, MGC44947 ENSG00000185774 Kv channel interacting protein 4 4 20728616-21948799 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA022862, HPA066717 Supported Approved Vesicles Mixed Tissue enhanced cerebral cortex: 57.4 cervix, uterine: 20.5 KCNJ1 Kir1.1, ROMK1 ENSG00000151704 Potassium channel, inwardly rectifying subfamily J, member 1 11 128836315-128867373 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA026962 Supported Tissue enriched Tissue enriched 118 kidney: 209.0 epididymis: 1.7 KCNJ11 BIR, Kir6.2 ENSG00000187486 Potassium channel, inwardly rectifying subfamily J, member 11 11 17385859-17389331 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA048891 Approved Renal cancer:1.56e-4 (favourable) Mixed Tissue enhanced skeletal muscle: 32.7 cerebral cortex: 10.2 KCNJ12 hIRK1, IRK2, KCNJN1, Kir2.2, Kir2.2v ENSG00000184185 Potassium channel, inwardly rectifying subfamily J, member 12 17 21376197-21419872 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA027021 Approved Uncertain Nucleoplasm
Golgi apparatus
Cytosol Endometrial cancer:7.84e-5 (unfavourable) Mixed Group enriched 5 parathyroid gland: 18.9;skeletal muscle: 23.1 heart muscle: 3.9 KCNJ14 IRK4, Kir2.4 ENSG00000182324 Potassium channel, inwardly rectifying subfamily J, member 14 19 48455509-48466980 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA071765 Approved Nucleoli Mixed Mixed testis: 2.9 KCNJ15 IRKK, Kir1.3, Kir4.2 ENSG00000157551 Potassium channel, inwardly rectifying subfamily J, member 15 21 38157034-38307357 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA016702 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:4.09e-10 (favourable), Urothelial cancer:1.95e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 259.2;thyroid gland: 215.5 lung: 63.5 KCNJ16 BIR9, Kir5.1 ENSG00000153822 Potassium channel, inwardly rectifying subfamily J, member 16 17 70053429-70135608 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at transcript level HPA059563 Approved Uncertain Vesicles Renal cancer:9.61e-7 (favourable), Thyroid cancer:6.58e-4 (favourable) Group enriched Group enriched 7 kidney: 207.9;parathyroid gland: 268.8;thyroid gland: 233.9 seminal vesicle: 31.9 KCNJ18 KIR2.6, TTPP2 ENSG00000260458 Potassium channel, inwardly rectifying subfamily J, member 18 17 21692523-21704612 Disease related genes, Predicted membrane proteins Evidence at protein level HPA027021 Uncertain Uncertain Nucleoplasm
Golgi apparatus
Cytosol Tissue enhanced Group enriched 8 skin: 3.9;tonsil: 1.3 testis: 0.3 KCNJ2 IRK1, Kir2.1, LQT7 ENSG00000123700 Potassium channel, inwardly rectifying subfamily J, member 2 17 70168673-70180048 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA029109 Approved Mixed Tissue enhanced parathyroid gland: 46.5 fallopian tube: 11.6 KCNJ3 GIRK1, KGA, Kir3.1 ENSG00000162989 Potassium channel, inwardly rectifying subfamily J, member 3 2 154698299-154858352 Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA024231 Uncertain Group enriched Tissue enhanced cerebral cortex: 25.5;parathyroid gland: 39.5 seminal vesicle: 14.1 KCNJ5 CIR, GIRK4, KATP1, Kir3.4, LQT13 ENSG00000120457 Potassium channel, inwardly rectifying subfamily J, member 5 11 128891356-128921035 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA014722, HPA017353, CAB022569 Supported Mixed Tissue enhanced adrenal gland: 85.2 spleen: 19.1 KCNJ8 Kir6.1 ENSG00000121361 Potassium channel, inwardly rectifying subfamily J, member 8 12 21764955-21775581 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031066 Uncertain Renal cancer:1.62e-6 (unfavourable), Colorectal cancer:9.29e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 31.6 KCNJ9 GIRK3, Kir3.3 ENSG00000162728 Potassium channel, inwardly rectifying subfamily J, member 9 1 160081570-160090563 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA070478 Supported Tissue enriched Tissue enriched 112 cerebral cortex: 52.5 adrenal gland,testis: 0.4 KCNK1 DPK, K2p1.1, TWIK-1 ENSG00000135750 Potassium channel, two pore domain subfamily K, member 1 1 233614004-233672512 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA016049, CAB022588 Approved Approved Vesicles Renal cancer:8.69e-8 (unfavourable), Liver cancer:3.84e-4 (favourable), Pancreatic cancer:7.29e-4 (unfavourable) Mixed Mixed cerebral cortex: 46.6 KCNK10 K2p10.1, PPP1R97, TREK-2, TREK2 ENSG00000100433 Potassium channel, two pore domain subfamily K, member 10 14 88180103-88326907 Predicted membrane proteins Evidence at protein level HPA030462 Approved Mixed Tissue enhanced cerebral cortex: 5.6;duodenum: 5.3 small intestine: 2.8 KCNK13 K2p13.1, THIK-1, THIK1 ENSG00000152315 Potassium channel, two pore domain subfamily K, member 13 14 90061765-90185857 Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA003514 Approved Approved Nuclear speckles
Cell Junctions Mixed Tissue enhanced parathyroid gland: 14.3;testis: 14.4 kidney: 3.3 KCNK15 dJ781B1.1, K2p15.1, KCNK11, KCNK14, KIAA0237, KT3.3, TASK-5, TASK5 ENSG00000124249 Potassium channel, two pore domain subfamily K, member 15 20 44745780-44752313 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA064861 Uncertain Cervical cancer:3.68e-4 (unfavourable) Tissue enriched Tissue enhanced fallopian tube: 8.0 testis: 2.9 KCNK17 K2p17.1, TALK-2, TALK2, TASK-4, TASK4 ENSG00000124780 Potassium channel, two pore domain subfamily K, member 17 6 39299001-39314553 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at transcript level HPA043892 Uncertain Mixed Tissue enhanced lung: 5.6 placenta: 5.2 KCNK18 K2p18.1, TRESK, TRESK-2, TRESK2, TRIK ENSG00000186795 Potassium channel, two pore domain subfamily K, member 18 10 117197489-117210299 Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA044739 Uncertain Not detected Not detected testis: 0.2 KCNK2 K2p2.1, TREK-1 ENSG00000082482 Potassium channel, two pore domain subfamily K, member 2 1 215005775-215237093 FDA approved drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA056054 Uncertain Approved Mitochondria
Cytosol Mixed Tissue enhanced adrenal gland: 75.5 thyroid gland: 17.3 KCNK5 K2p5.1, TASK-2 ENSG00000164626 Potassium channel, two pore domain subfamily K, member 5 6 39188973-39229450 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA059148 Uncertain Approved Nucleus Renal cancer:4.98e-7 (favourable), Cervical cancer:3.29e-4 (favourable), Urothelial cancer:4.45e-4 (favourable), Pancreatic cancer:5.85e-4 (unfavourable) Mixed Tissue enhanced small intestine: 40.1 gallbladder: 29.6 KCNK6 K2p6.1, TWIK-2 ENSG00000099337 Potassium channel, two pore domain subfamily K, member 6 19 38319844-38332076 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022637, HPA040184 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Endometrial cancer:1.45e-6 (favourable), Renal cancer:1.04e-5 (unfavourable) Expressed in all Mixed endometrium: 22.8 KCNK7 K2p7.1 ENSG00000173338 Potassium channel, two pore domain subfamily K, member 7 11 65592855-65595996 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Voltage-gated ion channels Evidence at transcript level HPA077577 Approved Plasma membrane Tissue enhanced Tissue enriched 7 skin: 53.1 esophagus: 8.0 KCNMA1 KCa1.1, mSLO1, SLO ENSG00000156113 Potassium channel, calcium activated large conductance subfamily M alpha, member 1 10 76869601-77638595 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA054648 Approved Mixed Tissue enhanced smooth muscle: 147.6 endometrium: 122.5 KCNMB2 ENSG00000197584 Potassium channel subfamily M regulatory beta subunit 2 3 178272932-178844429 Predicted membrane proteins, Transporters Evidence at protein level CAB022649 Uncertain Mixed Tissue enhanced epididymis: 41.5;fallopian tube: 22.1;ovary: 19.0 adrenal gland: 7.6 KCNMB3 KCNMB2, KCNMBL ENSG00000171121 Potassium channel subfamily M regulatory beta subunit 3 3 179236691-179267002 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015665, HPA019185 Approved Approved Nucleus
Mitochondria Not detected Mixed placenta: 5.9 KCNMB4 ENSG00000135643 Potassium channel subfamily M regulatory beta subunit 4 12 70366276-70434292 Predicted membrane proteins Evidence at protein level HPA072287 Approved Cytosol Mixed Group enriched 8 adrenal gland: 19.6;cerebral cortex: 38.2 placenta: 3.7 KCNN1 hSK1, KCa2.1 ENSG00000105642 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 1 19 17951293-18000080 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA065938 Approved Actin filaments
Cytosol Tissue enhanced Tissue enriched 10 cerebral cortex: 21.5 testis: 2.0 KCNN2 hSK2, KCa2.2 ENSG00000080709 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 2 5 114360945-114496500 Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA038221 Uncertain Uncertain Nucleoplasm
Cytosol Group enriched Tissue enhanced adrenal gland: 27.4;prostate: 18.5 liver: 15.9 KCNN3 hSK3, KCa2.3, SKCA3 ENSG00000143603 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 3 1 154697455-154870280 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA017990, HPA057127 Uncertain Approved Nucleoplasm Renal cancer:1.97e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 25.4 fallopian tube: 9.4 KCNN4 hIKCa1, hKCa4, hSK4, IK, KCa3.1 ENSG00000104783 Potassium channel, calcium activated intermediate/small conductance subfamily N alpha, member 4 19 43766533-43781257 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053841, HPA059622 Approved Renal cancer:1.05e-14 (unfavourable), Urothelial cancer:1.75e-4 (favourable), Glioma:3.77e-4 (unfavourable), Pancreatic cancer:4.56e-4 (unfavourable) Expressed in all Tissue enhanced salivary gland: 74.3 stomach: 37.1 KCNQ1 JLNS1, KCNA8, KCNA9, Kv7.1, KVLQT1, LQT, LQT1 ENSG00000053918 Potassium channel, voltage gated KQT-like subfamily Q, member 1 11 2444684-2849109 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB018656, HPA048553 Supported Stomach cancer:9.85e-4 (favourable) Expressed in all Tissue enhanced adrenal gland: 134.2;thyroid gland: 102.8 seminal vesicle: 60.3 KCNQ2 BFNC, EBN, EBN1, ENB1, HNSPC, KCNA11, Kv7.2 ENSG00000075043 Potassium channel, voltage gated KQT-like subfamily Q, member 2 20 63400210-63472677 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016642, HPA057112 Approved Approved Endoplasmic reticulum Tissue enriched Tissue enriched 7 cerebral cortex: 56.3 adrenal gland: 8.2 KCNQ4 DFNA2, Kv7.4 ENSG00000117013 Potassium channel, voltage gated KQT-like subfamily Q, member 4 1 40784012-40840452 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA018305 Uncertain Mixed Mixed smooth muscle: 2.5 KCNQ5 Kv7.5 ENSG00000185760 Potassium channel, voltage gated KQT-like subfamily Q, member 5 6 72621792-73198851 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA016655 Approved Approved Vesicles Mixed Tissue enhanced cerebral cortex: 22.4 thyroid gland: 7.8 KCNS2 Kv9.2 ENSG00000156486 Potassium voltage-gated channel, modifier subfamily S, member 2 8 98427022-98432848 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA051417 Uncertain Not detected Tissue enhanced cerebral cortex: 7.2 placenta: 2.2 KCNS3 Kv9.3 ENSG00000170745 Potassium voltage-gated channel, modifier subfamily S, member 3 2 17877847-18361616 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA014864 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:1.53e-4 (unfavourable) Expressed in all Tissue enhanced lung: 35.5 skeletal muscle: 29.6 KCNT1 KCa4.1, KIAA1422, SLACK, Slo2.2 ENSG00000107147 Potassium channel, sodium activated subfamily T, member 1 9 135702185-135795508 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA059880 Uncertain Tissue enhanced Group enriched 5 cerebral cortex: 11.7;ovary: 3.9;skeletal muscle: 3.9;spleen: 6.7 testis: 1.2 KCNT2 KCa4.2, SLICK, SLO2.1 ENSG00000162687 Potassium channel, sodium activated subfamily T, member 2 1 196225779-196609225 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA051218 Uncertain Approved Vesicles Renal cancer:1.67e-5 (unfavourable) Mixed Tissue enhanced ovary: 6.0 cerebral cortex: 3.5 KCNV2 Kv8.2 ENSG00000168263 Potassium channel, voltage gated modifier subfamily V, member 2 9 2717502-2730037 Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA031131 Uncertain Tissue enriched Tissue enriched 44 testis: 6.6 skin: 0.1 KCTD8 ENSG00000183783 Potassium channel tetramerization domain containing 8 4 44173909-44448807 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031562 Supported Approved Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 11.5;thyroid gland: 5.1 testis: 2.4 KDELR1 ERD2, ERD2.1, HDEL ENSG00000105438 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 1 19 48382570-48391553 Predicted membrane proteins, Transporters Evidence at protein level CAB017455 Approved Supported Golgi apparatus
Vesicles Liver cancer:1.61e-4 (unfavourable), Head and neck cancer:3.49e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 259.3 KDELR2 ELP-1, ERD2.2 ENSG00000136240 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 7 6445953-6484242 Predicted membrane proteins Evidence at protein level HPA016459 Approved Renal cancer:6.79e-8 (unfavourable), Head and neck cancer:1.03e-5 (unfavourable), Glioma:8.16e-5 (unfavourable) Expressed in all Expressed in all placenta: 202.3 KDELR3 ENSG00000100196 KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 3 22 38468062-38483447 Predicted membrane proteins Evidence at protein level HPA043477, HPA076405 Uncertain Validated Endoplasmic reticulum Renal cancer:6.05e-10 (unfavourable), Liver cancer:1.19e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 46.3 KDR CD309, FLK1, VEGFR, VEGFR2 ENSG00000128052 Kinase insert domain receptor 4 55078477-55125589 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB004028 Approved Supported Plasma membrane Renal cancer:7.26e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 118.2 thyroid gland: 54.5 KDSR DHSR, FVT1, SDR35C1 ENSG00000119537 3-ketodihydrosphingosine reductase 18 63327726-63367510 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB003673, HPA044884 Approved Renal cancer:9.53e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 45.6 KHDC1 bA257K9.4, C6orf147, C6orf148, Em:AC019205.8, MGC10818, NDG1 ENSG00000135314 KH homology domain containing 1 6 73241314-73310365 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA029032 Approved Approved Mitochondria
Cytosol Mixed Tissue enhanced cerebral cortex: 10.0 testis: 6.7 KIAA0040 ENSG00000235750 KIAA0040 1 175156987-175192999 Predicted intracellular proteins Evidence at protein level HPA016895, HPA068812 Approved Approved Nucleoplasm Expressed in all Expressed in all placenta: 142.4 KIAA0319L KIAA1837 ENSG00000142687 KIAA0319-like 1 35433490-35557950 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072692 Approved Nucleoli
Golgi apparatus Liver cancer:5.92e-5 (unfavourable), Renal cancer:1.27e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 82.6 KIAA0368 ECM29, FLJ22036 ENSG00000136813 KIAA0368 9 111360692-111484745 Predicted intracellular proteins Evidence at protein level HPA021646, HPA059795 Uncertain Supported Nucleus Expressed in all Expressed in all parathyroid gland: 79.3 KIAA0922 DKFZp586H1322, TMEM131L ENSG00000121210 KIAA0922 4 153466346-153636711 Predicted membrane proteins Evidence at protein level HPA043472, HPA048443 Uncertain Approved Nucleoli fibrillar center
Vesicles Cervical cancer:6.69e-6 (favourable) Expressed in all Expressed in all lymph node: 57.0 KIAA1024 ENSG00000169330 KIAA1024 15 79432516-79472290 Predicted membrane proteins Evidence at protein level HPA011545 Uncertain Approved Golgi apparatus Mixed Tissue enriched 11 adrenal gland: 14.0 prostate,salivary gland: 1.2 KIAA1024L ENSG00000186367 KIAA1024-like 5 129748079-129766732 Predicted membrane proteins Evidence at transcript level HPA013760 Uncertain Not detected Tissue enriched 11 skeletal muscle: 11.5 testis: 1.0 KIAA1109 FLJ21404, FSA, KIAA1371, Tweek ENSG00000138688 KIAA1109 4 122152333-122362758 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038076 Approved Approved Nucleoplasm
Centrosome Renal cancer:4.33e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 128.4 KIAA1161 NET37 ENSG00000164976 KIAA1161 9 34366670-34376853 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060533, HPA067487 Approved Approved Mitochondria Renal cancer:1.20e-13 (favourable), Endometrial cancer:6.96e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 29.4 KIAA1324 EIG121, maba1 ENSG00000116299 KIAA1324 1 109113679-109206781 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029869, HPA070749 Supported Supported Plasma membrane Endometrial cancer:2.14e-7 (favourable), Lung cancer:5.69e-5 (favourable), Ovarian cancer:2.16e-4 (favourable) Mixed Mixed cervix, uterine: 128.0 KIAA1324L EIG121L, FLJ31340 ENSG00000164659 KIAA1324-like 7 86876906-87059699 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044527, HPA076093 Uncertain Approved Endoplasmic reticulum Mixed Tissue enhanced lung: 32.3 cerebral cortex: 21.8 KIAA1524 CIP2A ENSG00000163507 KIAA1524 3 108549869-108589644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039570 Approved Supported Plasma membrane
Cytosol Endometrial cancer:6.24e-5 (unfavourable), Renal cancer:1.42e-4 (unfavourable), Pancreatic cancer:9.18e-4 (unfavourable) Expressed in all Mixed testis: 10.2 KIAA1549 ENSG00000122778 KIAA1549 7 138831381-138981318 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level HPA019560 Approved Approved Nuclear membrane
Intermediate filaments Renal cancer:3.93e-7 (favourable) Mixed Mixed seminal vesicle: 10.4 KIAA1549L C11orf41, C11orf69, G2, MGC34830 ENSG00000110427 KIAA1549-like 11 33542072-33674102 Predicted membrane proteins Evidence at protein level HPA051594 Approved Nucleoplasm Mixed Group enriched 40 cerebral cortex: 35.0;parathyroid gland: 143.5 skin: 2.2 KIAA1644 ENSG00000138944 KIAA1644 22 44243667-44312851 Predicted membrane proteins Evidence at transcript level HPA051178 Uncertain Approved Vesicles
Cytosol Mixed Tissue enhanced cerebral cortex: 27.6;endometrium: 42.5;smooth muscle: 44.0 cervix, uterine: 19.1 KIAA1715 LNP, LNP1, Ul, ulnaless ENSG00000144320 KIAA1715 2 175923892-176002839 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014205 Approved Supported Nucleoplasm
Endoplasmic reticulum Expressed in all Expressed in all testis: 45.8 KIAA1919 MFSD4B, MGC33953 ENSG00000173214 KIAA1919 6 111259348-111271167 Predicted membrane proteins Evidence at protein level HPA031784 Approved Uncertain Intermediate filaments Expressed in all Mixed placenta: 5.0 KIAA2013 MGC33867, RP5-1077B9.1 ENSG00000116685 KIAA2013 1 11919591-11926428 Predicted membrane proteins Evidence at protein level HPA052677, HPA060536 Uncertain Approved Golgi apparatus
Cytosol Expressed in all Expressed in all small intestine: 69.5 KIDINS220 ARMS ENSG00000134313 Kinase D-interacting substrate, 220kDa 2 8725278-8837630 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014790 Supported Approved Nucleoplasm Renal cancer:9.29e-6 (favourable), Lung cancer:9.64e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 99.9 KIRREL NEPH1 ENSG00000183853 Kin of IRRE like (Drosophila) 1 157993273-158100262 Predicted membrane proteins Evidence at protein level HPA030458 Approved Renal cancer:1.12e-8 (unfavourable), Cervical cancer:1.87e-4 (unfavourable), Urothelial cancer:2.85e-4 (unfavourable) Expressed in all Mixed placenta: 46.8 KIRREL2 DKFZp564A1164, FILTRIN, MGC15718, NEPH3, NLG1 ENSG00000126259 Kin of IRRE like 2 (Drosophila) 19 35855861-35867109 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041170 Approved Vesicles Mixed Tissue enriched 8 pancreas: 11.6 cerebral cortex: 1.4 KIRREL3 KIAA1867, KIRRE, NEPH2 ENSG00000149571 Kin of IRRE like 3 (Drosophila) 11 126423359-127003460 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA053324, HPA056320 Supported Tissue enhanced Tissue enriched 11 cerebral cortex: 20.5 adrenal gland: 1.9 KISS1R AXOR12, GPR54, HOT7T175 ENSG00000116014 KISS1 receptor 19 917287-921015 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071913 Supported Vesicles
Plasma membrane Renal cancer:3.33e-6 (unfavourable) Tissue enhanced Tissue enriched 5 cerebral cortex: 1.2 appendix,lymph node,placenta: 0.2 KIT C-Kit, CD117, PBT, SCFR ENSG00000157404 V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4 54657918-54740715 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB003288, HPA004471, CAB068253, CAB072867, HPA073252 Supported Supported Plasma membrane Renal cancer:5.63e-4 (favourable) Mixed Tissue enhanced breast: 133.8 thyroid gland: 78.4 KITLG FPH2, Kitl, KL-1, MGF, SCF, SF ENSG00000049130 KIT ligand 12 88492793-88580851 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA070395 Approved Approved Vesicles Renal cancer:5.81e-7 (favourable), Liver cancer:4.01e-4 (unfavourable) Expressed in all Mixed lung: 24.2 KLB ENSG00000134962 Klotho beta 4 39406853-39451536 Predicted membrane proteins, Transporters Evidence at protein level HPA021136 Uncertain Tissue enriched Tissue enhanced adipose tissue: 20.6;liver: 9.1 testis: 5.1 KLHDC7A FLJ38753 ENSG00000179023 Kelch domain containing 7A 1 18480982-18486126 Predicted intracellular proteins Evidence at protein level HPA056616 Uncertain Approved Nuclear speckles Renal cancer:7.81e-9 (favourable), Urothelial cancer:1.88e-4 (favourable) Tissue enhanced Tissue enhanced kidney: 20.7 urinary bladder: 6.6 KLHL2 MAV ENSG00000109466 Kelch-like family member 2 4 165207618-165323156 Predicted intracellular proteins Evidence at protein level HPA051637 Uncertain Nucleoplasm
Vesicles Renal cancer:3.77e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 77.5 thyroid gland: 21.5 KLHL28 BTBD5, FLJ20081 ENSG00000179454 Kelch-like family member 28 14 44924319-45042322 Predicted intracellular proteins Evidence at transcript level HPA000988 Approved Cytosol Expressed in all Mixed bone marrow: 17.2 KLHL5 ENSG00000109790 Kelch-like family member 5 4 39045039-39126857 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013958 Approved Expressed in all Expressed in all seminal vesicle: 90.3 KLHL7 KLHL6, RP42, SBBI26 ENSG00000122550 Kelch-like family member 7 7 23105758-23177914 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA029491, HPA029492 Uncertain Supported Nucleoplasm
Cytosol Renal cancer:8.98e-5 (favourable), Liver cancer:7.96e-4 (unfavourable) Expressed in all Expressed in all testis: 75.7 KLRB1 CD161, CLEC5B, hNKR-P1A, NKR, NKR-P1, NKR-P1A ENSG00000111796 Killer cell lectin-like receptor subfamily B, member 1 12 9594551-9607886 CD markers, Predicted membrane proteins Evidence at protein level HPA039113 Approved Uncertain Nucleoplasm
Cytosol Endometrial cancer:1.42e-5 (favourable), Breast cancer:3.51e-5 (favourable), Head and neck cancer:6.99e-5 (favourable), Thyroid cancer:5.61e-4 (favourable) Mixed Mixed spleen: 41.3 KLRC1 CD159a, NKG2, NKG2-A, NKG2-B ENSG00000134545 Killer cell lectin-like receptor subfamily C, member 1 12 10442264-10454685 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058052 Approved Plasma membrane Mixed Mixed spleen: 10.3 KLRC2 CD159c, NKG2-C ENSG00000205809 Killer cell lectin-like receptor subfamily C, member 2 12 10426854-10442300 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058052 Approved Plasma membrane Tissue enriched Group enriched 6 cerebral cortex: 17.4;spleen: 8.3 stomach: 2.0 KLRC3 NKG2-E ENSG00000205810 Killer cell lectin-like receptor subfamily C, member 3 12 10412312-10420595 Predicted membrane proteins Evidence at transcript level HPA039910, HPA062570 Approved Uncertain Vesicles Tissue enriched Tissue enhanced cerebral cortex: 9.3;spleen: 6.3 lymph node: 2.3 KLRD1 CD94 ENSG00000134539 Killer cell lectin-like receptor subfamily D, member 1 12 10226058-10329600 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069688 Uncertain Mixed Tissue enhanced spleen: 19.1 lymph node: 6.8 KLRG1 2F1, CLEC15A, MAFA, MAFA-L ENSG00000139187 Killer cell lectin-like receptor subfamily G, member 1 12 8950044-9010760 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051403, HPA076494 Supported Vesicles Mixed Tissue enhanced spleen: 16.1 lymph node: 13.8 KLRG2 CLEC15B, FLJ44186 ENSG00000188883 Killer cell lectin-like receptor subfamily G, member 2 7 139452690-139483712 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018199 Uncertain Lung cancer:8.61e-4 (favourable) Tissue enriched Tissue enhanced lung: 4.4;parathyroid gland: 5.7;thyroid gland: 6.7 kidney: 2.7 KLRK1 CD314, D12S2489E, KLR, NKG2-D, NKG2D ENSG00000213809 Killer cell lectin-like receptor subfamily K, member 1 12 10372353-10391874 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level CAB021896, HPA068877 Supported Supported Plasma membrane Not detected Tissue enhanced lymph node: 35.7;spleen: 53.6 tonsil: 16.7 KMO ENSG00000117009 Kynurenine 3-monooxygenase (kynurenine 3-hydroxylase) 1 241532134-241595642 Enzymes, Predicted membrane proteins Evidence at protein level HPA031115, HPA056942 Supported Renal cancer:6.49e-8 (unfavourable) Mixed Tissue enhanced kidney: 31.3;liver: 46.5 spleen: 10.8 KMT2E HDCMC04P, MLL5 ENSG00000005483 Lysine (K)-specific methyltransferase 2E 7 105014179-105114361 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022812, HPA056125 Approved Approved Renal cancer:3.80e-5 (unfavourable) Expressed in all Expressed in all endometrium: 52.2 KNCN FLJ32011, KINO, L5 ENSG00000162456 Kinocilin 1 46545644-46551527 Predicted membrane proteins Evidence at transcript level HPA046357 Uncertain Not detected Not detected testis: 0.7 KREMEN1 KREMEN, KRM1 ENSG00000183762 Kringle containing transmembrane protein 1 22 29073078-29168333 Predicted membrane proteins Evidence at protein level HPA058513 Approved Nucleoplasm
Nuclear bodies
Cytosol Not detected Mixed skin: 43.5 KREMEN2 KRM2, MGC10791 ENSG00000131650 Kringle containing transmembrane protein 2 16 2963944-2968383 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA003223 Uncertain Approved Nucleoli Lung cancer:8.98e-4 (unfavourable) Mixed Tissue enhanced skin: 6.9 cerebral cortex: 2.1 KRTCAP3 KCP3 ENSG00000157992 Keratinocyte associated protein 3 2 27442366-27446481 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047136, HPA060203 Supported Approved Nucleus
Cytosol Breast cancer:2.67e-5 (favourable) Expressed in all Mixed small intestine: 35.5 KTN1 CG1, KIAA0004 ENSG00000126777 Kinectin 1 (kinesin receptor) 14 55559072-55701526 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003178, CAB015331, HPA017876 Supported Validated Endoplasmic reticulum Renal cancer:1.01e-6 (favourable), Head and neck cancer:6.83e-5 (unfavourable), Liver cancer:3.76e-4 (unfavourable) Expressed in all Expressed in all testis: 269.6 KYNU ENSG00000115919 Kynureninase 2 142877498-143055832 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA031686 Approved Mixed Mixed liver: 45.7 L1CAM CD171, HSAS, HSAS1, MASA, MIC5, S10, SPG1 ENSG00000198910 L1 cell adhesion molecule X 153861514-153909223 CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005830, CAB010896 Approved Approved Nucleoplasm
Plasma membrane Endometrial cancer:8.51e-10 (unfavourable), Lung cancer:2.36e-6 (unfavourable), Renal cancer:1.17e-4 (unfavourable), Head and neck cancer:3.81e-4 (unfavourable) Tissue enhanced Tissue enhanced adrenal gland: 36.2;cerebral cortex: 67.1 seminal vesicle: 12.7 LAG3 CD223 ENSG00000089692 Lymphocyte-activation gene 3 12 6772512-6778455 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002301, HPA013967 Supported Renal cancer:4.62e-11 (unfavourable), Cervical cancer:3.89e-4 (favourable) Expressed in all Tissue enhanced spleen: 32.6 lymph node: 17.8 LAIR1 CD305 ENSG00000167613 Leukocyte-associated immunoglobulin-like receptor 1 19 54351384-54370558 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011155 Supported Supported Plasma membrane Renal cancer:5.01e-5 (unfavourable) Expressed in all Tissue enhanced lymph node: 7.2 appendix: 4.3 LAMP1 CD107a ENSG00000185896 Lysosomal-associated membrane protein 1 13 113297241-113323672 CD markers, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB004260, HPA014750 Supported Renal cancer:4.15e-5 (favourable) Expressed in all Expressed in all thyroid gland: 210.9 LAMP2 CD107b ENSG00000005893 Lysosomal-associated membrane protein 2 X 120427827-120469365 CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB005272, HPA029100 Supported Expressed in all Expressed in all gallbladder: 223.9 LAMP3 CD208, DC-LAMP, DCLAMP, LAMP, TSC403 ENSG00000078081 Lysosomal-associated membrane protein 3 3 183122213-183163839 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025133, HPA051467 Supported Supported Nucleus
Vesicles Renal cancer:1.89e-7 (unfavourable), Ovarian cancer:9.90e-4 (favourable) Mixed Tissue enriched 7 lung: 320.1 appendix: 46.2 LAMP5 BAD-LAMP, C20orf103, dJ1119D9.3, UNC-43 ENSG00000125869 Lysosomal-associated membrane protein family, member 5 20 9514358-9530524 Predicted membrane proteins Evidence at protein level HPA004802, HPA070765 Uncertain Approved Cytosol Renal cancer:6.46e-6 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 45.0;ovary: 24.5 fallopian tube: 14.8 LAMTOR4 C7orf59 ENSG00000188186 Late endosomal/lysosomal adaptor, MAPK and MTOR activator 4 7 100148907-100155944 Predicted intracellular proteins Evidence at protein level HPA020998 Supported Validated Vesicles Breast cancer:2.48e-4 (favourable), Cervical cancer:6.08e-4 (favourable) Expressed in all Expressed in all skin: 314.2 LAPTM4A HUMORF13, KIAA0108, LAPTM4, MBNT, Mtrp ENSG00000068697 Lysosomal protein transmembrane 4 alpha 2 20032650-20052028 Predicted membrane proteins Evidence at protein level HPA031402, HPA031404, HPA068554 Approved Approved Golgi apparatus
Vesicles
Plasma membrane Pancreatic cancer:4.37e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 627.8 LAPTM4B LC27 ENSG00000104341 Lysosomal protein transmembrane 4 beta 8 97775057-97853013 Predicted membrane proteins, Transporters Evidence at protein level CAB020782, HPA068830 Uncertain Approved Golgi apparatus Liver cancer:2.70e-6 (unfavourable), Breast cancer:5.63e-4 (unfavourable), Head and neck cancer:5.70e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 134.9 LAPTM5 ENSG00000162511 Lysosomal protein transmembrane 5 1 30732469-30757820 Predicted membrane proteins, Transporters Evidence at protein level HPA051293 Approved Approved Cytosol Renal cancer:5.89e-5 (unfavourable), Cervical cancer:3.40e-4 (favourable) Expressed in all Expressed in all bone marrow: 801.2 LAT LAT1 ENSG00000213658 Linker for activation of T cells 16 28984826-28990783 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB002223, HPA011157, CAB012978 Supported Not detected Tissue enhanced lymph node: 76.5 appendix: 33.0 LAX1 FLJ20340, LAX ENSG00000122188 Lymphocyte transmembrane adaptor 1 1 203765176-203776233 Predicted membrane proteins Evidence at protein level HPA002461, HPA003887, CAB025358 Supported Validated Golgi apparatus
Plasma membrane
Cytosol Mixed Tissue enhanced tonsil: 16.0 lymph node: 10.4 LAYN FLJ30977, FLJ31092 ENSG00000204381 Layilin 11 111540280-111561745 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040087 Approved Approved Cytosol Expressed in all Mixed ovary: 49.5 LBR DHCR14B, TDRD18 ENSG00000143815 Lamin B receptor 1 225401502-225428925 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049840, HPA062236 Supported Validated Nuclear membrane Liver cancer:7.30e-4 (unfavourable) Expressed in all Expressed in all lymph node: 99.8 LCAT ENSG00000213398 Lecithin-cholesterol acyltransferase 16 67939750-67944131 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA044767 Approved Nucleoplasm Liver cancer:4.21e-8 (favourable), Renal cancer:1.71e-4 (unfavourable), Colorectal cancer:8.50e-4 (unfavourable) Expressed in all Expressed in all liver: 105.3 LCLAT1 AGPAT8, ALCAT1, FLJ37965, LYCAT ENSG00000172954 Lysocardiolipin acyltransferase 1 2 30447226-30644225 Enzymes, Predicted membrane proteins Evidence at protein level HPA031880, HPA049217 Uncertain Supported Endoplasmic reticulum
Cytosol Liver cancer:8.72e-4 (unfavourable), Head and neck cancer:9.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 19.2 LCT ENSG00000115850 Lactase 2 135787840-135837180 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007408 Uncertain Not detected Group enriched 640 duodenum: 229.4;small intestine: 146.2 appendix,breast,lymph node,testis: 0.2 LCTL FLJ33279, KLG, KLPH ENSG00000188501 Lactase-like 15 66547179-66565979 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA071640 Approved Endoplasmic reticulum
Plasma membrane Group enriched Mixed cerebral cortex: 1.0 LDAH C2orf43, FLJ21820 ENSG00000118961 Lipid droplet associated hydrolase 2 20684014-20823130 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034729, HPA034730 Approved Uncertain Nuclear speckles
Cytosol Liver cancer:6.09e-6 (unfavourable), Renal cancer:1.18e-4 (favourable) Expressed in all Mixed parathyroid gland: 20.2 LDHA ENSG00000134333 Lactate dehydrogenase A 11 18394388-18408425 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level CAB015336 Approved Supported Vesicles
Cytosol Renal cancer:9.69e-9 (unfavourable), Liver cancer:3.26e-8 (unfavourable), Lung cancer:2.27e-6 (unfavourable), Pancreatic cancer:8.09e-6 (unfavourable), Cervical cancer:2.78e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 499.8 LDLR LDLCQ2 ENSG00000130164 Low density lipoprotein receptor 19 11089362-11133816 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009647, HPA013159 Approved Pancreatic cancer:6.60e-5 (unfavourable), Urothelial cancer:3.43e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable) Expressed in all Expressed in all lung: 87.7 LDLRAD1 ENSG00000203985 Low density lipoprotein receptor class A domain containing 1 1 54007299-54018186 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052489 Approved Uncertain Nucleoplasm
Golgi apparatus Endometrial cancer:9.21e-4 (favourable) Tissue enhanced Tissue enriched 21 fallopian tube: 253.3 lung: 11.8 LDLRAD3 LRAD3 ENSG00000179241 Low density lipoprotein receptor class A domain containing 3 11 35943981-36232136 Predicted membrane proteins Evidence at protein level HPA038251 Approved Supported Cell Junctions Renal cancer:5.05e-8 (unfavourable), Lung cancer:9.34e-6 (unfavourable), Urothelial cancer:2.14e-5 (unfavourable), Cervical cancer:2.24e-4 (unfavourable) Expressed in all Mixed breast: 22.9 LDLRAD4 C18orf1 ENSG00000168675 Low density lipoprotein receptor class A domain containing 4 18 13217498-13652755 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047633, HPA054556, HPA065246 Approved Supported Nucleoplasm
Vesicles Renal cancer:4.58e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 27.6 LECT1 BRICD3, CHM-I, CHM1, chondromodulin, MYETS1 ENSG00000136110 Leukocyte cell derived chemotaxin 1 13 52703264-52739812 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010510 Uncertain Group enriched Tissue enhanced salivary gland: 3.1;testis: 3.5;thyroid gland: 5.8 lung: 2.5 LEMD1 CT50, LEMP-1 ENSG00000186007 LEM domain containing 1 1 205381378-205457091 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA045425 Approved Nucleoli
Cytosol Ovarian cancer:1.26e-4 (favourable), Pancreatic cancer:1.70e-4 (unfavourable) Tissue enhanced Group enriched 17 epididymis: 17.7;testis: 71.0 fallopian tube: 2.6 LEMD2 dJ482C21.1, NET25 ENSG00000161904 LEM domain containing 2 6 33771202-33789136 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017340 Approved Validated Nuclear membrane Renal cancer:1.12e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 68.5 LEMD3 MAN1 ENSG00000174106 LEM domain containing 3 12 65169571-65248327 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA025078, HPA076986 Uncertain Supported Nuclear membrane Renal cancer:2.30e-4 (favourable) Expressed in all Expressed in all testis: 28.8 LENG8 KIAA1932, MGC40108, pp13842 ENSG00000167615 Leukocyte receptor cluster (LRC) member 8 19 54448887-54462037 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042004, HPA042056, HPA061571 Uncertain Supported Nucleus Renal cancer:3.30e-7 (unfavourable), Urothelial cancer:2.73e-6 (favourable), Head and neck cancer:7.59e-4 (favourable) Expressed in all Expressed in all spleen: 167.8 LEPR CD295, OBR ENSG00000116678 Leptin receptor 1 65420652-65641559 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030899 Approved Vesicles Tissue enriched Mixed liver: 69.9 LEPROT FLJ90360, OB-RGRP, OBRGRP, VPS55 ENSG00000213625 Leptin receptor overlapping transcript 1 65420587-65436007 Predicted membrane proteins Evidence at protein level HPA069444 Approved Centrosome Expressed in all Expressed in all placenta: 79.7 LEPROTL1 my047, Vps55 ENSG00000104660 Leptin receptor overlapping transcript-like 1 8 30095398-30177208 Predicted membrane proteins Evidence at protein level HPA047911 Uncertain Renal cancer:1.94e-5 (unfavourable), Colorectal cancer:9.04e-4 (favourable) Expressed in all Expressed in all placenta: 119.4 LETM1 ENSG00000168924 Leucine zipper-EF-hand containing transmembrane protein 1 4 1811479-1856247 Predicted membrane proteins, Transporters Evidence at protein level HPA011029, HPA011100 Supported Validated Mitochondria Prostate cancer:1.77e-4 (unfavourable), Liver cancer:1.79e-4 (unfavourable), Renal cancer:8.90e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 16.3 LETM2 FLJ25409 ENSG00000165046 Leucine zipper-EF-hand containing transmembrane protein 2 8 38386207-38409527 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA025032, HPA053676 Uncertain Approved Nucleus
Nuclear bodies
Cytosol Mixed Tissue enriched 9 testis: 39.3 cerebral cortex: 4.2 LETMD1 HCCR1 ENSG00000050426 LETM1 domain containing 1 12 51047962-51060424 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA074361 Supported Nucleoplasm
Mitochondria Urothelial cancer:3.16e-4 (favourable), Renal cancer:3.26e-4 (favourable) Expressed in all Expressed in all thyroid gland: 61.5 LGR4 GPR48 ENSG00000205213 Leucine-rich repeat containing G protein-coupled receptor 4 11 27365961-27472775 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030267, HPA054350 Uncertain Approved Microtubule organizing center Renal cancer:2.00e-7 (favourable) Expressed in all Expressed in all kidney: 55.7 LGR5 FEX, GPR49, GPR67, HG38 ENSG00000139292 Leucine-rich repeat containing G protein-coupled receptor 5 12 71439770-71586310 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA012530 Approved Lung cancer:5.09e-4 (favourable) Group enriched Tissue enhanced fallopian tube: 26.3;placenta: 26.7 seminal vesicle: 9.7 LGR6 FLJ14471 ENSG00000133067 Leucine-rich repeat containing G protein-coupled receptor 6 1 202193901-202319781 G-protein coupled receptors, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008556 Approved Approved Nucleoplasm
Plasma membrane Glioma:2.00e-4 (unfavourable) Tissue enhanced Tissue enhanced fallopian tube: 14.1 gallbladder: 9.6 LHCGR HHG, LCGR, LGR2, LHR, ULG5 ENSG00000138039 Luteinizing hormone/choriogonadotropin receptor 2 48686775-48755730 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009814 Uncertain Not detected Group enriched 5 adipose tissue: 1.3;adrenal gland: 1.1;ovary: 1.5;testis: 4.3;thyroid gland: 1.1 breast,esophagus: 0.3 LHFP MGC22429 ENSG00000183722 Lipoma HMGIC fusion partner 13 39342892-39603528 Cancer-related genes, Disease related genes, Predicted membrane proteins Evidence at protein level HPA058975 Approved Approved Nucleoli Renal cancer:1.20e-7 (unfavourable), Urothelial cancer:2.30e-4 (unfavourable) Expressed in all Mixed placenta: 195.0 LHFPL1 ENSG00000182508 Lipoma HMGIC fusion partner-like 1 X 112630648-112680054 Predicted membrane proteins Evidence at transcript level HPA003029 Uncertain Mixed Tissue enhanced cerebral cortex: 1.8 seminal vesicle: 1.3 LHFPL2 KIAA0206 ENSG00000145685 Lipoma HMGIC fusion partner-like 2 5 78485215-78770021 Predicted membrane proteins Evidence at protein level HPA042402 Uncertain Approved Vesicles
Actin filaments Renal cancer:3.45e-7 (unfavourable), Liver cancer:2.73e-4 (unfavourable) Expressed in all Mixed gallbladder: 36.4 LHFPL3 LHFPL4 ENSG00000187416 Lipoma HMGIC fusion partner-like 3 7 104328656-104907232 Predicted membrane proteins Evidence at transcript level HPA069691 Approved Vesicles Tissue enriched Tissue enriched 11 cerebral cortex: 48.9 cervix, uterine: 4.6 LHFPL4 ENSG00000156959 Lipoma HMGIC fusion partner-like 4 3 9498361-9553802 Predicted membrane proteins Evidence at protein level HPA041421 Uncertain Approved Nucleus
Golgi apparatus Group enriched Tissue enriched 9 cerebral cortex: 23.1 adrenal gland: 2.6 LHFPL5 DFNB67, dJ510O8.8, MGC33835, Tmhs ENSG00000197753 Lipoma HMGIC fusion partner-like 5 6 35805293-35833874 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA055110 Uncertain Not detected Tissue enhanced epididymis: 12.0 bone marrow: 4.2 LIFR CD118 ENSG00000113594 Leukemia inhibitory factor receptor alpha 5 38474963-38608354 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004478, CAB010252 Approved Approved Nuclear speckles
Golgi apparatus Renal cancer:1.40e-7 (favourable), Lung cancer:1.92e-4 (favourable) Mixed Mixed thyroid gland: 71.7 LILRA4 CD85g, ILT7 ENSG00000239961 Leukocyte immunoglobulin-like receptor, subfamily A (with TM domain), member 4 19 54333185-54339150 CD markers, Predicted membrane proteins Evidence at protein level HPA049418 Approved Mixed Tissue enhanced spleen: 2.1;tonsil: 2.6 lymph node: 0.9 LILRB4 CD85k, HM18, ILT3, LIR-5, LIR5 ENSG00000186818 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 4 19 54643889-54670359 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052807 Approved Expressed in all Tissue enhanced appendix: 15.1;lymph node: 13.6 urinary bladder: 8.5 LILRB5 CD85c, LIR-8, LIR8 ENSG00000105609 Leukocyte immunoglobulin-like receptor, subfamily B (with TM and ITIM domains), member 5 19 54249431-54257301 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012069 Approved Mixed Tissue enhanced spleen: 26.5 adipose tissue: 11.4 LIME1 dJ583P15.4, FLJ20406, LIME ENSG00000203896 Lck interacting transmembrane adaptor 1 20 63736283-63739103 Predicted secreted proteins Evidence at protein level CAB015363 Approved Urothelial cancer:6.92e-6 (favourable), Renal cancer:5.04e-5 (unfavourable) Expressed in all Tissue enhanced liver: 19.5;stomach: 17.9 kidney: 14.9 LINC00493 LOC388789 ENSG00000232388 Long intergenic non-protein coding RNA 493 20 18567347-18569563 Predicted membrane proteins Evidence at transcript level HPA068733 Approved Nucleoplasm
Cytosol Urothelial cancer:7.84e-5 (favourable) Expressed in all Expressed in all epididymis: 155.5 LINGO1 FLJ14594, LERN1, LRRN6A ENSG00000169783 Leucine rich repeat and Ig domain containing 1 15 77613027-77820900 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA074653 Approved Plasma membrane Renal cancer:3.23e-7 (unfavourable) Expressed in all Tissue enriched 13 cerebral cortex: 131.2 heart muscle,placenta: 9.7 LINGO2 LERN3, LRRN6C ENSG00000174482 Leucine rich repeat and Ig domain containing 2 9 27948078-28670286 Predicted membrane proteins Evidence at transcript level HPA016633, CAB025361 Approved Mixed Tissue enhanced endometrium: 11.8;smooth muscle: 12.8 thyroid gland: 4.9 LINGO3 LERN2, LRRN6B ENSG00000220008 Leucine rich repeat and Ig domain containing 3 19 2289784-2292024 Predicted membrane proteins Evidence at protein level HPA043781, HPA055932, HPA059558 Uncertain Approved Mitochondria Tissue enhanced Tissue enhanced spleen: 3.9 appendix: 1.7 LINGO4 LRRN6D ENSG00000213171 Leucine rich repeat and Ig domain containing 4 1 151800264-151806154 Predicted membrane proteins Evidence at transcript level HPA060781 Uncertain Mixed Tissue enhanced adrenal gland: 2.3;skeletal muscle: 4.1 fallopian tube: 1.0 LINS1 LINS, WINS1 ENSG00000140471 Lines homolog 1 15 100559369-100603230 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA038578, HPA038579 Approved Approved Nucleoplasm Expressed in all Expressed in all thyroid gland: 14.0 LIPH LPDLR, mPA-PLA1, mPA-PLA1alpha, PLA1B ENSG00000163898 Lipase, member H 3 185506262-185552613 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA049079 Approved Renal cancer:9.20e-5 (favourable), Thyroid cancer:4.21e-4 (favourable), Pancreatic cancer:4.59e-4 (unfavourable), Endometrial cancer:9.40e-4 (unfavourable) Mixed Tissue enhanced rectum: 41.5;stomach: 45.3 colon: 36.4 LITAF FLJ38636, PIG7, SIMPLE, TP53I7 ENSG00000189067 Lipopolysaccharide-induced TNF factor 16 11547722-11636381 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006960 Approved Supported Nucleoplasm
Vesicles
Cytosol Glioma:1.78e-4 (unfavourable), Testis cancer:6.25e-4 (unfavourable) Expressed in all Expressed in all appendix: 231.9 LMAN1 ERGIC-53, ERGIC53, F5F8D, FMFD1, gp58, MCFD1, MR60 ENSG00000074695 Lectin, mannose-binding, 1 18 59327823-59359962 Disease related genes, Predicted membrane proteins Evidence at protein level HPA002320, CAB037163 Supported Uncertain Cytosol Expressed in all Expressed in all thyroid gland: 124.8 LMAN2 C5orf8, GP36B, VIP36 ENSG00000169223 Lectin, mannose-binding 2 5 177331562-177351852 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003927 Approved Renal cancer:8.53e-4 (unfavourable) Expressed in all Expressed in all epididymis: 162.0 LMAN2L DKFZp564L2423, VIPL ENSG00000114988 Lectin, mannose-binding 2-like 2 96705929-96740064 Predicted membrane proteins Evidence at protein level HPA026600 Approved Expressed in all Mixed fallopian tube: 27.7 LMBR1 ACHP, C7orf2, FLJ11665, ZRS ENSG00000105983 Limb development membrane protein 1 7 156668946-156893230 Disease related genes, Predicted membrane proteins Evidence at protein level HPA016592 Approved Approved Cytosol Renal cancer:1.44e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 45.4 LMBRD1 bA810I22.1, C6orf209, cblF, FLJ11240 ENSG00000168216 LMBR1 domain containing 1 6 69675802-69797111 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019547 Uncertain Renal cancer:1.07e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 170.0 LMBRD2 DKFZp434H2226 ENSG00000164187 LMBR1 domain containing 2 5 36098412-36151961 Predicted membrane proteins Evidence at protein level HPA012165 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all cerebral cortex: 25.5 LMF2 TMEM112B, TMEM153 ENSG00000100258 Lipase maturation factor 2 22 50502949-50507691 Predicted membrane proteins Evidence at protein level HPA062626 Approved Approved Centrosome Cervical cancer:3.47e-4 (favourable) Expressed in all Expressed in all pancreas: 38.0 LMLN Gp63, Msp ENSG00000185621 Leishmanolysin-like (metallopeptidase M8 family) 3 197960200-198043720 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016481, HPA028844 Uncertain Supported Focal adhesion sites
Cytosol Endometrial cancer:6.77e-4 (favourable) Expressed in all Tissue enhanced testis: 18.7 epididymis: 12.7 LMO7 FBX20, FBXO20, KIAA0858 ENSG00000136153 LIM domain 7 13 75620434-75859870 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020923, HPA050184 Approved Supported Actin filaments
Cytosol Renal cancer:7.75e-12 (favourable), Pancreatic cancer:3.51e-4 (unfavourable), Endometrial cancer:5.12e-4 (unfavourable) Expressed in all Expressed in all lung: 269.8 LMTK2 AATYK2, BREK, cprk, KIAA1079, KPI-2, KPI2, LMR2, PPP1R100 ENSG00000164715 Lemur tyrosine kinase 2 7 98106885-98209633 Enzymes, Predicted membrane proteins Evidence at protein level HPA010657, HPA041836 Uncertain Approved Nuclear speckles
Plasma membrane
Microtubule organizing center
Cytosol Renal cancer:1.12e-7 (favourable), Ovarian cancer:8.03e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 28.0 LMTK3 KIAA1883, LMR3, PPP1R101, TYKLM3 ENSG00000142235 Lemur tyrosine kinase 3 19 48485271-48513189 Enzymes, Predicted membrane proteins Evidence at protein level HPA040203 Approved Nucleoplasm
Cell Junctions Renal cancer:3.18e-8 (favourable) Mixed Group enriched 5 cerebral cortex: 20.4;parathyroid gland: 4.8 duodenum: 2.3 LNPEP CAP, P-LAP, PLAP ENSG00000113441 Leucyl/cystinyl aminopeptidase 5 96935394-97037515 Enzymes, Predicted membrane proteins Evidence at protein level HPA043642 Approved Expressed in all Mixed parathyroid gland: 22.9 LONRF2 FLJ45273, RNF192 ENSG00000170500 LON peptidase N-terminal domain and ring finger 2 2 100273291-100322733 Predicted intracellular proteins Evidence at protein level HPA057366 Supported Nucleus Pancreatic cancer:6.42e-5 (favourable) Tissue enhanced Tissue enhanced epididymis: 54.9 endometrium: 44.9 LPAR1 edg-2, EDG2, Gpcr26, GPR26, LPA1, Mrec1.3, rec.1.3, vzg-1 ENSG00000198121 Lysophosphatidic acid receptor 1 9 110873263-111038458 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA050667 Approved Nuclear speckles
Plasma membrane Expressed in all Mixed cervix, uterine: 90.9 LPAR2 EDG-4, EDG4, LPA2 ENSG00000064547 Lysophosphatidic acid receptor 2 19 19623668-19628930 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA019616 Approved Renal cancer:1.61e-7 (unfavourable), Stomach cancer:1.43e-4 (favourable) Expressed in all Mixed testis: 40.7 LPAR3 Edg-7, EDG7, HOFNH30, LP-A3, LPA3, RP4-678I3 ENSG00000171517 Lysophosphatidic acid receptor 3 1 84811602-84893213 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013421 Uncertain Supported Plasma membrane Ovarian cancer:4.31e-5 (favourable) Tissue enhanced Tissue enhanced fallopian tube: 66.2 prostate: 21.5 LPAR4 GPR23, LPA4, P2RY9, P2Y5-LIKE, P2Y9 ENSG00000147145 Lysophosphatidic acid receptor 4 X 78747709-78757094 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054951, HPA055571 Uncertain Tissue enhanced Tissue enhanced ovary: 4.5 cerebral cortex: 2.2 LPAR5 GPR92, GPR93, KPG_010, LPA5 ENSG00000184574 Lysophosphatidic acid receptor 5 12 6618835-6636447 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013170 Approved Thyroid cancer:6.56e-5 (favourable) Mixed Mixed tonsil: 11.0 LPAR6 P2RY5, P2Y5 ENSG00000139679 Lysophosphatidic acid receptor 6 13 48389567-48444704 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA028934, HPA076273 Approved Supported Vesicles
Plasma membrane Renal cancer:3.60e-4 (unfavourable), Lung cancer:6.22e-4 (favourable) Expressed in all Expressed in all placenta: 100.1 LPCAT1 AGPAT10, AGPAT9, AYTL2, FLJ12443 ENSG00000153395 Lysophosphatidylcholine acyltransferase 1 5 1456480-1523977 Enzymes, Predicted membrane proteins Evidence at protein level HPA012501, HPA022268 Supported Supported Endoplasmic reticulum
Lipid droplets Liver cancer:1.88e-8 (unfavourable), Renal cancer:2.64e-7 (unfavourable), Pancreatic cancer:4.90e-5 (favourable), Cervical cancer:7.11e-5 (unfavourable), Endometrial cancer:3.67e-4 (unfavourable) Expressed in all Tissue enhanced lung: 19.2;spleen: 15.1 cerebral cortex: 4.4 LPCAT2 AGPAT11, AYTL1, FLJ20481, LysoPAFAT ENSG00000087253 Lysophosphatidylcholine acyltransferase 2 16 55508998-55586670 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007891, HPA008433 Supported Supported Validated Endoplasmic reticulum
Lipid droplets Endometrial cancer:8.03e-6 (favourable), Colorectal cancer:3.43e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 141.9 bone marrow: 56.6 LPCAT4 AGPAT7, AYTL3, FLJ10257, LPAAT-eta, LPEAT2 ENSG00000176454 Lysophosphatidylcholine acyltransferase 4 15 34358618-34367278 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030719 Uncertain Liver cancer:9.99e-4 (unfavourable) Expressed in all Mixed rectum: 39.2 LPGAT1 FAM34A, FAM34A1, KIAA0205, NET8 ENSG00000123684 Lysophosphatidylglycerol acyltransferase 1 1 211743457-211830772 Predicted membrane proteins Evidence at protein level HPA008304 Approved Expressed in all Expressed in all thyroid gland: 43.0 LRAT LCA14 ENSG00000121207 Lecithin retinol acyltransferase (phosphatidylcholine--retinol O-acyltransferase) 4 154626945-154753118 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008397, HPA070726 Uncertain Uncertain Endoplasmic reticulum
Golgi apparatus Mixed Mixed thyroid gland: 2.3 LRBA BGL, CDC4L, LAB300, LBA ENSG00000198589 LPS-responsive vesicle trafficking, beach and anchor containing 4 150264531-151015727 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019366, HPA023597 Approved Approved Golgi apparatus
Cytosol Renal cancer:2.22e-16 (favourable) Expressed in all Expressed in all parathyroid gland: 61.5 LRCH1 CHDC1, KIAA1016 ENSG00000136141 Leucine-rich repeats and calponin homology (CH) domain containing 1 13 46553168-46753040 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021536 Uncertain Approved Nucleoli
Actin filaments
Cytosol Renal cancer:1.04e-4 (favourable), Ovarian cancer:5.75e-4 (unfavourable), Cervical cancer:6.24e-4 (unfavourable), Lung cancer:6.67e-4 (unfavourable) Expressed in all Expressed in all endometrium: 26.6 LRCH3 MGC4126 ENSG00000186001 Leucine-rich repeats and calponin homology (CH) domain containing 3 3 197791226-197888436 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012380, HPA017299 Uncertain Validated Cytosol Liver cancer:2.95e-4 (unfavourable) Expressed in all Expressed in all testis: 26.2 LRCH4 LRN, LRRN1 ENSG00000077454 Leucine-rich repeats and calponin homology (CH) domain containing 4 7 100574011-100586153 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA037667, HPA037668 Supported Approved Nucleoplasm
Focal adhesion sites
Cytosol Colorectal cancer:1.61e-7 (unfavourable) Expressed in all Expressed in all spleen: 107.7 LRFN2 FIGLER2, KIAA1246, SALM1 ENSG00000156564 Leucine rich repeat and fibronectin type III domain containing 2 6 40391586-40587465 Predicted membrane proteins Evidence at protein level HPA013653, HPA076660 Uncertain Supported Vesicles Not detected Tissue enriched 5 cerebral cortex: 6.9 spleen,testis: 1.3 LRFN3 FIGLER1, MGC2656, SALM4 ENSG00000126243 Leucine rich repeat and fibronectin type III domain containing 3 19 35935358-35945767 Predicted membrane proteins Evidence at transcript level HPA048923 Approved Renal cancer:8.46e-7 (favourable) Expressed in all Mixed cerebral cortex: 8.2 LRFN5 C14orf146, FIGLER8, SALM5 ENSG00000165379 Leucine rich repeat and fibronectin type III domain containing 5 14 41607570-41904549 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001177 Uncertain Mixed Tissue enhanced parathyroid gland: 51.4 cervix, uterine: 16.7 LRIG1 DKFZP586O1624, LIG-1, LIG1 ENSG00000144749 Leucine-rich repeats and immunoglobulin-like domains 1 3 66378797-66501263 Predicted membrane proteins Evidence at protein level HPA011846 Approved Approved Cytosol Lung cancer:3.01e-5 (favourable), Urothelial cancer:1.50e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 59.8 LRIG2 KIAA0806 ENSG00000198799 Leucine-rich repeats and immunoglobulin-like domains 2 1 113073209-113132260 Disease related genes, Predicted membrane proteins Evidence at protein level HPA015538 Uncertain Supported Nucleus
Golgi apparatus Endometrial cancer:9.37e-4 (unfavourable) Expressed in all Mixed parathyroid gland,thyroid gland: 5.6 LRIG3 FLJ90440, KIAA3016 ENSG00000139263 Leucine-rich repeats and immunoglobulin-like domains 3 12 58872149-58920522 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010773 Approved Approved Cytosol Expressed in all Tissue enhanced thyroid gland: 97.1 skin: 33.1 LRIT2 AC022389.4, LRRC22 ENSG00000204033 Leucine-rich repeat, immunoglobulin-like and transmembrane domains 2 10 84220495-84225589 Predicted membrane proteins Evidence at protein level HPA037788 Uncertain Not detected Tissue enhanced cerebral cortex: 1.0;rectum: 1.2;skin: 3.1 colon: 0.6 LRIT3 CSNB1F, FIGLER4, FLJ44691 ENSG00000183423 Leucine-rich repeat, immunoglobulin-like and transmembrane domains 3 4 109848202-109872315 Disease related genes, Predicted membrane proteins Evidence at protein level HPA013454 Uncertain Approved Nucleoplasm
Mitochondria
Cytosol Not detected Not detected kidney: 0.9 LRMP JAW1 ENSG00000118308 Lymphoid-restricted membrane protein 12 25021002-25108334 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002967, HPA018505 Supported Supported Nucleus
Vesicles
Cytosol Mixed Tissue enhanced lymph node: 210.1;tonsil: 193.0 appendix: 65.5 LRP1 A2MR, APOER, APR, CD91, LRP, LRP1A ENSG00000123384 Low density lipoprotein receptor-related protein 1 12 57128493-57213351 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004182, CAB018621, HPA022903 Supported Supported Nucleoli
Cytosol Urothelial cancer:1.29e-5 (unfavourable), Renal cancer:1.52e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 123.2 LRP10 DKFZP564C1940, LRP9, MGC8675, MST087, MSTP087 ENSG00000197324 Low density lipoprotein receptor-related protein 10 14 22871613-22881580 Predicted membrane proteins Evidence at protein level HPA000932 Approved Nucleus
Nucleoli Liver cancer:3.54e-7 (unfavourable), Renal cancer:6.31e-5 (favourable), Lung cancer:9.17e-4 (unfavourable) Expressed in all Expressed in all esophagus: 180.2 LRP11 bA350J20.3, MANSC3 ENSG00000120256 Low density lipoprotein receptor-related protein 11 6 149818798-149864026 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064002 Approved Mitochondria Breast cancer:2.31e-8 (unfavourable), Liver cancer:2.01e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 88.0 LRP12 FLJ12929, ST7 ENSG00000147650 Low density lipoprotein receptor-related protein 12 8 104489231-104589024 Predicted membrane proteins Evidence at protein level HPA017245 Uncertain Approved Nucleoli fibrillar center
Plasma membrane
Mitochondria Endometrial cancer:2.67e-4 (unfavourable) Expressed in all Mixed endometrium: 27.6 LRP1B LRP-DIT, LRPDIT ENSG00000168702 Low density lipoprotein receptor-related protein 1B 2 140231423-142131701 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA069094, HPA074788 Approved Uncertain Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 16.5;thyroid gland: 9.6 epididymis: 2.7 LRP2 DBS, gp330 ENSG00000081479 Low density lipoprotein receptor-related protein 2 2 169127109-169362685 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005980, HPA064792 Supported Approved Vesicles
Mitochondria Renal cancer:3.43e-5 (favourable) Group enriched Group enriched 6 kidney: 49.4;parathyroid gland: 153.0;thyroid gland: 36.8 breast: 14.1 LRP4 CLSS, LRP-4, MEGF7, SOST2 ENSG00000134569 Low density lipoprotein receptor-related protein 4 11 46856868-46918642 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011934, HPA012300 Approved Uncertain Nucleus
Nucleoli
Mitochondria Expressed in all Tissue enhanced cerebral cortex: 35.5;skin: 38.0 parathyroid gland: 12.9 LRP5 BMND1, EVR1, EVR4, HBM, LR3, LRP7, OPPG, OPS, OPTA1, VBCH2 ENSG00000162337 Low density lipoprotein receptor-related protein 5 11 68312609-68449275 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013001, HPA030505 Approved Renal cancer:3.55e-10 (favourable) Expressed in all Expressed in all small intestine: 50.8 LRP6 ADCAD2 ENSG00000070018 Low density lipoprotein receptor-related protein 6 12 12116025-12267012 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004490, HPA029925 Supported Expressed in all Mixed parathyroid gland: 16.2 LRPPRC GP130, LRP130, LSFC ENSG00000138095 Leucine-rich pentatricopeptide repeat containing 2 43886508-43996005 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB033786, HPA036408, HPA036409 Supported Validated Mitochondria Liver cancer:2.31e-7 (unfavourable), Renal cancer:6.65e-6 (favourable), Endometrial cancer:1.72e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 78.8 LRRC15 LIB ENSG00000172061 Leucine rich repeat containing 15 3 194355247-194369743 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035503 Uncertain Approved Vesicles
Plasma membrane Tissue enhanced Mixed cervix, uterine,tonsil: 4.7 LRRC24 LRRC14OS ENSG00000254402 Leucine rich repeat containing 24 8 144522377-144527032 Predicted membrane proteins Evidence at protein level HPA028171, HPA052250 Supported Approved Vesicles Not detected Tissue enhanced cerebral cortex: 3.1;prostate: 3.0 parathyroid gland: 1.7 LRRC25 FLJ38116, MAPA ENSG00000175489 Leucine rich repeat containing 25 19 18391144-18397617 Predicted membrane proteins Evidence at protein level HPA029459 Approved Testis cancer:6.93e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 31.2;spleen: 41.3 bone marrow: 20.8 LRRC26 bA350O14.10 ENSG00000184709 Leucine rich repeat containing 26 9 137168758-137170051 Predicted membrane proteins Evidence at protein level HPA056312 Approved Supported Plasma membrane Endometrial cancer:4.82e-6 (favourable), Stomach cancer:3.48e-4 (favourable) Tissue enriched Group enriched 6 colon: 10.5;prostate: 29.3;salivary gland: 26.7 small intestine: 3.6 LRRC3 C21orf102 ENSG00000160233 Leucine rich repeat containing 3 21 44455486-44462196 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA017975 Uncertain Mixed Mixed liver: 4.1 LRRC37A KIAA0563 ENSG00000176681 Leucine rich repeat containing 37A 17 46292733-46337794 Predicted membrane proteins Evidence at protein level HPA042121, HPA042701, HPA043056, HPA045090, HPA049080 Supported Approved Vesicles Not detected Tissue enriched 8 testis: 13.5 skeletal muscle: 1.6 LRRC37A2 FLJ45049 ENSG00000238083 Leucine rich repeat containing 37, member A2 17 46511511-46555650 Predicted membrane proteins Evidence at protein level HPA042121, HPA042701, HPA043056, HPA045090, HPA049080 Supported Approved Vesicles Mixed Tissue enriched 35 testis: 11.8 appendix,bone marrow,lymph node: 0.3 LRRC37A3 FLJ34306, KIAA0563 ENSG00000176809 Leucine rich repeat containing 37, member A3 17 64854312-64919480 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042121, HPA042701, HPA043056, HPA045090 Supported Approved Vesicles Renal cancer:3.25e-6 (unfavourable) Mixed Tissue enhanced testis: 31.5 epididymis: 14.5 LRRC37B ENSG00000185158 Leucine rich repeat containing 37B 17 32007872-32053504 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015134, HPA015135 Approved Approved Cytosol Mixed Tissue enhanced testis: 32.4 bone marrow: 16.5 LRRC38 ENSG00000162494 Leucine rich repeat containing 38 1 13474977-13514048 Predicted membrane proteins Evidence at protein level HPA038778 Approved Mixed Group enriched 19 adrenal gland: 20.0;skeletal muscle: 10.5 placenta: 0.8 LRRC3B LRP15 ENSG00000179796 Leucine rich repeat containing 3B 3 26622806-26710776 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015568 Approved Group enriched Group enriched 7 cerebral cortex: 19.2;skeletal muscle: 3.9;testis: 13.0 endometrium,ovary: 1.6 LRRC3C ENSG00000204913 Leucine rich repeat containing 3C 17 39941474-39944747 Predicted membrane proteins Evidence at protein level HPA071271 Uncertain Not detected Not detected testis: 0.9 LRRC4 NAG14 ENSG00000128594 Leucine rich repeat containing 4 7 128027071-128032107 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051100 Uncertain Golgi apparatus Renal cancer:6.98e-4 (favourable), Endometrial cancer:8.19e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 53.0 parathyroid gland: 13.0 LRRC41 MUF1 ENSG00000132128 Leucine rich repeat containing 41 1 46261196-46303608 Predicted intracellular proteins Evidence at protein level HPA051941 Uncertain Approved Nucleoplasm
Nuclear bodies Liver cancer:1.66e-9 (unfavourable), Cervical cancer:5.50e-4 (unfavourable), Renal cancer:6.34e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 68.8 LRRC4B DKFZp761A179, HSM, LRIG4 ENSG00000131409 Leucine rich repeat containing 4B 19 50516892-50568045 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA058986 Uncertain Group enriched Tissue enhanced cerebral cortex: 61.6 cervix, uterine: 12.8 LRRC4C KIAA1580, NGL-1 ENSG00000148948 Leucine rich repeat containing 4C 11 40114203-41459773 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051335, HPA054800 Approved Approved Cytosol Tissue enhanced Tissue enriched 7 cerebral cortex: 34.5 cervix, uterine: 4.7 LRRC53 ENSG00000162621 Leucine rich repeat containing 53 1 74469878-74512614 Predicted membrane proteins No evidence HPA054062 Uncertain Not detected Not detected cerebral cortex: 0.5 LRRC55 FLJ45686 ENSG00000183908 Leucine rich repeat containing 55 11 57181747-57191717 Predicted membrane proteins, Transporters Evidence at protein level HPA014053 Uncertain Group enriched Tissue enhanced cerebral cortex: 6.6 lymph node: 2.4 LRRC59 FLJ21675, PRO1855 ENSG00000108829 Leucine rich repeat containing 59 17 50375059-50397553 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030827, HPA030829 Supported Validated Endoplasmic reticulum Renal cancer:1.19e-6 (unfavourable), Liver cancer:3.12e-6 (unfavourable), Head and neck cancer:1.00e-5 (unfavourable), Urothelial cancer:1.90e-5 (unfavourable), Colorectal cancer:2.60e-4 (favourable), Pancreatic cancer:6.87e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 91.6 LRRC6 CILD19, LRTP, TSLRP ENSG00000129295 Leucine rich repeat containing 6 8 132571953-132675617 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA028058 Approved Thyroid cancer:5.98e-4 (unfavourable) Mixed Tissue enhanced fallopian tube: 30.9;testis: 46.6 kidney: 12.5 LRRC63 RP11-139H14.4 ENSG00000173988 Leucine rich repeat containing 63 13 46211943-46277366 Predicted intracellular proteins Evidence at transcript level HPA039318, HPA039763 Uncertain Approved Golgi apparatus Not detected Tissue enhanced epididymis: 3.5;testis: 2.5 cerebral cortex: 1.1 LRRC66 ENSG00000188993 Leucine rich repeat containing 66 4 51993702-52017620 Predicted membrane proteins Evidence at transcript level HPA014549, HPA027839 Uncertain Mixed Tissue enhanced duodenum: 23.2;small intestine: 21.0 rectum: 6.5 LRRC70 LOC100130733, SLRN ENSG00000186105 Leucine rich repeat containing 70 5 62578735-62581448 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013409 Uncertain Mixed Mixed thyroid gland: 6.4 LRRC74A C14orf166B, LRRC74 ENSG00000100565 Leucine rich repeat containing 74A 14 76826372-76870302 Predicted intracellular proteins Evidence at transcript level HPA035094 Uncertain Not detected Tissue enriched 17 testis: 7.0 spleen,stomach: 0.4 LRRC8B KIAA0231, TA-LRRP ENSG00000197147 Leucine rich repeat containing 8 family, member B 1 89524836-89597864 Predicted membrane proteins, Transporters Evidence at protein level HPA017950 Uncertain Approved Nuclear speckles Colorectal cancer:7.15e-4 (favourable), Endometrial cancer:9.99e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 38.3 testis: 30.6 LRRC8C AD158 ENSG00000171488 Leucine rich repeat containing 8 family, member C 1 89633072-89769903 Predicted membrane proteins, Transporters Evidence at protein level HPA029347 Uncertain Approved Golgi apparatus Renal cancer:3.75e-4 (unfavourable) Expressed in all Mixed smooth muscle: 22.4 LRRC8D FLJ10470, LRRC5 ENSG00000171492 Leucine rich repeat containing 8 family, member D 1 89821014-89936611 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014745 Approved Nucleoplasm
Mitochondria Endometrial cancer:3.21e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 36.0 LRRC8E FLJ23420 ENSG00000171017 Leucine rich repeat containing 8 family, member E 19 7888505-7902021 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020466 Uncertain Mixed Mixed skin: 11.2 LRRN1 FIGLER3 ENSG00000175928 Leucine rich repeat neuronal 1 3 3799437-3847703 Predicted membrane proteins Evidence at protein level HPA011071 Approved Approved Cytosol Mixed Tissue enhanced cerebral cortex: 44.4 parathyroid gland: 18.0 LRRN2 FIGLER7, GAC1, LRANK1, LRRN5 ENSG00000170382 Leucine rich repeat neuronal 2 1 204617170-204685733 Predicted membrane proteins Evidence at transcript level HPA029124 Uncertain Approved Endoplasmic reticulum Endometrial cancer:2.59e-7 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 23.4;parathyroid gland: 21.0 fallopian tube: 11.9 LRRN3 FIGLER5, FLJ11129, NLRR3 ENSG00000173114 Leucine rich repeat neuronal 3 7 111091006-111125454 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA043820, HPA046792 Uncertain Approved Nucleus
Cytosol Group enriched Tissue enhanced adrenal gland: 30.9;cerebral cortex: 31.2;testis: 29.0;thyroid gland: 33.4 lung: 11.6 LRRN4 C20orf75, dJ1056H1.1, NLRR4 ENSG00000125872 Leucine rich repeat neuronal 4 20 6040778-6054049 Predicted membrane proteins Evidence at protein level HPA075974 Approved Nucleus
Nucleoli
Cytosol Group enriched Tissue enriched 11 lung: 13.6 fallopian tube: 1.3 LRRN4CL ENSG00000177363 LRRN4 C-terminal like 11 62686402-62689899 Predicted membrane proteins Evidence at protein level HPA050317 Approved Approved Nucleoplasm
Nuclear bodies Tissue enriched Mixed endometrium: 16.8 LRRTM1 FLJ32082 ENSG00000162951 Leucine rich repeat transmembrane neuronal 1 2 80288351-80304749 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA062660 Approved Group enriched Tissue enhanced cerebral cortex: 13.3;salivary gland: 4.9 thyroid gland: 2.2 LRTM1 HT017 ENSG00000144771 Leucine-rich repeats and transmembrane domains 1 3 54918237-54967088 Predicted membrane proteins Evidence at transcript level HPA013839 Uncertain Tissue enhanced Group enriched 5 esophagus: 4.3;skeletal muscle: 9.1;spleen: 9.0 prostate: 1.4 LRTM2 ENSG00000166159 Leucine-rich repeats and transmembrane domains 2 12 1820267-1836752 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055094 Uncertain Not detected Tissue enriched 47 cerebral cortex: 8.3 testis: 0.1 LRTOMT CFAP111, COMT2, DFNB63, LRRC51 ENSG00000184154 Leucine rich transmembrane and O-methyltransferase domain containing 11 72080331-72110782 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039949 Approved Approved Nucleoli
Microtubules Ovarian cancer:5.36e-4 (favourable), Endometrial cancer:7.70e-4 (favourable) Expressed in all Expressed in all testis: 137.8 LSAMP IGLON3, LAMP ENSG00000185565 Limbic system-associated membrane protein 3 115802363-117139389 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054051, HPA076122 Approved Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 103.1 prostate: 42.3 LSMEM1 C7orf53, FLJ39575 ENSG00000181016 Leucine-rich single-pass membrane protein 1 7 112480853-112491062 Predicted membrane proteins Evidence at protein level HPA013753, HPA047988 Uncertain Supported Cytosol Mixed Tissue enriched 11 skeletal muscle: 31.8 testis: 2.8 LSR ILDR3, LISCH7 ENSG00000105699 Lipolysis stimulated lipoprotein receptor 19 35248330-35267964 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007270 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.09e-4 (favourable) Expressed in all Expressed in all stomach: 131.1 LTB p33, TNFC, TNFSF3 ENSG00000227507 Lymphotoxin beta (TNF superfamily, member 3) 6 31580525-31582522 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048884 Approved Approved Centrosome Renal cancer:3.31e-7 (unfavourable), Endometrial cancer:2.36e-6 (favourable), Head and neck cancer:1.74e-4 (favourable) Expressed in all Group enriched 8 appendix: 19.4;lymph node: 22.5;spleen: 26.4;tonsil: 10.6 bone marrow: 2.6 LTB4R BLTR, CMKRL1, GPR16, LTB4R1, P2RY7, P2Y7 ENSG00000213903 Leukotriene B4 receptor 14 24311450-24318036 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA003873 Approved Renal cancer:3.44e-15 (unfavourable), Pancreatic cancer:1.85e-4 (favourable) Expressed in all Tissue enhanced skin: 165.5 esophagus: 42.8 LTB4R2 BLT2, BLTR2, JULF2, NOP9 ENSG00000213906 Leukotriene B4 receptor 2 14 24305734-24312053 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022689, HPA029680, HPA072921 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced skin: 40.6 spleen: 11.2 LTBR D12S370, TNF-R-III, TNFCR, TNFR-RP, TNFR2-RP, TNFRSF3 ENSG00000111321 Lymphotoxin beta receptor (TNFR superfamily, member 3) 12 6375045-6391571 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026202 Uncertain Approved Golgi apparatus Liver cancer:5.13e-4 (unfavourable), Renal cancer:5.92e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 88.1 LTK TYK1 ENSG00000062524 Leukocyte receptor tyrosine kinase 15 41503638-41513887 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA059545 Uncertain Approved Vesicles Mixed Mixed placenta: 15.1 LY6D E48 ENSG00000167656 Lymphocyte antigen 6 complex, locus D 8 142784880-142786592 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA024755, HPA064317 Supported Pancreatic cancer:1.94e-6 (unfavourable), Renal cancer:1.20e-4 (unfavourable) Group enriched Group enriched 11 esophagus: 634.4;skin: 717.6 tonsil: 63.5 LY6G5C C6orf20, G5c, NG33 ENSG00000204428 Lymphocyte antigen 6 complex, locus G5C 6 31676684-31684040 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038690 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:1.07e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 1.5 testis: 1.0 LY6G6F C6orf21, G6f, LY6G6D, NG32 ENSG00000204424 Lymphocyte antigen 6 complex, locus G6F 6 31706885-31710595 Predicted membrane proteins Evidence at protein level HPA008053 Uncertain Not detected Not detected bone marrow: 0.5 LY6K CT97, FLJ35226, HSJ001348 ENSG00000160886 Lymphocyte antigen 6 complex, locus K 8 142700111-142705127 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017770, CAB075742, CAB075743 Supported Supported Nucleoplasm
Plasma membrane Lung cancer:9.17e-5 (unfavourable) Mixed Tissue enriched 5 testis: 30.4 adipose tissue: 5.9 LY75 CD205, CLEC13B, DEC-205 ENSG00000054219 Lymphocyte antigen 75 2 159803355-159904749 CD markers, Predicted membrane proteins Evidence at protein level CAB001450, HPA049108, HPA054073 Supported Approved Golgi apparatus Renal cancer:2.39e-5 (unfavourable), Urothelial cancer:3.86e-4 (favourable) Mixed Mixed lymph node: 36.0 LY75-CD302 ENSG00000248672 LY75-CD302 readthrough 2 159771851-159904710 Predicted membrane proteins Evidence at protein level HPA049108 Uncertain Not detected Mixed appendix: 2.6 LY9 CD229, hly9, mLY9, SLAMF3 ENSG00000122224 Lymphocyte antigen 9 1 160796074-160828261 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050917 Approved Mixed Tissue enhanced lymph node: 35.0;spleen: 28.9;tonsil: 29.4 appendix: 18.5 LYPD3 C4.4A ENSG00000124466 LY6/PLAUR domain containing 3 19 43460787-43465660 Predicted membrane proteins Evidence at protein level HPA041529, HPA041797, HPA077859 Supported Approved Endoplasmic reticulum
Vesicles Lung cancer:7.86e-5 (unfavourable) Tissue enhanced Group enriched 5 esophagus: 676.5;skin: 594.5 tonsil: 118.9 LYPD5 FLJ30469 ENSG00000159871 LY6/PLAUR domain containing 5 19 43795929-43827206 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042511, HPA054670 Approved Approved Nucleoplasm
Cytosol Cervical cancer:5.84e-4 (favourable) Tissue enhanced Tissue enhanced skin: 43.8 testis: 12.3 LYPD6B CT116, LYPD7 ENSG00000150556 LY6/PLAUR domain containing 6B 2 149038107-149215262 Predicted secreted proteins, Transporters Evidence at transcript level HPA049239 Uncertain Mixed Tissue enhanced gallbladder: 58.8;skin: 56.6 testis: 42.1 LYPLA1 LPL1 ENSG00000120992 Lysophospholipase I 8 54046367-54102017 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050941, HPA063151 Supported Uncertain Nucleoplasm
Cytosol Pancreatic cancer:2.34e-4 (unfavourable) Expressed in all Expressed in all testis: 118.0 LYRM5 ENSG00000205707 LYR motif containing 5 12 25195216-25209645 Predicted intracellular proteins Evidence at protein level HPA044255 Approved Approved Microtubule organizing center Renal cancer:9.23e-5 (favourable), Breast cancer:9.63e-4 (favourable) Expressed in all Expressed in all testis: 111.5 LYSMD3 FLJ13542 ENSG00000176018 LysM, putative peptidoglycan-binding, domain containing 3 5 90515611-90529584 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018024 Approved Approved Cytosol Colorectal cancer:3.83e-4 (favourable), Renal cancer:9.25e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 39.0 LYSMD4 FLJ33008 ENSG00000183060 LysM, putative peptidoglycan-binding, domain containing 4 15 99715697-99733561 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA029152, HPA059824 Approved Approved Actin filaments
Cytosol Expressed in all Mixed skin: 18.4 LYVE1 LYVE-1, XLKD1 ENSG00000133800 Lymphatic vessel endothelial hyaluronan receptor 1 11 10556966-10611689 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025860, HPA042953 Supported Renal cancer:6.98e-5 (unfavourable), Ovarian cancer:1.07e-4 (unfavourable) Mixed Tissue enhanced adipose tissue: 155.7;placenta: 211.4 smooth muscle: 94.1 M6PR ENSG00000003056 Mannose-6-phosphate receptor (cation dependent) 12 8940363-8949955 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB034464, HPA040445 Approved Liver cancer:3.89e-4 (unfavourable) Expressed in all Expressed in all spleen: 178.5 MACF1 ABP620, ACF7, FLJ45612, FLJ46776, KIAA0465, KIAA1251, MACF ENSG00000127603 Microtubule-actin crosslinking factor 1 1 39081316-39487177 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013713, HPA068064, HPA068103 Approved Supported Plasma membrane
Cell Junctions
Actin filaments Renal cancer:2.77e-5 (favourable) Expressed in all Expressed in all lung: 137.3 MADD DENN, KIAA0358, RAB3GEP ENSG00000110514 MAP-kinase activating death domain 11 47269161-47330031 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038568 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.69e-5 (favourable), Endometrial cancer:6.62e-5 (favourable), Urothelial cancer:8.25e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 104.2 MAG GMA, S-MAG, SIGLEC-4A, SIGLEC4A ENSG00000105695 Myelin associated glycoprotein 19 35292125-35313804 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009345, HPA012499 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 164.0 ovary: 27.5 MAGEH1 APR1 ENSG00000187601 Melanoma antigen family H1 X 55452105-55453566 Predicted membrane proteins Evidence at protein level HPA011324 Uncertain Approved Nucleoli Endometrial cancer:1.37e-4 (unfavourable), Pancreatic cancer:2.60e-4 (favourable) Expressed in all Tissue enriched 5 epididymis: 607.0 cerebral cortex: 116.1 MAGOH MAGOH1, MAGOHA ENSG00000162385 Mago homolog, exon junction complex core component 1 53226892-53238610 Predicted intracellular proteins, Transporters Evidence at protein level CAB015425, HPA043036, HPA047754 Approved Supported Nucleus Renal cancer:1.45e-5 (unfavourable), Breast cancer:1.85e-4 (favourable) Expressed in all Expressed in all lymph node: 83.5 MAGOHB FLJ10292, MGN2 ENSG00000111196 Mago homolog B, exon junction complex core component 12 10604190-10613623 Predicted intracellular proteins Evidence at protein level HPA043036, HPA047754 Uncertain Renal cancer:5.04e-8 (unfavourable), Ovarian cancer:5.56e-6 (favourable), Stomach cancer:6.50e-4 (favourable) Expressed in all Mixed epididymis: 14.0 MAGT1 DKFZp564K142, IAP, MRX95, OST3B ENSG00000102158 Magnesium transporter 1 X 77826364-77895593 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA049851 Approved Breast cancer:1.30e-4 (unfavourable), Pancreatic cancer:3.55e-4 (unfavourable), Melanoma:8.98e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 136.9 MAL ENSG00000172005 Mal, T-cell differentiation protein 2 95025677-95053996 Predicted membrane proteins Evidence at protein level HPA065691 Approved Centrosome Renal cancer:3.96e-9 (favourable), Endometrial cancer:5.18e-6 (unfavourable) Mixed Tissue enriched 7 esophagus: 2459.4 tonsil: 328.8 MAL2 ENSG00000147676 Mal, T-cell differentiation protein 2 (gene/pseudogene) 8 119165034-119245673 Predicted membrane proteins Evidence at protein level HPA043831 Uncertain Breast cancer:4.57e-6 (unfavourable), Renal cancer:2.39e-5 (favourable), Endometrial cancer:8.44e-5 (unfavourable), Pancreatic cancer:3.98e-4 (unfavourable) Expressed in all Mixed esophagus: 267.5 MALL BENE ENSG00000144063 Mal, T-cell differentiation protein-like 2 110083870-110116566 Predicted membrane proteins Evidence at protein level HPA051410 Uncertain Pancreatic cancer:1.23e-4 (unfavourable) Mixed Tissue enhanced esophagus: 224.1;parathyroid gland: 315.0 small intestine: 186.2 MALRD1 bA265G8.2, C10orf112, Diet1 ENSG00000204740 MAM and LDL receptor class A domain containing 1 10 19048771-19790401 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035732, HPA038106, HPA046848 Uncertain Validated Golgi apparatus Tissue enhanced Group enriched 8 duodenum: 32.2;small intestine: 35.1 testis: 4.4 MAMDC4 AEGP, DKFZp434M1411 ENSG00000177943 MAM domain containing 4 9 136850943-136860799 Predicted membrane proteins Evidence at protein level CAB026377, HPA059977 Approved Approved Nucleoplasm
Cytosol Pancreatic cancer:1.88e-6 (favourable) Expressed in all Mixed spleen: 5.7 MAN1A1 ENSG00000111885 Mannosidase, alpha, class 1A, member 1 6 119177209-119349761 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037058, HPA053198, HPA063561 Uncertain Supported Golgi apparatus
Cytosol Expressed in all Expressed in all placenta: 111.4 MAN1A2 MAN1B ENSG00000198162 Mannosidase, alpha, class 1A, member 2 1 117367449-117528872 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034559, HPA057364 Supported Validated Golgi apparatus Ovarian cancer:4.08e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 43.5 MAN1B1 MANA-ER, MRT15 ENSG00000177239 Mannosidase, alpha, class 1B, member 1 9 137086927-137109187 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051516 Approved Uncertain Vesicles Liver cancer:1.45e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 33.0 MAN1C1 HMIC ENSG00000117643 Mannosidase, alpha, class 1C, member 1 1 25617468-25786207 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048352 Uncertain Uncertain Nucleus
Vesicles Pancreatic cancer:4.79e-4 (favourable), Lung cancer:7.55e-4 (favourable) Expressed in all Mixed thyroid gland: 40.6 MAN2A1 GOLIM7, MANA2 ENSG00000112893 Mannosidase, alpha, class 2A, member 1 5 109689366-109869625 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB022377, HPA026896 Supported Supported Golgi apparatus Expressed in all Expressed in all parathyroid gland: 39.9 MAN2A2 HsT19662, MANA2X ENSG00000196547 Mannosidase, alpha, class 2A, member 2 15 90902218-90922584 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017226 Approved Renal cancer:8.95e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 46.4 MAN2B1 LAMAN, MANB ENSG00000104774 Mannosidase, alpha, class 2B, member 1 19 12646511-12666742 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted secreted proteins Evidence at protein level HPA041530, HPA053404 Supported Approved Nucleoplasm
Vesicles Renal cancer:1.94e-5 (unfavourable) Expressed in all Expressed in all spleen: 96.8 MANBAL dJ1141E15.2 ENSG00000101363 Mannosidase, beta A, lysosomal-like 20 37289638-37317260 Predicted membrane proteins Evidence at protein level HPA052348 Approved Nucleus
Mitochondria Renal cancer:3.62e-4 (favourable), Liver cancer:7.07e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 95.1 MANSC1 FLJ10298, LOH12CR3 ENSG00000111261 MANSC domain containing 1 12 12326056-12350541 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007955, HPA007956 Approved Approved Golgi apparatus
Vesicles Renal cancer:3.30e-5 (favourable) Expressed in all Mixed parathyroid gland: 24.2 MANSC4 ENSG00000205693 MANSC domain containing 4 12 27762738-27771276 Predicted membrane proteins Evidence at transcript level HPA039454, HPA039682 Uncertain Not detected Tissue enhanced testis: 3.2 placenta: 0.8 MAOA ENSG00000189221 Monoamine oxidase A X 43654907-43746824 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009437, HPA054807, HPA059299 Supported Validated Mitochondria Expressed in all Mixed small intestine: 253.2 MAOB ENSG00000069535 Monoamine oxidase B X 43766611-43882447 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA002328, CAB037200 Supported Approved Nucleoli
Mitochondria Expressed in all Mixed seminal vesicle: 213.0 MAP10 KIAA1383, MTR120 ENSG00000212916 Microtubule-associated protein 10 1 232804892-232808407 Predicted intracellular proteins Evidence at protein level HPA052496 Approved Mixed Mixed testis: 5.8 MAP4K2 BL44, GCK, RAB8IP ENSG00000168067 Mitogen-activated protein kinase kinase kinase kinase 2 11 64784914-64803241 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA007330 Supported Approved Vesicles Liver cancer:3.10e-5 (unfavourable) Expressed in all Mixed spleen: 23.3 MAP9 ASAP, FLJ21159 ENSG00000164114 Microtubule-associated protein 9 4 155342658-155376970 Predicted intracellular proteins Evidence at protein level HPA037864 Uncertain Mixed Tissue enhanced parathyroid gland: 78.4 cerebral cortex: 27.2 MAPKAPK5 PRAK ENSG00000089022 Mitogen-activated protein kinase-activated protein kinase 5 12 111841978-111902238 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004546, HPA015515 Supported Supported Nucleoplasm
Cytosol Liver cancer:2.98e-8 (unfavourable) Expressed in all Expressed in all rectum: 34.4 MARC1 FLJ22390, MOSC1 ENSG00000186205 Mitochondrial amidoxime reducing component 1 1 220786759-220819657 Predicted intracellular proteins Evidence at protein level HPA028702 Approved Supported Mitochondria Renal cancer:4.51e-4 (unfavourable) Mixed Expressed in all adipose tissue: 225.6 MARC2 FLJ20605, MOSC2 ENSG00000117791 Mitochondrial amidoxime reducing component 2 1 220748225-220784815 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015085, HPA017572 Supported Liver cancer:1.40e-10 (favourable), Renal cancer:3.09e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 332.7 kidney: 138.5 MARCH1 FLJ20668, MARCH-I, RNF171 ENSG00000145416 Membrane-associated ring finger (C3HC4) 1, E3 ubiquitin protein ligase 4 163524298-164384050 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014600 Uncertain Supported Mitochondria Mixed Mixed lymph node: 36.5 MARCH11 MARCH-XI ENSG00000183654 Membrane-associated ring finger (C3HC4) 11 5 16067139-16180762 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA077262 Uncertain Vesicles Not detected Tissue enriched 20 testis: 89.9 cerebral cortex: 4.5 MARCH2 HSPC240, MARCH-II, RNF172 ENSG00000099785 Membrane-associated ring finger (C3HC4) 2, E3 ubiquitin protein ligase 19 8413270-8439017 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014063 Approved Uncertain Cytosol Endometrial cancer:1.05e-5 (favourable), Pancreatic cancer:6.21e-4 (favourable), Colorectal cancer:6.48e-4 (unfavourable), Head and neck cancer:8.29e-4 (favourable) Expressed in all Expressed in all epididymis: 63.9 MARCH3 MARCH-III, MGC48332, RNF173 ENSG00000173926 Membrane-associated ring finger (C3HC4) 3, E3 ubiquitin protein ligase 5 126867714-127030808 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043406 Uncertain Mixed Mixed testis: 10.9 MARCH4 KIAA1399, MARCH-IV, RNF174 ENSG00000144583 Membrane-associated ring finger (C3HC4) 4, E3 ubiquitin protein ligase 2 216257865-216372027 Predicted membrane proteins Evidence at protein level HPA014348 Approved Mixed Tissue enriched 6 cerebral cortex: 9.1 stomach: 1.6 MARCH5 FLJ20445, MARCH-V, RNF153 ENSG00000198060 Membrane-associated ring finger (C3HC4) 5 10 92291163-92353964 Predicted membrane proteins Evidence at protein level HPA056596 Supported Mitochondria Expressed in all Expressed in all thyroid gland: 28.6 MARCH6 MARCH-VI, RNF176, TEB4 ENSG00000145495 Membrane-associated ring finger (C3HC4) 6, E3 ubiquitin protein ligase 5 10353703-10440388 Predicted membrane proteins Evidence at protein level HPA040841, HPA063246 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all parathyroid gland: 95.0 MARCH8 c-MIR, CMIR, MARCH-VIII, MIR, RNF178 ENSG00000165406 Membrane-associated ring finger (C3HC4) 8, E3 ubiquitin protein ligase 10 45454585-45594906 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014597 Approved Pancreatic cancer:2.71e-4 (favourable), Renal cancer:6.64e-4 (favourable) Expressed in all Expressed in all testis: 104.3 MARCO SCARA2 ENSG00000019169 Macrophage receptor with collagenous structure 2 118942166-118994660 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063793 Supported Approved Golgi apparatus
Vesicles Mixed Tissue enhanced appendix: 125.3;lung: 288.5 adipose tissue: 77.1 MARK2 EMK1, PAR-1, PAR-1B, Par1b ENSG00000072518 MAP/microtubule affinity-regulating kinase 2 11 63838928-63911019 Enzymes, Predicted intracellular proteins Evidence at protein level HPA038790, HPA074905 Approved Supported Nucleoplasm
Plasma membrane Liver cancer:1.30e-4 (unfavourable), Endometrial cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all skin: 46.2 MARK4 FLJ90097, KIAA1860, MARKL1, Nbla00650, PAR-1D ENSG00000007047 MAP/microtubule affinity-regulating kinase 4 19 45079288-45305283 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039186 Approved Approved Cytosol Endometrial cancer:8.31e-8 (unfavourable), Head and neck cancer:3.05e-5 (unfavourable) Expressed in all Expressed in all testis: 51.2 MARVELD2 DFNB49, FLJ30532, MRVLDC2, TRIC ENSG00000152939 MARVEL domain containing 2 5 69415112-69444330 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018119, HPA061726 Uncertain Supported Cell Junctions Renal cancer:2.84e-13 (favourable) Mixed Tissue enhanced thyroid gland: 19.7 small intestine: 8.9 MARVELD3 MRVLDC3 ENSG00000140832 MARVEL domain containing 3 16 71626161-71642114 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043514, HPA045471 Approved Vesicles
Intermediate filaments Renal cancer:6.80e-10 (favourable) Mixed Tissue enhanced small intestine: 37.8 duodenum: 32.4 MAS1 ENSG00000130368 MAS1 proto-oncogene, G protein-coupled receptor 6 159906690-159916530 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA013564 Uncertain Not detected Tissue enhanced cerebral cortex: 1.8 cervix, uterine: 0.7 MAS1L dJ994E9.2, MAS-L, MRG ENSG00000204687 MAS1 proto-oncogene like, G protein-coupled receptor 6 29486697-29487956 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA017983 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Not detected Tissue enhanced cervix, uterine: 5.1 epididymis: 2.3 MASP1 CRARF, MASP, PRSS5 ENSG00000127241 Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) 3 187217285-187292022 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001617, HPA009641 Supported Supported Nucleoplasm
Cytosol Liver cancer:2.20e-4 (favourable) Group enriched Tissue enhanced cervix, uterine: 155.2 endometrium: 97.4 MAST2 KIAA0807, MAST205 ENSG00000086015 Microtubule associated serine/threonine kinase 2 1 45786987-46036124 Cancer-related genes, Enzymes, Predicted membrane proteins Evidence at protein level HPA039722, HPA040155 Approved Approved Cytosol Renal cancer:6.85e-13 (unfavourable), Liver cancer:4.31e-8 (unfavourable) Expressed in all Expressed in all testis: 78.5 MATR3 ENSG00000280987 Matrin 3 5 139273752-139331677 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA036564, HPA036565 Supported Approved Nucleoplasm Not detected Expressed in all cerebral cortex: 63.1 MAVS Cardif, IPS-1, KIAA1271, VISA ENSG00000088888 Mitochondrial antiviral signaling protein 20 3846799-3876123 Predicted membrane proteins Evidence at protein level CAB009187, HPA049850, HPA053524 Supported Validated Mitochondria Renal cancer:4.13e-5 (favourable), Pancreatic cancer:3.81e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 30.4 MBOAT1 dJ434O11.1, LPEAT1, MGC44669, OACT1 ENSG00000172197 Membrane bound O-acyltransferase domain containing 1 6 20102145-20212399 Enzymes, Predicted membrane proteins Evidence at protein level HPA052996 Approved Mitochondria Pancreatic cancer:9.15e-4 (unfavourable) Expressed in all Mixed fallopian tube: 55.1 MBOAT2 FLJ14415, FLJ90298, OACT2 ENSG00000143797 Membrane bound O-acyltransferase domain containing 2 2 8852690-9003813 Enzymes, Predicted membrane proteins Evidence at protein level HPA014836 Uncertain Approved Vesicles Endometrial cancer:2.13e-9 (unfavourable), Urothelial cancer:5.32e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 49.4 cerebral cortex: 29.8 MBOAT4 FKSG89, GOAT, OACT4 ENSG00000177669 Membrane bound O-acyltransferase domain containing 4 8 30131824-30144686 Predicted membrane proteins Evidence at protein level HPA044509 Supported Golgi apparatus Tissue enhanced Tissue enhanced fallopian tube: 3.0;stomach: 3.5 gallbladder: 1.6 MBOAT7 BB1, hMBOA-7, LENG4, LPIAT ENSG00000125505 Membrane bound O-acyltransferase domain containing 7 19 54173412-54189882 Enzymes, Predicted membrane proteins Evidence at protein level HPA055967 Approved Approved Cytosol Liver cancer:5.55e-6 (unfavourable), Renal cancer:6.62e-5 (unfavourable), Urothelial cancer:4.31e-4 (favourable), Lung cancer:5.13e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 24.3 MBTPS1 KIAA0091, PCSK8, S1P, SKI-1 ENSG00000140943 Membrane-bound transcription factor peptidase, site 1 16 84053761-84116906 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056109 Supported Renal cancer:2.21e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 116.3 MBTPS2 KFSD, S2P ENSG00000012174 Membrane-bound transcription factor peptidase, site 2 X 21839636-21885424 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA005494, CAB009486 Approved Approved Nucleoplasm
Mitochondria
Cytosol Expressed in all Expressed in all parathyroid gland: 19.0 MC4R ENSG00000166603 Melanocortin 4 receptor 18 60371110-60372775 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA016719 Uncertain Tissue enhanced Group enriched 10 cerebral cortex: 3.0;fallopian tube: 5.0 epididymis: 0.4 MC5R ENSG00000176136 Melanocortin 5 receptor 18 13824155-13826743 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA042365 Uncertain Not detected Tissue enriched 6 epididymis: 3.0 esophagus,testis: 0.5 MCAM CD146, MUC18 ENSG00000076706 Melanoma cell adhesion molecule 11 119308529-119321521 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002147, HPA008848 Supported Validated Plasma membrane Renal cancer:5.14e-4 (unfavourable), Cervical cancer:7.61e-4 (unfavourable) Expressed in all Mixed adipose tissue: 365.9 MCEMP1 C19orf59, MGC132456 ENSG00000183019 Mast cell-expressed membrane protein 1 19 7676628-7679826 Predicted membrane proteins Evidence at protein level HPA014731 Supported Mixed Group enriched 9 appendix: 28.5;bone marrow: 43.9;lung: 110.4 smooth muscle: 6.9 MCF2L2 ARHGEF22, KIAA0861 ENSG00000053524 MCF.2 cell line derived transforming sequence-like 2 3 183178043-183428778 Disease related genes, Predicted intracellular proteins Evidence at transcript level HPA038946, HPA038947 Uncertain Approved Plasma membrane
Cytosol Not detected Group enriched 8 adrenal gland: 10.3;cerebral cortex: 17.1;parathyroid gland: 7.4;spleen: 3.5;testis: 4.6 prostate: 1.0 MCL1 BCL2L3, Mcl-1 ENSG00000143384 Myeloid cell leukemia 1 1 150574551-150579738 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002781, HPA008455, HPA031125, CAB068195 Approved Validated Mitochondria Renal cancer:7.16e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 662.8 MCOLN1 ML4, MLIV, MST080, MSTP080, TRPM-L1, TRPML1 ENSG00000090674 Mucolipin 1 19 7522626-7534009 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA031763, CAB032637 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:5.60e-5 (favourable), Renal cancer:5.67e-4 (favourable) Expressed in all Expressed in all spleen: 49.0 MCOLN2 FLJ36691, TRP-ML2, TRPML2 ENSG00000153898 Mucolipin 2 1 84925583-84997113 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA019114, HPA048999 Uncertain Supported Intermediate filaments Lung cancer:2.56e-4 (favourable) Mixed Mixed rectum: 17.6 MCOLN3 FLJ11006, TRP-ML3, TRPML3 ENSG00000055732 Mucolipin 3 1 85018082-85048499 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA018106, HPA062137 Approved Approved Nucleoli
Cytosol Tissue enriched Tissue enhanced adrenal gland: 57.9;parathyroid gland: 42.1 epididymis: 17.3 MCTP1 FLJ22344 ENSG00000175471 Multiple C2 domains, transmembrane 1 5 94703741-95284575 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019018 Uncertain Approved Nucleoplasm
Cytosol Mixed Mixed bone marrow: 29.1 MCTP2 FLJ11175, FLJ33303 ENSG00000140563 Multiple C2 domains, transmembrane 2 15 94231538-94483952 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051176, HPA070541 Uncertain Validated Nucleoplasm
Cytosol Renal cancer:2.18e-5 (unfavourable) Mixed Mixed placenta: 28.3 MCU C10orf42, CCDC109A, FLJ46135 ENSG00000156026 Mitochondrial calcium uniporter 10 72692131-72887694 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016480 Approved Supported Mitochondria Liver cancer:6.06e-5 (unfavourable), Renal cancer:5.07e-4 (favourable) Expressed in all Expressed in all stomach: 41.1 MDGA2 MAMDC1 ENSG00000139915 MAM domain containing glycosylphosphatidylinositol anchor 2 14 46839629-47674954 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003084 Uncertain Tissue enhanced Group enriched 15 cerebral cortex: 6.3;testis: 6.9 skin: 0.4 MDH1 ENSG00000014641 Malate dehydrogenase 1, NAD (soluble) 2 63588609-63607197 Cancer-related genes, Citric acid cycle related proteins, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027296, CAB047333, HPA054276 Uncertain Supported Centrosome
Cytosol Endometrial cancer:7.13e-4 (unfavourable), Renal cancer:9.95e-4 (favourable) Expressed in all Expressed in all heart muscle: 736.3 MDM1 ENSG00000111554 Mdm1 nuclear protein 12 68272443-68332381 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040411, HPA041594 Uncertain Supported Centrosome
Cytosol Cervical cancer:6.01e-4 (favourable) Expressed in all Expressed in all testis: 37.3 MED12 CAGH45, FGS1, HOPA, KIAA0192, OKS, OPA1, TNRC11, TRAP230 ENSG00000184634 Mediator complex subunit 12 X 71118556-71142454 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA003184, HPA003185 Supported Approved Nucleoplasm Expressed in all Expressed in all spleen: 27.1 MED23 CRSP130, CRSP3, DRIP130, Sur2 ENSG00000112282 Mediator complex subunit 23 6 131573966-131628229 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070341 Approved Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 31.6 MEGF11 DKFZp434L121, KIAA1781 ENSG00000157890 Multiple EGF-like-domains 11 15 65895079-66253747 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA017982 Uncertain Tissue enhanced Group enriched 6 cerebral cortex: 13.0;fallopian tube: 12.2 testis: 1.9 MEGF8 C19orf49, EGFL4, FLJ22365, SBP1 ENSG00000105429 Multiple EGF-like-domains 8 19 42325609-42378769 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049248 Approved Renal cancer:2.17e-7 (favourable), Pancreatic cancer:6.03e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 38.1 MEGF9 EGFL5 ENSG00000106780 Multiple EGF-like-domains 9 9 120600813-120714470 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014319, HPA050238 Uncertain Approved Nucleus
Cytosol Renal cancer:5.48e-11 (favourable) Expressed in all Expressed in all thyroid gland: 47.1 MELK KIAA0175 ENSG00000165304 Maternal embryonic leucine zipper kinase 9 36572862-36677683 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017214 Uncertain Renal cancer:0.00e+0 (unfavourable), Liver cancer:2.91e-7 (unfavourable), Lung cancer:3.99e-4 (unfavourable), Pancreatic cancer:4.58e-4 (unfavourable) Expressed in all Tissue enhanced testis: 16.8 lymph node: 11.9 MEMO1 C2orf4, CGI-27, MEMO ENSG00000162959 Mediator of cell motility 1 2 31865060-32011230 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042603, HPA057952 Approved Approved Vesicles Mixed Expressed in all testis: 117.5 MEN1 ENSG00000133895 Multiple endocrine neoplasia I 11 64803510-64811294 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA030342 Uncertain Supported Nucleoplasm
Cytosol Stomach cancer:6.31e-5 (favourable), Liver cancer:1.08e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 22.2 MEP1A PPHA ENSG00000112818 Meprin A, alpha (PABA peptide hydrolase) 6 46793390-46839782 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025163, HPA029416 Supported Tissue enriched Group enriched 41 colon: 120.0;duodenum: 290.0;rectum: 116.2;small intestine: 549.0 appendix: 6.5 MEP1B ENSG00000141434 Meprin A, beta 18 32185069-32220404 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029119 Supported Group enriched Group enriched 34 duodenum: 258.3;small intestine: 410.0 colon: 9.9 MERTK c-Eyk, mer, RP38, Tyro12 ENSG00000153208 MER proto-oncogene, tyrosine kinase 2 111898479-112029561 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036196, HPA075622 Approved Approved Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:4.43e-5 (favourable), Lung cancer:4.74e-4 (favourable) Expressed in all Mixed adrenal gland: 77.4 MEST PEG1 ENSG00000106484 Mesoderm specific transcript 7 130486171-130506296 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA005623 Approved Golgi apparatus
Cytosol Renal cancer:6.20e-5 (unfavourable) Expressed in all Tissue enriched 8 placenta: 1079.4 adipose tissue: 131.7 MET DFNB97, HGFR, RCCP2 ENSG00000105976 MET proto-oncogene, receptor tyrosine kinase 7 116672390-116798386 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB005282, CAB018577, HPA055607 Uncertain Supported Plasma membrane
Cytosol Pancreatic cancer:1.21e-7 (unfavourable), Head and neck cancer:6.75e-4 (unfavourable) Expressed in all Mixed placenta: 38.7 METTL13 CGI-01, KIAA0859 ENSG00000010165 Methyltransferase like 13 1 171781664-171814023 Predicted intracellular proteins Evidence at protein level HPA044498, HPA053705 Approved Approved Cytosol Liver cancer:5.68e-4 (unfavourable) Expressed in all Expressed in all testis: 24.7 METTL14 KIAA1627 ENSG00000145388 Methyltransferase like 14 4 118685368-118715433 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA038002 Supported Supported Nucleoplasm Renal cancer:1.46e-5 (favourable) Expressed in all Expressed in all testis: 23.5 METTL21A FAM119A, HCA557b, HSPA-KMT, LOC151194 ENSG00000144401 Methyltransferase like 21A 2 207580631-207625928 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034712 Uncertain Approved Nucleus
Cytosol Liver cancer:1.87e-5 (unfavourable), Renal cancer:5.43e-4 (unfavourable) Expressed in all Expressed in all spleen: 22.4 METTL5 HSPC133 ENSG00000138382 Methyltransferase like 5 2 169810081-169824931 Predicted intracellular proteins Evidence at protein level HPA038223 Uncertain Approved Nucleoli
Cytosol Renal cancer:3.06e-8 (unfavourable), Liver cancer:6.64e-5 (unfavourable) Expressed in all Expressed in all epididymis: 75.3 METTL7A DKFZP586A0522 ENSG00000185432 Methyltransferase like 7A 12 50923472-50932517 Predicted membrane proteins Evidence at protein level HPA017434 Supported Lipid droplets Renal cancer:0.00e+0 (favourable) Expressed in all Expressed in all thyroid gland: 402.1 METTL9 DREV1 ENSG00000197006 Methyltransferase like 9 16 21597218-21657473 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA053588, HPA056347 Uncertain Approved Nucleus
Cell Junctions
Cytosol Liver cancer:8.71e-4 (unfavourable) Expressed in all Expressed in all kidney: 182.7 MFAP3 ENSG00000037749 Microfibrillar-associated protein 3 5 154038906-154220478 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015883, HPA049198 Approved Approved Nucleoplasm
Golgi apparatus Cervical cancer:4.28e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 73.4 MFAP3L KIAA0626, NYD-sp9 ENSG00000198948 Microfibrillar-associated protein 3-like 4 169986597-170033031 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017986, HPA077490 Approved Supported Plasma membrane Renal cancer:1.42e-8 (favourable) Expressed in all Tissue enhanced testis: 73.6 epididymis: 46.9 MFF C2orf33, GL004 ENSG00000168958 Mitochondrial fission factor 2 227325151-227357836 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010968, HPA074625 Approved Supported Mitochondria Liver cancer:1.20e-4 (unfavourable) Expressed in all Expressed in all testis: 351.8 MFN2 CMT2A2, CPRP1, KIAA0214, MARF ENSG00000116688 Mitofusin 2 1 11980181-12013514 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030554 Uncertain Renal cancer:2.36e-8 (favourable) Expressed in all Expressed in all heart muscle: 197.9 MFRP C1QTNF5, FLJ30570, NNO2, rd6 ENSG00000235718 Membrane frizzled-related protein 11 119338942-119346673 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042946 Uncertain Not detected Not detected parathyroid gland: 0.2 MFSD1 FLJ14153, UG0581B09 ENSG00000118855 Major facilitator superfamily domain containing 1 3 158732198-158829719 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057924, HPA065858 Approved Approved Nucleus
Nucleoli Renal cancer:5.60e-5 (favourable) Expressed in all Expressed in all spleen: 35.8 MFSD10 IT10C3, TETRAN ENSG00000109736 Major facilitator superfamily domain containing 10 4 2930561-2934859 Predicted membrane proteins Evidence at protein level HPA043209 Uncertain Approved Nucleoplasm
Nuclear membrane Renal cancer:5.68e-5 (unfavourable), Liver cancer:4.49e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 41.3 MFSD11 FLJ20226, FLJ22196 ENSG00000092931 Major facilitator superfamily domain containing 11 17 76735865-76781449 Predicted membrane proteins Evidence at protein level HPA022001 Uncertain Approved Nuclear speckles Endometrial cancer:7.69e-4 (unfavourable), Urothelial cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 33.9 MFSD12 C19orf28, MGC20700, PP3501 ENSG00000161091 Major facilitator superfamily domain containing 12 19 3538261-3574290 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042149, HPA043088 Uncertain Approved Nucleoplasm
Mitochondria Endometrial cancer:5.66e-6 (favourable), Lung cancer:2.34e-4 (unfavourable), Liver cancer:6.61e-4 (unfavourable), Stomach cancer:7.70e-4 (favourable) Tissue enriched Expressed in all skin: 64.2 MFSD2A FLJ14490, MFSD2 ENSG00000168389 Major facilitator superfamily domain containing 2A 1 39955112-39969968 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043107 Uncertain Approved Plasma membrane
Cytosol
Cytoplasmic bodies Renal cancer:4.22e-6 (unfavourable), Urothelial cancer:2.33e-4 (favourable) Mixed Tissue enhanced epididymis: 114.6;seminal vesicle: 109.6 testis: 63.3 MFSD2B ENSG00000205639 Major facilitator superfamily domain containing 2B 2 24010081-24063321 Predicted membrane proteins Evidence at protein level HPA044145 Supported Not detected Tissue enriched 9 bone marrow: 7.2 placenta: 0.7 MFSD3 ENSG00000167700 Major facilitator superfamily domain containing 3 8 144509074-144511213 Predicted membrane proteins Evidence at protein level HPA056013 Uncertain Approved Vesicles Renal cancer:5.44e-7 (favourable), Cervical cancer:5.08e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 14.2 MFSD5 MGC11308 ENSG00000182544 Major facilitator superfamily domain containing 5 12 53251251-53254405 Predicted membrane proteins Evidence at protein level HPA039773 Uncertain Liver cancer:1.43e-6 (unfavourable) Expressed in all Expressed in all skin: 49.7 MFSD6 FLJ20160 ENSG00000151690 Major facilitator superfamily domain containing 6 2 190408355-190509205 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022274 Approved Approved Nucleoplasm
Actin filaments
Cytosol Renal cancer:1.05e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 79.2 MFSD6L FLJ35773 ENSG00000185156 Major facilitator superfamily domain containing 6-like 17 8797162-8799349 Predicted membrane proteins, Transporters Evidence at transcript level HPA023164 Uncertain Breast cancer:1.84e-4 (favourable) Mixed Tissue enhanced testis: 29.7 parathyroid gland: 8.3 MFSD7 FLJ22269, LP2561 ENSG00000169026 Major facilitator superfamily domain containing 7 4 681829-689441 Predicted membrane proteins Evidence at transcript level HPA043593 Uncertain Renal cancer:2.66e-5 (favourable) Expressed in all Mixed parathyroid gland: 14.3 MFSD8 CLN7, MGC33302 ENSG00000164073 Major facilitator superfamily domain containing 8 4 127917805-127965995 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044802 Approved Supported Nucleoplasm
Vesicles Urothelial cancer:2.21e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 12.2 MFSD9 MGC11332 ENSG00000135953 Major facilitator superfamily domain containing 9 2 102715840-102736888 Predicted membrane proteins Evidence at protein level HPA055293, HPA061859 Approved Approved Nucleoli Glioma:7.48e-4 (unfavourable) Expressed in all Mixed duodenum: 10.1 MGAM MGA ENSG00000257335 Maltase-glucoamylase 7 141907813-142106747 Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002270 Supported Renal cancer:6.16e-5 (favourable) Tissue enriched Tissue enhanced duodenum: 61.0;small intestine: 99.1 epididymis: 30.6 MGAM2 ENSG00000257743 Maltase-glucoamylase 2 (putative) 7 142111749-142222324 Enzymes, Predicted membrane proteins Evidence at protein level HPA055697 Supported Approved Vesicles
Cytosol Group enriched Group enriched 5 duodenum: 12.2;small intestine: 10.6 salivary gland: 2.1 MGARP C4orf49, CESP-1, HUMMR, OSAP ENSG00000137463 Mitochondria-localized glutamic acid-rich protein 4 139266163-139280338 Predicted membrane proteins Evidence at protein level HPA015994 Supported Supported Mitochondria Tissue enhanced Tissue enriched 10 adrenal gland: 268.2 ovary: 27.0 MGAT1 GLCNAC-TI, GLYT1, GNT-1, MGAT ENSG00000131446 Mannosyl (alpha-1,3-)-glycoprotein beta-1,2-N-acetylglucosaminyltransferase 5 180784782-180815652 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017432 Approved Renal cancer:8.65e-4 (unfavourable) Expressed in all Expressed in all spleen: 120.7 MGAT3 GNT-III ENSG00000128268 Mannosyl (beta-1,4-)-glycoprotein beta-1,4-N-acetylglucosaminyltransferase 22 39457344-39492194 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA017598 Approved Renal cancer:5.04e-8 (unfavourable) Mixed Tissue enhanced cerebral cortex: 38.7 small intestine: 33.2 MGAT5 GNT-V ENSG00000152127 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase 2 134119983-134454621 Enzymes, Predicted membrane proteins Evidence at protein level HPA010919 Approved Expressed in all Mixed parathyroid gland: 32.0 MGAT5B FLJ25132, GnT-IX, GnT-VB ENSG00000167889 Mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-glucosaminyltransferase, isozyme B 17 76868456-76950393 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011082 Approved Nucleoplasm
Mitotic spindle Group enriched Tissue enriched 14 cerebral cortex: 23.2 testis: 1.6 MGLL HU-K5, MGL ENSG00000074416 Monoglyceride lipase 3 127689062-127823250 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA011348, HPA011993, HPA011994 Approved Supported Nucleoplasm Pancreatic cancer:6.41e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 188.0 MGST1 GST12, MGST-I ENSG00000008394 Microsomal glutathione S-transferase 1 12 16347142-16609259 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044840 Supported Approved Endoplasmic reticulum
Mitochondria Thyroid cancer:1.97e-4 (favourable), Renal cancer:7.45e-4 (unfavourable) Expressed in all Expressed in all liver: 1596.8 MGST2 MGST-II ENSG00000085871 Microsomal glutathione S-transferase 2 4 139665768-139740745 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010707 Approved Approved Nucleoplasm Renal cancer:3.22e-9 (favourable), Endometrial cancer:5.26e-5 (favourable) Expressed in all Expressed in all liver: 177.4 MGST3 GST-III ENSG00000143198 Microsomal glutathione S-transferase 3 1 165630861-165661796 Enzymes, Predicted membrane proteins Evidence at protein level HPA053311 Approved Nucleus Expressed in all Expressed in all epididymis: 621.5 MIA3 FLJ39207, KIAA0268, TANGO, UNQ6077 ENSG00000154305 Melanoma inhibitory activity family, member 3 1 222618086-222668012 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055922, HPA056816 Supported Validated Vesicles Renal cancer:3.73e-4 (unfavourable) Expressed in all Expressed in all testis: 80.7 MICAL2 KIAA0750 ENSG00000133816 Microtubule associated monooxygenase, calponin and LIM domain containing 2 11 12094008-12263789 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030437 Approved Approved Golgi apparatus Renal cancer:3.63e-5 (unfavourable) Expressed in all Mixed testis: 80.0 MICB PERB11.2 ENSG00000204516 MHC class I polypeptide-related sequence B 6 31494881-31511124 Disease related genes, Predicted membrane proteins Evidence at protein level HPA064618 Approved Golgi apparatus
Vesicles Renal cancer:4.94e-9 (unfavourable), Liver cancer:7.04e-5 (unfavourable) Mixed Tissue enhanced lymph node: 3.3 spleen: 2.8 MICU1 CALC, CBARA1, EFHA3, FLJ12684 ENSG00000107745 Mitochondrial calcium uptake 1 10 72367327-72626191 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA037479, HPA037480 Uncertain Supported Mitochondria Renal cancer:4.66e-7 (favourable) Expressed in all Expressed in all kidney: 107.0 MICU3 DKFZp313A0139, EFHA2 ENSG00000155970 Mitochondrial calcium uptake family, member 3 8 17027238-17122644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024048, HPA024771, HPA024779 Uncertain Mixed Tissue enhanced cerebral cortex: 34.9 parathyroid gland: 13.9 MID1 FXY, OS, RNF59, TRIM18 ENSG00000101871 Midline 1 X 10445310-10833654 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003715 Approved Liver cancer:3.06e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 20.4 MIEF1 FLJ20232, MiD51, SMCR7L ENSG00000100335 Mitochondrial elongation factor 1 22 39499432-39518132 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA061059 Approved Intermediate filaments
Mitochondria Renal cancer:3.96e-5 (favourable) Expressed in all Expressed in all testis: 22.4 MIEF2 MGC23130, MiD49, SMCR7 ENSG00000177427 Mitochondrial elongation factor 2 17 18260534-18266552 Predicted membrane proteins Evidence at protein level HPA042334 Uncertain Renal cancer:1.75e-7 (favourable) Expressed in all Expressed in all skeletal muscle: 14.1 MINOS1 C1orf151, FLJ36999, Mic10, MIO10, RP5-1056L3.2 ENSG00000173436 Mitochondrial inner membrane organizing system 1 1 19596977-19629821 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059930 Supported Supported Mitochondria Liver cancer:7.23e-4 (unfavourable), Urothelial cancer:8.11e-4 (favourable) Expressed in all Expressed in all prostate: 13.3 MINPP1 MIPP ENSG00000107789 Multiple inositol-polyphosphate phosphatase 1 10 87504875-87553460 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA026859 Approved Renal cancer:6.98e-5 (unfavourable) Expressed in all Expressed in all placenta: 27.3 MIP AQP0, LIM1, MP26 ENSG00000135517 Major intrinsic protein of lens fiber 12 56449502-56469166 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014940 Supported Not detected Tissue enhanced testis: 1.2 cerebral cortex,liver: 0.2 MKKS BBS6 ENSG00000125863 McKusick-Kaufman syndrome 20 10401009-10434222 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041071, HPA044233 Supported Supported Centrosome Renal cancer:3.79e-9 (favourable), Liver cancer:9.84e-5 (unfavourable) Expressed in all Expressed in all testis: 43.5 MLANA MART1 ENSG00000120215 Melan-A 9 5890802-5910606 Predicted membrane proteins Evidence at protein level CAB000057, HPA048662 Supported Tissue enriched Tissue enriched 21 skin: 50.5 breast: 2.3 MLC1 KIAA0027, LVM, MLC, VL ENSG00000100427 Megalencephalic leukoencephalopathy with subcortical cysts 1 22 50059391-50085902 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003040, HPA067533 Supported Tissue enriched Tissue enriched 8 cerebral cortex: 181.4 bone marrow: 23.1 MLLT10 AF10 ENSG00000078403 Myeloid/lymphoid or mixed-lineage leukemia; translocated to, 10 10 21524675-21743630 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA005747 Supported Supported Nucleoplasm Head and neck cancer:8.75e-4 (favourable) Expressed in all Expressed in all testis: 176.8 MMD MMA, PAQR11 ENSG00000108960 Monocyte to macrophage differentiation-associated 17 55392613-55421992 Predicted membrane proteins, Transporters Evidence at transcript level HPA026978 Approved Vesicles Colorectal cancer:3.52e-5 (favourable), Liver cancer:6.39e-5 (unfavourable), Renal cancer:2.85e-4 (unfavourable), Endometrial cancer:3.88e-4 (unfavourable), Thyroid cancer:8.62e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 141.1 cerebral cortex: 73.3 MME CALLA, CD10, NEP ENSG00000196549 Membrane metallo-endopeptidase 3 155024124-155183729 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000013, HPA052583, HPA056072 Supported Mixed Tissue enhanced duodenum: 440.1;kidney: 381.4;small intestine: 410.3 prostate: 151.9 MMEL1 MMEL2, NEPII, NL1, NL2, SEP ENSG00000142606 Membrane metallo-endopeptidase-like 1 1 2590639-2632990 Enzymes, Predicted intracellular proteins Evidence at protein level HPA007876, HPA008205, CAB020786 Uncertain Mixed Tissue enhanced testis: 5.4 stomach: 2.3 MMGT1 EMC5, TMEM32 ENSG00000169446 Membrane magnesium transporter 1 X 135962070-135974063 Predicted membrane proteins Evidence at protein level HPA032037 Approved Renal cancer:1.94e-5 (favourable), Breast cancer:8.54e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 34.4 MMP14 MT1-MMP ENSG00000157227 Matrix metallopeptidase 14 (membrane-inserted) 14 22836557-22849027 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009918, HPA051432 Approved Approved Intermediate filaments
Cytosol Renal cancer:1.34e-4 (unfavourable), Ovarian cancer:9.48e-4 (unfavourable) Expressed in all Mixed endometrium: 236.1 MMP15 MT2-MMP, MTMMP2, SMCP-2 ENSG00000102996 Matrix metallopeptidase 15 (membrane-inserted) 16 58025566-58046901 Cancer-related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002611, HPA040390 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.54e-8 (favourable), Urothelial cancer:3.08e-4 (favourable) Expressed in all Tissue enhanced thyroid gland: 69.9 duodenum: 39.8 MMP16 C8orf57, DKFZp761D112, MT3-MMP ENSG00000156103 Matrix metallopeptidase 16 (membrane-inserted) 8 88032009-88328025 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023693 Uncertain Approved Vesicles
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 9.6 gallbladder: 4.2 MMP24 MT5-MMP ENSG00000125966 Matrix metallopeptidase 24 (membrane-inserted) 20 35226654-35277000 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at transcript level HPA049280 Approved Nucleoli
Plasma membrane Renal cancer:8.17e-11 (favourable) Mixed Tissue enhanced cerebral cortex: 10.6 lung: 7.1 MOG BTN6, BTNL11 ENSG00000204655 Myelin oligodendrocyte glycoprotein 6 29656981-29672372 Disease related genes, Predicted membrane proteins Evidence at protein level HPA021873 Supported Tissue enriched Not detected cerebral cortex: 0.9 MOGAT1 DGAT2L, DGAT2L1, MGAT1 ENSG00000124003 Monoacylglycerol O-acyltransferase 1 2 222671786-222709930 Enzymes, Predicted membrane proteins Evidence at transcript level HPA049944 Uncertain Tissue enhanced Tissue enriched 11 gallbladder: 30.8 parathyroid gland: 2.8 MOGAT2 DGAT2L5, FLJ22644, MGAT2 ENSG00000166391 Monoacylglycerol O-acyltransferase 2 11 75717819-75732958 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028834 Uncertain Tissue enhanced Group enriched 12 colon: 12.7;duodenum: 38.2;liver: 12.1;rectum: 12.7;small intestine: 44.5 appendix: 2.0 MOGAT3 DC7, MGAT3 ENSG00000106384 Monoacylglycerol O-acyltransferase 3 7 101195007-101201021 Enzymes, Predicted membrane proteins Evidence at protein level HPA011940 Uncertain Approved Centrosome Tissue enhanced Group enriched 6 colon: 11.5;duodenum: 31.2;rectum: 12.0;small intestine: 34.2 liver: 3.4 MOGS CWH41, DER7, GCS1 ENSG00000115275 Mannosyl-oligosaccharide glucosidase 2 74461057-74465410 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011322, HPA011969 Approved Validated Endoplasmic reticulum Renal cancer:2.79e-8 (unfavourable), Liver cancer:2.34e-6 (unfavourable), Colorectal cancer:5.33e-4 (unfavourable) Expressed in all Expressed in all duodenum: 64.8 MOSPD1 dJ473B4 ENSG00000101928 Motile sperm domain containing 1 X 134887626-134915267 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031158 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all fallopian tube: 41.8 MOSPD2 MGC26706 ENSG00000130150 Motile sperm domain containing 2 X 14873441-14922327 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003334 Uncertain Approved Endoplasmic reticulum Liver cancer:8.91e-4 (unfavourable) Expressed in all Mixed skin: 29.1 MOSPD3 CDS3, NET30 ENSG00000106330 Motile sperm domain containing 3 7 100612102-100615384 Predicted membrane proteins Evidence at protein level HPA041137, HPA048240 Uncertain Approved Nucleoplasm
Cytosol Expressed in all Expressed in all testis: 29.7 MOXD1 dJ248E1.1, DKFZP564G202, MOX ENSG00000079931 Monooxygenase, DBH-like 1 6 132296055-132401545 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035740 Approved Approved Nucleoplasm
Cytosol Head and neck cancer:7.09e-5 (favourable), Stomach cancer:3.72e-4 (unfavourable) Expressed in all Tissue enhanced endometrium: 105.3;smooth muscle: 113.0 seminal vesicle: 53.1 MPC1 BRP44L, CGI-129, dJ68L15.3 ENSG00000060762 Mitochondrial pyruvate carrier 1 6 166364919-166383013 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA045119, HPA055790 Supported Validated Mitochondria Renal cancer:4.79e-11 (favourable), Lung cancer:1.29e-4 (favourable), Cervical cancer:1.45e-4 (favourable) Expressed in all Expressed in all heart muscle: 409.2 MPC2 BRP44, DKFZP564B167 ENSG00000143158 Mitochondrial pyruvate carrier 2 1 167916729-167937040 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA056091 Uncertain Expressed in all Expressed in all testis: 353.7 MPDU1 CDGIf, Lec35, PQLC5, SL15 ENSG00000129255 Mannose-P-dolichol utilization defect 1 17 7583529-7592789 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014845 Uncertain Supported Endoplasmic reticulum
Mitochondria Expressed in all Expressed in all rectum: 70.2 MPEG1 MPG1 ENSG00000197629 Macrophage expressed 1 11 59208510-59212951 Predicted membrane proteins, Transporters Evidence at protein level HPA046801 Approved Expressed in all Tissue enhanced spleen: 287.6 appendix: 156.3 MPG MDG ENSG00000103152 N-methylpurine DNA glycosylase 16 77007-85853 Enzymes, Predicted intracellular proteins Evidence at protein level HPA006531 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:2.82e-5 (favourable) Expressed in all Expressed in all thyroid gland: 48.9 MPHOSPH10 CT90, MPP10, MPP10P, PPP1R106 ENSG00000124383 M-phase phosphoprotein 10 (U3 small nucleolar ribonucleoprotein) 2 71130314-71150101 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035059, HPA035060, HPA049907 Supported Validated Nucleoli Renal cancer:3.89e-7 (unfavourable) Expressed in all Expressed in all prostate: 35.0 MPL CD110, TPOR ENSG00000117400 MPL proto-oncogene, thrombopoietin receptor 1 43337807-43352772 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA007619 Uncertain Plasma membrane Not detected Tissue enhanced testis: 1.8 ovary: 1.3 MPPE1 ENSG00000154889 Metallophosphoesterase 1 18 11882622-11909223 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012639 Uncertain Approved Nucleoplasm
Golgi apparatus Renal cancer:6.45e-7 (favourable), Melanoma:1.35e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 77.6 MPV17L FLJ39599, MLPH1, MLPH2, MPV17L1 ENSG00000156968 MPV17 mitochondrial membrane protein-like 16 15395754-15413268 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041180 Uncertain Supported Vesicles Renal cancer:1.48e-11 (favourable) Mixed Mixed breast: 11.4 MPV17L2 FKSG24, MGC12972 ENSG00000254858 MPV17 mitochondrial membrane protein-like 2 19 18193182-18196948 Predicted membrane proteins Evidence at protein level HPA043111 Uncertain Approved Plasma membrane
Cytosol Renal cancer:2.30e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 16.2 MPZL1 FLJ21047, PZR ENSG00000197965 Myelin protein zero-like 1 1 167721192-167791919 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026966, HPA063538 Approved Supported Vesicles
Plasma membrane Renal cancer:3.99e-7 (unfavourable), Liver cancer:4.27e-6 (unfavourable), Lung cancer:3.98e-4 (unfavourable), Thyroid cancer:8.08e-4 (unfavourable) Expressed in all Expressed in all breast: 111.3 MPZL2 EVA, EVA1 ENSG00000149573 Myelin protein zero-like 2 11 118253403-118264536 Predicted membrane proteins Evidence at protein level HPA051395, HPA060740 Approved Approved Cell Junctions Pancreatic cancer:1.14e-4 (unfavourable), Thyroid cancer:1.62e-4 (favourable) Expressed in all Tissue enhanced esophagus: 210.0 urinary bladder: 122.3 MPZL3 ENSG00000160588 Myelin protein zero-like 3 11 118226690-118252350 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029116 Approved Golgi apparatus Thyroid cancer:3.64e-4 (favourable), Pancreatic cancer:4.98e-4 (unfavourable) Expressed in all Mixed skin: 25.9 MR1 HLALS ENSG00000153029 Major histocompatibility complex, class I-related 1 181033425-181061938 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048304 Supported Plasma membrane Expressed in all Mixed thyroid gland: 28.1 MRAP B27, C21orf61, FALP ENSG00000170262 Melanocortin 2 receptor accessory protein 21 32291813-32314784 Disease related genes, Predicted membrane proteins Evidence at protein level HPA011024 Uncertain Not detected Group enriched 8 adipose tissue: 51.9;adrenal gland: 65.6 breast: 6.9 MRC1 bA541I19.1, CD206, CLEC13D, CLEC13DL, MRC1L1 ENSG00000260314 Mannose receptor, C type 1 10 17809344-17911170 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA004114, HPA045134, CAB068203 Supported Expressed in all Tissue enhanced lung: 180.0 placenta: 76.9 MRC2 CD280, CLEC13E, ENDO180, KIAA0709 ENSG00000011028 Mannose receptor, C type 2 17 62627401-62693597 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041991 Supported Renal cancer:4.94e-7 (unfavourable), Ovarian cancer:1.68e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 39.9 MRGPRD mrgD ENSG00000172938 MAS-related GPR, member D 11 68980021-68980986 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA031346 Uncertain Not detected Not detected seminal vesicle: 0.4 MRGPRE GPR167, mrgE ENSG00000184350 MAS-related GPR, member E 11 3227698-3232386 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA046556 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 1.0 endometrium,spleen: 0.6 MRGPRF GPR140, GPR168, MGC21621, mrgF ENSG00000172935 MAS-related GPR, member F 11 69004395-69013409 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA028811 Approved Supported Nuclear membrane
Plasma membrane Expressed in all Mixed smooth muscle: 77.8 MRGPRG GPR169, mrgG ENSG00000182170 MAS-related GPR, member G 11 3217944-3218813 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA058909 Uncertain Not detected Tissue enriched 18 testis: 1.7 all non-specific tissues: 0.0 MRGPRX2 MRGX2 ENSG00000183695 MAS-related GPR, member X2 11 19054455-19060681 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA055220 Approved Not detected Tissue enhanced breast: 1.2;skin: 1.2 cervix, uterine: 0.6 MRPS28 HSPC007, MRP-S28, MRPS35 ENSG00000147586 Mitochondrial ribosomal protein S28 8 79918717-80030289 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA027202 Approved Validated Mitochondria Renal cancer:1.20e-6 (favourable) Expressed in all Expressed in all adrenal gland: 114.6 MRS2 MRS2L ENSG00000124532 MRS2 magnesium transporter 6 24402908-24426194 Predicted membrane proteins Evidence at protein level HPA017642 Uncertain Ovarian cancer:5.14e-11 (favourable), Endometrial cancer:5.32e-4 (unfavourable), Thyroid cancer:8.03e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 29.8 MRVI1 IRAG, JAW1L ENSG00000072952 Murine retrovirus integration site 1 homolog 11 10573091-10693988 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008704 Uncertain Approved Nuclear bodies
Cytosol Endometrial cancer:5.78e-4 (favourable), Renal cancer:9.70e-4 (unfavourable) Mixed Mixed endometrium: 98.6 MS4A1 B1, Bp35, CD20, MS4A2 ENSG00000156738 Membrane-spanning 4-domains, subfamily A, member 1 11 60455752-60470760 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB000015, HPA014341, HPA014391 Supported Breast cancer:4.34e-5 (favourable) Mixed Group enriched 15 appendix: 249.3;lymph node: 780.6;spleen: 476.2;tonsil: 821.5 urinary bladder: 39.8 MS4A10 CD20L7, MS4A9 ENSG00000172689 Membrane-spanning 4-domains, subfamily A, member 10 11 60785348-60801305 Predicted membrane proteins, Transporters Evidence at transcript level HPA014778 Uncertain Not detected Group enriched 93 duodenum: 76.3;small intestine: 97.7 parathyroid gland: 0.9 MS4A12 FLJ20217, Ms4a10 ENSG00000071203 Membrane-spanning 4-domains, subfamily A, member 12 11 60492778-60507430 Predicted membrane proteins Evidence at protein level HPA057657 Supported Tissue enriched Group enriched 19 colon: 239.6;rectum: 284.9 appendix: 14.0 MS4A13 ENSG00000204979 Membrane-spanning 4-domains, subfamily A, member 13 11 60515413-60542721 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA045017, HPA063626 Uncertain Not detected Tissue enriched 54 testis: 5.3 all non-specific tissues: 0.0 MS4A18 ENSG00000214782 Membrane-spanning 4-domains, subfamily A, member 18 11 60729304-60744212 Predicted membrane proteins Evidence at transcript level HPA045121 Approved Not detected Tissue enhanced breast: 10.3;duodenum: 24.5 small intestine: 4.1 MS4A2 APY, FCER1B, IGER, MS4A1 ENSG00000149534 Membrane-spanning 4-domains, subfamily A, member 2 11 60088261-60098466 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059967 Supported Mixed Tissue enhanced lung: 24.8 gallbladder: 18.5 MS4A3 CD20L, HTM4 ENSG00000149516 Membrane-spanning 4-domains, subfamily A, member 3 (hematopoietic cell-specific) 11 60056587-60071128 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA019210 Supported Not detected Tissue enriched 254 bone marrow: 305.8 spleen: 1.2 MS4A4A CD20L1, MS4A4, MS4A7 ENSG00000110079 Membrane-spanning 4-domains, subfamily A, member 4A 11 60280541-60308972 Predicted membrane proteins Evidence at transcript level HPA029323 Approved Expressed in all Tissue enhanced placenta: 101.4 adipose tissue: 62.8 MS4A4E ENSG00000214787 Membrane-spanning 4-domains, subfamily A, member 4E 11 60201253-60243088 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040075 Uncertain Mixed Mixed adipose tissue,gallbladder: 5.8 MS4A5 CD20L2 ENSG00000166930 Membrane-spanning 4-domains, subfamily A, member 5 11 60429589-60455214 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043732 Uncertain Not detected Tissue enriched 270 testis: 72.6 duodenum: 0.2 MS4A6A CD20L3, MS4A6 ENSG00000110077 Membrane-spanning 4-domains, subfamily A, member 6A 11 60172014-60184666 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA011391, HPA076623 Approved Approved Vesicles Cervical cancer:6.33e-4 (favourable) Expressed in all Expressed in all lymph node: 115.2 MS4A6E ENSG00000166926 Membrane-spanning 4-domains, subfamily A, member 6E 11 60334831-60396596 Predicted membrane proteins Evidence at transcript level HPA076623 Approved Vesicles Not detected Tissue enriched 36 testis: 61.4 appendix: 1.6 MS4A7 CD20L4, CFFM4, MS4A8 ENSG00000166927 Membrane-spanning 4-domains, subfamily A, member 7 11 60378482-60395951 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017418, CAB026387 Approved Expressed in all Tissue enhanced spleen: 321.1 lung: 125.3 MS4A8 CD20L5, MS4A4, MS4A8B ENSG00000166959 Membrane-spanning 4-domains, subfamily A, member 8 11 60699574-60715811 Predicted membrane proteins Evidence at protein level HPA007318, HPA007319 Supported Tissue enhanced Tissue enhanced duodenum: 191.8;fallopian tube: 223.5;small intestine: 215.2 stomach: 49.6 MSH2 COCA1, HNPCC, HNPCC1 ENSG00000095002 MutS homolog 2 2 47402969-47562311 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009572, CAB070867 Supported Approved Nucleoplasm
Vesicles Liver cancer:1.72e-9 (unfavourable), Endometrial cancer:4.44e-4 (unfavourable), Pancreatic cancer:4.63e-4 (unfavourable) Expressed in all Expressed in all testis: 32.6 MSH5 ENSG00000204410 MutS homolog 5 6 31739948-31762834 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA062688 Approved Endoplasmic reticulum
Vesicles Mixed Mixed skin: 1.8 MSL1 DKFZp686P24239, hMSL1, MSL-1 ENSG00000188895 Male-specific lethal 1 homolog (Drosophila) 17 40122298-40136916 Predicted intracellular proteins Evidence at protein level HPA022800, HPA023567 Uncertain Validated Nucleoplasm Renal cancer:3.06e-6 (unfavourable) Expressed in all Expressed in all testis: 106.7 MSMO1 DESP4, ERG25, SC4MOL ENSG00000052802 Methylsterol monooxygenase 1 4 165327623-165343160 Enzymes, Predicted membrane proteins Evidence at protein level HPA056127 Approved Cervical cancer:2.97e-4 (unfavourable), Renal cancer:9.21e-4 (favourable) Expressed in all Expressed in all liver: 296.4 MSR1 CD204, SCARA1 ENSG00000038945 Macrophage scavenger receptor 1 8 16107878-16567490 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000272, CAB032491 Supported Expressed in all Tissue enhanced lung: 188.3 gallbladder: 50.3 MST1R CD136, CDw136, PTK8, RON ENSG00000164078 Macrophage stimulating 1 receptor 3 49887002-49903873 CD markers, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007657, HPA008180, CAB008972 Approved Approved Cytosol Urothelial cancer:2.33e-5 (favourable) Mixed Tissue enhanced skin: 69.4 stomach: 37.4 MT-CO1 COI, COX1, MTCO1 ENSG00000198804 Mitochondrially encoded cytochrome c oxidase I MT 5904-7445 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB016241, HPA069328 Supported Supported Mitochondria Liver cancer:2.29e-4 (favourable) Expressed in all Expressed in all heart muscle: 79793.3 MT-CO2 CO2, COX2, MTCO2 ENSG00000198712 Mitochondrially encoded cytochrome c oxidase II MT 7586-8269 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB016243, HPA051505, HPA054758 Supported Liver cancer:2.89e-4 (favourable), Pancreatic cancer:7.10e-4 (favourable) Expressed in all Expressed in all heart muscle: 42147.3 MT-CO3 CO3, COIII, COX3, MTCO3 ENSG00000198938 Mitochondrially encoded cytochrome c oxidase III MT 9207-9990 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042788 Approved Approved Nucleoplasm Pancreatic cancer:1.04e-4 (favourable), Liver cancer:2.01e-4 (favourable) Expressed in all Expressed in all heart muscle: 56545.8 MT-CYB COB, CYTB, MTCYB, UQCR3 ENSG00000198727 Mitochondrially encoded cytochrome b MT 14747-15887 Disease related genes, Predicted membrane proteins Evidence at protein level CAB032215, HPA068400 Approved Approved Mitochondria Liver cancer:5.96e-4 (favourable) Expressed in all Expressed in all heart muscle: 24037.9 MT-ND1 MTND1, NAD1, ND1 ENSG00000198888 Mitochondrially encoded NADH dehydrogenase 1 MT 3307-4262 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB033779 Approved Pancreatic cancer:3.26e-4 (favourable), Breast cancer:3.63e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 23823.0 MT-ND3 MTND3, NAD3, ND3 ENSG00000198840 Mitochondrially encoded NADH dehydrogenase 3 MT 10059-10404 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA063296 Supported Approved Cytosol Liver cancer:4.63e-5 (favourable) Expressed in all Expressed in all heart muscle: 30137.8 MT-ND4 LHON, MTND4, NAD4, ND4 ENSG00000198886 Mitochondrially encoded NADH dehydrogenase 4 MT 10760-12137 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA053928 Approved Ovarian cancer:1.76e-4 (favourable) Expressed in all Expressed in all heart muscle: 38133.1 MT-ND4L MTND4L, NAD4L, ND4L ENSG00000212907 Mitochondrially encoded NADH dehydrogenase 4L MT 10470-10766 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA075648 Approved Mitochondria Liver cancer:4.47e-4 (favourable) Expressed in all Expressed in all heart muscle: 23512.4 MTCH1 CGI-64, PSAP, SLC25A49 ENSG00000137409 Mitochondrial carrier 1 6 36968141-36986298 Predicted membrane proteins, Transporters Evidence at protein level HPA015971 Approved Renal cancer:1.16e-7 (favourable), Liver cancer:1.17e-4 (unfavourable), Endometrial cancer:2.06e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 568.7 MTDH 3D3, AEG-1, LYRIC ENSG00000147649 Metadherin 8 97644179-97728770 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010932, HPA015104, CAB068204, CAB068205 Supported Validated Endoplasmic reticulum Renal cancer:3.82e-4 (unfavourable), Pancreatic cancer:5.36e-4 (unfavourable), Lung cancer:7.76e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 104.0 MTFP1 HSPC242, MTP18 ENSG00000242114 Mitochondrial fission process 1 22 30425530-30429053 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA077396 Approved Mitochondria Expressed in all Expressed in all epididymis: 18.7 MTFR2 DUFD1, FAM54A ENSG00000146410 Mitochondrial fission regulator 2 6 136231024-136250335 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029792, HPA029794 Approved Uncertain Vesicles Lung cancer:8.28e-4 (unfavourable), Endometrial cancer:9.64e-4 (unfavourable) Mixed Tissue enhanced testis: 12.7 bone marrow: 10.2 MTHFD1 MTHFC, MTHFD ENSG00000100714 Methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1, methenyltetrahydrofolate cyclohydrolase, formyltetrahydrofolate synthetase 14 64388031-64463457 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000704, HPA001290, HPA015006, HPA050052 Approved Validated Cytosol Renal cancer:5.93e-5 (favourable), Pancreatic cancer:6.96e-4 (unfavourable) Expressed in all Expressed in all liver: 198.3 MTMR1 ENSG00000063601 Myotubularin related protein 1 X 150692971-150765103 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA002977, HPA018502 Approved Approved Nucleoplasm
Vesicles
Plasma membrane Expressed in all Expressed in all parathyroid gland: 26.3 MTPAP FLJ10486, mtPAP, PAPD1, SPAX4 ENSG00000107951 Mitochondrial poly(A) polymerase 10 30309801-30374448 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA038620, HPA058232 Approved Supported Mitochondria Liver cancer:4.20e-6 (unfavourable) Expressed in all Expressed in all bone marrow: 22.7 MTUS1 ATBP, ATIP1, DKFZp586D1519, FLJ14295, ICIS, KIAA1288, MP44, MTSG1 ENSG00000129422 Microtubule associated tumor suppressor 1 8 17643795-17800917 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067903, HPA069795 Validated Nucleoli
Microtubules Colorectal cancer:1.05e-4 (favourable), Renal cancer:2.76e-4 (favourable) Expressed in all Mixed parathyroid gland: 125.8 MTX1 MTX, MTXN ENSG00000173171 Metaxin 1 1 155208699-155213824 Predicted membrane proteins Evidence at protein level HPA011543 Uncertain Supported Mitochondria Renal cancer:3.39e-4 (unfavourable) Expressed in all Expressed in all testis: 71.3 MUC1 ADMCKD, ADMCKD1, CD227, MCD, MCKD, MCKD1, PEM, PUM ENSG00000185499 Mucin 1, cell surface associated 1 155185824-155192916 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000036, CAB001986, HPA004179, HPA007235, HPA008855 Supported Validated Vesicles
Plasma membrane Pancreatic cancer:4.60e-4 (unfavourable) Expressed in all Tissue enhanced lung: 447.5;stomach: 650.2 cervix, uterine: 286.5 MUC12 MUC11 ENSG00000205277 Mucin 12, cell surface associated 7 100969623-101018949 Predicted membrane proteins Evidence at protein level HPA023835 Approved Tissue enriched Group enriched 24 colon: 50.6;rectum: 75.4 appendix: 2.6 MUC13 DRCC1 ENSG00000173702 Mucin 13, cell surface associated 3 124905442-124953819 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045163 Supported Renal cancer:9.73e-5 (unfavourable) Tissue enhanced Group enriched 6 colon: 307.7;duodenum: 631.7;rectum: 335.1;small intestine: 567.0 appendix: 82.8 MUC15 ENSG00000169550 Mucin 15, cell surface associated 11 26559033-26572233 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA026110 Approved Tissue enriched Tissue enriched 18 epididymis: 2780.4 thyroid gland: 158.6 MUC16 CA125, FLJ14303 ENSG00000181143 Mucin 16, cell surface associated 19 8848844-8981342 Predicted membrane proteins Evidence at protein level CAB055172 Supported Tissue enhanced Tissue enhanced cervix, uterine: 23.8;fallopian tube: 9.3 endometrium: 3.5 MUC17 ENSG00000169876 Mucin 17, cell surface associated 7 101020072-101058745 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA031634 Supported Group enriched Group enriched 8 duodenum: 22.4;small intestine: 43.3 rectum: 3.9 MUC21 bCX31G15.2, C6orf205 ENSG00000204544 Mucin 21, cell surface associated 6 30983718-30989903 Predicted membrane proteins Evidence at protein level HPA052028 Supported Group enriched Tissue enriched 47 esophagus: 598.5 tonsil: 12.7 MUC3A MUC3 ENSG00000169894 Mucin 3A, cell surface associated 7 100949555-100968346 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA010871 Uncertain Tissue enhanced Tissue enhanced duodenum: 42.7;gallbladder: 21.9;small intestine: 37.9 rectum: 14.7 MUC4 ENSG00000145113 Mucin 4, cell surface associated 3 195746765-195812277 Predicted membrane proteins Evidence at protein level HPA005895, CAB013536 Approved Tissue enhanced Tissue enhanced colon: 1.1 esophagus: 0.4 MUL1 C1orf166, FLJ12875, GIDE, MAPL, MULAN, RNF218 ENSG00000090432 Mitochondrial E3 ubiquitin protein ligase 1 1 20499448-20508161 Predicted membrane proteins Evidence at protein level HPA026827 Approved Nucleoplasm
Mitochondria
Cytosol Renal cancer:6.15e-14 (favourable) Expressed in all Expressed in all parathyroid gland: 39.0 MXRA8 DKFZp586E2023 ENSG00000162576 Matrix-remodelling associated 8 1 1352689-1361777 Predicted membrane proteins Evidence at protein level HPA053958, HPA055780 Uncertain Approved Nucleoli Renal cancer:3.43e-6 (unfavourable), Urothelial cancer:9.87e-4 (unfavourable), Stomach cancer:9.93e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 57.3 endometrium: 44.5 MYADM ENSG00000179820 Myeloid-associated differentiation marker 19 53866223-53876437 Predicted membrane proteins, Transporters Evidence at protein level HPA056301 Approved Nuclear speckles Renal cancer:7.71e-7 (unfavourable), Lung cancer:8.15e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 257.6 MYADML2 LOC255275 ENSG00000185105 Myeloid-associated differentiation marker-like 2 17 81939645-81947233 Predicted membrane proteins Evidence at transcript level HPA041856, HPA048476 Uncertain Tissue enhanced Tissue enriched 20 skeletal muscle: 30.9 heart muscle: 1.5 MYCT1 FLJ21269, MTLC ENSG00000120279 Myc target 1 6 152697895-152724567 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047992 Uncertain Nucleoplasm Renal cancer:4.73e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 69.9 placenta: 29.6 MYEOV OCIM ENSG00000172927 Myeloma overexpressed 11 69294138-69367726 Predicted membrane proteins Evidence at transcript level HPA012949 Uncertain Approved Nucleus
Vesicles Pancreatic cancer:1.54e-7 (unfavourable), Renal cancer:1.48e-5 (unfavourable), Lung cancer:2.00e-4 (unfavourable) Mixed Group enriched 5 adipose tissue: 4.0;breast: 5.8;esophagus: 9.2;skin: 1.8;stomach: 7.0 appendix: 1.0 MYO5C MGC74969 ENSG00000128833 Myosin VC 15 52192322-52295798 Predicted intracellular proteins Evidence at protein level CAB020790, HPA032115, HPA032116 Supported Supported Nucleus
Cytosol Renal cancer:2.47e-5 (favourable), Endometrial cancer:5.18e-5 (favourable), Stomach cancer:5.82e-4 (favourable) Expressed in all Mixed parathyroid gland: 38.0 MYO9A FLJ11061, FLJ13244, MGC71859 ENSG00000066933 Myosin IXA 15 71822289-72118577 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA039812, HPA040071 Approved Approved Plasma membrane Renal cancer:2.14e-4 (favourable) Mixed Tissue enhanced testis: 51.3 thyroid gland: 22.1 MYOF FER1L3, KIAA1207 ENSG00000138119 Myoferlin 10 93306429-93482317 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014245 Approved Supported Vesicles
Plasma membrane Pancreatic cancer:1.40e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 100.7 MYRF C11orf9, MRF, Ndt80, pqn-47 ENSG00000124920 Myelin regulatory factor 11 61752642-61788518 Enzymes, Plasma proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA018310 Approved Nucleoplasm
Cytosol Renal cancer:2.01e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 67.6;stomach: 62.4 gallbladder: 38.4 MYRFL bcm1377, C12orf15, C12orf28, FLJ25056 ENSG00000166268 Myelin regulatory factor-like 12 69825304-69959097 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA049340 Approved Approved Nucleoli Mixed Group enriched 6 duodenum: 24.4;small intestine: 24.5 testis: 4.3 NAA25 C12orf30, FLJ13089 ENSG00000111300 N(alpha)-acetyltransferase 25, NatB auxiliary subunit 12 112026689-112109022 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039322 Approved Supported Golgi apparatus
Cytosol Renal cancer:1.32e-8 (unfavourable), Liver cancer:5.53e-5 (unfavourable), Endometrial cancer:2.26e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 9.4 NAA60 FLJ14154, NAT15 ENSG00000122390 N(alpha)-acetyltransferase 60, NatF catalytic subunit 16 3443611-3486963 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040916 Approved Uncertain Actin filaments
Cytosol Endometrial cancer:3.14e-4 (favourable), Pancreatic cancer:4.30e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 84.6 NAAA ASAHL ENSG00000138744 N-acylethanolamine acid amidase 4 75913657-75941051 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026135 Approved Endometrial cancer:1.93e-4 (favourable), Pancreatic cancer:4.90e-4 (favourable) Expressed in all Expressed in all prostate: 112.5 NAALAD2 GPCIII, NAADALASE2, NAALADASE2 ENSG00000077616 N-acetylated alpha-linked acidic dipeptidase 2 11 90131515-90192894 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060820, HPA065419 Approved Approved Nucleus Tissue enhanced Tissue enhanced testis: 27.2 adrenal gland,endometrium: 13.7 NAALADL2 ENSG00000177694 N-acetylated alpha-linked acidic dipeptidase-like 2 3 174438573-175810552 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012413, HPA017425, CAB025586 Approved Mixed Tissue enhanced parathyroid gland: 42.8 cervix, uterine: 11.8 NAGPA APAA, UCE ENSG00000103174 N-acetylglucosamine-1-phosphodiester alpha-N-acetylglucosaminidase 16 5024844-5034141 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA064055 Approved Renal cancer:2.67e-5 (unfavourable), Liver cancer:4.67e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 9.6 NALCN bA430M15.1, CanIon, VGCNL1 ENSG00000102452 Sodium leak channel, non selective 13 101053776-101416492 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA031889, HPA031890, HPA031958 Approved Mixed Tissue enhanced cerebral cortex: 28.2 adrenal gland: 6.0 NAT10 FLJ10774, FLJ12179, hALP, KIAA1709, NET43 ENSG00000135372 N-acetyltransferase 10 (GCN5-related) 11 34105602-34147670 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB035546, HPA057576, HPA071628 Supported Validated Nucleoli
Midbody Liver cancer:9.61e-8 (unfavourable), Renal cancer:8.83e-5 (unfavourable), Head and neck cancer:1.07e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.0 NAT14 KLP1 ENSG00000090971 N-acetyltransferase 14 (GCN5-related, putative) 19 55485004-55487568 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047187 Approved Mitochondria Renal cancer:3.61e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 26.8 NAT2 AAC2 ENSG00000156006 N-acetyltransferase 2 (arylamine N-acetyltransferase) 8 18391245-18401218 Cancer-related genes, Enzymes, Predicted intracellular proteins Evidence at protein level HPA043704 Uncertain Colorectal cancer:4.61e-5 (favourable) Tissue enhanced Group enriched 13 colon: 14.7;duodenum: 33.6;liver: 62.2;rectum: 14.2;small intestine: 27.7 smooth muscle: 2.3 NAT8 ATase2, GLA, Hcml1, TSC501 ENSG00000144035 N-acetyltransferase 8 (GCN5-related, putative) 2 73640832-73642393 Enzymes, Predicted membrane proteins Evidence at protein level CAB045990, HPA074519 Uncertain Approved Endoplasmic reticulum Tissue enriched Tissue enriched 18 kidney: 885.6 liver: 49.4 NAT8L FLJ37478, Hcml3 ENSG00000185818 N-acetyltransferase 8-like (GCN5-related, putative) 4 2059512-2069089 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040677 Supported Mitochondria Endometrial cancer:1.01e-5 (unfavourable) Group enriched Group enriched 7 adipose tissue: 48.6;cerebral cortex: 65.1;testis: 19.0 kidney: 6.7 NAV3 KIAA0938, POMFIL1 ENSG00000067798 Neuron navigator 3 12 77830905-78213008 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA032111, HPA032112, CAB037063 Uncertain Approved Nuclear membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 23.1;ovary: 22.9 spleen: 12.1 NBAS NAG ENSG00000151779 Neuroblastoma amplified sequence 2 15166909-15561330 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036817 Approved Approved Nuclear membrane
Nucleoli
Golgi apparatus Urothelial cancer:5.84e-5 (unfavourable), Liver cancer:1.10e-4 (unfavourable) Expressed in all Expressed in all testis: 37.4 NBEA BCL8B, FLJ10197, KIAA1544 ENSG00000172915 Neurobeachin 13 34942287-35673022 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039730, HPA040385 Approved Approved Nucleus
Nucleoli
Golgi apparatus Renal cancer:7.86e-8 (favourable) Mixed Tissue enhanced cerebral cortex: 30.4 prostate: 12.3 NBL1 D1S1733E, DAN, DAND1, NB, NO3 ENSG00000158747 Neuroblastoma 1, DAN family BMP antagonist 1 19640554-19658456 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA007394, CAB026132 Uncertain Expressed in all Expressed in all ovary: 551.6 NBPF10 AG1 ENSG00000271425 Neuroblastoma breakpoint family, member 10 1 146064699-146144942 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA038748, HPA038752, HPA042595, HPA043105, HPA043692, HPA044023, HPA046971, HPA058050 Approved Approved Vesicles Not detected Expressed in all skin: 38.4 NBPF19 ENSG00000271383 Neuroblastoma breakpoint family, member 19 1 149390623-149556361 Predicted intracellular proteins Evidence at protein level HPA042595, HPA043105, HPA043692, HPA044023, HPA046392, HPA046971, HPA058050 Uncertain Approved Vesicles Mixed Expressed in all skin: 74.9 NCAM1 CD56, NCAM ENSG00000149294 Neural cell adhesion molecule 1 11 112961247-113278436 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000142, CAB018071, HPA039835 Supported Validated Plasma membrane
Cytosol Pancreatic cancer:9.11e-6 (favourable), Renal cancer:8.20e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 335.9 adrenal gland: 87.0 NCAM2 MGC51008, NCAM21 ENSG00000154654 Neural cell adhesion molecule 2 21 20998315-21543329 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA030900, HPA030901 Approved Supported Nuclear bodies
Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 69.0 adrenal gland: 15.9 NCAPG2 CAP-G2, FLJ20311, hCAP-G2, LUZP5, MTB ENSG00000146918 Non-SMC condensin II complex, subunit G2 7 158631311-158704829 Predicted intracellular proteins Evidence at protein level HPA026631 Approved Supported Nuclear speckles Liver cancer:3.00e-5 (unfavourable), Renal cancer:4.06e-5 (unfavourable), Head and neck cancer:1.91e-4 (favourable), Melanoma:3.21e-4 (unfavourable), Endometrial cancer:7.94e-4 (unfavourable), Pancreatic cancer:8.50e-4 (unfavourable) Expressed in all Mixed testis: 27.6 NCEH1 AADACL1, KIAA1363, NCEH ENSG00000144959 Neutral cholesterol ester hydrolase 1 3 172630249-172711218 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026888 Supported Approved Endoplasmic reticulum Pancreatic cancer:8.25e-5 (unfavourable) Expressed in all Mixed cerebral cortex: 35.1 NCKAP1 HEM2, Nap1, NAP125 ENSG00000061676 NCK-associated protein 1 2 182909115-183038858 Predicted membrane proteins Evidence at protein level HPA020449 Approved Approved Cytosol Pancreatic cancer:3.81e-4 (unfavourable), Lung cancer:9.71e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 145.6 NCKAP1L HEM1 ENSG00000123338 NCK-associated protein 1-like 12 54497711-54548238 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA039490, HPA040772 Approved Uncertain Plasma membrane
Cytosol Expressed in all Mixed spleen: 55.8 NCKIPSD AF3P21, DIP1, ORF1, SPIN90, WASLBP, WISH ENSG00000213672 NCK interacting protein with SH3 domain 3 48673844-48686364 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB019267, HPA050005 Validated Plasma membrane
Cytosol Renal cancer:1.20e-5 (favourable), Liver cancer:8.57e-4 (unfavourable) Expressed in all Tissue enriched 9 parathyroid gland: 300.2 cerebral cortex: 35.1 NCLN NET59, NICALIN ENSG00000125912 Nicalin 19 3185563-3209575 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006625 Approved Uncertain Nucleoplasm
Lipid droplets Renal cancer:8.37e-5 (unfavourable), Stomach cancer:8.82e-5 (favourable), Endometrial cancer:1.19e-4 (favourable), Liver cancer:2.15e-4 (unfavourable) Expressed in all Expressed in all duodenum: 34.8 NCMAP C1orf130, FLJ42528, MP11 ENSG00000184454 Noncompact myelin associated protein 1 24556111-24609328 Predicted membrane proteins Evidence at transcript level HPA013656 Uncertain Endometrial cancer:2.83e-6 (favourable) Mixed Tissue enhanced gallbladder: 11.5 thyroid gland: 7.1 NCR1 CD335, LY94, NK-p46, NKP46 ENSG00000189430 Natural cytotoxicity triggering receptor 1 19 54906150-54916140 CD markers, Predicted membrane proteins Evidence at protein level HPA049311 Approved Endoplasmic reticulum Tissue enhanced Tissue enhanced spleen: 2.0 bone marrow: 0.5 NCR2 CD336, LY95, NK-p44 ENSG00000096264 Natural cytotoxicity triggering receptor 2 6 41335655-41350887 CD markers, Predicted membrane proteins Evidence at protein level HPA067249 Uncertain Not detected Not detected duodenum: 0.5 NCR3LG1 B7-H6, DKFZp686O24166 ENSG00000188211 Natural killer cell cytotoxicity receptor 3 ligand 1 11 17351726-17377341 Predicted membrane proteins Evidence at protein level HPA024137 Uncertain Renal cancer:4.21e-12 (favourable) Mixed Tissue enhanced parathyroid gland: 12.6 rectum: 5.6 NCSTN APH2, KIAA0253 ENSG00000162736 Nicastrin 1 160343272-160358952 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB021982, HPA054846, HPA070642 Approved Approved Cytosol Renal cancer:7.75e-9 (unfavourable) Expressed in all Expressed in all parathyroid gland: 140.4 NDC1 FLJ10407, NET3, TMEM48 ENSG00000058804 NDC1 transmembrane nucleoporin 1 53765460-53838860 Predicted membrane proteins, Transporters Evidence at protein level HPA069751, HPA070882 Approved Supported Nuclear membrane
Plasma membrane
Actin filaments Liver cancer:7.52e-7 (unfavourable), Colorectal cancer:4.48e-5 (favourable), Pancreatic cancer:3.58e-4 (unfavourable) Expressed in all Mixed lymph node: 16.6 NDFIP1 MGC10924, N4WBP5 ENSG00000131507 Nedd4 family interacting protein 1 5 142108505-142154443 Predicted membrane proteins Evidence at protein level HPA009682 Approved Head and neck cancer:2.33e-7 (unfavourable), Renal cancer:2.39e-7 (favourable) Expressed in all Expressed in all cerebral cortex: 246.7 NDFIP2 KIAA1165, N4wbp5a ENSG00000102471 Nedd4 family interacting protein 2 13 79481124-79556075 Predicted membrane proteins Evidence at protein level HPA009160 Uncertain Validated Vesicles Renal cancer:4.18e-5 (favourable), Head and neck cancer:5.99e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 96.3 NDN HsT16328, PWCR ENSG00000182636 Necdin, melanoma antigen (MAGE) family member 15 23685400-23687330 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA074457 Approved Nucleoplasm
Cytosol Renal cancer:4.52e-4 (unfavourable) Expressed in all Mixed ovary: 84.9 NDOR1 bA350O14.9, NR1 ENSG00000188566 NADPH dependent diflavin oxidoreductase 1 9 137205670-137217009 Predicted intracellular proteins Evidence at protein level HPA024504 Approved Supported Nucleus
Intermediate filaments
Cytosol Expressed in all Mixed spleen: 12.9 NDRG2 KIAA1248, SYLD ENSG00000165795 NDRG family member 2 14 21016763-21070872 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002896, HPA003590, CAB017491 Supported Approved Nucleoplasm
Microtubule organizing center
Cytosol Renal cancer:1.43e-12 (favourable), Liver cancer:6.71e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1032.4 NDRG4 KIAA1180, SMAP-8 ENSG00000103034 NDRG family member 4 16 58462846-58513628 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015313, HPA017587 Supported Uncertain Nucleus
Cytosol Tissue enriched Tissue enhanced adrenal gland: 147.3;cerebral cortex: 421.4 heart muscle: 140.8 NDST1 HSST, NST1 ENSG00000070614 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 1 5 150485818-150558211 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060532 Approved Ovarian cancer:5.13e-4 (unfavourable), Endometrial cancer:6.99e-4 (unfavourable) Expressed in all Expressed in all spleen: 60.7 NDST2 HSST2, NST2 ENSG00000166507 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 10 73801911-73811798 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051515 Approved Approved Cytosol Mixed Expressed in all spleen: 44.9 NDST3 HSST3 ENSG00000164100 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 3 4 118033618-118258648 Enzymes, Predicted intracellular proteins Evidence at protein level HPA056189 Uncertain Not detected Tissue enhanced cerebral cortex: 3.0;spleen: 2.8 cervix, uterine: 0.7 NDST4 ENSG00000138653 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 4 4 114827763-115113876 Enzymes, Predicted intracellular proteins Evidence at protein level HPA011129 Uncertain Not detected Tissue enhanced cerebral cortex: 1.4;ovary: 1.8 spleen: 1.0 NDUFA1 CI-MWFE, MWFE ENSG00000125356 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5kDa X 119871487-119876662 Disease related genes, Predicted membrane proteins Evidence at protein level HPA029768, HPA054359 Supported Supported Mitochondria
Cytosol Renal cancer:3.48e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 224.9 NDUFA13 B16.6, CDA016, CGI-39, GRIM-19, GRIM19 ENSG00000186010 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 13 19 19515736-19529054 Disease related genes, Predicted membrane proteins Evidence at protein level HPA041213 Supported Validated Mitochondria Expressed in all Expressed in all heart muscle: 220.4 NDUFA3 B9 ENSG00000170906 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 3, 9kDa 19 54102728-54109257 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046976 Supported Urothelial cancer:4.80e-4 (favourable), Pancreatic cancer:9.65e-4 (favourable) Expressed in all Expressed in all skin: 16.0 NDUFA4 CI-9k, MLRQ ENSG00000189043 NDUFA4, mitochondrial complex associated 7 10931951-10940256 Disease related genes, Predicted membrane proteins Evidence at protein level HPA055323 Supported Mitochondria Renal cancer:4.61e-8 (favourable) Expressed in all Expressed in all heart muscle: 249.3 NDUFA4L2 FLJ26118, NUOMS ENSG00000185633 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4-like 2 12 57234903-57240715 Predicted membrane proteins Evidence at protein level HPA055323 Approved Mitochondria Renal cancer:1.37e-5 (unfavourable) Expressed in all Tissue enhanced esophagus: 152.9;skin: 191.9 placenta: 103.6 NDUFA9 CI-39k, NDUFS2L, SDR22E1 ENSG00000139180 NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 9, 39kDa 12 4649095-4694317 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042268, HPA073212 Supported Supported Nucleoplasm
Mitochondria Renal cancer:2.57e-7 (favourable), Urothelial cancer:5.75e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 38.4 NDUFB1 CI-MNLL, MNLL ENSG00000183648 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 1, 7kDa 14 92116122-92121917 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063737 Supported Nuclear speckles
Mitochondria Renal cancer:1.31e-5 (favourable) Expressed in all Expressed in all skeletal muscle: 278.9 NDUFB11 ESSS, Np15, NP17.3 ENSG00000147123 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 11, 17.3kDa X 47142216-47145504 Disease related genes, Predicted membrane proteins Evidence at protein level HPA030367 Supported Validated Mitochondria Expressed in all Expressed in all skeletal muscle: 129.1 NDUFB2 AGGG, CI-AGGG ENSG00000090266 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa 7 140690777-140722790 Predicted intracellular proteins Evidence at protein level HPA051377 Approved Renal cancer:7.60e-7 (favourable) Expressed in all Expressed in all thyroid gland: 495.8 NDUFB3 B12 ENSG00000119013 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 3, 12kDa 2 201071433-201085750 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034596 Approved Head and neck cancer:7.24e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 180.0 NDUFB4 B15 ENSG00000065518 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 4, 15kDa 3 120596309-120602500 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051739 Supported Supported Nuclear membrane
Mitochondria Urothelial cancer:1.79e-4 (favourable) Expressed in all Expressed in all adrenal gland: 365.9 NDUFB5 CI-SGDH, MGC12314, SGDH ENSG00000136521 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5, 16kDa 3 179604690-179627647 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005640 Supported Supported Nucleoplasm
Mitochondria Renal cancer:3.32e-5 (favourable) Expressed in all Expressed in all heart muscle: 133.4 NDUFB6 B17, CI ENSG00000165264 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa 9 32552999-32573184 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044001, HPA053334 Supported Validated Mitochondria Renal cancer:7.47e-10 (favourable), Cervical cancer:3.18e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 70.5 NDUFB8 ASHI, CI-ASHI ENSG00000166136 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8, 19kDa 10 100523740-100530000 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA003886 Supported Supported Mitochondria Expressed in all Expressed in all heart muscle: 292.4 NDUFC1 KFYI ENSG00000109390 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1, 6kDa 4 139266880-139302551 Predicted membrane proteins Evidence at protein level HPA044556 Approved Supported Mitochondria Endometrial cancer:8.23e-5 (favourable), Urothelial cancer:7.25e-4 (favourable), Renal cancer:9.96e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 86.7 NDUFC2 B14.5b, HLC-1 ENSG00000151366 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2, 14.5kDa 11 78068304-78080219 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038873, HPA056195 Approved Supported Mitochondria Renal cancer:5.00e-5 (favourable) Expressed in all Expressed in all thyroid gland: 369.3 NDUFC2-KCTD14 ENSG00000259112 NDUFC2-KCTD14 readthrough 11 78016971-78079865 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038873, HPA056195 Approved Supported Mitochondria Not detected Tissue enhanced duodenum: 5.1 stomach: 2.6 NEGR1 IGLON4, KILON, MGC46680, Ntra ENSG00000172260 Neuronal growth regulator 1 1 71395940-72282734 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011894 Uncertain Approved Vesicles
Actin filaments
Cytosol Mixed Tissue enhanced cerebral cortex: 56.3 gallbladder: 17.5 NEK9 DKFZp434D0935, MGC16714, Nek8, NERCC ENSG00000119638 NIMA-related kinase 9 14 75079353-75127344 Enzymes, Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA001405 Approved Approved Mitochondria Pancreatic cancer:5.63e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 30.1 NELL2 NRP2 ENSG00000184613 Neural EGFL like 2 12 44508275-44921848 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035714, HPA035715 Uncertain Approved Vesicles Pancreatic cancer:5.56e-4 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 204.7;fallopian tube: 95.3 prostate: 40.8 NEMP1 KIAA0286, TMEM194, TMEM194A ENSG00000166881 Nuclear envelope integral membrane protein 1 12 57055643-57088063 Predicted membrane proteins Evidence at protein level HPA014394 Uncertain Approved Nucleoplasm Renal cancer:1.09e-5 (unfavourable), Liver cancer:1.93e-4 (unfavourable) Expressed in all Mixed lymph node: 14.6 NEMP2 TMEM194B ENSG00000189362 Nuclear envelope integral membrane protein 2 2 190504342-190534722 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA057719 Approved Nucleoplasm Renal cancer:6.42e-4 (unfavourable) Expressed in all Mixed testis: 5.8 NEO1 HsT17534, IGDCC2, NGN, NTN1R2 ENSG00000067141 Neogenin 1 15 73051710-73305206 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009320, HPA027804, HPA027805, HPA027806 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Renal cancer:4.39e-4 (favourable) Expressed in all Mixed parathyroid gland: 100.9 NETO1 BCTL1, BTCL1 ENSG00000166342 Neuropilin (NRP) and tolloid (TLL)-like 1 18 72742314-72868146 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA064630 Approved Golgi apparatus Tissue enhanced Tissue enriched 15 cerebral cortex: 64.1 spleen: 4.1 NETO2 FLJ10430, NEOT2 ENSG00000171208 Neuropilin (NRP) and tolloid (TLL)-like 2 16 47077703-47143997 Predicted membrane proteins, Transporters Evidence at protein level HPA013180 Uncertain Approved Golgi apparatus Renal cancer:5.53e-6 (unfavourable) Mixed Tissue enhanced spleen: 32.0 cerebral cortex: 21.0 NEU1 NEU ENSG00000204386 Sialidase 1 (lysosomal sialidase) 6 31857659-31862906 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015634, HPA021506 Approved Supported Vesicles
Cell Junctions Expressed in all Mixed thyroid gland: 14.3 NFAM1 CNAIP ENSG00000235568 NFAT activating protein with ITAM motif 1 22 42380410-42432395 Predicted membrane proteins Evidence at protein level HPA031812 Uncertain Endometrial cancer:6.16e-4 (favourable) Expressed in all Tissue enhanced appendix: 17.6;bone marrow: 20.3 spleen: 14.8 NFASC FLJ46866, KIAA0756, NF, NRCAML ENSG00000163531 Neurofascin 1 204828651-205022822 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008832 Supported Renal cancer:2.93e-5 (unfavourable), Pancreatic cancer:3.21e-5 (favourable) Tissue enhanced Tissue enhanced cerebral cortex: 55.8 seminal vesicle: 22.1 NFIB NFI-RED, NFIB2, NFIB3 ENSG00000147862 Nuclear factor I/B 9 14081843-14398983 Cancer-related genes, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA003956 Supported Supported Nucleus
Nucleoli fibrillar center Renal cancer:3.53e-4 (favourable) Expressed in all Mixed breast: 44.4 NFXL1 HOZFP ENSG00000170448 Nuclear transcription factor, X-box binding-like 1 4 47847233-47914667 Predicted membrane proteins, Transcription factors Evidence at protein level HPA059132 Approved Approved Nucleoplasm Liver cancer:9.28e-4 (unfavourable) Expressed in all Mixed testis: 24.8 NGFR CD271, p75NTR, TNFRSF16 ENSG00000064300 Nerve growth factor receptor 17 49495293-49515017 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level CAB000143, CAB001995, HPA004765 Supported Approved Nucleoplasm
Plasma membrane Urothelial cancer:3.40e-4 (unfavourable) Expressed in all Mixed adipose tissue: 32.2 NGLY1 FLJ11005, PNG1 ENSG00000151092 N-glycanase 1 3 25718944-25790039 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA036825 Approved Liver cancer:1.96e-6 (unfavourable), Colorectal cancer:1.17e-5 (favourable) Expressed in all Expressed in all testis: 115.4 NIM1K MGC42105, NIM1 ENSG00000177453 NIM1 serine/threonine protein kinase 5 43192071-43280850 Enzymes, Predicted membrane proteins Evidence at protein level HPA007695 Uncertain Approved Cytosol Tissue enriched Tissue enriched 8 cerebral cortex: 16.4 lung: 2.0 NINJ1 NIN1 ENSG00000131669 Ninjurin 1 9 93121489-93134288 Predicted membrane proteins Evidence at protein level HPA045063 Uncertain Expressed in all Expressed in all bone marrow: 158.5 NINJ2 ENSG00000171840 Ninjurin 2 12 564296-663779 Predicted membrane proteins Evidence at protein level HPA058980 Approved Endoplasmic reticulum Head and neck cancer:5.31e-4 (favourable) Expressed in all Tissue enhanced lung: 55.8 bone marrow: 24.0 NIPA1 MGC35570, SPG6 ENSG00000170113 Non imprinted in Prader-Willi/Angelman syndrome 1 15 22773063-22829791 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA023269 Uncertain Expressed in all Tissue enhanced cerebral cortex: 38.3 parathyroid gland: 16.6 NIPA2 ENSG00000140157 Non imprinted in Prader-Willi/Angelman syndrome 2 15 22838641-22868384 Predicted membrane proteins, Transporters Evidence at protein level HPA067160, HPA071342 Approved Approved Golgi apparatus Expressed in all Expressed in all appendix: 45.7 NIPAL1 DKFZp686A06115, NPAL1 ENSG00000163293 NIPA-like domain containing 1 4 47914142-48040173 Predicted membrane proteins Evidence at transcript level HPA036765 Uncertain Approved Golgi apparatus Mixed Tissue enhanced esophagus: 24.2;skin: 31.0 rectum: 14.9 NIPAL2 FLJ13955, NPAL2 ENSG00000104361 NIPA-like domain containing 2 8 98189833-98294393 Predicted membrane proteins Evidence at transcript level HPA071759 Uncertain Expressed in all Mixed skin: 62.5 NIPAL3 DJ462O23.2, NPAL3 ENSG00000001461 NIPA-like domain containing 3 1 24415794-24472976 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039978 Approved Approved Nucleoplasm Renal cancer:3.03e-7 (favourable), Thyroid cancer:3.95e-4 (favourable) Expressed in all Expressed in all prostate: 94.7 NIPAL4 ICHYN ENSG00000172548 NIPA-like domain containing 4 5 157460019-157474717 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038259 Approved Urothelial cancer:6.82e-4 (favourable) Tissue enhanced Tissue enhanced skin: 42.0 esophagus: 10.2 NKAIN1 FAM77C, FLJ12650 ENSG00000084628 Na+/K+ transporting ATPase interacting 1 1 31179745-31239554 Predicted membrane proteins Evidence at transcript level HPA006873 Uncertain Group enriched Tissue enhanced adrenal gland: 13.9;cerebral cortex: 13.1;skeletal muscle: 7.4 epididymis: 4.4 NKAIN2 FAM77B, TCBA1 ENSG00000188580 Na+/K+ transporting ATPase interacting 2 6 123804141-124825657 Disease related genes, Predicted membrane proteins Evidence at transcript level HPA045860 Approved Cytosol Mixed Tissue enriched 44 cerebral cortex: 48.0 adipose tissue,skeletal muscle,testis: 1.0 NKAIN3 FAM77D, FLJ39630 ENSG00000185942 Na+/K+ transporting ATPase interacting 3 8 62248591-62999652 Predicted membrane proteins Evidence at transcript level HPA018833 Uncertain Tissue enhanced Not detected adrenal gland: 0.4 NKAIN4 bA261N11.2, C20orf58, FAM77A ENSG00000101198 Na+/K+ transporting ATPase interacting 4 20 63240784-63272694 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA029876 Approved Endometrial cancer:3.14e-4 (unfavourable) Tissue enriched Tissue enriched 13 cerebral cortex: 71.9 kidney: 5.5 NKG7 GIG1, GMP-17 ENSG00000105374 Natural killer cell granule protein 7 19 51371606-51372715 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071454 Approved Vesicles Renal cancer:3.32e-6 (unfavourable), Endometrial cancer:7.42e-6 (favourable) Expressed in all Tissue enhanced bone marrow: 352.2;spleen: 153.8 lymph node: 124.8 NKPD1 FLJ33600 ENSG00000179846 NTPase, KAP family P-loop domain containing 1 19 45149750-45160150 Predicted membrane proteins Evidence at protein level HPA043339 Uncertain Mixed Tissue enriched 18 skin: 13.9 breast,seminal vesicle: 0.7 NLGN1 KIAA1070 ENSG00000169760 Neuroligin 1 3 173396284-174286644 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006572, HPA006680 Approved Uncertain Nuclear bodies
Plasma membrane Group enriched Tissue enhanced cerebral cortex: 25.5 testis: 12.5 NLGN2 KIAA1366 ENSG00000169992 Neuroligin 2 17 7404874-7419860 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055321, HPA069278 Supported Approved Mitochondria Renal cancer:3.44e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 81.7 endometrium: 43.6 NLGN3 ASPGX1, AUTSX1, HNL3, KIAA1480 ENSG00000196338 Neuroligin 3 X 71144831-71171201 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003183 Supported Tissue enriched Tissue enhanced cerebral cortex: 62.4 seminal vesicle: 17.1 NLGN4X HLNX, KIAA1260, NLGN, NLGN4 ENSG00000146938 Neuroligin 4, X-linked X 5840637-6228863 Disease related genes, Predicted membrane proteins Evidence at protein level HPA001651 Approved Tissue enhanced Tissue enhanced cerebral cortex: 20.2 ovary: 12.9 NLGN4Y KIAA0951 ENSG00000165246 Neuroligin 4, Y-linked Y 14522638-14845650 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA001651 Approved Mixed Tissue enhanced prostate: 11.0;seminal vesicle: 12.3 cerebral cortex: 7.4 NLRC3 CLR16.2, FLJ00348, NOD3 ENSG00000167984 NLR family, CARD domain containing 3 16 3539033-3577400 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048062 Supported Microtubule organizing center
Cytosol Mixed Tissue enhanced lymph node: 16.7 spleen: 11.8 NLRP1 CARD7, CLR17.1, DEFCAP, DKFZp586O1822, KIAA0926, NAC, NALP1, SLEV1, VAMAS1 ENSG00000091592 NLR family, pyrin domain containing 1 17 5499427-5619424 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009189, HPA064431 Supported Supported Nucleoplasm
Cytosol Renal cancer:1.60e-5 (unfavourable), Pancreatic cancer:7.57e-4 (favourable) Expressed in all Mixed skin: 35.2 NLRP3 AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1, FCAS, FCU, MWS, NALP3, PYPAF1 ENSG00000162711 NLR family, pyrin domain containing 3 1 247416156-247449108 Cancer-related genes, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA012878 Uncertain Mixed Tissue enhanced bone marrow: 34.5 appendix: 14.9 NLRP4 CLR19.5, CT58, FLJ32126, NALP4, PAN2, PYPAF4, RNH2 ENSG00000160505 NLR family, pyrin domain containing 4 19 55836578-55881854 Predicted intracellular proteins Evidence at protein level HPA042561 Uncertain Tissue enriched Tissue enhanced testis: 12.6;tonsil: 4.8 lymph node: 2.0 NLRP6 CLR11.4, NALP6, PAN3, PYPAF5 ENSG00000174885 NLR family, pyrin domain containing 6 11 278365-285359 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA043681, HPA048500 Supported Liver cancer:4.23e-5 (favourable) Mixed Group enriched 13 duodenum: 40.5;small intestine: 41.0 appendix: 3.1 NLRP8 CLR19.2, NALP8, NOD16, PAN4 ENSG00000179709 NLR family, pyrin domain containing 8 19 55947832-55988629 Predicted intracellular proteins Evidence at transcript level HPA056989 Uncertain Not detected Not detected breast: 0.5 NLRP9 CLR19.1, NALP9, NOD6, PAN12 ENSG00000185792 NLR family, pyrin domain containing 9 19 55708432-55738402 Predicted intracellular proteins Evidence at transcript level HPA042623 Uncertain Tissue enriched Tissue enhanced prostate: 1.5 testis: 0.6 NMBR BB1 ENSG00000135577 Neuromedin B receptor 6 142058330-142088799 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA026665 Supported Plasma membrane
Cytosol Not detected Group enriched 5 fallopian tube: 1.3;testis: 2.6 cerebral cortex: 0.3 NMUR1 FM-3, GPC-R, GPR66, NMU1R ENSG00000171596 Neuromedin U receptor 1 2 231523160-231530495 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA027895 Uncertain Mixed Mixed adipose tissue: 5.5 NMUR2 NMU2R ENSG00000132911 Neuromedin U receptor 2 5 152391532-152433368 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA045836 Approved Group enriched Tissue enhanced stomach: 1.1;testis: 2.2 thyroid gland: 0.9 NNT ENSG00000112992 Nicotinamide nucleotide transhydrogenase 5 43602692-43707405 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004829, CAB004975 Supported Validated Mitochondria Renal cancer:1.22e-15 (favourable) Expressed in all Expressed in all heart muscle: 139.6 NOC2L DKFZP564C186, NET15, NET7, NIR, PPP1R112 ENSG00000188976 NOC2-like nucleolar associated transcriptional repressor 1 944204-959309 Predicted intracellular proteins Evidence at protein level HPA044258, HPA062195 Approved Validated Nucleoli Expressed in all Expressed in all skin: 42.1 NOL11 DKFZP586L0724 ENSG00000130935 Nucleolar protein 11 17 67717833-67744531 Predicted intracellular proteins Evidence at protein level HPA022010 Approved Validated Nucleoli Colorectal cancer:1.00e-6 (favourable), Liver cancer:2.59e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.0 NOL6 bA311H10.1, FLJ21959, MGC14896, MGC14921, MGC20838, Nrap, UTP22 ENSG00000165271 Nucleolar protein 6 (RNA-associated) 9 33461441-33473930 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055891, HPA061002 Supported Validated Nucleus
Nucleoli
Mitochondria Liver cancer:4.83e-5 (unfavourable), Thyroid cancer:9.49e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 28.1 NOMO1 PM5 ENSG00000103512 NODAL modulator 1 16 14833681-14896160 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025192, HPA046697, HPA061174 Approved Approved Endoplasmic reticulum Urothelial cancer:3.15e-4 (unfavourable) Expressed in all Mixed thyroid gland: 11.8 NOMO2 NOMO, PM5 ENSG00000185164 NODAL modulator 2 16 18417325-18562211 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046697, HPA061174 Approved Expressed in all Expressed in all parathyroid gland: 154.9 NOMO3 ENSG00000103226 NODAL modulator 3 16 16232495-16294814 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046697, HPA061174 Approved Mixed Mixed skin: 1.9 NOTCH1 TAN1 ENSG00000148400 Notch 1 9 136494444-136545862 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB008112, CAB022466, HPA067168 Supported Approved Nucleoplasm Renal cancer:5.45e-4 (unfavourable) Expressed in all Expressed in all skin: 24.0 NOTCH2 ENSG00000134250 Notch 2 1 119911553-120069626 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046392, HPA048743 Uncertain Supported Nucleoplasm
Plasma membrane Ovarian cancer:5.24e-4 (unfavourable), Pancreatic cancer:9.48e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 46.5 NOTCH3 CADASIL, CASIL ENSG00000074181 Notch 3 19 15159038-15200981 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB005393, HPA044392 Approved Supported Nucleoplasm
Actin filaments
Cytosol Renal cancer:2.53e-7 (unfavourable), Endometrial cancer:5.92e-4 (unfavourable) Expressed in all Mixed skin: 93.5 NOX3 GP91-3 ENSG00000074771 NADPH oxidase 3 6 155395370-155455903 Predicted membrane proteins, Transporters Evidence at protein level HPA073837 Uncertain Vesicles Not detected Not detected adrenal gland: 0.1 NOX4 KOX, KOX-1 ENSG00000086991 NADPH oxidase 4 11 89324356-89498187 Predicted membrane proteins, Transporters Evidence at protein level HPA015475 Uncertain Approved Nucleus Renal cancer:6.14e-4 (favourable) Mixed Tissue enriched 12 kidney: 133.6 parathyroid gland: 10.7 NPC1 ENSG00000141458 Niemann-Pick disease, type C1 18 23506184-23586898 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA026618, CAB070132 Approved Liver cancer:2.26e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 110.9 NPC1L1 ENSG00000015520 NPC1-like 1 7 44512535-44541315 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB070127, CAB070128 Supported Group enriched Tissue enhanced duodenum: 58.7;small intestine: 59.3 liver: 14.2 NPDC1 CAB-, CAB1, DKFZp586J0523 ENSG00000107281 Neural proliferation, differentiation and control, 1 9 137039470-137046203 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008189 Approved Approved Nucleus
Cytosol Colorectal cancer:2.01e-5 (unfavourable), Endometrial cancer:6.19e-5 (favourable), Pancreatic cancer:3.18e-4 (favourable) Expressed in all Expressed in all prostate: 108.1 NPFFR1 GPR147, NPFF1R1, OT7T022 ENSG00000148734 Neuropeptide FF receptor 1 10 70247329-70283676 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA037521 Uncertain Tissue enhanced Tissue enhanced testis: 2.1 cerebral cortex,lymph node: 0.8 NPFFR2 GPR74, NPFF2, NPGPR ENSG00000056291 Neuropeptide FF receptor 2 4 72031804-72148067 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026825 Approved Plasma membrane
Actin filaments Mixed Tissue enhanced placenta: 2.3;seminal vesicle: 4.5 epididymis: 1.1 NPHP4 KIAA0673, POC10, SLSN4 ENSG00000131697 Nephronophthisis 4 1 5862811-5992473 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065526 Approved Mixed Mixed fallopian tube: 12.4 NPHS1 CNF, NPHN ENSG00000161270 Nephrosis 1, congenital, Finnish type (nephrin) 19 35825964-35869287 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB035555 Supported Mixed Tissue enhanced kidney: 17.7;lymph node: 5.5;pancreas: 5.5 tonsil: 2.4 NPHS2 PDCN, SRN1 ENSG00000116218 Nephrosis 2, idiopathic, steroid-resistant (podocin) 1 179550539-179575952 Disease related genes, Predicted membrane proteins Evidence at protein level CAB037267, HPA049486 Supported Not detected Tissue enriched 79 kidney: 92.9 testis: 1.1 NPIPA1 morpheus, NPIP ENSG00000183426 Nuclear pore complex interacting protein family, member A1 16 14750813-14952060 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA053611 Supported Approved Nucleoplasm Mixed Mixed ovary: 68.2 NPIPB11 ENSG00000254206 Nuclear pore complex interacting protein family, member B11 16 29381354-29404029 Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Mixed parathyroid gland: 14.2 NPIPB3 KIAA0220, NPIPL3 ENSG00000169246 Nuclear pore complex interacting protein family, member B3 16 21402237-21448567 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Expressed in all skin: 229.8 NPIPB4 ENSG00000185864 Nuclear pore complex interacting protein family, member B4 16 21834569-21880827 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Expressed in all skin: 125.9 NPIPB5 ENSG00000243716 Nuclear pore complex interacting protein family, member B5 16 22479121-22536521 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Mixed Expressed in all skin: 271.1 NPIPB8 ENSG00000255524 Nuclear pore complex interacting protein family, member B8 16 28637654-28658682 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011188, HPA053611 Uncertain Approved Nucleoplasm Not detected Tissue enriched 11 testis: 12.8 small intestine: 1.1 NPR1 ANPa, ANPRA, GUCY2A, NPRA ENSG00000169418 Natriuretic peptide receptor 1 1 153678637-153693992 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA031087 Approved Nucleus
Nucleoli
Plasma membrane Pancreatic cancer:2.49e-4 (favourable), Endometrial cancer:3.97e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 71.8;fallopian tube: 57.6 placenta: 25.2 NPR3 ANPRC, C5orf23, FLJ14054, GUCY2B, NPRC ENSG00000113389 Natriuretic peptide receptor 3 5 32689070-32791724 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031065, HPA052702 Uncertain Approved Cytosol Renal cancer:5.43e-6 (favourable) Tissue enhanced Tissue enriched 5 kidney: 113.3 adipose tissue: 21.9 NPSR1 GPR154, GPRA, PGR14 ENSG00000187258 Neuropeptide S receptor 1 7 34658239-34878332 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007489 Supported Tissue enhanced Not detected stomach: 0.5 NPTN GP55, GP65, np55, np65, SDFR1, SDR1 ENSG00000156642 Neuroplastin 15 73560014-73634134 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051497, HPA072453 Approved Approved Cytokinetic bridge
Mitochondria Expressed in all Expressed in all smooth muscle: 428.0 NPY1R NPYR ENSG00000164128 Neuropeptide Y receptor Y1 4 163323961-163344832 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029903 Approved Nucleus
Mitochondria
Cytosol Breast cancer:7.68e-5 (favourable) Tissue enriched Tissue enhanced spleen: 153.9 breast: 39.0 NPY4R PP1, PPYR1, Y4 ENSG00000204174 Neuropeptide Y receptor Y4 10 46461099-46465881 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA027863 Approved Tissue enhanced Tissue enhanced colon: 9.0;rectum: 10.5 skin: 6.4 NR2C1 TR2, TR2-11 ENSG00000120798 Nuclear receptor subfamily 2, group C, member 1 12 95020229-95073703 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA035040, HPA035041, HPA067767 Supported Supported Nucleus
Cell Junctions
Cytosol Renal cancer:1.03e-6 (unfavourable), Liver cancer:5.18e-5 (unfavourable), Urothelial cancer:5.62e-5 (favourable) Expressed in all Mixed testis: 21.8 NR2C2 hTAK1, TAK1, TR2R1, TR4 ENSG00000177463 Nuclear receptor subfamily 2, group C, member 2 3 14947584-15053600 Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA006313 Approved Validated Nucleoplasm Head and neck cancer:1.51e-5 (favourable) Expressed in all Expressed in all testis: 38.8 NR3C1 GR, GRL ENSG00000113580 Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) 5 143277931-143435512 Disease related genes, FDA approved drug targets, Nuclear receptors, Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA004248, CAB010435 Supported Validated Nucleoplasm
Mitochondria
Cytosol Renal cancer:1.72e-6 (unfavourable), Endometrial cancer:3.64e-5 (unfavourable) Expressed in all Expressed in all placenta: 66.4 NR4A1 GFRP1, HMR, N10, NAK-1, NGFIB, NUR77, TR3 ENSG00000123358 Nuclear receptor subfamily 4, group A, member 1 12 52022832-52059507 Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA059742 Supported Nucleus
Cytosol Renal cancer:6.99e-4 (favourable) Expressed in all Expressed in all adrenal gland: 753.5 NRCAM Bravo, KIAA0343 ENSG00000091129 Neuronal cell adhesion molecule 7 108147623-108456717 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012606 Approved Tissue enriched Tissue enhanced cerebral cortex: 180.9 adrenal gland: 49.7 NRDE2 C14orf102, FLJ14051 ENSG00000119720 NRDE-2, necessary for RNA interference, domain containing 14 90267856-90332137 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047050, HPA050583 Uncertain Supported Nucleoplasm
Mitochondria Expressed in all Mixed endometrium,thyroid gland: 2.7 NRG1 GGF, HGL, HRG, NDF, NRG1-IT2 ENSG00000157168 Neuregulin 1 8 31639386-32767959 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010964 Uncertain Approved Nucleoplasm Tissue enhanced Mixed thyroid gland: 19.9 NRG2 Don-1, HRG2, NTAK ENSG00000158458 Neuregulin 2 5 139846779-140043299 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA038935, HPA047973 Uncertain Supported Nucleus
Nucleoli Mixed Tissue enhanced parathyroid gland: 13.1 ovary: 10.2 NRG4 HRG4 ENSG00000169752 Neuregulin 4 15 75935969-76059795 Predicted membrane proteins Evidence at protein level HPA010957 Uncertain Mixed Tissue enhanced fallopian tube: 1.0;testis: 1.3 stomach: 0.9 NRK DKFZp686A17109 ENSG00000123572 Nik related kinase X 105822543-105958610 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017238 Uncertain Approved Nucleoplasm
Cytosol Tissue enriched Tissue enhanced ovary: 39.6;placenta: 34.0 adrenal gland: 21.0 NRM NRM29 ENSG00000137404 Nurim (nuclear envelope membrane protein) 6 30688047-30691420 Predicted membrane proteins Evidence at protein level HPA072545, HPA073982 Validated Nuclear membrane Renal cancer:3.52e-8 (unfavourable) Expressed in all Mixed skin: 1.6 NRP1 CD304, NRP, VEGF165R ENSG00000099250 Neuropilin 1 10 33177492-33336262 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004511, HPA030278 Approved Uncertain Mitochondria Stomach cancer:1.22e-5 (unfavourable), Cervical cancer:7.10e-5 (unfavourable), Renal cancer:3.87e-4 (unfavourable), Glioma:7.78e-4 (unfavourable) Expressed in all Expressed in all placenta: 193.5 NRP2 VEGF165R2 ENSG00000118257 Neuropilin 2 2 205681990-205798133 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039980, HPA054974 Approved Supported Vesicles
Plasma membrane Renal cancer:7.68e-7 (unfavourable), Urothelial cancer:7.80e-5 (unfavourable) Expressed in all Mixed smooth muscle: 83.5 NRROS ELLP3030, GARPL1, LRRC33, MGC50789, UNQ3030 ENSG00000174004 Negative regulator of reactive oxygen species 3 196639686-196662004 Predicted membrane proteins Evidence at protein level HPA031586 Uncertain Ovarian cancer:9.63e-4 (unfavourable) Expressed in all Mixed bone marrow: 19.9 NRSN1 p24, VMP ENSG00000152954 Neurensin 1 6 24126122-24154900 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA061006 Approved Approved Nucleus
Vesicles Tissue enriched Tissue enriched 14 cerebral cortex: 96.7 adrenal gland: 6.7 NRSN2 C20orf98, dJ1103G7.6 ENSG00000125841 Neurensin 2 20 346782-359660 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015967 Approved Approved Nucleoplasm
Vesicles
Cytosol Pancreatic cancer:1.61e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 126.5 parathyroid gland: 68.4 NRXN2 ENSG00000110076 Neurexin 2 11 64606174-64723188 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051470 Approved Nucleus
Nuclear membrane
Cytosol Tissue enhanced Tissue enriched 8 cerebral cortex: 143.0 testis: 17.0 NRXN3 C14orf60, KIAA0743 ENSG00000021645 Neurexin 3 14 78170373-79868290 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002727 Approved Renal cancer:1.83e-7 (favourable) Mixed Tissue enhanced cerebral cortex: 43.1;smooth muscle: 28.6 testis: 21.4 NSDHL H105e3, SDR31E1, XAP104 ENSG00000147383 NAD(P) dependent steroid dehydrogenase-like X 152830967-152869729 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000248, HPA000571 Supported Validated Endoplasmic reticulum
Lipid droplets Renal cancer:6.09e-5 (favourable), Liver cancer:5.04e-4 (unfavourable), Cervical cancer:5.65e-4 (favourable) Expressed in all Expressed in all epididymis: 53.2 NSG1 ENSG00000168824 Neuron specific gene family member 1 4 4348140-4419058 Predicted membrane proteins Evidence at protein level HPA035775 Uncertain Approved Mitochondria Pancreatic cancer:9.49e-4 (favourable) Tissue enhanced Tissue enhanced skin: 143.0 cerebral cortex: 68.8 NT5E CALJA, CD73, eN, eNT, NT5 ENSG00000135318 5'-nucleotidase, ecto (CD73) 6 85449584-85495791 CD markers, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017357 Approved Supported Plasma membrane
Cytosol Pancreatic cancer:1.32e-5 (unfavourable), Stomach cancer:1.02e-4 (unfavourable), Lung cancer:6.66e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 171.7 smooth muscle: 104.9 NTF3 NGF2 ENSG00000185652 Neurotrophin 3 12 5432112-5521536 Cancer-related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA032001 Approved Mixed Tissue enhanced ovary: 13.5 spleen: 6.3 NTRK1 MTC, TRK, TRKA ENSG00000198400 Neurotrophic tyrosine kinase, receptor, type 1 1 156815640-156881850 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB004606, HPA035799, HPA076570 Approved Uncertain Vesicles
Cytosol Tissue enhanced Tissue enriched 6 adrenal gland: 9.6 testis: 1.6 NTRK2 TRKB ENSG00000148053 Neurotrophic tyrosine kinase, receptor, type 2 9 84668551-85027070 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA007637 Approved Approved Cytosol Group enriched Tissue enhanced cerebral cortex: 441.0;thyroid gland: 214.8 breast: 81.9 NTRK3 TRKC ENSG00000140538 Neurotrophic tyrosine kinase, receptor, type 3 15 87859751-88256768 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009233, HPA027484, HPA048065 Supported Supported Nuclear membrane
Nucleoli Tissue enhanced Tissue enhanced cerebral cortex: 39.7 testis: 15.2 NTSR1 NTR ENSG00000101188 Neurotensin receptor 1 (high affinity) 20 62708837-62762771 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA050299 Supported Plasma membrane Tissue enhanced Not detected cerebral cortex: 0.5 NUDC NudC ENSG00000090273 NudC nuclear distribution protein 1 26900238-26946862 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027183, HPA028105 Supported Validated Cytosol Liver cancer:1.21e-6 (unfavourable) Expressed in all Expressed in all fallopian tube: 149.4 NUDT8 FLJ41567 ENSG00000167799 Nudix (nucleoside diphosphate linked moiety X)-type motif 8 11 67627938-67629930 Predicted intracellular proteins Evidence at protein level HPA041252, HPA041466 Supported Approved Nucleoli
Cytosol Renal cancer:3.70e-4 (favourable) Expressed in all Expressed in all heart muscle: 21.0 NUP205 C7orf14, KIAA0225 ENSG00000155561 Nucleoporin 205kDa 7 135557919-135648757 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA024574 Uncertain Liver cancer:1.90e-7 (unfavourable) Expressed in all Expressed in all parathyroid gland: 29.7 NUP210 FLJ22389, GP210, KIAA0906, POM210 ENSG00000132182 Nucleoporin 210kDa 3 13316235-13420309 Predicted membrane proteins, Transporters Evidence at protein level HPA066888 Approved Liver cancer:6.03e-6 (unfavourable) Expressed in all Expressed in all lymph node: 49.2 NUP210L ENSG00000143552 Nucleoporin 210kDa-like 1 153992685-154155116 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA047195, HPA064245, HPA066707 Supported Approved Nuclear bodies Not detected Tissue enriched 93 testis: 47.5 seminal vesicle: 0.5 NUP50 NPAP60L ENSG00000093000 Nucleoporin 50kDa 22 45163841-45188015 Plasma proteins, Predicted intracellular proteins, Transporters Evidence at protein level HPA047162, HPA048328 Supported Validated Nucleoplasm
Nuclear membrane Stomach cancer:4.06e-4 (favourable) Expressed in all Expressed in all testis: 54.5 NUP93 KIAA0095 ENSG00000102900 Nucleoporin 93kDa 16 56730105-56850286 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA017937 Uncertain Liver cancer:1.72e-6 (unfavourable) Expressed in all Expressed in all testis: 74.3 NXPE1 FAM55A, MGC34290 ENSG00000095110 Neurexophilin and PC-esterase domain family, member 1 11 114521715-114559895 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049133 Supported Tissue enriched Group enriched 13 colon: 114.0;rectum: 168.7 appendix: 11.0 NXPE2 FAM55B, FLJ25224 ENSG00000204361 Neurexophilin and PC-esterase domain family, member 2 11 114678386-114706933 Predicted intracellular proteins Evidence at protein level HPA039744, HPA039876 Supported Colorectal cancer:9.29e-5 (favourable) Tissue enhanced Tissue enhanced colon: 9.7;epididymis: 29.8;rectum: 9.9 salivary gland: 8.2 NYNRIN CGIN1, FLJ11811, KIAA1305 ENSG00000205978 NYN domain and retroviral integrase containing 14 24398786-24419288 Predicted intracellular proteins Evidence at protein level HPA018945 Approved Approved Nucleoplasm
Golgi apparatus
Vesicles Expressed in all Mixed ovary: 42.6 OCEL1 FLJ22709 ENSG00000099330 Occludin/ELL domain containing 1 19 17226204-17229219 Predicted intracellular proteins Evidence at protein level HPA042070, HPA043223 Uncertain Approved Golgi apparatus Expressed in all Expressed in all epididymis: 21.9 OCIAD1 Asrij, FLJ20455, OCIA, TPA018 ENSG00000109180 OCIA domain containing 1 4 48805212-48861817 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044803 Approved Approved Mitochondria Expressed in all Expressed in all cerebral cortex: 326.5 OCLN PPP1R115 ENSG00000197822 Occludin 5 69492292-69558104 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA005933, CAB013075, CAB068212, CAB068213, CAB068214 Supported Supported Plasma membrane
Cell Junctions Renal cancer:6.59e-11 (favourable) Mixed Tissue enhanced thyroid gland: 78.3 lung: 39.9 OCSTAMP C20orf123, dJ257E24.3 ENSG00000149635 Osteoclast stimulatory transmembrane protein 20 46540946-46550574 Predicted membrane proteins Evidence at transcript level HPA031116 Uncertain Not detected Not detected testis: 0.2 OFCC1 MRDS1 ENSG00000181355 Orofacial cleft 1 candidate 1 6 9596110-10211608 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035725, HPA050619 Uncertain Uncertain Nucleoplasm Not detected Tissue enriched 5 breast: 20.9 testis: 4.0 OGFOD3 C17orf101, FLJ22222 ENSG00000181396 2-oxoglutarate and iron-dependent oxygenase domain containing 3 17 82389223-82418637 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052099 Uncertain Approved Nucleoplasm Renal cancer:5.72e-4 (favourable) Expressed in all Expressed in all thyroid gland: 26.3 OLAH FLJ11106, SAST, THEDC1 ENSG00000152463 Oleoyl-ACP hydrolase 10 15032227-15073852 Enzymes, Predicted intracellular proteins Evidence at protein level HPA037947, HPA037948 Approved Group enriched Tissue enriched 6 testis: 46.1 breast: 7.1 OLR1 CLEC8A, LOX-1, SCARE1 ENSG00000173391 Oxidized low density lipoprotein (lectin-like) receptor 1 12 10158301-10172138 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050798 Supported Nucleoplasm
Vesicles
Plasma membrane Head and neck cancer:8.24e-5 (unfavourable) Expressed in all Group enriched 6 appendix: 42.1;cerebral cortex: 32.8;lung: 146.2;placenta: 159.6 bone marrow: 15.8 OMA1 FLJ33782, MPRP-1, YKR087C, ZMPOMA1 ENSG00000162600 OMA1 zinc metallopeptidase 1 58415384-58546802 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055120 Approved Approved Nucleoplasm
Mitochondria Breast cancer:1.63e-4 (favourable), Colorectal cancer:7.70e-4 (favourable), Lung cancer:8.52e-4 (favourable) Expressed in all Expressed in all prostate: 32.2 OPA3 FLJ22187, MGA3 ENSG00000125741 Optic atrophy 3 (autosomal recessive, with chorea and spastic paraplegia) 19 45527427-45602212 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044881 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:9.30e-12 (favourable), Liver cancer:5.60e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 18.0 OPALIN HTMP10, TMEM10, TMP10 ENSG00000197430 Oligodendrocytic myelin paranodal and inner loop protein 10 96343216-96359365 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014372 Supported Tissue enriched Tissue enriched 866 cerebral cortex: 86.6 all non-specific tissues: 0.0 OPN1SW BCP, BOP, CBT ENSG00000128617 Opsin 1 (cone pigments), short-wave-sensitive 7 128772491-128775790 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA013562, HPA014083 Supported Renal cancer:2.26e-8 (unfavourable), Stomach cancer:5.98e-8 (unfavourable), Liver cancer:8.50e-5 (unfavourable), Urothelial cancer:9.33e-4 (unfavourable) Expressed in all Mixed smooth muscle: 14.7 OPN3 ECPN, encephalopsin, ERO, NMO-1, PPP1R116 ENSG00000054277 Opsin 3 1 241590102-241677376 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB013682, HPA064443 Uncertain Approved Nucleoplasm Cervical cancer:3.17e-5 (unfavourable), Glioma:2.51e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 26.8 lung: 12.7 OPN4 melanopsin, MOP ENSG00000122375 Opsin 4 10 86654557-86666848 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA039147 Approved Not detected Tissue enhanced cerebral cortex: 2.2;parathyroid gland: 1.4 skeletal muscle: 0.9 OPN5 dJ402H5.1, neuropsin, TMEM13 ENSG00000124818 Opsin 5 6 47781982-47832780 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA026084 Supported Not detected Tissue enriched 42 testis: 4.3 heart muscle: 0.1 OPRD1 ENSG00000116329 Opioid receptor, delta 1 1 28812142-28871267 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013744 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 2.6 adrenal gland: 0.8 OPRK1 KOR, OPRK ENSG00000082556 Opioid receptor, kappa 1 8 53225716-53251697 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022595 Uncertain Tissue enhanced Group enriched 7 cerebral cortex: 3.6;prostate: 3.2;testis: 1.8 placenta,skeletal muscle: 0.3 OPRM1 MOR1 ENSG00000112038 Opioid receptor, mu 1 6 154010496-154246867 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014509, HPA067435 Supported Supported Not detected Tissue enhanced testis: 4.2 adrenal gland,esophagus: 1.2 OR10A7 ENSG00000179919 Olfactory receptor, family 10, subfamily A, member 7 12 55221025-55221975 G-protein coupled receptors, Predicted membrane proteins No evidence HPA055111 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR10AD1 OR10AD1P ENSG00000172640 Olfactory receptor, family 10, subfamily AD, member 1 12 48202083-48203387 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA049913 Uncertain Not detected Mixed testis: 1.2 OR10C1 hs6M1-17, OR10C1P, OR10C2 ENSG00000279941 Olfactory receptor, family 10, subfamily C, member 1 (gene/pseudogene) 6 29440016-29440954 Predicted membrane proteins No evidence HPA049336 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR10D3 HTPCRX09, OR10D3P ENSG00000197309 Olfactory receptor, family 10, subfamily D, member 3 (non-functional) 11 124185216-124186245 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049991 Uncertain Not detected Not detected testis: 0.7 OR10G3 ENSG00000169208 Olfactory receptor, family 10, subfamily G, member 3 14 21569803-21570744 G-protein coupled receptors, Predicted membrane proteins No evidence HPA019766 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR10J3 OR10J3P ENSG00000196266 Olfactory receptor, family 10, subfamily J, member 3 1 159313670-159314659 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA042963 Uncertain Not detected Not detected placenta: 0.6 OR10K1 ENSG00000173285 Olfactory receptor, family 10, subfamily K, member 1 1 158465562-158466503 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA059125 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR10K2 ENSG00000180708 Olfactory receptor, family 10, subfamily K, member 2 1 158419928-158420866 G-protein coupled receptors, Predicted membrane proteins No evidence HPA059125 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR10Q1 ENSG00000180475 Olfactory receptor, family 10, subfamily Q, member 1 11 58227882-58228918 G-protein coupled receptors, Predicted membrane proteins No evidence HPA046968 Uncertain Not detected Not detected placenta: 0.1 OR10R2 OR10R2Q ENSG00000198965 Olfactory receptor, family 10, subfamily R, member 2 1 158479878-158480885 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA059775, HPA060399 Uncertain Not detected Not detected thyroid gland: 0.1 OR10S1 ENSG00000196248 Olfactory receptor, family 10, subfamily S, member 1 11 123976661-123977781 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA019038 Uncertain Not detected Not detected thyroid gland: 0.1 OR10V1 ENSG00000172289 Olfactory receptor, family 10, subfamily V, member 1 11 59712823-59713864 G-protein coupled receptors, Predicted membrane proteins No evidence HPA060076 Uncertain Not detected Not detected cervix, uterine: 0.2 OR10X1 OR10X1P ENSG00000186400 Olfactory receptor, family 10, subfamily X, member 1 (gene/pseudogene) 1 158578919-158579899 G-protein coupled receptors, Predicted membrane proteins No evidence HPA060990 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR10Z1 ENSG00000198967 Olfactory receptor, family 10, subfamily Z, member 1 1 158606439-158607380 G-protein coupled receptors, Predicted membrane proteins No evidence HPA058072 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR11H1 OR22-1 ENSG00000130538 Olfactory receptor, family 11, subfamily H, member 1 22 15528158-15529139 G-protein coupled receptors, Predicted membrane proteins No evidence HPA047370 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR11H12 ENSG00000257115 Olfactory receptor, family 11, subfamily H, member 12 14 18601045-18602129 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047370 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR11H2 C14orf15, OR11H2P, OR11H8P ENSG00000258453 Olfactory receptor, family 11, subfamily H, member 2 14 19712936-19713920 G-protein coupled receptors, Predicted membrane proteins No evidence HPA047370 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR11H4 ENSG00000176198 Olfactory receptor, family 11, subfamily H, member 4 14 20242739-20243820 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA052790 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR13A1 ENSG00000256574 Olfactory receptor, family 13, subfamily A, member 1 10 45302654-45315608 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057237 Uncertain Tissue enhanced Not detected urinary bladder: 0.5 OR13C3 ENSG00000204246 Olfactory receptor, family 13, subfamily C, member 3 9 104535749-104536856 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA053978 Uncertain Not detected Not detected testis: 0.7 OR13D1 ENSG00000179055 Olfactory receptor, family 13, subfamily D, member 1 9 104694422-104695462 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055921 Uncertain Not detected Not detected testis: 0.5 OR14A2 OR5AX1, OR5AX1P ENSG00000241128 Olfactory receptor, family 14, subfamily A, member 2 1 247723099-247724043 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA052685 Uncertain Not detected Tissue enriched 51 testis: 5.1 all non-specific tissues: 0.0 OR14J1 hs6M1-28, OR5U1 ENSG00000204695 Olfactory receptor, family 14, subfamily J, member 1 6 29306690-29307655 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA045575 Uncertain Not detected Not detected testis: 0.1 OR14K1 OR5AY1 ENSG00000153230 Olfactory receptor, family 14, subfamily K, member 1 1 247738615-247739559 G-protein coupled receptors, Predicted membrane proteins No evidence HPA016643 Uncertain Not detected Not detected testis: 0.3 OR1B1 OR9-B ENSG00000171484 Olfactory receptor, family 1, subfamily B, member 1 (gene/pseudogene) 9 122628579-122629535 G-protein coupled receptors, Predicted membrane proteins No evidence HPA058654 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR1L3 OR9-D ENSG00000171481 Olfactory receptor, family 1, subfamily L, member 3 9 122675130-122676104 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058878 Uncertain Not detected Not detected cerebral cortex: 0.1 OR1Q1 HSTPCR106, OR1Q2, OR1Q3, OR9-A, OST226, OST226OR9-A, TPCR106 ENSG00000165202 Olfactory receptor, family 1, subfamily Q, member 1 9 122614738-122615682 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA044828 Uncertain Not detected Not detected epididymis: 0.9 OR1S1 OST034 ENSG00000172774 Olfactory receptor, family 1, subfamily S, member 1 (gene/pseudogene) 11 58214745-58215722 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049304 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR1S2 ENSG00000197887 Olfactory receptor, family 1, subfamily S, member 2 11 58203202-58204181 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049304 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2A1 ENSG00000221970 Olfactory receptor, family 2, subfamily A, member 1 7 144318125-144319057 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058272 Uncertain Not detected Tissue enhanced thyroid gland: 3.2 ovary: 1.4 OR2A25 OR2A25P, OR2A27 ENSG00000221933 Olfactory receptor, family 2, subfamily A, member 25 7 144074182-144075195 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058272 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2A4 OR2A10 ENSG00000180658 Olfactory receptor, family 2, subfamily A, member 4 6 131700469-131701401 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058272 Uncertain Tissue enriched Not detected testis: 0.2 OR2A42 ENSG00000212807 Olfactory receptor, family 2, subfamily A, member 42 7 144231911-144232843 G-protein coupled receptors, Predicted membrane proteins No evidence HPA058272 Uncertain Not detected Not detected thyroid gland: 0.8 OR2A7 HSDJ0798C17 ENSG00000243896 Olfactory receptor, family 2, subfamily A, member 7 7 144258607-144259722 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058272 Uncertain Mixed Mixed thyroid gland: 20.0 OR2AE1 OR2AE2 ENSG00000244623 Olfactory receptor, family 2, subfamily AE, member 1 7 99875987-99877057 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA042957 Uncertain Not detected Not detected parathyroid gland: 0.2 OR2AK2 OR2AK1P ENSG00000187080 Olfactory receptor, family 2, subfamily AK, member 2 1 247965233-247966339 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA052544 Uncertain Not detected Not detected testis: 0.2 OR2AT4 ENSG00000171561 Olfactory receptor, family 2, subfamily AT, member 4 11 75088713-75089754 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA060357 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2B11 ENSG00000177535 Olfactory receptor, family 2, subfamily B, member 11 1 247451029-247451982 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047459 Uncertain Not detected Not detected adipose tissue: 0.7 OR2C3 OR2C4, OR2C5P, OST742 ENSG00000196242 Olfactory receptor, family 2, subfamily C, member 3 1 247530132-247533839 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA053920, HPA058578 Uncertain Supported Plasma membrane Not detected Expressed in all parathyroid gland: 26.6 OR2D3 ENSG00000178358 Olfactory receptor, family 2, subfamily D, member 3 11 6920974-6922043 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA052551 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2K2 HSHTPCRH06, HTPCRH06, OR2AR1P ENSG00000171133 Olfactory receptor, family 2, subfamily K, member 2 9 111327483-111328520 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA024261 Uncertain Not detected Not detected testis: 0.3 OR2M4 HSHTPCRX18, HTPCRX18, OST710, TPCR100 ENSG00000171180 Olfactory receptor, family 2, subfamily M, member 4 1 248238929-248239864 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA051308 Uncertain Not detected Not detected cerebral cortex: 0.2 OR2T1 OR1-25 ENSG00000175143 Olfactory receptor, family 2, subfamily T, member 1 1 248405995-248407104 G-protein coupled receptors, Predicted membrane proteins No evidence HPA063064 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2T10 ENSG00000184022 Olfactory receptor, family 2, subfamily T, member 10 1 248592830-248593768 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA052019 Uncertain Tissue enhanced Tissue enriched 13 kidney: 7.1 prostate: 0.5 OR2T11 OR2T11Q ENSG00000183130 Olfactory receptor, family 2, subfamily T, member 11 (gene/pseudogene) 1 248626178-248627128 G-protein coupled receptors, Predicted membrane proteins No evidence HPA047416 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR2V1 OR2V1P, OST265 ENSG00000185372 Olfactory receptor, family 2, subfamily V, member 1 5 181124357-181125304 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA049953 Uncertain Not detected Tissue enriched 24 fallopian tube: 2.5 testis: 0.1 OR2V2 OR2V3, OST713 ENSG00000182613 Olfactory receptor, family 2, subfamily V, member 2 5 181154943-181155890 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049953 Uncertain Not detected Not detected fallopian tube: 0.4 OR2W3 OR2W3P, OR2W8P, OST718 ENSG00000238243 Olfactory receptor, family 2, subfamily W, member 3 1 247895587-247896531 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA045594 Uncertain Tissue enhanced Tissue enhanced bone marrow: 7.8;thyroid gland: 10.5 cerebral cortex: 2.9 OR2Z1 OR2Z2 ENSG00000181733 Olfactory receptor, family 2, subfamily Z, member 1 19 8730954-8732009 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA048760 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4A47 ENSG00000237388 Olfactory receptor, family 4, subfamily A, member 47 11 48488717-48489780 G-protein coupled receptors, Predicted membrane proteins No evidence HPA059763 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4B1 OST208 ENSG00000175619 Olfactory receptor, family 4, subfamily B, member 1 11 48216792-48217762 G-protein coupled receptors, Predicted membrane proteins No evidence HPA059443 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4C15 ENSG00000181939 Olfactory receptor, family 4, subfamily C, member 15 11 55554307-55555419 G-protein coupled receptors, Predicted membrane proteins No evidence HPA061939 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4C16 ENSG00000181935 Olfactory receptor, family 4, subfamily C, member 16 (gene/pseudogene) 11 55572128-55573060 G-protein coupled receptors, Plasma proteins, Predicted membrane proteins No evidence HPA059128 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4C3 ENSG00000176547 Olfactory receptor, family 4, subfamily C, member 3 11 48324920-48328471 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA049116 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4C5 OR4C5P, OR4C5Q ENSG00000176540 Olfactory receptor, family 4, subfamily C, member 5 (gene/pseudogene) 11 48365485-48366465 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049516 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4D5 ENSG00000171014 Olfactory receptor, family 4, subfamily D, member 5 11 123939543-123940637 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA045005 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4F16 ENSG00000273547 Olfactory receptor, family 4, subfamily F, member 16 1 685716-686654 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047705 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4F21 OR4F21P ENSG00000176269 Olfactory receptor, family 4, subfamily F, member 21 8 166049-167043 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047705 Uncertain Not detected Not detected testis: 0.2 OR4F29 ENSG00000278566 Olfactory receptor, family 4, subfamily F, member 29 1 450740-451678 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047705 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4F3 ENSG00000230178 Olfactory receptor, family 4, subfamily F, member 3 5 181367268-181368262 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047705 Uncertain Not detected Not detected testis: 0.6 OR4K1 ENSG00000155249 Olfactory receptor, family 4, subfamily K, member 1 14 19935608-19936683 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA028877 Uncertain Not detected Not detected testis: 0.3 OR4K15 OR4K15Q ENSG00000169488 Olfactory receptor, family 4, subfamily K, member 15 14 19975444-19976659 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055732 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4M1 ENSG00000176299 Olfactory receptor, family 4, subfamily M, member 1 14 19780242-19781357 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058889 Uncertain Not detected Tissue enriched 10 testis: 1.0 all non-specific tissues: 0.0 OR4M2 ENSG00000274102 Olfactory receptor, family 4, subfamily M, member 2 15 22080527-22081659 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058889 Uncertain Not detected Tissue enriched 10 testis: 1.2 cerebral cortex: 0.1 OR4N4 ENSG00000183706 Olfactory receptor, family 4, subfamily N, member 4 15 22094431-22095556 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057442 Uncertain Uncertain Centrosome Not detected Tissue enriched 103 testis: 10.3 cervix, uterine: 0.1 OR4P4 OR4P3P ENSG00000181927 Olfactory receptor, family 4, subfamily P, member 4 11 55638358-55639296 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA059458 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR4Q3 C14orf13, OR4Q4 ENSG00000182652 Olfactory receptor, family 4, subfamily Q, member 3 14 19747428-19748369 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA049924 Uncertain Not detected Tissue enriched 20 testis: 2.7 cerebral cortex: 0.1 OR4X2 ENSG00000279556 Olfactory receptor, family 4, subfamily X, member 2 (gene/pseudogene) 11 48245104-48246015 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA060249 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR51A7 ENSG00000176895 Olfactory receptor, family 51, subfamily A, member 7 11 4907370-4908308 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA061356 Uncertain Not detected Not detected testis: 0.2 OR51B5 ENSG00000242180 Olfactory receptor, family 51, subfamily B, member 5 11 5342586-5343524 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA063124 Uncertain Not detected Not detected testis: 0.3 OR51D1 OR51D1Q ENSG00000197428 Olfactory receptor, family 51, subfamily D, member 1 11 4639715-4640838 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA061240 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR51E1 GPR136, GPR164, OR51E1P, OR52A3P ENSG00000180785 Olfactory receptor, family 51, subfamily E, member 1 11 4643420-4655488 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level CAB019995, HPA051439 Approved Renal cancer:1.23e-6 (unfavourable) Tissue enriched Tissue enhanced adipose tissue: 6.3;placenta: 9.5;prostate: 8.0 urinary bladder: 1.8 OR51G1 OR51G3P ENSG00000176879 Olfactory receptor, family 51, subfamily G, member 1 (gene/pseudogene) 11 4923374-4924339 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA050482 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR51J1 OR51J1P, OR51J2 ENSG00000184321 Olfactory receptor, family 51, subfamily J, member 1 (gene/pseudogene) 11 5402597-5403547 G-protein coupled receptors, Predicted membrane proteins No evidence HPA017605 Uncertain Not detected Not detected epididymis: 0.1 OR51M1 ENSG00000184698 Olfactory receptor, family 51, subfamily M, member 1 11 5389399-5390379 G-protein coupled receptors, Predicted membrane proteins No evidence HPA056773 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR51Q1 ENSG00000167360 Olfactory receptor, family 51, subfamily Q, member 1 (gene/pseudogene) 11 5422111-5423206 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA044998 Uncertain Not detected Not detected epididymis: 0.1 OR51T1 ENSG00000176900 Olfactory receptor, family 51, subfamily T, member 1 11 4881819-4882883 G-protein coupled receptors, Predicted membrane proteins No evidence HPA046877 Uncertain Not detected Not detected prostate: 0.1 OR52D1 ENSG00000181609 Olfactory receptor, family 52, subfamily D, member 1 11 5488685-5489749 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA046965 Uncertain Not detected Tissue enriched 6 testis: 2.3 epididymis: 0.3 OR52E2 ENSG00000176787 Olfactory receptor, family 52, subfamily E, member 2 11 5058650-5059627 G-protein coupled receptors, Predicted membrane proteins No evidence HPA045748 Uncertain Not detected Not detected testis: 0.4 OR52I2 ENSG00000226288 Olfactory receptor, family 52, subfamily I, member 2 11 4586791-4587905 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA049343 Uncertain Not detected Not detected epididymis: 0.2 OR52N1 ENSG00000181001 Olfactory receptor, family 52, subfamily N, member 1 11 5787854-5788816 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins No evidence HPA054028 Uncertain Not detected Not detected adipose tissue: 0.1 OR56B1 OR56B1P ENSG00000181023 Olfactory receptor, family 56, subfamily B, member 1 11 5736517-5737491 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA045043 Uncertain Not detected Not detected parathyroid gland: 0.3 OR5A2 ENSG00000172324 Olfactory receptor, family 5, subfamily A, member 2 11 59421943-59422976 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047135, HPA049575 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5D16 ENSG00000205029 Olfactory receptor, family 5, subfamily D, member 16 11 55838752-55839738 G-protein coupled receptors, Predicted membrane proteins No evidence HPA046711 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5F1 OR11-10 ENSG00000149133 Olfactory receptor, family 5, subfamily F, member 1 11 55993681-55994625 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA059360 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5J2 ENSG00000174957 Olfactory receptor, family 5, subfamily J, member 2 11 56176618-56177556 G-protein coupled receptors, Predicted membrane proteins No evidence HPA059466 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5L1 OST262 ENSG00000186117 Olfactory receptor, family 5, subfamily L, member 1 (gene/pseudogene) 11 55811467-55812402 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047524 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5L2 HSHTPCRX16, HTPCRX16 ENSG00000205030 Olfactory receptor, family 5, subfamily L, member 2 11 55827219-55828154 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047524 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5P3 JCG1 ENSG00000182334 Olfactory receptor, family 5, subfamily P, member 3 11 7825037-7825972 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA060787 Uncertain Not detected Not detected epididymis,skin: 0.1 OR5R1 OR5R1P ENSG00000174942 Olfactory receptor, family 5, subfamily R, member 1 (gene/pseudogene) 11 56417258-56418232 G-protein coupled receptors, Predicted membrane proteins No evidence HPA049992 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5T1 OR5T1P ENSG00000181698 Olfactory receptor, family 5, subfamily T, member 1 11 56275639-56276619 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA050952 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5T3 OR5T3Q ENSG00000172489 Olfactory receptor, family 5, subfamily T, member 3 11 56252200-56253222 G-protein coupled receptors, Predicted membrane proteins No evidence HPA044986 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR5V1 hs6M1-21 ENSG00000243729 Olfactory receptor, family 5, subfamily V, member 1 6 29355230-29431967 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA046707 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR6B1 OR7-3 ENSG00000221813 Olfactory receptor, family 6, subfamily B, member 1 7 144003929-144004983 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA053164 Uncertain Not detected Not detected testis: 0.3 OR6B2 OR6B2P ENSG00000182083 Olfactory receptor, family 6, subfamily B, member 2 2 240028965-240030456 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047529 Uncertain Not detected Not detected testis: 0.6 OR6B3 OR6B3P, OR6B3Q ENSG00000178586 Olfactory receptor, family 6, subfamily B, member 3 2 240045077-240046072 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047529 Uncertain Not detected Tissue enhanced epididymis: 1.9 testis: 0.7 OR6C6 ENSG00000188324 Olfactory receptor, family 6, subfamily C, member 6 12 55294288-55295232 G-protein coupled receptors, Predicted membrane proteins No evidence HPA051090 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR6K3 ENSG00000203757 Olfactory receptor, family 6, subfamily K, member 3 1 158717168-158718163 G-protein coupled receptors, Predicted membrane proteins No evidence HPA055949 Uncertain Not detected Not detected bone marrow: 0.8 OR6M1 ENSG00000196099 Olfactory receptor, family 6, subfamily M, member 1 11 123805335-123806387 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA048674 Uncertain Not detected Not detected testis: 0.3 OR6N2 ENSG00000188340 Olfactory receptor, family 6, subfamily N, member 2 1 158776682-158777635 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA056637 Uncertain Not detected Tissue enriched 12 bone marrow: 1.1 all non-specific tissues: 0.0 OR6P1 ENSG00000186440 Olfactory receptor, family 6, subfamily P, member 1 1 158562651-158563604 G-protein coupled receptors, Predicted membrane proteins No evidence HPA047466 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR6T1 ENSG00000181499 Olfactory receptor, family 6, subfamily T, member 1 11 123942785-123943873 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA060893 Uncertain Not detected Not detected testis: 0.6 OR7A5 HTPCR2 ENSG00000188269 Olfactory receptor, family 7, subfamily A, member 5 19 14792490-14835376 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA053823 Uncertain Tissue enriched Tissue enhanced epididymis: 5.4;parathyroid gland: 5.2;testis: 2.8 breast,seminal vesicle: 0.9 OR7C1 OR19-5, OR7C4 ENSG00000127530 Olfactory receptor, family 7, subfamily C, member 1 19 14799146-14800211 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA047127 Uncertain Tissue enriched Tissue enhanced epididymis: 3.4;parathyroid gland: 4.9;testis: 3.9 seminal vesicle: 1.5 OR7C2 OR19-18, OR7C3 ENSG00000127529 Olfactory receptor, family 7, subfamily C, member 2 19 14941489-14942448 G-protein coupled receptors, Predicted membrane proteins No evidence HPA047295 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR8B4 OR8B4P ENSG00000198657 Olfactory receptor, family 8, subfamily B, member 4 (gene/pseudogene) 11 124423942-124424871 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA049884 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR8D1 OR8D3, OST004 ENSG00000196341 Olfactory receptor, family 8, subfamily D, member 1 11 124309812-124310837 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA059510 Uncertain Not detected Tissue enriched 21 testis: 2.0 all non-specific tissues: 0.0 OR8K1 ENSG00000150261 Olfactory receptor, family 8, subfamily K, member 1 11 56346039-56346998 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055233 Uncertain Not detected Not detected all non-specific tissues: 0.0 OR8S1 ENSG00000197376 Olfactory receptor, family 8, subfamily S, member 1 12 48507354-48529897 G-protein coupled receptors, Predicted membrane proteins No evidence HPA045595 Uncertain Approved Plasma membrane Not detected Not detected breast,testis: 0.1 OR9K2 ENSG00000170605 Olfactory receptor, family 9, subfamily K, member 2 12 55129681-55130802 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA015808 Uncertain Not detected Not detected all non-specific tissues: 0.0 ORAI1 CRACM1, FLJ14466, TMEM142A ENSG00000276045 ORAI calcium release-activated calcium modulator 1 12 121626550-121642677 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA016583, HPA061823 Approved Supported Cytosol Ovarian cancer:4.30e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 48.9 ORAI2 C7orf19, CBCIP2, FLJ12474, FLJ14733, H_NH0514P08.8, TMEM142B ENSG00000160991 ORAI calcium release-activated calcium modulator 2 7 102433106-102456821 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055137, HPA065937 Uncertain Approved Nucleus Pancreatic cancer:8.49e-5 (favourable), Thyroid cancer:6.65e-4 (favourable) Expressed in all Mixed appendix: 43.3 ORAI3 MGC13024, TMEM142C ENSG00000175938 ORAI calcium release-activated calcium modulator 3 16 30949066-30956461 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015022 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:3.87e-5 (unfavourable) Expressed in all Expressed in all prostate: 26.7 ORC3 IMAGE50150, LATHEO, ORC3L ENSG00000135336 Origin recognition complex, subunit 3 6 87590067-87667453 Predicted intracellular proteins Evidence at protein level HPA039553, HPA053748 Supported Validated Nucleoplasm Endometrial cancer:2.89e-5 (unfavourable), Renal cancer:7.23e-4 (unfavourable) Expressed in all Expressed in all testis: 48.7 ORMDL1 ENSG00000128699 ORMDL sphingolipid biosynthesis regulator 1 2 189770323-189784371 Predicted membrane proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Renal cancer:5.84e-9 (unfavourable), Urothelial cancer:1.49e-5 (favourable), Ovarian cancer:3.04e-5 (favourable) Expressed in all Expressed in all epididymis: 153.1 ORMDL2 adoplin-2, HSPC160, MST095, MSTP095 ENSG00000123353 ORMDL sphingolipid biosynthesis regulator 2 12 55817919-55821879 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Endometrial cancer:3.30e-5 (favourable), Liver cancer:9.75e-4 (unfavourable) Expressed in all Expressed in all epididymis: 62.1 ORMDL3 ENSG00000172057 ORMDL sphingolipid biosynthesis regulator 3 17 39921041-39927601 Disease related genes, Predicted membrane proteins Evidence at protein level HPA065643 Supported Endoplasmic reticulum Urothelial cancer:5.18e-4 (favourable), Lung cancer:9.29e-4 (favourable) Expressed in all Expressed in all adipose tissue: 165.1 OSBPL5 KIAA1534, ORP5 ENSG00000021762 Oxysterol binding protein-like 5 11 3087116-3166739 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA038335, HPA038712, HPA058727 Approved Validated Vesicles Expressed in all Mixed spleen: 20.1 OSBPL8 MST120, MSTP120, ORP8, OSBP10 ENSG00000091039 Oxysterol binding protein-like 8 12 76351797-76559809 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA001309 Uncertain Approved Vesicles
Cytosol Pancreatic cancer:9.79e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 39.6 OSBPL9 ENSG00000117859 Oxysterol binding protein-like 9 1 51577179-51798427 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA027378, HPA027397 Supported Supported Golgi apparatus
Vesicles Expressed in all Expressed in all parathyroid gland: 96.5 OSCAR ENSG00000170909 Osteoclast associated, immunoglobulin-like receptor 19 54094668-54102692 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062740 Approved Nucleus
Nuclear membrane
Vesicles Renal cancer:2.71e-5 (unfavourable) Expressed in all Tissue enhanced bone marrow: 9.1;lung: 14.2 appendix: 3.4 OSGEPL1 Qri7 ENSG00000128694 O-sialoglycoprotein endopeptidase-like 1 2 189746660-189763227 Enzymes, Predicted intracellular proteins Evidence at protein level HPA030693 Uncertain Validated Mitochondria Ovarian cancer:3.19e-4 (favourable), Liver cancer:3.71e-4 (unfavourable) Expressed in all Mixed testis: 12.2 OSMR OSMRB ENSG00000145623 Oncostatin M receptor 5 38845858-38945596 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017278 Approved Approved Nucleoli Renal cancer:3.96e-6 (unfavourable), Cervical cancer:4.87e-4 (unfavourable) Expressed in all Mixed smooth muscle: 54.4 OSR2 FLJ90037 ENSG00000164920 Odd-skipped related transciption factor 2 8 98944403-98952104 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA052425, HPA063486 Uncertain Approved Nucleus
Plasma membrane Head and neck cancer:2.44e-5 (favourable) Mixed Tissue enhanced endometrium: 204.6;fallopian tube: 143.0 ovary: 102.5 OSTC DC2 ENSG00000198856 Oligosaccharyltransferase complex subunit (non-catalytic) 4 108650584-108667820 Predicted membrane proteins Evidence at protein level HPA065174 Approved Nucleoplasm Renal cancer:2.31e-8 (unfavourable), Endometrial cancer:1.44e-4 (favourable), Lung cancer:2.84e-4 (unfavourable), Head and neck cancer:6.66e-4 (unfavourable) Expressed in all Expressed in all epididymis: 211.5 OSTM1 GL, HSPC019 ENSG00000081087 Osteopetrosis associated transmembrane protein 1 6 108041409-108165854 Disease related genes, Predicted membrane proteins Evidence at protein level HPA010851 Uncertain Approved Nucleus
Vesicles
Cytosol Renal cancer:1.34e-6 (unfavourable), Stomach cancer:1.20e-4 (unfavourable), Liver cancer:4.26e-4 (unfavourable), Breast cancer:4.36e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 33.3 OTOA CT108, DFNB22 ENSG00000155719 Otoancorin 16 21678514-21760729 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041405 Uncertain Not detected Group enriched 14 spleen: 2.7;testis: 6.2 cerebral cortex,epididymis: 0.3 OTOF DFNB6, DFNB9, FER1L2 ENSG00000115155 Otoferlin 2 26457203-26558698 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007502, HPA012410 Uncertain Not detected Tissue enhanced bone marrow: 4.3 cerebral cortex: 1.1 OTOP1 ENSG00000163982 Otopetrin 1 4 4188803-4226889 Predicted membrane proteins Evidence at transcript level HPA035599 Uncertain Not detected Not detected skin: 0.2 OTOP2 ENSG00000183034 Otopetrin 2 17 74924275-74933912 Predicted membrane proteins Evidence at transcript level HPA024524, HPA053090 Uncertain Not detected Tissue enhanced colon: 20.3;rectum: 11.6 testis: 3.9 OTOP3 ENSG00000182938 Otopetrin 3 17 74935719-74949992 Predicted membrane proteins Evidence at protein level HPA023498 Uncertain Head and neck cancer:3.86e-4 (favourable) Tissue enhanced Not detected small intestine: 0.5 OXA1L MGC133129, OXA1 ENSG00000155463 Oxidase (cytochrome c) assembly 1-like 14 22766522-22773041 Predicted membrane proteins, Transporters Evidence at protein level HPA003531 Approved Supported Mitochondria Renal cancer:4.82e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 139.8 OXER1 GPCR, GPR170, TG1019 ENSG00000162881 Oxoeicosanoid (OXE) receptor 1 2 42762481-42764261 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA051433 Uncertain Expressed in all Mixed small intestine: 9.3 OXGR1 aKGR, GPR80, GPR99, P2RY15, P2Y15 ENSG00000165621 Oxoglutarate (alpha-ketoglutarate) receptor 1 13 96985719-96994730 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA067673 Supported Plasma membrane Mixed Mixed breast: 5.2 P2RX3 P2X3 ENSG00000109991 Purinergic receptor P2X, ligand gated ion channel, 3 11 57338374-57370600 Predicted membrane proteins, Transporters Evidence at transcript level HPA057776 Uncertain Not detected Tissue enhanced heart muscle: 2.0;testis: 6.1 liver: 0.9 P2RX4 P2X4 ENSG00000135124 Purinergic receptor P2X, ligand gated ion channel, 4 12 121209857-121234106 Predicted membrane proteins, Transporters Evidence at protein level HPA039494 Approved Approved Actin filaments
Cytosol Endometrial cancer:6.30e-10 (favourable) Expressed in all Mixed placenta: 33.5 P2RX5 LRH-1, P2X5 ENSG00000083454 Purinergic receptor P2X, ligand gated ion channel, 5 17 3672199-3696404 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021948, HPA067827 Supported Supported Cytosol Mixed Group enriched 10 appendix: 42.6;lymph node: 90.9;spleen: 75.5;tonsil: 48.4 bone marrow: 6.2 P2RX6 MGC129625, P2RXL1, P2X6, P2XM ENSG00000099957 Purinergic receptor P2X, ligand gated ion channel, 6 22 21009808-21028830 Predicted membrane proteins Evidence at protein level HPA028776, HPA028777 Approved Approved Nucleoli
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 3.4 skeletal muscle: 3.0 P2RX7 MGC20089, P2X7 ENSG00000089041 Purinergic receptor P2X, ligand gated ion channel, 7 12 121132819-121188032 Predicted membrane proteins, Transporters Evidence at protein level HPA034968, HPA042013, HPA044141 Approved Renal cancer:2.92e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.1 P2RY1 P2Y1 ENSG00000169860 Purinergic receptor P2Y, G-protein coupled, 1 3 152834693-152841439 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA015577 Approved Renal cancer:2.04e-7 (unfavourable) Mixed Tissue enhanced placenta: 33.7 esophagus: 20.0 P2RY10 P2Y10 ENSG00000078589 Purinergic receptor P2Y, G-protein coupled, 10 X 78945332-78961954 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA036757, HPA065766 Approved Renal cancer:3.63e-4 (unfavourable) Mixed Tissue enhanced lymph node: 33.5;spleen: 23.0;tonsil: 24.9 appendix: 20.1 P2RY11 P2Y11 ENSG00000244165 Purinergic receptor P2Y, G-protein coupled, 11 19 10111538-10115372 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014232 Approved Urothelial cancer:1.77e-4 (favourable) Expressed in all Mixed lymph node: 7.3 P2RY12 HORK3, P2Y12, SP1999 ENSG00000169313 Purinergic receptor P2Y, G-protein coupled, 12 3 151337380-151384812 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA013796, HPA014518 Supported Tissue enriched Tissue enriched 6 cerebral cortex: 84.0 lymph node: 13.3 P2RY13 FKSG77, GPR86, GPR94, P2Y13 ENSG00000181631 Purinergic receptor P2Y, G-protein coupled, 13 3 151326312-151329548 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA049047 Supported Expressed in all Tissue enhanced spleen: 51.9 appendix: 28.7 P2RY14 GPR105, KIAA0001 ENSG00000174944 Purinergic receptor P2Y, G-protein coupled, 14 3 151212117-151278467 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level CAB022646 Uncertain Renal cancer:1.72e-5 (unfavourable) Mixed Tissue enhanced placenta: 45.4 esophagus: 23.4 P2RY2 P2U ENSG00000175591 Purinergic receptor P2Y, G-protein coupled, 2 11 73218298-73236352 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022642 Uncertain Uncertain Cytosol Pancreatic cancer:2.19e-5 (unfavourable) Mixed Tissue enhanced esophagus: 19.0 skeletal muscle: 14.9 P2RY4 NRU, P2P, P2Y4, UNR ENSG00000186912 Pyrimidinergic receptor P2Y, G-protein coupled, 4 X 70258170-70259764 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022644 Uncertain Not detected Tissue enhanced small intestine: 3.1 rectum,skin: 0.6 P2RY6 P2Y6 ENSG00000171631 Pyrimidinergic receptor P2Y, G-protein coupled, 6 11 73264505-73298617 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022740 Uncertain Renal cancer:2.50e-7 (unfavourable) Mixed Tissue enhanced placenta: 16.8;spleen: 36.2 appendix: 11.0 P2RY8 P2Y8 ENSG00000182162 Purinergic receptor P2Y, G-protein coupled, 8 X 1462572-1537107 Cancer-related genes, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA003631 Supported Head and neck cancer:7.80e-5 (favourable), Liver cancer:1.73e-4 (favourable), Pancreatic cancer:6.54e-4 (favourable) Expressed in all Tissue enhanced lymph node: 43.1 tonsil: 29.0 P4HTM EGLN4, FLJ20262, HIFPH4, P4H-TM, PH-4, PH4, PHD4 ENSG00000178467 Prolyl 4-hydroxylase, transmembrane (endoplasmic reticulum) 3 48989886-49007154 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007199 Supported Uncertain Vesicles
Cytosol Renal cancer:3.28e-5 (favourable), Endometrial cancer:8.18e-4 (favourable) Expressed in all Expressed in all fallopian tube: 49.9 PAAF1 FLJ11848, Rpn14, WDR71 ENSG00000175575 Proteasomal ATPase-associated factor 1 11 73876699-73931124 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039952, HPA040020 Uncertain Approved Nucleus
Cytosol Expressed in all Expressed in all testis: 58.0 PACRG FLJ32724, Glup, HAK005771, PARK2CRG ENSG00000112530 PARK2 co-regulated 6 162727132-163315492 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066293 Supported Renal cancer:2.55e-6 (favourable) Mixed Tissue enhanced fallopian tube: 56.4;testis: 53.1 epididymis: 12.1 PAG1 CBP, PAG ENSG00000076641 Phosphoprotein membrane anchor with glycosphingolipid microdomains 1 8 80967810-81112068 Predicted intracellular proteins Evidence at protein level HPA001632, HPA066527 Uncertain Supported Vesicles
Plasma membrane Renal cancer:1.24e-6 (unfavourable), Testis cancer:6.82e-4 (unfavourable) Expressed in all Mixed placenta: 22.8 PAM PAL, PHM ENSG00000145730 Peptidylglycine alpha-amidating monooxygenase 5 102753981-103031105 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB026119, HPA042260 Supported Approved Golgi apparatus
Cytosol Endometrial cancer:1.63e-4 (favourable), Liver cancer:6.20e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 1092.7 PANK2 C20orf48, FLJ11729, HARP, HSS, NBIA1, PKAN ENSG00000125779 Pantothenate kinase 2 20 3888839-3929882 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA008440 Approved Supported Cytosol Liver cancer:1.20e-5 (unfavourable) Expressed in all Expressed in all testis: 51.6 PANX1 MRS1, PX1, UNQ2529 ENSG00000110218 Pannexin 1 11 94128928-94181972 Predicted membrane proteins, Transporters Evidence at protein level HPA016930 Uncertain Validated Plasma membrane Renal cancer:1.49e-7 (unfavourable), Lung cancer:7.09e-5 (unfavourable), Endometrial cancer:1.13e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex,testis: 19.4 PANX2 hPANX2, PX2 ENSG00000073150 Pannexin 2 22 50170731-50180294 Predicted membrane proteins, Transporters Evidence at transcript level HPA004624, HPA039117 Approved Approved Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.7 seminal vesicle: 2.1 PAOX PAO ENSG00000148832 Polyamine oxidase (exo-N4-amino) 10 133379234-133391694 Enzymes, Predicted intracellular proteins Evidence at protein level HPA047782 Uncertain Nucleoplasm
Centrosome Head and neck cancer:1.38e-5 (favourable), Cervical cancer:6.07e-5 (favourable), Renal cancer:9.49e-4 (favourable) Expressed in all Tissue enhanced testis: 7.6 cerebral cortex: 3.2 PAPD7 LAK-1, POLK, POLS, TRF4, TRF4-1 ENSG00000112941 PAP associated domain containing 7 5 6713007-6757048 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045487, HPA046742 Supported Supported Nucleoplasm
Nuclear membrane
Golgi apparatus Renal cancer:7.99e-5 (unfavourable), Urothelial cancer:8.55e-4 (favourable) Expressed in all Expressed in all ovary,testis: 19.0 PAPOLA PAP ENSG00000090060 Poly(A) polymerase alpha 14 96501433-96567111 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001788 Supported Validated Nucleoplasm Liver cancer:2.41e-5 (unfavourable) Expressed in all Expressed in all testis: 166.1 PAPOLG FLJ12972 ENSG00000115421 Poly(A) polymerase gamma 2 60756230-60802085 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB017795, HPA035349, HPA035350 Approved Validated Nucleoplasm Renal cancer:4.21e-4 (unfavourable) Expressed in all Mixed thyroid gland: 22.1 PAPPA2 PAPP-A2, PAPPE, PLAC3 ENSG00000116183 Pappalysin 2 1 176463171-176845605 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018412, HPA018430 Supported Approved Endoplasmic reticulum
Vesicles Mixed Tissue enriched 8 placenta: 82.1 cervix, uterine: 10.8 PAQR3 ENSG00000163291 Progestin and adipoQ receptor family member III 4 78887127-78939438 Predicted membrane proteins Evidence at protein level HPA058453 Uncertain Expressed in all Tissue enhanced testis: 1.1 cerebral cortex,duodenum,lymph node: 0.3 PAQR4 FLJ30002 ENSG00000162073 Progestin and adipoQ receptor family member IV 16 2969245-2973489 Predicted membrane proteins Evidence at protein level HPA068394 Approved Vesicles Renal cancer:3.01e-6 (unfavourable), Stomach cancer:1.70e-4 (favourable), Liver cancer:6.86e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 54.1;parathyroid gland: 64.2 skin: 19.2 PAQR5 FLJ20190, MPRG ENSG00000137819 Progestin and adipoQ receptor family member V 15 69298947-69407780 Predicted membrane proteins Evidence at protein level HPA076729 Approved Vesicles Renal cancer:1.47e-14 (favourable), Pancreatic cancer:2.15e-5 (unfavourable) Mixed Tissue enhanced kidney: 55.6 adrenal gland: 20.9 PAQR6 FLJ22672, PRdelta ENSG00000160781 Progestin and adipoQ receptor family member VI 1 156243321-156248117 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA073505 Approved Nucleus
Nucleoli Renal cancer:1.58e-8 (unfavourable), Colorectal cancer:1.60e-5 (unfavourable), Urothelial cancer:1.86e-4 (favourable), Prostate cancer:1.99e-4 (unfavourable) Tissue enriched Tissue enriched 9 cerebral cortex: 97.8 skin: 10.8 PAQR7 MPRA, mSR ENSG00000182749 Progestin and adipoQ receptor family member VII 1 25861210-25871253 Predicted membrane proteins Evidence at protein level HPA046936 Approved Approved Cytosol Renal cancer:1.05e-5 (favourable), Liver cancer:1.14e-4 (unfavourable) Expressed in all Mixed testis: 51.0 PAQR8 C6orf33, LMPB1, MPRB ENSG00000170915 Progestin and adipoQ receptor family member VIII 6 52361421-52407777 Predicted membrane proteins Evidence at protein level HPA064625 Supported Golgi apparatus
Plasma membrane Breast cancer:4.61e-4 (favourable), Urothelial cancer:6.40e-4 (favourable) Expressed in all Mixed cerebral cortex: 65.1 PAQR9 FLJ41938 ENSG00000188582 Progestin and adipoQ receptor family member IX 3 142949164-142963682 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052798 Uncertain Tissue enriched Tissue enhanced liver: 8.3;testis: 19.3 heart muscle: 5.2 PARL PRO2207, PSARL, PSARL1, RHBDS1 ENSG00000175193 Presenilin associated, rhomboid-like 3 183829385-183884933 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA019545 Approved Supported Mitochondria Urothelial cancer:9.11e-5 (favourable) Expressed in all Expressed in all epididymis: 71.5 PARM1 Cipar1, DKFZP564O0823, WSC4 ENSG00000169116 Prostate androgen-regulated mucin-like protein 1 4 74933095-75050115 Predicted membrane proteins Evidence at protein level HPA038236 Approved Approved Nucleus
Vesicles
Cytosol Thyroid cancer:1.78e-4 (unfavourable) Expressed in all Mixed thyroid gland: 205.6 PARP15 FLJ40597, pART7 ENSG00000173200 Poly (ADP-ribose) polymerase family, member 15 3 122577602-122639047 Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA075786 Approved Mitochondria Mixed Tissue enhanced lymph node: 56.0;spleen: 61.8;tonsil: 51.1 appendix: 36.8 PARP16 C15orf30, FLJ20509, FLJ25281, pART15 ENSG00000138617 Poly (ADP-ribose) polymerase family, member 16 15 65234460-65300618 Enzymes, Predicted membrane proteins Evidence at protein level HPA017081 Approved Expressed in all Expressed in all ovary: 13.0 PARP3 ADPRT3, ADPRTL3, hPARP-3, IRT1, pADPRT-3 ENSG00000041880 Poly (ADP-ribose) polymerase family, member 3 3 51942345-51948867 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA067657 Supported Approved Nucleoli
Cytosol Renal cancer:1.25e-8 (favourable), Breast cancer:6.39e-5 (favourable) Expressed in all Mixed parathyroid gland: 52.0 PBLD FLJ14767, MAWBP, MAWDBP ENSG00000108187 Phenazine biosynthesis-like protein domain containing 10 68282660-68333049 Predicted intracellular proteins Evidence at protein level HPA038035, HPA038036 Supported Approved Vesicles Liver cancer:1.44e-4 (favourable) Expressed in all Expressed in all kidney: 276.9 PBOV1 UC28, UROC28 ENSG00000254440 Prostate and breast cancer overexpressed 1 6 138215986-138218491 Predicted intracellular proteins Evidence at transcript level HPA063021 Uncertain Not detected Not detected bone marrow,breast,kidney,parathyroid gland,skin,testis: 0.1 PBXIP1 HPIP ENSG00000163346 Pre-B-cell leukemia homeobox interacting protein 1 1 154944076-154956123 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006949 Approved Approved Vesicles
Cytosol Renal cancer:9.22e-6 (favourable), Pancreatic cancer:2.64e-4 (favourable), Colorectal cancer:2.73e-4 (unfavourable), Head and neck cancer:7.19e-4 (favourable), Lung cancer:8.99e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 137.9 PCDH1 pc42 ENSG00000156453 Protocadherin 1 5 141853111-141879246 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047720, HPA050538 Approved Approved Nucleus
Nucleoli
Cell Junctions Liver cancer:4.96e-5 (unfavourable), Renal cancer:7.55e-5 (favourable), Pancreatic cancer:3.61e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 40.4 PCDH10 KIAA1400, OL-PCDH ENSG00000138650 Protocadherin 10 4 133149315-133208606 Predicted membrane proteins Evidence at protein level HPA011220, HPA073462 Approved Approved Nucleus
Golgi apparatus
Vesicles Tissue enhanced Group enriched 5 cerebral cortex: 62.2;placenta: 36.4;prostate: 17.0;seminal vesicle: 24.4 adrenal gland: 6.9 PCDH11X PCDH-X, PCDH11, PCDHX, PPP1R119 ENSG00000102290 Protocadherin 11 X-linked X 91779261-92623230 Predicted membrane proteins Evidence at transcript level HPA000432 Approved Not detected Tissue enhanced cerebral cortex: 5.3;ovary: 9.9;parathyroid gland: 4.8 cervix, uterine: 1.7 PCDH11Y PCDH22, PCDHY ENSG00000099715 Protocadherin 11 Y-linked Y 5000226-5742224 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000432 Uncertain Not detected Tissue enriched 6 cerebral cortex: 4.4 placenta,seminal vesicle: 0.7 PCDH12 VE-cadherin-2 ENSG00000113555 Protocadherin 12 5 141943585-141969741 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051242 Uncertain Renal cancer:2.56e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 38.5 spleen: 22.9 PCDH17 PCDH68, PCH68 ENSG00000118946 Protocadherin 17 13 57631810-57729311 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026817 Uncertain Approved Vesicles
Plasma membrane
Cytosol Renal cancer:3.31e-5 (unfavourable) Mixed Tissue enhanced cerebral cortex: 25.8;spleen: 34.3 lung: 18.3 PCDH18 KIAA1562, PCDH68L ENSG00000189184 Protocadherin 18 4 137518918-137532494 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017976 Approved Approved Golgi apparatus
Cytosol Renal cancer:3.21e-4 (unfavourable), Urothelial cancer:4.71e-4 (unfavourable) Mixed Mixed placenta: 64.0 PCDH19 EFMR, EIEE9, KIAA1313 ENSG00000165194 Protocadherin 19 X 100291644-100410273 Disease related genes, Predicted membrane proteins Evidence at protein level HPA027533 Approved Approved Cytosol Mixed Tissue enhanced cerebral cortex: 10.8 cervix, uterine: 2.5 PCDH7 BH-Pcdh, PPP1R120 ENSG00000169851 Protocadherin 7 4 30720415-31146805 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011866, HPA046521 Uncertain Validated Plasma membrane
Cell Junctions Lung cancer:6.46e-5 (unfavourable), Stomach cancer:6.42e-4 (unfavourable) Mixed Mixed cerebral cortex: 46.1 PCDH8 ARCADLIN, PAPC ENSG00000136099 Protocadherin 8 13 52842889-52848641 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA010509 Uncertain Tissue enhanced Tissue enriched 8 cerebral cortex: 5.7 testis: 0.7 PCDH9 ENSG00000184226 Protocadherin 9 13 66302834-67230445 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA015581 Approved Nucleoplasm
Centrosome Tissue enriched Tissue enriched 11 cerebral cortex: 69.0 seminal vesicle: 6.0 PCDHA1 ENSG00000204970 Protocadherin alpha 1 5 140786136-141012347 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA035969 Approved Approved Plasma membrane Not detected Tissue enhanced cerebral cortex: 2.8;testis: 1.6 adrenal gland: 0.4 PCDHA11 CNR7, CNRN7, CNRS7, CRNR7, PCDH-ALPHA11 ENSG00000249158 Protocadherin alpha 11 5 140868183-141012344 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077160 Approved Vesicles
Cell Junctions Not detected Tissue enhanced cerebral cortex: 7.6;parathyroid gland: 4.7 testis: 2.3 PCDHA12 PCDH-ALPHA12 ENSG00000251664 Protocadherin alpha 12 5 140875302-141012344 Predicted membrane proteins Evidence at transcript level HPA035812 Approved Approved Cytosol Not detected Tissue enhanced lung: 2.7 cerebral cortex: 1.8 PCDHA2 ENSG00000204969 Protocadherin alpha 2 5 140794852-141012344 Predicted membrane proteins Evidence at protein level HPA035653 Uncertain Not detected Tissue enhanced endometrium: 1.0 cerebral cortex: 0.9 PCDHA3 PCDH-ALPHA3 ENSG00000255408 Protocadherin alpha 3 5 140801028-141012344 Predicted membrane proteins Evidence at transcript level HPA035667 Uncertain Not detected Mixed endometrium: 2.5 PCDHA4 CNR1, CNRN1, CRNR1, PCDH-ALPHA4 ENSG00000204967 Protocadherin alpha 4 5 140806929-141012344 Predicted membrane proteins Evidence at protein level HPA043180, HPA073478 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Not detected Tissue enhanced cerebral cortex: 4.4 gallbladder: 2.6 PCDHA5 CNR6, CNRN6, CNRS6, CRNR6, PCDH-ALPHA5 ENSG00000204965 Protocadherin alpha 5 5 140821604-141012344 Predicted membrane proteins Evidence at transcript level HPA044557 Approved Not detected Tissue enriched 10 cerebral cortex: 4.1 endometrium: 0.4 PCDHA6 CNR2, CNRS2, CRNR2, PCDH-ALPHA6 ENSG00000081842 Protocadherin alpha 6 5 140827958-141012344 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA059326 Approved Vesicles Not detected Tissue enhanced cerebral cortex: 4.8 parathyroid gland: 1.9 PCDHA8 ENSG00000204962 Protocadherin alpha 8 5 140841187-141012344 Predicted membrane proteins Evidence at protein level HPA044585 Uncertain Not detected Not detected cerebral cortex: 0.7 PCDHAC1 ENSG00000248383 Protocadherin alpha subfamily C, 1 5 140926369-141012344 Predicted membrane proteins Evidence at transcript level HPA052775 Approved Nucleus
Nucleoli
Vesicles Not detected Tissue enriched 26 parathyroid gland: 68.4 cerebral cortex: 2.6 PCDHAC2 PCDH-ALPHA-C2 ENSG00000243232 Protocadherin alpha subfamily C, 2 5 140966235-141012344 Predicted membrane proteins Evidence at transcript level HPA076190 Approved Nucleoplasm
Mitochondria Mixed Tissue enriched 6 parathyroid gland: 90.7 cerebral cortex: 14.2 PCDHB1 PCDH-BETA1 ENSG00000171815 Protocadherin beta 1 5 141051135-141059344 Predicted membrane proteins Evidence at protein level HPA053921 Uncertain Not detected Not detected testis: 0.9 PCDHB10 ENSG00000120324 Protocadherin beta 10 5 141182560-141195642 Predicted membrane proteins Evidence at protein level HPA013445, HPA014668, HPA029441 Approved Approved Vesicles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 8.3 endometrium: 5.1 PCDHB11 ME2, PCDH-BETA11 ENSG00000197479 Protocadherin beta 11 5 141199582-141203779 Predicted membrane proteins Evidence at transcript level HPA045042 Uncertain Approved Plasma membrane Mixed Tissue enhanced parathyroid gland: 8.1 endometrium: 2.5 PCDHB12 PCDH-BETA12 ENSG00000120328 Protocadherin beta 12 5 141208697-141212571 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA045042 Uncertain Approved Plasma membrane Mixed Mixed endometrium: 3.6 PCDHB14 PCDH-BETA14 ENSG00000120327 Protocadherin beta 14 5 141222932-141227759 Predicted membrane proteins Evidence at protein level HPA007692, HPA045248 Uncertain Approved Vesicles Renal cancer:6.09e-4 (unfavourable) Mixed Mixed parathyroid gland: 7.4 PCDHB15 PCDH-BETA15 ENSG00000113248 Protocadherin beta 15 5 141245349-141249365 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007172, CAB026471 Uncertain Mixed Mixed cerebral cortex: 12.7 PCDHB16 KIAA1621, ME1, PCDH-BETA16, PCDH3X, PCDHB8a ENSG00000272674 Protocadherin beta 16 5 141181399-141186399 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014668 Supported Vesicles
Plasma membrane Mixed Mixed parathyroid gland: 10.6 PCDHB2 PCDH-BETA2 ENSG00000112852 Protocadherin beta 2 5 141094578-141098703 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007548 Uncertain Approved Nucleoplasm Urothelial cancer:4.84e-4 (unfavourable), Renal cancer:6.99e-4 (unfavourable) Mixed Tissue enhanced testis: 10.0 cerebral cortex: 7.7 PCDHB3 PCDH-BETA3 ENSG00000113205 Protocadherin beta 3 5 141100473-141103827 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050296 Uncertain Supported Vesicles Mixed Tissue enhanced testis: 10.4 endometrium,prostate: 2.3 PCDHB4 PCDH-BETA4 ENSG00000081818 Protocadherin beta 4 5 141121799-141125623 Predicted membrane proteins Evidence at transcript level HPA014466 Approved Uncertain Plasma membrane
Intermediate filaments
Cytosol Mixed Mixed endometrium: 8.9 PCDHB5 DKFZp586B0217, PCDH-BETA5 ENSG00000113209 Protocadherin beta 5 5 141135218-141138625 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA013191 Approved Mixed Mixed ovary: 7.3 PCDHB6 PCDH-BETA6 ENSG00000113211 Protocadherin beta 6 5 141150022-141153287 Predicted membrane proteins Evidence at transcript level HPA029566 Uncertain Uncertain Nucleus
Plasma membrane
Cytosol Renal cancer:5.52e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 7.1 testis: 3.5 PCDHB7 PCDH-BETA7 ENSG00000113212 Protocadherin beta 7 5 141172619-141176383 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA059271 Approved Tissue enhanced Tissue enhanced endometrium: 6.6 smooth muscle: 4.4 PCDHB8 PCDH-BETA8, PCDH3I ENSG00000120322 Protocadherin beta 8 5 141177790-141180529 Predicted membrane proteins Evidence at transcript level HPA057773 Uncertain Mixed Mixed endometrium: 2.1 PCDHB9 PCDH-BETA9, PCDH3H ENSG00000177839 Protocadherin beta 9 5 141187127-141191541 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA013445, HPA029441 Uncertain Mixed Tissue enhanced cerebral cortex: 7.9 ovary: 2.5 PCDHGA1 PCDH-GAMMA-A1 ENSG00000204956 Protocadherin gamma subfamily A, 1 5 141330571-141512981 Predicted membrane proteins Evidence at transcript level HPA008755, HPA036547 Uncertain Mixed Tissue enhanced cerebral cortex: 3.2 testis: 1.4 PCDHGA10 PCDH-GAMMA-A10 ENSG00000253846 Protocadherin gamma subfamily A, 10 5 141412987-141512979 Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Mixed Tissue enriched 5 cerebral cortex: 28.1 placenta: 5.1 PCDHGA11 PCDH-GAMMA-A11 ENSG00000253873 Protocadherin gamma subfamily A, 11 5 141421047-141512979 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA008755 Uncertain Mixed Mixed cerebral cortex: 3.2 PCDHGA12 CDH21, FIB3, KIAA0588, PCDH-GAMMA-A12 ENSG00000253159 Protocadherin gamma subfamily A, 12 5 141430589-141512979 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Tissue enhanced Mixed cerebral cortex: 8.1 PCDHGA2 PCDH-GAMMA-A2 ENSG00000081853 Protocadherin gamma subfamily A, 2 5 141338760-141512979 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA008755 Uncertain Mixed Mixed cerebral cortex: 8.5 PCDHGA3 PCDH-GAMMA-A3 ENSG00000254245 Protocadherin gamma subfamily A, 3 5 141343829-141512979 Predicted membrane proteins Evidence at protein level HPA008755, HPA039295 Uncertain Approved Nucleoplasm
Centrosome Not detected Tissue enhanced cerebral cortex: 6.5 ovary: 3.1 PCDHGA4 PCDH-GAMMA-A4 ENSG00000262576 Protocadherin gamma subfamily A, 4 5 141355025-141512979 Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Mixed Mixed cerebral cortex: 5.7 PCDHGA5 CDH-GAMMA-A5, ME3, PCDH-GAMMA-A5 ENSG00000253485 Protocadherin gamma subfamily A, 5 5 141364232-141512979 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Tissue enhanced Mixed cerebral cortex: 3.8 PCDHGA6 PCDH-GAMMA-A6 ENSG00000253731 Protocadherin gamma subfamily A, 6 5 141373914-141512979 Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Mixed Mixed ovary: 3.8 PCDHGA7 PCDH-GAMMA-A7 ENSG00000253537 Protocadherin gamma subfamily A, 7 5 141382739-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA077995 Uncertain Uncertain Plasma membrane
Cell Junctions Mixed Tissue enhanced cerebral cortex: 7.4 thyroid gland: 3.2 PCDHGA8 KIAA0327, PCDH-GAMMA-A8 ENSG00000253767 Protocadherin gamma subfamily A, 8 5 141390157-141512979 Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Not detected Not detected thyroid gland: 0.7 PCDHGA9 PCDH-GAMMA-A9 ENSG00000261934 Protocadherin gamma subfamily A, 9 5 141402932-141512979 Predicted membrane proteins Evidence at protein level HPA008755 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.6 endometrium: 4.1 PCDHGB1 PCDH-GAMMA-B1 ENSG00000254221 Protocadherin gamma subfamily B, 1 5 141350102-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA076182 Uncertain Approved Plasma membrane
Focal adhesion sites
Midbody Mixed Tissue enriched 12 cerebral cortex: 23.8 endometrium: 2.0 PCDHGB2 PCDH-GAMMA-B2 ENSG00000253910 Protocadherin gamma subfamily B, 2 5 141360042-141512979 Predicted membrane proteins Evidence at transcript level HPA008755, HPA077526 Uncertain Uncertain Vesicles Tissue enriched Mixed cerebral cortex: 6.5 PCDHGB3 PCDH-GAMMA-B3 ENSG00000262209 Protocadherin gamma subfamily B, 3 5 141370264-141512979 Plasma proteins, Predicted membrane proteins Evidence at transcript level HPA008755, HPA035823 Uncertain Mixed Mixed endometrium: 1.5 PCDHGB4 CDH20, FIB2, PCDH-GAMMA-B4 ENSG00000253953 Protocadherin gamma subfamily B, 4 5 141387698-141512979 Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Mixed Mixed placenta: 4.2 PCDHGB5 PCDH-GAMMA-B5 ENSG00000276547 Protocadherin gamma subfamily B, 5 5 141397987-141512979 Predicted membrane proteins Evidence at transcript level HPA008755 Uncertain Mixed Tissue enhanced parathyroid gland: 19.4 thyroid gland: 7.5 PCDHGB6 PCDH-GAMMA-B6 ENSG00000253305 Protocadherin gamma subfamily B, 6 5 141408021-141512979 Predicted membrane proteins Evidence at protein level HPA008755 Uncertain Mixed Tissue enhanced cerebral cortex: 20.9 parathyroid gland: 11.7 PCDHGB7 ME6, PCDH-GAMMA-B7 ENSG00000254122 Protocadherin gamma subfamily B, 7 5 141417645-141512979 Predicted membrane proteins Evidence at protein level HPA008755 Uncertain Tissue enhanced Mixed ovary: 10.2 PCDHGC3 PC-43, PC43, PCDH-GAMMA-C3, PCDH2 ENSG00000240184 Protocadherin gamma subfamily C, 3 5 141475947-141512979 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008755, HPA077289 Approved Approved Plasma membrane Urothelial cancer:6.00e-4 (unfavourable), Ovarian cancer:6.19e-4 (unfavourable), Renal cancer:8.18e-4 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 377.1 cervix, uterine: 93.4 PCDHGC4 PCDH-GAMMA-C4 ENSG00000242419 Protocadherin gamma subfamily C, 4 5 141484997-141512979 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008755, HPA078024 Uncertain Approved Golgi apparatus Tissue enriched Tissue enriched 11 cerebral cortex: 16.4 adrenal gland: 1.4 PCDHGC5 PCDH-GAMMA-C5 ENSG00000240764 Protocadherin gamma subfamily C, 5 5 141489121-141512979 Predicted membrane proteins Evidence at protein level HPA008755, HPA051540 Uncertain Approved Nucleoplasm Group enriched Tissue enriched 44 cerebral cortex: 50.8 smooth muscle: 1.1 PCGF3 DONG1, FLJ36550, MGC40413, RNF3, RNF3A ENSG00000185619 Polycomb group ring finger 3 4 705748-770640 Predicted intracellular proteins Evidence at protein level HPA061879 Supported Nucleoplasm Pancreatic cancer:1.44e-4 (favourable), Head and neck cancer:3.73e-4 (favourable), Urothelial cancer:5.25e-4 (favourable) Expressed in all Expressed in all skin: 79.4 PCLO ACZ, DKFZp779G1236, KIAA0559 ENSG00000186472 Piccolo presynaptic cytomatrix protein 7 82754013-83162930 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015858, HPA029579 Approved Approved Nuclear speckles
Plasma membrane Mixed Tissue enhanced cerebral cortex: 17.5 parathyroid gland: 9.6 PCMT1 ENSG00000120265 Protein-L-isoaspartate (D-aspartate) O-methyltransferase 6 149749443-149811420 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003239 Approved Supported Cytosol Breast cancer:4.02e-7 (unfavourable), Head and neck cancer:1.88e-4 (unfavourable), Liver cancer:2.58e-4 (unfavourable), Endometrial cancer:4.27e-4 (unfavourable), Urothelial cancer:6.38e-4 (unfavourable), Cervical cancer:9.58e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 195.3 PCNX KIAA0805, KIAA0995, PCNXL1, pecanex ENSG00000100731 Pecanex homolog (Drosophila) 14 70907405-71115382 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053532 Approved Nucleoplasm Renal cancer:4.05e-5 (favourable) Expressed in all Expressed in all testis: 38.1 PCNXL2 FLJ11383, KIAA0435 ENSG00000135749 Pecanex-like 2 (Drosophila) 1 232983435-233295713 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013815, HPA014427 Uncertain Approved Endoplasmic reticulum Renal cancer:2.27e-5 (unfavourable) Mixed Mixed cerebral cortex: 14.0 PCNXL3 FLJ22427 ENSG00000197136 Pecanex-like 3 (Drosophila) 11 65615773-65637439 Predicted membrane proteins Evidence at protein level HPA018084 Uncertain Approved Cytosol Expressed in all Mixed testis: 17.3 PCNXL4 C14orf135 ENSG00000126773 Pecanex-like 4 (Drosophila) 14 60091911-60169133 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002076, HPA003390 Uncertain Approved Cytosol Renal cancer:6.84e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 31.6 PCSK4 DKFZp434B217, MGC34749, PC4, SPC5 ENSG00000115257 Proprotein convertase subtilisin/kexin type 4 19 1481428-1490752 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA005572 Uncertain Endometrial cancer:9.45e-5 (favourable) Expressed in all Tissue enriched 9 testis: 41.3 fallopian tube: 4.7 PCSK5 PC5, PC6, SPC6 ENSG00000099139 Proprotein convertase subtilisin/kexin type 5 9 75890644-76362339 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA031072 Supported Supported Golgi apparatus Renal cancer:9.61e-5 (unfavourable) Mixed Mixed small intestine: 28.7 PCSK7 LPC, PC7, PC8, SPC7 ENSG00000160613 Proprotein convertase subtilisin/kexin type 7 11 117204337-117232525 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043181, HPA052957 Uncertain Nucleus
Nuclear membrane
Nucleoli Expressed in all Expressed in all smooth muscle: 305.0 PDCD1 CD279, hSLE1, PD-1, PD1, SLEB2 ENSG00000188389 Programmed cell death 1 2 241849881-241858908 CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035981, CAB038418 Supported Renal cancer:3.48e-7 (unfavourable), Endometrial cancer:9.44e-5 (favourable) Mixed Tissue enhanced lymph node: 12.2 appendix: 3.4 PDCD1LG2 B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2 ENSG00000197646 Programmed cell death 1 ligand 2 9 5510570-5571254 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA013411 Approved Approved Cytosol Renal cancer:1.15e-4 (unfavourable) Mixed Tissue enhanced spleen: 21.8 lymph node: 12.2 PDE3A CGI-PDE ENSG00000172572 Phosphodiesterase 3A, cGMP-inhibited 12 20369245-20684381 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014492 Uncertain Supported Cytosol Renal cancer:1.72e-6 (unfavourable) Expressed in all Tissue enhanced heart muscle: 38.3 placenta: 31.1 PDE3B HcGIP1 ENSG00000152270 Phosphodiesterase 3B, cGMP-inhibited 11 14643723-14872044 Enzymes, Predicted membrane proteins Evidence at protein level HPA056111 Supported Endoplasmic reticulum Pancreatic cancer:7.91e-4 (favourable) Mixed Tissue enhanced adipose tissue: 65.3 lymph node: 17.4 PDE6A PDEA, RP43 ENSG00000132915 Phosphodiesterase 6A, cGMP-specific, rod, alpha 5 149857955-149944793 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA016970 Uncertain Not detected Tissue enriched 8 epididymis: 20.2 testis: 2.4 PDE6B CSNB3, CSNBAD2, PDEB, rd1, RP40 ENSG00000133256 Phosphodiesterase 6B, cGMP-specific, rod, beta 4 625584-670782 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA054148, HPA059929 Supported Approved Cytosol Lung cancer:5.34e-4 (favourable) Mixed Mixed cerebral cortex: 22.4 PDGFRA CD140a, GAS9, PDGFR2 ENSG00000134853 Platelet-derived growth factor receptor, alpha polypeptide 4 54229097-54298247 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level HPA004947, CAB018143 Supported Supported Nucleus
Plasma membrane
Cell Junctions Renal cancer:9.79e-6 (unfavourable), Head and neck cancer:9.33e-4 (favourable) Expressed in all Expressed in all ovary: 222.0 PDGFRB CD140b, JTK12, PDGFR, PDGFR1 ENSG00000113721 Platelet-derived growth factor receptor, beta polypeptide 5 150113837-150155872 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB003842, CAB018144, HPA028499 Approved Approved Vesicles
Cytosol Renal cancer:5.87e-8 (unfavourable), Urothelial cancer:8.11e-4 (unfavourable) Expressed in all Mixed gallbladder: 194.6 PDPN aggrus, Gp38, GP40, PA2.26, T1A-2 ENSG00000162493 Podoplanin 1 13583465-13617957 Predicted membrane proteins Evidence at protein level HPA007534, CAB008376, HPA073453 Supported Approved Vesicles Tissue enhanced Tissue enhanced placenta: 192.4 appendix: 80.4 PDXK C21orf124, C21orf97, FLJ21324, FLJ31940, MGC15873, PKH, PNK, PRED79 ENSG00000160209 Pyridoxal (pyridoxine, vitamin B6) kinase 21 43719094-43762307 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA030196, HPA030197, HPA030198, CAB033918 Approved Validated Nucleus Expressed in all Expressed in all cerebral cortex: 47.6 PDZK1IP1 DD96, MAP17, SPAP ENSG00000162366 PDZK1 interacting protein 1 1 47183593-47191044 Predicted membrane proteins Evidence at protein level HPA014907 Approved Approved Nuclear speckles
Cytosol Pancreatic cancer:3.45e-4 (unfavourable), Glioma:9.46e-4 (unfavourable) Expressed in all Group enriched 6 gallbladder: 299.6;kidney: 1048.6 esophagus: 121.8 PEAR1 FLJ00193, JEDI, MEGF12 ENSG00000187800 Platelet endothelial aggregation receptor 1 1 156893698-156916434 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035217 Approved Approved Nucleoplasm
Cell Junctions
Centrosome Renal cancer:4.31e-4 (unfavourable) Expressed in all Mixed placenta: 16.8 PEBP4 CORK1, hPEBP4, MGC22776 ENSG00000134020 Phosphatidylethanolamine-binding protein 4 8 22713251-23000000 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA025064 Uncertain Group enriched Tissue enhanced epididymis: 462.3;lung: 173.6;skeletal muscle: 233.0 thyroid gland: 95.9 PECAM1 CD31 ENSG00000261371 Platelet/endothelial cell adhesion molecule 1 17 64319415-64413776 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004690 Supported Renal cancer:8.98e-5 (unfavourable) Expressed in all Expressed in all placenta: 654.4 PEMT PEMPT, PEMT2 ENSG00000133027 Phosphatidylethanolamine N-methyltransferase 17 17505563-17591708 Enzymes, Predicted membrane proteins Evidence at protein level HPA042375 Approved Approved Cytosol Endometrial cancer:6.77e-6 (favourable) Expressed in all Expressed in all epididymis: 205.4 PERP dJ496H19.1, KCP1, KRTCAP1, PIGPC1, THW ENSG00000112378 PERP, TP53 apoptosis effector 6 138088505-138107511 Predicted membrane proteins Evidence at protein level HPA022269 Supported Pancreatic cancer:1.05e-5 (unfavourable), Lung cancer:3.73e-4 (unfavourable), Breast cancer:5.46e-4 (unfavourable) Expressed in all Group enriched 6 esophagus: 574.1;skin: 1238.6 breast: 149.6 PEX10 RNF69 ENSG00000157911 Peroxisomal biogenesis factor 10 1 2403964-2413797 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA049458, HPA049755 Approved Approved Nucleoplasm Renal cancer:4.16e-6 (favourable), Breast cancer:4.50e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 19.3 PEX11B ENSG00000131779 Peroxisomal biogenesis factor 11 beta 1 145911350-145918837 Disease related genes, Predicted membrane proteins Evidence at protein level HPA050104 Supported Liver cancer:2.67e-4 (unfavourable), Lung cancer:6.85e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 44.9 PEX11G ENSG00000104883 Peroxisomal biogenesis factor 11 gamma 19 7476875-7497449 Predicted membrane proteins Evidence at protein level HPA069817 Uncertain Renal cancer:1.83e-9 (favourable), Liver cancer:3.27e-4 (favourable), Endometrial cancer:3.60e-4 (favourable) Expressed in all Mixed testis: 15.6 PEX13 ENSG00000162928 Peroxisomal biogenesis factor 13 2 61017225-61051990 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032141, HPA032142, CAB032689 Supported Supported Vesicles Pancreatic cancer:8.07e-5 (unfavourable) Expressed in all Expressed in all testis: 27.4 PEX14 ENSG00000142655 Peroxisomal biogenesis factor 14 1 10472288-10630758 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046104, HPA049231 Supported Supported Nucleoli fibrillar center
Peroxisomes Expressed in all Expressed in all seminal vesicle: 32.3 PEX16 ENSG00000121680 Peroxisomal biogenesis factor 16 11 45909669-45918812 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043286 Approved Urothelial cancer:9.06e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 27.5 PEX2 PAF-1, PMP35, PXMP3, RNF72, ZWS3 ENSG00000164751 Peroxisomal biogenesis factor 2 8 76980258-77001044 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA010983, HPA011410, HPA027729 Approved Supported Vesicles Expressed in all Expressed in all seminal vesicle: 111.4 PFDN1 PFD1 ENSG00000113068 Prefoldin subunit 1 5 140245039-140303121 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006499 Approved Approved Nucleoli
Plasma membrane
Cytosol Liver cancer:8.81e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 106.6 PFN2 ENSG00000070087 Profilin 2 3 149964904-150050788 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035611, CAB037073 Supported Liver cancer:2.19e-7 (unfavourable), Endometrial cancer:2.93e-4 (unfavourable), Head and neck cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 420.7 PGAP1 Bst1, FLJ12377, SPG67 ENSG00000197121 Post-GPI attachment to proteins 1 2 196833004-196927796 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069704 Uncertain Mixed Mixed skin: 14.7 PGAP2 CWH43-N, FRAG1, MRT21 ENSG00000148985 Post-GPI attachment to proteins 2 11 3797724-3826371 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA063099 Approved Approved Microtubules Liver cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all epididymis: 258.9 PGAP3 CAB2, MGC9753, PER1, PERLD1, PP1498 ENSG00000161395 Post-GPI attachment to proteins 3 17 39671122-39696797 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016591 Approved Approved Plasma membrane
Cytosol Renal cancer:3.89e-4 (favourable), Liver cancer:3.94e-4 (favourable), Ovarian cancer:6.82e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 35.5 PGBD4 FLJ32638, FLJ37497 ENSG00000182405 PiggyBac transposable element derived 4 15 34102073-34108684 Predicted intracellular proteins Evidence at protein level HPA040896, HPA059823 Uncertain Approved Nucleoplasm
Centrosome Mixed Mixed testis: 3.6 PGBD5 DKFZp761A0620, FLJ11413 ENSG00000177614 PiggyBac transposable element derived 5 1 230314482-230425729 Predicted intracellular proteins Evidence at protein level HPA065010 Approved Nucleoplasm Glioma:1.20e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 40.2;cervix, uterine: 28.9 adrenal gland: 12.7 PGR NR3C3, PR ENSG00000082175 Progesterone receptor 11 101029624-101130524 Cancer-related genes, FDA approved drug targets, Nuclear receptors, Predicted intracellular proteins, Transcription factors Evidence at protein level CAB000068, HPA004751, HPA008428, HPA017176, CAB055100 Supported Endometrial cancer:5.76e-8 (favourable) Group enriched Group enriched 6 cervix, uterine: 95.8;endometrium: 171.3;fallopian tube: 52.8;smooth muscle: 113.5 ovary: 19.4 PGRMC1 HPR6.6 ENSG00000101856 Progesterone receptor membrane component 1 X 119236245-119244466 Predicted membrane proteins Evidence at protein level HPA002877 Supported Approved Nucleoli
Endoplasmic reticulum Head and neck cancer:3.02e-4 (unfavourable) Expressed in all Expressed in all liver: 339.5 PGRMC2 DG6, PMBP ENSG00000164040 Progesterone receptor membrane component 2 4 128269237-128288829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041172, HPA058652 Approved Approved Nuclear bodies
Plasma membrane
Cytosol Endometrial cancer:3.62e-4 (favourable), Renal cancer:9.60e-4 (favourable) Expressed in all Expressed in all small intestine: 136.2 PHF8 JHDM1F, KIAA1111, ZNF422 ENSG00000172943 PHD finger protein 8 X 53936676-54048958 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA038779, HPA062015 Approved Supported Nucleus Urothelial cancer:3.74e-5 (favourable) Expressed in all Expressed in all epididymis: 84.6 PHKG1 PHKG ENSG00000164776 Phosphorylase kinase, gamma 1 (muscle) 7 56080283-56092996 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012057 Supported Tissue enriched Tissue enriched 7 skeletal muscle: 100.5 cerebral cortex: 14.3 PHKG2 ENSG00000156873 Phosphorylase kinase, gamma 2 (testis) 16 30748270-30761176 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA065618, HPA068751 Supported Cytosol Lung cancer:1.90e-4 (favourable), Cervical cancer:7.90e-4 (favourable), Pancreatic cancer:8.02e-4 (favourable), Colorectal cancer:9.92e-4 (unfavourable) Expressed in all Expressed in all testis: 149.6 PHLDB2 FLJ21791, LL5b, LL5beta ENSG00000144824 Pleckstrin homology-like domain, family B, member 2 3 111732497-111976517 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035146, HPA035147 Approved Supported Plasma membrane
Cytosol Renal cancer:7.03e-8 (favourable), Head and neck cancer:2.59e-4 (unfavourable) Expressed in all Mixed placenta: 59.4 PHTF1 PHTF ENSG00000116793 Putative homeodomain transcription factor 1 1 113696831-113759489 Plasma proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA059486 Approved Nucleoli
Nuclear bodies Renal cancer:1.21e-6 (unfavourable) Expressed in all Tissue enhanced testis: 54.1 parathyroid gland: 18.8 PHTF2 DKFZp434D166 ENSG00000006576 Putative homeodomain transcription factor 2 7 77798792-77957503 Predicted membrane proteins, Transcription factors Evidence at protein level HPA012312 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:3.09e-7 (unfavourable), Thyroid cancer:2.78e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 60.8 PI16 CD364, dJ90K10.5, MGC45378, MSMBBP ENSG00000164530 Peptidase inhibitor 16 6 36948263-36964837 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA043763 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 198.3 urinary bladder: 81.1 PI4KA PI4K-ALPHA, pi4K230, PIK4CA ENSG00000241973 Phosphatidylinositol 4-kinase, catalytic, alpha 22 20707691-20859417 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009092, HPA075515 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:7.22e-5 (favourable), Lung cancer:5.24e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 114.0 PIANP C12orf53, DKFZp547D2210, PANP ENSG00000139200 PILR alpha associated neural protein 12 6693792-6700800 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010631 Approved Approved Nucleoplasm Tissue enhanced Tissue enhanced cerebral cortex: 64.5 endometrium: 13.5 PIAS2 miz, PIASX-ALPHA, PIASX-BETA, ZMIZ4 ENSG00000078043 Protein inhibitor of activated STAT, 2 18 46803224-46920160 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA068792 Supported Approved Nucleoplasm Thyroid cancer:1.27e-4 (unfavourable) Expressed in all Group enriched 5 parathyroid gland: 28.3;testis: 118.8 cerebral cortex,thyroid gland: 13.8 PIEZO1 FAM38A, KIAA0233 ENSG00000103335 Piezo-type mechanosensitive ion channel component 1 16 88715343-88785211 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047185 Uncertain Renal cancer:8.89e-7 (unfavourable), Lung cancer:2.36e-5 (unfavourable), Cervical cancer:2.37e-4 (unfavourable), Ovarian cancer:3.78e-4 (unfavourable) Expressed in all Mixed adipose tissue: 42.0 PIEZO2 C18orf30, C18orf58, FAM38B, FAM38B2, FLJ23144, FLJ23403, FLJ34907, HsT748, HsT771 ENSG00000154864 Piezo-type mechanosensitive ion channel component 2 18 10666483-11148762 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015986, HPA031974, HPA031975, HPA040616 Approved Approved Vesicles Renal cancer:9.57e-7 (unfavourable) Mixed Mixed lung: 12.8 PIGA GPI3 ENSG00000165195 Phosphatidylinositol glycan anchor biosynthesis, class A X 15319451-15335580 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001174 Approved Pancreatic cancer:7.64e-4 (unfavourable) Expressed in all Mixed lung: 10.5 PIGB ENSG00000069943 Phosphatidylinositol glycan anchor biosynthesis, class B 15 55318960-55355648 Predicted membrane proteins Evidence at protein level HPA039929 Uncertain Uncertain Plasma membrane
Cytosol Expressed in all Mixed parathyroid gland: 22.8 PIGC ENSG00000135845 Phosphatidylinositol glycan anchor biosynthesis, class C 1 172370189-172444086 Enzymes, Predicted membrane proteins Evidence at protein level HPA036663 Uncertain Renal cancer:1.43e-8 (unfavourable), Liver cancer:4.49e-4 (unfavourable) Expressed in all Expressed in all epididymis: 47.0 PIGF ENSG00000151665 Phosphatidylinositol glycan anchor biosynthesis, class F 2 46580937-46617119 Predicted membrane proteins Evidence at protein level HPA051389 Uncertain Liver cancer:1.39e-5 (unfavourable) Expressed in all Expressed in all testis: 47.8 PIGG FLJ20265, GPI7, LAS21 ENSG00000174227 Phosphatidylinositol glycan anchor biosynthesis, class G 4 499210-540196 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015997 Uncertain Uncertain Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 34.9 PIGH GPI-H ENSG00000100564 Phosphatidylinositol glycan anchor biosynthesis, class H 14 67581955-67600287 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031624 Approved Renal cancer:2.68e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 105.5 PIGK GPI8, hGPI8 ENSG00000142892 Phosphatidylinositol glycan anchor biosynthesis, class K 1 77088990-77219430 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA056383, HPA057040 Uncertain Liver cancer:4.68e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 28.0 PIGM GPI-MT-I ENSG00000143315 Phosphatidylinositol glycan anchor biosynthesis, class M 1 160027673-160031991 Disease related genes, Predicted membrane proteins Evidence at protein level HPA047418 Uncertain Ovarian cancer:3.27e-4 (favourable) Expressed in all Mixed parathyroid gland: 16.1 PIGN MDC4, PIG-N ENSG00000197563 Phosphatidylinositol glycan anchor biosynthesis, class N 18 62043567-62187118 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039922, HPA040374 Approved Supported Plasma membrane
Cytosol Colorectal cancer:6.51e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 31.3 PIGO DKFZp434M222, FLJ00135 ENSG00000165282 Phosphatidylinositol glycan anchor biosynthesis, class O 9 35088688-35096601 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014905 Approved Nucleus
Nucleoli Renal cancer:3.05e-10 (favourable) Expressed in all Expressed in all parathyroid gland: 73.2 PIGP DCRC, DSCR5, DSRC ENSG00000185808 Phosphatidylinositol glycan anchor biosynthesis, class P 21 37059170-37073170 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026921 Uncertain Approved Vesicles Expressed in all Expressed in all epididymis: 123.4 PIGQ GPI1, hGPI1 ENSG00000007541 Phosphatidylinositol glycan anchor biosynthesis, class Q 16 566995-584136 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039105, HPA039828, HPA061414 Approved Approved Nucleoplasm
Golgi apparatus
Vesicles Renal cancer:2.53e-6 (favourable) Expressed in all Expressed in all bone marrow: 24.2 PIGR ENSG00000162896 Polymeric immunoglobulin receptor 1 206928518-206946466 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006154, CAB009454, HPA012012 Supported Uncertain Nucleus
Nucleoli
Cytosol Breast cancer:1.22e-5 (favourable), Renal cancer:5.08e-5 (favourable), Endometrial cancer:2.57e-4 (favourable) Tissue enhanced Tissue enhanced colon: 1721.7;duodenum: 2732.8 rectum: 1357.3 PIGS ENSG00000087111 Phosphatidylinositol glycan anchor biosynthesis, class S 17 28553383-28571872 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA018149 Approved Liver cancer:1.86e-4 (unfavourable), Urothelial cancer:5.31e-4 (unfavourable) Expressed in all Mixed thyroid gland: 13.5 PIGU bA346K17.2, CDC91L1, GAB1 ENSG00000101464 Phosphatidylinositol glycan anchor biosynthesis, class U 20 34560542-34698790 Predicted membrane proteins Evidence at protein level HPA041706, HPA046766 Uncertain Approved Nucleoplasm
Cytosol Liver cancer:1.49e-7 (unfavourable) Expressed in all Expressed in all parathyroid gland: 47.2 PIGV FLJ20477 ENSG00000060642 Phosphatidylinositol glycan anchor biosynthesis, class V 1 26787472-26798398 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054181 Approved Endoplasmic reticulum
Cytosol Renal cancer:7.60e-7 (favourable) Expressed in all Expressed in all testis: 83.5 PIGW FLJ37433, Gwt1 ENSG00000277161 Phosphatidylinositol glycan anchor biosynthesis, class W 17 36535020-36539310 Disease related genes, Predicted membrane proteins Evidence at protein level HPA023499 Approved Plasma membrane Expressed in all Mixed appendix: 5.3 PIGX FLJ20522 ENSG00000163964 Phosphatidylinositol glycan anchor biosynthesis, class X 3 196639775-196736007 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029409 Uncertain Approved Nucleoplasm
Cytosol Liver cancer:7.45e-5 (unfavourable), Cervical cancer:2.12e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 28.0 PIGY MGC14156 ENSG00000255072 Phosphatidylinositol glycan anchor biosynthesis, class Y 4 88521573-88521789 Predicted membrane proteins Evidence at protein level HPA059018 Uncertain Not detected Tissue enriched 10 colon: 1.0 all non-specific tissues: 0.0 PIGZ FLJ12768, MGC52163, SMP3 ENSG00000119227 Phosphatidylinositol glycan anchor biosynthesis, class Z 3 196946343-196969060 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA058599, HPA059920 Approved Uncertain Vesicles Renal cancer:5.60e-5 (unfavourable) Expressed in all Tissue enhanced colon: 18.8;rectum: 18.4 cerebral cortex: 10.9 PILRA FDF03 ENSG00000085514 Paired immunoglobin-like type 2 receptor alpha 7 100367530-100400099 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA056132 Approved Renal cancer:1.61e-4 (unfavourable), Cervical cancer:2.99e-4 (favourable) Expressed in all Tissue enhanced appendix: 53.6 lung: 43.8 PILRB FDFACT1, FDFACT2 ENSG00000121716 Paired immunoglobin-like type 2 receptor beta 7 100352176-100367733 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026750 Approved Approved Mitochondria Renal cancer:1.42e-4 (unfavourable) Expressed in all Expressed in all testis: 167.1 PIRT ENSG00000233670 Phosphoinositide-interacting regulator of transient receptor potential channels 17 10822475-10838445 Predicted membrane proteins, Transporters Evidence at transcript level HPA042337 Uncertain Uncertain Plasma membrane
Cytosol Tissue enriched Tissue enhanced adrenal gland: 3.1;cerebral cortex: 2.7;rectum: 2.7 colon: 2.1 PISD dJ858B16.2, PSDC ENSG00000241878 Phosphatidylserine decarboxylase 22 31618491-31662432 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031090, HPA031091 Approved Approved Golgi apparatus
Cytosol Urothelial cancer:5.27e-5 (favourable) Expressed in all Expressed in all adipose tissue: 35.9 PKD1 PBP, Pc-1, TRPP1 ENSG00000008710 Polycystic kidney disease 1 (autosomal dominant) 16 2088710-2135898 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB046448 Approved Pancreatic cancer:3.38e-5 (favourable), Head and neck cancer:3.35e-4 (favourable), Colorectal cancer:7.43e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.6 PKD1L1 PRO19563 ENSG00000158683 Polycystic kidney disease 1 like 1 7 47774652-47948491 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020422, HPA022424 Uncertain Tissue enhanced Tissue enhanced testis: 2.4 adipose tissue: 1.8 PKD2 Pc-2, PC2, PKD4, TRPP2 ENSG00000118762 Polycystic kidney disease 2 (autosomal dominant) 4 88007668-88077777 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB004544, HPA015794 Approved Validated Endoplasmic reticulum Expressed in all Expressed in all endometrium: 100.4 PKD2L1 PCL, PKD2L, PKDL, TRPP3 ENSG00000107593 Polycystic kidney disease 2-like 1 10 100288154-100330486 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022621 Uncertain Mixed Tissue enhanced spleen: 10.0 lung: 3.4 PKD2L2 TRPP5 ENSG00000078795 Polycystic kidney disease 2-like 2 5 137887968-137942747 Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at transcript level HPA041903, HPA043634 Approved Approved Plasma membrane
Cytosol Not detected Tissue enriched 11 testis: 15.6 thyroid gland: 1.4 PKDREJ ENSG00000130943 Polycystin (PKD) family receptor for egg jelly 22 46255663-46263355 Predicted membrane proteins Evidence at protein level HPA034587 Supported Not detected Tissue enriched 9 testis: 6.2 skin: 0.7 PKHD1 ARPKD, FCYT, TIGM1 ENSG00000170927 Polycystic kidney and hepatic disease 1 (autosomal recessive) 6 51615300-52087625 Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA031227 Supported Renal cancer:9.74e-8 (favourable) Group enriched Group enriched 5 epididymis: 5.7;kidney: 15.2 pancreas: 1.9 PKHD1L1 ENSG00000205038 Polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 8 109362477-109530330 Predicted membrane proteins Evidence at protein level HPA044458 Uncertain Endometrial cancer:7.61e-4 (favourable) Group enriched Group enriched 6 cervix, uterine: 21.2;fallopian tube: 19.5;thyroid gland: 56.9 endometrium: 5.4 PKN2 Pak-2, PRK2, PRKCL2, STK7 ENSG00000065243 Protein kinase N2 1 88684222-88836255 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034861 Uncertain Colorectal cancer:5.67e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 48.2 PLA2G16 AdPLA, H-REV107-1, HRASLS3, HREV107, HREV107-3, MGC118754. ENSG00000176485 Phospholipase A2, group XVI 11 63573195-63616883 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA058997 Uncertain Approved Mitochondria Pancreatic cancer:5.58e-6 (unfavourable), Thyroid cancer:2.54e-5 (favourable) Expressed in all Expressed in all adipose tissue: 327.0 PLA2G6 iPLA2, iPLA2beta, NBIA2, PARK14, PNPLA9 ENSG00000184381 Phospholipase A2, group VI (cytosolic, calcium-independent) 22 38111495-38205690 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, RAS pathway related proteins Evidence at protein level HPA001171 Approved Approved Microtubule organizing center
Cytosol Urothelial cancer:1.55e-4 (favourable), Cervical cancer:7.29e-4 (favourable) Expressed in all Expressed in all testis: 60.3 PLA2R1 CLEC13C, PLA2-R, PLA2G1R, PLA2IR ENSG00000153246 Phospholipase A2 receptor 1, 180kDa 2 159932006-160062610 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB068217, CAB068218 Approved Approved Cytosol Stomach cancer:3.08e-4 (unfavourable) Mixed Tissue enhanced thyroid gland: 71.7 parathyroid gland: 35.1 PLB1 FLJ30866, PLB ENSG00000163803 Phospholipase B1 2 28457145-28643788 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014045 Approved Cytosol Mixed Group enriched 7 skin: 9.5;small intestine: 46.5 testis: 4.2 PLD3 HU-K4 ENSG00000105223 Phospholipase D family, member 3 19 40348456-40380439 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012800, CAB020812 Approved Renal cancer:2.21e-4 (favourable), Pancreatic cancer:6.44e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 496.2 PLD4 C14orf175 ENSG00000166428 Phospholipase D family, member 4 14 104924816-104937790 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051512 Approved Mixed Mixed lymph node: 14.1 PLD5 FLJ40773 ENSG00000180287 Phospholipase D family, member 5 1 242082986-242524696 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA028389, HPA050367 Uncertain Approved Vesicles
Mitochondria
Cytosol Tissue enhanced Mixed cerebral cortex: 4.2 PLD6 ENSG00000179598 Phospholipase D family, member 6 17 17200995-17206315 Predicted membrane proteins Evidence at protein level HPA049345 Approved Pancreatic cancer:1.05e-4 (favourable) Expressed in all Tissue enhanced testis: 29.2 ovary: 8.9 PLEC EBS1, PCN, PLEC1, PLTN ENSG00000178209 Plectin 8 143915147-143976734 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB003847, HPA025967, HPA029906 Supported Validated Intermediate filaments
Focal adhesion sites
Cytosol Renal cancer:7.98e-6 (unfavourable), Colorectal cancer:4.29e-4 (unfavourable), Lung cancer:5.33e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 94.9 PLEKHH2 KIAA2028, PLEKHH1L ENSG00000152527 Pleckstrin homology domain containing, family H (with MyTH4 domain) member 2 2 43637273-43767987 Predicted intracellular proteins Evidence at protein level HPA077225 Supported Plasma membrane Tissue enhanced Mixed endometrium: 31.8 PLIN1 PLIN ENSG00000166819 Perilipin 1 15 89664365-89679427 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024299, CAB033821, CAB037333 Supported Uncertain Peroxisomes Tissue enhanced Tissue enriched 10 adipose tissue: 1011.2 breast: 99.5 PLLP PMLP, TM4SF11 ENSG00000102934 Plasmolipin 16 57248547-57284687 Predicted membrane proteins Evidence at protein level HPA041862 Supported Renal cancer:6.21e-9 (favourable), Endometrial cancer:2.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.4 PLN CMD1P, PLB ENSG00000198523 Phospholamban 6 118548298-118560730 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB005597, HPA026900 Supported Renal cancer:4.11e-4 (unfavourable), Urothelial cancer:5.59e-4 (unfavourable) Mixed Tissue enriched 6 heart muscle: 1486.3 smooth muscle: 266.8 PLOD2 LH2 ENSG00000152952 Procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2 3 146069440-146163653 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025898, HPA069126 Approved Uncertain Nucleoli
Cytosol Renal cancer:4.99e-11 (unfavourable), Liver cancer:7.64e-10 (unfavourable), Lung cancer:1.42e-4 (unfavourable), Cervical cancer:1.97e-4 (unfavourable), Stomach cancer:2.83e-4 (unfavourable) Expressed in all Mixed thyroid gland: 150.3 PLP1 GPM6C, PLP, SPG2 ENSG00000123560 Proteolipid protein 1 X 103773718-103792619 Cancer-related genes, Disease related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA004128 Supported Group enriched Tissue enriched 30 cerebral cortex: 3225.1 parathyroid gland: 106.1 PLP2 A4, A4-LSB, MGC126187 ENSG00000102007 Proteolipid protein 2 (colonic epithelium-enriched) X 49171926-49175239 Predicted membrane proteins, Transporters Evidence at protein level HPA042415 Approved Renal cancer:5.55e-10 (unfavourable), Endometrial cancer:3.32e-5 (unfavourable) Expressed in all Expressed in all skin: 480.7 PLPP1 LPP1, PAP-2a, PPAP2A ENSG00000067113 Phospholipid phosphatase 1 5 55424854-55535050 Enzymes, Predicted membrane proteins Evidence at protein level CAB033331, HPA047815 Supported Supported Plasma membrane Stomach cancer:5.77e-4 (unfavourable), Liver cancer:6.06e-4 (favourable) Expressed in all Mixed prostate: 344.0 PLPP2 LPP2, PAP-2c, PPAP2C ENSG00000141934 Phospholipid phosphatase 2 19 281040-291504 Enzymes, Predicted membrane proteins Evidence at protein level HPA055540 Uncertain Approved Mitochondria Endometrial cancer:3.21e-8 (favourable), Breast cancer:4.55e-4 (unfavourable) Expressed in all Tissue enhanced fallopian tube: 126.8 cervix, uterine: 91.2 PLPP3 LPP3, PAP-2b, PPAP2B ENSG00000162407 Phospholipid phosphatase 3 1 56494747-56645301 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA028892, HPA072751 Uncertain Supported Golgi apparatus Renal cancer:4.59e-4 (favourable) Expressed in all Expressed in all thyroid gland: 543.7 PLPP4 DPPL2, PPAPDC1, PPAPDC1A ENSG00000203805 Phospholipid phosphatase 4 10 120456954-120589855 Enzymes, Predicted membrane proteins Evidence at protein level HPA045188 Approved Approved Nucleus
Nucleoli Mixed Tissue enhanced cerebral cortex: 17.2;gallbladder: 10.4;testis: 12.7 kidney: 7.7 PLPP5 DPPL1, HTPAP, PPAPDC1B ENSG00000147535 Phospholipid phosphatase 5 8 38263130-38269243 Enzymes, Predicted membrane proteins Evidence at protein level HPA055777 Approved Vesicles Renal cancer:8.33e-10 (unfavourable), Endometrial cancer:1.48e-5 (favourable), Ovarian cancer:2.42e-5 (favourable), Lung cancer:8.72e-5 (favourable) Expressed in all Expressed in all prostate: 123.7 PLPP6 FLJ46512, FLJ90191, PDP1, PPAPDC2 ENSG00000205808 Phospholipid phosphatase 6 9 4662315-4665258 Predicted membrane proteins Evidence at protein level HPA018096 Approved Approved Nucleoplasm
Vesicles Renal cancer:3.99e-4 (favourable) Expressed in all Mixed prostate: 26.8 PLPP7 C9orf67, FLJ14662, MGC12921, NET39, PPAPDC3 ENSG00000160539 Phospholipid phosphatase 7 (inactive) 9 131289694-131309262 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA070252 Uncertain Approved Nucleus
Vesicles Mixed Group enriched 5 heart muscle: 33.8;skeletal muscle: 72.2 cerebral cortex: 10.1 PLPPR1 FLJ20300, LPPR1, MGC26189, PRG-3 ENSG00000148123 Phospholipid phosphatase related 1 9 101028709-101325135 Predicted membrane proteins Evidence at protein level HPA014760, HPA014968, HPA014979 Supported Approved Nucleoplasm Lung cancer:1.37e-4 (favourable) Group enriched Group enriched 6 cerebral cortex: 23.9;kidney: 15.7 epididymis: 3.2 PLPPR2 LPPR2, PRG-4 ENSG00000105520 Phospholipid phosphatase related 2 19 11355386-11365698 Enzymes, Predicted membrane proteins Evidence at protein level HPA048973 Uncertain Approved Nucleoplasm Renal cancer:7.46e-11 (unfavourable), Colorectal cancer:6.45e-4 (unfavourable), Pancreatic cancer:6.82e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 77.4 PLPPR3 FLJ11535, LPPR3, PRG-2, PRG2 ENSG00000129951 Phospholipid phosphatase related 3 19 812488-821977 Enzymes, Predicted membrane proteins Evidence at protein level HPA052293, HPA057034 Uncertain Approved Nucleoplasm
Golgi apparatus
Cytosol Tissue enhanced Tissue enhanced bone marrow: 6.1;cerebral cortex: 9.6;fallopian tube: 8.8 testis: 2.1 PLPPR5 LPPR5, PAP2, PAP2D, PRG5 ENSG00000117598 Phospholipid phosphatase related 5 1 98890245-99005032 Predicted membrane proteins Evidence at transcript level HPA018072 Uncertain Approved Nucleus
Plasma membrane
Centrosome Renal cancer:6.22e-4 (unfavourable) Group enriched Group enriched 11 cerebral cortex: 12.0;testis: 4.0 adrenal gland: 0.7 PLSCR4 ENSG00000114698 Phospholipid scramblase 4 3 146192339-146251179 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002276 Approved Approved Nucleoplasm
Nuclear bodies Endometrial cancer:3.90e-4 (unfavourable), Renal cancer:4.13e-4 (unfavourable) Expressed in all Expressed in all placenta: 79.5 PLVAP FELS, gp68, PV-1, PV1 ENSG00000130300 Plasmalemma vesicle associated protein 19 17351448-17377350 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002279 Supported Uncertain Cytosol Expressed in all Expressed in all thyroid gland: 328.6 PLXDC1 TEM3, TEM7 ENSG00000161381 Plexin domain containing 1 17 39063303-39154394 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012805 Approved Renal cancer:9.15e-8 (unfavourable) Expressed in all Mixed gallbladder: 22.9 PLXDC2 FLJ14623, TEM7R ENSG00000120594 Plexin domain containing 2 10 19816239-20289856 Predicted membrane proteins Evidence at protein level HPA017268, HPA070793 Approved Supported Nuclear bodies Expressed in all Mixed gallbladder: 25.1 PLXNA1 NOV, PLXN1 ENSG00000114554 Plexin A1 3 126988594-127037392 Predicted membrane proteins Evidence at protein level HPA007499, CAB012483 Uncertain Supported Nucleus
Cytosol Liver cancer:4.13e-6 (unfavourable), Renal cancer:5.64e-5 (unfavourable), Ovarian cancer:1.35e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 42.7 skin: 16.8 PLXNA2 FLJ11751, FLJ30634, KIAA0463, OCT, PLXN2 ENSG00000076356 Plexin A2 1 208022242-208244320 Predicted membrane proteins Evidence at protein level CAB009763 Approved Expressed in all Mixed ovary: 16.9 PLXNA3 6.3, Plxn3, PLXN4, SEX, XAP-6 ENSG00000130827 Plexin A3 X 154458281-154477779 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA058989 Supported Vesicles
Plasma membrane
Cell Junctions Expressed in all Mixed skin: 12.1 PLXNA4 DKFZp434G0625PRO34003, FAYV2820, KIAA1550, PLXNA4A, PLXNA4B ENSG00000221866 Plexin A4 7 132123332-132648688 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029919, HPA052141 Supported Endometrial cancer:1.61e-6 (unfavourable) Tissue enhanced Tissue enhanced adipose tissue: 15.2;cervix, uterine: 12.4 cerebral cortex: 10.5 PLXNB1 KIAA0407, PLXN5, SEP ENSG00000164050 Plexin B1 3 48403854-48430051 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA040586 Approved Renal cancer:2.77e-5 (favourable), Head and neck cancer:5.03e-4 (favourable), Urothelial cancer:7.60e-4 (favourable) Expressed in all Mixed fallopian tube: 36.3 PLXNB2 KIAA0315, MM1, PLEXB2 ENSG00000196576 Plexin B2 22 50274979-50307627 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003100 Uncertain Stomach cancer:4.75e-4 (favourable), Ovarian cancer:7.37e-4 (unfavourable) Expressed in all Expressed in all spleen: 123.1 PLXNB3 PLEXB3, PLEXR, PLXN6 ENSG00000198753 Plexin B3 X 153764196-153779346 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048046 Supported Breast cancer:6.13e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 67.4 adrenal gland: 19.7 PLXNC1 CD232, VESPR ENSG00000136040 Plexin C1 12 94148723-94307675 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026155, HPA066899 Uncertain Approved Mitochondria Expressed in all Mixed appendix: 29.0 PLXND1 KIAA0620 ENSG00000004399 Plexin D1 3 129555175-129606818 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB020819 Approved Renal cancer:5.93e-7 (unfavourable) Expressed in all Expressed in all placenta: 159.8 PMEL D12S53E, gp100, Pmel17, SI, SIL, SILV ENSG00000185664 Premelanosome protein 12 55954105-55973317 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA031649 Supported Renal cancer:3.70e-4 (favourable) Tissue enriched Tissue enriched 12 skin: 133.7 breast: 10.8 PMEPA1 STAG1, TMEPAI ENSG00000124225 Prostate transmembrane protein, androgen induced 1 20 57648392-57711536 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA072291 Supported Vesicles Renal cancer:2.87e-7 (unfavourable), Lung cancer:4.73e-5 (unfavourable), Cervical cancer:2.45e-4 (unfavourable), Urothelial cancer:7.60e-4 (unfavourable) Expressed in all Tissue enhanced cervix, uterine: 145.4;prostate: 181.8 endometrium: 60.1 PMS1 MLH2, PMSL1 ENSG00000064933 PMS1 homolog 1, mismatch repair system component 2 189784085-189877629 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB010233, HPA031013 Approved Supported Nucleoplasm
Nuclear bodies Renal cancer:1.86e-6 (unfavourable), Liver cancer:2.38e-6 (unfavourable), Urothelial cancer:3.73e-4 (favourable) Expressed in all Expressed in all testis: 84.8 PNKD BRP17, DKFZp564N1362, DYT8, FKSG19, FPD1, KIAA1184, KIPP1184, MGC31943, MR-1, PDC, PKND1, TAHCCP2 ENSG00000127838 Paroxysmal nonkinesigenic dyskinesia 2 218270392-218346793 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010134, HPA017068 Approved Validated Mitochondria Renal cancer:5.13e-5 (unfavourable) Expressed in all Expressed in all prostate: 117.3 PNLDC1 dJ195P10.2, FLJ40240 ENSG00000146453 Poly(A)-specific ribonuclease (PARN)-like domain containing 1 6 159800249-159820704 Predicted membrane proteins Evidence at protein level HPA052026 Uncertain Mixed Tissue enriched 5 testis: 12.2 fallopian tube: 2.3 PNPLA6 iPLA2delta, NTE, SPG39, sws ENSG00000032444 Patatin-like phospholipase domain containing 6 19 7534004-7561764 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007522 Uncertain Pancreatic cancer:3.51e-5 (favourable), Head and neck cancer:5.25e-4 (favourable), Renal cancer:7.53e-4 (favourable) Expressed in all Expressed in all testis: 49.2 PNPLA7 C9orf111, FLJ31318, FLJ43070, FLJ44279, NTE-R1, NTEL1, RP11-48C7.2 ENSG00000130653 Patatin-like phospholipase domain containing 7 9 137459953-137550534 Predicted membrane proteins Evidence at protein level HPA009130 Uncertain Uncertain Microtubule organizing center
Cytosol Pancreatic cancer:2.24e-5 (favourable) Tissue enhanced Mixed prostate: 15.7 PNPLA8 IPLA2-2, IPLA2G, iPLA2gamma ENSG00000135241 Patatin-like phospholipase domain containing 8 7 108470422-108569666 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020083 Approved Approved Nucleoplasm
Golgi apparatus
Cytosol Renal cancer:1.86e-6 (favourable) Expressed in all Expressed in all adrenal gland: 63.4 PODXL Gp200, PC, PCLP ENSG00000128567 Podocalyxin-like 7 131500262-131558217 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA002110, CAB016169, HPA045507, CAB062558, CAB068219, CAB068220 Supported Approved Vesicles
Plasma membrane
Microtubule organizing center Renal cancer:2.89e-4 (favourable) Expressed in all Mixed fallopian tube: 29.2 PODXL2 endoglycan, PODLX2 ENSG00000114631 Podocalyxin-like 2 3 127629181-127672809 Predicted membrane proteins Evidence at protein level CAB024934, HPA042265 Approved Approved Golgi apparatus
Vesicles Expressed in all Tissue enhanced cerebral cortex: 77.3 testis: 35.9 POLE POLE1 ENSG00000177084 Polymerase (DNA directed), epsilon, catalytic subunit 12 132623753-132687365 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA058210, HPA067385 Validated Nucleus
Plasma membrane Renal cancer:3.19e-8 (unfavourable), Melanoma:1.44e-4 (unfavourable) Expressed in all Expressed in all testis: 22.0 POLR1E FLJ13390, FLJ13970, PAF53, PRAF1 ENSG00000137054 Polymerase (RNA) I polypeptide E, 53kDa 9 37485935-37503697 Predicted intracellular proteins, Predicted membrane proteins, RNA polymerase related proteins Evidence at protein level HPA022527, HPA052400 Supported Supported Nucleus
Nucleoli fibrillar center Breast cancer:2.27e-4 (favourable) Expressed in all Expressed in all ovary: 51.4 POM121 DKFZP586G1822, DKFZP586P2220, KIAA0618, POM121A ENSG00000196313 POM121 transmembrane nucleoporin 7 72879365-72951440 Predicted intracellular proteins, Transporters Evidence at protein level CAB003710, HPA043809, HPA049817 Approved Validated Nucleoplasm
Nuclear membrane Expressed in all Expressed in all cerebral cortex: 30.2 POM121C ENSG00000272391 POM121 transmembrane nucleoporin C 7 75416787-75486271 Predicted intracellular proteins Evidence at transcript level HPA043809, HPA049817 Approved Approved Nucleoplasm
Nuclear membrane Expressed in all Expressed in all thyroid gland: 27.8 POMGNT1 FLJ20277, LGMD2O, MEB, MGAT1.2 ENSG00000085998 Protein O-linked mannose N-acetylglucosaminyltransferase 1 (beta 1,2-) 1 46188682-46220305 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044518 Approved Liver cancer:3.52e-4 (unfavourable), Pancreatic cancer:4.27e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 121.6 POMK FLJ23356, SgK196 ENSG00000185900 Protein-O-mannose kinase 8 43093506-43123434 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA013321 Uncertain Approved Nucleus
Cytosol Mixed Mixed cerebral cortex: 6.4 POMT1 LGMD2K ENSG00000130714 Protein-O-mannosyltransferase 1 9 131502902-131523806 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA065252 Approved Golgi apparatus Pancreatic cancer:3.90e-5 (favourable), Renal cancer:4.68e-5 (favourable) Expressed in all Expressed in all testis: 62.7 POMT2 LGMD2N ENSG00000009830 Protein-O-mannosyltransferase 2 14 77274956-77320884 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA003663 Uncertain Liver cancer:2.40e-4 (unfavourable) Expressed in all Expressed in all testis: 28.8 PON2 ENSG00000105854 Paraoxonase 2 7 95404863-95435329 Candidate cardiovascular disease genes, Enzymes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB025430, HPA029193 Supported Renal cancer:4.30e-8 (unfavourable), Cervical cancer:1.43e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 226.9 POPDC2 POP2 ENSG00000121577 Popeye domain containing 2 3 119636457-119665324 Predicted membrane proteins Evidence at protein level HPA024255 Supported Mixed Tissue enhanced heart muscle: 191.4;seminal vesicle: 63.4 smooth muscle: 35.0 POPDC3 bA355M14.1, MGC22671, POP3 ENSG00000132429 Popeye domain containing 3 6 105158280-105179995 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012514 Uncertain Approved Nucleoli
Cytosol Head and neck cancer:4.43e-4 (unfavourable), Lung cancer:5.79e-4 (unfavourable) Mixed Group enriched 6 cerebral cortex: 8.8;heart muscle: 18.4;skeletal muscle: 41.8;testis: 9.7 epididymis: 3.4 POR CYPOR, FLJ26468 ENSG00000127948 P450 (cytochrome) oxidoreductase 7 75899200-75986855 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB004372, HPA010136 Supported Approved Nucleoplasm
Vesicles
Cytosol Glioma:5.23e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 219.8 PORCN DHOF, MG61, por, PORC, PPN ENSG00000102312 Porcupine homolog (Drosophila) X 48508962-48520814 Disease related genes, Predicted membrane proteins Evidence at protein level HPA049215, HPA058413 Approved Approved Vesicles Expressed in all Mixed adrenal gland: 34.6 POTEE A26C1, A26C1A, CT104.2, POTE-2, POTE2, POTE2gamma ENSG00000188219 POTE ankyrin domain family, member E 2 131218067-131265278 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA041264, HPA041271, HPA042822, HPA043260 Uncertain Not detected Tissue enhanced testis: 2.0 prostate: 0.7 POTEF A26C1B, POTE2alpha, POTEACTIN ENSG00000196604 POTE ankyrin domain family, member F 2 130073535-130129222 Cancer-related genes, Predicted intracellular proteins Evidence at protein level HPA041264, HPA041271, HPA042822, HPA043260 Uncertain Not detected Tissue enriched 5 testis: 2.2 prostate: 0.4 POTEG A26C2, CT104.4, POTE-14, POTE14, POTE14alpha ENSG00000187537 POTE ankyrin domain family, member G 14 19402486-19434341 Predicted intracellular proteins Evidence at transcript level HPA042822 Uncertain Tissue enhanced Tissue enhanced prostate: 3.3 testis: 0.7 POTEH A26C3, ACTBL1, CT104.7, POTE22 ENSG00000198062 POTE ankyrin domain family, member H 22 15690026-15721631 Predicted intracellular proteins Evidence at transcript level HPA042822 Uncertain Tissue enriched Group enriched 36 prostate: 5.7;testis: 1.3 all non-specific tissues: 0.0 POTEI POTE2beta ENSG00000196834 POTE ankyrin domain family, member I 2 130459455-130509666 Predicted intracellular proteins Evidence at protein level HPA041264, HPA041271, HPA042822, HPA043260 Uncertain Not detected Group enriched 13 prostate: 18.0;testis: 10.4 breast: 1.1 POTEJ POTE2beta ENSG00000222038 POTE ankyrin domain family, member J 2 130611481-130658091 Predicted intracellular proteins Evidence at protein level HPA041264, HPA041271, HPA042822, HPA043260 Uncertain Not detected Tissue enhanced testis: 1.0 prostate: 0.6 POTEM ACT, P704P, POTE14beta ENSG00000222036 POTE ankyrin domain family, member M 14 18967434-18999012 Predicted intracellular proteins No evidence HPA042822 Uncertain Not detected Not detected all non-specific tissues: 0.0 PPAN-P2RY11 ENSG00000243207 PPAN-P2RY11 readthrough 19 10106223-10114780 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014232 Uncertain Not detected Mixed fallopian tube: 2.4 PPCDC FLJ14585, MDS018 ENSG00000138621 Phosphopantothenoylcysteine decarboxylase 15 75023555-75117462 Enzymes, Predicted intracellular proteins Evidence at protein level HPA045667 Approved Approved Cytosol Expressed in all Expressed in all parathyroid gland: 21.9 PPFIA1 LIP.1, LIPRIN ENSG00000131626 Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 1 11 70270700-70384403 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008272, CAB017032, HPA042271 Uncertain Validated Focal adhesion sites
Cytosol Renal cancer:3.76e-4 (favourable), Head and neck cancer:5.58e-4 (unfavourable), Pancreatic cancer:8.26e-4 (unfavourable) Expressed in all Expressed in all testis: 56.9 PPIL3 CyPJ ENSG00000240344 Peptidylprolyl isomerase (cyclophilin)-like 3 2 200870907-200889303 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040765, HPA062187 Approved Supported Nucleus Ovarian cancer:1.19e-4 (favourable), Renal cancer:5.16e-4 (unfavourable) Expressed in all Expressed in all ovary: 45.4 PPM1L PP2CE ENSG00000163590 Protein phosphatase, Mg2+/Mn2+ dependent, 1L 3 160755602-161078907 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019891, HPA019953 Approved Approved Nucleoplasm
Cytosol Breast cancer:4.90e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 39.0 cerebral cortex: 28.0 PPP1CC PP1C, PP1gamma ENSG00000186298 Protein phosphatase 1, catalytic subunit, gamma isozyme 12 110719680-110742939 Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB022645 Uncertain Liver cancer:2.75e-6 (unfavourable), Cervical cancer:7.44e-4 (favourable) Expressed in all Expressed in all testis: 256.1 PPP1R3F Hb2E ENSG00000049769 Protein phosphatase 1, regulatory subunit 3F X 49269843-49301461 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000244, HPA000918 Approved Approved Nucleoplasm Pancreatic cancer:1.85e-6 (favourable) Expressed in all Tissue enhanced cerebral cortex: 27.0 epididymis: 15.0 PPP4R3A FLFL1, FLJ20707, KIAA2010, MSTP033, PP4R3, SMEK1, smk-1, smk1 ENSG00000100796 Protein phosphatase 4, regulatory subunit 3A 14 91457611-91510554 Predicted intracellular proteins Evidence at protein level HPA002568, HPA063917 Approved Supported Nucleoplasm Expressed in all Expressed in all testis: 61.0 PQLC1 FLJ22378 ENSG00000122490 PQ loop repeat containing 1 18 79902420-79951664 Predicted membrane proteins Evidence at protein level HPA051666 Uncertain Approved Nucleoplasm Expressed in all Expressed in all adipose tissue: 40.5 PQLC2 FLJ20320 ENSG00000040487 PQ loop repeat containing 2 1 19312326-19329300 Predicted membrane proteins, Transporters Evidence at protein level HPA057810 Approved Validated Vesicles Liver cancer:2.64e-5 (unfavourable), Endometrial cancer:3.50e-4 (favourable) Expressed in all Expressed in all testis: 16.3 PQLC2L C3orf55 ENSG00000174899 PQ loop repeat containing 2-like 3 157543246-157677749 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054395 Uncertain Approved Nucleoplasm
Nuclear bodies Mixed Tissue enhanced adipose tissue: 21.5;thyroid gland: 16.0 breast: 6.0 PQLC3 C2orf22, MGC33602 ENSG00000162976 PQ loop repeat containing 3 2 11155198-11178874 Predicted membrane proteins Evidence at protein level HPA061607 Approved Cytosol Expressed in all Expressed in all cervix, uterine: 54.2 PRAF2 JM4 ENSG00000243279 PRA1 domain family, member 2 X 49071156-49074071 Predicted membrane proteins Evidence at protein level HPA002859, HPA005504, CAB011655 Supported Approved Endoplasmic reticulum
Vesicles Liver cancer:1.66e-6 (unfavourable), Pancreatic cancer:4.88e-6 (favourable), Renal cancer:5.83e-6 (unfavourable), Lung cancer:2.81e-4 (favourable), Cervical cancer:7.42e-4 (favourable) Expressed in all Expressed in all epididymis: 181.8 PRAP1 UPA ENSG00000165828 Proline-rich acidic protein 1 10 133309410-133352683 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035360, HPA038713, HPA052451 Supported Approved Nucleoplasm
Vesicles
Plasma membrane Group enriched Group enriched 6 duodenum: 981.7;liver: 306.9;small intestine: 1145.9 kidney: 136.1 PRDM11 PFM8 ENSG00000019485 PR domain containing 11 11 45095806-45235124 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA057072 Approved Mixed Mixed thyroid gland: 13.9 PREB SEC12 ENSG00000138073 Prolactin regulatory element binding 2 27130756-27134675 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013582, HPA014133 Uncertain Approved Endoplasmic reticulum Expressed in all Expressed in all epididymis: 106.0 PRIMA1 PRIMA ENSG00000175785 Proline rich membrane anchor 1 14 93718298-93788481 Predicted membrane proteins Evidence at protein level HPA046671, HPA060047 Approved Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:2.62e-7 (unfavourable), Endometrial cancer:6.99e-5 (unfavourable) Mixed Mixed smooth muscle: 11.5 PRKAG1 ENSG00000181929 Protein kinase, AMP-activated, gamma 1 non-catalytic subunit 12 49002274-49019197 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA077805 Approved Nucleoplasm
Cytosol Liver cancer:2.84e-7 (unfavourable), Renal cancer:1.83e-4 (favourable) Expressed in all Expressed in all breast: 57.0 PRLHR GPR10, PrRPR ENSG00000119973 Prolactin releasing hormone receptor 10 118589989-118595699 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA039361 Supported Not detected Group enriched 7 adrenal gland: 6.5;cerebral cortex: 3.5;endometrium: 3.9;smooth muscle: 5.4 seminal vesicle: 0.7 PRNP AltPrP, CD230, CJD, GSS, PRIP, PRP ENSG00000171867 Prion protein 20 4686236-4701590 CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042754, HPA043398 Supported Approved Nuclear membrane
Vesicles
Cytosol Liver cancer:7.41e-5 (unfavourable), Glioma:1.99e-4 (unfavourable), Colorectal cancer:2.96e-4 (unfavourable), Endometrial cancer:4.64e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 621.3 PROCR CCD41, CD201, EPCR ENSG00000101000 Protein C receptor, endothelial 20 35172073-35216240 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039461 Supported Renal cancer:7.62e-6 (unfavourable) Expressed in all Expressed in all adipose tissue: 62.7 PROKR1 GPR73, GPR73a, PKR1, ZAQ ENSG00000169618 Prokineticin receptor 1 2 68643589-68658247 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA029396 Uncertain Not detected Group enriched 8 adipose tissue: 1.7;adrenal gland: 1.4;epididymis: 4.3 testis: 0.3 PROKR2 dJ680N4.3, GPR73b, GPR73L1, GPRg2, KAL3, PKR2 ENSG00000101292 Prokineticin receptor 2 20 5302040-5314369 Disease related genes, G-protein coupled receptors, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA047281 Uncertain Not detected Tissue enhanced cerebral cortex: 3.0 bone marrow: 0.8 PROM1 AC133, CD133, CORD12, MCDR2, PROML1, RP41, STGD4 ENSG00000007062 Prominin 1 4 15963076-16084378 CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004922, CAB011525, HPA031053 Approved Renal cancer:2.56e-5 (favourable) Expressed in all Tissue enhanced cervix, uterine: 66.8 gallbladder: 47.7 PROM2 ENSG00000155066 Prominin 2 2 95274453-95291308 Predicted membrane proteins Evidence at protein level CAB046005, HPA063728 Supported Approved Nucleoplasm
Plasma membrane
Cell Junctions Renal cancer:1.55e-6 (unfavourable), Breast cancer:2.16e-4 (unfavourable), Pancreatic cancer:2.90e-4 (unfavourable) Mixed Tissue enhanced skin: 71.3 esophagus: 44.8 PROS1 PROS ENSG00000184500 Protein S (alpha) 3 93873033-93974066 Candidate cardiovascular disease genes, Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007724, HPA023974 Supported Urothelial cancer:4.42e-5 (unfavourable), Stomach cancer:8.35e-4 (unfavourable) Expressed in all Tissue enhanced liver: 177.6 heart muscle: 75.3 PRPH2 CACD2, rd2, RDS, RP7, TSPAN22 ENSG00000112619 Peripherin 2 (retinal degeneration, slow) 6 42696600-42722574 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029458 Supported Mixed Mixed parathyroid gland: 8.5 PRPSAP1 PAP39 ENSG00000161542 Phosphoribosyl pyrophosphate synthetase-associated protein 1 17 76309486-76384521 Predicted intracellular proteins Evidence at protein level HPA062396 Approved Cytosol Colorectal cancer:1.39e-5 (favourable) Expressed in all Expressed in all thyroid gland: 82.1 PRR7 MGC10772 ENSG00000131188 Proline rich 7 (synaptic) 5 177446445-177456286 Predicted intracellular proteins Evidence at transcript level HPA046636 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.50e-4 (unfavourable), Renal cancer:1.98e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 8.1 bone marrow: 3.7 PRRC1 FLJ32875 ENSG00000164244 Proline-rich coiled-coil 1 5 127517609-127555089 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039212 Approved Approved Vesicles Breast cancer:9.35e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 53.1 PRRG1 PRGP1 ENSG00000130962 Proline rich Gla (G-carboxyglutamic acid) 1 X 37349275-37457295 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056029, HPA078129 Uncertain Approved Vesicles
Plasma membrane Renal cancer:2.05e-7 (favourable), Pancreatic cancer:1.22e-4 (unfavourable), Cervical cancer:4.65e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.6 PRRG2 PRGP2 ENSG00000126460 Proline rich Gla (G-carboxyglutamic acid) 2 19 49580646-49591015 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010702 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:3.82e-9 (favourable) Expressed in all Mixed parathyroid gland: 28.8 PRRG3 TMG3 ENSG00000130032 Proline rich Gla (G-carboxyglutamic acid) 3 (transmembrane) X 151695124-151705924 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060566 Uncertain Mixed Tissue enhanced cerebral cortex: 8.9 cervix, uterine: 7.5 PRRG4 TMG4 ENSG00000135378 Proline rich Gla (G-carboxyglutamic acid) 4 (transmembrane) 11 32829943-32858123 Predicted membrane proteins Evidence at protein level HPA009040, HPA024566 Uncertain Approved Golgi apparatus Expressed in all Mixed skin: 25.1 PRRT1 C6orf31, IFITMD7, NG5 ENSG00000204314 Proline-rich transmembrane protein 1 6 32148359-32154373 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055149 Approved Mixed Tissue enriched 8 cerebral cortex: 4.5 ovary: 0.6 PRRT2 DKFZp547J199, DSPB3, DYT10, EKD1, FICCA, FLJ25513, ICCA, IFITMD1, PKC ENSG00000167371 Proline-rich transmembrane protein 2 16 29811382-29815892 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014447, HPA019203 Approved Supported Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 92.9 ovary: 51.5 PRRT3 FLJ33674 ENSG00000163704 Proline-rich transmembrane protein 3 3 9945542-9952394 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA035127, HPA035128 Uncertain Approved Nucleus
Plasma membrane
Cytosol Mixed Tissue enhanced cerebral cortex: 19.5;parathyroid gland: 27.5 fallopian tube: 12.3 PRRT4 ENSG00000224940 Proline-rich transmembrane protein 4 7 128350325-128361685 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046373, HPA052681 Uncertain Approved Nucleoplasm
Peroxisomes
Plasma membrane Mixed Group enriched 12 adipose tissue: 15.7;bone marrow: 41.2 cerebral cortex: 2.3 PRSS45 TESSP5 ENSG00000188086 Protease, serine, 45 3 46742092-46812558 Enzymes, Predicted intracellular proteins Evidence at transcript level HPA060284 Uncertain Mixed Tissue enhanced epididymis: 4.1 parathyroid gland: 1.5 PRSS8 ENSG00000052344 Protease, serine, 8 16 31131433-31135762 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA030436, HPA063533 Uncertain Uncertain Cytosol Renal cancer:2.05e-10 (favourable) Mixed Mixed small intestine: 168.0 PRTG FLJ25756, IGDCC5 ENSG00000166450 Protogenin 15 55611546-55743090 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA032138 Uncertain Approved Vesicles
Plasma membrane
Cytosol Mixed Tissue enhanced thyroid gland: 18.2 testis: 6.7 PRUNE2 A214N16.3, bA214N16.3, BMCC1, BNIPXL, C9orf65, KIAA0367 ENSG00000106772 Prune homolog 2 (Drosophila) 9 76611376-76906087 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA022470, HPA031079 Uncertain Renal cancer:1.37e-6 (favourable) Mixed Mixed seminal vesicle: 89.2 PSEN1 AD3, FAD, PS1, S182 ENSG00000080815 Presenilin 1 14 73136418-73223691 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB006844, HPA030760, HPA067496 Approved Approved Nucleus
Golgi apparatus
Cell Junctions Renal cancer:1.52e-8 (favourable), Liver cancer:1.99e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 66.1 PSEN2 AD3L, AD4, PS2, STM2 ENSG00000143801 Presenilin 2 1 226870184-226896105 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB013634, HPA038005 Supported Nucleus Expressed in all Expressed in all parathyroid gland: 29.1 PSENEN PEN2 ENSG00000205155 Presenilin enhancer gamma secretase subunit 19 35745114-35747519 Disease related genes, Predicted membrane proteins Evidence at protein level HPA047435 Approved Renal cancer:8.70e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 369.9 PSG9 PSG11, PSGII ENSG00000183668 Pregnancy specific beta-1-glycoprotein 9 19 43211791-43269530 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA046327 Approved Not detected Tissue enriched 120 placenta: 146.9 smooth muscle: 1.2 PSKH1 ENSG00000159792 Protein serine kinase H1 16 67893272-67929678 Enzymes, Predicted membrane proteins Evidence at protein level HPA053927 Approved Approved Nucleoplasm Renal cancer:4.28e-10 (favourable) Expressed in all Expressed in all parathyroid gland: 48.6 PSKH2 ENSG00000147613 Protein serine kinase H2 8 86048373-86088621 Enzymes, Predicted membrane proteins Evidence at protein level HPA015095 Uncertain Tissue enhanced Not detected testis: 0.4 PSMD1 P112, Rpn2, S1 ENSG00000173692 Proteasome 26S subunit, non-ATPase 1 2 231056864-231172827 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB021092, HPA036736, HPA036737 Approved Approved Nucleoplasm
Actin filaments Liver cancer:8.63e-12 (unfavourable), Lung cancer:2.34e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 200.6 PSMD2 MGC14274, P97, Rpn1, S2, TRAP2 ENSG00000175166 Proteasome 26S subunit, non-ATPase 2 3 184298709-184309054 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045192 Approved Liver cancer:6.63e-7 (unfavourable), Lung cancer:1.55e-4 (unfavourable), Head and neck cancer:9.98e-4 (unfavourable) Expressed in all Expressed in all testis: 163.1 PTAFR ENSG00000169403 Platelet-activating factor receptor 1 28147166-28193936 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA027543 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Expressed in all Tissue enhanced appendix: 42.1 bone marrow: 26.2 PTCH1 BCNS, NBCCS, PTCH ENSG00000185920 Patched 1 9 95442980-95517057 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013717, HPA075072 Uncertain Approved Golgi apparatus Mixed Tissue enhanced cervix, uterine: 41.6 endometrium: 27.2 PTCHD1 FLJ30296 ENSG00000165186 Patched domain containing 1 X 23334015-23404372 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA046110 Uncertain Mixed Tissue enhanced epididymis: 9.6 seminal vesicle: 5.3 PTCHD2 DISP3, KIAA1337 ENSG00000204624 Patched domain containing 2 1 11479166-11537584 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA054579 Uncertain Uncertain Nucleoplasm
Cytosol Tissue enhanced Group enriched 14 cerebral cortex: 8.7;testis: 4.3 adrenal gland: 0.4 PTCHD3 FLJ44037, PTR ENSG00000182077 Patched domain containing 3 10 27398187-27414368 Predicted membrane proteins Evidence at protein level HPA044613 Supported Not detected Tissue enriched 9 testis: 4.1 adipose tissue: 0.4 PTCHD4 C6orf138, dJ402H5.2, FLJ41841 ENSG00000244694 Patched domain containing 4 6 47878028-48068689 Predicted membrane proteins Evidence at transcript level HPA041276 Uncertain Approved Plasma membrane
Cytosol Renal cancer:1.49e-6 (favourable) Group enriched Mixed seminal vesicle: 2.8 PTDSS1 KIAA0024, PSS1, PSSA ENSG00000156471 Phosphatidylserine synthase 1 8 96261715-96336995 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA016852 Uncertain Approved Nucleoplasm
Endoplasmic reticulum Liver cancer:1.08e-5 (unfavourable), Lung cancer:9.83e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 13.9 PTDSS2 PSS2 ENSG00000174915 Phosphatidylserine synthase 2 11 448268-491399 Enzymes, Predicted membrane proteins Evidence at protein level HPA038928, HPA038929 Approved Liver cancer:5.12e-9 (unfavourable) Expressed in all Expressed in all testis: 25.4 PTGDR2 CD294, CRTH2, DP2, GPR44 ENSG00000183134 Prostaglandin D2 receptor 2 11 60850940-60855971 CD markers, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014259 Uncertain Mixed Tissue enhanced small intestine: 7.3;stomach: 7.5 parathyroid gland: 5.3 PTGER3 EP3 ENSG00000050628 Prostaglandin E receptor 3 (subtype EP3) 1 70852353-71047808 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA010689 Uncertain Renal cancer:3.50e-4 (unfavourable) Group enriched Group enriched 7 adipose tissue: 58.5;endometrium: 114.7;kidney: 87.6;smooth muscle: 103.9 skin: 14.0 PTGER4 EP4 ENSG00000171522 Prostaglandin E receptor 4 (subtype EP4) 5 40679498-40693735 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA011226, HPA012756 Approved Urothelial cancer:2.48e-4 (favourable) Expressed in all Expressed in all bone marrow: 48.1 PTGES MGST-IV, MGST1-L1, MGST1L1, PIG12, TP53I12 ENSG00000148344 Prostaglandin E synthase 9 129738331-129753047 Enzymes, Predicted membrane proteins Evidence at protein level HPA045064 Supported Supported Endoplasmic reticulum Pancreatic cancer:7.97e-5 (unfavourable), Colorectal cancer:2.32e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 82.2;seminal vesicle: 118.1 urinary bladder: 37.5 PTGFRN CD315, CD9P-1, EWI-F, FLJ11001, FPRP, KIAA1436, SMAP-6 ENSG00000134247 Prostaglandin F2 receptor inhibitor 1 116910057-116990358 CD markers, Predicted membrane proteins Evidence at protein level HPA017074 Approved Renal cancer:3.98e-4 (unfavourable) Expressed in all Mixed smooth muscle: 68.4 PTGS1 COX1, PGHS-1, PTGHS ENSG00000095303 Prostaglandin-endoperoxide synthase 1 (prostaglandin G/H synthase and cyclooxygenase) 9 122370530-122395703 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA002834, CAB020315 Supported Supported Golgi apparatus
Vesicles Renal cancer:8.68e-4 (unfavourable), Urothelial cancer:9.35e-4 (unfavourable) Expressed in all Tissue enhanced skin: 161.9 esophagus: 85.8 PTH1R PTHR, PTHR1 ENSG00000160801 Parathyroid hormone 1 receptor 3 46877746-46903799 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA007978 Approved Renal cancer:6.79e-6 (favourable) Tissue enhanced Tissue enhanced kidney: 158.5 adrenal gland: 36.8 PTH2R PTHR2 ENSG00000144407 Parathyroid hormone 2 receptor 2 208359714-208854503 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA010655 Approved Tissue enhanced Mixed bone marrow: 2.9 PTK7 CCK4 ENSG00000112655 Protein tyrosine kinase 7 (inactive) 6 43076268-43161719 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA003222 Approved Expressed in all Mixed endometrium: 117.0 PTPMT1 DUSP23, MOSP, PLIP ENSG00000110536 Protein tyrosine phosphatase, mitochondrial 1 11 47565430-47573461 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040348, HPA043932 Approved Supported Mitochondria Liver cancer:3.04e-5 (unfavourable) Expressed in all Expressed in all testis: 89.5 PTPN1 PTP1B ENSG00000196396 Protein tyrosine phosphatase, non-receptor type 1 20 50510321-50585241 Enzymes, Predicted membrane proteins Evidence at protein level CAB009329, HPA012542, CAB015217 Approved Validated Endoplasmic reticulum Expressed in all Expressed in all appendix: 62.0 PTPN2 PTPT, TC-PTP, TCELLPTP, TCPTP ENSG00000175354 Protein tyrosine phosphatase, non-receptor type 2 18 12785478-12929643 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015004, HPA046176 Supported Validated Nucleoplasm Renal cancer:1.20e-8 (unfavourable), Ovarian cancer:1.37e-4 (favourable) Expressed in all Expressed in all lymph node: 53.2 PTPN22 Lyp, Lyp1, Lyp2, PTPN8 ENSG00000134242 Protein tyrosine phosphatase, non-receptor type 22 (lymphoid) 1 113813811-113871759 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA004912, CAB012209, HPA013350 Approved Uncertain Nucleoplasm
Vesicles
Plasma membrane Mixed Tissue enhanced bone marrow: 24.9 lymph node: 23.6 PTPN5 PTPSTEP, STEP ENSG00000110786 Protein tyrosine phosphatase, non-receptor type 5 (striatum-enriched) 11 18727928-18792721 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031014, HPA072091 Supported Approved Endoplasmic reticulum Group enriched Tissue enriched 15 cerebral cortex: 58.9 testis: 3.8 PTPRA HLPR, HPTPA, LRP, PTPA, PTPRL2, RPTPA ENSG00000132670 Protein tyrosine phosphatase, receptor type, A 20 2864184-3039076 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA029412, CAB034366, HPA069480 Approved Approved Nucleus
Vesicles Renal cancer:3.29e-6 (favourable) Expressed in all Expressed in all cerebral cortex: 167.8 PTPRB PTPB ENSG00000127329 Protein tyrosine phosphatase, receptor type, B 12 70515866-70637440 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB004782, HPA067868 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Renal cancer:1.02e-4 (favourable), Liver cancer:6.05e-4 (favourable) Expressed in all Mixed lung: 54.1 PTPRC CD45, GP180, LCA, T200 ENSG00000081237 Protein tyrosine phosphatase, receptor type, C 1 198638671-198757283 Cancer-related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000052, HPA000440, CAB002800, CAB056154, CAB068221 Supported Renal cancer:2.42e-4 (unfavourable) Expressed in all Expressed in all lymph node: 378.0 PTPRCAP CD45-AP, LPAP ENSG00000213402 Protein tyrosine phosphatase, receptor type, C-associated protein 11 67435510-67438067 Predicted secreted proteins Evidence at protein level HPA043734 Supported Not detected Tissue enhanced appendix: 66.5;lymph node: 92.8;spleen: 86.7 tonsil: 30.0 PTPRD HPTP, PTPD ENSG00000153707 Protein tyrosine phosphatase, receptor type, D 9 8314246-10612723 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054829 Uncertain Approved Vesicles Renal cancer:7.45e-6 (favourable) Mixed Tissue enhanced cerebral cortex: 32.5;parathyroid gland: 46.2 ovary: 11.6 PTPRE PTPE ENSG00000132334 Protein tyrosine phosphatase, receptor type, E 10 127907061-128085855 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015870, HPA021872 Supported Approved Intermediate filaments Renal cancer:4.08e-5 (unfavourable) Expressed in all Mixed appendix: 35.7 PTPRF LAR ENSG00000142949 Protein tyrosine phosphatase, receptor type, F 1 43525187-43623666 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012710 Uncertain Approved Golgi apparatus Liver cancer:3.47e-4 (unfavourable), Stomach cancer:7.03e-4 (favourable) Expressed in all Mixed skin: 128.3 PTPRG PTPG, RPTPG ENSG00000144724 Protein tyrosine phosphatase, receptor type, G 3 61561569-62297613 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA064237 Uncertain Renal cancer:3.10e-6 (favourable) Expressed in all Tissue enhanced parathyroid gland: 78.3 thyroid gland: 24.1 PTPRH SAP-1 ENSG00000080031 Protein tyrosine phosphatase, receptor type, H 19 55181248-55209506 Enzymes, Predicted membrane proteins Evidence at protein level HPA042300 Approved Mitochondria Mixed Tissue enhanced duodenum: 70.8;small intestine: 78.5 gallbladder: 38.8 PTPRJ CD148, DEP1, HPTPeta ENSG00000149177 Protein tyrosine phosphatase, receptor type, J 11 47980558-48170841 CD markers, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006026 Approved Renal cancer:1.13e-5 (favourable) Expressed in all Mixed parathyroid gland: 37.8 PTPRK R-PTP-kappa ENSG00000152894 Protein tyrosine phosphatase, receptor type, K 6 127968779-128520674 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054056, HPA054822 Uncertain Supported Vesicles
Plasma membrane
Cell Junctions Renal cancer:9.33e-5 (favourable), Pancreatic cancer:1.99e-4 (unfavourable) Expressed in all Mixed gallbladder: 27.9 PTPRM hR-PTPu, PTPRL1, RPTPU ENSG00000173482 Protein tyrosine phosphatase, receptor type, M 18 7566782-8406861 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003891, CAB022442, CAB022443 Supported Approved Plasma membrane Cervical cancer:8.65e-5 (unfavourable), Urothelial cancer:1.07e-4 (favourable) Expressed in all Mixed thyroid gland: 91.3 PTPRN IA-2 ENSG00000054356 Protein tyrosine phosphatase, receptor type, N 2 219289623-219309648 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007152, HPA007179 Supported Approved Endoplasmic reticulum Glioma:2.45e-7 (unfavourable) Group enriched Tissue enriched 5 cerebral cortex: 183.6 adrenal gland: 35.2 PTPRN2 IA-2beta, ICAAR, KIAA0387, phogrin ENSG00000155093 Protein tyrosine phosphatase, receptor type, N polypeptide 2 7 157539056-158587788 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006900, HPA026656 Approved Uncertain Vesicles
Plasma membrane Glioma:7.72e-5 (unfavourable), Renal cancer:8.68e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 82.5 stomach: 39.0 PTPRO GLEPP1, NPHS6, PTP-oc, PTP-U2, PTPU2 ENSG00000151490 Protein tyrosine phosphatase, receptor type, O 12 15322397-15597399 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA034525 Supported Tissue enhanced Tissue enhanced rectum: 33.5 cerebral cortex: 21.8 PTPRQ DFNB84 ENSG00000139304 Protein tyrosine phosphatase, receptor type, Q 12 80402178-80680234 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053245 Uncertain Approved Cytosol Not detected Tissue enhanced testis: 4.8 lung: 3.4 PTPRR EC-PTP, PCPTP1, PTP-SL, PTPBR7, PTPRQ ENSG00000153233 Protein tyrosine phosphatase, receptor type, R 12 70638073-70920843 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011461, HPA011851, HPA071067 Uncertain Supported Plasma membrane
Cell Junctions
Cytosol Urothelial cancer:1.40e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 20.9 endometrium: 8.9 PTPRS ENSG00000105426 Protein tyrosine phosphatase, receptor type, S 19 5158495-5340803 Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054747 Approved Plasma membrane
Cytosol Pancreatic cancer:1.07e-4 (favourable), Renal cancer:1.70e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 70.8 PTPRT KIAA0283, RPTPrho ENSG00000196090 Protein tyrosine phosphatase, receptor type, T 20 42072752-43189970 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017336, CAB069423 Approved Tissue enhanced Group enriched 5 cerebral cortex: 24.4;fallopian tube: 17.2 placenta: 3.9 PTPRU FMI, hPTP-J, PCP-2, PTP, PTPRO ENSG00000060656 Protein tyrosine phosphatase, receptor type, U 1 29236516-29326813 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011476, HPA039832 Approved Head and neck cancer:8.32e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 27.8 PTPRZ1 phosphacan, PTP18, PTPRZ, PTPZ, RPTPB ENSG00000106278 Protein tyrosine phosphatase, receptor-type, Z polypeptide 1 7 121873089-122062036 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA015103, CAB025106 Supported Approved Vesicles Urothelial cancer:9.36e-4 (unfavourable) Tissue enriched Tissue enriched 9 cerebral cortex: 258.6 skin: 30.2 PTRH2 BIT1, CFAP37, CGI-147, PTH2 ENSG00000141378 Peptidyl-tRNA hydrolase 2 17 59674636-59707626 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA012897 Supported Supported Mitochondria Renal cancer:1.01e-8 (unfavourable), Liver cancer:1.50e-4 (unfavourable) Expressed in all Expressed in all epididymis: 43.1 PTTG1IP C21orf1, C21orf3, PBF ENSG00000183255 Pituitary tumor-transforming 1 interacting protein 21 44849585-44873903 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB034146, HPA061827 Uncertain Supported Nucleoplasm Pancreatic cancer:2.28e-4 (unfavourable), Stomach cancer:5.40e-4 (unfavourable), Cervical cancer:8.61e-4 (unfavourable) Expressed in all Expressed in all placenta: 241.9 PVR CD155, HVED, Necl-5, NECL5, PVS, Tage4 ENSG00000073008 Poliovirus receptor 19 44643798-44663583 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012568 Approved Supported Nucleoplasm
Vesicles
Plasma membrane Cervical cancer:1.29e-4 (unfavourable), Urothelial cancer:2.75e-4 (unfavourable), Lung cancer:9.30e-4 (unfavourable) Expressed in all Expressed in all placenta: 16.9 PVRIG C7orf15, MGC2463 ENSG00000213413 Poliovirus receptor related immunoglobulin domain containing 7 100218241-100221490 Predicted membrane proteins Evidence at transcript level HPA047497 Uncertain Approved Nucleoli
Endoplasmic reticulum Not detected Tissue enhanced lymph node: 20.8;spleen: 11.3 appendix: 8.8 PVRL1 CD111, CLPED1, ED4, HIgR, HVEC, OFC7, PRR, PRR1, PVRR1, SK-12 ENSG00000110400 Poliovirus receptor-related 1 (herpesvirus entry mediator C) 11 119623408-119729084 CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB016135, HPA026846 Approved Expressed in all Tissue enhanced esophagus: 109.0;skin: 162.1 cerebral cortex: 50.5 PVRL2 CD112, HVEB, PRR2, PVRR2 ENSG00000130202 Poliovirus receptor-related 2 (herpesvirus entry mediator B) 19 44846175-44889228 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012759, CAB026138, HPA073459 Supported Uncertain Nucleoli fibrillar center
Cell Junctions Expressed in all Expressed in all placenta: 111.0 PVRL3 CD113, CDw113, DKFZP566B0846, nectin-3, PPR3, PVRR3 ENSG00000177707 Poliovirus receptor-related 3 3 111070071-111275563 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009869, HPA011038 Approved Approved Microtubule organizing center Renal cancer:9.82e-7 (favourable) Expressed in all Tissue enhanced testis: 99.0 thyroid gland: 74.6 PVRL4 LNIR, nectin-4, PRR4 ENSG00000143217 Poliovirus receptor-related 4 1 161070995-161089599 Disease related genes, Predicted membrane proteins Evidence at protein level HPA010775 Supported Supported Plasma membrane Mixed Tissue enhanced esophagus: 46.1;skin: 79.8 placenta: 17.1 PXMP4 PMP24 ENSG00000101417 Peroxisomal membrane protein 4, 24kDa 20 33702754-33720319 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050077 Approved Approved Nucleoli fibrillar center
Peroxisomes Renal cancer:4.03e-10 (favourable), Lung cancer:3.88e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 29.8 PYHIN1 IFIX, MGC23885 ENSG00000163564 Pyrin and HIN domain family, member 1 1 158930796-158977054 Predicted intracellular proteins Evidence at protein level HPA051224 Approved Mixed Tissue enhanced lymph node: 26.7;spleen: 19.5 tonsil: 11.8 QARS ENSG00000172053 Glutaminyl-tRNA synthetase 3 49095932-49105135 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036986, HPA036987 Supported Validated Cytosol Renal cancer:5.60e-6 (favourable), Breast cancer:1.43e-4 (favourable) Expressed in all Expressed in all rectum: 121.1 QPCTL FLJ20084 ENSG00000011478 Glutaminyl-peptide cyclotransferase-like 19 45692483-45703989 Enzymes, Predicted intracellular proteins Evidence at protein level HPA040797 Approved Supported Golgi apparatus Renal cancer:2.15e-8 (unfavourable) Expressed in all Mixed thyroid gland: 8.6 QRFP 26RFa, P518 ENSG00000188710 Pyroglutamylated RFamide peptide 9 130892702-130896812 Predicted secreted proteins Evidence at transcript level HPA043377 Uncertain Mixed Mixed prostate: 1.6 QRFPR GPR103 ENSG00000186867 Pyroglutamylated RFamide peptide receptor 4 121329312-121381059 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA014300 Uncertain Renal cancer:3.09e-4 (favourable) Tissue enriched Not detected heart muscle: 0.6 QSOX1 QSCN6 ENSG00000116260 Quiescin Q6 sulfhydryl oxidase 1 1 180154834-180204030 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042127, HPA056243 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.86e-5 (unfavourable) Expressed in all Expressed in all gallbladder: 234.2 QSOX2 DKFZp762A2013, QSCN6L1, SOXN ENSG00000165661 Quiescin Q6 sulfhydryl oxidase 2 9 136206333-136245841 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012716, HPA017280 Uncertain Validated Nucleoplasm
Golgi apparatus Renal cancer:9.64e-6 (unfavourable) Expressed in all Expressed in all lymph node: 20.9 RABAC1 PRA1, PRAF1, YIP3 ENSG00000105404 Rab acceptor 1 (prenylated) 19 41956681-41959390 Predicted membrane proteins Evidence at protein level CAB019320, HPA029171 Supported Approved Nuclear membrane
Nucleoli fibrillar center Expressed in all Expressed in all cerebral cortex: 107.6 RABGAP1 GAPCenA, TBC1D11 ENSG00000011454 RAB GTPase activating protein 1 9 122940833-123104866 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041651, HPA064860, HPA072273 Approved Validated Cytosol Renal cancer:6.06e-6 (favourable), Breast cancer:8.09e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 66.1 RABGAP1L FLJ38519, HHL, KIAA0471, TBC1D18 ENSG00000152061 RAB GTPase activating protein 1-like 1 174159410-174995308 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054695 Uncertain Approved Nucleoli
Cytosol Lung cancer:1.16e-4 (favourable) Expressed in all Expressed in all heart muscle: 89.1 RAD51B hREC2, R51H2, RAD51L1, REC2 ENSG00000182185 RAD51 paralog B 14 67819779-68730218 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB016191, HPA051869 Supported Approved Nucleoplasm
Nuclear bodies Mixed Mixed epididymis: 11.3 RAET1E bA350J20.7, LETAL, ULBP4 ENSG00000164520 Retinoic acid early transcript 1E 6 149883375-149898102 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054022 Approved Focal adhesion sites
Cytosol Tissue enhanced Tissue enhanced esophagus: 71.1;skin: 29.0 tonsil: 10.8 RAET1G ULBP5 ENSG00000203722 Retinoic acid early transcript 1G 6 149916878-149923121 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062673 Approved Vesicles Lung cancer:5.35e-4 (unfavourable) Mixed Tissue enhanced adrenal gland: 8.3;esophagus: 9.6 skin: 3.4 RALGAPA1 DKFZp667F074, GARNL1, GRIPE, KIAA0884, RalGAPalpha1, Tulip1 ENSG00000174373 Ral GTPase activating protein, alpha subunit 1 (catalytic) 14 35538352-35809304 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000851 Approved Approved Mitochondria
Cytosol Renal cancer:9.76e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 50.5 RALGAPA2 AS250, C20orf74, dJ1049G11.4, KIAA1272, RapGAPalpha2 ENSG00000188559 Ral GTPase activating protein, alpha subunit 2 (catalytic) 20 20389552-20712488 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042707, HPA043622 Uncertain Supported Plasma membrane
Cytosol Renal cancer:3.77e-5 (favourable) Expressed in all Expressed in all thyroid gland: 39.8 RAMP1 ENSG00000132329 Receptor (G protein-coupled) activity modifying protein 1 2 237858893-237912114 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA057814 Approved Nucleoplasm
Nuclear membrane Stomach cancer:1.68e-4 (unfavourable), Liver cancer:7.61e-4 (favourable) Expressed in all Tissue enhanced endometrium: 233.7 smooth muscle: 169.4 RAMP2 ENSG00000131477 Receptor (G protein-coupled) activity modifying protein 2 17 42758447-42763041 FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA052020 Approved Vesicles Expressed in all Mixed lung: 179.1 RAPGEF4 cAMP-GEFII, CGEF2 ENSG00000091428 Rap guanine nucleotide exchange factor (GEF) 4 2 172735274-173052893 Predicted intracellular proteins Evidence at protein level CAB004388, HPA028968 Approved Approved Focal adhesion sites Pancreatic cancer:1.32e-4 (favourable) Mixed Tissue enhanced adrenal gland: 53.6;cerebral cortex: 119.5 liver: 18.2 RAPGEFL1 Link-GEFII ENSG00000108352 Rap guanine nucleotide exchange factor (GEF)-like 1 17 40177010-40195656 Predicted intracellular proteins Evidence at protein level HPA022895 Approved Nucleus
Microtubules
Cytokinetic bridge Renal cancer:0.00e+0 (unfavourable), Cervical cancer:3.28e-4 (favourable), Breast cancer:8.43e-4 (favourable) Expressed in all Tissue enhanced skin: 277.6 esophagus: 93.6 RASSF4 AD037, MGC44914 ENSG00000107551 Ras association (RalGDS/AF-6) domain family member 4 10 44959407-44995891 Predicted intracellular proteins Evidence at protein level HPA038834 Approved Approved Nucleus
Nucleoli
Cell Junctions Expressed in all Expressed in all cerebral cortex: 71.6 RBL2 p130, Rb2 ENSG00000103479 Retinoblastoma-like 2 16 53433977-53491649 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB016547, HPA019703 Supported Approved Nucleus
Nucleoli
Cytosol Renal cancer:3.57e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 158.3 RBM14 COAA, DKFZp779J0927, SIP, SYTIP1 ENSG00000239306 RNA binding motif protein 14 11 66616582-66627347 Predicted intracellular proteins Evidence at protein level HPA006628 Supported Supported Nuclear speckles Liver cancer:2.02e-7 (unfavourable), Pancreatic cancer:1.04e-4 (favourable) Expressed in all Expressed in all testis: 49.9 RC3H2 FLJ20301, FLJ20713, MNAB, RNF164 ENSG00000056586 Ring finger and CCCH-type domains 2 9 122844556-122905341 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA042863 Approved Supported Cytosol Renal cancer:5.50e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 25.0 RCAN2 DSCR1L1, ZAKI-4 ENSG00000172348 Regulator of calcineurin 2 6 46220736-46491972 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053880 Uncertain Approved Nucleoplasm
Mitochondria Renal cancer:1.12e-6 (favourable), Pancreatic cancer:2.48e-4 (favourable) Expressed in all Mixed parathyroid gland: 142.7 RCN3 RLP49 ENSG00000142552 Reticulocalbin 3, EF-hand calcium binding domain 19 49527618-49546962 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043134, HPA050402 Uncertain Approved Endoplasmic reticulum
Vesicles Renal cancer:5.80e-12 (unfavourable) Expressed in all Expressed in all small intestine: 46.0 RDH10 SDR16C4 ENSG00000121039 Retinol dehydrogenase 10 (all-trans) 8 73294612-73325281 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049199 Approved Lipid droplets Expressed in all Expressed in all placenta: 51.3 RDH16 RODH-4, SDR9C8 ENSG00000139547 Retinol dehydrogenase 16 (all-trans) 12 56951431-56959374 Predicted membrane proteins Evidence at protein level HPA038518 Supported Liver cancer:2.16e-5 (favourable) Tissue enriched Tissue enriched 71 liver: 278.4 prostate: 3.9 RDM1 MGC33977, RAD52B ENSG00000278023 RAD52 motif containing 1 17 35918066-35930773 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024794 Supported Nucleoli
Cytosol Mixed Tissue enriched 8 testis: 9.5 lymph node: 1.2 REC8 kleisin-alpha, REC8L1, Rec8p ENSG00000100918 REC8 meiotic recombination protein 14 24171853-24180257 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA031727, HPA031729 Approved Approved Nucleoplasm Renal cancer:1.41e-7 (unfavourable), Breast cancer:2.19e-4 (favourable), Pancreatic cancer:5.57e-4 (favourable) Expressed in all Tissue enhanced fallopian tube: 36.9 testis: 28.8 RECK hRECK, ST15 ENSG00000122707 Reversion-inducing-cysteine-rich protein with kazal motifs 9 36036433-36124451 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025109, HPA071729 Supported Supported Plasma membrane Stomach cancer:7.31e-4 (unfavourable) Expressed in all Mixed endometrium: 21.3 REEP1 C2orf23, FLJ13110, SPG31 ENSG00000068615 Receptor accessory protein 1 2 86213993-86338083 Disease related genes, Predicted membrane proteins Evidence at protein level HPA058061 Approved Mixed Tissue enhanced cerebral cortex: 54.2;testis: 90.8 smooth muscle: 34.1 REEP2 C5orf19, SGC32445, SPG72 ENSG00000132563 Receptor accessory protein 2 5 138439017-138446969 Disease related genes, Predicted membrane proteins Evidence at protein level HPA031813 Supported Breast cancer:7.83e-5 (favourable), Glioma:3.43e-4 (unfavourable), Melanoma:9.31e-4 (favourable) Tissue enriched Tissue enriched 5 cerebral cortex: 90.3 smooth muscle: 17.8 REEP4 C8orf20, FLJ22246, FLJ22277, PP432 ENSG00000168476 Receptor accessory protein 4 8 22138020-22141951 Predicted membrane proteins Evidence at protein level HPA042683 Approved Approved Cytosol Renal cancer:2.88e-5 (unfavourable), Liver cancer:4.14e-5 (unfavourable) Expressed in all Expressed in all skin: 66.5 REEP5 C5orf18, D5S346, DP1, TB2 ENSG00000129625 Receptor accessory protein 5 5 112876379-112922539 Predicted membrane proteins Evidence at protein level HPA003895, HPA069960 Approved Approved Endoplasmic reticulum Endometrial cancer:5.23e-6 (favourable), Renal cancer:2.05e-5 (favourable) Expressed in all Expressed in all thyroid gland: 341.6 REEP6 C19orf32, DP1L1, FLJ25383 ENSG00000115255 Receptor accessory protein 6 19 1490747-1497927 Predicted membrane proteins Evidence at protein level HPA003895, HPA048015 Approved Supported Endoplasmic reticulum Expressed in all Group enriched 8 adrenal gland: 48.4;duodenum: 170.8;liver: 76.3;small intestine: 170.5;testis: 181.6 prostate: 17.0 RELL1 ENSG00000181826 RELT-like 1 4 37590800-37686376 Predicted membrane proteins Evidence at protein level HPA013377 Approved Supported Plasma membrane
Microtubules Expressed in all Mixed thyroid gland: 27.6 RELL2 C5orf16, FLJ90583 ENSG00000164620 RELT-like 2 5 141636950-141641077 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA077928 Uncertain Vesicles Mixed Tissue enhanced cerebral cortex: 13.2;parathyroid gland: 20.4 testis: 4.2 RELT FLJ14993, TNFRSF19L ENSG00000054967 RELT tumor necrosis factor receptor 11 73376264-73397474 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062824, HPA071518 Supported Nucleus Renal cancer:4.07e-11 (unfavourable) Mixed Tissue enriched 5 bone marrow: 96.0 spleen: 17.5 RER1 ENSG00000157916 Retention in endoplasmic reticulum sorting receptor 1 1 2391775-2405444 Predicted membrane proteins, Transporters Evidence at protein level CAB037240, HPA051400 Supported Validated Golgi apparatus Renal cancer:8.23e-8 (unfavourable) Expressed in all Expressed in all testis: 183.8 RET CDHF12, CDHR16, HSCR1, MEN2A, MEN2B, MTC1, PTC, RET51 ENSG00000165731 Ret proto-oncogene 10 43077027-43130351 Cancer-related genes, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002581, HPA008356, HPA008495, CAB018342 Approved Supported Supported Vesicles
Plasma membrane
Cytosol Endometrial cancer:5.02e-4 (unfavourable) Tissue enhanced Tissue enriched 5 parathyroid gland: 146.8 adrenal gland: 29.2 RFT1 CDG1N ENSG00000163933 RFT1 homolog 3 53088483-53130462 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA060327 Approved Vesicles Liver cancer:1.69e-4 (unfavourable) Expressed in all Expressed in all testis: 25.8 RGMB DRAGON, FLJ90406 ENSG00000174136 Repulsive guidance molecule family member b 5 98768650-98798643 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016993 Approved Nucleoplasm Expressed in all Mixed cerebral cortex: 39.4 RGS6 ENSG00000182732 Regulator of G-protein signaling 6 14 71932439-72566529 Predicted intracellular proteins Evidence at protein level HPA003067 Uncertain Group enriched Tissue enhanced cerebral cortex: 17.5;testis: 18.6 thyroid gland: 8.7 RHAG CD241, RH50A, SLC42A1 ENSG00000112077 Rh-associated glycoprotein 6 49605158-49636839 CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA055331 Approved Not detected Tissue enriched 24 bone marrow: 73.8 placenta: 3.0 RHBDD1 DKFZp547E052 ENSG00000144468 Rhomboid domain containing 1 2 226835581-226999215 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013972, HPA057125 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all testis: 32.2 RHBDD2 NPD007, RHBDL7 ENSG00000005486 Rhomboid domain containing 2 7 75842602-75888926 Enzymes, Predicted membrane proteins Evidence at protein level HPA045074, HPA051960 Uncertain Validated Golgi apparatus Renal cancer:8.68e-6 (favourable), Colorectal cancer:3.31e-5 (unfavourable), Glioma:1.25e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 253.1 RHBDD3 C22orf3, PTAG ENSG00000100263 Rhomboid domain containing 3 22 29259852-29268209 Predicted membrane proteins Evidence at protein level HPA043979 Approved Approved Microtubules Endometrial cancer:2.67e-6 (favourable), Renal cancer:2.24e-4 (unfavourable) Expressed in all Mixed testis: 10.5 RHBDF1 C16orf8, Dist1, EGFR-RS, FLJ2235, iRhom1 ENSG00000007384 Rhomboid 5 homolog 1 (Drosophila) 16 58059-76355 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA077399 Uncertain Vesicles Renal cancer:2.49e-5 (unfavourable) Expressed in all Mixed placenta: 39.6 RHBDF2 FLJ22341, iRhom2, RHBDL5, RHBDL6, TOC, TOCG ENSG00000129667 Rhomboid 5 homolog 2 (Drosophila) 17 76470891-76501790 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018080 Uncertain Renal cancer:3.96e-11 (unfavourable) Expressed in all Expressed in all appendix: 51.0 RHBDL1 RHBDL, RRP ENSG00000103269 Rhomboid, veinlet-like 1 (Drosophila) 16 675666-678268 Enzymes, Predicted membrane proteins Evidence at protein level HPA030359, HPA030360, HPA046593 Uncertain Approved Nucleoplasm Breast cancer:8.12e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 8.0 adrenal gland: 3.3 RHBDL2 FLJ20435 ENSG00000158315 Rhomboid, veinlet-like 2 (Drosophila) 1 38885807-38941799 Enzymes, Predicted membrane proteins Evidence at protein level HPA043807 Approved Mixed Mixed rectum: 22.5 RHBDL3 RHBDL4, VRHO ENSG00000141314 Rhomboid, veinlet-like 3 (Drosophila) 17 32266176-32324661 Enzymes, Predicted membrane proteins Evidence at transcript level HPA059607 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 20.7 adrenal gland: 5.5 RHBG SLC42A2 ENSG00000132677 Rh family, B glycoprotein (gene/pseudogene) 1 156369212-156385219 Predicted membrane proteins, Transporters Evidence at protein level HPA042726, HPA048489 Approved Approved Nucleoplasm Urothelial cancer:8.06e-4 (favourable) Group enriched Tissue enhanced kidney: 3.5;ovary: 2.0 esophagus,liver: 0.6 RHCG C15orf6, PDRC2, RHGK, SLC42A3 ENSG00000140519 Rh family, C glycoprotein 15 89471398-89496613 Predicted membrane proteins, Transporters Evidence at protein level HPA041874, HPA043317 Supported Lung cancer:3.80e-4 (unfavourable) Tissue enhanced Tissue enriched 7 esophagus: 2912.7 tonsil: 436.1 RHO CSNBAD1, OPN2, RP4 ENSG00000163914 Rhodopsin 3 129528640-129535169 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA013440, CAB022486 Supported Not detected Not detected cerebral cortex: 0.3 RHOT1 ARHT1, FLJ11040, MIRO-1 ENSG00000126858 Ras homolog family member T1 17 32142454-32253374 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010687, CAB068223, CAB068224 Supported Expressed in all Expressed in all parathyroid gland: 47.9 RHOT2 ARHT2, C16orf39, MIRO-2 ENSG00000140983 Ras homolog family member T2 16 668086-674174 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012624, HPA012895 Approved Supported Cytosol Head and neck cancer:5.01e-4 (favourable), Renal cancer:5.43e-4 (favourable) Expressed in all Expressed in all spleen: 31.7 RIC1 bA207C16.1, KIAA1432 ENSG00000107036 RIC1 homolog, RAB6A GEF complex partner 1 9 5629025-5776557 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051578 Supported Expressed in all Expressed in all parathyroid gland: 22.1 RIC3 AYST720, FLJ11608, PRO1385 ENSG00000166405 RIC3 acetylcholine receptor chaperone 11 8106093-8169055 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065016 Approved Mixed Mixed parathyroid gland: 27.9 RIF1 FLJ10599, FLJ12870 ENSG00000080345 Replication timing regulatory factor 1 2 151409883-151508013 Predicted intracellular proteins Evidence at protein level HPA036887, HPA036888 Supported Uncertain Nucleus
Nuclear bodies
Plasma membrane Expressed in all Expressed in all testis: 21.1 RMDN2 FAM82A, FAM82A1, FLJ32954, RMD2 ENSG00000115841 Regulator of microtubule dynamics 2 2 37923187-38067142 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034705, HPA034706 Approved Supported Cytosol Lung cancer:2.63e-4 (favourable) Mixed Expressed in all adrenal gland: 69.2 RMDN3 FAM82A2, FAM82C, FLJ10579, PTPIP51, RMD3 ENSG00000137824 Regulator of microtubule dynamics 3 15 40735884-40755851 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009975 Supported Validated Mitochondria Renal cancer:6.70e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 58.3 RMND1 bA351K16.3, C6orf96, FLJ20627, RMD1 ENSG00000155906 Required for meiotic nuclear division 1 homolog 6 151404763-151452181 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031397, HPA031398, HPA031399 Approved Supported Mitochondria Head and neck cancer:6.96e-4 (unfavourable) Expressed in all Expressed in all kidney: 43.8 RNASE10 RAH1, RNASE9 ENSG00000182545 Ribonuclease, RNase A family, 10 (non-active) 14 20505537-20511169 Predicted intracellular proteins, Predicted secreted proteins Evidence at transcript level HPA052593 Uncertain Group enriched Mixed testis: 4.1 RNASEK MGC71993 ENSG00000219200 Ribonuclease, RNase K 17 7012417-7014532 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA044708 Uncertain Pancreatic cancer:1.92e-4 (favourable) Expressed in all Expressed in all adrenal gland: 470.3 RNASEK-C17orf49 ENSG00000161939 RNASEK-C17orf49 readthrough 17 7012635-7017520 Predicted membrane proteins Evidence at protein level HPA022961, HPA024457 Approved Uncertain Nucleoplasm
Cytosol Not detected Tissue enhanced testis: 1.0 endometrium,small intestine: 0.9 RNF103 hkf-1, KF1, ZFP103 ENSG00000239305 Ring finger protein 103 2 86603393-86623866 Predicted membrane proteins Evidence at protein level HPA057922 Approved Urothelial cancer:6.77e-5 (favourable) Expressed in all Expressed in all epididymis: 54.2 RNF121 FLJ11099 ENSG00000137522 Ring finger protein 121 11 71928701-71997597 Predicted membrane proteins Evidence at protein level HPA046041 Uncertain Approved Nucleus
Golgi apparatus
Vesicles Renal cancer:2.72e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 27.9 RNF122 FLJ12526 ENSG00000133874 Ring finger protein 122 8 33547755-33567125 Predicted membrane proteins Evidence at transcript level HPA003888 Uncertain Renal cancer:4.50e-7 (unfavourable), Thyroid cancer:1.88e-4 (unfavourable), Prostate cancer:5.37e-4 (favourable) Expressed in all Expressed in all fallopian tube: 21.4 RNF128 FLJ23516, GRAIL ENSG00000133135 Ring finger protein 128, E3 ubiquitin protein ligase X 106693794-106796993 Predicted membrane proteins Evidence at protein level HPA019675 Uncertain Renal cancer:1.07e-7 (unfavourable) Mixed Mixed small intestine: 68.3 RNF13 RZF ENSG00000082996 Ring finger protein 13 3 149812708-149962139 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA064784 Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:2.00e-8 (favourable) Expressed in all Expressed in all thyroid gland: 94.0 RNF130 G1RZFP, GOLIATH, GP ENSG00000113269 Ring finger protein 130 5 179911651-180072118 Predicted membrane proteins Evidence at protein level HPA014499 Approved Cervical cancer:6.32e-4 (favourable) Expressed in all Expressed in all adipose tissue: 74.3 RNF139 HRCA1, RCA1, TRC8 ENSG00000170881 Ring finger protein 139 8 124474738-124487914 Disease related genes, Predicted membrane proteins Evidence at protein level HPA001202 Approved Pancreatic cancer:3.54e-4 (unfavourable) Expressed in all Expressed in all testis: 114.1 RNF144A KIAA0161, RNF144, UBCE7IP4 ENSG00000151692 Ring finger protein 144A 2 6917392-7068286 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049939 Approved Approved Vesicles Stomach cancer:7.32e-5 (unfavourable), Endometrial cancer:6.00e-4 (unfavourable), Head and neck cancer:6.96e-4 (favourable) Expressed in all Mixed endometrium: 42.8 RNF144B bA528A10.3, IBRDC2 ENSG00000137393 Ring finger protein 144B 6 18387350-18468874 Predicted membrane proteins Evidence at protein level CAB046013, HPA054127, HPA072469 Uncertain Approved Nucleoli
Mitochondria Expressed in all Tissue enhanced thyroid gland: 67.9 breast: 34.9 RNF145 FLJ31951 ENSG00000145860 Ring finger protein 145 5 159157409-159210053 Predicted membrane proteins Evidence at protein level HPA036562 Uncertain Approved Nucleoplasm
Plasma membrane
Cytosol Liver cancer:1.64e-6 (unfavourable) Expressed in all Expressed in all lung: 109.1 RNF149 FLJ90504 ENSG00000163162 Ring finger protein 149 2 101271219-101308701 Predicted membrane proteins Evidence at protein level HPA011424 Approved Approved Vesicles
Plasma membrane Renal cancer:2.04e-8 (unfavourable), Urothelial cancer:2.91e-4 (favourable) Expressed in all Expressed in all appendix: 69.4 RNF150 KIAA1214 ENSG00000170153 Ring finger protein 150 4 140859807-141212877 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA037987 Uncertain Breast cancer:1.41e-4 (favourable) Mixed Mixed endometrium: 21.2 RNF165 ARKL2, RNF111L2 ENSG00000141622 Ring finger protein 165 18 46326809-46463140 Predicted intracellular proteins Evidence at protein level HPA041615, HPA047798 Uncertain Approved Nucleus
Plasma membrane Mixed Tissue enhanced cerebral cortex: 9.3;parathyroid gland: 9.6 thyroid gland: 6.9 RNF167 DKFZP566H073 ENSG00000108523 Ring finger protein 167 17 4940008-4945222 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049810 Approved Approved Cytosol Pancreatic cancer:2.03e-6 (favourable), Renal cancer:4.47e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 114.7 RNF170 ADSA, DKFZP564A022, SNAX1 ENSG00000120925 Ring finger protein 170 8 42849637-42897290 Disease related genes, Predicted membrane proteins Evidence at protein level HPA050931, HPA054621 Uncertain Expressed in all Expressed in all thyroid gland: 47.6 RNF175 FLJ34190 ENSG00000145428 Ring finger protein 175 4 153710125-153760235 Predicted membrane proteins Evidence at protein level HPA035837 Uncertain Glioma:4.15e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 13.2 seminal vesicle: 4.8 RNF180 ENSG00000164197 Ring finger protein 180 5 64165844-64372869 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006897 Approved Approved Cytosol Renal cancer:6.81e-5 (favourable) Tissue enhanced Tissue enhanced parathyroid gland: 62.3 thyroid gland: 24.9 RNF182 MGC33993 ENSG00000180537 Ring finger protein 182 6 13924446-13980302 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012309 Approved Approved Nucleus
Golgi apparatus
Vesicles Endometrial cancer:4.66e-5 (unfavourable) Mixed Tissue enhanced cerebral cortex: 14.6 testis: 6.8 RNF183 MGC4734 ENSG00000165188 Ring finger protein 183 9 113297093-113303376 Predicted membrane proteins Evidence at protein level HPA057675 Uncertain Endometrial cancer:7.95e-6 (favourable), Renal cancer:3.51e-4 (favourable) Tissue enhanced Tissue enhanced epididymis: 19.6;gallbladder: 9.0 kidney: 4.3 RNF186 FLJ20225 ENSG00000178828 Ring finger protein 186 1 19814029-19815278 Predicted membrane proteins Evidence at protein level HPA034547, HPA035558 Supported Tissue enhanced Tissue enhanced duodenum: 136.0;epididymis: 82.8;small intestine: 47.7 kidney: 26.4 RNF19A DKFZp566B1346, dorfin, RNF19 ENSG00000034677 Ring finger protein 19A, RBR E3 ubiquitin protein ligase 8 100257059-100410015 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB011455, HPA023652 Approved Urothelial cancer:3.28e-5 (favourable), Renal cancer:7.99e-5 (unfavourable) Expressed in all Expressed in all testis: 98.8 RNF19B FLJ90005, IBRDC3 ENSG00000116514 Ring finger protein 19B 1 32936445-32964685 Predicted membrane proteins Evidence at protein level HPA049587 Approved Approved Cytosol Liver cancer:5.41e-6 (unfavourable), Renal cancer:4.39e-5 (favourable), Head and neck cancer:3.39e-4 (favourable) Expressed in all Expressed in all testis: 154.8 RNF213 C17orf27, KIAA1554, KIAA1618, MYMY2, NET57 ENSG00000173821 Ring finger protein 213 17 80260866-80398786 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003347, HPA026790 Approved Supported Cytosol Endometrial cancer:4.65e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 66.8 RNF215 ENSG00000099999 Ring finger protein 215 22 30368811-30421771 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019262, HPA056498 Approved Approved Nucleoli
Microtubules Renal cancer:6.37e-10 (unfavourable) Expressed in all Expressed in all cerebral cortex: 19.3 RNF217 C6orf172, dJ84N20.1, IBRDC1, MGC26996 ENSG00000146373 Ring finger protein 217 6 124962545-125092633 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029598 Uncertain Renal cancer:4.60e-5 (unfavourable), Urothelial cancer:1.92e-4 (unfavourable) Expressed in all Tissue enriched 8 parathyroid gland: 94.6 testis: 12.4 RNF222 ENSG00000189051 Ring finger protein 222 17 8390704-8397826 Predicted membrane proteins Evidence at transcript level HPA048916 Uncertain Tissue enhanced Group enriched 6 esophagus: 9.8;skin: 4.2;tonsil: 2.2 bone marrow: 0.9 RNF24 G1L ENSG00000101236 Ring finger protein 24 20 3927309-4015582 Predicted membrane proteins Evidence at protein level HPA011900 Approved Supported Golgi apparatus Renal cancer:2.67e-7 (unfavourable), Liver cancer:3.81e-5 (unfavourable) Expressed in all Mixed bone marrow: 34.3 RNF26 MGC2642 ENSG00000173456 Ring finger protein 26 11 119334527-119337313 Predicted membrane proteins Evidence at transcript level HPA027620 Uncertain Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:3.45e-6 (favourable), Liver cancer:3.19e-4 (unfavourable), Urothelial cancer:7.73e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 33.3 RNF34 FLJ21786, RIF, RIFF ENSG00000170633 Ring finger protein 34, E3 ubiquitin protein ligase 12 121400041-121430623 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA074151 Supported Nucleoplasm
Nuclear bodies Liver cancer:6.72e-8 (unfavourable), Urothelial cancer:3.02e-4 (favourable), Renal cancer:4.63e-4 (unfavourable) Expressed in all Expressed in all testis: 45.8 RNF43 DKFZp781H0392, FLJ20315, URCC ENSG00000108375 Ring finger protein 43 17 58352500-58417595 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA008079 Uncertain Renal cancer:6.04e-9 (favourable) Tissue enhanced Mixed duodenum: 24.1 RNF5 G16, NG2, RING5, RMA1 ENSG00000204308 Ring finger protein 5, E3 ubiquitin protein ligase 6 32178354-32180793 Predicted membrane proteins Evidence at protein level CAB034107, HPA065032 Uncertain Supported Endoplasmic reticulum Ovarian cancer:2.44e-4 (favourable) Expressed in all Mixed kidney: 18.5 RNFT1 PTD016 ENSG00000189050 Ring finger protein, transmembrane 1 17 59952240-59964761 Predicted membrane proteins Evidence at protein level HPA013739 Approved Nucleoli Thyroid cancer:2.57e-4 (favourable), Colorectal cancer:6.57e-4 (favourable), Lung cancer:7.48e-4 (favourable) Expressed in all Tissue enriched 9 testis: 113.2 epididymis: 12.3 RNFT2 FLJ14627, TMEM118 ENSG00000135119 Ring finger protein, transmembrane 2 12 116738178-116853631 Predicted membrane proteins Evidence at protein level HPA064161 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced cerebral cortex: 15.4 testis: 6.1 ROBO1 DUTT1, FLJ21882, SAX3 ENSG00000169855 Roundabout guidance receptor 1 3 78597240-79767815 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013524, HPA052968 Uncertain Supported Plasma membrane Liver cancer:9.88e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 33.0 ROBO2 KIAA1568 ENSG00000185008 Roundabout guidance receptor 2 3 75906695-77649964 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013371 Approved Approved Nucleus
Microtubule organizing center Tissue enhanced Tissue enhanced cerebral cortex: 33.9 lung: 15.2 ROBO4 ECSM4, FLJ20798, MRB ENSG00000154133 Roundabout guidance receptor 4 11 124883691-124898500 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA065212 Approved Plasma membrane Liver cancer:4.85e-4 (favourable), Stomach cancer:8.73e-4 (unfavourable) Expressed in all Tissue enhanced spleen: 59.1 adipose tissue: 45.0 ROM1 ROM, TSPAN23 ENSG00000149489 Retinal outer segment membrane protein 1 11 62611722-62615120 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028910 Supported Approved Plasma membrane
Cytosol Renal cancer:2.85e-6 (unfavourable), Lung cancer:2.20e-4 (favourable) Tissue enriched Tissue enhanced cerebral cortex: 25.5 ovary: 13.2 ROMO1 bA353C18.2, C20orf52, MTGMP ENSG00000125995 Reactive oxygen species modulator 1 20 35699272-35700984 Predicted intracellular proteins, Transporters Evidence at protein level HPA012782 Uncertain Expressed in all Expressed in all adrenal gland: 121.3 ROR1 NTRKR1 ENSG00000185483 Receptor tyrosine kinase-like orphan receptor 1 1 63774022-64181498 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA057016 Uncertain Microtubules
Cytokinetic bridge Mixed Tissue enhanced parathyroid gland: 51.2 endometrium: 12.1 ROR2 BDB, BDB1, NTRKR2 ENSG00000169071 Receptor tyrosine kinase-like orphan receptor 2 9 91563091-91950162 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA021868 Uncertain Thyroid cancer:4.28e-8 (unfavourable), Renal cancer:9.86e-7 (unfavourable) Mixed Tissue enhanced parathyroid gland: 34.5 endometrium: 21.3 ROS1 c-ros-1, MCF3, ROS ENSG00000047936 ROS proto-oncogene 1 , receptor tyrosine kinase 6 117288300-117425855 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049098, HPA072424 Uncertain Approved Vesicles Tissue enriched Group enriched 18 epididymis: 69.7;lung: 47.3 seminal vesicle: 3.2 RP11-1035H13.3 ENSG00000260342 16 18788063-18801519 Predicted membrane proteins Evidence at transcript level HPA045307 Uncertain Approved Endoplasmic reticulum Mixed Tissue enhanced testis: 25.7 cerebral cortex: 7.2 RP11-108O10.8 ENSG00000258529 11 111786286-111879425 Predicted membrane proteins Evidence at protein level HPA038575 Uncertain Approved Endoplasmic reticulum Not detected Tissue enhanced testis: 1.7 skin: 0.9 RP11-1212A22.4 ENSG00000233024 16 18358086-18379331 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Uncertain Nucleoplasm Not detected Expressed in all parathyroid gland: 129.0 RP11-166B2.1 ENSG00000234719 Putative NPIP-like protein LOC729978 16 11927373-11976643 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Supported Approved Nucleoplasm Mixed Tissue enhanced testis: 15.4 parathyroid gland: 8.9 RP11-231C14.4 ENSG00000169203 16 29483642-29505999 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Uncertain Nucleoplasm Not detected Expressed in all skin: 135.7 RP11-277P12.6 ENSG00000255641 12 10412312-10436001 Predicted membrane proteins Evidence at transcript level HPA062570 Uncertain Not detected Group enriched 7 cerebral cortex: 8.2;spleen: 6.2 bone marrow: 1.0 RP11-294C11.1 ENSG00000182974 Olfactory receptor 4M2 15 21637909-21638992 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA058889 Uncertain Not detected Tissue enriched 24 testis: 2.3 all non-specific tissues: 0.0 RP11-294C11.3 ENSG00000279408 15 21651844-21653039 Predicted membrane proteins Evidence at transcript level HPA057442 Uncertain Uncertain Centrosome Not detected Tissue enriched 17 testis: 14.6 cerebral cortex: 0.8 RP11-347C12.1 ENSG00000198064 Putative NPIP-like protein LOC613037 16 30222937-30254510 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053611 Approved Approved Nucleoplasm Not detected Mixed skin: 9.1 RP11-407N17.3 ENSG00000258941 14 39233902-39350423 Predicted membrane proteins Evidence at protein level HPA000387, HPA000922, HPA054066, HPA055459 Uncertain Approved Endoplasmic reticulum Not detected Group enriched 5 duodenum: 16.1;kidney: 10.3;liver: 13.3;parathyroid gland: 21.0;small intestine: 19.1 gallbladder: 3.0 RP11-468E2.1 ENSG00000254692 14 24189157-24213473 Predicted membrane proteins Evidence at protein level HPA059249 Approved Approved Golgi apparatus Not detected Expressed in all parathyroid gland: 53.3 RP11-545J16.1 ENSG00000257046 12 20815674-21090245 Predicted membrane proteins Evidence at transcript level HPA050892 Uncertain Not detected Tissue enriched 13 breast: 26.4 liver: 2.0 RP11-566K11.2 ENSG00000198211 16 89919165-89936092 Predicted membrane proteins Evidence at protein level CAB011512, HPA043640, HPA046280 Uncertain Validated Microtubules Not detected Tissue enhanced skin: 1.1 testis: 0.7 RP11-77K12.1 ENSG00000261717 16 75412684-75464706 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA041316, HPA055071 Uncertain Not detected Not detected parathyroid gland,testis: 0.8 RP11-872D17.8 ENSG00000254979 11 57387365-57424059 Predicted membrane proteins Evidence at protein level HPA038515 Supported Mixed Tissue enhanced bone marrow: 7.8;placenta: 10.5 skin: 5.8 RP5-877J2.1 ENSG00000250424 7 30852273-30923812 Predicted membrane proteins Evidence at protein level HPA019206, HPA030130 Approved Approved Plasma membrane Not detected Tissue enhanced gallbladder: 1.3 fallopian tube: 1.0 RP5-972B16.2 ENSG00000250349 X 37349330-38687674 Predicted membrane proteins Evidence at protein level HPA003140 Uncertain Not detected Not detected skeletal muscle: 0.9 RPAP1 DKFZP727M111, FLJ12732, KIAA1403, MGC858 ENSG00000103932 RNA polymerase II associated protein 1 15 41517176-41544269 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041739 Approved Approved Nucleoplasm
Cytosol Thyroid cancer:9.32e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 13.1 RPAP2 C1orf82, FLJ13150, Rtr1 ENSG00000122484 RNA polymerase II associated protein 2 1 92298965-92402056 Enzymes, Predicted membrane proteins Evidence at protein level HPA046443 Approved Supported Nucleoli
Cytosol Expressed in all Mixed epididymis: 6.0 RPLP1 LP1 ENSG00000137818 Ribosomal protein, large, P1 15 69452784-69456194 Plasma proteins, Predicted intracellular proteins, Ribosomal proteins Evidence at protein level HPA003368 Uncertain Validated Endoplasmic reticulum
Cytosol Renal cancer:2.30e-9 (unfavourable) Expressed in all Expressed in all ovary: 1839.8 RPN1 OST1 ENSG00000163902 Ribophorin I 3 128619970-128681075 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB009748, HPA026828, HPA051520 Supported Validated Endoplasmic reticulum Liver cancer:4.80e-4 (unfavourable) Expressed in all Expressed in all epididymis: 416.3 RPN2 RIBIIR, RPN-II, RPNII, SWP1 ENSG00000118705 Ribophorin II 20 37178410-37241623 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008297, CAB019277, HPA025922 Supported Supported Endoplasmic reticulum Renal cancer:1.44e-10 (unfavourable), Liver cancer:1.38e-4 (unfavourable), Urothelial cancer:2.44e-4 (unfavourable) Expressed in all Expressed in all epididymis: 358.1 RPRML MGC43894 ENSG00000179673 Reprimo-like 17 46978156-46979248 Predicted membrane proteins Evidence at transcript level HPA062668 Uncertain Tissue enhanced Tissue enriched 11 cerebral cortex: 8.4 epididymis: 0.7 RPS27L ENSG00000185088 Ribosomal protein S27-like 15 63125872-63158021 Predicted intracellular proteins, Predicted secreted proteins, Ribosomal proteins Evidence at protein level HPA066851 Supported Nucleoli
Endoplasmic reticulum
Cytosol Endometrial cancer:9.08e-6 (favourable) Expressed in all Expressed in all adrenal gland: 223.3 RPTOR KIAA1303, KOG1, Mip1, raptor ENSG00000141564 Regulatory associated protein of MTOR, complex 1 17 80544819-80966371 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013514, HPA064306 Approved Validated Nucleoplasm
Lysosomes
Cytosol Expressed in all Mixed cerebral cortex: 11.2 RRBP1 ES/130, hES ENSG00000125844 Ribosome binding protein 1 20 17613678-17682295 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009026, HPA011924 Supported Validated Endoplasmic reticulum Endometrial cancer:1.41e-4 (favourable), Urothelial cancer:9.38e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 219.5 RRM2 ENSG00000171848 Ribonucleotide reductase M2 2 10122328-10131419 Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056994 Approved Supported Cytosol Renal cancer:0.00e+0 (unfavourable), Liver cancer:1.39e-5 (unfavourable), Pancreatic cancer:1.62e-4 (unfavourable) Expressed in all Mixed lymph node: 47.8 RRM2B p53R2 ENSG00000048392 Ribonucleotide reductase M2 B (TP53 inducible) 8 102204502-102239118 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB006854, HPA028812 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all parathyroid gland: 73.7 RRNAD1 C1orf66, CGI-41 ENSG00000143303 Ribosomal RNA adenine dimethylase domain containing 1 1 156728442-156736960 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA047426 Approved Approved Nucleoli
Cytosol Colorectal cancer:5.60e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 49.0 RRP12 KIAA0690 ENSG00000052749 Ribosomal RNA processing 12 homolog 10 97356358-97426076 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049945 Supported Nucleoli Liver cancer:3.12e-8 (unfavourable), Renal cancer:2.54e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 58.3 RSAD2 cig5, vig1, viperin ENSG00000134321 Radical S-adenosyl methionine domain containing 2 2 6865806-6898239 Predicted intracellular proteins Evidence at protein level HPA041160, HPA049409 Approved Supported Nucleoli fibrillar center
Endoplasmic reticulum Endometrial cancer:4.60e-4 (unfavourable) Expressed in all Mixed spleen: 18.0 RSPO3 FLJ14440, THSD2 ENSG00000146374 R-spondin 3 6 127118604-127197765 Cancer-related genes, Predicted secreted proteins Evidence at protein level HPA029957 Approved Mixed Tissue enhanced endometrium: 102.8;smooth muscle: 102.3 placenta: 72.8 RTL1 Mar1, MART1, PEG11 ENSG00000254656 Retrotransposon-like 1 14 100880655-100884847 Predicted membrane proteins Evidence at protein level HPA066979 Approved Cytosol Tissue enhanced Group enriched 10 adrenal gland: 2.4;placenta: 4.8 cerebral cortex,testis: 0.3 RTN1 NSP ENSG00000139970 Reticulon 1 14 59595976-59870966 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002745, HPA040945, HPA044249 Supported Validated Endoplasmic reticulum Pancreatic cancer:3.69e-4 (favourable) Tissue enhanced Tissue enriched 8 cerebral cortex: 412.9 parathyroid gland: 48.8 RTN2 NSP2, NSPL1, SPG12 ENSG00000125744 Reticulon 2 19 45485289-45497061 Disease related genes, Predicted membrane proteins Evidence at protein level HPA034941, HPA034948 Approved Approved Nuclear speckles Renal cancer:5.58e-6 (unfavourable) Expressed in all Tissue enriched 6 skeletal muscle: 175.3 placenta: 27.3 RTN3 ASYIP, HAP, NSPL2, NSPLII, RTN3-A1 ENSG00000133318 Reticulon 3 11 63681446-63759891 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015649, HPA015650 Supported Supported Endoplasmic reticulum Liver cancer:1.30e-6 (unfavourable), Renal cancer:9.87e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 1033.6 RTN4 ASY, KIAA0886, NOGO, NSP-CL ENSG00000115310 Reticulon 4 2 54972187-55112621 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB005388, HPA023977 Supported Validated Endoplasmic reticulum Head and neck cancer:1.00e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 638.6 RTP2 MGC78665, Z3CXXC2 ENSG00000198471 Receptor (chemosensory) transporter protein 2 3 187698259-187702557 Predicted membrane proteins Evidence at protein level HPA026875 Uncertain Not detected Tissue enhanced testis: 1.0 skeletal muscle: 0.5 RTP3 LTM1, TMEM7, Z3CXXC3 ENSG00000163825 Receptor (chemosensory) transporter protein 3 3 46497491-46500949 Predicted membrane proteins Evidence at protein level HPA075932 Uncertain Mitochondria Liver cancer:3.11e-6 (favourable) Group enriched Tissue enriched 24 liver: 33.7 testis: 1.4 RTP4 IFRG28, Z3CXXC4 ENSG00000136514 Receptor (chemosensory) transporter protein 4 3 187368332-187372076 Predicted membrane proteins Evidence at protein level HPA064887, HPA071189 Uncertain Supported Nucleus Urothelial cancer:1.45e-4 (favourable), Thyroid cancer:4.35e-4 (favourable), Pancreatic cancer:6.83e-4 (unfavourable) Expressed in all Mixed fallopian tube: 16.5 RTP5 C2orf85, CXXC11, FLJ33590, Z3CXXC5 ENSG00000188011 Receptor (chemosensory) transporter protein 5 (putative) 2 241869600-241873823 Predicted membrane proteins Evidence at protein level HPA050902 Uncertain Tissue enriched Tissue enriched 9 cerebral cortex: 5.3 lymph node: 0.5 RUFY2 FLJ10063, KIAA1537, RABIP4R, ZFYVE13 ENSG00000204130 RUN and FYVE domain containing 2 10 68341107-68407294 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039792 Approved Approved Nucleoplasm Expressed in all Expressed in all cerebral cortex: 36.9 RXFP1 LGR7, RXFPR1 ENSG00000171509 Relaxin/insulin-like family peptide receptor 1 4 158315311-158653372 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA027067 Approved Tissue enriched Tissue enhanced cerebral cortex: 21.7;endometrium: 10.1 adrenal gland: 5.7 RXFP3 GPCR135, RLN3R1, RXFPR3, SALPR ENSG00000182631 Relaxin/insulin-like family peptide receptor 3 5 33936386-33938237 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA027833 Uncertain Not detected Not detected adrenal gland: 0.3 RYK D3S3195, JTK5, JTK5A, RYK1 ENSG00000163785 Receptor-like tyrosine kinase 3 134065303-134250744 Predicted membrane proteins Evidence at protein level CAB034117, HPA045503 Uncertain Approved Nucleus
Nucleoli fibrillar center Liver cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all ovary: 100.7 RYR1 CCO, MHS, MHS1, PPP1R137, RYR ENSG00000196218 Ryanodine receptor 1 (skeletal) 19 38433699-38587564 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA056416 Supported Approved Golgi apparatus
Vesicles
Cytosol Mixed Tissue enriched 30 skeletal muscle: 572.4 esophagus: 18.7 RYR2 ARVC2, ARVD2, VTSIP ENSG00000198626 Ryanodine receptor 2 (cardiac) 1 237042205-237833988 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020028 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Mixed Tissue enriched 9 heart muscle: 68.2 cerebral cortex: 8.0 RYR3 ENSG00000198838 Ryanodine receptor 3 15 33310945-33866121 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA062004 Uncertain Vesicles Tissue enhanced Tissue enhanced parathyroid gland: 44.5 skeletal muscle: 13.3 S100A10 42C, ANX2LG, CAL1L, CLP11, P11 ENSG00000197747 S100 calcium binding protein A10 1 151982915-151994390 Predicted membrane proteins Evidence at protein level HPA003340, CAB025484 Supported Approved Mitochondria Renal cancer:3.80e-8 (unfavourable), Lung cancer:2.66e-5 (unfavourable), Liver cancer:1.00e-4 (unfavourable), Head and neck cancer:3.33e-4 (unfavourable), Urothelial cancer:3.84e-4 (unfavourable), Pancreatic cancer:3.88e-4 (unfavourable) Expressed in all Expressed in all esophagus: 978.3 S1PR1 CD363, D1S3362, edg-1, EDG1 ENSG00000170989 Sphingosine-1-phosphate receptor 1 1 101236888-101241518 Cancer-related genes, CD markers, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level CAB010104, HPA075568 Supported Supported Vesicles Urothelial cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 86.5 S1PR2 AGR16, EDG5, Gpcr13, H218 ENSG00000267534 Sphingosine-1-phosphate receptor 2 19 10221435-10231272 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA014307 Approved Renal cancer:4.36e-10 (unfavourable) Expressed in all Tissue enhanced placenta: 26.9 lymph node: 13.5 S1PR4 EDG6 ENSG00000125910 Sphingosine-1-phosphate receptor 4 19 3172346-3180332 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA060601, HPA067232 Uncertain Mitochondria Head and neck cancer:1.45e-6 (favourable), Cervical cancer:1.33e-4 (favourable), Endometrial cancer:2.22e-4 (favourable), Renal cancer:2.87e-4 (unfavourable), Breast cancer:3.13e-4 (favourable) Expressed in all Tissue enhanced lymph node: 18.3;spleen: 27.0 appendix: 14.5 S1PR5 Edg-8, EDG8 ENSG00000180739 Sphingosine-1-phosphate receptor 5 19 10512742-10517931 FDA approved drug targets, G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029683 Supported Renal cancer:6.71e-7 (unfavourable) Group enriched Tissue enhanced cerebral cortex: 14.9;skin: 22.1 spleen: 12.2 SACM1L KIAA0851, SAC1 ENSG00000211456 SAC1 suppressor of actin mutations 1-like (yeast) 3 45689056-45745424 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039573, HPA069869 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:5.47e-7 (favourable) Expressed in all Expressed in all thyroid gland: 67.2 SAMD5 dJ875H10.1 ENSG00000203727 Sterile alpha motif domain containing 5 6 147508927-147737547 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA067811 Uncertain Supported Vesicles Liver cancer:2.23e-4 (unfavourable) Mixed Tissue enhanced parathyroid gland: 22.2 placenta: 18.0 SAMD8 FLJ25082, SMSr ENSG00000156671 Sterile alpha motif domain containing 8 10 75099586-75182123 Predicted membrane proteins Evidence at protein level HPA044402 Supported Endoplasmic reticulum Expressed in all Expressed in all cerebral cortex: 43.2 SARAF MGC8721, TMEM66 ENSG00000133872 Store-operated calcium entry-associated regulatory factor 8 30063012-30083208 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA040400 Supported Endoplasmic reticulum
Rods & Rings Lung cancer:5.28e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 287.8 SAYSD1 C6orf64, FLJ11101 ENSG00000112167 SAYSVFN motif domain containing 1 6 39104064-39115189 Predicted membrane proteins Evidence at protein level HPA007959 Approved Validated Vesicles Expressed in all Tissue enriched 6 testis: 85.5 prostate: 14.9 SC5D SC5DL ENSG00000109929 Sterol-C5-desaturase 11 121292453-121308694 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA066283, HPA070248 Approved Approved Nucleoplasm
Endoplasmic reticulum
Plasma membrane
Cytosol Renal cancer:1.07e-7 (favourable), Head and neck cancer:3.30e-4 (unfavourable), Melanoma:3.98e-4 (unfavourable) Expressed in all Expressed in all liver: 193.1 SCAF11 CASP11, SFRS2IP, SIP1, SRRP129, SRSF2IP ENSG00000139218 SR-related CTD-associated factor 11 12 45919131-45992120 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038862, HPA045456, HPA046345 Supported Validated Nucleoplasm
Nuclear bodies Expressed in all Expressed in all parathyroid gland: 85.0 SCAI C9orf126, FLJ36664, NET40 ENSG00000173611 Suppressor of cancer cell invasion 9 124942608-125143506 Predicted intracellular proteins Evidence at protein level HPA020632 Approved Supported Nucleus
Nuclear membrane Mixed Mixed cerebral cortex: 11.8 SCAMP1 SCAMP37 ENSG00000085365 Secretory carrier membrane protein 1 5 78360583-78479071 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044753 Approved Nucleoplasm
Vesicles
Cell Junctions Renal cancer:1.92e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 69.4 SCAMP2 ENSG00000140497 Secretory carrier membrane protein 2 15 74843730-74873365 Predicted membrane proteins Evidence at protein level HPA014699, HPA019194 Approved Supported Golgi apparatus
Vesicles Renal cancer:1.12e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 126.3 SCAMP3 C1orf3 ENSG00000116521 Secretory carrier membrane protein 3 1 155255979-155262430 Predicted membrane proteins Evidence at protein level HPA071167 Supported Vesicles Liver cancer:2.92e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 46.1 SCAMP4 FLJ33847 ENSG00000227500 Secretory carrier membrane protein 4 19 1905214-1926013 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043284 Approved Approved Golgi apparatus
Vesicles
Lipid droplets
Plasma membrane Endometrial cancer:4.40e-6 (favourable), Liver cancer:1.92e-5 (unfavourable), Renal cancer:3.56e-4 (favourable) Expressed in all Expressed in all fallopian tube: 58.6 SCAMP5 MGC24969 ENSG00000198794 Secretory carrier membrane protein 5 15 74957219-75021496 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046645 Approved Renal cancer:1.34e-6 (favourable), Pancreatic cancer:5.67e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 276.3 parathyroid gland: 80.7 SCAP KIAA0199 ENSG00000114650 SREBF chaperone 3 47413694-47477126 Predicted membrane proteins Evidence at protein level HPA004713 Approved Renal cancer:4.33e-5 (favourable), Pancreatic cancer:7.14e-4 (favourable) Expressed in all Expressed in all adrenal gland: 67.3 SCARA3 APC7, CSR, CSR1, MSLR1, MSRL1 ENSG00000168077 Scavenger receptor class A, member 3 8 27633868-27676776 Predicted membrane proteins Evidence at protein level HPA029861, HPA047386 Uncertain Supported Endoplasmic reticulum Expressed in all Tissue enhanced fallopian tube: 150.2 smooth muscle: 107.0 SCARA5 FLJ23907, MGC45780, NET33 ENSG00000168079 Scavenger receptor class A, member 5 8 27869882-27992727 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024661 Approved Mixed Mixed adipose tissue: 65.7 SCARB1 CD36L1, CLA-1, CLA1, SR-BI, SRB1 ENSG00000073060 Scavenger receptor class B, member 1 12 124776856-124882668 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA066285, CAB070124 Supported Approved Vesicles Renal cancer:1.49e-5 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Lung cancer:4.02e-4 (unfavourable) Expressed in all Group enriched 7 adrenal gland: 762.1;placenta: 284.3 liver: 71.6 SCARB2 CD36L2, HLGP85, LIMP-2, LIMPII, SR-BII ENSG00000138760 Scavenger receptor class B, member 2 4 76158737-76213893 Disease related genes, Predicted membrane proteins Evidence at protein level CAB015415, HPA018014 Supported Approved Cytosol Breast cancer:2.82e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 180.4 SCARF1 KIAA0149, SREC ENSG00000074660 Scavenger receptor class F, member 1 17 1633858-1645747 Predicted secreted proteins Evidence at protein level HPA072936 Approved Expressed in all Tissue enhanced spleen: 16.9 lung: 8.1 SCARF2 HUMZD58C02, SREC-II, SREC2 ENSG00000244486 Scavenger receptor class F, member 2 22 20424585-20437859 Disease related genes, Predicted membrane proteins Evidence at protein level HPA035079 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Renal cancer:2.78e-5 (unfavourable), Urothelial cancer:4.28e-4 (unfavourable) Expressed in all Mixed seminal vesicle,spleen: 6.0 SCCPDH CGI-49, NET11 ENSG00000143653 Saccharopine dehydrogenase (putative) 1 246724047-246768137 Predicted membrane proteins Evidence at protein level HPA050775 Uncertain Approved Vesicles Expressed in all Expressed in all testis: 240.1 SCD FADS5, SCDOS ENSG00000099194 Stearoyl-CoA desaturase (delta-9-desaturase) 10 100347124-100364834 Enzymes, Predicted membrane proteins Evidence at protein level HPA012107, HPA063921 Uncertain Validated Endoplasmic reticulum Renal cancer:7.56e-5 (unfavourable), Urothelial cancer:7.79e-5 (unfavourable) Expressed in all Expressed in all adipose tissue: 1252.9 SCD5 ACOD4, FADS4, FLJ21032, HSCD5, SCD4 ENSG00000145284 Stearoyl-CoA desaturase 5 4 82629539-82798857 Enzymes, Predicted membrane proteins Evidence at protein level HPA042380 Uncertain Renal cancer:2.32e-5 (favourable) Group enriched Tissue enhanced adrenal gland: 201.7;cerebral cortex: 502.5 epididymis: 117.9 SCIMP C17orf87, DTFT5783, FLJ32580, MGC163426, MGC163428, UNQ5783 ENSG00000161929 SLP adaptor and CSK interacting membrane protein 17 5208961-5234860 Predicted membrane proteins Evidence at protein level HPA006117 Supported Mixed Tissue enhanced spleen: 69.8 lymph node: 46.6 SCN11A NaN, Nav1.9, SCN12A, SNS-2 ENSG00000168356 Sodium channel, voltage gated, type XI alpha subunit 3 38845769-38950561 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA036746, HPA036747 Uncertain Not detected Tissue enhanced placenta: 3.7;spleen: 5.4 testis: 2.1 SCN1A FEB3, GEFSP2, HBSCI, NAC1, Nav1.1, SCN1, SMEI ENSG00000144285 Sodium channel, voltage gated, type I alpha subunit 2 165989160-166128047 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA078664 Approved Nucleoplasm
Nuclear bodies
Plasma membrane Tissue enriched Tissue enhanced cerebral cortex: 12.0;fallopian tube: 4.4;lung: 3.2 testis: 2.2 SCN2A HBSCI, HBSCII, Nav1.2, SCN2A1, SCN2A2 ENSG00000136531 Sodium channel, voltage gated, type II alpha subunit 2 165239402-165392310 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022567 Supported Tissue enhanced Tissue enriched 22 cerebral cortex: 58.5 kidney: 2.7 SCN3A Nav1.3 ENSG00000153253 Sodium channel, voltage gated, type III alpha subunit 2 165087522-165204067 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA035396 Approved Tissue enriched Tissue enriched 6 cerebral cortex: 18.0 adrenal gland: 3.0 SCN3B HSA243396 ENSG00000166257 Sodium channel, voltage gated, type III beta subunit 11 123629187-123655244 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042518 Approved Nuclear membrane
Cytokinetic bridge Tissue enhanced Tissue enriched 11 cerebral cortex: 132.5 adrenal gland: 11.6 SCN4A HYKPP, HYPP, Nav1.4, SkM1 ENSG00000007314 Sodium channel, voltage gated, type IV alpha subunit 17 63938554-63972918 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA053992 Approved Nucleoplasm
Microtubule organizing center Tissue enhanced Group enriched 9 adipose tissue: 12.3;skeletal muscle: 47.2 thyroid gland: 3.3 SCN4B LQT10 ENSG00000177098 Sodium channel, voltage gated, type IV beta subunit 11 118133377-118152888 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017293 Approved Mixed Tissue enhanced adipose tissue: 25.0 thyroid gland: 17.0 SCN7A NaG, Nav2.1, Nav2.2, SCN6A ENSG00000136546 Sodium channel, voltage gated, type VII alpha subunit 2 166403573-166494247 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA004879 Uncertain Mixed Tissue enhanced ovary: 63.0 lung: 41.0 SCN8A CerIII, MED, NaCh6, Nav1.6, PN4 ENSG00000196876 Sodium channel, voltage gated, type VIII alpha subunit 12 51590266-51812864 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB022169 Supported Vesicles
Cell Junctions Mixed Tissue enriched 6 cerebral cortex: 22.1 testis: 3.5 SCN9A ETHA, Nav1.7, NE-NA, NENA, PN1 ENSG00000169432 Sodium channel, voltage gated, type IX alpha subunit 2 166195185-166375993 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB013679, HPA061843 Uncertain Approved Plasma membrane
Actin filaments
Focal adhesion sites Renal cancer:2.30e-5 (unfavourable) Mixed Tissue enhanced testis: 9.1 placenta: 5.9 SCNN1A ENaCalpha, SCNN1 ENSG00000111319 Sodium channel, non voltage gated 1 alpha subunit 12 6346843-6377730 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA012743 Supported Renal cancer:9.21e-8 (favourable), Pancreatic cancer:2.30e-4 (unfavourable), Ovarian cancer:8.86e-4 (unfavourable) Mixed Mixed cervix, uterine: 94.4 SCNN1B ENaCbeta ENSG00000168447 Sodium channel, non voltage gated 1 beta subunit 16 23278231-23381299 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015612 Uncertain Renal cancer:2.09e-6 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 71.5 esophagus: 45.0 SCNN1D dNaCh, ENaCdelta ENSG00000162572 Sodium channel, non voltage gated 1 delta subunit 1 1280436-1292029 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB009540, HPA026884 Approved Supported Plasma membrane
Actin filaments Renal cancer:6.67e-5 (unfavourable), Pancreatic cancer:1.32e-4 (favourable), Head and neck cancer:1.60e-4 (favourable) Mixed Tissue enhanced testis: 13.8 cerebral cortex: 7.3 SCNN1G ENaCgamma, SCNEG ENSG00000166828 Sodium channel, non voltage gated 1 gamma subunit 16 23182715-23216883 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA071194 Approved Nucleoplasm
Nucleoli
Plasma membrane Renal cancer:3.20e-7 (unfavourable) Tissue enhanced Tissue enhanced cervix, uterine: 24.5;kidney: 46.4 thyroid gland: 9.5 SCO1 SCOD1 ENSG00000133028 SCO1 cytochrome c oxidase assembly protein 17 10672474-10698375 Disease related genes, Predicted membrane proteins Evidence at protein level HPA021565, HPA021579 Approved Renal cancer:9.69e-7 (favourable), Thyroid cancer:7.44e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 22.5 SCO2 MYP6, SCO1L ENSG00000130489 SCO2 cytochrome c oxidase assembly protein 22 50523568-50526439 Disease related genes, Predicted membrane proteins Evidence at protein level HPA056254 Approved Supported Nucleoplasm
Mitochondria Renal cancer:1.67e-4 (unfavourable) Expressed in all Expressed in all appendix: 50.4 SCTR ENSG00000080293 Secretin receptor 2 119439843-119525301 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA007269 Uncertain Tissue enhanced Tissue enhanced duodenum: 27.4;lung: 13.0;pancreas: 14.3 stomach: 4.2 SDAD1 FLJ10498 ENSG00000198301 SDA1 domain containing 1 4 75940950-75990962 Predicted intracellular proteins Evidence at protein level HPA035949 Uncertain Supported Nucleus
Nucleoli Liver cancer:1.32e-4 (unfavourable), Renal cancer:2.13e-4 (favourable) Expressed in all Expressed in all testis: 37.9 SDC1 CD138, SDC, SYND1, syndecan ENSG00000115884 Syndecan 1 2 20200797-20225433 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB002424, HPA006185 Approved Approved Focal adhesion sites Breast cancer:2.22e-4 (unfavourable), Glioma:8.05e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 251.7;skin: 288.6 liver: 144.9 SDC2 CD362, fibroglycan, HSPG, HSPG1, SYND2 ENSG00000169439 Syndecan 2 8 96493351-96611780 CD markers, Predicted membrane proteins Evidence at protein level CAB025123, HPA044416 Uncertain Approved Plasma membrane
Cytosol Expressed in all Expressed in all thyroid gland: 708.5 SDC3 N-syndecan, SYND3 ENSG00000162512 Syndecan 3 1 30869467-30908761 Predicted membrane proteins Evidence at protein level HPA017087, CAB025786, HPA048085 Approved Approved Nucleoplasm
Mitochondria Renal cancer:1.71e-4 (unfavourable), Melanoma:2.36e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 136.8 SDC4 amphiglycan, ryudocan, SYND4 ENSG00000124145 Syndecan 4 20 45325288-45348424 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA005716, CAB013240 Supported Approved Golgi apparatus
Plasma membrane Renal cancer:2.44e-7 (favourable), Thyroid cancer:2.67e-4 (favourable), Pancreatic cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all lung: 250.5 SDCBP SYCL ENSG00000137575 Syndecan binding protein (syntenin) 8 58552924-58582860 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB012245, HPA023840 Approved Approved Nucleoplasm
Nuclear membrane
Cytosol Expressed in all Expressed in all placenta: 362.0 SDK1 FLJ31425 ENSG00000146555 Sidekick cell adhesion molecule 1 7 3301448-4269000 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011392 Approved Approved Cytosol Pancreatic cancer:4.08e-4 (favourable) Mixed Tissue enhanced cervix, uterine: 14.9 spleen: 6.1 SDK2 FLJ10832, KIAA1514 ENSG00000069188 Sidekick cell adhesion molecule 2 17 73334384-73644089 Predicted membrane proteins Evidence at protein level HPA014725 Approved Nucleoplasm Mixed Tissue enhanced cervix, uterine: 9.0;testis: 18.7 fallopian tube: 3.9 SDR16C5 RDH-E2, RDHE2 ENSG00000170786 Short chain dehydrogenase/reductase family 16C, member 5 8 56300010-56320776 Enzymes, Predicted membrane proteins Evidence at protein level HPA025224 Supported Head and neck cancer:7.88e-4 (favourable) Mixed Group enriched 6 breast: 14.9;esophagus: 36.4;lung: 40.3;skin: 73.0;small intestine: 22.1;stomach: 21.3;tonsil: 26.3 cervix, uterine: 5.6 SDR42E1 HSPC105 ENSG00000184860 Short chain dehydrogenase/reductase family 42E, member 1 16 81988855-82011488 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA014388 Uncertain Mixed Mixed skin: 10.7 SDR42E2 ENSG00000183921 Short chain dehydrogenase/reductase family 42E, member 2 16 22165583-22191754 Predicted membrane proteins Evidence at transcript level HPA061278 Uncertain Not detected Tissue enhanced fallopian tube: 1.1;testis: 1.0 lung,parathyroid gland: 0.2 SEC11A SEC11L1, sid2895, SPC18, SPCS4A ENSG00000140612 SEC11 homolog A, signal peptidase complex subunit 15 84669538-84716716 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047533 Approved Nuclear membrane
Golgi apparatus Endometrial cancer:1.94e-5 (favourable), Head and neck cancer:5.99e-5 (unfavourable), Thyroid cancer:2.95e-4 (favourable) Expressed in all Expressed in all thyroid gland: 211.4 SEC11C SEC11L3, SPC21, SPCS4C ENSG00000166562 SEC11 homolog C, signal peptidase complex subunit 18 59139477-59158836 Enzymes, Predicted membrane proteins Evidence at protein level HPA026816, HPA047533 Approved Approved Nuclear membrane
Golgi apparatus Expressed in all Expressed in all prostate: 275.4 SEC14L1 PRELID4A, SEC14L ENSG00000129657 SEC14-like lipid binding 1 17 77086716-77217101 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA021463, HPA028703 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all placenta: 118.5 SEC16B LZTR2, PGPR-p117, RGPR, Sec16S ENSG00000120341 SEC16 homolog B, endoplasmic reticulum export factor 1 177923956-177984303 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA031202, HPA054292 Uncertain Approved Endoplasmic reticulum
Plasma membrane
Actin filaments Not detected Tissue enhanced duodenum: 28.9;small intestine: 31.5 liver: 18.8 SEC22C MGC13261, MGC5373, SEC22L3 ENSG00000093183 SEC22 homolog C, vesicle trafficking protein 3 42547969-42601080 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA055594 Approved Golgi apparatus Renal cancer:1.35e-7 (favourable), Liver cancer:3.04e-5 (unfavourable) Expressed in all Expressed in all prostate: 66.4 SEC24A ENSG00000113615 SEC24 homolog A, COPII coat complex component 5 134648789-134727823 Predicted intracellular proteins Evidence at protein level HPA038901, HPA056825 Approved Approved Nucleoli fibrillar center
Vesicles Cervical cancer:3.70e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 25.3 SEC61A1 ENSG00000058262 Sec61 translocon alpha 1 subunit 3 128051641-128071683 Predicted membrane proteins, Transporters Evidence at protein level CAB022076 Supported Endoplasmic reticulum Renal cancer:6.84e-9 (unfavourable), Liver cancer:1.07e-6 (unfavourable), Endometrial cancer:7.82e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 217.0 SEC61B ENSG00000106803 Sec61 translocon beta subunit 9 99222064-99230615 Predicted membrane proteins, Transporters Evidence at protein level HPA049407 Approved Validated Endoplasmic reticulum Endometrial cancer:1.26e-5 (favourable) Expressed in all Expressed in all epididymis: 333.0 SEC61G SSS1 ENSG00000132432 Sec61 translocon gamma subunit 7 54752250-54759974 Predicted membrane proteins, Transporters Evidence at protein level HPA053196 Uncertain Renal cancer:6.60e-8 (unfavourable), Head and neck cancer:4.64e-7 (unfavourable), Liver cancer:3.85e-6 (unfavourable) Expressed in all Expressed in all epididymis: 401.2 SEC62 Dtrp1, HTP1, TLOC1 ENSG00000008952 SEC62 homolog, preprotein translocation factor 3 169966635-169998373 Predicted membrane proteins Evidence at protein level HPA014059, HPA061450 Approved Approved Endoplasmic reticulum
Intermediate filaments Expressed in all Expressed in all thyroid gland: 202.4 SEC63 DNAJC23, ERdj2, PRO2507, SEC63L ENSG00000025796 SEC63 homolog, protein translocation regulator 6 107867756-107958189 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA053295, HPA060535 Supported Supported Endoplasmic reticulum Breast cancer:3.32e-4 (unfavourable), Cervical cancer:4.01e-4 (unfavourable), Renal cancer:6.16e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 87.1 SECTM1 K12 ENSG00000141574 Secreted and transmembrane 1 17 82321024-82334074 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051214 Approved Expressed in all Tissue enhanced small intestine: 98.6 duodenum: 66.3 SEL1L IBD2, SEL1L1 ENSG00000071537 Sel-1 suppressor of lin-12-like (C. elegans) 14 81471549-81533861 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA024267 Approved Expressed in all Expressed in all thyroid gland: 90.3 SEL1L2 C20orf50, DKFZp434C1826 ENSG00000101251 Sel-1 suppressor of lin-12-like 2 (C. elegans) 20 13849247-13996443 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059121 Approved Not detected Tissue enriched 63 testis: 12.5 endometrium,ovary,seminal vesicle: 0.1 SEL1L3 KIAA0746 ENSG00000091490 Sel-1 suppressor of lin-12-like 3 (C. elegans) 4 25747427-25863760 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040045, HPA058792 Approved Validated Nucleus Urothelial cancer:4.33e-4 (favourable) Expressed in all Expressed in all lymph node: 148.5 SELE CD62E, ELAM, ELAM1, ESEL ENSG00000007908 Selectin E 1 169722641-169764705 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002143 Supported Mixed Tissue enhanced parathyroid gland: 44.4;prostate: 40.0 urinary bladder: 28.6 SELK ENSG00000113811 Selenoprotein K 3 53884410-53891988 Predicted membrane proteins Evidence at protein level HPA008196 Uncertain Approved Nucleoplasm
Cytosol Lung cancer:3.76e-4 (favourable), Endometrial cancer:7.18e-4 (favourable) Expressed in all Expressed in all epididymis: 74.5 SELL CD62L, hLHRc, LAM-1, LAM1, Leu-8, LNHR, LSEL, Lyam-1, LYAM1, PLNHR ENSG00000188404 Selectin L 1 169690667-169711698 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002144, HPA051972 Supported Uncertain Cytosol Renal cancer:4.96e-5 (unfavourable), Cervical cancer:2.25e-4 (favourable), Ovarian cancer:3.14e-4 (favourable), Breast cancer:3.76e-4 (favourable), Head and neck cancer:6.43e-4 (favourable) Expressed in all Tissue enhanced lymph node: 258.2;spleen: 222.6;tonsil: 185.9 appendix: 157.5 SELP CD62, CD62P, GMP140, GRMP, PADGEM, PSEL ENSG00000174175 Selectin P (granule membrane protein 140kDa, antigen CD62) 1 169588849-169630193 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002145, HPA002655, HPA005990 Supported Head and neck cancer:3.12e-4 (favourable) Mixed Mixed smooth muscle: 20.4 SELPLG CD162, PSGL-1 ENSG00000110876 Selectin P ligand 12 108622277-108633959 Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002431 Supported Cervical cancer:1.46e-4 (favourable), Thyroid cancer:2.74e-4 (favourable), Melanoma:2.92e-4 (favourable), Renal cancer:5.86e-4 (unfavourable), Head and neck cancer:6.94e-4 (favourable) Expressed in all Mixed spleen: 86.7 SELT ENSG00000198843 Selenoprotein T 3 150602875-150630445 Predicted membrane proteins Evidence at protein level HPA039780 Approved Expressed in all Expressed in all thyroid gland: 108.8 SEMA3D coll-2, Sema-Z2 ENSG00000153993 Sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3D 7 84995553-85186855 Predicted intracellular proteins Evidence at protein level HPA037522 Uncertain Approved Golgi apparatus
Plasma membrane Mixed Group enriched 5 spleen: 67.1;thyroid gland: 76.0 prostate: 13.5 SEMA4A CORD10, FLJ12287, SEMAB, SemB ENSG00000196189 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4A 1 156147366-156177752 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA053726, HPA066006, HPA069136 Supported Validated Nucleus Head and neck cancer:1.09e-4 (favourable), Renal cancer:8.20e-4 (unfavourable) Expressed in all Mixed epididymis: 61.2 SEMA4B KIAA1745, MGC131831, SEMAC, SemC ENSG00000185033 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B 15 90160604-90229679 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013372 Approved Renal cancer:3.33e-8 (unfavourable), Lung cancer:1.25e-4 (unfavourable) Expressed in all Expressed in all esophagus: 49.5 SEMA4C Semacl1, Semaf, SEMAI ENSG00000168758 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4C 2 96859716-96870757 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011090 Approved Renal cancer:9.50e-7 (unfavourable), Colorectal cancer:3.53e-5 (unfavourable) Expressed in all Expressed in all placenta: 63.0 SEMA4D C9orf164, CD100, coll-4, FLJ39737, SEMAJ ENSG00000187764 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4D 9 89360787-89498130 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015662, HPA023277 Approved Supported Endoplasmic reticulum
Vesicles Urothelial cancer:4.06e-5 (favourable), Cervical cancer:4.17e-4 (favourable) Expressed in all Expressed in all lymph node: 73.3 SEMA4F SEMAM, SEMAW ENSG00000135622 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4F 2 74654228-74683853 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA065969 Approved Nucleus
Plasma membrane
Centrosome Renal cancer:9.74e-6 (unfavourable), Endometrial cancer:5.94e-5 (unfavourable), Glioma:3.18e-4 (unfavourable), Thyroid cancer:6.94e-4 (favourable) Expressed in all Mixed cerebral cortex: 14.2 SEMA4G FLJ20590, KIAA1619 ENSG00000095539 Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4G 10 100969518-100985871 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA038362 Uncertain Mixed Tissue enhanced rectum: 94.4 duodenum: 55.4 SEMA5A SEMAF, semF ENSG00000112902 Sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5A 5 9035026-9546075 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004632 Approved Renal cancer:3.66e-8 (favourable), Head and neck cancer:2.45e-4 (favourable) Expressed in all Mixed cervix, uterine: 19.2 SEMA5B FLJ10372, KIAA1445, SEMAG, SemG ENSG00000082684 Sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B 3 122909193-123028605 Predicted membrane proteins Evidence at protein level HPA017084, HPA066548 Uncertain Approved Cytosol Renal cancer:7.57e-4 (unfavourable) Tissue enhanced Tissue enhanced cerebral cortex: 11.5 heart muscle: 4.2 SEMA6A HT018, KIAA1368, SEMA, SEMA6A1, SEMAQ ENSG00000092421 Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6A 5 116443616-116574934 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA031265, HPA031267 Approved Supported Nucleus
Intermediate filaments Liver cancer:4.39e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 49.3 SEMA6B SEM-SEMA-Y, SEMA-VIB, SEMAN, semaZ ENSG00000167680 Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6B 19 4542593-4559808 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB025157, HPA055778, HPA058523 Approved Renal cancer:3.29e-5 (unfavourable), Thyroid cancer:1.45e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 65.7 spleen: 24.9 SEMA6C KIAA1869 ENSG00000143434 Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6C 1 151131685-151146664 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA071220 Approved Endoplasmic reticulum Pancreatic cancer:3.06e-5 (favourable), Endometrial cancer:3.27e-4 (unfavourable) Expressed in all Tissue enhanced skeletal muscle: 111.3 testis: 33.9 SEMA6D FLJ11598, KIAA1479 ENSG00000137872 Sema domain, transmembrane domain (TM), and cytoplasmic domain, (semaphorin) 6D 15 47184101-47774223 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043109 Approved Golgi apparatus
Plasma membrane Renal cancer:5.96e-5 (favourable) Tissue enhanced Tissue enhanced placenta: 64.3 small intestine: 45.7 SEMA7A CD108, H-Sema-L, SEMAL ENSG00000138623 Semaphorin 7A, GPI membrane anchor (John Milton Hagen blood group) 15 74409289-74434467 Blood group antigen proteins, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008210, HPA042273 Uncertain Uncertain Vesicles Renal cancer:2.45e-11 (unfavourable) Expressed in all Tissue enhanced spleen: 60.5;testis: 57.0 placenta: 44.5 SEPP1 SelP, SeP, SEPP ENSG00000250722 Selenoprotein P, plasma, 1 5 42799880-42887392 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA036287 Approved Approved Nucleus
Golgi apparatus Renal cancer:6.97e-6 (favourable) Expressed in all Expressed in all liver: 2937.1 SERF1A 4F5, FAM2A, H4F5, SERF1, SMAM1 ENSG00000172058 Small EDRK-rich factor 1A (telomeric) 5 70900665-70918530 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA075271 Approved Nuclear bodies Not detected Mixed cerebral cortex: 9.2 SERF1B FAM2B, H4F5C ENSG00000205572 Small EDRK-rich factor 1B (centromeric) 5 70025247-70043113 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA075271 Approved Nuclear bodies Mixed Tissue enhanced testis: 48.1 epididymis: 31.6 SERINC1 KIAA1253, TDE1L, TDE2, TMS-2 ENSG00000111897 Serine incorporator 1 6 122443354-122471822 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035738, HPA035739 Uncertain Approved Cytosol Expressed in all Expressed in all cerebral cortex: 617.2 SERINC2 FKSG84, PRO0899, TDE2, TDE2L ENSG00000168528 Serine incorporator 2 1 31409565-31434680 Predicted membrane proteins Evidence at protein level HPA005974 Approved Endometrial cancer:1.69e-7 (favourable), Liver cancer:2.11e-4 (unfavourable), Lung cancer:5.70e-4 (unfavourable) Expressed in all Mixed urinary bladder: 138.8 SERINC3 AIGP1, DIFF33, SBBI99, TDE, TDE1, TMS-1 ENSG00000132824 Serine incorporator 3 20 44496221-44522109 Predicted membrane proteins Evidence at protein level HPA048116 Uncertain Cervical cancer:1.01e-4 (unfavourable) Expressed in all Expressed in all testis: 200.8 SERINC4 FLJ40363 ENSG00000184716 Serine incorporator 4 15 43794162-43800221 Predicted membrane proteins Evidence at transcript level HPA018526 Uncertain Not detected Tissue enriched 10 testis: 2.2 endometrium: 0.2 SERINC5 C5orf12, TPO1 ENSG00000164300 Serine incorporator 5 5 80111651-80256079 Predicted membrane proteins Evidence at protein level HPA037898, HPA037899 Supported Uncertain Nucleus
Golgi apparatus
Vesicles Expressed in all Mixed testis: 55.9 SERP1 FLJ43424, RAMP4 ENSG00000120742 Stress-associated endoplasmic reticulum protein 1 3 150541994-150603228 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038970 Approved Approved Endoplasmic reticulum Pancreatic cancer:1.03e-5 (unfavourable) Expressed in all Expressed in all epididymis: 179.5 SERP2 bA269C23.1, C13orf21 ENSG00000151778 Stress-associated endoplasmic reticulum protein family member 2 13 44373665-44397714 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038970 Uncertain Approved Endoplasmic reticulum Renal cancer:1.94e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 52.9;testis: 23.7 epididymis: 11.3 SERPINA10 PZI, ZPI ENSG00000140093 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 10 14 94280455-94293271 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048739 Approved Nucleoplasm
Cytosol Liver cancer:9.00e-4 (favourable) Tissue enriched Tissue enriched 89 liver: 193.5 bone marrow: 2.1 SERPINA5 PAI3, PCI, PLANH3, PROCI ENSG00000188488 Serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 5 14 94561442-94593120 Cancer-related genes, Candidate cardiovascular disease genes, Plasma proteins, Predicted secreted proteins Evidence at protein level HPA056919 Approved Mitochondria Endometrial cancer:7.72e-4 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 516.7;liver: 406.5;testis: 816.1 gallbladder: 251.6 SERPINB13 headpin, HUR7, hurpin, PI13 ENSG00000197641 Serpin peptidase inhibitor, clade B (ovalbumin), member 13 18 63586989-63604639 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052630, HPA057129 Supported Approved Nuclear speckles
Cytosol Tissue enhanced Tissue enriched 9 esophagus: 185.3 tonsil: 21.6 SERPINB3 HsT1196, SCC, SCCA1, T4-A ENSG00000057149 Serpin peptidase inhibitor, clade B (ovalbumin), member 3 18 63637719-63661963 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB018772, CAB036006, CAB036007, HPA048341, HPA049988, HPA055992 Supported Approved Plasma membrane
Cytosol Pancreatic cancer:3.19e-4 (unfavourable) Tissue enhanced Group enriched 6 cervix, uterine: 297.6;esophagus: 851.2 urinary bladder: 90.5 SERPINB4 LEUPIN, PI11, SCCA-2, SCCA1, SCCA2 ENSG00000206073 Serpin peptidase inhibitor, clade B (ovalbumin), member 4 18 63637259-63644298 Cancer-related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA048341, HPA049988, HPA055992 Supported Pancreatic cancer:5.48e-4 (unfavourable) Tissue enhanced Group enriched 6 esophagus: 98.6;urinary bladder: 20.1 skin: 9.4 SERPINB6 CAP, DFNB91, PI6, PTI ENSG00000124570 Serpin peptidase inhibitor, clade B (ovalbumin), member 6 6 2948159-2972165 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA009668, HPA012736 Supported Approved Centrosome Renal cancer:2.21e-4 (unfavourable), Ovarian cancer:4.81e-4 (favourable) Expressed in all Expressed in all testis: 254.5 SERPINB7 MEGSIN ENSG00000166396 Serpin peptidase inhibitor, clade B (ovalbumin), member 7 18 63752935-63805376 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA024200 Approved Approved Endoplasmic reticulum
Mitochondria Pancreatic cancer:3.03e-5 (unfavourable) Mixed Tissue enhanced skin: 123.8;tonsil: 35.5 breast: 17.2 SERPINB8 CAP2, PI8 ENSG00000166401 Serpin peptidase inhibitor, clade B (ovalbumin), member 8 18 63969925-64005667 Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB034300 Approved Approved Nucleus
Cytosol Renal cancer:3.31e-5 (unfavourable) Expressed in all Mixed skin: 48.0 SERPING1 C1-INH, C1IN, C1NH, HAE1, HAE2 ENSG00000149131 Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1 11 57597387-57614853 Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level CAB026161, HPA048738 Supported Renal cancer:1.55e-4 (unfavourable), Ovarian cancer:8.03e-4 (favourable), Colorectal cancer:9.96e-4 (unfavourable) Expressed in all Expressed in all liver: 1365.4 SERPINI1 neuroserpin, PI12 ENSG00000163536 Serpin peptidase inhibitor, clade I (neuroserpin), member 1 3 167735243-167825568 Disease related genes, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA001565, CAB026059, HPA056092 Supported Approved Cytosol Liver cancer:4.25e-4 (unfavourable) Expressed in all Tissue enriched 10 cerebral cortex: 323.2 kidney: 31.1 SERTM1 C13orf36 ENSG00000180440 Serine-rich and transmembrane domain containing 1 13 36673912-36697839 Predicted membrane proteins Evidence at protein level HPA054814, HPA070485 Uncertain Supported Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 47.8;endometrium: 37.3;fallopian tube: 29.3 smooth muscle: 24.5 SETDB1 ESET, KG1T, KIAA0067, KMT1E, TDRD21 ENSG00000143379 SET domain, bifurcated 1 1 150926263-150964744 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018142, HPA058484 Uncertain Validated Nucleoplasm
Cytosol Renal cancer:4.25e-4 (unfavourable), Liver cancer:8.88e-4 (unfavourable) Expressed in all Expressed in all testis: 46.1 SEZ6 ENSG00000063015 Seizure related 6 homolog (mouse) 17 28954901-29006440 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011777 Supported Uncertain Intermediate filaments Tissue enriched Tissue enriched 51 cerebral cortex: 54.1 duodenum: 1.0 SEZ6L2 FLJ90517, PSK-1 ENSG00000174938 Seizure related 6 homolog (mouse)-like 2 16 29871159-29899547 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA064471 Approved Colorectal cancer:1.31e-4 (unfavourable), Glioma:7.27e-4 (unfavourable), Cervical cancer:7.46e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 82.7;parathyroid gland: 57.3 adrenal gland: 30.8 SF3B1 Hsh155, Prp10, PRPF10, SAP155, SF3b155 ENSG00000115524 Splicing factor 3b, subunit 1, 155kDa 2 197389784-197435091 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA050275 Approved Validated Nuclear speckles Expressed in all Expressed in all endometrium: 345.5 SFT2D1 C6orf83, MGC19825, pRGR1 ENSG00000198818 SFT2 domain containing 1 6 166319728-166342591 Predicted membrane proteins Evidence at protein level HPA014677 Approved Approved Nucleoplasm
Nuclear bodies
Cytosol Liver cancer:2.19e-5 (unfavourable), Renal cancer:3.59e-4 (unfavourable), Thyroid cancer:5.90e-4 (favourable), Head and neck cancer:7.47e-4 (unfavourable) Expressed in all Expressed in all prostate: 77.5 SFT2D2 dJ747L4.C1.2, UNQ512 ENSG00000213064 SFT2 domain containing 2 1 168225938-168253025 Predicted membrane proteins Evidence at protein level HPA042207 Approved Liver cancer:4.86e-4 (unfavourable) Expressed in all Mixed bone marrow: 21.3 SFTPC BRICD6, PSP-C, SFTP2, SMDP2, SP-C ENSG00000168484 Surfactant protein C 8 22156913-22164479 Disease related genes, Predicted intracellular proteins Evidence at protein level CAB009313, HPA010928 Supported Tissue enriched Tissue enriched 832 lung: 25336.5 adrenal gland: 30.4 SFXN1 FLJ12876 ENSG00000164466 Sideroflexin 1 5 175477062-175529742 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019543, HPA063745 Uncertain Validated Mitochondria Expressed in all Expressed in all liver: 51.5 SFXN2 ENSG00000156398 Sideroflexin 2 10 102714538-102743492 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018150, HPA026834 Supported Approved Mitochondria Renal cancer:2.28e-5 (favourable), Cervical cancer:2.28e-4 (favourable), Urothelial cancer:6.52e-4 (favourable), Liver cancer:9.95e-4 (favourable) Expressed in all Tissue enhanced kidney: 18.8 parathyroid gland: 13.2 SFXN3 SFX3 ENSG00000107819 Sideroflexin 3 10 101031234-101041244 Predicted membrane proteins Evidence at protein level HPA008028, HPA048105 Approved Validated Mitochondria Head and neck cancer:3.79e-4 (unfavourable), Renal cancer:4.94e-4 (unfavourable) Expressed in all Expressed in all small intestine: 42.2 SFXN4 ENSG00000183605 Sideroflexin 4 10 119140767-119165667 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018028, HPA020872 Approved Supported Vesicles Expressed in all Expressed in all thyroid gland: 47.1 SFXN5 BBG-TCC ENSG00000144040 Sideroflexin 5 2 72942036-73075619 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015473, HPA056866 Approved Approved Nucleoplasm
Mitochondria Pancreatic cancer:2.26e-6 (favourable) Expressed in all Tissue enhanced cerebral cortex: 39.5 epididymis: 18.2 SGCA A2, adhalin, ADL, DMDA2, LGMD2D, SCARMD1 ENSG00000108823 Sarcoglycan, alpha (50kDa dystrophin-associated glycoprotein) 17 50164214-50175931 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007537 Uncertain Mixed Tissue enhanced heart muscle: 79.5;skeletal muscle: 181.4 seminal vesicle: 37.7 SGCB A3b, LGMD2E, SGC ENSG00000163069 Sarcoglycan, beta (43kDa dystrophin-associated glycoprotein) 4 52020706-52038482 Disease related genes, Predicted membrane proteins Evidence at protein level HPA011422, HPA058656 Supported Approved Cytosol Renal cancer:5.53e-6 (favourable), Urothelial cancer:7.61e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 74.2 SGCD CMD1L, DAGD, LGMD2F ENSG00000170624 Sarcoglycan, delta (35kDa dystrophin-associated glycoprotein) 5 155870344-156767788 Disease related genes, Predicted membrane proteins Evidence at protein level HPA026969 Uncertain Tissue enhanced Mixed thyroid gland: 37.3 SGCE DYT11 ENSG00000127990 Sarcoglycan, epsilon 7 94585230-94656209 Disease related genes, Predicted membrane proteins Evidence at protein level HPA074790 Approved Nucleoplasm
Golgi apparatus
Vesicles
Plasma membrane Head and neck cancer:1.61e-5 (unfavourable), Stomach cancer:1.35e-4 (unfavourable) Expressed in all Mixed ovary: 132.8 SGCG A4, DAGA4, DMDA, DMDA1, LGMD2C, MAM, MGC130048, SCARMD2, SCG3, TYPE ENSG00000102683 Sarcoglycan, gamma (35kDa dystrophin-associated glycoprotein) 13 23180952-23325165 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA007476, HPA011922 Supported Supported Nucleoplasm Mixed Tissue enhanced heart muscle: 70.1;skeletal muscle: 54.0 adipose tissue: 14.5 SGCZ ZSG1 ENSG00000185053 Sarcoglycan, zeta 8 14089864-15238339 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA017585 Uncertain Not detected Tissue enhanced cerebral cortex: 1.3;ovary: 3.4 breast: 0.7 SGMS1 MGC17342, MOB, SMS1, TMEM23 ENSG00000198964 Sphingomyelin synthase 1 10 50305586-50625163 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045191 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.95e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 114.4 SGMS2 MGC26963, SMS2 ENSG00000164023 Sphingomyelin synthase 2 4 107824563-107915047 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015076 Supported Renal cancer:1.37e-4 (favourable) Expressed in all Mixed gallbladder: 64.5 SGPL1 SPL ENSG00000166224 Sphingosine-1-phosphate lyase 1 10 70815961-70881173 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021125, HPA023086 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all skin: 34.6 SGPP1 ENSG00000126821 Sphingosine-1-phosphate phosphatase 1 14 63684214-63728039 Predicted membrane proteins Evidence at protein level HPA053149, HPA064908 Approved Supported Nucleus Expressed in all Expressed in all placenta: 34.5 SGSM3 DJ1042K10.2, RabGAP-5, RABGAP5, RUSC3, RUTBC3 ENSG00000100359 Small G protein signaling modulator 3 22 40370591-40410289 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048980 Approved Supported Golgi apparatus Endometrial cancer:4.47e-5 (favourable) Expressed in all Expressed in all stomach: 76.7 SH2D1B EAT2 ENSG00000198574 SH2 domain containing 1B 1 162395266-162412138 Predicted intracellular proteins Evidence at protein level HPA054791 Uncertain Not detected Tissue enhanced spleen: 10.4 lung: 3.3 SH3TC1 FLJ20356 ENSG00000125089 SH3 domain and tetratricopeptide repeats 1 4 8182072-8241803 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038132, HPA056807 Uncertain Approved Nucleus
Nucleoli
Cytosol Expressed in all Mixed spleen: 12.8 SHISA2 bA398O19.2, C13orf13, hShisa, PRO28631, TMEM46, WGAR9166 ENSG00000180730 Shisa family member 2 13 26044597-26051031 Predicted membrane proteins Evidence at protein level HPA049752, HPA050172 Uncertain Approved Nucleoplasm
Nuclear bodies
Vesicles Renal cancer:2.43e-4 (favourable), Lung cancer:3.30e-4 (favourable) Mixed Tissue enhanced breast: 21.9;thyroid gland: 48.1 epididymis: 12.9 SHISA3 hShisa3 ENSG00000178343 Shisa family member 3 4 42397839-42402487 Predicted membrane proteins Evidence at protein level HPA054754 Approved Lipid droplets
Cytosol Mixed Tissue enhanced kidney: 24.9 lymph node: 8.8 SHISA4 C1orf40, hShisa4, TMEM58 ENSG00000198892 Shisa family member 4 1 201888680-201892306 Predicted membrane proteins Evidence at protein level HPA061273 Uncertain Expressed in all Group enriched 5 adrenal gland: 23.6;cerebral cortex: 45.5;skeletal muscle: 94.5 heart muscle: 10.8 SHISA5 hShisa5, SCOTIN ENSG00000164054 Shisa family member 5 3 48467798-48504826 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042295 Approved Liver cancer:3.72e-6 (unfavourable), Renal cancer:8.64e-5 (unfavourable) Expressed in all Expressed in all placenta: 197.8 SHISA6 FLJ45455 ENSG00000188803 Shisa family member 6 17 11241263-11564063 Predicted membrane proteins Evidence at transcript level HPA023440 Uncertain Mixed Tissue enhanced cervix, uterine: 24.6 seminal vesicle: 10.2 SHISA7 ENSG00000187902 Shisa family member 7 19 55428740-55442863 Predicted membrane proteins Evidence at protein level HPA058935 Uncertain Tissue enriched Tissue enriched 11 cerebral cortex: 18.3 testis: 1.7 SHISA8 C22orf17, Orf26 ENSG00000234965 Shisa family member 8 22 41909554-41914667 Predicted membrane proteins Evidence at transcript level HPA059173 Uncertain Endometrial cancer:2.76e-4 (favourable) Mixed Tissue enhanced adrenal gland: 4.4 lymph node,spleen: 1.4 SHISA9 ENSG00000237515 Shisa family member 9 16 12901620-13240413 Predicted membrane proteins Evidence at transcript level HPA072399 Approved Endoplasmic reticulum Renal cancer:1.53e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 23.0 prostate: 7.7 SI ENSG00000090402 Sucrase-isomaltase (alpha-glucosidase) 3 164978898-165078495 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011897 Supported Tissue enhanced Group enriched 15 duodenum: 562.3;small intestine: 503.3 rectum: 34.9 SIDT1 FLJ20174, SID-1 ENSG00000072858 SID1 transmembrane family, member 1 3 113532296-113629578 Predicted membrane proteins, Transporters Evidence at protein level HPA035862 Approved Urothelial cancer:4.09e-5 (favourable), Cervical cancer:3.78e-4 (favourable) Mixed Mixed cerebral cortex,rectum: 10.7 SIDT2 CGI-40 ENSG00000149577 SID1 transmembrane family, member 2 11 117178733-117197445 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA052352 Approved Renal cancer:4.18e-5 (unfavourable) Expressed in all Expressed in all prostate: 59.7 SIGIRR TIR8 ENSG00000185187 Single immunoglobulin and toll-interleukin 1 receptor (TIR) domain 11 405716-417455 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023188 Approved Approved Nucleoli fibrillar center
Cytosol Renal cancer:7.61e-6 (favourable), Endometrial cancer:1.34e-5 (favourable), Urothelial cancer:1.54e-5 (favourable), Cervical cancer:7.44e-5 (favourable), Head and neck cancer:9.08e-4 (favourable) Expressed in all Expressed in all spleen: 65.9 SIGLEC1 CD169, dJ1009E24.1, FLJ00051, FLJ00055, FLJ00073, FLJ32150, sialoadhesin, SIGLEC-1, SN ENSG00000088827 Sialic acid binding Ig-like lectin 1, sialoadhesin 20 3686970-3707128 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053457 Supported Renal cancer:8.69e-5 (unfavourable), Testis cancer:4.36e-4 (unfavourable) Expressed in all Mixed placenta: 27.1 SIGLEC10 MGC126774, PRO940, SIGLEC-10, SLG2 ENSG00000142512 Sialic acid binding Ig-like lectin 10 19 51410021-51417803 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025807, HPA027093 Approved Supported Plasma membrane
Actin filaments
Cytosol Renal cancer:4.74e-5 (unfavourable) Expressed in all Tissue enhanced appendix: 49.9;spleen: 37.9 lymph node: 22.4 SIGLEC11 ENSG00000161640 Sialic acid binding Ig-like lectin 11 19 49948985-49961172 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA060278 Approved Mixed Group enriched 7 ovary: 79.9;spleen: 32.2 adrenal gland: 8.2 SIGLEC14 ENSG00000254415 Sialic acid binding Ig-like lectin 14 19 51642553-51646801 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA014377 Uncertain Mixed Tissue enhanced appendix: 36.1;spleen: 56.5 bone marrow: 18.7 SIGLEC15 CD33L3, HsT1361 ENSG00000197046 Sialic acid binding Ig-like lectin 15 18 45825512-45844080 Predicted membrane proteins Evidence at protein level HPA053509 Supported Nucleoplasm
Golgi apparatus Urothelial cancer:9.14e-5 (favourable) Mixed Not detected spleen: 0.6 SIGLEC5 CD170, CD33L2, OB-BP2, SIGLEC-5 ENSG00000105501 Sialic acid binding Ig-like lectin 5 19 51611503-51645545 CD markers, Predicted membrane proteins Evidence at protein level HPA009085, CAB024900 Supported Tissue enhanced Tissue enhanced appendix: 13.5;bone marrow: 13.3;spleen: 11.6 lymph node: 4.2 SIGLEC6 CD327, CD33L, CD33L1, OB-BP1, SIGLEC-6 ENSG00000105492 Sialic acid binding Ig-like lectin 6 19 51519525-51531856 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA009084, HPA018198 Supported Tissue enhanced Tissue enriched 24 placenta: 147.1 lung: 6.0 SIGLEC8 MGC59785, SAF2, SIGLEC-8, SIGLEC8L ENSG00000105366 Sialic acid binding Ig-like lectin 8 19 51450847-51458456 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012556 Approved Uncertain Cytosol Tissue enhanced Mixed lymph node,spleen: 7.6 SIGLEC9 CD329 ENSG00000129450 Sialic acid binding Ig-like lectin 9 19 51124908-51136651 Predicted membrane proteins Evidence at protein level HPA010682 Uncertain Renal cancer:6.17e-5 (unfavourable) Mixed Tissue enhanced appendix: 25.4;spleen: 24.1 lung: 12.2 SIGMAR1 OPRS1, SR-BP1 ENSG00000147955 Sigma non-opioid intracellular receptor 1 9 34634722-34637809 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB013470, HPA018002, HPA024071 Approved Urothelial cancer:3.42e-4 (unfavourable) Expressed in all Expressed in all liver: 67.8 SIRPA BIT, CD172a, MFR, MYD-1, P84, PTPNS1, SHPS-1, SHPS1, SIRP, SIRP-ALPHA-1, SIRPalpha, SIRPalpha2 ENSG00000198053 Signal-regulatory protein alpha 20 1894167-1940592 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB002776, CAB015122, HPA054437, HPA058511 Approved Expressed in all Expressed in all cerebral cortex: 208.5 SIRPB1 CD172b, SIRP-BETA-1 ENSG00000101307 Signal-regulatory protein beta 1 20 1563521-1620061 CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047463 Uncertain Uncertain Vesicles Mixed Tissue enhanced appendix: 39.7;bone marrow: 33.8 lung: 28.0 SIRPB2 dJ776F14.2, PTPN1L, PTPNS1L3 ENSG00000196209 Signal-regulatory protein beta 2 20 1470741-1491587 Predicted membrane proteins Evidence at protein level HPA011548, HPA048032 Uncertain Approved Nuclear bodies Mixed Tissue enhanced appendix: 17.4 lung,placenta: 10.8 SIRPD dJ576H24.4, PTPNS1L2 ENSG00000125900 Signal-regulatory protein delta 20 1534251-1558843 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA042663 Supported Not detected Tissue enriched 18 testis: 72.3 appendix: 4.0 SIT1 SIT ENSG00000137078 Signaling threshold regulating transmembrane adaptor 1 9 35649295-35650950 Predicted membrane proteins Evidence at protein level HPA018506 Supported Endometrial cancer:1.94e-6 (favourable), Renal cancer:1.75e-5 (unfavourable), Head and neck cancer:1.14e-4 (favourable), Cervical cancer:6.56e-4 (favourable), Melanoma:8.17e-4 (favourable) Mixed Group enriched 5 appendix: 25.6;lymph node: 56.9;spleen: 22.3;tonsil: 30.9 urinary bladder: 6.3 SKIDA1 C10orf140, FLJ45187 ENSG00000180592 SKI/DACH domain containing 1 10 21513478-21526368 Predicted intracellular proteins Evidence at protein level HPA039208, HPA040439 Uncertain Mixed Tissue enhanced parathyroid gland: 4.0 testis: 3.1 SKP2 FBL1, FBXL1, p45 ENSG00000145604 S-phase kinase-associated protein 2, E3 ubiquitin protein ligase 5 36151989-36184319 Cancer-related genes, Predicted intracellular proteins Evidence at protein level CAB013491, CAB013533, HPA051196, HPA054633 Approved Supported Nucleus
Cytosol Renal cancer:4.77e-15 (unfavourable), Melanoma:3.72e-7 (unfavourable), Ovarian cancer:8.57e-4 (favourable) Expressed in all Tissue enriched 6 placenta: 83.9 lymph node: 13.9 SLAMF1 CD150, SLAM ENSG00000117090 Signaling lymphocytic activation molecule family member 1 1 160608100-160647295 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002438 Approved Mixed Tissue enhanced appendix: 15.9;lymph node: 21.3;tonsil: 14.8 spleen: 8.0 SLAMF6 CD352, KALI, KALIb, Ly108, NTB-A, NTBA, SF2000 ENSG00000162739 SLAM family member 6 1 160485030-160523262 CD markers, Predicted membrane proteins Evidence at protein level HPA051363, HPA051903 Uncertain Renal cancer:2.09e-6 (unfavourable), Head and neck cancer:7.34e-5 (favourable), Melanoma:1.25e-4 (favourable), Cervical cancer:2.78e-4 (favourable), Breast cancer:9.42e-4 (favourable), Endometrial cancer:9.53e-4 (favourable) Mixed Tissue enhanced lymph node: 71.8;spleen: 44.1;tonsil: 46.5 appendix: 28.3 SLAMF7 19A, CD319, CRACC, CS1 ENSG00000026751 SLAM family member 7 1 160739057-160754821 CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB015445, HPA055945, HPA061654 Supported Approved Vesicles Renal cancer:8.57e-5 (unfavourable), Ovarian cancer:3.93e-4 (favourable) Mixed Mixed spleen: 59.2 SLAMF8 BLAME, CD353, SBBI42 ENSG00000158714 SLAM family member 8 1 159826750-159837249 CD markers, Predicted membrane proteins Evidence at protein level HPA067601 Supported Renal cancer:5.42e-5 (unfavourable) Expressed in all Tissue enhanced appendix: 40.5 lymph node: 36.7 SLAMF9 CD2F-10, CD84-H1, SF2001 ENSG00000162723 SLAM family member 9 1 159951492-159954254 Predicted membrane proteins Evidence at transcript level HPA035153 Uncertain Mixed Tissue enhanced testis: 1.3 appendix: 0.6 SLC10A1 NTCP ENSG00000100652 Solute carrier family 10 (sodium/bile acid cotransporter), member 1 14 69775417-69797289 Predicted membrane proteins, Transporters Evidence at protein level HPA042727 Approved Liver cancer:9.53e-6 (favourable) Tissue enriched Tissue enriched 392 liver: 212.1 gallbladder: 0.5 SLC10A2 ASBT, ISBT ENSG00000125255 Solute carrier family 10 (sodium/bile acid cotransporter), member 2 13 103043998-103066846 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA004795 Approved Renal cancer:5.78e-5 (favourable) Tissue enriched Group enriched 32 duodenum: 21.6;kidney: 15.3;small intestine: 52.2 gallbladder: 0.9 SLC10A3 DXS253E, P3 ENSG00000126903 Solute carrier family 10, member 3 X 154487306-154490690 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA021656 Approved Approved Intermediate filaments Colorectal cancer:4.15e-5 (unfavourable), Cervical cancer:4.53e-4 (favourable), Pancreatic cancer:7.22e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.2 SLC10A4 MGC29802 ENSG00000145248 Solute carrier family 10, member 4 4 48483343-48489196 Predicted membrane proteins, Transporters Evidence at protein level HPA028835 Uncertain Supported Tissue enhanced Tissue enhanced adrenal gland: 6.2;cerebral cortex: 4.0 cervix, uterine: 1.5 SLC10A5 ENSG00000253598 Solute carrier family 10, member 5 8 81693607-81696174 Predicted membrane proteins, Transporters Evidence at protein level HPA025966 Uncertain Approved Plasma membrane Mixed Mixed liver: 3.0 SLC10A6 SOAT ENSG00000145283 Solute carrier family 10 (sodium/bile acid cotransporter), member 6 4 86823468-86849263 Predicted membrane proteins Evidence at protein level HPA016662 Supported Group enriched Tissue enhanced esophagus: 11.0;skin: 17.3 adipose tissue: 6.2 SLC10A7 C4orf13, DKFZp313H0531, DKFZp566M114, DKFZp779O2438, MGC25043 ENSG00000120519 Solute carrier family 10, member 7 4 146253975-146521964 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039996, HPA057906 Uncertain Approved Nucleoli Expressed in all Mixed epididymis: 16.0 SLC11A1 LSH, NRAMP, NRAMP1 ENSG00000018280 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 1 2 218382029-218396894 Predicted membrane proteins, Transporters Evidence at protein level HPA029590 Uncertain Renal cancer:2.58e-8 (unfavourable) Mixed Tissue enhanced appendix: 9.3;lung: 13.2 spleen: 4.8 SLC11A2 DCT1, DMT1, NRAMP2 ENSG00000110911 Solute carrier family 11 (proton-coupled divalent metal ion transporter), member 2 12 50979401-51028566 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA032139, HPA032140 Uncertain Supported Mitochondria Lung cancer:3.07e-6 (favourable) Expressed in all Expressed in all thyroid gland: 74.8 SLC12A1 NKCC2 ENSG00000074803 Solute carrier family 12 (sodium/potassium/chloride transporter), member 1 15 48191664-48304078 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014967, HPA018107 Supported Tissue enhanced Tissue enriched 456 kidney: 773.2 testis: 1.6 SLC12A2 BSC, BSC2, NKCC1, PPP1R141 ENSG00000064651 Solute carrier family 12 (sodium/potassium/chloride transporter), member 2 5 128083766-128189688 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA020130, HPA063697 Approved Approved Vesicles
Plasma membrane Renal cancer:7.09e-4 (favourable), Endometrial cancer:8.60e-4 (favourable) Expressed in all Expressed in all rectum: 66.4 SLC12A3 NCCT ENSG00000070915 Solute carrier family 12 (sodium/chloride transporter), member 3 16 56865207-56915850 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA028748 Supported Tissue enhanced Tissue enriched 107 kidney: 109.3 lymph node: 1.0 SLC12A4 KCC1 ENSG00000124067 Solute carrier family 12 (potassium/chloride transporter), member 4 16 67943474-67969601 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041138 Approved Approved Endosomes Renal cancer:2.25e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 62.5 SLC12A5 KCC2, KIAA1176 ENSG00000124140 Solute carrier family 12 (potassium/chloride transporter), member 5 20 46021690-46060152 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA072058 Supported Glioma:8.45e-4 (unfavourable) Mixed Tissue enriched 8 cerebral cortex: 94.5 adrenal gland: 12.0 SLC12A6 ACCPN, KCC3 ENSG00000140199 Solute carrier family 12 (potassium/chloride transporter), member 6 15 34229996-34338060 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034563 Uncertain Approved Vesicles
Cytosol Renal cancer:3.33e-6 (favourable) Expressed in all Mixed testis: 46.2 SLC12A7 DKFZP434F076, KCC4 ENSG00000113504 Solute carrier family 12 (potassium/chloride transporter), member 7 5 1050376-1112035 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041652 Approved Uncertain Cytosol Liver cancer:2.12e-6 (unfavourable), Urothelial cancer:3.16e-5 (favourable) Expressed in all Mixed duodenum: 25.0 SLC12A8 CCC9 ENSG00000221955 Solute carrier family 12, member 8 3 125082636-125212864 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA031123 Uncertain Supported Nucleoplasm Renal cancer:5.56e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 39.4 gallbladder: 16.3 SLC13A1 NAS1, NaSi-1 ENSG00000081800 Solute carrier family 13 (sodium/sulfate symporter), member 1 7 123113531-123199986 Predicted membrane proteins, Transporters Evidence at protein level HPA053615, HPA062714 Approved Renal cancer:8.95e-5 (favourable) Tissue enriched Tissue enriched 6 kidney: 84.4 small intestine: 14.3 SLC13A2 NaDC-1 ENSG00000007216 Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 2 17 28473293-28497781 Predicted membrane proteins, Transporters Evidence at protein level HPA014963 Supported Renal cancer:9.00e-4 (favourable) Mixed Tissue enhanced duodenum: 70.6;small intestine: 55.4 kidney: 19.6 SLC13A3 NADC3, SDCT2 ENSG00000158296 Solute carrier family 13 (sodium-dependent dicarboxylate transporter), member 3 20 46557823-46684467 Predicted membrane proteins, Transporters Evidence at protein level HPA014353, HPA014736 Supported Mixed Tissue enriched 7 kidney: 428.6 placenta: 60.6 SLC13A4 SUT-1, SUT1 ENSG00000164707 Solute carrier family 13 (sodium/sulfate symporter), member 4 7 135681237-135729258 Predicted membrane proteins, Transporters Evidence at transcript level HPA048582 Approved Mixed Tissue enriched 10 placenta: 76.2 testis: 7.3 SLC13A5 NACT ENSG00000141485 Solute carrier family 13 (sodium-dependent citrate transporter), member 5 17 6684713-6713567 Predicted membrane proteins, Transporters Evidence at protein level HPA044343, HPA057088 Approved Uncertain Nucleoplasm Tissue enriched Tissue enriched 9 liver: 118.1 salivary gland: 12.8 SLC14A1 HsT1341, JK, RACH1, RACH2 ENSG00000141469 Solute carrier family 14 (urea transporter), member 1 (Kidd blood group) 18 45724127-45752520 Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA058353, HPA059570 Supported Supported Vesicles Group enriched Group enriched 5 prostate: 132.1;urinary bladder: 51.9 cerebral cortex: 18.2 SLC15A1 HPECT1, HPEPT1, PEPT1 ENSG00000088386 Solute carrier family 15 (oligopeptide transporter), member 1 13 98683801-98752654 Predicted membrane proteins, Transporters Evidence at protein level HPA002827 Uncertain Approved Nucleoplasm
Cytosol Mixed Group enriched 5 duodenum: 157.7;gallbladder: 68.0;small intestine: 230.1 skin: 27.9 SLC15A3 hPTR3, PHT2 ENSG00000110446 Solute carrier family 15 (oligopeptide transporter), member 3 11 60937083-60952530 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA047880, HPA057642 Approved Supported Vesicles Cervical cancer:4.07e-5 (favourable) Expressed in all Expressed in all lung: 102.3 SLC15A4 PHT1, PTR4 ENSG00000139370 Solute carrier family 15 (oligopeptide transporter), member 4 12 128793191-128823983 Predicted membrane proteins, Transporters Evidence at protein level HPA016713 Approved Renal cancer:7.56e-6 (unfavourable), Liver cancer:6.78e-4 (unfavourable), Head and neck cancer:8.45e-4 (unfavourable) Expressed in all Expressed in all lymph node: 27.7 SLC15A5 ENSG00000188991 Solute carrier family 15, member 5 12 16188485-16277685 Predicted membrane proteins, Transporters No evidence HPA041638 Uncertain Not detected Not detected testis: 0.3 SLC16A1 MCT, MCT1 ENSG00000155380 Solute carrier family 16 (monocarboxylate transporter), member 1 1 112911847-112957013 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003324, CAB017489, HPA071055 Supported Validated Plasma membrane
Cell Junctions Renal cancer:6.78e-8 (unfavourable), Endometrial cancer:8.37e-6 (unfavourable), Pancreatic cancer:2.10e-4 (unfavourable), Lung cancer:4.05e-4 (unfavourable) Expressed in all Mixed testis: 32.0 SLC16A10 MCT10, TAT1 ENSG00000112394 Solute carrier family 16 (aromatic amino acid transporter), member 10 6 111087503-111231194 Predicted membrane proteins, Transporters Evidence at protein level HPA016860 Approved Approved Vesicles
Cell Junctions Tissue enriched Tissue enhanced placenta: 38.2 skin: 22.5 SLC16A13 MCT13 ENSG00000174327 Solute carrier family 16, member 13 17 7036075-7040121 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA065245 Supported Golgi apparatus Pancreatic cancer:1.50e-4 (favourable) Expressed in all Mixed liver: 15.4 SLC16A14 FLJ30794, MCT14 ENSG00000163053 Solute carrier family 16, member 14 2 230034974-230068999 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA040518 Uncertain Approved Cytosol Mixed Mixed parathyroid gland: 14.6 SLC16A2 AHDS, DXS128, MCT7, MCT8, MRX22, XPCT ENSG00000147100 Solute carrier family 16, member 2 (thyroid hormone transporter) X 74421461-74533917 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA072719 Approved Plasma membrane Breast cancer:8.88e-5 (unfavourable), Renal cancer:1.83e-4 (unfavourable), Urothelial cancer:3.16e-4 (unfavourable) Expressed in all Mixed liver: 41.9 SLC16A3 MCT3, MCT4 ENSG00000141526 Solute carrier family 16 (monocarboxylate transporter), member 3 17 82228397-82261129 Predicted membrane proteins, Transporters Evidence at protein level CAB017490, HPA021451 Approved Supported Nuclear membrane
Plasma membrane Liver cancer:1.19e-7 (unfavourable), Renal cancer:3.71e-7 (unfavourable), Lung cancer:2.02e-5 (unfavourable), Cervical cancer:6.07e-4 (unfavourable) Expressed in all Expressed in all skeletal muscle: 74.4 SLC16A4 MCT4, MCT5 ENSG00000168679 Solute carrier family 16, member 4 1 110362848-110391082 Predicted membrane proteins Evidence at transcript level HPA046986, HPA060163 Approved Approved Microtubules
Cytokinetic bridge
Cytosol Renal cancer:1.69e-4 (favourable) Expressed in all Tissue enhanced kidney: 124.3 placenta: 39.9 SLC16A6 MCT6, MCT7 ENSG00000108932 Solute carrier family 16, member 6 17 68267026-68291267 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054459, HPA066328 Uncertain Approved Vesicles Group enriched Tissue enhanced epididymis: 39.8 esophagus: 12.1 SLC16A7 MCT2 ENSG00000118596 Solute carrier family 16 (monocarboxylate transporter), member 7 12 59596067-59789855 Predicted membrane proteins, Transporters Evidence at protein level HPA005911 Approved Approved Nucleoplasm
Plasma membrane Renal cancer:8.85e-5 (favourable) Mixed Mixed adipose tissue: 24.8 SLC16A8 MCT3, REMP ENSG00000100156 Solute carrier family 16 (monocarboxylate transporter), member 8 22 38078134-38084093 Plasma proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA075017 Approved Intermediate filaments
Focal adhesion sites Mixed Mixed prostate: 5.7 SLC16A9 C10orf36, FLJ43803, MCT9 ENSG00000165449 Solute carrier family 16, member 9 10 59650761-59736002 Predicted membrane proteins, Transporters Evidence at protein level HPA049286 Approved Approved Nucleus
Cell Junctions Renal cancer:2.56e-6 (favourable) Mixed Tissue enhanced adrenal gland: 199.5;kidney: 199.2 spleen: 57.0 SLC17A1 NAPI-1, NPT1 ENSG00000124568 Solute carrier family 17 (organic anion transporter), member 1 6 25782897-25832059 Predicted membrane proteins, Transporters Evidence at protein level HPA050513 Approved Golgi apparatus Group enriched Tissue enriched 7 kidney: 173.1 liver: 25.2 SLC17A2 NPT3 ENSG00000112337 Solute carrier family 17, member 2 6 25912754-25930726 Predicted membrane proteins, Transporters Evidence at protein level HPA038270 Uncertain Liver cancer:8.54e-4 (favourable) Tissue enriched Tissue enriched 85 liver: 40.9 kidney,testis: 0.4 SLC17A3 NPT4 ENSG00000124564 Solute carrier family 17 (organic anion transporter), member 3 6 25833066-25882286 Predicted membrane proteins, Transporters Evidence at protein level HPA016569 Uncertain Tissue enriched Tissue enriched 9 kidney: 167.2 liver: 18.5 SLC17A4 KIAA2138 ENSG00000146039 Solute carrier family 17, member 4 6 25754699-25781191 Predicted membrane proteins, Transporters Evidence at transcript level HPA055564 Approved Group enriched Group enriched 6 colon: 20.8;duodenum: 29.4;gallbladder: 25.5;liver: 22.4;rectum: 29.4;small intestine: 35.7 pancreas: 4.2 SLC17A5 AST, ISSD, NSD, SD, SIALIN, SIASD, SLD ENSG00000119899 Solute carrier family 17 (acidic sugar transporter), member 5 6 73593379-73654155 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044479 Supported Plasma membrane
Cytosol Thyroid cancer:3.52e-4 (favourable) Expressed in all Tissue enriched 9 parathyroid gland: 640.5 thyroid gland: 69.8 SLC17A6 DNPI, VGLUT2 ENSG00000091664 Solute carrier family 17 (vesicular glutamate transporter), member 6 11 22338097-22379503 Predicted membrane proteins, Transporters Evidence at protein level CAB037130, HPA039226 Supported Supported Not detected Tissue enriched 65 cerebral cortex: 6.5 all non-specific tissues: 0.0 SLC17A7 BNPI, VGLUT1 ENSG00000104888 Solute carrier family 17 (vesicular glutamate transporter), member 7 19 49429401-49442360 Predicted membrane proteins, Transporters Evidence at protein level CAB037183, HPA050458, HPA063679 Supported Tissue enriched Tissue enriched 178 cerebral cortex: 586.2 adipose tissue: 3.2 SLC17A9 C20orf59, FLJ23412, VNUT ENSG00000101194 Solute carrier family 17 (vesicular nucleotide transporter), member 9 20 62952647-62969585 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA047470, HPA056499 Uncertain Approved Nucleoplasm Renal cancer:2.78e-15 (unfavourable) Mixed Mixed stomach: 8.7 SLC18A1 CGAT, VAT1, VMAT1 ENSG00000036565 Solute carrier family 18 (vesicular monoamine transporter), member 1 8 20144855-20183206 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA006877, HPA063797 Supported Tissue enhanced Tissue enriched 10 adrenal gland: 32.8 rectum: 3.1 SLC18A3 VACHT ENSG00000187714 Solute carrier family 18 (vesicular acetylcholine transporter), member 3 10 49610301-49612720 Predicted membrane proteins, Transporters Evidence at transcript level CAB037102 Uncertain Mixed Not detected placenta: 0.6 SLC18B1 C6orf192, dJ55C23.6 ENSG00000146409 Solute carrier family 18, subfamily B, member 1 6 132769370-132798553 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029747, HPA049659 Approved Supported Golgi apparatus
Cytosol Head and neck cancer:3.55e-4 (favourable), Liver cancer:7.90e-4 (unfavourable), Renal cancer:9.24e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 37.6 SLC19A1 FOLT ENSG00000173638 Solute carrier family 19 (folate transporter), member 1 21 45493572-45544411 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA024802 Approved Approved Plasma membrane Renal cancer:1.07e-10 (unfavourable), Cervical cancer:4.15e-4 (unfavourable) Expressed in all Mixed duodenum: 22.6 SLC19A2 THTR1, TRMA ENSG00000117479 Solute carrier family 19 (thiamine transporter), member 2 1 169463909-169486003 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA006119, HPA016599 Uncertain Approved Cytosol Renal cancer:2.70e-5 (favourable), Glioma:2.11e-4 (favourable), Breast cancer:8.41e-4 (favourable) Expressed in all Expressed in all gallbladder: 49.3 SLC19A3 THTR2 ENSG00000135917 Solute carrier family 19 (thiamine transporter), member 3 2 227685210-227718012 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038898 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced adipose tissue: 50.1;placenta: 34.5 duodenum: 12.7 SLC1A1 EAAC1, EAAT3 ENSG00000106688 Solute carrier family 1 (neuronal/epithelial high affinity glutamate transporter, system Xag), member 1 9 4490444-4587469 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015466, HPA020086 Approved Renal cancer:2.86e-8 (favourable) Expressed in all Tissue enhanced small intestine: 72.7 epididymis: 53.8 SLC1A2 EAAT2, GLT-1 ENSG00000110436 Solute carrier family 1 (glial high affinity glutamate transporter), member 2 11 35251206-35420063 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB002574, HPA009172 Supported Tissue enriched Tissue enriched 30 cerebral cortex: 367.1 liver: 12.2 SLC1A3 EA6, EAAT1, GLAST ENSG00000079215 Solute carrier family 1 (glial high affinity glutamate transporter), member 3 5 36606355-36688334 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002573, HPA037467, HPA037468 Supported Approved Nucleoli
Mitochondria Tissue enriched Tissue enriched 16 cerebral cortex: 519.6 adipose tissue: 31.7 SLC1A4 ASCT1, SATT ENSG00000115902 Solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 2 64988477-65023865 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034963, HPA034964 Approved Validated Microtubule organizing center
Centrosome Liver cancer:4.23e-5 (unfavourable), Cervical cancer:3.59e-4 (favourable), Renal cancer:4.87e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 79.3 SLC1A5 AAAT, ASCT2, M7V1, RDRC ENSG00000105281 Solute carrier family 1 (neutral amino acid transporter), member 5 19 46774883-46788594 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035239, HPA035240 Supported Validated Plasma membrane Liver cancer:1.66e-8 (unfavourable), Renal cancer:1.18e-7 (unfavourable) Expressed in all Expressed in all epididymis: 117.4 SLC1A6 EAAT4 ENSG00000105143 Solute carrier family 1 (high affinity aspartate/glutamate transporter), member 6 19 14950034-15022990 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041505, HPA044066 Supported Uncertain Intermediate filaments Urothelial cancer:6.88e-6 (unfavourable) Tissue enriched Group enriched 6 cerebral cortex: 16.2;skin: 8.9;testis: 36.8 epididymis: 3.7 SLC20A1 Glvr-1, GLVR1, PiT-1 ENSG00000144136 Solute carrier family 20 (phosphate transporter), member 1 2 112645857-112663827 Predicted membrane proteins, Transporters Evidence at protein level CAB019279, HPA035834 Approved Approved Vesicles Renal cancer:3.44e-5 (unfavourable), Head and neck cancer:6.56e-5 (unfavourable) Expressed in all Expressed in all colon: 51.9 SLC20A2 Glvr-2, GLVR2, MLVAR, PiT-2 ENSG00000168575 Solute carrier family 20 (phosphate transporter), member 2 8 42416475-42541926 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA026540 Approved Renal cancer:1.01e-4 (favourable), Breast cancer:7.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 137.7 SLC22A1 OCT1 ENSG00000175003 Solute carrier family 22 (organic cation transporter), member 1 6 160121789-160158718 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029846 Approved Liver cancer:1.35e-5 (favourable) Tissue enriched Tissue enriched 252 liver: 286.8 gallbladder: 1.1 SLC22A11 OAT4 ENSG00000168065 Solute carrier family 22 (organic anion/urate transporter), member 11 11 64555626-64572875 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026076 Approved Renal cancer:3.68e-5 (favourable) Group enriched Group enriched 134 epididymis: 10.0;kidney: 25.9;placenta: 44.5 seminal vesicle: 0.2 SLC22A12 OAT4L, RST, URAT1 ENSG00000197891 Solute carrier family 22 (organic anion/urate transporter), member 12 11 64590641-64602353 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024575 Supported Renal cancer:2.63e-4 (favourable) Group enriched Tissue enriched 195 kidney: 104.6 adipose tissue: 0.5 SLC22A13 OAT10, OCTL1, OCTL3, ORCTL3 ENSG00000172940 Solute carrier family 22 (organic anion/urate transporter), member 13 3 38265812-38278315 Predicted membrane proteins, Transporters Evidence at protein level HPA035603, HPA035962 Supported Tissue enriched Tissue enriched 39 kidney: 10.6 testis: 0.2 SLC22A15 FLIPT1 ENSG00000163393 Solute carrier family 22, member 15 1 115976498-116070054 Predicted membrane proteins, Transporters Evidence at protein level HPA019785 Approved Approved Vesicles Expressed in all Tissue enhanced bone marrow: 20.5 skin: 11.1 SLC22A16 CT2, FLIPT2, OAT6, OKB1 ENSG00000004809 Solute carrier family 22 (organic cation/carnitine transporter), member 16 6 110424687-110476641 Predicted membrane proteins Evidence at protein level HPA036902 Uncertain Tissue enriched Group enriched 8 bone marrow: 13.0;parathyroid gland: 16.1;testis: 38.4 smooth muscle: 2.7 SLC22A17 BOCT, BOIT, NGALR ENSG00000092096 Solute carrier family 22, member 17 14 23346306-23352912 Predicted membrane proteins, Transporters Evidence at protein level HPA002728 Uncertain Pancreatic cancer:1.73e-4 (favourable), Stomach cancer:5.95e-4 (unfavourable) Expressed in all Tissue enriched 6 cerebral cortex: 229.2 prostate: 38.6 SLC22A18 BWR1A, BWSCR1A, IMPT1, ITM, ORCTL2, SLC22A1L, TSSC5 ENSG00000110628 Solute carrier family 22, member 18 11 2899721-2925246 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA067812, HPA071461 Approved Expressed in all Tissue enhanced duodenum: 44.5;small intestine: 32.4 colon: 10.5 SLC22A2 OCT2 ENSG00000112499 Solute carrier family 22 (organic cation transporter), member 2 6 160171061-160277638 Predicted membrane proteins, Transporters Evidence at protein level HPA008567, CAB068236, CAB068237 Supported Renal cancer:1.85e-7 (favourable) Tissue enriched Tissue enriched 83 kidney: 149.2 seminal vesicle: 1.7 SLC22A23 C6orf85, FLJ22174 ENSG00000137266 Solute carrier family 22, member 23 6 3268962-3457022 Predicted membrane proteins, Transporters Evidence at protein level HPA014697 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:2.39e-4 (unfavourable), Endometrial cancer:6.57e-4 (favourable) Expressed in all Expressed in all stomach: 28.2 SLC22A24 MGC34821, NET46 ENSG00000197658 Solute carrier family 22, member 24 11 63079940-63144221 Predicted membrane proteins, Transporters Evidence at transcript level HPA045015 Uncertain Tissue enriched Tissue enriched 46 kidney: 4.6 all non-specific tissues: 0.0 SLC22A25 HIMTP, MGC120420, UST6 ENSG00000196600 Solute carrier family 22, member 25 11 63163776-63229652 Predicted membrane proteins, Transporters Evidence at transcript level HPA039390 Uncertain Liver cancer:7.04e-4 (favourable) Tissue enriched Tissue enriched 57 liver: 5.7 all non-specific tissues: 0.0 SLC22A3 EMT, OCT3 ENSG00000146477 Solute carrier family 22 (organic cation transporter), member 3 6 160348268-160452581 Predicted membrane proteins, Transporters Evidence at protein level HPA029750 Approved Approved Nucleoplasm
Vesicles
Cytosol Cervical cancer:7.19e-5 (unfavourable), Urothelial cancer:7.26e-4 (unfavourable) Mixed Mixed seminal vesicle: 70.0 SLC22A4 MGC34546, OCTN1 ENSG00000197208 Solute carrier family 22 (organic cation/zwitterion transporter), member 4 5 132294443-132344206 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015468, HPA036973 Approved Uncertain Nucleoplasm
Cytosol Mixed Tissue enhanced fallopian tube: 18.6 bone marrow: 13.2 SLC22A5 CDSP, OCTN2, SCD ENSG00000197375 Solute carrier family 22 (organic cation/carnitine transporter), member 5 5 132369752-132395614 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA063062 Approved Mitochondria Endometrial cancer:2.87e-5 (favourable), Pancreatic cancer:7.36e-4 (favourable), Renal cancer:8.36e-4 (favourable) Expressed in all Mixed parathyroid gland: 31.4 SLC22A7 NLT, OAT2 ENSG00000137204 Solute carrier family 22 (organic anion transporter), member 7 6 43295694-43305538 Predicted membrane proteins, Transporters Evidence at protein level HPA030220 Approved Liver cancer:5.48e-6 (favourable), Renal cancer:8.98e-4 (favourable) Tissue enriched Group enriched 63 kidney: 50.1;liver: 167.4 testis: 1.7 SLC22A8 OAT3 ENSG00000149452 Solute carrier family 22 (organic anion transporter), member 8 11 62989154-63015839 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044174 Supported Tissue enhanced Tissue enriched 391 kidney: 337.6 cerebral cortex: 0.8 SLC23A1 SLC23A2, SVCT1, YSPL3 ENSG00000170482 Solute carrier family 23 (ascorbic acid transporter), member 1 5 139367196-139384553 Predicted membrane proteins, Transporters Evidence at protein level HPA047612 Supported Group enriched Group enriched 5 duodenum: 27.5;fallopian tube: 85.7;kidney: 41.7;small intestine: 73.4 liver: 10.7 SLC23A2 KIAA0238, SLC23A1, SVCT2, YSPL2 ENSG00000089057 Solute carrier family 23 (ascorbic acid transporter), member 2 20 4852356-5010293 Predicted membrane proteins, Transporters Evidence at protein level HPA052825, HPA059314 Approved Supported Golgi apparatus
Vesicles Urothelial cancer:6.08e-5 (favourable), Pancreatic cancer:7.14e-5 (favourable), Liver cancer:3.35e-4 (favourable) Expressed in all Expressed in all adrenal gland: 98.6 SLC23A3 FLJ31168, SVCT3, Yspl1 ENSG00000213901 Solute carrier family 23, member 3 2 219161465-219170095 Predicted membrane proteins, Transporters Evidence at protein level HPA019059 Approved Nucleus
Cell Junctions Tissue enriched Tissue enhanced kidney: 52.7;small intestine: 23.3 duodenum: 9.0 SLC24A1 CSNB1D, HsT17412, KIAA0702, NCKX, NCKX1, RODX ENSG00000074621 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 1 15 65611366-65660995 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039370 Supported Approved Microtubules Renal cancer:2.33e-6 (favourable) Expressed in all Mixed fallopian tube: 8.7 SLC24A3 ENSG00000185052 Solute carrier family 24 (sodium/potassium/calcium exchanger), member 3 20 19212646-19722937 Predicted membrane proteins, Transporters Evidence at protein level HPA043400, HPA045497 Uncertain Thyroid cancer:6.08e-4 (unfavourable) Mixed Mixed endometrium: 47.4 SLC25A17 PMP34 ENSG00000100372 Solute carrier family 25 (mitochondrial carrier; peroxisomal membrane protein, 34kDa), member 17 22 40769630-40819399 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA052708, HPA060972 Approved Supported Peroxisomes Expressed in all Expressed in all ovary: 24.0 SLC25A2 ORNT2 ENSG00000120329 Solute carrier family 25 (mitochondrial carrier; ornithine transporter) member 2 5 141302629-141304045 Predicted membrane proteins, Transporters Evidence at protein level HPA042146 Uncertain Not detected Tissue enriched 116 testis: 11.6 all non-specific tissues: 0.0 SLC25A20 CAC, CACT ENSG00000178537 Solute carrier family 25 (carnitine/acylcarnitine translocase), member 20 3 48856931-48898993 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016862, HPA029863 Approved Supported Mitochondria
Cytosol Expressed in all Expressed in all liver: 70.8 SLC25A22 EIEE3, FLJ13044, GC1, NET44 ENSG00000177542 Solute carrier family 25 (mitochondrial carrier: glutamate), member 22 11 790475-798333 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA014662 Approved Validated Nucleoplasm
Mitochondria Expressed in all Tissue enriched 6 cerebral cortex: 89.9 testis: 15.2 SLC25A23 APC2, FLJ30339, MGC2615 ENSG00000125648 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23 19 6436079-6465203 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA009675, HPA050883 Approved Supported Mitochondria Renal cancer:1.10e-12 (favourable), Endometrial cancer:1.29e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 141.8 SLC25A26 ENSG00000144741 Solute carrier family 25 (S-adenosylmethionine carrier), member 26 3 66133610-66388116 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA026887 Supported Supported Mitochondria Renal cancer:1.73e-5 (favourable) Expressed in all Expressed in all thyroid gland: 17.4 SLC25A3 PHC ENSG00000075415 Solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 3 12 98593591-98606379 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA045709 Supported Mitochondria Renal cancer:8.11e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 583.9 SLC25A31 ANT4, DKFZP434N1235 ENSG00000151475 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 31 4 127730378-127774299 Predicted membrane proteins, Transporters Evidence at protein level HPA015064, HPA016841, HPA046835, HPA071684 Uncertain Validated Mitochondria Not detected Tissue enriched 849 testis: 84.9 all non-specific tissues: 0.0 SLC25A33 BMSC-MCP, MGC4399, PNC1 ENSG00000171612 Solute carrier family 25 (pyrimidine nucleotide carrier), member 33 1 9539482-9585179 Predicted membrane proteins, Transporters Evidence at protein level HPA049982 Uncertain Cervical cancer:4.86e-4 (favourable), Lung cancer:7.02e-4 (favourable) Expressed in all Mixed testis: 22.0 SLC25A34 DKFZp781A10161 ENSG00000162461 Solute carrier family 25, member 34 1 15736405-15741396 Predicted membrane proteins, Transporters Evidence at protein level HPA069806 Supported Mitochondria Mixed Tissue enhanced duodenum: 14.9;small intestine: 15.5 skeletal muscle: 8.2 SLC25A35 FLJ40217 ENSG00000125434 Solute carrier family 25, member 35 17 8287763-8295343 Predicted membrane proteins, Transporters Evidence at protein level HPA051720 Uncertain Approved Vesicles
Mitochondria Endometrial cancer:3.37e-7 (favourable), Renal cancer:1.14e-6 (favourable), Urothelial cancer:1.91e-5 (favourable) Expressed in all Mixed testis: 19.6 SLC25A36 FLJ10618, PNC2 ENSG00000114120 Solute carrier family 25 (pyrimidine nucleotide carrier), member 36 3 140941830-140979933 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA027036 Approved Approved Nucleus
Mitochondria
Cytosol Urothelial cancer:1.55e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 68.3 SLC25A38 FLJ20551 ENSG00000144659 Solute carrier family 25, member 38 3 39383348-39397351 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041027 Approved Renal cancer:1.58e-5 (favourable), Urothelial cancer:7.29e-4 (favourable) Expressed in all Expressed in all thyroid gland: 65.8 SLC25A39 CGI-69, FLJ22407 ENSG00000013306 Solute carrier family 25, member 39 17 44319625-44324870 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA026785 Approved Renal cancer:3.58e-5 (favourable), Liver cancer:5.90e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 181.5 SLC25A4 ANT1, PEO2, PEO3, T1 ENSG00000151729 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 4 4 185143241-185150382 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:0.00e+0 (favourable), Pancreatic cancer:3.41e-4 (favourable) Expressed in all Tissue enhanced heart muscle: 119.0;skeletal muscle: 66.2 cerebral cortex: 38.2 SLC25A40 MCFP ENSG00000075303 Solute carrier family 25, member 40 7 87833568-87876357 Predicted membrane proteins, Transporters Evidence at protein level HPA055197 Uncertain Renal cancer:1.52e-5 (favourable), Liver cancer:1.93e-4 (unfavourable) Expressed in all Mixed prostate: 13.6 SLC25A42 MGC26694 ENSG00000181035 Solute carrier family 25, member 42 19 19063999-19112888 Predicted membrane proteins, Transporters Evidence at protein level HPA049449 Approved Supported Mitochondria Lung cancer:4.11e-4 (favourable), Cervical cancer:5.04e-4 (favourable) Expressed in all Expressed in all kidney: 28.7 SLC25A43 ENSG00000077713 Solute carrier family 25, member 43 X 119399060-119454478 Predicted membrane proteins, Transporters Evidence at transcript level HPA035188 Uncertain Approved Nucleus Renal cancer:5.06e-8 (unfavourable), Endometrial cancer:3.76e-5 (unfavourable) Expressed in all Mixed esophagus: 20.6 SLC25A44 FLJ90431, KIAA0446 ENSG00000160785 Solute carrier family 25, member 44 1 156193932-156212796 Predicted membrane proteins, Transporters Evidence at protein level HPA065411 Approved Nucleus
Mitochondria Pancreatic cancer:2.49e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 43.1 SLC25A45 ENSG00000162241 Solute carrier family 25, member 45 11 65375192-65383701 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050821 Uncertain Approved Nucleoplasm
Cytosol Pancreatic cancer:2.83e-4 (favourable) Expressed in all Expressed in all spleen: 12.6 SLC25A46 ENSG00000164209 Solute carrier family 25, member 46 5 110738136-110765161 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039601, HPA071582 Approved Supported Mitochondria Thyroid cancer:2.52e-4 (unfavourable), Colorectal cancer:8.41e-4 (favourable) Expressed in all Expressed in all testis: 37.3 SLC25A48 FLJ44862, HDMCP ENSG00000145832 Solute carrier family 25, member 48 5 135834649-135888637 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014674 Uncertain Approved Intermediate filaments
Actin filaments Mixed Tissue enhanced cerebral cortex: 17.7;kidney: 7.3 skeletal muscle: 2.7 SLC25A5 2F1, ANT2, T2, T3 ENSG00000005022 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 5 X 119468400-119471319 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Renal cancer:8.06e-6 (favourable), Cervical cancer:7.35e-4 (favourable), Colorectal cancer:7.47e-4 (favourable) Expressed in all Expressed in all duodenum: 791.0 SLC25A51 CG7943, MCART1, MGC14836 ENSG00000122696 Solute carrier family 25, member 51 9 37879400-37904353 Predicted membrane proteins, Transporters Evidence at protein level HPA046388, HPA058261 Uncertain Approved Mitochondria Liver cancer:5.67e-5 (unfavourable), Renal cancer:1.52e-4 (favourable), Thyroid cancer:2.21e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 16.4 SLC25A52 MCART2 ENSG00000141437 Solute carrier family 25, member 52 18 31759562-31760880 Predicted membrane proteins Evidence at transcript level HPA046388, HPA058261 Uncertain Approved Mitochondria Not detected Tissue enriched 104 testis: 15.3 breast,duodenum,liver,prostate,skin: 0.1 SLC25A6 ANT3, ANT3Y, MGC17525 ENSG00000169100 Solute carrier family 25 (mitochondrial carrier; adenine nucleotide translocator), member 6 X 1386152-1392724 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA046835, HPA071684 Approved Supported Mitochondria Expressed in all Expressed in all duodenum: 294.5 SLC26A1 EDM4, SAT-1 ENSG00000145217 Solute carrier family 26 (anion exchanger), member 1 4 979073-993440 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041654 Uncertain Approved Microtubules Renal cancer:1.19e-4 (favourable) Mixed Mixed kidney: 6.1 SLC26A10 ENSG00000135502 Solute carrier family 26, member 10 12 57619527-57626151 Predicted membrane proteins, Transporters Evidence at transcript level HPA044719 Uncertain Tissue enhanced Not detected endometrium: 0.5 SLC26A11 ENSG00000181045 Solute carrier family 26 (anion exchanger), member 11 17 80219699-80253500 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029893 Approved Supported Nucleoplasm
Golgi apparatus
Vesicles Liver cancer:1.82e-6 (unfavourable), Pancreatic cancer:1.43e-5 (favourable), Endometrial cancer:1.55e-5 (unfavourable) Expressed in all Expressed in all adrenal gland: 34.5 SLC26A2 DTD, DTDST ENSG00000155850 Solute carrier family 26 (anion exchanger), member 2 5 149960737-149993455 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041957, HPA058090 Supported Approved Vesicles Renal cancer:3.27e-4 (unfavourable), Liver cancer:4.66e-4 (unfavourable), Endometrial cancer:7.29e-4 (favourable) Expressed in all Tissue enhanced colon: 215.9;rectum: 209.8 parathyroid gland: 81.4 SLC26A3 CLD, DRA ENSG00000091138 Solute carrier family 26 (anion exchanger), member 3 7 107765467-107803225 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA036055 Approved Tissue enriched Tissue enhanced colon: 1092.5;duodenum: 594.0;rectum: 974.8 seminal vesicle: 183.9 SLC26A4 DFNB4, PDS ENSG00000091137 Solute carrier family 26 (anion exchanger), member 4 7 107660635-107717809 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042860 Approved Tissue enriched Tissue enriched 28 thyroid gland: 422.9 cerebral cortex: 15.2 SLC26A6 DKFZp586E1422 ENSG00000225697 Solute carrier family 26 (anion exchanger), member 6 3 48625723-48635493 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA048363 Approved Uncertain Cytosol Renal cancer:1.53e-5 (unfavourable), Liver cancer:3.92e-4 (unfavourable) Expressed in all Expressed in all rectum: 24.3 SLC26A8 ENSG00000112053 Solute carrier family 26 (anion exchanger), member 8 6 35943514-36024868 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA038080, HPA038081 Uncertain Not detected Tissue enriched 27 testis: 75.6 bone marrow: 2.8 SLC26A9 ENSG00000174502 Solute carrier family 26 (anion exchanger), member 9 1 205913048-205943460 Predicted membrane proteins, Transporters Evidence at protein level HPA051485 Approved Approved Nucleus
Cell Junctions Head and neck cancer:8.55e-5 (favourable) Tissue enhanced Tissue enhanced salivary gland: 31.7;stomach: 30.4 lung: 11.4 SLC27A2 ACSVL1, FACVL1, FATP2, hFACVL1, HsT17226, VLACS, VLCS ENSG00000140284 Solute carrier family 27 (fatty acid transporter), member 2 15 50182196-50236395 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA026089 Supported Renal cancer:7.48e-6 (favourable), Urothelial cancer:6.40e-4 (favourable) Tissue enhanced Group enriched 5 epididymis: 79.2;kidney: 160.9;liver: 145.2 placenta: 24.5 SLC27A3 ACSVL3, FATP3, MGC4365 ENSG00000143554 Solute carrier family 27 (fatty acid transporter), member 3 1 153774354-153780157 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006935, HPA067508 Uncertain Supported Endoplasmic reticulum Pancreatic cancer:5.23e-4 (favourable), Renal cancer:6.33e-4 (unfavourable) Expressed in all Tissue enhanced epididymis: 43.7 lung: 20.9 SLC27A5 ACSB, ACSVL6, FACVL3, FATP5, FLJ22987, VLACSR, VLCS-H2, VLCSH2 ENSG00000083807 Solute carrier family 27 (fatty acid transporter), member 5 19 58479512-58512413 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA007292, CAB056160, CAB068239 Supported Liver cancer:1.57e-4 (favourable) Tissue enriched Tissue enriched 23 liver: 335.8 fallopian tube: 14.4 SLC27A6 ACSVL2, FACVL2, FATP6, VLCS-H1 ENSG00000113396 Solute carrier family 27 (fatty acid transporter), member 6 5 128538013-129033642 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008987 Approved Approved Nuclear bodies Tissue enriched Tissue enhanced adrenal gland: 32.7;fallopian tube: 33.7 testis: 24.1 SLC28A1 CNT1 ENSG00000156222 Solute carrier family 28 (concentrative nucleoside transporter), member 1 15 84884654-84945796 Predicted membrane proteins, Transporters Evidence at protein level HPA019551 Supported Group enriched Group enriched 26 duodenum: 39.0;kidney: 49.1;liver: 35.4;small intestine: 54.7 placenta: 1.6 SLC28A2 CNT2, HCNT2, HsT17153, SPNT1 ENSG00000137860 Solute carrier family 28 (concentrative nucleoside transporter), member 2 15 45252230-45277845 Predicted membrane proteins, Transporters Evidence at protein level HPA046068, HPA055623 Supported Tissue enhanced Tissue enhanced duodenum: 66.8;rectum: 37.9;small intestine: 100.1 stomach: 21.4 SLC28A3 CNT3 ENSG00000197506 Solute carrier family 28 (concentrative nucleoside transporter), member 3 9 84275457-84340683 Predicted membrane proteins, Transporters Evidence at protein level HPA023311, HPA024729 Approved Breast cancer:3.37e-4 (favourable) Mixed Tissue enhanced breast: 10.7;gallbladder: 11.7;skin: 9.8 bone marrow: 6.2 SLC29A1 ENT1 ENSG00000112759 Solute carrier family 29 (equilibrative nucleoside transporter), member 1 6 44219505-44234151 Predicted membrane proteins, Transporters Evidence at protein level HPA012384 Approved Renal cancer:2.96e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 125.1 SLC29A2 DER12, ENT2, HNP36 ENSG00000174669 Solute carrier family 29 (equilibrative nucleoside transporter), member 2 11 66362521-66372214 Predicted membrane proteins, Transporters Evidence at protein level HPA018168 Approved Uncertain Nucleoplasm Endometrial cancer:2.04e-4 (unfavourable), Renal cancer:2.78e-4 (favourable) Expressed in all Tissue enhanced skeletal muscle: 36.4 parathyroid gland: 21.8 SLC29A3 ENT3, FLJ11160 ENSG00000198246 Solute carrier family 29 (equilibrative nucleoside transporter), member 3 10 71319258-71363385 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046085, HPA054976, HPA057905 Approved Supported Golgi apparatus
Vesicles Liver cancer:6.07e-6 (unfavourable), Renal cancer:5.53e-5 (unfavourable), Thyroid cancer:1.16e-4 (favourable) Expressed in all Mixed placenta: 18.7 SLC29A4 ENT4, FLJ34923 ENSG00000164638 Solute carrier family 29 (equilibrative nucleoside transporter), member 4 7 5274369-5306870 Predicted membrane proteins, Transporters Evidence at protein level HPA052829 Supported Microtubules
Cytokinetic bridge Pancreatic cancer:4.52e-4 (favourable) Expressed in all Tissue enhanced adipose tissue: 44.2 cerebral cortex: 12.0 SLC2A1 CSE, DYT18, DYT9, GLUT, GLUT1, HTLVR ENSG00000117394 Solute carrier family 2 (facilitated glucose transporter), member 1 1 42925375-42959173 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002759, HPA031345, HPA058494 Supported Supported Validated Plasma membrane Renal cancer:4.55e-9 (unfavourable), Liver cancer:3.65e-8 (unfavourable), Pancreatic cancer:4.39e-5 (unfavourable), Lung cancer:1.09e-4 (unfavourable), Urothelial cancer:4.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 133.9 skin: 31.3 SLC2A10 GLUT10 ENSG00000197496 Solute carrier family 2 (facilitated glucose transporter), member 10 20 46709487-46736347 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041015, HPA055673 Approved Supported Cytosol Expressed in all Mixed prostate: 46.7 SLC2A11 GLUT10, GLUT11 ENSG00000133460 Solute carrier family 2 (facilitated glucose transporter), member 11 22 23856703-23886309 Predicted membrane proteins, Transporters Evidence at transcript level HPA042960, HPA071184 Uncertain Uncertain Nucleus
Cell Junctions Renal cancer:5.77e-7 (favourable), Pancreatic cancer:3.83e-4 (favourable) Mixed Mixed parathyroid gland: 10.7 SLC2A12 GLUT12, GLUT8 ENSG00000146411 Solute carrier family 2 (facilitated glucose transporter), member 12 6 133988697-134052636 Predicted membrane proteins, Transporters Evidence at protein level HPA031593, HPA031594 Approved Validated Plasma membrane
Cell Junctions Tissue enriched Tissue enhanced prostate: 38.8 endometrium: 15.7 SLC2A13 HMIT ENSG00000151229 Solute carrier family 2 (facilitated glucose transporter), member 13 12 39755021-40106089 Predicted membrane proteins, Transporters Evidence at protein level HPA006584 Approved Approved Nuclear membrane Mixed Tissue enhanced cerebral cortex: 49.5;parathyroid gland: 73.3 cervix, uterine: 20.3 SLC2A14 GLUT14, SLC2A3P3 ENSG00000173262 Solute carrier family 2 (facilitated glucose transporter), member 14 12 7812512-7891148 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006539 Approved Approved Plasma membrane Tissue enriched Tissue enriched 9 testis: 151.1 breast: 17.2 SLC2A2 GLUT2 ENSG00000163581 Solute carrier family 2 (facilitated glucose transporter), member 2 3 170996348-171026750 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB010444, HPA028997, HPA028998 Supported Approved Nucleoplasm Liver cancer:2.63e-5 (favourable) Tissue enriched Tissue enriched 6 liver: 432.5 duodenum: 67.5 SLC2A3 GLUT3 ENSG00000059804 Solute carrier family 2 (facilitated glucose transporter), member 3 12 7919230-7936275 Predicted membrane proteins, Transporters Evidence at protein level CAB002763, HPA006539 Approved Approved Plasma membrane Renal cancer:6.36e-8 (unfavourable), Stomach cancer:2.89e-5 (unfavourable), Colorectal cancer:8.58e-4 (unfavourable) Tissue enriched Tissue enhanced bone marrow: 271.6 placenta: 137.6 SLC2A4 GLUT4 ENSG00000181856 Solute carrier family 2 (facilitated glucose transporter), member 4 17 7281667-7288257 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB016544 Supported Mixed Tissue enhanced heart muscle: 30.1;skeletal muscle: 45.0 adipose tissue: 21.9 SLC2A5 GLUT5 ENSG00000142583 Solute carrier family 2 (facilitated glucose/fructose transporter), member 5 1 9035107-9088478 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005449 Supported Renal cancer:5.44e-5 (unfavourable) Group enriched Tissue enhanced duodenum: 112.1;small intestine: 94.6;testis: 139.5 bone marrow: 64.6 SLC2A6 GLUT6, GLUT9, HSA011372 ENSG00000160326 Solute carrier family 2 (facilitated glucose transporter), member 6 9 133471095-133479137 Predicted membrane proteins, Transporters Evidence at protein level HPA042272, CAB046014 Uncertain Renal cancer:1.02e-11 (unfavourable), Glioma:1.94e-4 (unfavourable), Liver cancer:8.82e-4 (unfavourable) Expressed in all Mixed appendix: 6.3 SLC2A7 GLUT7 ENSG00000197241 Solute carrier family 2 (facilitated glucose transporter), member 7 1 9003300-9026345 Predicted membrane proteins, Transporters Evidence at protein level HPA039931 Uncertain Not detected Group enriched 9 duodenum: 3.1;small intestine: 3.1 epididymis,testis: 0.3 SLC2A8 GLUT8, GLUTX1 ENSG00000136856 Solute carrier family 2 (facilitated glucose transporter), member 8 9 127397138-127408424 Predicted membrane proteins, Transporters Evidence at protein level HPA011935 Uncertain Approved Vesicles Cervical cancer:2.57e-6 (favourable), Renal cancer:6.55e-6 (favourable), Pancreatic cancer:9.86e-6 (favourable) Expressed in all Expressed in all testis: 50.1 SLC2A9 Glut9, GLUTX, URATv1 ENSG00000109667 Solute carrier family 2 (facilitated glucose transporter), member 9 4 9771153-10054936 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA066229 Approved Renal cancer:1.32e-11 (favourable) Mixed Tissue enhanced kidney: 30.9;seminal vesicle: 29.4 duodenum: 11.1 SLC30A1 ZNT1, ZRC1 ENSG00000170385 Solute carrier family 30 (zinc transporter), member 1 1 211571568-211578742 Predicted membrane proteins, Transporters Evidence at protein level HPA015275, HPA049000 Uncertain Supported Vesicles
Plasma membrane Expressed in all Mixed liver: 47.3 SLC30A10 DKFZp547M236, ZnT-10, ZNT8, ZRC1 ENSG00000196660 Solute carrier family 30, member 10 1 219685427-219958647 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017989 Uncertain Tissue enriched Tissue enhanced duodenum: 2.2;liver: 2.3 testis: 1.1 SLC30A2 ZNT2 ENSG00000158014 Solute carrier family 30 (zinc transporter), member 2 1 26037252-26046133 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA017979 Approved Vesicles Renal cancer:2.86e-6 (favourable) Tissue enhanced Tissue enhanced kidney: 21.9;thyroid gland: 42.3 pancreas: 16.5 SLC30A3 ZNT3 ENSG00000115194 Solute carrier family 30 (zinc transporter), member 3 2 27253684-27275817 Predicted membrane proteins, Transporters Evidence at protein level HPA060505, HPA067637 Approved Approved Nucleus
Nucleoli
Vesicles
Cytosol Mixed Group enriched 14 cerebral cortex: 36.7;epididymis: 65.2;testis: 43.6 heart muscle: 3.4 SLC30A4 ZNT4 ENSG00000104154 Solute carrier family 30 (zinc transporter), member 4 15 45479611-45522807 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018178 Uncertain Pancreatic cancer:6.02e-4 (favourable) Tissue enriched Tissue enriched 5 prostate: 64.1 testis: 11.8 SLC30A5 FLJ12496, FLJ12756, MGC5499, ZnT-5, ZNT5, ZNTL1, ZTL1 ENSG00000145740 Solute carrier family 30 (zinc transporter), member 5 5 69093646-69131069 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035373 Approved Supported Nucleus
Golgi apparatus Expressed in all Expressed in all thyroid gland: 61.6 SLC30A6 FLJ31101, ZNT6 ENSG00000152683 Solute carrier family 30 (zinc transporter), member 6 2 32165841-32224379 Predicted membrane proteins, Transporters Evidence at protein level HPA055032, HPA057328 Uncertain Validated Golgi apparatus Liver cancer:9.58e-6 (unfavourable), Endometrial cancer:6.55e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 19.7 SLC30A7 ZNT7, ZnTL2 ENSG00000162695 Solute carrier family 30 (zinc transporter), member 7 1 100896076-100981753 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018034 Uncertain Supported Golgi apparatus Expressed in all Mixed parathyroid gland: 20.6 SLC30A9 C4orf1, GAC63, HUEL, ZNT9 ENSG00000014824 Solute carrier family 30 (zinc transporter), member 9 4 41990472-42090457 Predicted membrane proteins, Transporters Evidence at protein level HPA004014 Approved Renal cancer:2.86e-14 (favourable) Expressed in all Expressed in all parathyroid gland: 35.7 SLC31A1 COPT1, CTR1, hCTR1 ENSG00000136868 Solute carrier family 31 (copper transporter), member 1 9 113221562-113264492 Predicted membrane proteins, Transporters Evidence at protein level HPA013810 Approved Renal cancer:2.20e-6 (favourable), Thyroid cancer:2.03e-4 (unfavourable) Expressed in all Expressed in all liver: 56.5 SLC31A2 COPT2, CTR2, hCTR2 ENSG00000136867 Solute carrier family 31 (copper transporter), member 2 9 113150942-113164137 Predicted membrane proteins, Transporters Evidence at protein level HPA014861 Approved Approved Nuclear speckles
Plasma membrane
Intermediate filaments Mixed Expressed in all salivary gland: 170.9 SLC32A1 bA122O1.1, VGAT, VIAAT ENSG00000101438 Solute carrier family 32 (GABA vesicular transporter), member 1 20 38724462-38729372 Predicted membrane proteins, Transporters Evidence at protein level CAB037156, HPA058859, HPA059985 Supported Tissue enhanced Tissue enriched 34 cerebral cortex: 15.9 testis: 0.4 SLC33A1 ACATN, AT-1, AT1, SPG42 ENSG00000169359 Solute carrier family 33 (acetyl-CoA transporter), member 1 3 155821024-155854429 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042430 Uncertain Expressed in all Expressed in all thyroid gland: 67.1 SLC34A1 NAPI-3, NPT2, NPTIIa, SLC11, SLC17A2 ENSG00000131183 Solute carrier family 34 (type II sodium/phosphate cotransporter), member 1 5 177379235-177398848 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA051255 Approved Tissue enriched Tissue enriched 164 kidney: 161.0 liver: 0.9 SLC34A2 NAPI-3B ENSG00000157765 Solute carrier family 34 (type II sodium/phosphate cotransporter), member 2 4 25655301-25678748 Cancer-related genes, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA037989 Supported Tissue enhanced Tissue enriched 10 lung: 1127.5 fallopian tube: 111.7 SLC34A3 FLJ38680, NPTIIc ENSG00000198569 Solute carrier family 34 (type II sodium/phosphate cotransporter), member 3 9 137230757-137236554 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA023776 Supported Mixed Group enriched 14 kidney: 11.8;small intestine: 9.2 testis: 0.7 SLC35A2 UGALT, UGAT, UGT, UGT1, UGT2, UGTL ENSG00000102100 Solute carrier family 35 (UDP-galactose transporter), member A2 X 48903180-48911958 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036087 Approved Supported Golgi apparatus Liver cancer:9.64e-5 (unfavourable), Breast cancer:3.16e-4 (unfavourable), Stomach cancer:8.23e-4 (favourable) Expressed in all Expressed in all fallopian tube: 44.1 SLC35A3 ENSG00000117620 Solute carrier family 35 (UDP-N-acetylglucosamine (UDP-GlcNAc) transporter), member A3 1 99969789-100026979 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA015253 Uncertain Expressed in all Expressed in all rectum: 47.2 SLC35A4 ENSG00000176087 Solute carrier family 35, member A4 5 140564456-140569103 Predicted membrane proteins, Transporters Evidence at protein level HPA062210 Approved Nucleoplasm Renal cancer:4.56e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 110.8 SLC35A5 FLJ20730 ENSG00000138459 Solute carrier family 35, member A5 3 112561709-112585577 Predicted membrane proteins, Transporters Evidence at protein level HPA035519, HPA057964 Uncertain Approved Golgi apparatus Renal cancer:4.10e-5 (favourable) Expressed in all Expressed in all thyroid gland: 43.7 SLC35B1 UGTREL1 ENSG00000121073 Solute carrier family 35, member B1 17 49700943-49709014 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA048655, HPA057418 Approved Approved Nucleus
Endoplasmic reticulum
Vesicles Renal cancer:5.69e-7 (unfavourable) Expressed in all Expressed in all thyroid gland: 52.0 SLC35B2 UGTrel4 ENSG00000157593 Solute carrier family 35 (adenosine 3'-phospho 5'-phosphosulfate transporter), member B2 6 44254096-44257890 Predicted membrane proteins, Transporters Evidence at protein level HPA029638 Approved Approved Vesicles Liver cancer:8.59e-5 (unfavourable), Prostate cancer:6.07e-4 (favourable), Breast cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 58.0 SLC35B3 C6orf196, CGI-19, dJ453H5.1, PAPST2 ENSG00000124786 Solute carrier family 35 (adenosine 3'-phospho 5'-phosphosulfate transporter), member B3 6 8413068-8435483 Predicted membrane proteins, Transporters Evidence at protein level HPA054661, HPA057801 Approved Expressed in all Expressed in all epididymis: 62.2 SLC35B4 FLJ14697, YEA4 ENSG00000205060 Solute carrier family 35 (UDP-xylose/UDP-N-acetylglucosamine transporter), member B4 7 134289332-134317051 Predicted membrane proteins Evidence at protein level HPA049779 Approved Expressed in all Mixed cerebral cortex: 17.9 SLC35C1 FLJ11320, FUCT1 ENSG00000181830 Solute carrier family 35 (GDP-fucose transporter), member C1 11 45804072-45813015 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA064001 Supported Supported Golgi apparatus Thyroid cancer:3.64e-4 (favourable) Expressed in all Expressed in all esophagus: 29.5 SLC35C2 bA394O2.1, C20orf5, CGI-15, OVCOV1 ENSG00000080189 Solute carrier family 35 (GDP-fucose transporter), member C2 20 46345980-46364458 Predicted membrane proteins, Transporters Evidence at protein level HPA027011 Approved Supported Nucleoplasm
Golgi apparatus Liver cancer:1.08e-4 (unfavourable), Renal cancer:8.68e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 36.6 SLC35D2 SQV7L, UGTrel8 ENSG00000130958 Solute carrier family 35 (UDP-GlcNAc/UDP-glucose transporter), member D2 9 96320706-96383710 Predicted membrane proteins, Transporters Evidence at protein level HPA064047 Approved Validated Golgi apparatus Expressed in all Expressed in all small intestine: 73.8 SLC35D3 FRCL1 ENSG00000182747 Solute carrier family 35, member D3 6 136922264-136925639 Predicted membrane proteins, Transporters Evidence at protein level HPA030431, HPA067497 Uncertain Approved Microtubule organizing center Tissue enhanced Tissue enhanced adrenal gland: 1.2 lung,stomach: 0.6 SLC35E1 FLJ14251 ENSG00000127526 Solute carrier family 35, member E1 19 16549831-16572382 Predicted membrane proteins, Transporters Evidence at protein level HPA016570, HPA062214 Approved Validated Golgi apparatus Expressed in all Expressed in all parathyroid gland: 29.2 SLC35E2 KIAA0447 ENSG00000215790 Solute carrier family 35, member E2 1 1724838-1745992 Predicted membrane proteins Evidence at transcript level HPA062711 Uncertain Uncertain Nucleus Mixed Mixed thyroid gland: 7.5 SLC35E2B ENSG00000189339 Solute carrier family 35, member E2B 1 1659529-1692728 Predicted membrane proteins, Transporters Evidence at protein level HPA045641, HPA062711 Uncertain Uncertain Nucleus Urothelial cancer:5.15e-4 (favourable), Head and neck cancer:7.64e-4 (favourable) Expressed in all Expressed in all smooth muscle: 47.0 SLC35E3 BLOV1 ENSG00000175782 Solute carrier family 35, member E3 12 68746106-68793964 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA049403 Uncertain Endometrial cancer:1.78e-4 (favourable) Expressed in all Mixed skin: 6.1 SLC35E4 ENSG00000100036 Solute carrier family 35, member E4 22 30635652-30669016 Predicted membrane proteins, Transporters Evidence at transcript level HPA049558 Approved Approved Cytosol Mixed Tissue enhanced testis: 17.6 cerebral cortex: 5.1 SLC35F1 C6orf169, dJ230I3.1 ENSG00000196376 Solute carrier family 35, member F1 6 117907526-118317676 Predicted membrane proteins, Transporters Evidence at protein level HPA019576 Approved Approved Nucleoplasm
Microtubule organizing center
Cytosol Group enriched Tissue enriched 12 cerebral cortex: 45.6 epididymis: 3.7 SLC35F2 FLJ13018 ENSG00000110660 Solute carrier family 35, member F2 11 107790991-107928293 Predicted membrane proteins, Transporters Evidence at protein level HPA048185, HPA050695 Uncertain Approved Mitochondria Pancreatic cancer:5.92e-6 (unfavourable), Lung cancer:4.03e-4 (unfavourable), Glioma:7.31e-4 (favourable) Expressed in all Mixed prostate: 33.0 SLC35F3 FLJ37712 ENSG00000183780 Solute carrier family 35, member F3 1 233904933-234324516 Predicted membrane proteins, Transporters Evidence at protein level HPA051327, HPA061582 Uncertain Approved Nucleoli
Golgi apparatus Mixed Tissue enhanced cerebral cortex: 10.2 breast: 3.0 SLC35F4 C14orf36, FLJ37712 ENSG00000151812 Solute carrier family 35, member F4 14 57563922-57982194 Predicted membrane proteins, Transporters Evidence at transcript level HPA043853 Uncertain Approved Nucleoli fibrillar center Not detected Tissue enhanced prostate: 1.9;seminal vesicle: 4.9;testis: 1.8 thyroid gland: 1.0 SLC35F5 FLJ22004 ENSG00000115084 Solute carrier family 35, member F5 2 113705011-113756823 Predicted membrane proteins, Transporters Evidence at transcript level HPA034828, HPA049229 Uncertain Uncertain Plasma membrane Renal cancer:1.71e-5 (favourable), Cervical cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 65.7 SLC35F6 ANT2BP, C2orf18, FLJ20555, TANGO9 ENSG00000213699 Solute carrier family 35, member F6 2 26764284-26781231 Predicted membrane proteins, Transporters Evidence at protein level HPA034655 Approved Approved Nucleoplasm
Vesicles
Cytosol Liver cancer:1.11e-4 (unfavourable), Lung cancer:3.71e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 26.2 SLC35G2 DKFZp564K2464, MGC3295, TMEM22 ENSG00000168917 Solute carrier family 35, member G2 3 136818647-136855892 Predicted membrane proteins, Transporters Evidence at protein level HPA052054, HPA064728 Approved Approved Cytosol Renal cancer:1.16e-7 (unfavourable) Mixed Mixed testis: 21.2 SLC36A1 LYAAT-1, PAT1, TRAMD3 ENSG00000123643 Solute carrier family 36 (proton/amino acid symporter), member 1 5 151437046-151492381 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035937 Approved Renal cancer:1.83e-6 (unfavourable), Liver cancer:6.30e-5 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 64.1 duodenum: 45.5 SLC36A2 PAT2, TRAMD1, tramdorin ENSG00000186335 Solute carrier family 36 (proton/amino acid symporter), member 2 5 151314978-151347590 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA044002, HPA062229 Supported Tissue enriched Group enriched 26 kidney: 67.2;skeletal muscle: 28.1 testis: 1.8 SLC36A4 FLJ38932, PAT4 ENSG00000180773 Solute carrier family 36 (proton/amino acid symporter), member 4 11 93144171-93197964 Predicted membrane proteins, Transporters Evidence at protein level HPA017887 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Expressed in all Mixed thyroid gland: 14.7 SLC37A1 ENSG00000160190 Solute carrier family 37 (glucose-6-phosphate transporter), member 1 21 42496008-42581440 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030418, CAB034154 Approved Approved Nucleus Thyroid cancer:3.43e-5 (favourable), Endometrial cancer:9.22e-5 (favourable) Expressed in all Mixed duodenum: 46.9 SLC37A2 FLJ00171 ENSG00000134955 Solute carrier family 37 (glucose-6-phosphate transporter), member 2 11 125063067-125090312 Predicted membrane proteins, Transporters Evidence at protein level HPA014948 Uncertain Expressed in all Mixed adrenal gland: 24.8 SLC37A3 DKFZp761N0624 ENSG00000157800 Solute carrier family 37, member 3 7 140293693-140404433 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014713, HPA061841 Supported Cytosol Liver cancer:4.78e-5 (unfavourable), Cervical cancer:9.54e-4 (unfavourable) Expressed in all Expressed in all endometrium: 72.5 SLC37A4 G6PT1, G6PT2, G6PT3, GSD1b, GSD1c, GSD1d ENSG00000137700 Solute carrier family 37 (glucose-6-phosphate transporter), member 4 11 119024114-119030906 Predicted membrane proteins Evidence at protein level HPA038939, HPA038940 Approved Approved Mitochondria Expressed in all Tissue enhanced duodenum: 31.4;kidney: 36.1 epididymis: 20.7 SLC38A1 ATA1, NAT2, SAT1 ENSG00000111371 Solute carrier family 38, member 1 12 46183063-46270017 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA039460, HPA052272 Uncertain Supported Liver cancer:6.95e-8 (unfavourable), Endometrial cancer:4.76e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 153.2 SLC38A10 MGC15523, PP1744 ENSG00000157637 Solute carrier family 38, member 10 17 81245000-81295547 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA021374, HPA023161, HPA024631 Supported Validated Golgi apparatus Renal cancer:5.34e-7 (unfavourable), Pancreatic cancer:2.92e-4 (favourable) Expressed in all Expressed in all thyroid gland: 44.6 SLC38A11 AVT2, FLJ39822 ENSG00000169507 Solute carrier family 38, member 11 2 164896186-164955525 Predicted membrane proteins, Transporters Evidence at transcript level HPA043432 Uncertain Renal cancer:2.00e-8 (favourable) Tissue enriched Tissue enhanced epididymis: 47.1;gallbladder: 28.3 seminal vesicle: 23.3 SLC38A2 ATA2, KIAA1382, SAT2, SNAT2 ENSG00000134294 Solute carrier family 38, member 2 12 46358189-46372867 Predicted membrane proteins Evidence at protein level HPA035180 Approved Approved Vesicles Expressed in all Expressed in all skin: 239.3 SLC38A3 G17, SN1 ENSG00000188338 Solute carrier family 38, member 3 3 50205246-50221486 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA031871 Approved Microtubules
Cytosol Tissue enriched Tissue enriched 7 liver: 173.5 cerebral cortex: 25.6 SLC38A5 JM24, SN2 ENSG00000017483 Solute carrier family 38, member 5 X 48458537-48470256 Predicted membrane proteins, Transporters Evidence at protein level HPA047411 Approved Approved Vesicles
Plasma membrane
Cytosol Renal cancer:2.22e-16 (unfavourable), Pancreatic cancer:2.13e-4 (unfavourable) Expressed in all Mixed pancreas: 50.0 SLC38A6 NAT-1 ENSG00000139974 Solute carrier family 38, member 6 14 60981114-61083733 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018508 Approved Approved Plasma membrane
Cell Junctions
Microtubules Liver cancer:9.47e-6 (unfavourable), Renal cancer:1.37e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 24.3 SLC38A7 FLJ10815 ENSG00000103042 Solute carrier family 38, member 7 16 58665109-58685104 Predicted membrane proteins, Transporters Evidence at protein level HPA041777 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:2.87e-4 (favourable), Endometrial cancer:6.87e-4 (favourable) Expressed in all Mixed testis: 34.8 SLC38A9 FLJ90709 ENSG00000177058 Solute carrier family 38, member 9 5 55625845-55773194 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA043785 Uncertain Approved Nucleoplasm
Vesicles Endometrial cancer:7.24e-5 (unfavourable) Expressed in all Expressed in all placenta: 79.8 SLC39A1 ZIP1, ZIRTL ENSG00000143570 Solute carrier family 39 (zinc transporter), member 1 1 153959099-153968184 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016506 Uncertain Cytosol Liver cancer:4.12e-7 (unfavourable), Head and neck cancer:5.26e-5 (unfavourable), Cervical cancer:4.83e-4 (unfavourable) Expressed in all Expressed in all placenta: 133.4 SLC39A10 DKFZp564L2123, FLJ90515, KIAA1265 ENSG00000196950 Solute carrier family 39 (zinc transporter), member 10 2 195575977-195737702 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA036512, HPA036513, HPA066087 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Glioma:2.05e-5 (favourable), Liver cancer:4.39e-5 (unfavourable), Pancreatic cancer:3.23e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 78.0;thyroid gland: 79.0 prostate: 27.6 SLC39A11 C17orf26 ENSG00000133195 Solute carrier family 39, member 11 17 72645949-73092712 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA021455 Approved Nucleoplasm Expressed in all Expressed in all thyroid gland: 60.0 SLC39A13 FLJ25785 ENSG00000165915 Solute carrier family 39 (zinc transporter), member 13 11 47407132-47416501 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA043971 Approved Uncertain Cytosol Ovarian cancer:2.73e-5 (unfavourable), Renal cancer:1.96e-4 (favourable), Colorectal cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all placenta: 58.0 SLC39A14 KIAA0062, NET34, ZIP14 ENSG00000104635 Solute carrier family 39 (zinc transporter), member 14 8 22367249-22434129 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA016508 Approved Approved Endoplasmic reticulum
Golgi apparatus
Plasma membrane Renal cancer:3.79e-7 (unfavourable), Colorectal cancer:5.00e-5 (favourable) Expressed in all Mixed liver: 202.8 SLC39A2 ZIP2 ENSG00000165794 Solute carrier family 39 (zinc transporter), member 2 14 20999255-21001871 Predicted membrane proteins Evidence at protein level HPA030489 Uncertain Mixed Group enriched 12 esophagus: 19.0;prostate: 20.5;seminal vesicle: 46.3;skin: 34.2 tonsil: 2.6 SLC39A3 ZIP3 ENSG00000141873 Solute carrier family 39 (zinc transporter), member 3 19 2732204-2740152 Predicted membrane proteins, Transporters Evidence at protein level HPA042139, HPA058526 Uncertain Approved Vesicles Endometrial cancer:9.76e-5 (favourable) Expressed in all Expressed in all testis: 109.9 SLC39A5 ENSG00000139540 Solute carrier family 39 (zinc transporter), member 5 12 56230049-56237846 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA018423 Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:5.05e-4 (favourable) Tissue enhanced Group enriched 12 colon: 74.5;duodenum: 247.0;kidney: 114.6;liver: 85.7;pancreas: 53.1;rectum: 49.7;small intestine: 245.4 gallbladder: 10.0 SLC39A6 LIV-1 ENSG00000141424 Solute carrier family 39 (zinc transporter), member 6 18 36108532-36129385 Predicted membrane proteins, Transporters Evidence at protein level HPA042377 Approved Liver cancer:5.33e-4 (unfavourable) Expressed in all Expressed in all prostate: 209.0 SLC39A7 D6S2244E, H2-KE4, HKE4, KE4, RING5, ZIP7 ENSG00000112473 Solute carrier family 39 (zinc transporter), member 7 6 33200445-33204439 Predicted membrane proteins, Transporters Evidence at protein level HPA053999 Approved Supported Endoplasmic reticulum Liver cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 40.2 SLC39A8 BIGM103 ENSG00000138821 Solute carrier family 39 (zinc transporter), member 8 4 102251041-102431258 Predicted membrane proteins, Transporters Evidence at protein level HPA038832, HPA038833 Approved Renal cancer:6.34e-6 (favourable), Colorectal cancer:1.34e-4 (favourable), Breast cancer:6.69e-4 (favourable) Expressed in all Tissue enhanced lung: 257.1 cervix, uterine: 128.6 SLC39A9 FLJ11274 ENSG00000029364 Solute carrier family 39, member 9 14 69398015-69462388 Predicted membrane proteins, Transporters Evidence at protein level HPA007921, HPA075390 Approved Approved Endoplasmic reticulum Renal cancer:1.05e-6 (favourable) Expressed in all Expressed in all parathyroid gland,thyroid gland: 44.1 SLC3A1 ATR1, CSNU1, D2H, NBAT, RBAT ENSG00000138079 Solute carrier family 3 (amino acid transporter heavy chain), member 1 2 44275458-44321494 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA038360 Supported Renal cancer:3.67e-7 (favourable) Tissue enriched Tissue enhanced kidney: 649.8 small intestine: 151.9 SLC3A2 4F2, 4F2HC, 4T2HC, CD98, CD98HC, MDU1, NACAE ENSG00000168003 Solute carrier family 3 (amino acid transporter heavy chain), member 2 11 62856102-62888875 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB010455, HPA017980 Supported Supported Nucleus
Plasma membrane
Cytosol Urothelial cancer:1.48e-4 (unfavourable), Liver cancer:8.17e-4 (unfavourable), Renal cancer:8.22e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 424.3 SLC40A1 FPN1, HFE4, IREG1, MTP1, SLC11A3 ENSG00000138449 Solute carrier family 40 (iron-regulated transporter), member 1 2 189560579-189583758 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA065634 Approved Approved Nucleoplasm
Plasma membrane
Cytosol Renal cancer:8.55e-5 (favourable) Expressed in all Expressed in all spleen: 496.0 SLC41A1 MgtE ENSG00000133065 Solute carrier family 41 (magnesium transporter), member 1 1 205789093-205813748 Predicted membrane proteins, Transporters Evidence at protein level HPA014721, HPA015138 Uncertain Approved Mitochondria Cervical cancer:1.48e-4 (unfavourable) Expressed in all Tissue enhanced heart muscle: 72.6 testis: 37.3 SLC41A2 DKFZP434K0427 ENSG00000136052 Solute carrier family 41 (magnesium transporter), member 2 12 104802553-104958744 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA038658 Approved Renal cancer:3.35e-4 (unfavourable), Liver cancer:9.94e-4 (favourable) Expressed in all Mixed liver: 59.8 SLC41A3 FLJ20473 ENSG00000114544 Solute carrier family 41, member 3 3 126006355-126101561 Predicted membrane proteins, Transporters Evidence at protein level HPA045847 Approved Supported Plasma membrane Liver cancer:1.49e-7 (unfavourable), Renal cancer:6.04e-7 (favourable) Expressed in all Expressed in all testis: 79.0 SLC43A1 PB39, POV1, R00504 ENSG00000149150 Solute carrier family 43 (amino acid system L transporter), member 1 11 57484534-57515786 Predicted membrane proteins, Transporters Evidence at protein level HPA018813, HPA018826 Supported Approved Golgi apparatus
Vesicles
Plasma membrane Renal cancer:2.97e-5 (unfavourable), Endometrial cancer:3.19e-4 (favourable), Thyroid cancer:5.27e-4 (unfavourable) Expressed in all Expressed in all liver: 50.0 SLC43A2 MGC34680 ENSG00000167703 Solute carrier family 43 (amino acid system L transporter), member 2 17 1569267-1628886 Predicted membrane proteins, Transporters Evidence at protein level HPA021564 Approved Pancreatic cancer:1.05e-6 (favourable), Renal cancer:5.40e-5 (favourable) Expressed in all Tissue enhanced placenta: 31.6 appendix: 17.4 SLC43A3 DKFZp762A227, Eeg1, FOAP-13, PRO1659, SEEEG-1 ENSG00000134802 Solute carrier family 43, member 3 11 57406954-57427580 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030551 Approved Renal cancer:3.97e-13 (unfavourable) Expressed in all Expressed in all thyroid gland: 121.6 SLC44A1 CD92, CDW92, CHTL1, CTL1 ENSG00000070214 Solute carrier family 44 (choline transporter), member 1 9 105244622-105439171 CD markers, Predicted membrane proteins, Transporters Evidence at protein level HPA064714 Supported Nucleoplasm
Mitochondria Renal cancer:1.85e-4 (favourable), Lung cancer:4.49e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 107.8 SLC44A2 CTL2 ENSG00000129353 Solute carrier family 44 (choline transporter), member 2 19 10602457-10644559 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA003228, HPA070799 Approved Approved Vesicles
Cell Junctions Renal cancer:1.71e-5 (favourable), Pancreatic cancer:6.01e-4 (unfavourable) Expressed in all Expressed in all placenta: 224.3 SLC44A3 CTL3, MGC45474 ENSG00000143036 Solute carrier family 44, member 3 1 94820342-94895246 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047433 Approved Renal cancer:7.63e-5 (favourable) Expressed in all Mixed rectum: 39.1 SLC44A4 C6orf29, CTL4, FLJ14491, NG22, TPPT ENSG00000204385 Solute carrier family 44, member 4 6 31863192-31879046 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046977, HPA054176 Approved Renal cancer:1.06e-6 (favourable), Head and neck cancer:3.54e-4 (favourable), Urothelial cancer:6.06e-4 (favourable) Tissue enhanced Tissue enhanced duodenum: 36.0 prostate: 30.1 SLC44A5 CTL5, MGC34032 ENSG00000137968 Solute carrier family 44, member 5 1 75202131-75611116 Predicted membrane proteins, Transporters Evidence at protein level HPA047455, HPA051011 Uncertain Approved Cytosol Renal cancer:6.52e-4 (unfavourable) Mixed Tissue enhanced skin: 12.6 parathyroid gland,testis: 8.0 SLC45A3 IPCA-2, IPCA-6, IPCA-8, PCANAP2, PCANAP6, PCANAP8, prostein ENSG00000158715 Solute carrier family 45, member 3 1 205657851-205680459 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA019073, HPA019075 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:4.04e-5 (unfavourable), Urothelial cancer:7.33e-5 (favourable) Tissue enriched Tissue enriched 25 prostate: 430.6 stomach: 16.9 SLC45A4 KIAA1126 ENSG00000022567 Solute carrier family 45, member 4 8 141207166-141308305 Predicted membrane proteins, Transporters Evidence at protein level HPA023154 Uncertain Approved Plasma membrane Renal cancer:1.73e-6 (favourable) Expressed in all Mixed testis: 21.1 SLC46A1 HCP1, MGC9564, PCFT ENSG00000076351 Solute carrier family 46 (folate transporter), member 1 17 28394756-28407197 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011614 Approved Supported Plasma membrane
Cytosol Glioma:3.90e-4 (unfavourable) Expressed in all Expressed in all duodenum: 97.7 SLC46A2 Ly110, TSCOT ENSG00000119457 Solute carrier family 46, member 2 9 112878920-112890913 Predicted membrane proteins, Transporters Evidence at transcript level HPA020098 Approved Tissue enhanced Group enriched 6 cervix, uterine: 23.0;endometrium: 5.5;epididymis: 5.4;lung: 15.2;skin: 11.3 seminal vesicle: 2.0 SLC46A3 DKFZp686A1775, FLJ42613 ENSG00000139508 Solute carrier family 46, member 3 13 28700064-28718970 Predicted membrane proteins, Transporters Evidence at protein level HPA039930 Uncertain Approved Plasma membrane
Actin filaments
Cytosol Lung cancer:7.09e-4 (favourable) Expressed in all Expressed in all small intestine: 89.4 SLC47A1 FLJ10847, MATE1 ENSG00000142494 Solute carrier family 47 (multidrug and toxin extrusion), member 1 17 19495385-19579034 Predicted membrane proteins, Transporters Evidence at protein level HPA021987 Supported Endometrial cancer:5.54e-8 (favourable), Renal cancer:1.06e-5 (favourable), Lung cancer:1.88e-5 (favourable) Tissue enhanced Tissue enhanced adrenal gland: 139.0;kidney: 105.0 liver: 55.2 SLC48A1 FLJ20489, hHRG-1, HRG1 ENSG00000211584 Solute carrier family 48 (heme transporter), member 1 12 47753916-47782753 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA073994 Supported Vesicles Renal cancer:1.34e-6 (favourable), Liver cancer:9.39e-5 (unfavourable), Cervical cancer:4.27e-4 (favourable) Expressed in all Expressed in all thyroid gland: 79.4 SLC4A1 AE1, CD233, DI, EPB3, FR, RTA1A, SW, WD, WR ENSG00000004939 Solute carrier family 4 (anion exchanger), member 1 (Diego blood group) 17 44248385-44268141 Blood group antigen proteins, CD markers, Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA015584, CAB034438, HPA063911 Supported Tissue enriched Tissue enriched 8 bone marrow: 238.4 kidney: 29.9 SLC4A10 NBCn2, NCBE ENSG00000144290 Solute carrier family 4, sodium bicarbonate transporter, member 10 2 161424332-161985282 Predicted membrane proteins, Transporters Evidence at protein level HPA034755 Supported Tissue enhanced Tissue enriched 22 cerebral cortex: 57.7 adrenal gland: 2.6 SLC4A11 BTR1, CDPD1, CHED2, dJ794I6.2, FECD4, NaBC1 ENSG00000088836 Solute carrier family 4, sodium borate transporter, member 11 20 3227417-3239190 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018120, HPA058377 Uncertain Uncertain Nucleoplasm
Vesicles Renal cancer:6.21e-6 (favourable), Cervical cancer:9.03e-4 (favourable) Expressed in all Tissue enhanced salivary gland: 19.3;thyroid gland: 27.6 cervix, uterine: 14.3 SLC4A2 AE2, BND3L, EPB3L1, HKB3, NBND3 ENSG00000164889 Solute carrier family 4 (anion exchanger), member 2 7 151057210-151076527 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA019339 Supported Approved Nuclear speckles
Plasma membrane
Cytosol Liver cancer:9.04e-6 (unfavourable), Renal cancer:1.26e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 87.8 SLC4A3 AE3, SLC2C ENSG00000114923 Solute carrier family 4 (anion exchanger), member 3 2 219627327-219641980 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA063498 Approved Nucleoplasm Urothelial cancer:4.12e-4 (unfavourable) Expressed in all Group enriched 6 cerebral cortex: 30.1;heart muscle: 125.7;ovary: 47.6 testis: 10.9 SLC4A4 hhNMC, HNBC1, NBC1, NBC2, pNBC, SLC4A5 ENSG00000080493 Solute carrier family 4 (sodium bicarbonate cotransporter), member 4 4 71187286-71572087 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022493, HPA035628, HPA035629 Supported Renal cancer:1.18e-4 (favourable), Colorectal cancer:7.69e-4 (favourable) Group enriched Tissue enhanced kidney: 124.6 cerebral cortex: 57.5 SLC4A5 NBC4 ENSG00000188687 Solute carrier family 4 (sodium bicarbonate cotransporter), member 5 2 74216242-74343414 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036621 Approved Tissue enriched Group enriched 9 testis: 25.5;thyroid gland: 40.5 skin: 3.7 SLC4A7 NBC3, SBC2, SLC4A6 ENSG00000033867 Solute carrier family 4, sodium bicarbonate cotransporter, member 7 3 27372721-27484420 Predicted membrane proteins, Transporters Evidence at protein level CAB022494, HPA035857 Supported Supported Plasma membrane
Focal adhesion sites Renal cancer:7.91e-6 (unfavourable) Expressed in all Tissue enhanced duodenum: 59.2 breast: 23.6 SLC4A8 NBC3 ENSG00000050438 Solute carrier family 4, sodium bicarbonate cotransporter, member 8 12 51391317-51515763 Predicted membrane proteins Evidence at protein level HPA031536 Uncertain Actin filaments Group enriched Tissue enhanced cerebral cortex: 14.6;testis: 15.4 ovary: 4.2 SLC4A9 AE4 ENSG00000113073 Solute carrier family 4, sodium bicarbonate cotransporter, member 9 5 140360202-140375143 Plasma proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA051307 Uncertain Tissue enriched Tissue enriched 17 kidney: 12.1 testis: 0.6 SLC50A1 HsSWEET1, RAG1AP1, RP11-540D14.5, RZPDo834D038D, SCP, slv, SWEET1 ENSG00000169241 Solute carrier family 50 (sugar efflux transporter), member 1 1 155135344-155138857 Predicted membrane proteins, Transporters Evidence at protein level HPA018095 Approved Renal cancer:3.88e-7 (unfavourable) Expressed in all Expressed in all epididymis: 133.2 SLC51A OSTalpha ENSG00000163959 Solute carrier family 51, alpha subunit 3 196211487-196243178 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA039123 Approved Liver cancer:7.54e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 30.1;liver: 35.2;small intestine: 72.7 colon: 10.2 SLC51B OSTbeta ENSG00000186198 Solute carrier family 51, beta subunit 15 65045370-65053396 Predicted membrane proteins, Transporters Evidence at protein level HPA008398, HPA008533 Supported Approved Vesicles
Mitochondria Renal cancer:8.46e-5 (favourable) Tissue enhanced Tissue enhanced duodenum: 87.8;small intestine: 120.6 cervix, uterine: 63.7 SLC52A1 FLJ10060, GPCR42, GPR172B, hRFT1, PAR2, RFVT1 ENSG00000132517 Solute carrier family 52 (riboflavin transporter), member 1 17 5032600-5052009 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011449 Uncertain Cervical cancer:9.54e-4 (favourable) Mixed Group enriched 10 duodenum: 37.1;placenta: 26.0;skin: 13.3;small intestine: 26.8 parathyroid gland: 2.6 SLC52A2 D15Ertd747e, FLJ11856, GPCR41, GPR172A, hRFT3, PAR1, RFVT2 ENSG00000185803 Solute carrier family 52 (riboflavin transporter), member 2 8 144354135-144361272 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA063036 Approved Liver cancer:2.04e-6 (unfavourable), Renal cancer:1.23e-4 (unfavourable), Cervical cancer:7.55e-4 (unfavourable) Expressed in all Expressed in all placenta: 24.0 SLC52A3 bA371L19.1, C20orf54, hRFT2, RFVT3 ENSG00000101276 Solute carrier family 52 (riboflavin transporter), member 3 20 760080-776015 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA049391 Approved Stomach cancer:5.51e-6 (favourable) Expressed in all Tissue enhanced testis: 62.2 small intestine: 18.5 SLC5A1 D22S675, NAGT, SGLT1 ENSG00000100170 Solute carrier family 5 (sodium/glucose cotransporter), member 1 22 32043032-32113029 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB015467, HPA051805, HPA055106 Supported Approved Nucleoplasm
Vesicles Renal cancer:6.97e-7 (favourable), Endometrial cancer:2.59e-4 (favourable) Mixed Group enriched 10 duodenum: 518.9;small intestine: 320.2 gallbladder: 40.3 SLC5A10 SGLT5 ENSG00000154025 Solute carrier family 5 (sodium/sugar cotransporter), member 10 17 18950345-19022595 Predicted membrane proteins, Transporters Evidence at protein level HPA052014 Uncertain Tissue enriched Tissue enriched 25 kidney: 43.7 bone marrow: 1.7 SLC5A11 KST1, SGLT6, SMIT2 ENSG00000158865 Solute carrier family 5 (sodium/inositol cotransporter), member 11 16 24845841-24911628 Predicted membrane proteins Evidence at protein level HPA035331 Uncertain Approved Nucleus
Cytosol Mixed Group enriched 6 cerebral cortex: 10.5;duodenum: 6.8;kidney: 6.0;small intestine: 15.5 breast: 1.7 SLC5A12 MGC52019, SMCT2 ENSG00000148942 Solute carrier family 5 (sodium/monocarboxylate cotransporter), member 12 11 26667019-26723427 Predicted membrane proteins, Transporters Evidence at protein level HPA060904 Supported Tissue enriched Tissue enhanced epididymis: 57.8;kidney: 172.6 small intestine: 34.0 SLC5A2 SGLT2 ENSG00000140675 Solute carrier family 5 (sodium/glucose cotransporter), member 2 16 31483002-31490860 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA041603 Supported Not detected Tissue enriched 9 kidney: 25.3 testis: 2.8 SLC5A3 SMIT, SMIT1 ENSG00000198743 Solute carrier family 5 (sodium/myo-inositol cotransporter), member 3 21 34073570-34106260 Predicted membrane proteins, Transporters Evidence at protein level HPA029791 Approved Plasma membrane
Cytosol Pancreatic cancer:1.98e-5 (unfavourable), Renal cancer:4.72e-4 (unfavourable) Expressed in all Tissue enhanced thyroid gland: 42.0 kidney: 32.9 SLC5A5 NIS ENSG00000105641 Solute carrier family 5 (sodium/iodide cotransporter), member 5 19 17871973-17895174 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022364, HPA049055 Supported Mixed Tissue enhanced salivary gland: 28.5;stomach: 56.7;thyroid gland: 20.6 cervix, uterine: 8.3 SLC5A6 SMVT ENSG00000138074 Solute carrier family 5 (sodium/multivitamin and iodide cotransporter), member 6 2 27199587-27212958 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA036958 Approved Approved Cell Junctions Renal cancer:3.60e-7 (unfavourable) Expressed in all Expressed in all epididymis: 82.1 SLC5A7 CHT1, hCHT ENSG00000115665 Solute carrier family 5 (sodium/choline cotransporter), member 7 2 107986523-108013994 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA046105 Approved Nuclear bodies
Cell Junctions
Intermediate filaments Tissue enhanced Mixed thyroid gland: 2.0 SLC5A9 SGLT4 ENSG00000117834 Solute carrier family 5 (sodium/sugar cotransporter), member 9 1 48222685-48248644 Predicted membrane proteins, Transporters Evidence at protein level HPA050263 Approved Actin filaments
Cytosol Renal cancer:1.84e-5 (unfavourable) Tissue enhanced Group enriched 10 duodenum: 43.8;small intestine: 46.4 lung: 4.5 SLC6A1 GABATHG, GABATR, GAT1 ENSG00000157103 Solute carrier family 6 (neurotransmitter transporter), member 1 3 10992724-11039247 Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013341, CAB022293 Supported Uncertain Mitochondria Renal cancer:5.05e-6 (unfavourable), Liver cancer:3.20e-4 (favourable) Group enriched Group enriched 5 cerebral cortex: 119.7;liver: 50.3 parathyroid gland: 15.7 SLC6A11 GAT3 ENSG00000132164 Solute carrier family 6 (neurotransmitter transporter), member 11 3 10816200-10940733 Predicted membrane proteins, Transporters Evidence at protein level HPA037981 Supported Supported Tissue enhanced Tissue enhanced cerebral cortex: 18.2;skin: 6.7 esophagus: 5.5 SLC6A12 BGT-1 ENSG00000111181 Solute carrier family 6 (neurotransmitter transporter), member 12 12 190077-214570 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA034973, HPA057917 Approved Approved Golgi apparatus Renal cancer:2.70e-6 (favourable), Endometrial cancer:1.59e-4 (unfavourable) Tissue enhanced Tissue enhanced kidney: 29.4;liver: 43.6 cerebral cortex: 14.8 SLC6A13 GAT2 ENSG00000010379 Solute carrier family 6 (neurotransmitter transporter), member 13 12 220621-262873 Predicted membrane proteins, Transporters Evidence at protein level HPA036449, HPA052726 Approved Approved Mitochondria Tissue enriched Tissue enriched 14 kidney: 152.9 fallopian tube: 11.2 SLC6A14 ENSG00000268104 Solute carrier family 6 (amino acid transporter), member 14 X 116436622-116461458 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at transcript level HPA003193 Uncertain Approved Vesicles Pancreatic cancer:9.74e-4 (unfavourable) Mixed Tissue enhanced cervix, uterine: 11.0;lung: 23.9 breast: 9.2 SLC6A15 FLJ10316, hv7-3, NTT73, SBAT1, V7-3 ENSG00000072041 Solute carrier family 6 (neutral amino acid transporter), member 15 12 84859488-84913615 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008609 Uncertain Approved Nucleoli
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 23.1 placenta: 5.5 SLC6A16 NTT5 ENSG00000063127 Solute carrier family 6, member 16 19 49289638-49325225 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA076812 Approved Golgi apparatus Mixed Tissue enriched 18 testis: 161.8 lymph node: 9.0 SLC6A17 ENSG00000197106 Solute carrier family 6 (neutral amino acid transporter), member 17 1 110150486-110202202 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA007663, HPA008044 Approved Approved Nucleus
Golgi apparatus Tissue enriched Tissue enriched 10 cerebral cortex: 75.6 adrenal gland: 7.9 SLC6A18 FLJ31236, Xtrp2 ENSG00000164363 Solute carrier family 6 (neutral amino acid transporter), member 18 5 1225355-1246189 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA011885 Supported Tissue enriched Tissue enriched 83 kidney: 8.2 all non-specific tissues: 0.0 SLC6A19 ENSG00000174358 Solute carrier family 6 (neutral amino acid transporter), member 19 5 1201595-1225117 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA037415, HPA043207 Supported Renal cancer:4.14e-6 (favourable) Tissue enhanced Group enriched 21 duodenum: 143.3;kidney: 91.3;small intestine: 160.0 rectum: 6.3 SLC6A2 NAT1, NET, NET1, SLC6A5 ENSG00000103546 Solute carrier family 6 (neurotransmitter transporter), member 2 16 55655604-55706192 Disease related genes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA004057, CAB078195 Supported Supported Approved Mitochondria
Cytosol Tissue enhanced Tissue enhanced adrenal gland: 29.4;placenta: 18.2;skin: 15.7 testis: 11.4 SLC6A20 XT3, Xtrp3 ENSG00000163817 Solute carrier family 6 (proline IMINO transporter), member 20 3 45755450-45796535 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029873 Approved Renal cancer:1.55e-5 (favourable) Mixed Tissue enhanced duodenum: 25.1;small intestine: 19.7 gallbladder: 10.9 SLC6A3 DAT, DAT1 ENSG00000142319 Solute carrier family 6 (neurotransmitter transporter), member 3 5 1392790-1445430 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA013602, CAB016249, CAB078172 Uncertain Supported Approved Vesicles Renal cancer:3.40e-7 (unfavourable) Tissue enriched Not detected thyroid gland: 0.3 SLC6A4 5-HTT, HTT, OCD1, SERT1 ENSG00000108576 Solute carrier family 6 (neurotransmitter transporter), member 4 17 30194319-30236002 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA054723, HPA074728 Supported Supported Golgi apparatus
Vesicles Tissue enhanced Group enriched 10 duodenum: 10.7;lung: 44.2;placenta: 26.3;small intestine: 46.2 esophagus: 3.1 SLC6A6 TAUT ENSG00000131389 Solute carrier family 6 (neurotransmitter transporter), member 6 3 14402576-14489349 Predicted membrane proteins, Transporters Evidence at protein level HPA015028, HPA016488 Supported Approved Cell Junctions
Cytosol Glioma:1.09e-7 (unfavourable), Endometrial cancer:5.22e-5 (favourable), Liver cancer:8.78e-4 (unfavourable) Expressed in all Mixed ovary: 50.7 SLC6A7 PROT ENSG00000011083 Solute carrier family 6 (neurotransmitter transporter), member 7 5 150189957-150222788 Predicted membrane proteins, Transporters Evidence at protein level HPA028907 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 17.0;rectum: 4.3 colon: 2.9 SLC6A9 GLYT1 ENSG00000196517 Solute carrier family 6 (neurotransmitter transporter, glycine), member 9 1 43991500-44031467 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA013977 Uncertain Approved Nucleus
Golgi apparatus Renal cancer:5.93e-4 (unfavourable), Endometrial cancer:9.50e-4 (unfavourable) Expressed in all Tissue enhanced skin: 49.8 adrenal gland: 31.0 SLC7A1 ATRC1, CAT-1, ERR, HCAT1, REC1L ENSG00000139514 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 13 29509410-29595688 Predicted membrane proteins, Transporters Evidence at protein level HPA039721 Approved Renal cancer:1.32e-5 (unfavourable) Expressed in all Mixed esophagus: 42.0 SLC7A10 asc-1 ENSG00000130876 Solute carrier family 7 (neutral amino acid transporter light chain, asc system), member 10 19 33208664-33225850 Predicted membrane proteins, Transporters Evidence at transcript level HPA041884, HPA057036 Uncertain Uncertain Nucleus
Nucleoli Mixed Group enriched 23 adipose tissue: 31.5;cerebral cortex: 6.6 breast: 0.8 SLC7A11 xCT ENSG00000151012 Solute carrier family 7 (anionic amino acid transporter light chain, xc- system), member 11 4 138164097-138242349 FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA064215 Approved Vesicles Ovarian cancer:1.77e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 22.5 epididymis: 8.2 SLC7A14 KIAA1613, PPP1R142 ENSG00000013293 Solute carrier family 7, member 14 3 170459584-170586074 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA045929 Approved Group enriched Tissue enriched 8 cerebral cortex: 26.8 adrenal gland: 3.1 SLC7A2 ATRC2, CAT-2, HCAT2 ENSG00000003989 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 8 17497088-17570573 Predicted membrane proteins, Transporters Evidence at protein level HPA009277 Supported Plasma membrane
Cell Junctions Renal cancer:2.65e-7 (unfavourable), Stomach cancer:3.08e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 373.7 liver: 92.6 SLC7A3 ATRC3, CAT-3, FLJ14541 ENSG00000165349 Solute carrier family 7 (cationic amino acid transporter, y+ system), member 3 X 70925582-70931125 Predicted membrane proteins, Transporters Evidence at protein level HPA003629 Approved Tissue enriched Tissue enhanced endometrium: 7.8;prostate: 9.6;seminal vesicle: 7.4 smooth muscle: 4.0 SLC7A4 CAT-4, HCAT3, VH ENSG00000099960 Solute carrier family 7, member 4 22 21028718-21032840 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA031023 Approved Mixed Tissue enhanced testis: 22.5 esophagus: 6.0 SLC7A5 CD98, D16S469E, E16, LAT1, MPE16 ENSG00000103257 Solute carrier family 7 (amino acid transporter light chain, L system), member 5 16 87830023-87869488 Predicted membrane proteins, Transporters Evidence at protein level HPA052673, HPA056077 Approved Supported Vesicles
Plasma membrane
Cytosol Renal cancer:0.00e+0 (unfavourable), Lung cancer:2.43e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 90.5;testis: 84.4 bone marrow: 66.3 SLC7A6 KIAA0245, LAT-2, LAT3, y+LAT-2 ENSG00000103064 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 6 16 68264516-68301823 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050713 Uncertain Approved Vesicles
Plasma membrane Urothelial cancer:1.84e-4 (unfavourable) Expressed in all Mixed adipose tissue: 35.1 SLC7A7 LPI, y+LAT-1 ENSG00000155465 Solute carrier family 7 (amino acid transporter light chain, y+L system), member 7 14 22773222-22829820 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036227 Approved Renal cancer:6.28e-6 (unfavourable) Expressed in all Tissue enhanced kidney: 279.7 parathyroid gland: 159.0 SLC7A8 LAT2, LPI-PC1 ENSG00000092068 Solute carrier family 7 (amino acid transporter light chain, L system), member 8 14 23125295-23183674 Predicted membrane proteins, Transporters Evidence at protein level CAB046015, HPA051950, HPA060672 Supported Urothelial cancer:1.52e-4 (unfavourable), Liver cancer:1.97e-4 (unfavourable), Lung cancer:3.15e-4 (favourable) Expressed in all Tissue enriched 8 parathyroid gland: 1066.4 kidney: 131.5 SLC7A9 CSNU3 ENSG00000021488 Solute carrier family 7 (amino acid transporter light chain, bo,+ system), member 9 19 32830509-32869766 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA042591 Supported Group enriched Group enriched 10 duodenum: 81.2;kidney: 69.6;small intestine: 125.7 liver: 8.9 SLC8A1 NCX1 ENSG00000183023 Solute carrier family 8 (sodium/calcium exchanger), member 1 2 40097270-40611053 FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level CAB022694, HPA070007 Uncertain Supported Nucleoplasm
Plasma membrane Mixed Tissue enhanced heart muscle: 79.5 seminal vesicle: 38.2 SLC8A2 KIAA1087, NCX2 ENSG00000118160 Solute carrier family 8 (sodium/calcium exchanger), member 2 19 47428017-47472168 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA050818, HPA054671 Supported Mixed Tissue enriched 11 cerebral cortex: 68.4 endometrium: 6.2 SLC8B1 FLJ22233, NCKX6, NCLX, SLC24A6 ENSG00000089060 Solute carrier family 8 (sodium/lithium/calcium exchanger), member B1 12 113298759-113359493 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA040668 Approved Urothelial cancer:5.02e-4 (favourable), Breast cancer:9.52e-4 (favourable) Expressed in all Expressed in all adrenal gland: 48.6 SLC9A1 APNH, NHE1, PPP1R143 ENSG00000090020 Solute carrier family 9, subfamily A (NHE1, cation proton antiporter 1), member 1 1 27098815-27166981 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB022371, HPA048532, HPA052891 Supported Supported Plasma membrane Glioma:6.32e-4 (unfavourable), Ovarian cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all stomach: 66.4 SLC9A2 NHE2 ENSG00000115616 Solute carrier family 9, subfamily A (NHE2, cation proton antiporter 2), member 2 2 102619707-102711318 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035121, HPA035122 Approved Approved Cell Junctions Mixed Tissue enhanced colon: 20.9;rectum: 23.7;stomach: 25.8 testis: 10.6 SLC9A3 NHE3 ENSG00000066230 Solute carrier family 9, subfamily A (NHE3, cation proton antiporter 3), member 3 5 473310-524332 Predicted membrane proteins, Transporters Evidence at protein level HPA036493, HPA036669 Supported Supported Plasma membrane Melanoma:8.49e-4 (unfavourable) Mixed Tissue enhanced colon: 82.6;small intestine: 74.1 gallbladder: 66.3 SLC9A4 NHE4 ENSG00000180251 Solute carrier family 9, subfamily A (NHE4, cation proton antiporter 4), member 4 2 102473303-102533972 Predicted membrane proteins, Transporters Evidence at protein level HPA036096 Approved Approved Nucleoplasm
Plasma membrane Mixed Tissue enriched 5 stomach: 51.1 kidney: 9.5 SLC9A5 NHE5 ENSG00000135740 Solute carrier family 9, subfamily A (NHE5, cation proton antiporter 5), member 5 16 67237683-67272190 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA041004, HPA041329 Uncertain Approved Nucleoplasm
Cytosol Mixed Tissue enhanced spleen: 7.8 cerebral cortex: 2.5 SLC9A6 KIAA0267, NHE6 ENSG00000198689 Solute carrier family 9, subfamily A (NHE6, cation proton antiporter 6), member 6 X 135985424-136047269 Disease related genes, Potential drug targets, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA059445, HPA059590 Approved Supported Vesicles Expressed in all Tissue enhanced cerebral cortex: 76.1 parathyroid gland: 17.3 SLC9A7 NHE7 ENSG00000065923 Solute carrier family 9, subfamily A (NHE7, cation proton antiporter 7), member 7 X 46599252-46759172 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA048938, HPA075385 Approved Supported Vesicles Endometrial cancer:8.58e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 14.4 SLC9A8 KIAA0939, NHE8 ENSG00000197818 Solute carrier family 9, subfamily A (NHE8, cation proton antiporter 8), member 8 20 49812713-49892242 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB033682 Approved Expressed in all Expressed in all bone marrow: 13.2 SLC9A9 FLJ35613, NHE9 ENSG00000181804 Solute carrier family 9, subfamily A (NHE9, cation proton antiporter 9), member 9 3 143265222-143848531 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA058234 Approved Renal cancer:5.57e-7 (unfavourable), Lung cancer:8.18e-4 (favourable) Expressed in all Mixed placenta: 22.1 SLC9B1 NHA1, NHEDC1 ENSG00000164037 Solute carrier family 9, subfamily B (NHA1, cation proton antiporter 1), member 1 4 102885048-103019739 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA035435, HPA058971, HPA065520 Uncertain Approved Mitochondria Mixed Tissue enriched 25 testis: 73.9 epididymis: 2.9 SLC9B2 FLJ23984, NHA2, NHEDC2 ENSG00000164038 Solute carrier family 9, subfamily B (NHA2, cation proton antiporter 2), member 2 4 103019868-103085829 Predicted membrane proteins, Transporters Evidence at protein level HPA047008 Uncertain Approved Nucleoplasm
Cell Junctions Expressed in all Tissue enhanced cerebral cortex: 32.6 liver: 20.5 SLCO1A2 OATP, OATP-A, OATP1A2, SLC21A3 ENSG00000084453 Solute carrier organic anion transporter family, member 1A2 12 21264600-21419594 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA071152 Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 28.8 salivary gland: 6.6 SLCO1B1 LST-1, OATP-C, OATP1B1, SLC21A6 ENSG00000134538 Solute carrier organic anion transporter family, member 1B1 12 21131202-21239246 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA050892 Supported Tissue enriched Tissue enriched 249 liver: 307.4 breast: 1.2 SLCO1B3 OATP1B3, OATP8, SLC21A8 ENSG00000111700 Solute carrier organic anion transporter family, member 1B3 12 20810702-20916911 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA004943, HPA050892 Supported Supported Plasma membrane Tissue enhanced Tissue enriched 7 liver: 138.5 cervix, uterine: 19.4 SLCO1B7 LST3, SLC21A21 ENSG00000205754 Solute carrier organic anion transporter family, member 1B7 (non-functional) 12 21015696-21092745 Predicted membrane proteins Evidence at transcript level HPA050892 Uncertain Not detected Tissue enriched 21 breast: 42.5 liver: 2.0 SLCO2A1 MATR1, OATP2A1, PGT, SLC21A2 ENSG00000174640 Solute carrier organic anion transporter family, member 2A1 3 133932696-134052184 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA013742 Supported Liver cancer:9.24e-5 (favourable), Stomach cancer:3.25e-4 (unfavourable), Endometrial cancer:9.69e-4 (favourable) Expressed in all Tissue enhanced seminal vesicle: 113.4 thyroid gland: 71.0 SLCO2B1 OATP-B, OATP2B1, SLC21A9 ENSG00000137491 Solute carrier organic anion transporter family, member 2B1 11 75100563-75206549 FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA020659 Uncertain Expressed in all Expressed in all liver: 123.0 SLCO4A1 OATP-E, OATP4A1, SLC21A12 ENSG00000101187 Solute carrier organic anion transporter family, member 4A1 20 62642445-62685785 Predicted membrane proteins, Transporters Evidence at protein level HPA030669, HPA030670 Uncertain Approved Cell Junctions Lung cancer:4.74e-4 (unfavourable) Expressed in all Mixed esophagus: 10.6 SLCO5A1 OATP-J, OATP5A1, OATPRP4, SLC21A15 ENSG00000137571 Solute carrier organic anion transporter family, member 5A1 8 69667047-69835064 Predicted membrane proteins, Transporters Evidence at transcript level HPA025062 Uncertain Mixed Tissue enhanced prostate: 3.6 skeletal muscle: 2.6 SLCO6A1 CT48, MGC26949, OATP6A1, OATPY ENSG00000205359 Solute carrier organic anion transporter family, member 6A1 5 102371782-102499016 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA054126 Supported Not detected Tissue enriched 136 testis: 53.7 placenta: 0.3 SLF1 ANKRD32, BRCTD1, BRCTx, DKFZp564C0469, DKFZp761C121 ENSG00000133302 SMC5-SMC6 complex localization factor 1 5 94618347-94739436 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040793, HPA054213 Uncertain Approved Nucleus Expressed in all Tissue enhanced testis: 12.8 cerebral cortex: 4.4 SLF2 C10orf6, FAM178A, FLJ10512, FLJ25012 ENSG00000119906 SMC5-SMC6 complex localization factor 2 10 100912569-100965136 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038499, HPA057568 Approved Supported Nucleus
Vesicles Expressed in all Expressed in all epididymis: 56.6 SLFN12L ENSG00000205045 Schlafen family member 12-like 17 35464249-35537861 Predicted membrane proteins Evidence at protein level HPA024447 Uncertain Mixed Mixed spleen: 7.5 SLIT2 SLIL3, Slit-2 ENSG00000145147 Slit guidance ligand 2 4 20253260-20620561 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB007590, HPA019511, HPA023088 Uncertain Renal cancer:6.51e-4 (favourable) Mixed Mixed lung: 49.5 SLITRK1 KIAA1910, LRRC12 ENSG00000178235 SLIT and NTRK-like family, member 1 13 83877205-83882393 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA012414 Supported Tissue enriched Tissue enriched 82 cerebral cortex: 23.9 adrenal gland,cervix, uterine,pancreas,seminal vesicle: 0.2 SLITRK3 KIAA0848 ENSG00000121871 SLIT and NTRK-like family, member 3 3 165186720-165197109 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017636 Approved Mitochondria Tissue enriched Tissue enhanced cerebral cortex: 17.4;endometrium: 12.4 fallopian tube: 9.7 SLITRK4 DKFZp547M2010 ENSG00000179542 SLIT and NTRK-like family, member 4 X 143622790-143635777 Predicted membrane proteins Evidence at protein level HPA000431 Approved Uncertain Microtubules Tissue enhanced Tissue enhanced adrenal gland: 14.0;cerebral cortex: 12.8 cervix, uterine: 8.3 SLITRK5 bA364G4.2, KIAA0918, LRRC11 ENSG00000165300 SLIT and NTRK-like family, member 5 13 87672615-87696272 Predicted membrane proteins Evidence at protein level HPA013843 Uncertain Supported Nucleoplasm
Golgi apparatus Not detected Tissue enhanced cerebral cortex: 4.9;fallopian tube: 4.7 seminal vesicle: 1.8 SLITRK6 FLJ22774 ENSG00000184564 SLIT and NTRK-like family, member 6 13 85792790-85799488 Disease related genes, Predicted membrane proteins Evidence at protein level HPA014491, HPA014513 Uncertain Supported Plasma membrane Head and neck cancer:8.52e-4 (unfavourable) Tissue enhanced Tissue enhanced urinary bladder: 20.4 salivary gland: 11.8 SLMAP KIAA1601, SLAP ENSG00000163681 Sarcolemma associated protein 3 57755450-57929168 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002357, HPA002358 Supported Approved Endoplasmic reticulum Renal cancer:1.58e-6 (favourable), Lung cancer:7.98e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 262.4 SLN MGC12301, MGC125854, MGC125855 ENSG00000170290 Sarcolipin 11 107707378-107719693 Predicted membrane proteins, Transporters Evidence at protein level CAB011628 Approved Microtubules Renal cancer:3.52e-9 (unfavourable) Group enriched Tissue enriched 11 skeletal muscle: 2802.5 heart muscle: 263.2 SMAD2 JV18-1, MADH2, MADR2 ENSG00000175387 SMAD family member 2 18 47808957-47931146 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB025507, HPA067203, CAB073546 Approved Supported Nucleus
Nucleoli
Cytosol Liver cancer:9.44e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 126.1 SMAGP hSMAGP, MGC149453, MGC149454 ENSG00000170545 Small cell adhesion glycoprotein 12 51244558-51270890 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039711 Approved Supported Nucleoplasm
Plasma membrane Renal cancer:2.24e-4 (favourable), Pancreatic cancer:4.38e-4 (unfavourable), Glioma:7.05e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 144.1 esophagus: 83.7 SMARCB1 BAF47, hSNFS, Ini1, PPP1R144, RDT, Sfh1p, SNF5, SNF5L1, Snr1 ENSG00000099956 SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1 22 23786963-23834516 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level CAB009196, HPA018248, HPA019127 Supported Supported Nucleoplasm
Nucleoli fibrillar center Renal cancer:1.14e-6 (favourable), Liver cancer:6.52e-4 (unfavourable) Expressed in all Expressed in all testis: 51.2 SMCO2 C12orf70, LOC341346 ENSG00000165935 Single-pass membrane protein with coiled-coil domains 2 12 27466810-27502185 Predicted membrane proteins Evidence at protein level HPA014366 Uncertain Mixed Tissue enhanced testis: 1.3 skin: 0.6 SMCO4 C11orf75, FN5 ENSG00000166002 Single-pass membrane protein with coiled-coil domains 4 11 93478472-93543508 Predicted membrane proteins Evidence at protein level HPA041120 Uncertain Renal cancer:5.81e-7 (unfavourable) Expressed in all Expressed in all salivary gland: 98.0 SMDT1 C22orf32, DDDD, dJ186O1.1, EMRE ENSG00000183172 Single-pass membrane protein with aspartate-rich tail 1 22 42079691-42084284 Predicted membrane proteins, Transporters Evidence at protein level HPA032117, HPA060340 Uncertain Supported Nucleus
Mitochondria Renal cancer:2.36e-9 (favourable), Endometrial cancer:5.32e-8 (favourable), Pancreatic cancer:5.87e-4 (favourable) Expressed in all Expressed in all thyroid gland: 7.8 SMG5 EST1B, KIAA1089, LPTS-RP1, LPTSRP1, RP11-54H19.7, SMG-5 ENSG00000198952 SMG5 nonsense mediated mRNA decay factor 1 156249224-156282825 Predicted membrane proteins Evidence at protein level HPA072651 Supported Cytoplasmic bodies Liver cancer:6.70e-9 (unfavourable), Endometrial cancer:3.39e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 74.7 SMIM1 Vel ENSG00000235169 Small integral membrane protein 1 (Vel blood group) 1 3772788-3775982 Blood group antigen proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069088 Uncertain Expressed in all Tissue enhanced bone marrow: 17.6;testis: 24.7 seminal vesicle: 7.5 SMIM11A C21orf51, FAM165B, SMIM11 ENSG00000205670 Small integral membrane protein 11A 21 34375480-34407866 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051321 Uncertain Approved Focal adhesion sites Not detected Mixed thyroid gland: 32.0 SMIM11B ENSG00000273590 Small integral membrane protein 11B 21 7744962-7777853 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051321 Uncertain Approved Focal adhesion sites Not detected Expressed in all epididymis: 25.9 SMIM12 C1orf212, FLJ90372 ENSG00000163866 Small integral membrane protein 12 1 34712737-34859816 Predicted membrane proteins Evidence at protein level HPA065331 Approved Approved Mitochondria Renal cancer:1.15e-5 (favourable), Liver cancer:1.18e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 44.8 SMIM13 C6orf228 ENSG00000224531 Small integral membrane protein 13 6 11094033-11138733 Predicted membrane proteins Evidence at protein level HPA065706 Approved Approved Nucleus
Nuclear membrane
Golgi apparatus Renal cancer:1.03e-5 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 47.3 placenta: 18.7 SMIM14 C4orf34, FLJ13289 ENSG00000163683 Small integral membrane protein 14 4 39546330-39639090 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051299 Uncertain Approved Mitochondria Head and neck cancer:3.00e-6 (favourable), Renal cancer:2.07e-4 (favourable), Endometrial cancer:2.63e-4 (favourable), Liver cancer:3.47e-4 (favourable) Expressed in all Expressed in all liver: 54.1 SMIM17 ENSG00000268182 Small integral membrane protein 17 19 56643145-56655766 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071857, HPA071861 Supported Approved Vesicles Mixed Tissue enhanced cerebral cortex: 8.7 epididymis: 2.0 SMIM18 ENSG00000253457 Small integral membrane protein 18 8 30638600-30646064 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066648 Supported Uncertain Nucleus
Centrosome Tissue enriched Tissue enriched 9 cerebral cortex: 11.1 adrenal gland: 1.3 SMIM19 C8orf40 ENSG00000176209 Small integral membrane protein 19 8 42541155-42555193 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011145 Uncertain Renal cancer:1.74e-6 (favourable) Expressed in all Expressed in all thyroid gland: 122.6 SMIM2 C13orf44, MGC5590 ENSG00000139656 Small integral membrane protein 2 13 44143543-44161257 Predicted membrane proteins Evidence at protein level HPA026891 Approved Not detected Tissue enriched 8 testis: 40.8 epididymis: 5.2 SMIM20 C4orf52 ENSG00000250317 Small integral membrane protein 20 4 25861830-25929874 Predicted membrane proteins Evidence at protein level HPA016552 Approved Approved Nucleus
Nucleoli
Cytosol Renal cancer:8.97e-5 (favourable) Expressed in all Expressed in all epididymis: 86.3 SMIM21 C18orf62 ENSG00000206026 Small integral membrane protein 21 18 75409476-75427703 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041686 Supported Not detected Tissue enriched 56 testis: 5.5 all non-specific tissues: 0.0 SMIM22 ENSG00000267795 Small integral membrane protein 22 16 4788397-4796491 Predicted membrane proteins Evidence at transcript level HPA077331 Approved Nucleoplasm
Cytosol Mixed Mixed colon: 229.8 SMIM24 C19orf77, HSPC323 ENSG00000095932 Small integral membrane protein 24 19 3473986-3480542 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045046, HPA056027 Supported Approved Nucleoplasm
Cytosol Renal cancer:4.13e-10 (favourable) Tissue enhanced Group enriched 8 duodenum: 780.7;epididymis: 1898.5;kidney: 832.6;small intestine: 696.9 stomach: 139.3 SMIM3 C5orf62, MSTP150, NID67 ENSG00000256235 Small integral membrane protein 3 5 150777946-150796734 Predicted membrane proteins Evidence at protein level HPA075345 Approved Vesicles Renal cancer:1.15e-8 (unfavourable) Expressed in all Expressed in all adipose tissue: 108.7 SMIM4 C3orf78 ENSG00000168273 Small integral membrane protein 4 3 52534013-52579237 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047771 Uncertain Approved Nucleoplasm
Mitochondria Lung cancer:1.78e-5 (favourable), Renal cancer:1.63e-4 (favourable), Pancreatic cancer:5.00e-4 (favourable) Expressed in all Expressed in all adrenal gland: 102.7 SMIM5 C17orf109 ENSG00000204323 Small integral membrane protein 5 17 75633434-75641404 Predicted membrane proteins Evidence at protein level HPA065332, HPA071268 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.12e-4 (favourable), Cervical cancer:5.52e-4 (favourable) Mixed Mixed thyroid gland: 14.7 SMIM6 C17orf110 ENSG00000259120 Small integral membrane protein 6 17 75646243-75647977 Predicted membrane proteins Evidence at transcript level HPA065721 Uncertain Approved Nucleus Endometrial cancer:1.49e-4 (favourable), Urothelial cancer:1.64e-4 (favourable), Renal cancer:4.09e-4 (favourable) Mixed Tissue enhanced fallopian tube: 39.8;stomach: 34.4 testis: 22.7 SMIM7 C19orf42, MGC2747 ENSG00000214046 Small integral membrane protein 7 19 16630751-16660442 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043127 Uncertain Approved Golgi apparatus Expressed in all Expressed in all epididymis: 55.0 SMIM8 C6orf162, dJ102H19.2, DKFZP586E1923 ENSG00000111850 Small integral membrane protein 8 6 87322583-87399749 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA007401, HPA067453 Approved Approved Vesicles Expressed in all Mixed cerebral cortex: 14.0 SMIM9 CXorf68 ENSG00000203870 Small integral membrane protein 9 X 154823348-154834662 Predicted membrane proteins Evidence at transcript level HPA060970 Uncertain Not detected Tissue enriched 5 testis: 1.3 placenta: 0.2 SMLR1 ENSG00000256162 Small leucine-rich protein 1 6 130827406-130837135 Predicted membrane proteins Evidence at protein level HPA066060 Uncertain Tissue enriched Group enriched 5 duodenum: 12.5;liver: 28.9;small intestine: 11.6 kidney: 3.2 SMO FZD11, SMOH ENSG00000128602 Smoothened, frizzled class receptor 7 129188872-129213545 Cancer-related genes, FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011446 Approved Expressed in all Mixed ovary: 30.3 SMOC2 SMAP2 ENSG00000112562 SPARC related modular calcium binding 2 6 168441151-168673445 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB033979 Uncertain Renal cancer:1.16e-6 (unfavourable) Expressed in all Mixed endometrium: 182.8 SMOX C20orf16, dJ779E11.1, FLJ20746, MGC1010, PAO, PAOh1, SMO ENSG00000088826 Spermine oxidase 20 4120980-4187747 Enzymes, FDA approved drug targets, Predicted intracellular proteins Evidence at protein level HPA047117, HPA060198 Approved Supported Nucleoplasm
Nuclear membrane
Vesicles Liver cancer:3.33e-6 (unfavourable), Renal cancer:1.06e-4 (unfavourable), Lung cancer:1.36e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 49.8 gallbladder: 23.5 SMPD2 ISC1, nSMase ENSG00000135587 Sphingomyelin phosphodiesterase 2, neutral membrane (neutral sphingomyelinase) 6 109440763-109443919 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018110, HPA018125 Uncertain Approved Vesicles
Plasma membrane
Cell Junctions Liver cancer:1.17e-4 (unfavourable), Urothelial cancer:1.70e-4 (favourable), Pancreatic cancer:1.00e-3 (favourable) Expressed in all Mixed testis: 55.6 SMPD3 NSMASE2 ENSG00000103056 Sphingomyelin phosphodiesterase 3, neutral membrane (neutral sphingomyelinase II) 16 68358325-68448688 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB033885, HPA065535, HPA069383 Approved Supported Endoplasmic reticulum Endometrial cancer:3.86e-4 (favourable), Cervical cancer:7.72e-4 (favourable) Mixed Tissue enhanced duodenum: 62.7;small intestine: 64.1 stomach: 22.9 SMPD4 FLJ20297, FLJ20756, KIAA1418, NET13, nSMase-3, NSMASE3 ENSG00000136699 Sphingomyelin phosphodiesterase 4, neutral membrane (neutral sphingomyelinase-3) 2 130151392-130182750 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA046279, HPA049426 Approved Approved Nuclear membrane
Cytosol Renal cancer:8.16e-8 (unfavourable), Liver cancer:8.37e-6 (unfavourable), Endometrial cancer:7.47e-5 (unfavourable), Prostate cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all testis: 36.3 SMYD4 KIAA1936, ZMYND21 ENSG00000186532 SET and MYND domain containing 4 17 1779485-1830634 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030059 Uncertain Approved Nucleoplasm
Golgi apparatus
Vesicles
Cytosol Expressed in all Expressed in all testis: 10.9 SNAP23 HsT17016, SNAP23A, SNAP23B ENSG00000092531 Synaptosomal-associated protein, 23kDa 15 42491233-42545356 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA001214, CAB037083, CAB037317 Approved Supported Plasma membrane Expressed in all Expressed in all spleen: 88.1 SNN ENSG00000184602 Stannin 16 11668414-11679159 Predicted membrane proteins Evidence at protein level HPA011055 Approved Approved Cytosol Liver cancer:1.85e-6 (unfavourable), Renal cancer:1.83e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 151.1 SNPH bA314N13.5 ENSG00000101298 Syntaphilin 20 1266316-1309328 Predicted membrane proteins Evidence at protein level HPA049393 Approved Uncertain Cytokinetic bridge
Mitochondria Pancreatic cancer:6.97e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 33.7 seminal vesicle: 15.4 SNRNP40 HPRP8BP, PRP8BP, PRPF8BP, SPF38, WDR57 ENSG00000060688 Small nuclear ribonucleoprotein 40kDa (U5) 1 31259568-31296782 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026527, HPA027345 Supported Supported Nuclear speckles Liver cancer:4.73e-6 (unfavourable), Glioma:9.74e-4 (favourable) Expressed in all Expressed in all lymph node: 41.5 SNRPB COD, Sm-B/B', SmB/SmB', snRNP-B, SNRPB1 ENSG00000125835 Small nuclear ribonucleoprotein polypeptides B and B1 20 2461634-2470853 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA003482, CAB009610, HPA067842 Approved Supported Nucleoplasm Liver cancer:1.07e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 202.5 SNX1 HsT17379, MGC8664, SNX1A, Vps5 ENSG00000028528 Sorting nexin 1 15 64094123-64146090 Predicted intracellular proteins Evidence at protein level HPA047373, HPA052761 Approved Validated Endosomes
Lysosomes Renal cancer:9.88e-6 (favourable) Expressed in all Expressed in all thyroid gland: 162.7 SNX14 RGS-PX2 ENSG00000135317 Sorting nexin 14 6 85505496-85594156 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017639 Approved Supported Cytosol Head and neck cancer:2.78e-4 (unfavourable) Expressed in all Expressed in all testis: 154.6 SNX19 CHET8, KIAA0254 ENSG00000120451 Sorting nexin 19 11 130875436-130916509 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013447 Uncertain Supported Mitochondria Renal cancer:3.56e-5 (favourable) Expressed in all Expressed in all testis: 51.6 SOAT1 ACAT, SOAT, STAT ENSG00000057252 Sterol O-acyltransferase 1 1 179293714-179358680 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB009533, HPA047171 Supported Validated Endoplasmic reticulum Expressed in all Tissue enhanced adrenal gland: 219.3 prostate: 44.0 SOAT2 ACAT2 ENSG00000167780 Sterol O-acyltransferase 2 12 53103518-53124538 Enzymes, Predicted membrane proteins Evidence at protein level HPA062409 Uncertain Group enriched Tissue enhanced duodenum: 12.4;small intestine: 22.4 spleen: 3.5 SOGA3 C6orf174, dJ403A15.3 ENSG00000214338 SOGA family member 3 6 127472794-127519191 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035388, HPA035389 Uncertain Approved Nucleus
Cytosol Not detected Tissue enhanced cerebral cortex: 10.2 endometrium: 2.1 SORCS1 sorCS1 ENSG00000108018 Sortilin-related VPS10 domain containing receptor 1 10 106573663-107164534 Predicted membrane proteins Evidence at protein level HPA011948 Approved Approved Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 12.2;thyroid gland: 18.0 kidney: 4.8 SORCS2 KIAA1329 ENSG00000184985 Sortilin-related VPS10 domain containing receptor 2 4 7192538-7742836 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA061916 Approved Nucleus
Cytosol Renal cancer:3.09e-4 (unfavourable), Ovarian cancer:3.55e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 19.4 cervix, uterine: 10.4 SORL1 C11orf32, gp250, LR11, LRP9, SorLA, SorLA-1 ENSG00000137642 Sortilin-related receptor, L(DLR class) A repeats containing 11 121452203-121633693 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011500, HPA031321 Uncertain Approved Nucleoplasm
Cell Junctions Renal cancer:1.80e-7 (favourable) Expressed in all Mixed cervix, uterine: 67.4 SORT1 Gp95, NT3 ENSG00000134243 Sortilin 1 1 109309568-109397951 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006889, CAB011498 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Colorectal cancer:7.74e-6 (favourable), Liver cancer:1.23e-4 (unfavourable) Expressed in all Expressed in all epididymis: 166.9 SPACA1 SAMP32 ENSG00000118434 Sperm acrosome associated 1 6 88047789-88066832 Predicted membrane proteins Evidence at protein level HPA026744, HPA043297 Supported Not detected Tissue enriched 422 testis: 51.0 kidney: 0.1 SPACA3 ALLP17, CT54, LYC3, LYZL3, SLLP1 ENSG00000141316 Sperm acrosome associated 3 17 32970376-32997877 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023633 Supported Tissue enhanced Tissue enriched 17 testis: 77.2 pancreas: 4.5 SPAG4 CT127, SUN4 ENSG00000061656 Sperm associated antigen 4 20 35615892-35621049 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048393, HPA061789 Approved Endometrial cancer:9.52e-8 (favourable), Colorectal cancer:1.09e-5 (unfavourable), Glioma:8.89e-5 (unfavourable), Renal cancer:1.28e-4 (unfavourable), Urothelial cancer:6.66e-4 (favourable) Expressed in all Mixed testis: 22.6 SPAG9 CT89, FLJ13450, FLJ14006, FLJ26141, FLJ34602, HLC4, HSS, JLP, KIAA0516, MGC117291, MGC14967, MGC74461, PHET, PIG6, SYD1 ENSG00000008294 Sperm associated antigen 9 17 50962174-51120865 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040446, HPA061458 Approved Validated Microtubule organizing center
Cytosol Urothelial cancer:8.10e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 106.4 SPAM1 HYAL5, PH-20, SPAG15 ENSG00000106304 Sperm adhesion molecule 1 (PH-20 hyaluronidase, zona pellucida binding) 7 123925237-123971414 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017984 Supported Not detected Tissue enriched 63 testis: 30.0 duodenum,small intestine: 0.4 SPAST ADPSP, FSP2, KIAA1083, SPG4 ENSG00000021574 Spastin 2 32063611-32157637 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017311 Approved Approved Nucleoplasm
Cytosol Liver cancer:1.62e-4 (unfavourable), Renal cancer:4.15e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 20.1 SPATA3 TSARG1 ENSG00000173699 Spermatogenesis associated 3 2 230996121-231025055 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018254 Supported Not detected Tissue enriched 445 testis: 159.4 cerebral cortex: 0.3 SPATA31D1 FAM75D1, FLJ46321 ENSG00000214929 SPATA31 subfamily D, member 1 9 81988772-81995256 Predicted membrane proteins Evidence at transcript level HPA047897 Uncertain Not detected Tissue enriched 95 testis: 9.5 all non-specific tissues: 0.0 SPATA31E1 C9orf79, FAM75E1, FLJ35866 ENSG00000177992 SPATA31 subfamily E, member 1 9 87882826-87888899 Predicted membrane proteins Evidence at protein level HPA024253 Supported Not detected Tissue enriched 100 testis: 9.9 all non-specific tissues: 0.0 SPATA9 FLJ35906, NYD-SP16 ENSG00000145757 Spermatogenesis associated 9 5 95652181-95698711 Predicted membrane proteins Evidence at protein level HPA010848 Uncertain Approved Mitochondria Not detected Tissue enriched 39 testis: 53.1 adipose tissue: 1.3 SPCS1 HSPC033, SPC1, SPC12, YJR010C-A ENSG00000114902 Signal peptidase complex subunit 1 3 52704955-52711146 Predicted membrane proteins Evidence at protein level HPA046091, HPA055273 Supported Approved Golgi apparatus
Vesicles Renal cancer:2.90e-4 (favourable), Colorectal cancer:9.28e-4 (favourable) Expressed in all Expressed in all testis: 215.4 SPCS2 KIAA0102 ENSG00000118363 Signal peptidase complex subunit 2 11 74949247-74979031 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013386 Approved Approved Nucleus Expressed in all Expressed in all epididymis: 264.2 SPCS3 FLJ22649, PRO3567, SPC22/23, SPC3, YLR066W ENSG00000129128 Signal peptidase complex subunit 3 4 176319964-176332245 Predicted intracellular proteins Evidence at protein level HPA053180 Approved Endometrial cancer:8.89e-6 (favourable), Pancreatic cancer:1.87e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 103.8 SPDYE4 ENSG00000183318 Speedy/RINGO cell cycle regulator family member E4 17 8753106-8758559 Predicted intracellular proteins Evidence at protein level HPA025704, HPA051750 Uncertain Not detected Tissue enriched 21 testis: 10.9 bone marrow,epididymis: 0.5 SPG11 FLJ21439, KIAA1840 ENSG00000104133 Spastic paraplegia 11 (autosomal recessive) 15 44562696-44663678 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040412, HPA040947 Approved Supported Nucleoli
Plasma membrane
Cytosol Renal cancer:6.28e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 49.0 SPI1 OF, PU.1, SFPI1, SPI-1, SPI-A ENSG00000066336 Spi-1 proto-oncogene 11 47354860-47378576 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB004079, HPA044653 Supported Supported Nucleoplasm Renal cancer:2.07e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 212.9 SPIDR KIAA0146 ENSG00000164808 Scaffolding protein involved in DNA repair 8 47260575-47736306 Predicted intracellular proteins Evidence at protein level HPA027201, HPA041582 Approved Supported Nucleoplasm Renal cancer:2.04e-6 (unfavourable), Ovarian cancer:8.91e-4 (unfavourable) Expressed in all Expressed in all placenta: 32.4 SPINT1 HAI, MANSC2 ENSG00000166145 Serine peptidase inhibitor, Kunitz type 1 15 40844018-40858207 Cancer-related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006903 Uncertain Uncertain Plasma membrane
Cytosol Renal cancer:1.37e-7 (favourable), Breast cancer:6.97e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 219.8 SPINT2 HAI-2, Kop ENSG00000167642 Serine peptidase inhibitor, Kunitz type, 2 19 38244035-38292614 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA011101, CAB018969 Approved Uncertain Plasma membrane
Intermediate filaments
Cytosol Renal cancer:3.41e-4 (favourable) Expressed in all Mixed thyroid gland: 536.5 SPN CD43, GPL115, LSN ENSG00000197471 Sialophorin 16 29662979-29670876 CD markers, Predicted membrane proteins Evidence at protein level CAB002666, HPA055244 Supported Uncertain Golgi apparatus
Plasma membrane
Cell Junctions Endometrial cancer:3.08e-5 (favourable), Breast cancer:1.40e-4 (favourable), Melanoma:1.88e-4 (favourable) Expressed in all Tissue enhanced bone marrow: 38.7;lung: 33.4 lymph node: 25.8 SPNS1 HSpin1, LAT, nrs, PP2030, SPIN1, SPINL ENSG00000169682 Spinster homolog 1 (Drosophila) 16 28974221-28984548 Predicted membrane proteins, Transporters Evidence at protein level HPA041995, HPA042988 Supported Approved Nucleoli fibrillar center
Golgi apparatus
Vesicles
Cytosol Mixed Expressed in all parathyroid gland: 36.3 SPNS2 ENSG00000183018 Spinster homolog 2 (Drosophila) 17 4498838-4539035 Predicted membrane proteins, Transporters Evidence at protein level HPA068717 Uncertain Expressed in all Tissue enhanced esophagus: 46.5 kidney: 29.9 SPNS3 MGC29671 ENSG00000182557 Spinster homolog 3 (Drosophila) 17 4433688-4488208 Predicted membrane proteins Evidence at protein level HPA023928 Uncertain Renal cancer:8.09e-4 (unfavourable) Mixed Tissue enriched 6 bone marrow: 12.4 spleen: 2.1 SPPL2A IMP3, PSL2 ENSG00000138600 Signal peptide peptidase like 2A 15 50702266-50765808 Enzymes, Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036062, HPA067304 Supported Supported Vesicles Expressed in all Expressed in all parathyroid gland: 285.5 SPPL2B IMP4, KIAA1532, PSL1 ENSG00000005206 Signal peptide peptidase like 2B 19 2328615-2354806 Enzymes, Predicted membrane proteins Evidence at protein level HPA039292 Approved Nucleoplasm
Plasma membrane
Centrosome Endometrial cancer:5.00e-5 (favourable), Pancreatic cancer:1.33e-4 (favourable), Renal cancer:6.45e-4 (unfavourable) Expressed in all Expressed in all testis: 49.2 SPPL3 DKFZP586C1324, IMP2, MGC126674, MGC126676, MGC90402, PSL4 ENSG00000157837 Signal peptide peptidase like 3 12 120762510-120904371 Enzymes, Predicted membrane proteins Evidence at protein level HPA004194, HPA059958 Uncertain Supported Vesicles
Plasma membrane Liver cancer:1.29e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 82.3 SPRED1 FLJ33903, PPP1R147 ENSG00000166068 Sprouty-related, EVH1 domain containing 1 15 38252326-38357249 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042193, HPA061805 Approved Supported Nucleus Renal cancer:7.37e-5 (unfavourable), Stomach cancer:8.29e-5 (unfavourable), Endometrial cancer:7.08e-4 (favourable) Expressed in all Mixed thyroid gland: 48.1 SPRED2 FLJ21897, FLJ31917, Spred-2 ENSG00000198369 Sprouty-related, EVH1 domain containing 2 2 65310851-65432637 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038256 Uncertain Nucleoplasm
Cytosol Expressed in all Expressed in all cerebral cortex: 44.1 SPRY1 hSPRY1 ENSG00000164056 Sprouty RTK signaling antagonist 1 4 123396795-123403760 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB013538, HPA051369, HPA070554 Approved Approved Nucleoplasm
Golgi apparatus
Cytosol Expressed in all Expressed in all gallbladder: 132.5 SPRY2 hSPRY2 ENSG00000136158 Sprouty RTK signaling antagonist 2 13 80335976-80340951 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB037205, HPA042198 Approved Supported Microtubules Expressed in all Expressed in all adipose tissue: 69.8 SPRY3 HSPRY3 ENSG00000168939 Sprouty RTK signaling antagonist 3 X 155767812-155782459 Predicted membrane proteins Evidence at transcript level CAB013505 Uncertain Approved Nucleoli
Cytosol Mixed Mixed epididymis: 2.6 SPRY4 ENSG00000187678 Sprouty RTK signaling antagonist 4 5 142310427-142326455 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB008086, HPA055471 Approved Supported Golgi apparatus
Cytosol Renal cancer:2.20e-4 (unfavourable), Cervical cancer:7.12e-4 (unfavourable) Expressed in all Mixed adipose tissue: 26.7 SPTLC1 hLCB1, HSAN1, HSN1, LCB1, SPTI ENSG00000090054 Serine palmitoyltransferase, long chain base subunit 1 9 92031999-92115384 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA010860, CAB018747, HPA063907 Supported Supported Endoplasmic reticulum Renal cancer:1.36e-6 (favourable) Expressed in all Expressed in all thyroid gland: 108.0 SPTLC2 hLCB2a, KIAA0526, LCB2, LCB2A ENSG00000100596 Serine palmitoyltransferase, long chain base subunit 2 14 77505997-77616773 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027552 Approved Mitochondria Renal cancer:6.69e-8 (favourable), Liver cancer:3.62e-4 (unfavourable) Expressed in all Expressed in all placenta: 29.0 SPTLC3 C20orf38, FLJ11112, hLCB2b, LCB2B, SPTLC2L ENSG00000172296 Serine palmitoyltransferase, long chain base subunit 3 20 13008979-13169103 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044247, HPA048079 Approved Supported Microtubules Renal cancer:4.51e-7 (favourable), Pancreatic cancer:6.02e-4 (unfavourable) Expressed in all Mixed thyroid gland: 40.7 SPTSSB ADMP, C3orf57, ssSPTb ENSG00000196542 Serine palmitoyltransferase, small subunit B 3 161344792-161372880 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047712 Approved Nuclear speckles Tissue enhanced Tissue enhanced skin: 48.4;stomach: 60.1;urinary bladder: 37.7 prostate: 23.2 SQLE ENSG00000104549 Squalene epoxidase 8 124998497-125022283 Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018038, HPA020762 Approved Uncertain Vesicles
Cytosol Pancreatic cancer:2.73e-4 (unfavourable), Lung cancer:4.67e-4 (unfavourable), Renal cancer:5.70e-4 (unfavourable), Head and neck cancer:7.42e-4 (unfavourable) Expressed in all Mixed testis: 107.2 SRD5A1 ENSG00000145545 Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1) 5 6633343-6674386 Cancer-related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA051402 Approved Endometrial cancer:8.73e-6 (unfavourable) Expressed in all Mixed skin: 17.1 SRD5A3 FLJ13352, SRD5A2L, SRD5A2L1 ENSG00000128039 Steroid 5 alpha-reductase 3 4 55346109-55373096 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA027006 Uncertain Approved Plasma membrane
Cytosol Renal cancer:4.85e-10 (unfavourable), Liver cancer:1.80e-6 (unfavourable), Endometrial cancer:9.39e-4 (favourable) Expressed in all Expressed in all gallbladder: 28.3 SREBF1 bHLHd1, SREBP-1c, SREBP1 ENSG00000072310 Sterol regulatory element binding transcription factor 1 17 17810399-17837002 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level CAB005406, HPA043343, HPA043878 Uncertain Supported Golgi apparatus
Cytosol Endometrial cancer:2.66e-4 (favourable), Pancreatic cancer:9.05e-4 (favourable) Expressed in all Expressed in all adrenal gland: 92.9 SREBF2 bHLHd2, SREBP2 ENSG00000198911 Sterol regulatory element binding transcription factor 2 22 41833079-41907308 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA031962, HPA031963 Approved Supported Nucleoplasm
Vesicles
Mitochondria Renal cancer:1.37e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 118.8 SRPRB APMCF1 ENSG00000144867 Signal recognition particle receptor, B subunit 3 133784033-133825772 Predicted membrane proteins Evidence at protein level HPA011173 Approved Approved Plasma membrane Liver cancer:3.12e-5 (unfavourable) Expressed in all Expressed in all epididymis: 51.1 SSH1 KIAA1298 ENSG00000084112 Slingshot protein phosphatase 1 12 108778192-108857590 Enzymes, Predicted intracellular proteins Evidence at protein level HPA019845 Uncertain Uncertain Nucleoplasm
Plasma membrane
Cytosol Liver cancer:5.80e-5 (unfavourable) Expressed in all Mixed parathyroid gland: 9.5 SSPN KRAG, SPN1, SPN2 ENSG00000123096 Sarcospan 12 26121991-26299290 Predicted membrane proteins Evidence at protein level HPA066432 Approved Nucleus
Nuclear membrane Renal cancer:2.77e-5 (unfavourable) Mixed Mixed cervix, uterine: 64.1 SSR1 TRAPA ENSG00000124783 Signal sequence receptor, alpha 6 7268306-7347446 Predicted membrane proteins Evidence at protein level HPA011276, HPA017062 Supported Supported Endoplasmic reticulum Renal cancer:5.79e-6 (unfavourable), Liver cancer:4.92e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 140.5 SSR3 TRAPG ENSG00000114850 Signal sequence receptor, gamma (translocon-associated protein gamma) 3 156540140-156555184 Predicted membrane proteins Evidence at protein level HPA014906 Approved Approved Uncertain Cytosol Liver cancer:4.46e-7 (unfavourable), Renal cancer:2.84e-4 (unfavourable), Head and neck cancer:3.43e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 203.5 SSR4 TRAPD ENSG00000180879 Signal sequence receptor, delta X 153793516-153798505 Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA045209 Supported Renal cancer:5.51e-6 (unfavourable), Endometrial cancer:1.76e-4 (favourable) Expressed in all Expressed in all epididymis: 962.9 SSTR1 ENSG00000139874 Somatostatin receptor 1 14 38207999-38213067 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA031506 Approved Renal cancer:4.28e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 13.6;duodenum: 14.6;stomach: 21.4 small intestine: 9.3 SSTR2 ENSG00000180616 Somatostatin receptor 2 17 73165012-73176633 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA007264 Uncertain Supported Cytosol Renal cancer:9.04e-7 (unfavourable), Pancreatic cancer:6.63e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 22.9 spleen: 5.9 SSTR3 ENSG00000278195 Somatostatin receptor 3 22 37204238-37212322 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022647 Approved Tissue enhanced Tissue enhanced testis: 10.9 cerebral cortex: 3.9 SSTR4 ENSG00000132671 Somatostatin receptor 4 20 23035386-23036812 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA064252 Uncertain Not detected Not detected cerebral cortex: 0.8 SSTR5 ENSG00000162009 Somatostatin receptor 5 16 1078781-1080142 FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA066503 Supported Plasma membrane Mixed Tissue enhanced adrenal gland: 1.2 heart muscle: 0.8 ST14 HAI, MT-SP1, PRSS14, SNC19, TMPRSS14 ENSG00000149418 Suppression of tumorigenicity 14 (colon carcinoma) 11 130159562-130210376 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA047014 Approved Nucleoplasm
Vesicles Renal cancer:5.03e-11 (favourable) Expressed in all Mixed small intestine: 152.0 ST3GAL2 SIAT4B, ST3GalA.2, ST3GALII ENSG00000157350 ST3 beta-galactoside alpha-2,3-sialyltransferase 2 16 70375978-70439237 Enzymes, Predicted membrane proteins Evidence at protein level HPA017270 Approved Approved Vesicles Renal cancer:3.34e-6 (unfavourable), Pancreatic cancer:2.33e-4 (favourable), Liver cancer:2.79e-4 (unfavourable) Expressed in all Mixed appendix: 15.7 ST3GAL3 MRT12, SIAT6 ENSG00000126091 ST3 beta-galactoside alpha-2,3-sialyltransferase 3 1 43705824-43931165 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051102 Uncertain Expressed in all Expressed in all skeletal muscle: 30.5 ST3GAL4 CGS23, FLJ11867, NANTA3, SAT3, SIAT4, SIAT4C, STZ ENSG00000110080 ST3 beta-galactoside alpha-2,3-sialyltransferase 4 11 126355640-126440344 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA049827 Approved Expressed in all Mixed adrenal gland: 105.8 ST3GAL5 SIAT9, SIATGM3S, ST3GalV ENSG00000115525 ST3 beta-galactoside alpha-2,3-sialyltransferase 5 2 85839144-85889014 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA034708, HPA040425, HPA068928 Uncertain Approved Vesicles Renal cancer:2.25e-7 (unfavourable), Urothelial cancer:4.48e-4 (favourable), Thyroid cancer:4.99e-4 (favourable) Expressed in all Mixed thyroid gland: 72.2 ST3GAL6 SIAT10, ST3GALVI ENSG00000064225 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 3 98732236-98821201 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018792 Approved Tissue enhanced Mixed liver: 28.4 ST6GAL2 KIAA1877, SIAT2, St6gal2, St6GalII ENSG00000144057 ST6 beta-galactosamide alpha-2,6-sialyltranferase 2 2 106801600-106887108 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014459 Uncertain Approved Nucleus
Nucleoli fibrillar center Tissue enriched Tissue enhanced cerebral cortex: 22.2;thyroid gland: 47.8 testis: 9.9 ST6GALNAC1 SIAT7A, ST6GalNAcI ENSG00000070526 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 1 17 76624761-76643838 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014975 Uncertain Head and neck cancer:2.54e-5 (favourable) Mixed Tissue enhanced colon: 166.2;rectum: 239.7 cervix, uterine: 90.8 ST6GALNAC4 SIAT3C, SIAT7D, ST6GALNACIV ENSG00000136840 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 4 9 127907886-127917038 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA009042 Approved Nucleus
Golgi apparatus Liver cancer:8.63e-7 (unfavourable), Ovarian cancer:5.12e-4 (unfavourable), Renal cancer:8.39e-4 (unfavourable) Expressed in all Mixed bone marrow: 24.5 ST6GALNAC6 SIAT7F, ST6GALNACVI ENSG00000160408 ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-acetylgalactosaminide alpha-2,6-sialyltransferase 6 9 127885321-127905408 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018890 Approved Approved Nucleus Expressed in all Expressed in all rectum: 156.5 ST7 ETS7q, FAM4A, FAM4A1, HELG, RAY1, SEN4, TSG7 ENSG00000004866 Suppression of tumorigenicity 7 7 116953238-117230103 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038325, HPA038326 Approved Supported Nucleoplasm
Cytosol Renal cancer:3.39e-5 (favourable) Expressed in all Expressed in all thyroid gland: 50.9 ST7L FAM4B, FLJ20284, ST7R, STLR ENSG00000007341 Suppression of tumorigenicity 7 like 1 112523518-112620825 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA042324, HPA075418 Uncertain Approved Centrosome Ovarian cancer:3.04e-5 (favourable), Colorectal cancer:8.34e-5 (favourable), Melanoma:5.16e-4 (unfavourable), Endometrial cancer:8.96e-4 (unfavourable) Expressed in all Tissue enriched 5 testis: 64.6 thyroid gland: 12.3 ST8SIA1 SIAT8, SIAT8A ENSG00000111728 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 1 12 22063773-22437041 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026775 Approved Mixed Mixed cerebral cortex: 9.1 ST8SIA3 SIAT8C ENSG00000177511 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 3 18 57350813-57371731 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA063398, HPA066783 Supported Supported Golgi apparatus Group enriched Tissue enriched 7 cerebral cortex: 31.9 adrenal gland: 4.8 ST8SIA5 SIAT8E ENSG00000101638 ST8 alpha-N-acetyl-neuraminide alpha-2,8-sialyltransferase 5 18 46667821-46759257 Predicted membrane proteins Evidence at protein level HPA043813, HPA046771 Approved Approved Plasma membrane
Midbody Tissue enriched Tissue enhanced adrenal gland: 5.5;cerebral cortex: 11.5 parathyroid gland: 3.4 STAB1 CLEVER-1, FEEL-1, FELE-1, FEX1, KIAA0246, STAB-1 ENSG00000010327 Stabilin 1 3 52495338-52524495 Predicted membrane proteins Evidence at protein level HPA005434 Approved Renal cancer:3.88e-7 (unfavourable), Colorectal cancer:7.59e-4 (unfavourable) Expressed in all Expressed in all spleen: 125.2 STAB2 DKFZP434E0321, FEEL-2, FELL, HARE, STAB-2 ENSG00000136011 Stabilin 2 12 103587273-103766727 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026871 Supported Uncertain Cytosol Not detected Tissue enriched 6 spleen: 49.0 liver: 7.9 STAG1 SA-1, SA1, SCC3A ENSG00000118007 Stromal antigen 1 3 136336233-136752403 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA035015, HPA058653 Supported Validated Nucleus
Nuclear bodies Expressed in all Expressed in all endometrium: 31.7 STARD3 es64, MLN64 ENSG00000131748 StAR-related lipid transfer (START) domain containing 3 17 39637065-39663484 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level CAB017021 Uncertain Liver cancer:3.60e-5 (unfavourable), Renal cancer:7.70e-4 (unfavourable) Expressed in all Expressed in all testis: 33.3 STARD3NL MENTHO, MGC3251 ENSG00000010270 STARD3 N-terminal like 7 38178222-38230671 Predicted membrane proteins Evidence at protein level HPA019204 Supported Supported Vesicles Liver cancer:1.44e-5 (unfavourable), Head and neck cancer:2.20e-4 (unfavourable), Pancreatic cancer:8.48e-4 (favourable) Expressed in all Expressed in all placenta: 69.9 STARD4 ENSG00000164211 StAR-related lipid transfer (START) domain containing 4 5 111496033-111512590 Predicted intracellular proteins Evidence at protein level HPA046177, HPA048081 Approved Approved Plasma membrane Liver cancer:4.80e-5 (unfavourable), Renal cancer:5.89e-5 (unfavourable), Urothelial cancer:2.84e-4 (unfavourable) Expressed in all Mixed duodenum: 42.6 STEAP1 PRSS24, STEAP ENSG00000164647 Six transmembrane epithelial antigen of the prostate 1 7 90154375-90164829 Cancer-related genes, Predicted membrane proteins, Transporters Evidence at protein level HPA030985 Uncertain Tissue enriched Tissue enhanced prostate: 124.2 appendix: 41.5 STEAP2 IPCA-1, PCANAP1, STAMP1, STMP ENSG00000157214 STEAP family member 2, metalloreductase 7 90167590-90238137 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA029115, HPA055603 Uncertain Supported Vesicles Tissue enriched Tissue enriched 11 prostate: 205.1 parathyroid gland: 18.5 STEAP3 dudlin-2, STMP3, TSAP6 ENSG00000115107 STEAP family member 3, metalloreductase 2 119223831-119265652 Disease related genes, Predicted membrane proteins Evidence at protein level HPA050510 Uncertain Approved Nucleoli
Cytosol Renal cancer:0.00e+0 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 190.8 liver: 53.0 STEAP4 FLJ23153, STAMP2, TIARP, TNFAIP9 ENSG00000127954 STEAP family member 4 7 88270892-88306891 Predicted membrane proteins, Transporters Evidence at protein level HPA075871 Supported Golgi apparatus Liver cancer:2.97e-4 (favourable), Stomach cancer:5.77e-4 (unfavourable) Tissue enhanced Expressed in all adipose tissue: 129.9 STIM1 D11S4896E, GOK ENSG00000167323 Stromal interaction molecule 1 11 3854527-4093210 Disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA011088, HPA012123, CAB037128, CAB037288 Supported Validated Endoplasmic reticulum Expressed in all Expressed in all parathyroid gland: 86.3 STIM2 ENSG00000109689 Stromal interaction molecule 2 4 26857678-27025381 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA036933, CAB037196, HPA057511 Supported Approved Vesicles Liver cancer:3.97e-5 (unfavourable), Pancreatic cancer:5.01e-4 (favourable) Expressed in all Expressed in all gallbladder: 44.5 STK40 MGC4796, SgK495 ENSG00000196182 Serine/threonine kinase 40 1 36339624-36385896 Enzymes, Predicted membrane proteins Evidence at protein level HPA008026 Uncertain Supported Nucleoplasm
Cytosol Pancreatic cancer:5.59e-4 (favourable) Expressed in all Expressed in all testis: 57.0 STOM BND7, EPB7, EPB72 ENSG00000148175 Stomatin 9 121338988-121370304 Plasma proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA010961, HPA011419 Approved Validated Cytosol Expressed in all Expressed in all adipose tissue: 461.2 STOML1 FLJ36370, hUNC-24, SLP-1, STORP ENSG00000067221 Stomatin (EPB72)-like 1 15 73978923-73994622 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042353 Approved Approved Cytosol Expressed in all Expressed in all cerebral cortex: 43.8 STOML3 Epb7.2l, SRO ENSG00000133115 Stomatin (EPB72)-like 3 13 38965925-38991066 Predicted membrane proteins Evidence at protein level HPA012892, CAB014880 Approved Endometrial cancer:1.49e-4 (favourable) Tissue enhanced Tissue enriched 17 fallopian tube: 49.7 lung: 2.8 STON2 STN2, STNB2 ENSG00000140022 Stonin 2 14 81260656-81436465 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003086 Approved Supported Nucleoli
Cytosol Endometrial cancer:4.96e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 34.3 STRA6 FLJ12541 ENSG00000137868 Stimulated by retinoic acid 6 15 74179466-74212267 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA040839 Approved Approved Nucleus
Cytosol Mixed Tissue enhanced cervix, uterine: 37.3;placenta: 20.4 endometrium: 13.5 STRADB ALS2CR2, CALS-21, ILPIP, ILPIPA, PAPK ENSG00000082146 STE20-related kinase adaptor beta 2 201387858-201480846 Enzymes, Predicted intracellular proteins Evidence at protein level HPA026549, HPA028520 Approved Supported Aggresome
Cytosol Renal cancer:1.35e-4 (unfavourable), Thyroid cancer:4.45e-4 (favourable) Expressed in all Expressed in all kidney: 72.8 STRN4 ZIN, zinedin ENSG00000090372 Striatin, calmodulin binding protein 4 19 46719507-46746994 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043051, HPA043527, HPA056706 Supported Approved Cytosol Liver cancer:6.06e-8 (unfavourable), Ovarian cancer:2.98e-4 (unfavourable) Expressed in all Expressed in all testis: 105.0 STS ARSC, ARSC1 ENSG00000101846 Steroid sulfatase (microsomal), isozyme S X 7219456-7354810 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA002904 Approved Pancreatic cancer:3.47e-4 (unfavourable) Expressed in all Tissue enhanced placenta: 36.3 adipose tissue: 18.9 STT3A ITM1, MGC9042, STT3-A, TMC ENSG00000134910 STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 11 125591712-125625215 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA030735 Approved Uncertain Nucleoplasm
Vesicles
Cytosol Endometrial cancer:1.32e-4 (favourable), Liver cancer:3.57e-4 (unfavourable), Renal cancer:4.96e-4 (unfavourable) Expressed in all Tissue enriched 6 parathyroid gland: 1111.5 epididymis: 173.1 STT3B FLJ90106, SIMP, STT3-B ENSG00000163527 STT3B, subunit of the oligosaccharyltransferase complex (catalytic) 3 31532638-31637622 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA036448, HPA036646 Approved Supported Endoplasmic reticulum Colorectal cancer:7.91e-5 (favourable) Expressed in all Expressed in all testis: 164.6 STX10 hsyn10, SYN10 ENSG00000104915 Syntaxin 10 19 13144058-13150383 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035303, HPA056439 Approved Approved Golgi apparatus Renal cancer:1.69e-7 (unfavourable), Lung cancer:8.26e-4 (favourable) Expressed in all Expressed in all skin: 57.0 STX12 STX13, STX14 ENSG00000117758 Syntaxin 12 1 27773183-27824452 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041038, HPA055300 Approved Supported Nucleoplasm
Golgi apparatus
Vesicles Expressed in all Expressed in all thyroid gland: 155.4 STX16 hsyn16, SYN16 ENSG00000124222 Syntaxin 16 20 58651253-58679526 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041019, HPA042033 Uncertain Validated Vesicles Renal cancer:1.11e-16 (unfavourable), Liver cancer:4.18e-4 (unfavourable) Expressed in all Expressed in all skin: 64.0 STX17 FLJ20651 ENSG00000136874 Syntaxin 17 9 99906633-99970341 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001204 Approved Uncertain Nucleoli
Cytosol Renal cancer:1.62e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 36.1 STX18 Ufe1 ENSG00000168818 Syntaxin 18 4 4415742-4542346 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003019 Approved Approved Plasma membrane Endometrial cancer:6.33e-8 (favourable), Colorectal cancer:2.84e-4 (favourable), Urothelial cancer:4.69e-4 (favourable), Renal cancer:7.03e-4 (favourable) Expressed in all Expressed in all cervix, uterine: 181.9 STX1A HPC-1, p35-1, STX1 ENSG00000106089 Syntaxin 1A (brain) 7 73699206-73719672 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level CAB008372, HPA069176 Supported Endometrial cancer:1.94e-5 (unfavourable), Cervical cancer:3.63e-4 (unfavourable) Expressed in all Tissue enriched 15 cerebral cortex: 167.1 gallbladder: 10.8 STX1B STX1B1, STX1B2 ENSG00000099365 Syntaxin 1B 16 30989256-31010628 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA069176 Supported Tissue enriched Tissue enriched 21 cerebral cortex: 89.7 testis: 4.3 STX2 EPIM, EPM, STX2A, STX2B, STX2C ENSG00000111450 Syntaxin 2 12 130789600-130839266 Cancer-related genes, Predicted membrane proteins Evidence at protein level HPA038189, HPA069176 Uncertain Approved Nucleus
Cytosol Renal cancer:5.15e-5 (unfavourable) Expressed in all Expressed in all testis: 35.1 STX3 STX3A ENSG00000166900 Syntaxin 3 11 59713456-59805882 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002191, HPA069176 Approved Supported Nucleus
Nuclear bodies
Cytosol Liver cancer:8.41e-7 (unfavourable), Renal cancer:1.14e-6 (favourable) Expressed in all Expressed in all placenta: 71.8 STX4 p35-2, STX4A ENSG00000103496 Syntaxin 4 16 31032889-31042975 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA001330 Approved Validated Plasma membrane Renal cancer:2.88e-9 (unfavourable), Cervical cancer:3.65e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 63.4 STX5 SED5, STX5A ENSG00000162236 Syntaxin 5 11 62806897-62832088 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001358 Uncertain Supported Nucleoplasm
Golgi apparatus Expressed in all Expressed in all thyroid gland: 58.9 STX6 ENSG00000135823 Syntaxin 6 1 180972712-181023121 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA038557, HPA038558 Approved Validated Nucleoplasm
Golgi apparatus Renal cancer:1.93e-8 (unfavourable), Liver cancer:6.24e-5 (unfavourable) Expressed in all Mixed cerebral cortex: 30.3 STX7 ENSG00000079950 Syntaxin 7 6 132445867-132513198 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001467, CAB062564 Supported Validated Lysosomes Liver cancer:1.60e-4 (unfavourable) Expressed in all Expressed in all lymph node: 92.5 STX8 CARB ENSG00000170310 Syntaxin 8 17 9250471-9576591 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001540 Approved Uncertain Nuclear bodies
Golgi apparatus
Actin filaments
Cytosol Expressed in all Expressed in all testis: 96.0 STXBP2 Hunc18b, UNC18B ENSG00000076944 Syntaxin binding protein 2 19 7636881-7647873 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA015564, HPA063868 Approved Validated Cytosol Urothelial cancer:5.13e-6 (favourable), Endometrial cancer:2.29e-4 (favourable), Liver cancer:4.65e-4 (unfavourable), Thyroid cancer:7.68e-4 (favourable) Expressed in all Mixed bone marrow: 125.6 STXBP5 LLGL3, tomosyn ENSG00000164506 Syntaxin binding protein 5 (tomosyn) 6 147204425-147390476 Predicted intracellular proteins Evidence at protein level HPA039991, HPA049727 Validated Cytosol Renal cancer:2.74e-7 (unfavourable), Breast cancer:4.48e-4 (unfavourable) Expressed in all Tissue enriched 7 parathyroid gland: 273.3 testis: 40.1 STYK1 DKFZp761P1010, NOK, SuRTK106 ENSG00000060140 Serine/threonine/tyrosine kinase 1 12 10618939-10674318 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040468, HPA048569 Uncertain Approved Nucleus
Plasma membrane Mixed Mixed rectum: 17.8 SUCNR1 GPR91 ENSG00000198829 Succinate receptor 1 3 151873643-151884619 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level CAB022745 Uncertain Mixed Tissue enhanced kidney: 42.0 thyroid gland: 15.8 SUCO C1orf9, CH1, OPT, SLP1 ENSG00000094975 SUN domain containing ossification factor 1 172532349-172611833 Predicted membrane proteins Evidence at protein level HPA047251 Approved Approved Nucleoli fibrillar center
Cytosol Liver cancer:2.86e-4 (unfavourable) Expressed in all Mixed epididymis: 75.0 SUN1 FLJ12407, KIAA0810, UNC84A ENSG00000164828 Sad1 and UNC84 domain containing 1 7 816615-896435 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008346, HPA008461 Supported Validated Nuclear membrane Expressed in all Expressed in all endometrium: 120.0 SUN2 UNC84B ENSG00000100242 Sad1 and UNC84 domain containing 2 22 38734725-38794143 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA001209 Supported Supported Nuclear membrane Expressed in all Expressed in all lymph node: 120.6 SUN3 MGC33329, SUNC1 ENSG00000164744 Sad1 and UNC84 domain containing 3 7 47987148-48029119 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008344 Approved Golgi apparatus Tissue enhanced Tissue enriched 153 testis: 74.2 placenta: 0.4 SUN5 dJ726C3.1, SPAG4L, TSARG4 ENSG00000167098 Sad1 and UNC84 domain containing 5 20 32983773-33004433 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048529 Supported Not detected Tissue enriched 409 testis: 40.8 all non-specific tissues: 0.0 SURF1 ENSG00000148290 Surfeit 1 9 133351755-133356676 Disease related genes, Predicted membrane proteins Evidence at protein level CAB033946 Uncertain Renal cancer:6.92e-9 (favourable) Expressed in all Expressed in all epididymis: 46.0 SURF4 ERV29, FLJ22993, MGC102753 ENSG00000148248 Surfeit 4 9 133361449-133376166 Predicted membrane proteins Evidence at protein level HPA064613 Approved Head and neck cancer:1.47e-5 (unfavourable), Breast cancer:5.85e-4 (unfavourable), Liver cancer:8.11e-4 (unfavourable) Expressed in all Expressed in all small intestine: 84.4 SUSD1 DKFZP761E1824 ENSG00000106868 Sushi domain containing 1 9 112040785-112175408 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA048554 Approved Approved Nucleoplasm Renal cancer:3.63e-6 (favourable) Expressed in all Mixed placenta: 21.3 SUSD2 BK65A6.2, FLJ22778 ENSG00000099994 Sushi domain containing 2 22 24181259-24189110 Predicted membrane proteins Evidence at protein level HPA004117 Approved Approved Plasma membrane Renal cancer:3.29e-5 (unfavourable) Expressed in all Tissue enhanced lung: 139.6 small intestine: 35.8 SUSD3 MGC26847 ENSG00000157303 Sushi domain containing 3 9 93058688-93085138 Predicted membrane proteins Evidence at protein level HPA042310 Uncertain Approved Nucleus Breast cancer:5.13e-4 (favourable) Expressed in all Tissue enhanced testis: 91.7 lymph node: 67.3 SUSD4 FLJ10052 ENSG00000143502 Sushi domain containing 4 1 223220819-223364202 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA058296 Uncertain Approved Vesicles Endometrial cancer:4.28e-4 (unfavourable) Mixed Tissue enhanced esophagus: 42.6 cerebral cortex: 38.6 SUSD5 KIAA0527 ENSG00000173705 Sushi domain containing 5 3 33150042-33219215 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA052788 Uncertain Uncertain Golgi apparatus
Vesicles Tissue enhanced Mixed cerebral cortex: 11.0 SUSD6 KIAA0247 ENSG00000100647 Sushi domain containing 6 14 69611596-69715142 Predicted membrane proteins Evidence at protein level HPA030464 Uncertain Approved Nucleoplasm
Intermediate filaments Renal cancer:2.16e-4 (favourable) Expressed in all Expressed in all epididymis: 51.6 SV2A KIAA0736, SV2 ENSG00000159164 Synaptic vesicle glycoprotein 2A 1 149903318-149917882 FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB002226, HPA007863 Supported Approved Cytosol Renal cancer:3.22e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 167.4;parathyroid gland: 70.8 epididymis: 27.9 SV2B HsT19680, KIAA0735 ENSG00000185518 Synaptic vesicle glycoprotein 2B 15 91099950-91301309 Predicted membrane proteins Evidence at protein level HPA046247 Approved Mixed Tissue enriched 23 cerebral cortex: 48.1 adipose tissue: 2.1 SV2C ENSG00000122012 Synaptic vesicle glycoprotein 2C 5 76083172-76353939 Predicted membrane proteins Evidence at protein level HPA040722, HPA040770 Supported Approved Nucleoplasm
Vesicles Not detected Tissue enhanced adrenal gland: 1.7;cerebral cortex: 3.4 fallopian tube,ovary: 0.6 SVOP DKFZp761H039 ENSG00000166111 SV2 related protein 12 108907741-109021240 Predicted membrane proteins Evidence at protein level HPA016573 Uncertain Group enriched Tissue enriched 15 cerebral cortex: 32.4 adrenal gland: 2.1 SVOPL MGC46715 ENSG00000157703 SVOP-like 7 138594285-138701352 Predicted membrane proteins Evidence at transcript level HPA018035 Uncertain Mixed Tissue enriched 5 parathyroid gland: 14.0 fallopian tube: 2.6 SYBU FLJ20366, GOLSYN, KIAA1472, OCSYN, SNPHL ENSG00000147642 Syntabulin (syntaxin-interacting) 8 109573978-109691791 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053057 Uncertain Supported Vesicles Liver cancer:7.74e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 76.3 adrenal gland: 40.8 SYNDIG1 C20orf39, FLJ14220, IFITMD5, SynDIG1, TMEM90B ENSG00000101463 Synapse differentiation inducing 1 20 24469199-24666616 Predicted membrane proteins Evidence at protein level HPA059267 Uncertain Supported Vesicles Thyroid cancer:6.16e-6 (unfavourable) Mixed Tissue enhanced cerebral cortex: 26.9 heart muscle: 14.6 SYNDIG1L capucin, IFITMD4, TMEM90A ENSG00000183379 Synapse differentiation inducing 1-like 14 74405893-74426102 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA042594, HPA048487 Uncertain Mixed Tissue enriched 10 epididymis: 13.2 lung: 1.3 SYNE1 8B, ARCA1, C6orf98, CPG2, dJ45H2.2, enaptin, KIAA0796, MYNE1, Nesp1, Nesprin-1, SCAR8, SYNE-1B ENSG00000131018 Spectrin repeat containing, nuclear envelope 1 6 152121684-152637801 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019113 Approved Supported Nucleoplasm
Nuclear membrane Mixed Expressed in all parathyroid gland: 58.0 SYNE2 DKFZP434H2235, KIAA1011, Nesp2, Nesprin-2, NUA, NUANCE, SYNE-2 ENSG00000054654 Spectrin repeat containing, nuclear envelope 2 14 63852983-64226433 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003435, HPA050204 Supported Validated Nuclear membrane Renal cancer:3.56e-9 (favourable) Expressed in all Expressed in all parathyroid gland: 187.4 SYNE3 C14orf49, FLJ25605, Nesp3, Nesprin-3, NET53 ENSG00000176438 Spectrin repeat containing, nuclear envelope family member 3 14 95407266-95475836 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055227, HPA077140 Approved Supported Nuclear membrane Mixed Mixed adipose tissue: 14.6 SYNE4 C19orf46, DFNB76, FLJ36445, Nesp4, Nesprin-4 ENSG00000181392 Spectrin repeat containing, nuclear envelope family member 4 19 36003307-36008793 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060253 Uncertain Renal cancer:8.64e-9 (favourable) Mixed Tissue enhanced parathyroid gland: 18.3 prostate: 11.6 SYNGR1 ENSG00000100321 Synaptogyrin 1 22 39349925-39385588 Predicted membrane proteins Evidence at protein level HPA029673, CAB034277 Supported Supported Cytosol Renal cancer:4.98e-7 (favourable), Pancreatic cancer:2.41e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 175.9 SYNGR2 ENSG00000108639 Synaptogyrin 2 17 78168558-78173527 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014742 Approved Approved Golgi apparatus Renal cancer:5.37e-4 (unfavourable) Expressed in all Expressed in all lung: 155.0 SYNGR3 ENSG00000127561 Synaptogyrin 3 16 1989660-1994275 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB034278, HPA042842 Supported Approved Plasma membrane Renal cancer:7.12e-7 (favourable), Cervical cancer:6.92e-4 (favourable) Mixed Tissue enriched 7 cerebral cortex: 82.8 adrenal gland: 12.5 SYNGR4 ENSG00000105467 Synaptogyrin 4 19 48364395-48376376 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA030075, HPA059286 Approved Approved Golgi apparatus Mixed Tissue enriched 11 testis: 46.8 parathyroid gland: 4.4 SYNJ1 INPP5G, PARK20 ENSG00000159082 Synaptojanin 1 21 32628759-32728048 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA011916 Supported Approved Nucleoplasm
Centrosome
Cytosol Prostate cancer:2.58e-4 (unfavourable), Head and neck cancer:4.43e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 66.1 testis: 18.3 SYNJ2 INPP5H ENSG00000078269 Synaptojanin 2 6 157981887-158099176 Enzymes, Predicted intracellular proteins Evidence at protein level HPA031575 Approved Approved Microtubules
Cytosol Renal cancer:4.02e-6 (unfavourable), Breast cancer:2.63e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 35.6 SYNJ2BP Arip2 ENSG00000213463 Synaptojanin 2 binding protein 14 70366496-70417061 Predicted membrane proteins Evidence at protein level HPA000866 Approved Supported Approved Mitochondria Renal cancer:1.11e-16 (favourable) Expressed in all Mixed parathyroid gland: 40.3 SYNPR MGC26651, SPO ENSG00000163630 Synaptoporin 3 63228315-63616921 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051368, HPA061671 Supported Tissue enhanced Tissue enriched 23 cerebral cortex: 78.4 heart muscle: 3.3 SYP MRX96 ENSG00000102003 Synaptophysin X 49187804-49200259 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB000076, HPA002858, CAB055505 Supported Group enriched Tissue enriched 11 cerebral cortex: 573.3 adrenal gland: 51.4 SYPL1 SYPL ENSG00000008282 Synaptophysin-like 1 7 106090503-106112576 Predicted membrane proteins Evidence at protein level HPA014141 Approved Renal cancer:1.25e-9 (favourable) Expressed in all Expressed in all thyroid gland: 194.0 SYPL2 Mg29 ENSG00000143028 Synaptophysin-like 2 1 109466628-109482137 Predicted membrane proteins Evidence at protein level HPA018032 Approved Nucleoplasm Renal cancer:3.05e-4 (favourable) Mixed Tissue enriched 8 skeletal muscle: 129.4 parathyroid gland: 17.1 SYS1 C20orf169, dJ453C12.4 ENSG00000204070 Sys1 golgi trafficking protein 20 45361937-45376798 Predicted membrane proteins Evidence at protein level HPA046716 Approved Liver cancer:4.62e-4 (unfavourable) Expressed in all Expressed in all fallopian tube: 51.3 SYT1 P65, SVP65, SYT ENSG00000067715 Synaptotagmin I 12 78863993-79452008 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA008394, HPA064788 Supported Mixed Tissue enriched 13 cerebral cortex: 477.9 smooth muscle: 36.4 SYT10 ENSG00000110975 Synaptotagmin X 12 33374238-33439819 Predicted membrane proteins Evidence at transcript level HPA055426 Uncertain Approved Nucleoplasm
Vesicles Tissue enriched Tissue enhanced fallopian tube: 3.5 seminal vesicle: 1.1 SYT11 DKFZp781D015, KIAA0080, MGC10881, MGC17226 ENSG00000132718 Synaptotagmin XI 1 155859509-155885199 Predicted intracellular proteins Evidence at protein level HPA064091 Supported Endometrial cancer:2.93e-5 (unfavourable) Tissue enriched Tissue enriched 14 cerebral cortex: 403.4 endometrium: 28.3 SYT12 SRG1 ENSG00000173227 Synaptotagmin XII 11 67006778-67050863 Predicted intracellular proteins Evidence at protein level HPA011006 Uncertain Pancreatic cancer:4.13e-4 (unfavourable) Tissue enhanced Tissue enriched 7 parathyroid gland: 113.1 cerebral cortex: 17.2 SYT14 FLJ34198, sytXIV ENSG00000143469 Synaptotagmin XIV 1 209938174-210171315 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036963 Supported Vesicles Tissue enhanced Tissue enhanced testis: 6.1;thyroid gland: 8.7 cerebral cortex: 2.5 SYT15 CHR10SYT ENSG00000204176 Synaptotagmin XV 10 46578217-46594173 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA036971, HPA036972, HPA064559 Uncertain Approved Golgi apparatus Not detected Mixed lung: 21.5 SYT16 CHR14SYT, Strep14, SYT14L, yt14r ENSG00000139973 Synaptotagmin XVI 14 61995823-62112550 Predicted intracellular proteins Evidence at protein level HPA004199 Uncertain Mixed Tissue enriched 6 cerebral cortex: 13.9 prostate: 2.2 SYT2 ENSG00000143858 Synaptotagmin II 1 202590596-202710417 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA030372, HPA063655 Supported Approved Vesicles Tissue enriched Tissue enhanced cerebral cortex: 2.1 adrenal gland: 1.8 SYT4 HsT1192, KIAA1342 ENSG00000132872 Synaptotagmin IV 18 43267878-43277650 Predicted intracellular proteins Evidence at protein level HPA010574 Approved Supported Vesicles
Plasma membrane Tissue enhanced Tissue enhanced adrenal gland: 20.5;cerebral cortex: 82.7 seminal vesicle: 11.1 SYT6 ENSG00000134207 Synaptotagmin VI 1 114089291-114153919 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058362 Uncertain Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 6.5 kidney: 1.5 SYT7 IPCA-7, MGC150517, PCANAP7, SYT-VII ENSG00000011347 Synaptotagmin VII 11 61515313-61581148 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012869 Supported Renal cancer:1.16e-4 (unfavourable), Head and neck cancer:1.20e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 109.0;prostate: 79.3 placenta: 26.5 SYT8 DKFZp434K0322 ENSG00000149043 Synaptotagmin VIII 11 1828307-1837521 Predicted membrane proteins Evidence at transcript level HPA052700 Uncertain Approved Nucleoplasm
Cell Junctions Tissue enhanced Group enriched 5 gallbladder: 26.7;skin: 80.3;urinary bladder: 25.5 seminal vesicle: 8.5 SYVN1 DER3, HRD1 ENSG00000162298 Synovial apoptosis inhibitor 1, synoviolin 11 65121780-65134533 Predicted membrane proteins Evidence at protein level HPA005480, HPA024300, CAB037030 Supported Supported Nucleoplasm
Endoplasmic reticulum
Plasma membrane Head and neck cancer:6.88e-4 (favourable) Expressed in all Expressed in all tonsil: 76.7 TAAR1 TA1, TAR1, TRAR1 ENSG00000146399 Trace amine associated receptor 1 6 132644984-132646003 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA055614 Approved Tissue enhanced Group enriched 17 fallopian tube: 2.2;stomach: 7.9 duodenum,endometrium,prostate,urinary bladder: 0.2 TAAR5 PNR ENSG00000135569 Trace amine associated receptor 5 6 132588673-132589686 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA051703 Uncertain Not detected Not detected all non-specific tissues: 0.0 TACR1 NK1R, NKIR, SPR, TAC1R ENSG00000115353 Tachykinin receptor 1 2 75046463-75199700 FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA074573 Approved Mixed Tissue enhanced cervix, uterine: 7.3 fallopian tube: 4.7 TACR3 NK3R ENSG00000169836 Tachykinin receptor 3 4 103586031-103719816 Disease related genes, G-protein coupled receptors, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA009418 Uncertain Not detected Not detected cerebral cortex: 0.5 TACSTD2 EGP-1, GA733-1, M1S1, TROP2 ENSG00000184292 Tumor-associated calcium signal transducer 2 1 58575423-58577773 Disease related genes, Predicted membrane proteins Evidence at protein level HPA043104, HPA055067, CAB072852 Supported Supported Nucleoli
Vesicles
Plasma membrane Renal cancer:3.99e-4 (favourable) Mixed Tissue enhanced esophagus: 315.1 skin: 210.1 TAF1B RAF1B, RAFI63, SL1, TAFI63 ENSG00000115750 TATA box binding protein (TBP)-associated factor, RNA polymerase I, B, 63kDa 2 9843354-9934416 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071254 Supported Nucleus
Nucleoli Liver cancer:6.94e-7 (unfavourable), Colorectal cancer:8.58e-5 (favourable), Renal cancer:8.55e-4 (favourable) Expressed in all Mixed parathyroid gland: 23.5 TAF1D JOSD3, MGC5306, TAF(I)41 ENSG00000166012 TATA box binding protein (TBP)-associated factor, RNA polymerase I, D, 41kDa 11 93729948-93784391 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055935, HPA060385 Uncertain Supported Nucleoplasm
Microtubule organizing center Renal cancer:3.17e-7 (unfavourable) Expressed in all Expressed in all placenta: 14.0 TANC2 DKFZP564D166, FLJ10215, FLJ11824, KIAA1148, KIAA1636, rols, ROLSA ENSG00000170921 Tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 2 17 63009556-63427699 Predicted intracellular proteins Evidence at protein level HPA023274 Uncertain Approved Cytosol Mixed Tissue enhanced parathyroid gland: 76.6 testis: 35.1 TANGO6 FLJ12688, KIAA1746, TMCO7 ENSG00000103047 Transport and golgi organization 6 homolog 16 68843604-69085180 Predicted membrane proteins Evidence at protein level HPA041312 Approved Approved Golgi apparatus
Cytosol Renal cancer:3.20e-4 (favourable) Expressed in all Mixed parathyroid gland: 14.9 TAOK2 KIAA0881, MAP3K17, PSK, PSK1, TAO1, TAO2 ENSG00000149930 TAO kinase 2 16 29973641-29992261 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA010650 Approved Supported Nucleus
Nucleoli
Cytosol Endometrial cancer:3.87e-5 (favourable), Colorectal cancer:2.51e-4 (unfavourable), Renal cancer:3.66e-4 (favourable), Pancreatic cancer:4.78e-4 (favourable) Expressed in all Expressed in all testis: 36.9 TAP1 ABCB2, D6S114E, PSF1, RING4 ENSG00000168394 Transporter 1, ATP-binding cassette, sub-family B (MDR/TAP) 6 32845209-32853978 Cancer-related genes, Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB009516, HPA072354 Approved Supported Endoplasmic reticulum
Microtubule organizing center Renal cancer:6.58e-5 (unfavourable), Ovarian cancer:4.07e-4 (favourable), Colorectal cancer:9.01e-4 (favourable) Expressed in all Mixed appendix: 20.6 TAP2 ABCB3, D6S217E, PSF2, RING11 ENSG00000204267 Transporter 2, ATP-binding cassette, sub-family B (MDR/TAP) 6 32821833-32838780 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA001312 Approved Approved Nuclear speckles
Endoplasmic reticulum Renal cancer:5.22e-8 (unfavourable), Pancreatic cancer:1.51e-4 (unfavourable) Expressed in all Mixed urinary bladder: 15.7 TAPBP TAPA ENSG00000231925 TAP binding protein (tapasin) 6 33299694-33314387 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007066 Approved Breast cancer:2.76e-4 (favourable), Melanoma:6.29e-4 (favourable) Expressed in all Expressed in all spleen: 31.4 TAPBPL FLJ10143, TAPBP-R, TAPBPR ENSG00000139192 TAP binding protein-like 12 6451690-6466517 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA039545 Uncertain Renal cancer:6.04e-5 (favourable), Breast cancer:1.98e-4 (favourable), Urothelial cancer:7.86e-4 (favourable) Expressed in all Expressed in all thyroid gland: 39.0 TAPT1 FLJ90013 ENSG00000169762 Transmembrane anterior posterior transformation 1 4 16160505-16227410 Predicted membrane proteins Evidence at protein level HPA042567, HPA048658 Approved Approved Vesicles Urothelial cancer:4.18e-4 (favourable), Pancreatic cancer:5.34e-4 (favourable), Renal cancer:8.52e-4 (favourable), Endometrial cancer:9.75e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 21.6 TARM1 ENSG00000248385 T cell-interacting, activating receptor on myeloid cells 1 19 54069895-54081365 Predicted membrane proteins Evidence at transcript level HPA051022, HPA054401 Uncertain Not detected Not detected gallbladder,spleen: 0.2 TAS1R1 GPR70, T1R1, TR1 ENSG00000173662 Taste receptor, type 1, member 1 1 6555181-6579757 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level HPA034579, HPA034580 Approved Mixed Tissue enriched 7 testis: 4.2 gallbladder,skin: 0.5 TAS1R3 T1R3 ENSG00000169962 Taste receptor, type 1, member 3 1 1331314-1335306 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA053439 Approved Mixed Group enriched 5 epididymis: 14.7;salivary gland: 3.3 appendix: 1.7 TAS2R1 T2R1, TRB7 ENSG00000169777 Taste receptor, type 2, member 1 5 9628997-9712378 G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA051879 Uncertain Not detected Tissue enriched 41 testis: 13.2 fallopian tube: 0.3 TAS2R38 PTC, T2R61 ENSG00000257138 Taste receptor, type 2, member 38 7 141972631-141973773 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA043862, HPA054366 Uncertain Not detected Not detected rectum,small intestine: 0.3 TAS2R39 ENSG00000236398 Taste receptor, type 2, member 39 7 143183419-143184435 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA053456, HPA060680 Uncertain Not detected Not detected all non-specific tissues: 0.0 TAS2R41 T2R59 ENSG00000221855 Taste receptor, type 2, member 41 7 143477873-143478796 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA057063 Uncertain Not detected Not detected all non-specific tissues: 0.0 TAS2R42 hT2R55, T2R24, T2R55, TAS2R55 ENSG00000186136 Taste receptor, type 2, member 42 12 11185993-11186937 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA036149 Uncertain Approved Nucleoplasm
Actin filaments
Focal adhesion sites Not detected Not detected all non-specific tissues: 0.0 TAS2R60 T2R60 ENSG00000185899 Taste receptor, type 2, member 60 7 143443453-143444409 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA030416 Uncertain Not detected Not detected appendix,bone marrow,liver,parathyroid gland,placenta: 0.1 TAX1BP1 CALCOCO3, TXBP151 ENSG00000106052 Tax1 (human T-cell leukemia virus type I) binding protein 1 7 27739331-27844564 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA024432 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:2.80e-6 (favourable), Pancreatic cancer:1.06e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 181.0 TAZ BTHS, CMD3A, EFE, EFE2, G4.5, XAP-2 ENSG00000102125 Tafazzin X 154411518-154421726 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039557 Approved Approved Plasma membrane Renal cancer:1.22e-7 (unfavourable), Cervical cancer:5.70e-4 (favourable) Expressed in all Expressed in all spleen: 21.2 TBC1D19 FLJ11082 ENSG00000109680 TBC1 domain family, member 19 4 26576437-26755351 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039592 Approved Approved Nucleoplasm
Nuclear membrane Renal cancer:1.21e-7 (favourable), Thyroid cancer:4.06e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 22.7 TBC1D20 C20orf140, dJ852M4.2 ENSG00000125875 TBC1 domain family, member 20 20 435480-462553 Disease related genes, Predicted membrane proteins Evidence at protein level HPA043613 Approved Expressed in all Expressed in all parathyroid gland: 30.7 TBC1D32 bA57L9.1, BROMI, C6orf170, C6orf171, dJ310J6.1, FLJ30899, FLJ34235 ENSG00000146350 TBC1 domain family, member 32 6 121079494-121334745 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013413 Uncertain Approved Mitochondria Mixed Mixed testis: 6.0 TBC1D5 KIAA0210 ENSG00000131374 TBC1 domain family, member 5 3 17157162-18444817 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA035125, HPA035126 Uncertain Supported Golgi apparatus
Vesicles Renal cancer:1.75e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 55.9 TBC1D7 dJ257A7.3, FLJ32666 ENSG00000145979 TBC1 domain family, member 7 6 13266542-13328583 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034748 Approved Renal cancer:2.03e-7 (unfavourable), Ovarian cancer:4.98e-5 (favourable) Expressed in all Expressed in all testis: 24.4 TBCA ENSG00000171530 Tubulin folding cofactor A 5 77691166-77868780 Predicted intracellular proteins Evidence at protein level HPA036487 Approved Supported Nucleoli
Microtubules Expressed in all Expressed in all adrenal gland: 307.1 TBXA2R ENSG00000006638 Thromboxane A2 receptor 19 3594506-3606840 Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins Evidence at protein level HPA077366 Supported Nuclear speckles
Plasma membrane Renal cancer:1.45e-4 (unfavourable), Pancreatic cancer:7.17e-4 (favourable) Expressed in all Mixed spleen: 5.3 TBXAS1 CYP5, CYP5A1, THAS, TS, TXAS, TXS ENSG00000059377 Thromboxane A synthase 1 (platelet) 7 139777051-140020325 Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA031257, HPA031258, HPA031259 Supported Supported Vesicles Renal cancer:1.14e-4 (unfavourable) Expressed in all Mixed spleen: 57.1 TCIRG1 a3, Atp6i, ATP6N1C, ATP6V0A3, OC-116, OC116, TIRC7 ENSG00000110719 T-cell, immune regulator 1, ATPase, H+ transporting, lysosomal V0 subunit A3 11 68039016-68050895 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038742 Approved Approved Mitochondria Renal cancer:1.50e-11 (unfavourable), Urothelial cancer:9.45e-6 (favourable) Expressed in all Expressed in all spleen: 83.5 TCP11 D6S230E, FPPR, KIAA0229 ENSG00000124678 T-complex 11, testis-specific 6 35118071-35148610 Predicted intracellular proteins Evidence at protein level HPA048311 Supported Cervical cancer:5.02e-4 (favourable) Tissue enhanced Tissue enriched 331 testis: 558.6 ovary: 1.6 TCTA ENSG00000145022 T-cell leukemia translocation altered 3 49412206-49416475 Disease related genes, Predicted membrane proteins Evidence at protein level HPA007342 Approved Approved Cytosol Renal cancer:5.00e-15 (favourable), Lung cancer:6.76e-4 (favourable) Expressed in all Expressed in all thyroid gland: 75.9 TCTN2 C12orf38, FLJ12975, MKS8, TECT2 ENSG00000168778 Tectonic family member 2 12 123671113-123708403 Disease related genes, Predicted membrane proteins Evidence at protein level HPA039900 Approved Approved Golgi apparatus
Vesicles Expressed in all Mixed fallopian tube: 46.1 TCTN3 C10orf61, DKFZP564D116, JBTS18, TECT3 ENSG00000119977 Tectonic family member 3 10 95663396-95694143 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026987 Approved Approved Microtubules Endometrial cancer:5.77e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 135.3 TDP1 FLJ11090, SCAN1 ENSG00000042088 Tyrosyl-DNA phosphodiesterase 1 14 89954939-90044768 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA071317 Supported Nucleus
Plasma membrane Liver cancer:8.99e-5 (unfavourable) Expressed in all Mixed testis: 41.7 TDRKH TDRD2 ENSG00000182134 Tudor and KH domain containing 1 151770107-151791416 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA016419, HPA019625 Approved Approved Centrosome
Cytosol Endometrial cancer:1.66e-4 (unfavourable) Expressed in all Tissue enhanced parathyroid gland: 75.8;testis: 40.7 cerebral cortex: 13.0 TECR GPSN2, MRT14, SC2, TER ENSG00000099797 Trans-2,3-enoyl-CoA reductase 19 14517085-14565980 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029780, HPA056488 Supported Supported Endoplasmic reticulum Urothelial cancer:2.60e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 397.0 TECTA DFNA12, DFNA8, DFNB21 ENSG00000109927 Tectorin alpha 11 121101173-121191493 Disease related genes, Predicted membrane proteins Evidence at protein level HPA018870 Approved Mixed Tissue enhanced cerebral cortex: 2.7 parathyroid gland: 2.0 TEK CD202b, TIE-2, TIE2, VMCM, VMCM1 ENSG00000120156 TEK tyrosine kinase, endothelial 9 27109141-27230175 Cancer-related genes, CD markers, Disease related genes, Enzymes, FDA approved drug targets, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, RAS pathway related proteins Evidence at protein level CAB010359, HPA073265 Approved Supported Plasma membrane
Microtubule organizing center Liver cancer:2.31e-5 (favourable), Renal cancer:7.81e-4 (favourable) Expressed in all Tissue enhanced placenta: 65.3 lung: 42.7 TELO2 hCLK2, KIAA0683, TEL2 ENSG00000100726 Telomere maintenance 2 16 1493344-1510457 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041348, HPA041473 Approved Supported Nuclear bodies
Cytosol Expressed in all Expressed in all spleen: 15.8 TENM1 ODZ1, ODZ3, TEN-M1, TNM ENSG00000009694 Teneurin transmembrane protein 1 X 124375903-124963817 Predicted membrane proteins Evidence at protein level HPA002848 Uncertain Group enriched Mixed cerebral cortex: 3.8 TENM2 KIAA1127, ODZ2, Ten-M2 ENSG00000145934 Teneurin transmembrane protein 2 5 167284799-168264157 Predicted membrane proteins Evidence at protein level HPA038018, HPA038420, HPA068691 Uncertain Approved Nucleoli Urothelial cancer:7.52e-4 (unfavourable) Tissue enriched Tissue enhanced cerebral cortex: 9.2;heart muscle: 17.7 prostate: 3.4 TENM3 KIAA1455, ODZ3, Ten-M3 ENSG00000218336 Teneurin transmembrane protein 3 4 182143987-182803024 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047043 Approved Approved Nucleoplasm Mixed Tissue enhanced placenta: 18.7 parathyroid gland: 13.8 TENM4 KIAA1302, ODZ4, Ten-M4 ENSG00000149256 Teneurin transmembrane protein 4 11 78652831-79440948 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019521, HPA065961 Approved Mixed Tissue enhanced ovary: 21.0;parathyroid gland: 53.6 thyroid gland: 9.8 TERT EST2, hEST2, TCS1, TP2, TRT ENSG00000164362 Telomerase reverse transcriptase 5 1253147-1295069 Cancer-related genes, Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA054641, HPA065897 Validated Nucleoplasm Mixed Not detected lymph node,testis: 0.5 TEX101 CT131, MGC4766, SGRG, SPATA44 ENSG00000131126 Testis expressed 101 19 43401496-43418597 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041915, HPA042513 Supported Mixed Tissue enriched 107 testis: 173.0 skin: 1.6 TEX2 HT008, KIAA1738, TMEM96 ENSG00000136478 Testis expressed 2 17 64147227-64263301 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020648, HPA057116 Approved Approved Nucleus Colorectal cancer:3.90e-6 (favourable) Expressed in all Expressed in all testis: 99.2 TEX261 MGC32043, TEG-261 ENSG00000144043 Testis expressed 261 2 70985938-70994945 Predicted membrane proteins Evidence at transcript level HPA016631 Approved Approved Nucleoplasm
Cytosol Liver cancer:4.23e-4 (unfavourable), Endometrial cancer:6.17e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 91.4 TFG FLJ36137, SPG57, TF6 ENSG00000114354 TRK-fused gene 3 100709331-100748966 Cancer-related genes, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019473, HPA052206 Approved Approved Vesicles
Cytosol Pancreatic cancer:1.50e-4 (unfavourable), Liver cancer:5.48e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 161.6 TFR2 HFE3, TFRC2 ENSG00000106327 Transferrin receptor 2 7 100620416-100642779 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA011937, CAB016255 Supported Liver cancer:2.48e-4 (favourable) Tissue enriched Tissue enriched 11 liver: 155.8 bone marrow: 13.9 TFRC CD71, p90, TFR1 ENSG00000072274 Transferrin receptor 3 196027183-196082189 Cancer-related genes, CD markers, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000153, HPA028598 Supported Supported Endosomes
Lysosomes Liver cancer:1.15e-4 (unfavourable), Thyroid cancer:2.96e-4 (unfavourable), Cervical cancer:3.67e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 157.6 TGFA ENSG00000163235 Transforming growth factor, alpha 2 70447280-70554193 Cancer-related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA042297 Approved Approved Vesicles Pancreatic cancer:1.20e-5 (unfavourable), Thyroid cancer:1.52e-4 (favourable) Expressed in all Mixed esophagus: 27.4 TGFBR1 ACVRLK4, ALK-5, ESS1, MSSE ENSG00000106799 Transforming growth factor, beta receptor 1 9 99104038-99154192 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB002441, CAB031481, HPA056473 Uncertain Supported Vesicles
Plasma membrane Expressed in all Expressed in all placenta: 69.3 TGFBR2 MFS2 ENSG00000163513 Transforming growth factor, beta receptor II (70/80kDa) 3 30606502-30694142 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at protein level CAB073537 Supported Plasma membrane Expressed in all Expressed in all adipose tissue: 290.3 TGFBR3 betaglycan, BGCAN ENSG00000069702 Transforming growth factor, beta receptor III 1 91680343-91906335 Cancer-related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008257, CAB018971 Supported Approved Cytosol Thyroid cancer:3.14e-4 (unfavourable), Endometrial cancer:3.36e-4 (unfavourable), Head and neck cancer:4.84e-4 (favourable), Renal cancer:4.99e-4 (favourable) Expressed in all Expressed in all ovary: 99.5 TGFBR3L ENSG00000260001 Transforming growth factor, beta receptor III-like 19 7916145-7919097 Predicted membrane proteins Evidence at transcript level HPA074356 Approved Vesicles Mixed Tissue enhanced duodenum: 1.8;small intestine: 1.8 kidney: 1.2 TGOLN2 TGN38, TGN46, TGN48, TGN51, TTGN2 ENSG00000152291 Trans-golgi network protein 2 2 85318020-85328425 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011489, HPA012609, HPA012723 Supported Validated Nucleoplasm
Golgi apparatus Expressed in all Expressed in all thyroid gland: 145.8 THADA FLJ21877, GITA, KIAA1767 ENSG00000115970 Thyroid adenoma associated 2 43230836-43596046 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA035191, HPA035192 Uncertain Approved Cytosol Liver cancer:6.48e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 26.4 THAP4 CGI-36 ENSG00000176946 THAP domain containing 4 2 241584405-241637449 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA044982, HPA053448 Uncertain Approved Nucleoplasm
Nuclear speckles Renal cancer:1.46e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 81.6 THBD CD141 ENSG00000178726 Thrombomodulin 20 23045633-23049741 Candidate cardiovascular disease genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB002425, HPA002982 Supported Approved Nucleoplasm
Cytosol Expressed in all Expressed in all lung: 73.4 THOC1 HPR1, P84 ENSG00000079134 THO complex 1 18 214520-268050 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019096, HPA019687 Supported Validated Nuclear speckles Renal cancer:1.80e-6 (unfavourable), Liver cancer:1.83e-5 (unfavourable), Ovarian cancer:2.89e-5 (favourable), Breast cancer:8.43e-4 (favourable), Urothelial cancer:9.62e-4 (favourable) Expressed in all Mixed testis: 29.2 THSD1 TMTSP ENSG00000136114 Thrombospondin, type I, domain containing 1 13 52377167-52406494 Predicted membrane proteins Evidence at protein level HPA012611, CAB020796 Uncertain Validated Cytosol Expressed in all Mixed lung: 16.6 THSD4 ADAMTSL6, FLJ13710, FVSY9334, PRO34005 ENSG00000187720 Thrombospondin, type I, domain containing 4 15 71096952-71783383 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA026845 Approved Nucleus
Nucleoli Mixed Tissue enhanced cervix, uterine: 159.1 fallopian tube: 58.5 THSD7A KIAA0960 ENSG00000005108 Thrombospondin, type I, domain containing 7A 7 11370357-11832198 Predicted membrane proteins Evidence at protein level HPA000923 Supported Renal cancer:2.24e-6 (favourable) Mixed Mixed kidney: 8.3 THSD7B KIAA1679 ENSG00000144229 Thrombospondin, type I, domain containing 7B 2 136765545-137677717 Predicted membrane proteins Evidence at transcript level HPA051416, HPA056745 Uncertain Approved Nucleoplasm
Cytosol Mixed Tissue enhanced epididymis: 5.0 adipose tissue: 2.0 TIE1 JTK14, TIE ENSG00000066056 Tyrosine kinase with immunoglobulin-like and EGF-like domains 1 1 43300993-43323108 Cancer-related genes, Enzymes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045769 Approved Vesicles Expressed in all Tissue enhanced placenta: 70.1 lung: 40.1 TIMD4 ENSG00000145850 T-cell immunoglobulin and mucin domain containing 4 5 156919282-156963255 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA015625, CAB026027 Approved Approved Plasma membrane
Cytosol Renal cancer:3.37e-4 (favourable) Tissue enriched Group enriched 6 lymph node: 64.4;testis: 161.6 adipose tissue: 17.7 TIMM17B DXS9822, JM3 ENSG00000126768 Translocase of inner mitochondrial membrane 17 homolog B (yeast) X 48893447-48898143 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA029093 Approved Approved Microtubules
Mitochondria Cervical cancer:6.63e-4 (favourable), Urothelial cancer:7.88e-4 (favourable) Expressed in all Expressed in all fallopian tube: 43.4 TIMM21 C18orf55, HSPC154, TIM21 ENSG00000075336 Translocase of inner mitochondrial membrane 21 homolog (yeast) 18 74148511-74160530 Predicted membrane proteins Evidence at protein level HPA010587, HPA051543 Uncertain Approved Nucleoplasm Renal cancer:1.38e-9 (favourable), Liver cancer:9.22e-5 (unfavourable) Expressed in all Expressed in all heart muscle: 25.7 TIMM22 TEX4 ENSG00000177370 Translocase of inner mitochondrial membrane 22 homolog (yeast) 17 997117-1003671 Predicted membrane proteins Evidence at protein level HPA045138 Uncertain Renal cancer:1.41e-4 (favourable), Pancreatic cancer:3.42e-4 (favourable) Expressed in all Mixed parathyroid gland: 4.3 TIMM23 TIM23 ENSG00000265354 Translocase of inner mitochondrial membrane 23 homolog (yeast) 10 45972449-46003734 Predicted membrane proteins Evidence at protein level HPA031408 Approved Supported Mitochondria Liver cancer:2.77e-5 (unfavourable), Ovarian cancer:6.79e-4 (favourable) Expressed in all Expressed in all testis: 141.6 TIMM50 TIM50L ENSG00000105197 Translocase of inner mitochondrial membrane 50 homolog (S. cerevisiae) 19 39480412-39493785 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048843, HPA056448 Supported Supported Nucleoplasm
Mitochondria Expressed in all Expressed in all testis: 80.4 TIMMDC1 C3orf1, FLJ22597 ENSG00000113845 Translocase of inner mitochondrial membrane domain containing 1 3 119498532-119525090 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA053214, HPA055846 Uncertain Validated Nucleus
Mitochondria Liver cancer:1.12e-5 (unfavourable) Expressed in all Expressed in all thyroid gland: 31.5 TLCD1 ENSG00000160606 TLC domain containing 1 17 28724348-28727935 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042366 Approved Renal cancer:9.05e-5 (unfavourable), Liver cancer:3.28e-4 (unfavourable) Expressed in all Mixed fallopian tube: 23.1 TLCD2 ENSG00000185561 TLC domain containing 2 17 1702790-1710438 Predicted membrane proteins Evidence at transcript level HPA046063 Uncertain Approved Nucleoli
Vesicles Renal cancer:4.36e-5 (unfavourable) Expressed in all Mixed adipose tissue: 6.1 TLR2 CD282, TIL4 ENSG00000137462 Toll-like receptor 2 4 153701500-153705699 CD markers, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA060231, HPA071546 Supported Nucleus
Mitochondria Renal cancer:1.11e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 53.7 bone marrow: 34.9 TLR3 CD283 ENSG00000164342 Toll-like receptor 3 4 186069152-186088069 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB025658 Approved Pancreatic cancer:3.09e-4 (unfavourable) Mixed Mixed placenta: 24.3 TLR4 ARMD10, CD284, hToll, TLR-4 ENSG00000136869 Toll-like receptor 4 9 117704332-117716871 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB004025, HPA049174 Approved Approved Golgi apparatus
Cytosol Testis cancer:3.79e-4 (unfavourable), Endometrial cancer:6.29e-4 (favourable) Expressed in all Mixed spleen: 49.0 TLR5 FLJ10052, MGC126430, MGC126431, SLEB1, TIL3 ENSG00000187554 Toll-like receptor 5 1 223109406-223143282 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009013 Approved Nucleus
Golgi apparatus
Cytosol Renal cancer:4.95e-4 (unfavourable) Mixed Mixed ovary: 25.1 TLR6 CD286 ENSG00000174130 Toll-like receptor 6 4 38823715-38856817 CD markers, Predicted membrane proteins Evidence at protein level HPA062733 Approved Endoplasmic reticulum Mixed Mixed appendix: 14.5 TLR7 ENSG00000196664 Toll-like receptor 7 X 12867083-12890380 FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA059613 Supported Mixed Mixed placenta: 9.1 TLR8 CD288 ENSG00000101916 Toll-like receptor 8 X 12906620-12923169 CD markers, Predicted membrane proteins Evidence at protein level HPA001608 Supported Mixed Tissue enhanced appendix: 23.8;spleen: 18.6 lung: 15.6 TM2D1 BBP ENSG00000162604 TM2 domain containing 1 1 61681046-61725423 Predicted membrane proteins Evidence at protein level HPA046058, HPA055621 Approved Validated Nucleoplasm Liver cancer:2.02e-7 (unfavourable) Expressed in all Expressed in all thyroid gland: 67.8 TM2D2 BLP1 ENSG00000169490 TM2 domain containing 2 8 38988808-38996824 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047152, HPA050547 Approved Approved Nucleoplasm
Vesicles
Plasma membrane Colorectal cancer:1.71e-4 (favourable), Breast cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all testis: 51.1 TM2D3 BLP2, FLJ22604 ENSG00000184277 TM2 domain containing 3 15 101621444-101652391 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA054064 Uncertain Approved Nucleoplasm
Cytosol Expressed in all Expressed in all cerebral cortex: 97.5 TM4SF1 L6, M3S1 ENSG00000169908 Transmembrane 4 L six family member 1 3 149369022-149377865 Predicted membrane proteins Evidence at protein level CAB002760, HPA002823 Uncertain Urothelial cancer:3.43e-6 (unfavourable), Renal cancer:2.24e-4 (unfavourable), Pancreatic cancer:4.01e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 328.4 TM4SF18 L6D ENSG00000163762 Transmembrane 4 L six family member 18 3 149318498-149334414 Predicted membrane proteins Evidence at transcript level HPA053639, HPA069378 Approved Uncertain Nucleoli
Vesicles Liver cancer:8.63e-4 (favourable) Expressed in all Mixed spleen: 47.6 TM4SF20 FLJ22800, TCCE518 ENSG00000168955 Transmembrane 4 L six family member 20 2 227362156-227381995 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051838, HPA063184, HPA065531 Uncertain Supported Plasma membrane
Focal adhesion sites Group enriched Group enriched 36 duodenum: 285.0;small intestine: 167.3 testis: 6.3 TM4SF4 il-TMP ENSG00000169903 Transmembrane 4 L six family member 4 3 149473974-149503281 Predicted membrane proteins, Transporters Evidence at protein level HPA046430 Supported Approved Plasma membrane
Cytosol Group enriched Group enriched 34 duodenum: 595.8;gallbladder: 1326.5;liver: 343.7;small intestine: 515.2 stomach: 20.3 TM4SF5 ENSG00000142484 Transmembrane 4 L six family member 5 17 4771884-4783213 Predicted membrane proteins Evidence at protein level HPA055674 Uncertain Nucleoplasm
Plasma membrane
Cell Junctions Tissue enriched Group enriched 5 duodenum: 181.8;small intestine: 172.8 liver: 33.2 TM6SF1 ENSG00000136404 Transmembrane 6 superfamily member 1 15 83107407-83144854 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016051, HPA056857 Uncertain Approved Intermediate filaments Renal cancer:6.79e-4 (favourable) Mixed Mixed thyroid gland: 13.2 TM6SF2 Lpr4 ENSG00000213996 Transmembrane 6 superfamily member 2 19 19264364-19273391 Predicted membrane proteins Evidence at protein level HPA066026 Uncertain Tissue enhanced Group enriched 5 duodenum: 79.1;small intestine: 78.4 liver: 14.6 TM7SF2 ANG1, DHCR14A, NET47 ENSG00000149809 Transmembrane 7 superfamily member 2 11 65111845-65116384 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030691, HPA072704 Approved Supported Endoplasmic reticulum
Vesicles Renal cancer:8.49e-8 (favourable) Expressed in all Expressed in all adrenal gland: 161.3 TM7SF3 ENSG00000064115 Transmembrane 7 superfamily member 3 12 26973195-27014434 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA041097, HPA057640 Uncertain Approved Nucleus
Cytosol Renal cancer:1.32e-4 (favourable) Expressed in all Expressed in all kidney: 189.4 TM9SF1 HMP70, MP70 ENSG00000100926 Transmembrane 9 superfamily member 1 14 24189143-24195687 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA059249 Supported Approved Golgi apparatus Lung cancer:2.04e-4 (unfavourable), Cervical cancer:8.94e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 71.2 TM9SF2 P76 ENSG00000125304 Transmembrane 9 superfamily member 2 13 99501417-99564006 Predicted membrane proteins, Transporters Evidence at protein level HPA005657 Supported Renal cancer:5.21e-7 (favourable), Head and neck cancer:6.40e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 201.3 TM9SF3 SMBP ENSG00000077147 Transmembrane 9 superfamily member 3 10 96518109-96587452 Predicted membrane proteins Evidence at protein level HPA039609 Approved Approved Golgi apparatus
Vesicles Expressed in all Expressed in all stomach: 182.0 TM9SF4 dJ836N17.2, KIAA0255 ENSG00000101337 Transmembrane 9 superfamily protein member 4 20 32109506-32167258 Predicted membrane proteins, Transporters Evidence at protein level HPA064099 Approved Approved Mitochondria Endometrial cancer:6.37e-6 (unfavourable), Liver cancer:2.15e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 91.3 TMBIM1 LFG3, PP1201, RECS1 ENSG00000135926 Transmembrane BAX inhibitor motif containing 1 2 218274192-218292586 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012093, HPA070824 Approved Supported Vesicles Renal cancer:3.38e-4 (favourable), Pancreatic cancer:4.22e-4 (unfavourable) Expressed in all Expressed in all esophagus: 270.8 TMBIM4 CGI-119, GAAP, LFG4, S1R, ZPRO ENSG00000155957 Transmembrane BAX inhibitor motif containing 4 12 66135846-66170072 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA077642 Supported Golgi apparatus Expressed in all Expressed in all thyroid gland: 164.8 TMBIM6 BAXI1, BI-1, TEGT ENSG00000139644 Transmembrane BAX inhibitor motif containing 6 12 49707725-49764934 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA017378 Approved Renal cancer:1.00e-5 (favourable), Head and neck cancer:1.91e-4 (unfavourable), Breast cancer:3.54e-4 (unfavourable) Expressed in all Expressed in all kidney: 1179.3 TMC2 C20orf145, dJ686C3.3 ENSG00000149488 Transmembrane channel-like 2 20 2536607-2641784 Predicted membrane proteins Evidence at transcript level HPA046350 Uncertain Not detected Tissue enhanced testis: 1.0 lung: 0.8 TMC3 ENSG00000188869 Transmembrane channel-like 3 15 81331217-81374213 Predicted membrane proteins Evidence at protein level HPA040265, HPA040510 Approved Supported Cytosol Tissue enhanced Tissue enriched 79 parathyroid gland: 248.1 epididymis: 3.1 TMC4 ENSG00000167608 Transmembrane channel-like 4 19 54160108-54173250 Predicted membrane proteins Evidence at protein level HPA048635 Approved Renal cancer:1.54e-8 (favourable) Expressed in all Tissue enhanced duodenum: 31.3 small intestine: 22.6 TMC5 FLJ13593 ENSG00000103534 Transmembrane channel-like 5 16 19410496-19499113 Predicted membrane proteins Evidence at protein level HPA040810, HPA042037 Approved Approved Nucleus
Plasma membrane Liver cancer:7.96e-4 (unfavourable) Mixed Tissue enhanced small intestine: 60.2 duodenum: 46.6 TMC6 EVER1, EVIN1, LAK-4P ENSG00000141524 Transmembrane channel-like 6 17 78110458-78132407 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA051430 Uncertain Stomach cancer:1.82e-4 (favourable), Urothelial cancer:3.20e-4 (favourable) Expressed in all Expressed in all spleen: 84.5 TMC7 FLJ21240 ENSG00000170537 Transmembrane channel-like 7 16 18983934-19063942 Predicted membrane proteins Evidence at protein level HPA029465 Uncertain Approved Vesicles Lung cancer:3.20e-4 (unfavourable), Pancreatic cancer:7.64e-4 (unfavourable), Urothelial cancer:9.20e-4 (favourable) Mixed Tissue enhanced testis: 17.7 cerebral cortex: 10.7 TMC8 EVER2, EVIN2 ENSG00000167895 Transmembrane channel-like 8 17 78130770-78142968 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA047387, HPA054429 Uncertain Uncertain Golgi apparatus Renal cancer:1.96e-7 (unfavourable), Cervical cancer:8.45e-6 (favourable), Head and neck cancer:4.19e-5 (favourable) Expressed in all Tissue enhanced lymph node: 120.4;spleen: 107.5 appendix: 75.5 TMCC1 KIAA0779 ENSG00000172765 Transmembrane and coiled-coil domain family 1 3 129647792-129893576 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA053894 Uncertain Renal cancer:1.77e-6 (unfavourable), Pancreatic cancer:1.87e-4 (unfavourable), Liver cancer:9.15e-4 (unfavourable) Expressed in all Expressed in all testis: 25.1 TMCC2 FLJ38497, HUCEP11 ENSG00000133069 Transmembrane and coiled-coil domain family 2 1 205228176-205273343 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014254 Approved Mixed Tissue enhanced bone marrow: 53.3;cerebral cortex: 25.0 placenta: 8.1 TMCC3 KIAA1145 ENSG00000057704 Transmembrane and coiled-coil domain family 3 12 94567124-94650562 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014272 Approved Approved Cytosol Endometrial cancer:4.87e-4 (unfavourable) Expressed in all Mixed placenta: 25.5 TMCO1 HP10122, TMCC4 ENSG00000143183 Transmembrane and coiled-coil domains 1 1 165724293-165827755 Disease related genes, Predicted membrane proteins Evidence at protein level HPA054768 Supported Endoplasmic reticulum Head and neck cancer:5.17e-7 (unfavourable), Renal cancer:1.25e-4 (unfavourable), Liver cancer:3.21e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 157.3 TMCO3 C13orf11, FLJ20623 ENSG00000150403 Transmembrane and coiled-coil domains 3 13 113490995-113554590 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039561, HPA048126 Uncertain Approved Cytosol Liver cancer:1.14e-5 (unfavourable), Urothelial cancer:4.10e-4 (unfavourable), Cervical cancer:5.80e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 49.2 TMCO4 DKFZp686C23231 ENSG00000162542 Transmembrane and coiled-coil domains 4 1 19682213-19799945 Predicted membrane proteins Evidence at protein level HPA014601, HPA014620 Uncertain Approved Endoplasmic reticulum Renal cancer:4.12e-11 (favourable), Liver cancer:1.12e-4 (unfavourable), Urothelial cancer:3.64e-4 (favourable), Endometrial cancer:3.71e-4 (favourable) Expressed in all Mixed parathyroid gland: 36.3 TMCO5A MGC35118, TMCO5 ENSG00000166069 Transmembrane and coiled-coil domains 5A 15 37921939-37967724 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA056530 Supported Not detected Tissue enriched 177 testis: 122.1 fallopian tube: 0.6 TMCO6 FLJ39769, PRO1580 ENSG00000113119 Transmembrane and coiled-coil domains 6 5 140639427-140645408 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA037473, HPA037474 Uncertain Approved Nucleoplasm
Mitochondria Renal cancer:6.37e-4 (unfavourable) Expressed in all Mixed testis: 13.6 TMED1 Il1rl1l, IL1RL1LG, MGC1270, p24g1, p24gamma1, ST2L ENSG00000099203 Transmembrane p24 trafficking protein 1 19 10832438-10836318 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA018507, HPA078574 Uncertain Supported Vesicles Renal cancer:8.66e-5 (favourable) Expressed in all Expressed in all thyroid gland: 47.6 TMED10 p23, P24(DELTA), p24d1, p24delta1, TMP21 ENSG00000170348 Transmembrane p24 trafficking protein 10 14 75131470-75176631 Predicted membrane proteins Evidence at protein level CAB034442, CAB037251, HPA047139, HPA050539 Supported Supported Golgi apparatus Thyroid cancer:8.67e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 243.4 TMED2 P24A, p24b1, p24beta1, RNP24 ENSG00000086598 Transmembrane p24 trafficking protein 2 12 123584531-123598577 Plasma proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA014060 Approved Supported Vesicles Renal cancer:2.35e-7 (unfavourable), Head and neck cancer:3.36e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 327.0 TMED3 C15orf22, p24B, p24g4, p24gamma4 ENSG00000166557 Transmembrane p24 trafficking protein 3 15 79311062-79427432 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA049314, HPA076949 Approved Supported Golgi apparatus Renal cancer:3.73e-4 (unfavourable), Breast cancer:7.71e-4 (unfavourable) Expressed in all Mixed salivary gland: 164.3 TMED4 HNLF, p24a3, p24alpha3 ENSG00000158604 Transmembrane p24 trafficking protein 4 7 44577894-44582287 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014650 Approved Renal cancer:1.37e-4 (favourable), Endometrial cancer:7.37e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 190.1 TMED5 CGI-100, p24g2, p24gamma2 ENSG00000117500 Transmembrane p24 trafficking protein 5 1 93149742-93180728 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA050289 Approved Expressed in all Expressed in all kidney: 28.0 TMED6 MGC23911, p24g5, p24gamma5 ENSG00000157315 Transmembrane p24 trafficking protein 6 16 69343248-69351809 Predicted membrane proteins Evidence at protein level HPA012532 Approved Endometrial cancer:7.74e-5 (favourable) Mixed Tissue enhanced fallopian tube: 35.5;pancreas: 61.2;stomach: 36.5 epididymis: 21.9 TMED7 CGI-109, FLJ90481, p24g3, p24gamma3 ENSG00000134970 Transmembrane p24 trafficking protein 7 5 115613508-115632992 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008960, CAB025883 Supported Expressed in all Expressed in all thyroid gland: 138.5 TMED9 HSGP25L2G, p24a2, p24alpha2 ENSG00000184840 Transmembrane p24 trafficking protein 9 5 177592158-177596124 Predicted membrane proteins Evidence at protein level HPA014650 Approved Renal cancer:5.88e-5 (unfavourable) Expressed in all Expressed in all placenta: 211.2 TMEFF1 C9orf2, CT120.1, H7365 ENSG00000241697 Transmembrane protein with EGF-like and two follistatin-like domains 1 9 100473113-100577636 Predicted membrane proteins Evidence at protein level HPA051501 Uncertain Tissue enhanced Tissue enriched 5 cerebral cortex: 10.7 testis: 2.0 TMEFF2 CT120.2, HPP1, TENB2, TPEF, TR ENSG00000144339 Transmembrane protein with EGF-like and two follistatin-like domains 2 2 191949043-192195709 Predicted membrane proteins Evidence at protein level HPA015587 Uncertain Approved Microtubules
Cytokinetic bridge Tissue enriched Tissue enhanced cerebral cortex: 41.1;prostate: 54.9;seminal vesicle: 19.4 epididymis: 10.5 TMEM100 FLJ10970, FLJ37856 ENSG00000166292 Transmembrane protein 100 17 55719627-55732121 Predicted membrane proteins Evidence at protein level HPA055936 Approved Liver cancer:2.67e-5 (favourable), Renal cancer:1.32e-4 (unfavourable) Mixed Tissue enhanced lung: 131.4;placenta: 77.5 epididymis: 44.0 TMEM101 FLJ23987, MGC4251 ENSG00000091947 Transmembrane protein 101 17 44011188-44023946 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039739 Approved Nucleoplasm
Plasma membrane Renal cancer:4.10e-5 (favourable), Endometrial cancer:4.29e-4 (favourable), Liver cancer:7.10e-4 (unfavourable) Expressed in all Expressed in all seminal vesicle: 156.9 TMEM104 FLJ00021, FLJ20255 ENSG00000109066 Transmembrane protein 104 17 74776483-74839779 Predicted membrane proteins, Transporters Evidence at protein level HPA044330 Approved Approved Nucleoplasm
Golgi apparatus Pancreatic cancer:1.97e-5 (favourable), Liver cancer:1.71e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 14.7 TMEM106B FLJ11273, MGC33727 ENSG00000106460 Transmembrane protein 106B 7 12211241-12243367 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058342 Approved Supported Endosomes
Lysosomes Expressed in all Expressed in all thyroid gland: 64.7 TMEM106C MGC5576 ENSG00000134291 Transmembrane protein 106C 12 47963569-47968878 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047204 Supported Liver cancer:5.27e-8 (unfavourable), Renal cancer:4.62e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 165.9 TMEM107 MGC10744 ENSG00000179029 Transmembrane protein 107 17 8173237-8176399 Predicted membrane proteins Evidence at transcript level HPA052555, HPA059653 Approved Approved Nucleoplasm
Midbody
Midbody ring
Cytosol Endometrial cancer:9.39e-5 (favourable) Expressed in all Mixed fallopian tube: 71.3 TMEM108 CT124, MGC3040 ENSG00000144868 Transmembrane protein 108 3 133038391-133397792 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA063350 Uncertain Approved Nucleoli
Vesicles
Cytosol Tissue enhanced Tissue enhanced testis: 25.8 cerebral cortex: 22.0 TMEM109 MGC5508 ENSG00000110108 Transmembrane protein 109 11 60913874-60923443 Predicted membrane proteins, Transporters Evidence at protein level HPA011785 Approved Approved Nuclear membrane
Cytosol Urothelial cancer:2.68e-4 (unfavourable) Expressed in all Expressed in all endometrium: 94.2 TMEM110 MGC52022 ENSG00000213533 Transmembrane protein 110 3 52836219-52897596 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA051855 Uncertain Approved Cytosol Mixed Expressed in all fallopian tube: 20.8 TMEM110-MUSTN1 ENSG00000248592 TMEM110-MUSTN1 readthrough 3 52833121-52897562 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA051855 Uncertain Approved Cytosol Not detected Tissue enhanced skeletal muscle: 11.1 adipose tissue: 6.6 TMEM115 PL6 ENSG00000126062 Transmembrane protein 115 3 50354749-50359610 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB006319, HPA015497 Supported Supported Golgi apparatus Renal cancer:1.04e-7 (favourable), Liver cancer:3.73e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 36.8 TMEM116 FLJ90167 ENSG00000198270 Transmembrane protein 116 12 111931282-112013185 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA040720 Approved Approved Nucleoplasm
Microtubules Renal cancer:1.08e-4 (favourable) Expressed in all Tissue enhanced parathyroid gland: 56.1 testis: 47.8 TMEM117 DKFZp434K2435 ENSG00000139173 Transmembrane protein 117 12 43835967-44389762 Predicted membrane proteins Evidence at transcript level HPA046223 Uncertain Melanoma:3.94e-4 (unfavourable) Expressed in all Mixed seminal vesicle: 7.2 TMEM119 ENSG00000183160 Transmembrane protein 119 12 108589846-108598320 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA051870, HPA052650 Supported Renal cancer:2.06e-6 (unfavourable), Ovarian cancer:8.37e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 92.4 TMEM120B ENSG00000188735 Transmembrane protein 120B 12 121712752-121783001 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014066 Uncertain Liver cancer:1.66e-5 (unfavourable) Expressed in all Mixed endometrium: 12.1 TMEM121 hole, MGC4659 ENSG00000184986 Transmembrane protein 121 14 105526603-105530202 Predicted membrane proteins Evidence at transcript level HPA049857 Uncertain Approved Cytosol Thyroid cancer:5.87e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 4.8 spleen: 2.4 TMEM123 KCT3, PORIMIN ENSG00000152558 Transmembrane protein 123 11 102396332-102470384 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB026001 Approved Cytosol Pancreatic cancer:2.66e-4 (unfavourable), Melanoma:5.36e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 573.7 TMEM125 MGC17299 ENSG00000179178 Transmembrane protein 125 1 43269994-43274002 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA015796 Approved Midbody
Cytosol Renal cancer:2.91e-9 (favourable), Lung cancer:5.11e-5 (favourable) Mixed Tissue enhanced lung: 113.9 thyroid gland: 51.5 TMEM126A DKFZp586C1924, OPA7 ENSG00000171202 Transmembrane protein 126A 11 85647967-85656547 Disease related genes, Predicted membrane proteins Evidence at protein level HPA046648 Approved Approved Nucleus
Cytosol Liver cancer:8.60e-5 (unfavourable) Expressed in all Expressed in all testis: 66.9 TMEM126B HT007 ENSG00000171204 Transmembrane protein 126B 11 85628573-85636539 Predicted membrane proteins Evidence at protein level HPA014480, HPA019186 Uncertain Supported Mitochondria Expressed in all Expressed in all epididymis: 39.2 TMEM128 MGC13159 ENSG00000132406 Transmembrane protein 128 4 4235542-4248212 Predicted membrane proteins Evidence at protein level HPA044809 Uncertain Expressed in all Expressed in all thyroid gland: 63.7 TMEM129 D4S2561E ENSG00000168936 Transmembrane protein 129, E3 ubiquitin protein ligase 4 1715952-1721358 Predicted membrane proteins Evidence at protein level HPA060920 Approved Vesicles Renal cancer:9.64e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 35.6 TMEM130 DKFZp761L1417, FLJ42643 ENSG00000166448 Transmembrane protein 130 7 98846488-98870771 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012928 Uncertain Supported Golgi apparatus Lung cancer:7.84e-4 (favourable) Tissue enhanced Group enriched 9 adrenal gland: 49.3;cerebral cortex: 183.7;testis: 70.8 epididymis: 11.5 TMEM131 CC28, KIAA0257, PRO1048, RW1, YR-23 ENSG00000075568 Transmembrane protein 131 2 97756333-97995891 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017678, HPA017682 Approved Uncertain Vesicles
Intermediate filaments Expressed in all Expressed in all parathyroid gland: 46.7 TMEM132A FLJ20539, GBP, HSPA5BP1 ENSG00000006118 Transmembrane protein 132A 11 60924463-60937159 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051979, HPA060492 Supported Approved Mitochondria Renal cancer:1.55e-9 (unfavourable), Endometrial cancer:1.98e-5 (favourable) Expressed in all Tissue enhanced cerebral cortex: 94.5 placenta: 24.9 TMEM132B KIAA1786, KIAA1906 ENSG00000139364 Transmembrane protein 132B 12 125186836-125662377 Predicted membrane proteins Evidence at protein level HPA035661, HPA035662 Uncertain Tissue enriched Tissue enriched 7 cerebral cortex: 21.9 thyroid gland: 3.1 TMEM132C DKFZp761O2018, PPP1R152 ENSG00000181234 Transmembrane protein 132C 12 128267403-128707915 Predicted membrane proteins Evidence at protein level HPA015633, HPA015984 Uncertain Supported Centrosome
Cytosol Tissue enhanced Tissue enhanced adipose tissue: 34.7;cervix, uterine: 23.9 fallopian tube: 15.8 TMEM132D KIAA1944, MOLT, PPP1R153 ENSG00000151952 Transmembrane protein 132D 12 129071725-129903666 Predicted membrane proteins Evidence at protein level HPA010739 Approved Mixed Tissue enriched 9 cerebral cortex: 12.8 testis: 1.4 TMEM132E DFNB99 ENSG00000181291 Transmembrane protein 132E 17 34580749-34639318 Disease related genes, Predicted membrane proteins Evidence at protein level HPA070608 Approved Renal cancer:1.55e-4 (unfavourable) Group enriched Group enriched 5 cerebral cortex: 4.8;duodenum: 1.7;kidney: 3.2;small intestine: 1.1;testis: 1.5 cervix, uterine: 0.4 TMEM133 AD031 ENSG00000170647 Transmembrane protein 133 11 100991989-100993941 Predicted membrane proteins Evidence at protein level HPA060528, HPA065742 Uncertain Approved Endoplasmic reticulum
Golgi apparatus Pancreatic cancer:1.76e-4 (unfavourable) Expressed in all Mixed placenta: 18.2 TMEM134 FLJ21749 ENSG00000172663 Transmembrane protein 134 11 67461710-67469272 Predicted membrane proteins Evidence at protein level HPA043744 Approved Supported Cytosol Expressed in all Expressed in all skin: 38.4 TMEM135 FLJ22104 ENSG00000166575 Transmembrane protein 135 11 87037844-87323758 Predicted membrane proteins Evidence at protein level HPA056685, HPA069473 Uncertain Supported Vesicles Renal cancer:9.02e-4 (favourable) Expressed in all Expressed in all adipose tissue: 31.8 TMEM136 MGC17839 ENSG00000181264 Transmembrane protein 136 11 120325129-120333682 Predicted membrane proteins Evidence at transcript level HPA074432 Approved Vesicles
Cytosol Endometrial cancer:6.65e-4 (unfavourable) Expressed in all Mixed adrenal gland: 12.7 TMEM138 HSPC196, JBTS16 ENSG00000149483 Transmembrane protein 138 11 61362001-61369509 Disease related genes, Predicted membrane proteins Evidence at protein level HPA042373 Approved Approved Microtubules Renal cancer:4.12e-6 (unfavourable), Liver cancer:7.90e-4 (unfavourable) Expressed in all Expressed in all epididymis: 24.8 TMEM139 FLJ90586 ENSG00000178826 Transmembrane protein 139 7 143279957-143288048 Predicted membrane proteins, Transporters Evidence at protein level HPA036982, HPA036983 Approved Approved Plasma membrane
Focal adhesion sites Renal cancer:3.05e-5 (favourable), Pancreatic cancer:1.66e-4 (unfavourable) Mixed Tissue enhanced duodenum: 34.9;kidney: 34.4 small intestine: 21.2 TMEM141 MGC14141 ENSG00000244187 Transmembrane protein 141 9 136791355-136793257 Predicted membrane proteins Evidence at protein level HPA014615, HPA050244 Approved Supported Cell Junctions
Mitochondria Renal cancer:6.63e-4 (favourable) Expressed in all Expressed in all prostate: 214.3 TMEM143 FLJ10922 ENSG00000161558 Transmembrane protein 143 19 48332356-48364237 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014476 Uncertain Approved Nucleoli fibrillar center Renal cancer:1.53e-7 (favourable) Expressed in all Tissue enhanced skeletal muscle: 32.5 heart muscle: 15.9 TMEM144 FLJ11155 ENSG00000164124 Transmembrane protein 144 4 158201604-158255411 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA043767, HPA063554 Uncertain Approved Mitochondria Endometrial cancer:2.89e-4 (favourable), Pancreatic cancer:8.48e-4 (unfavourable) Mixed Tissue enhanced cerebral cortex: 90.8 testis: 46.6 TMEM145 FLJ90805 ENSG00000167619 Transmembrane protein 145 19 42313325-42325062 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060462 Supported Approved Vesicles Tissue enhanced Tissue enriched 6 cerebral cortex: 38.4 adrenal gland: 6.0 TMEM147 MGC1936, NIFIE14 ENSG00000105677 Transmembrane protein 147 19 35545595-35547526 Predicted membrane proteins Evidence at protein level HPA067837 Uncertain Golgi apparatus
Actin filaments
Cytosol Liver cancer:4.98e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 120.1 TMEM14A C6orf73, PTD011 ENSG00000096092 Transmembrane protein 14A 6 52671109-52686588 Predicted membrane proteins Evidence at protein level HPA072536 Approved Nucleoplasm
Endoplasmic reticulum Expressed in all Expressed in all cerebral cortex: 88.4 TMEM14EP TMEM14E ENSG00000221962 Transmembrane protein 14E, pseudogene 3 152340527-152340904 Predicted membrane proteins Evidence at transcript level HPA014550 Uncertain Not detected Tissue enhanced skin: 1.0 bone marrow: 0.9 TMEM150A FLJ90024, TM6P1, TMEM150 ENSG00000168890 Transmembrane protein 150A 2 85598548-85603196 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019015 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Mixed placenta: 33.3 TMEM150C FLJ12993 ENSG00000249242 Transmembrane protein 150C 4 82483170-82562357 Predicted membrane proteins Evidence at protein level HPA052921 Supported Renal cancer:4.59e-6 (favourable), Pancreatic cancer:5.68e-4 (favourable), Head and neck cancer:7.87e-4 (favourable) Expressed in all Tissue enhanced epididymis: 179.7 ovary: 43.5 TMEM151A MGC33486, TMEM151 ENSG00000179292 Transmembrane protein 151A 11 66291870-66296664 Predicted membrane proteins Evidence at transcript level HPA041035 Uncertain Approved Nucleoli
Cytosol Tissue enhanced Tissue enriched 24 cerebral cortex: 45.4 adrenal gland: 1.8 TMEM151B bA444E17.5, C6orf137, TMEM193 ENSG00000178233 Transmembrane protein 151B 6 44270466-44307506 Predicted membrane proteins Evidence at transcript level HPA055167 Uncertain Tissue enhanced Tissue enriched 10 cerebral cortex: 40.1 adrenal gland: 4.0 TMEM154 FLJ32028 ENSG00000170006 Transmembrane protein 154 4 152618632-152680165 Predicted membrane proteins Evidence at protein level HPA019184, HPA055411 Uncertain Approved Nucleoplasm
Nuclear membrane Mixed Tissue enhanced esophagus: 64.6;skin: 69.4 tonsil: 25.3 TMEM159 promethin ENSG00000011638 Transmembrane protein 159 16 21158377-21180616 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018033, HPA063509 Approved Approved Vesicles Renal cancer:8.11e-5 (favourable), Pancreatic cancer:1.59e-4 (unfavourable) Expressed in all Expressed in all skin: 90.6 TMEM160 FLJ20512 ENSG00000130748 Transmembrane protein 160 19 47045907-47048630 Predicted membrane proteins Evidence at protein level HPA055904 Uncertain Expressed in all Mixed cerebral cortex: 21.0 TMEM161A FLJ20422, FLJ39645 ENSG00000064545 Transmembrane protein 161A 19 19119169-19138513 Predicted membrane proteins Evidence at protein level HPA043365 Approved Approved Cytosol Stomach cancer:2.99e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 20.9 TMEM161B MGC33214 ENSG00000164180 Transmembrane protein 161B 5 88189633-88269476 Predicted membrane proteins Evidence at protein level HPA044562 Uncertain Expressed in all Expressed in all parathyroid gland: 58.9 TMEM163 DKFZP566N034, SV31 ENSG00000152128 Transmembrane protein 163 2 134455759-134719000 Predicted membrane proteins, Transporters Evidence at protein level HPA007224 Uncertain Urothelial cancer:3.15e-4 (favourable), Lung cancer:7.94e-4 (favourable) Mixed Mixed lung: 21.5 TMEM164 FLJ22679, RP13-360B22.2 ENSG00000157600 Transmembrane protein 164 X 110002631-110182734 Predicted membrane proteins Evidence at protein level HPA038784 Approved Approved Vesicles
Cell Junctions Liver cancer:8.17e-6 (unfavourable), Stomach cancer:3.14e-4 (favourable) Expressed in all Expressed in all lung: 26.7 TMEM165 GDT1, TMPT27, TPARL ENSG00000134851 Transmembrane protein 165 4 55395957-55453397 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038299 Supported Supported Golgi apparatus
Vesicles Renal cancer:1.18e-8 (unfavourable), Liver cancer:2.08e-5 (unfavourable) Expressed in all Expressed in all placenta: 86.4 TMEM168 DKFZp564C012, FLJ13576 ENSG00000146802 Transmembrane protein 168 7 112762382-112790592 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA020389 Approved Lung cancer:4.07e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 43.5 TMEM169 FLJ34263 ENSG00000163449 Transmembrane protein 169 2 216081866-216102783 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA070657 Uncertain Approved Focal adhesion sites Mixed Tissue enhanced cerebral cortex: 12.0 thyroid gland: 4.8 TMEM17 FLJ34583 ENSG00000186889 Transmembrane protein 17 2 62500221-62511894 Predicted membrane proteins Evidence at protein level HPA018100 Uncertain Approved Actin filaments Expressed in all Mixed testis: 8.1 TMEM170A FLJ37611, TMEM170 ENSG00000166822 Transmembrane protein 170A 16 75443054-75465497 Predicted membrane proteins Evidence at transcript level HPA055071 Uncertain Renal cancer:2.36e-9 (favourable) Expressed in all Expressed in all testis: 32.6 TMEM170B ENSG00000205269 Transmembrane protein 170B 6 11538278-11583524 Predicted membrane proteins Evidence at transcript level HPA055134 Uncertain Approved Centrosome Mixed Tissue enhanced cerebral cortex: 21.4 bone marrow: 16.9 TMEM171 PRP2 ENSG00000157111 Transmembrane protein 171 5 73120292-73131817 Predicted membrane proteins Evidence at protein level HPA042308 Approved Renal cancer:3.93e-10 (favourable) Mixed Tissue enhanced colon: 32.9;rectum: 32.7;thyroid gland: 47.0 duodenum: 27.1 TMEM173 FLJ38577, NET23 ENSG00000184584 Transmembrane protein 173 5 139475534-139482935 Disease related genes, Predicted membrane proteins Evidence at protein level HPA038116, HPA038534 Supported Supported Cytosol Renal cancer:3.59e-8 (unfavourable) Expressed in all Expressed in all lung: 70.2 TMEM174 FLJ31268, MGC13034 ENSG00000164325 Transmembrane protein 174 5 73173195-73175143 Predicted membrane proteins Evidence at protein level HPA037975 Supported Renal cancer:3.30e-6 (favourable) Tissue enriched Tissue enriched 685 kidney: 158.0 thyroid gland: 0.2 TMEM175 MGC4618 ENSG00000127419 Transmembrane protein 175 4 932387-958656 Predicted membrane proteins, Transporters Evidence at protein level HPA057160 Approved Approved Nucleus
Nuclear membrane Pancreatic cancer:9.85e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 20.8 TMEM176A HCA112, MS4B1 ENSG00000002933 Transmembrane protein 176A 7 150800403-150805120 Predicted membrane proteins Evidence at protein level HPA008770 Approved Approved Mitochondria Expressed in all Expressed in all liver: 579.4 TMEM176B LR8, MS4B2 ENSG00000106565 Transmembrane protein 176B 7 150791285-150801360 Predicted membrane proteins Evidence at protein level HPA047509 Uncertain Approved Nucleoplasm
Golgi apparatus
Plasma membrane Expressed in all Expressed in all liver: 842.9 TMEM177 MGC10993 ENSG00000144120 Transmembrane protein 177 2 119679167-119686507 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036689, HPA053816 Uncertain Approved Nucleus
Nucleoli fibrillar center Expressed in all Mixed duodenum: 16.9 TMEM178A MGC33926, TMEM178 ENSG00000152154 Transmembrane protein 178A 2 39664982-39717963 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at transcript level HPA052128, HPA058560 Uncertain Approved Nucleus
Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 55.6 kidney: 19.1 TMEM178B DKFZp547G036 ENSG00000261115 Transmembrane protein 178B 7 141074232-141480380 Predicted membrane proteins Evidence at protein level HPA048771 Uncertain Uncertain Nucleoli
Vesicles Renal cancer:4.10e-4 (favourable) Mixed Tissue enhanced cerebral cortex: 19.4;parathyroid gland: 28.5;thyroid gland: 14.3 heart muscle: 7.4 TMEM179 C14orf90, FLJ42486, TMEM179A ENSG00000258986 Transmembrane protein 179 14 104474678-104605647 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA002942 Uncertain Mitochondria Mixed Group enriched 8 adrenal gland: 14.7;cerebral cortex: 28.0 testis: 2.5 TMEM179B ENSG00000185475 Transmembrane protein 179B 11 62787415-62790405 Predicted membrane proteins Evidence at protein level HPA016585, HPA062068 Validated Nuclear speckles Expressed in all Expressed in all epididymis: 86.2 TMEM18 DKFZp434C1714 ENSG00000151353 Transmembrane protein 18 2 667335-677439 Predicted membrane proteins Evidence at protein level HPA040233 Approved Approved Mitochondria Melanoma:3.21e-4 (unfavourable) Expressed in all Expressed in all ovary: 43.9 TMEM180 bA18I14.8, C10orf77, FLJ22529 ENSG00000138111 Transmembrane protein 180 10 102461395-102477045 Predicted membrane proteins, Transporters Evidence at protein level HPA018031 Uncertain Approved Golgi apparatus
Cytosol Cervical cancer:8.29e-4 (favourable), Renal cancer:8.51e-4 (unfavourable) Expressed in all Mixed skin: 8.8 TMEM181 GPR178, KIAA1423 ENSG00000146433 Transmembrane protein 181 6 158536436-158635428 Predicted membrane proteins Evidence at protein level HPA040189 Approved Approved Golgi apparatus
Vesicles Ovarian cancer:1.09e-4 (unfavourable), Cervical cancer:7.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 41.5 TMEM182 FLJ30294 ENSG00000170417 Transmembrane protein 182 2 102736908-102843893 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA045861 Uncertain Approved Nucleoplasm
Vesicles Expressed in all Group enriched 10 heart muscle: 60.3;skeletal muscle: 44.1 prostate: 5.0 TMEM183A C1orf37 ENSG00000163444 Transmembrane protein 183A 1 203007386-203024848 Predicted membrane proteins Evidence at protein level HPA072607 Approved Nucleus
Plasma membrane
Cell Junctions Liver cancer:2.62e-4 (unfavourable) Expressed in all Expressed in all testis: 58.5 TMEM184A MGC9712 ENSG00000164855 Transmembrane protein 184A 7 1542235-1560821 Predicted membrane proteins Evidence at protein level HPA053790, HPA071312 Uncertain Approved Nucleoplasm Colorectal cancer:1.12e-4 (unfavourable), Thyroid cancer:9.94e-4 (unfavourable) Mixed Tissue enhanced skin: 33.5 esophagus: 26.7 TMEM184B C22orf5, DKFZP586A1024, FM08, HS5O6A ENSG00000198792 Transmembrane protein 184B 22 38219291-38273034 Predicted membrane proteins, Transporters Evidence at protein level HPA024076 Approved Approved Nucleoplasm
Golgi apparatus
Cytosol Liver cancer:5.94e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 57.5 TMEM184C FLJ10846, TMEM34 ENSG00000164168 Transmembrane protein 184C 4 147617383-147672044 Predicted membrane proteins Evidence at protein level HPA054013 Uncertain Approved Nucleoplasm
Vesicles Renal cancer:2.31e-7 (favourable), Pancreatic cancer:6.37e-4 (unfavourable) Expressed in all Group enriched 5 parathyroid gland: 253.7;thyroid gland: 54.5 placenta: 28.5 TMEM185A CXorf13, FAM11A, FRAXF ENSG00000269556 Transmembrane protein 185A X 149596556-149631912 Predicted membrane proteins Evidence at protein level HPA048295, HPA071744 Uncertain Approved Endoplasmic reticulum Expressed in all Expressed in all ovary: 36.3 TMEM185B FAM11B, FLJ20979 ENSG00000226479 Transmembrane protein 185B 2 120221278-120223408 Predicted membrane proteins Evidence at protein level HPA048295, HPA071744 Uncertain Approved Endoplasmic reticulum Liver cancer:5.71e-7 (unfavourable), Endometrial cancer:4.96e-6 (unfavourable), Colorectal cancer:5.44e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 61.4 TMEM186 C16orf51, DKFZP564K2062 ENSG00000184857 Transmembrane protein 186 16 8780384-8797648 Predicted membrane proteins Evidence at protein level HPA018226, HPA063559 Uncertain Approved Cell Junctions Renal cancer:1.93e-8 (favourable) Expressed in all Expressed in all parathyroid gland: 22.5 TMEM187 CXorf12, DXS9878E, ITBA1 ENSG00000177854 Transmembrane protein 187 X 153972327-153983195 Predicted membrane proteins Evidence at transcript level HPA038134 Uncertain Approved Nucleoli
Cytosol Renal cancer:9.14e-8 (favourable) Expressed in all Expressed in all fallopian tube: 11.2 TMEM189 Kua ENSG00000240849 Transmembrane protein 189 20 50118254-50153734 Predicted membrane proteins Evidence at protein level HPA059549 Approved Supported Endoplasmic reticulum Renal cancer:5.79e-11 (unfavourable), Endometrial cancer:7.51e-4 (unfavourable) Expressed in all Expressed in all smooth muscle: 31.1 TMEM189-UBE2V1 CROC-1B, Kua-UEV ENSG00000124208 TMEM189-UBE2V1 readthrough 20 50081124-50153637 Predicted membrane proteins Evidence at protein level HPA052535, HPA053186 Supported Nucleoplasm Not detected Mixed placenta: 5.5 TMEM19 FLJ10936 ENSG00000139291 Transmembrane protein 19 12 71686087-71705046 Predicted membrane proteins Evidence at protein level HPA016830 Approved Expressed in all Expressed in all kidney: 40.5 TMEM192 FLJ38482 ENSG00000170088 Transmembrane protein 192 4 165070608-165208549 Predicted membrane proteins, Transporters Evidence at protein level HPA014717, HPA024110 Supported Validated Nucleoplasm
Endosomes
Lysosomes Renal cancer:2.33e-14 (favourable), Breast cancer:9.52e-4 (unfavourable) Expressed in all Expressed in all kidney: 50.6 TMEM196 MGC42090 ENSG00000173452 Transmembrane protein 196 7 19719310-19773598 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA043163 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.2 endometrium: 2.1 TMEM198 MGC99813, TMEM198A ENSG00000188760 Transmembrane protein 198 2 219543663-219550595 Predicted membrane proteins Evidence at protein level HPA042385, HPA056598 Uncertain Approved Vesicles Pancreatic cancer:6.89e-4 (favourable) Expressed in all Tissue enhanced cerebral cortex: 15.8 duodenum: 9.1 TMEM199 C17orf32, MGC45714 ENSG00000244045 Transmembrane protein 199 17 28357581-28363683 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA027051 Uncertain Liver cancer:1.54e-4 (unfavourable), Endometrial cancer:5.55e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 19.1 TMEM2 ENSG00000135048 Transmembrane protein 2 9 71683366-71816690 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044889 Approved Approved Vesicles
Cytosol Renal cancer:1.31e-4 (unfavourable) Expressed in all Expressed in all placenta: 93.9 TMEM200A KIAA1913, TTMC ENSG00000164484 Transmembrane protein 200A 6 130365734-130443063 Predicted membrane proteins Evidence at protein level HPA014396 Uncertain Renal cancer:3.92e-4 (favourable) Mixed Tissue enhanced endometrium: 64.8 smooth muscle: 29.0 TMEM200B TTMB ENSG00000253304 Transmembrane protein 200B 1 29119428-29123935 Predicted membrane proteins Evidence at transcript level HPA055254 Uncertain Mixed Tissue enhanced endometrium: 68.0 seminal vesicle: 52.6 TMEM200C TTMA ENSG00000206432 Transmembrane protein 200C 18 5882072-5895955 Predicted membrane proteins Evidence at protein level HPA047253, HPA050490 Uncertain Approved Microtubules Tissue enhanced Tissue enhanced adrenal gland: 3.1;cerebral cortex: 3.5 salivary gland: 1.8 TMEM201 NET5, RP13-15M17.2 ENSG00000188807 Transmembrane protein 201 1 9588922-9614873 Predicted membrane proteins Evidence at protein level CAB039039 Approved Supported Nucleus
Nuclear membrane Liver cancer:9.61e-8 (unfavourable), Cervical cancer:5.36e-4 (favourable) Expressed in all Mixed testis: 9.9 TMEM204 C16orf30, CLP24, FLJ20898 ENSG00000131634 Transmembrane protein 204 16 1528688-1555580 Predicted membrane proteins Evidence at transcript level HPA014028 Approved Liver cancer:4.76e-4 (favourable), Melanoma:7.89e-4 (unfavourable) Expressed in all Mixed adipose tissue: 40.6 TMEM205 MBC3205, UNQ501 ENSG00000105518 Transmembrane protein 205 19 11342776-11346518 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA041504 Approved Approved Nucleoplasm
Nuclear membrane
Endoplasmic reticulum Expressed in all Expressed in all parathyroid gland: 253.1 TMEM206 C1orf75, FLJ10874 ENSG00000065600 Transmembrane protein 206 1 212363931-212414901 Predicted membrane proteins Evidence at protein level HPA008540 Uncertain Liver cancer:3.71e-5 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 25.4 kidney: 10.6 TMEM207 ENSG00000198398 Transmembrane protein 207 3 190428655-190449876 Predicted membrane proteins Evidence at protein level HPA014332 Uncertain Not detected Tissue enriched 62 kidney: 18.5 testis: 0.2 TMEM208 HSPC171 ENSG00000168701 Transmembrane protein 208 16 67227103-67229278 Predicted membrane proteins, Transporters Evidence at protein level HPA041868, HPA041949 Supported Head and neck cancer:9.63e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 88.4 TMEM209 FLJ14803, NET31 ENSG00000146842 Transmembrane protein 209 7 130164715-130207770 Predicted membrane proteins Evidence at protein level HPA031678 Uncertain Approved Nuclear membrane
Nuclear speckles
Vesicles Expressed in all Expressed in all testis: 27.7 TMEM210 ENSG00000185863 Transmembrane protein 210 9 137170858-137172409 Predicted membrane proteins Evidence at protein level HPA066907 Supported Tissue enhanced Tissue enriched 11 testis: 10.5 salivary gland: 0.9 TMEM211 bA9F11.1 ENSG00000206069 Transmembrane protein 211 22 24935110-24946695 Predicted membrane proteins Evidence at transcript level HPA066784 Uncertain Tissue enhanced Tissue enhanced cervix, uterine: 4.5;stomach: 3.4 salivary gland: 1.9 TMEM212 FLJ23172 ENSG00000186329 Transmembrane protein 212 3 171843349-171938715 Predicted membrane proteins Evidence at transcript level HPA045736, HPA053134 Uncertain Approved Nucleoli fibrillar center
Endoplasmic reticulum Not detected Tissue enriched 6 fallopian tube: 47.9 lung: 7.7 TMEM213 ENSG00000214128 Transmembrane protein 213 7 138797952-138838101 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA054059 Approved Renal cancer:5.54e-7 (favourable) Tissue enriched Group enriched 9 kidney: 80.1;salivary gland: 22.8 breast: 5.8 TMEM214 FLJ20254 ENSG00000119777 Transmembrane protein 214 2 27032910-27041695 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034551 Supported Endoplasmic reticulum
Golgi apparatus
Cytosol Renal cancer:2.39e-10 (unfavourable), Liver cancer:4.96e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 89.8 TMEM215 ENSG00000188133 Transmembrane protein 215 9 32783499-32787399 Predicted membrane proteins Evidence at transcript level HPA052804 Uncertain Tissue enriched Group enriched 5 cervix, uterine: 1.0;endometrium: 4.8;testis: 4.2;thyroid gland: 1.8 cerebral cortex: 0.5 TMEM218 ENSG00000150433 Transmembrane protein 218 11 125096545-125111763 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038489 Uncertain Approved Plasma membrane
Cytosol Liver cancer:1.93e-5 (unfavourable), Stomach cancer:5.50e-4 (favourable) Expressed in all Expressed in all fallopian tube: 21.7 TMEM219 ENSG00000149932 Transmembrane protein 219 16 29940885-29973052 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059185 Approved Endometrial cancer:5.79e-4 (favourable) Expressed in all Expressed in all fallopian tube: 196.0 TMEM221 ENSG00000188051 Transmembrane protein 221 19 17435509-17448567 Predicted membrane proteins Evidence at protein level HPA041580 Approved Uncertain Nuclear membrane Tissue enhanced Tissue enhanced parathyroid gland: 7.0 fallopian tube: 4.4 TMEM222 C1orf160, DKFZP564D0478 ENSG00000186501 Transmembrane protein 222 1 27322145-27336400 Predicted membrane proteins Evidence at protein level HPA016579, HPA059374 Approved Approved Plasma membrane
Cytosol Expressed in all Expressed in all fallopian tube: 47.4 TMEM223 MGC3196 ENSG00000168569 Transmembrane protein 223 11 62771629-62792021 Predicted membrane proteins Evidence at protein level HPA014504 Approved Approved Nucleus
Nuclear membrane
Mitochondria Expressed in all Expressed in all prostate: 16.9 TMEM229A ENSG00000234224 Transmembrane protein 229A 7 124030916-124033023 Predicted membrane proteins Evidence at protein level HPA056391 Uncertain Approved Plasma membrane Tissue enhanced Tissue enhanced cerebral cortex: 7.1;duodenum: 8.9;testis: 10.4 small intestine: 4.4 TMEM229B C14orf83, FLJ33387 ENSG00000198133 Transmembrane protein 229B 14 67447084-67533739 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA046562 Approved Endometrial cancer:1.21e-5 (favourable), Urothelial cancer:1.79e-5 (favourable), Breast cancer:5.38e-4 (favourable) Expressed in all Mixed duodenum: 16.2 TMEM230 C20orf30, HSPC274 ENSG00000089063 Transmembrane protein 230 20 5068232-5113103 Predicted membrane proteins Evidence at protein level HPA009078, HPA061421 Uncertain Validated Endoplasmic reticulum Expressed in all Expressed in all thyroid gland: 226.3 TMEM231 ALYE870, FLJ22167, JBTS20, MKS11, PRO1886 ENSG00000205084 Transmembrane protein 231 16 75536744-75556286 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042081 Supported Approved Vesicles Mixed Tissue enriched 8 fallopian tube: 76.4 thyroid gland: 9.8 TMEM232 FLJ43080 ENSG00000186952 Transmembrane protein 232 5 110289233-110738956 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA049386 Uncertain Not detected Tissue enhanced fallopian tube: 26.1;testis: 35.3 thyroid gland: 7.3 TMEM233 IFITMD2 ENSG00000224982 Transmembrane protein 233 12 119593459-119643066 Predicted membrane proteins Evidence at transcript level HPA047506 Uncertain Tissue enriched Group enriched 5 cerebral cortex: 16.3;skeletal muscle: 11.5;thyroid gland: 21.4 parathyroid gland: 3.1 TMEM234 C1orf91, dJ622L5.7, FLJ90779, RP4-622L5 ENSG00000160055 Transmembrane protein 234 1 32214472-32222359 Predicted membrane proteins, Transporters Evidence at protein level HPA015049 Uncertain Approved Vesicles Liver cancer:2.35e-5 (unfavourable), Renal cancer:4.12e-5 (unfavourable) Expressed in all Mixed epididymis: 12.8 TMEM235 ENSG00000204278 Transmembrane protein 235 17 78231310-78240987 Predicted membrane proteins Evidence at transcript level HPA053939 Uncertain Tissue enriched Tissue enriched 101 cerebral cortex: 15.7 placenta,testis: 0.1 TMEM237 ALS2CR4, JBTS14 ENSG00000155755 Transmembrane protein 237 2 201620184-201643570 Disease related genes, Predicted membrane proteins Evidence at protein level HPA052596, HPA054732 Supported Renal cancer:7.96e-6 (unfavourable), Melanoma:1.33e-4 (unfavourable), Endometrial cancer:2.51e-4 (unfavourable) Expressed in all Mixed skin: 21.9 TMEM241 C18orf45, FLJ44259, MGC11386 ENSG00000134490 Transmembrane protein 241 18 23197144-23437961 Predicted membrane proteins Evidence at protein level HPA029489, HPA059922 Uncertain Approved Golgi apparatus
Vesicles Urothelial cancer:5.80e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 4.3 TMEM242 BM033, C6orf35 ENSG00000215712 Transmembrane protein 242 6 157289386-157323601 Predicted membrane proteins Evidence at protein level HPA025764 Approved Expressed in all Expressed in all cerebral cortex: 17.0 TMEM243 C7orf23, MGC4175, MM-TRAG ENSG00000135185 Transmembrane protein 243, mitochondrial 7 87196160-87220587 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014918 Uncertain Lung cancer:5.45e-4 (favourable), Melanoma:6.84e-4 (unfavourable), Urothelial cancer:9.13e-4 (favourable) Expressed in all Expressed in all thyroid gland: 103.3 TMEM244 bA174C7.4, C6orf191 ENSG00000203756 Transmembrane protein 244 6 129831244-129861547 Predicted membrane proteins Evidence at transcript level HPA045247 Uncertain Not detected Tissue enhanced cerebral cortex: 1.7 lymph node: 0.6 TMEM245 C9orf5, CG-2 ENSG00000106771 Transmembrane protein 245 9 109015152-109119945 Predicted membrane proteins Evidence at protein level HPA023892 Approved Approved Plasma membrane
Cytosol Renal cancer:4.46e-9 (favourable) Expressed in all Expressed in all thyroid gland: 123.5 TMEM246 C9orf125, MGC12992 ENSG00000165152 Transmembrane protein 246 9 101473171-101533537 Predicted membrane proteins Evidence at protein level HPA011318, HPA054041 Uncertain Approved Mitochondria Renal cancer:1.55e-8 (favourable) Mixed Mixed cerebral cortex: 46.7 TMEM248 C7orf42, FLJ10099, FLJ13090 ENSG00000106609 Transmembrane protein 248 7 66921225-66958551 Predicted membrane proteins Evidence at protein level HPA016495 Uncertain Approved Vesicles Expressed in all Expressed in all parathyroid gland: 92.0 TMEM25 FLJ14399 ENSG00000149582 Transmembrane protein 25 11 118531041-118547280 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA012163, HPA051562 Approved Approved Golgi apparatus
Vesicles Renal cancer:0.00e+0 (favourable) Expressed in all Expressed in all duodenum: 48.3 TMEM251 C14orf109, DKFZP564F1123 ENSG00000153485 Transmembrane protein 251 14 93184951-93187089 Predicted membrane proteins Evidence at transcript level HPA048559 Uncertain Approved Golgi apparatus
Cell Junctions Liver cancer:6.14e-7 (unfavourable), Renal cancer:1.10e-4 (favourable) Expressed in all Expressed in all prostate: 27.9 TMEM253 C14orf176, C14orf95, NCRNA00220 ENSG00000232070 Transmembrane protein 253 14 21098937-21103724 Predicted membrane proteins Evidence at protein level HPA052329, HPA065092 Supported Mixed Group enriched 7 duodenum: 104.1;small intestine: 102.1 colon: 15.8 TMEM254 bA369J21.6, C10orf57, FLJ13263 ENSG00000133678 Transmembrane protein 254 10 80078646-80092557 Predicted membrane proteins Evidence at protein level HPA029105 Approved Nucleoplasm
Plasma membrane Expressed in all Expressed in all skin: 85.9 TMEM255A FAM70A, FLJ20716 ENSG00000125355 Transmembrane protein 255A X 120258650-120311556 Predicted membrane proteins Evidence at transcript level HPA048470 Uncertain Uncertain Nucleus
Nuclear bodies Group enriched Tissue enhanced ovary: 23.4 cervix, uterine: 10.4 TMEM255B FAM70B, MGC20579 ENSG00000184497 Transmembrane protein 255B 13 113759240-113816995 Predicted membrane proteins Evidence at protein level HPA043334 Approved Approved Nucleoplasm Renal cancer:4.12e-5 (unfavourable) Expressed in all Mixed lung: 8.3 TMEM256 C17orf61, MGC40107 ENSG00000205544 Transmembrane protein 256 17 7402975-7404137 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA062732 Approved Vesicles Renal cancer:9.36e-4 (unfavourable) Expressed in all Expressed in all duodenum: 140.8 TMEM258 C11orf10 ENSG00000134825 Transmembrane protein 258 11 61768501-61792802 Predicted membrane proteins Evidence at protein level HPA044602 Approved Approved Plasma membrane
Cytosol Ovarian cancer:4.37e-4 (favourable) Expressed in all Expressed in all epididymis: 429.6 TMEM259 ASBABP1, C19orf6, MBRL, MGC4022 ENSG00000182087 Transmembrane protein 259 19 1009648-1021179 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042669, HPA054801 Approved Approved Nuclear speckles
Endoplasmic reticulum Stomach cancer:8.92e-6 (favourable), Endometrial cancer:1.01e-4 (favourable) Expressed in all Expressed in all spleen: 132.3 TMEM260 C14orf101, FLJ20392 ENSG00000070269 Transmembrane protein 260 14 56488354-56650606 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003502 Uncertain Approved Nucleus
Focal adhesion sites
Cytosol Lung cancer:7.11e-4 (favourable) Expressed in all Tissue enhanced cervix, uterine: 63.2 thyroid gland: 14.0 TMEM261 C9orf123, MGC4730 ENSG00000137038 Transmembrane protein 261 9 7796490-7888380 Predicted membrane proteins Evidence at protein level HPA014585 Approved Renal cancer:1.96e-11 (favourable), Endometrial cancer:4.15e-4 (favourable) Expressed in all Expressed in all thyroid gland: 17.3 TMEM266 C15orf27, FLJ38190 ENSG00000169758 Transmembrane protein 266 15 76059837-76229121 Predicted membrane proteins Evidence at protein level HPA041921 Uncertain Supported Plasma membrane
Cytosol Tissue enhanced Tissue enhanced cerebral cortex: 1.9;skeletal muscle: 1.5 placenta: 1.1 TMEM27 NX17 ENSG00000147003 Transmembrane protein 27 X 15627318-15665031 Predicted membrane proteins, Transporters Evidence at protein level HPA048543 Approved Approved Endoplasmic reticulum
Vesicles Renal cancer:6.78e-9 (favourable), Ovarian cancer:5.65e-4 (favourable) Tissue enriched Tissue enriched 16 kidney: 418.5 parathyroid gland: 26.1 TMEM30A C6orf67, CDC50A, FLJ10856 ENSG00000112697 Transmembrane protein 30A 6 75252924-75284968 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014561 Approved Supported Mitochondria Expressed in all Expressed in all cerebral cortex: 167.9 TMEM30B CDC50B ENSG00000182107 Transmembrane protein 30B 14 61277370-61281840 Predicted membrane proteins, Transporters Evidence at protein level HPA043162 Uncertain Renal cancer:5.89e-5 (favourable) Mixed Mixed parathyroid gland: 80.6 TMEM31 MGC39655 ENSG00000179363 Transmembrane protein 31 X 103710909-103714028 Predicted membrane proteins Evidence at protein level HPA052760 Approved Nucleoli fibrillar center Tissue enhanced Tissue enriched 61 testis: 84.9 ovary,placenta: 1.3 TMEM35 FLJ14084 ENSG00000126950 Transmembrane protein 35 X 101078720-101096364 Predicted membrane proteins Evidence at protein level HPA048583 Supported Tissue enhanced Tissue enhanced cerebral cortex: 42.5;seminal vesicle: 64.8 prostate: 34.0 TMEM37 PR, PR1 ENSG00000171227 Transmembrane protein 37 2 119429901-119438520 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA053794 Approved Approved Nucleus
Nucleoli fibrillar center
Cytosol Expressed in all Mixed kidney: 107.7 TMEM38A MGC3169, TRIC-A ENSG00000072954 Transmembrane protein 38A 19 16661127-16690029 Predicted membrane proteins Evidence at protein level HPA048100, HPA050463 Supported Approved Nucleus Renal cancer:2.99e-10 (favourable), Lung cancer:2.78e-5 (favourable), Ovarian cancer:7.96e-4 (unfavourable) Expressed in all Tissue enriched 9 skeletal muscle: 199.8 cerebral cortex: 23.2 TMEM38B bA219P18.1, C9orf87, D4Ertd89e, FLJ10493, TRIC-B ENSG00000095209 Transmembrane protein 38B 9 105694544-105776612 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018465 Uncertain Renal cancer:7.96e-4 (favourable) Expressed in all Expressed in all testis: 51.9 TMEM39A FLJ10902 ENSG00000176142 Transmembrane protein 39A 3 119429500-119468830 Predicted membrane proteins Evidence at protein level HPA039140 Approved Approved Nucleoplasm
Vesicles Renal cancer:1.00e-5 (unfavourable), Liver cancer:3.26e-4 (unfavourable) Expressed in all Expressed in all cervix, uterine: 32.9 TMEM39B FLJ10315 ENSG00000121775 Transmembrane protein 39B 1 32072031-32102866 Predicted membrane proteins Evidence at protein level HPA040191, HPA040224 Approved Approved Vesicles Renal cancer:5.11e-9 (unfavourable), Liver cancer:2.82e-6 (unfavourable), Endometrial cancer:3.00e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 9.7 TMEM40 FLJ11036 ENSG00000088726 Transmembrane protein 40 3 12733525-12769457 Predicted membrane proteins Evidence at protein level HPA044165 Supported Approved Cytosol Tissue enhanced Group enriched 8 esophagus: 89.2;placenta: 23.2;skin: 55.5;tonsil: 24.8 urinary bladder: 6.4 TMEM41A MGC15397 ENSG00000163900 Transmembrane protein 41A 3 185476496-185499057 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059101, HPA059790 Approved Approved Nucleoplasm
Golgi apparatus
Cytosol Endometrial cancer:6.70e-6 (unfavourable), Liver cancer:1.04e-4 (unfavourable), Pancreatic cancer:4.72e-4 (unfavourable) Expressed in all Expressed in all adrenal gland: 28.3 TMEM41B KIAA0033 ENSG00000166471 Transmembrane protein 41B 11 9280654-9314780 Predicted membrane proteins Evidence at protein level HPA014946 Uncertain Approved Peroxisomes Liver cancer:9.18e-6 (unfavourable) Expressed in all Mixed thyroid gland: 22.3 TMEM42 MGC29956 ENSG00000169964 Transmembrane protein 42 3 44861869-44865670 Predicted membrane proteins Evidence at transcript level HPA052569 Uncertain Renal cancer:1.10e-5 (favourable), Breast cancer:5.23e-4 (favourable) Expressed in all Expressed in all epididymis: 12.5 TMEM43 ARVD5, DKFZp586G1919, LUMA, MGC3222 ENSG00000170876 Transmembrane protein 43 3 14124940-14143679 Disease related genes, Predicted membrane proteins Evidence at protein level HPA019198 Approved Pancreatic cancer:4.38e-4 (unfavourable) Expressed in all Expressed in all skin: 124.7 TMEM44 DKFZp686O18124 ENSG00000145014 Transmembrane protein 44 3 194587673-194633689 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA043718 Uncertain Approved Cytosol Renal cancer:6.55e-13 (unfavourable) Expressed in all Mixed epididymis: 15.8 TMEM45A DERP7, FLJ10134 ENSG00000181458 Transmembrane protein 45A 3 100492619-100577444 Predicted membrane proteins Evidence at protein level HPA024082, HPA062101 Uncertain Approved Intermediate filaments
Microtubules Renal cancer:6.18e-11 (unfavourable), Lung cancer:7.42e-4 (unfavourable) Expressed in all Tissue enriched 10 skin: 563.8 placenta: 58.1 TMEM45B BC016153, FLJ40787 ENSG00000151715 Transmembrane protein 45B 11 129815819-129860003 Predicted membrane proteins Evidence at protein level HPA015878 Approved Uncertain Nucleoplasm
Cytosol Expressed in all Tissue enhanced duodenum: 140.0;small intestine: 141.9 rectum: 104.8 TMEM47 BCMP1, DKFZp564E153, DKFZP761J17121, TM4SF10 ENSG00000147027 Transmembrane protein 47 X 34627064-34657288 Predicted membrane proteins Evidence at protein level HPA046658 Approved Approved Nuclear membrane Renal cancer:4.05e-6 (favourable), Melanoma:2.10e-4 (unfavourable) Expressed in all Mixed endometrium: 74.9 TMEM50A SMP1 ENSG00000183726 Transmembrane protein 50A 1 25337917-25362361 Predicted membrane proteins Evidence at protein level HPA065192 Approved Plasma membrane
Actin filaments
Cytosol Endometrial cancer:8.64e-5 (favourable), Liver cancer:3.34e-4 (unfavourable) Expressed in all Expressed in all prostate: 71.1 TMEM50B C21orf4 ENSG00000142188 Transmembrane protein 50B 21 33432485-33480011 Predicted membrane proteins Evidence at protein level CAB034199, HPA068995 Approved Approved Nucleoli fibrillar center Head and neck cancer:3.00e-4 (favourable), Lung cancer:3.33e-4 (favourable) Expressed in all Expressed in all thyroid gland: 74.3 TMEM51 C1orf72, FLJ10199 ENSG00000171729 Transmembrane protein 51 1 15152532-15220480 Predicted membrane proteins Evidence at protein level HPA014547, HPA019441 Approved Approved Nucleoplasm
Cytosol Renal cancer:8.16e-8 (favourable) Expressed in all Mixed gallbladder: 33.5 TMEM52B C12orf59, FLJ31166 ENSG00000165685 Transmembrane protein 52B 12 10170542-10191801 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA058096 Supported Approved Focal adhesion sites Tissue enriched Tissue enriched 21 kidney: 182.6 placenta: 8.7 TMEM53 FLJ22353, NET4 ENSG00000126106 Transmembrane protein 53 1 44635238-44674555 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA021134 Approved Approved Golgi apparatus
Focal adhesion sites Renal cancer:1.02e-5 (favourable), Ovarian cancer:6.96e-4 (favourable) Expressed in all Mixed testis: 23.3 TMEM54 CAC-1 ENSG00000121900 Transmembrane protein 54 1 32894594-32901438 Predicted membrane proteins Evidence at transcript level HPA061992 Approved Vesicles Liver cancer:3.08e-4 (unfavourable) Expressed in all Mixed colon: 226.8 TMEM55A DKFZp762O076 ENSG00000155099 Transmembrane protein 55A 8 90993796-91041064 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014591 Approved Liver cancer:3.76e-5 (unfavourable), Cervical cancer:1.01e-4 (unfavourable), Head and neck cancer:1.54e-4 (unfavourable), Stomach cancer:8.01e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 21.8 TMEM55B C14orf9, MGC26684 ENSG00000165782 Transmembrane protein 55B 14 20457719-20461612 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA048528 Approved Renal cancer:1.01e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 41.2 TMEM56 FLJ31842 ENSG00000152078 Transmembrane protein 56 1 95117338-95197607 Predicted membrane proteins Evidence at protein level HPA046762 Uncertain Approved Nuclear speckles Tissue enhanced Tissue enhanced liver: 66.0 heart muscle: 16.1 TMEM57 FLJ10747 ENSG00000204178 Transmembrane protein 57 1 25430858-25500209 Predicted membrane proteins, Transporters Evidence at protein level HPA019680 Approved Cytosol Renal cancer:7.13e-4 (favourable) Expressed in all Expressed in all testis: 36.0 TMEM59L BSMAP, C19orf4 ENSG00000105696 Transmembrane protein 59-like 19 18607430-18621039 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA010661, HPA070701 Approved Approved Nucleoplasm
Actin filaments Endometrial cancer:1.62e-4 (unfavourable), Pancreatic cancer:8.80e-4 (favourable) Tissue enriched Tissue enriched 16 cerebral cortex: 367.2 adrenal gland: 22.3 TMEM60 C7orf35, DC32 ENSG00000135211 Transmembrane protein 60 7 77793728-77798580 Predicted membrane proteins Evidence at transcript level HPA062625 Approved Breast cancer:3.09e-4 (favourable), Glioma:8.70e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 55.3 TMEM61 ENSG00000143001 Transmembrane protein 61 1 54980792-54992293 Predicted membrane proteins Evidence at transcript level HPA030614 Uncertain Renal cancer:1.78e-7 (favourable), Colorectal cancer:1.07e-4 (favourable) Mixed Tissue enhanced parathyroid gland: 11.0;salivary gland: 10.2 seminal vesicle: 8.1 TMEM62 FLJ23375 ENSG00000137842 Transmembrane protein 62 15 43123279-43185146 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044461, HPA062359 Approved Approved Nucleus
Nucleoli fibrillar center
Nuclear bodies
Cytoplasmic bodies Endometrial cancer:9.72e-7 (favourable) Expressed in all Expressed in all breast: 27.2 TMEM63A KIAA0792 ENSG00000196187 Transmembrane protein 63A 1 225845536-225882369 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066504, HPA066936, HPA068918 Validated Vesicles
Microtubule organizing center Endometrial cancer:8.79e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 77.4 TMEM63B C6orf110, dJ421H19.2, DKFZp434P0531 ENSG00000137216 Transmembrane protein 63B 6 44126914-44155519 Predicted membrane proteins, Transporters Evidence at protein level HPA029249, HPA029250, HPA029251 Uncertain Validated Plasma membrane
Actin filaments Expressed in all Expressed in all lung: 59.2 TMEM63C C14orf171, CSC1, DKFZp434P0111, hsCSC1 ENSG00000165548 Transmembrane protein 63C 14 77116568-77259495 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030657 Uncertain Approved Centrosome Mixed Tissue enhanced adrenal gland: 12.9;cerebral cortex: 18.6;testis: 13.8 epididymis: 5.5 TMEM64 DKFZp762C1112 ENSG00000180694 Transmembrane protein 64 8 90621995-90791632 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at transcript level CAB034221 Uncertain Expressed in all Expressed in all epididymis: 173.0 TMEM65 ENSG00000164983 Transmembrane protein 65 8 124306189-124372692 Predicted membrane proteins Evidence at protein level HPA025020 Uncertain Approved Nucleoplasm Endometrial cancer:1.05e-4 (unfavourable), Breast cancer:2.17e-4 (unfavourable), Liver cancer:2.56e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 17.4 TMEM67 JBTS6, MGC26979, MKS3, NPHP11 ENSG00000164953 Transmembrane protein 67 8 93754844-93819234 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA039940 Uncertain Renal cancer:7.62e-4 (unfavourable) Mixed Tissue enhanced fallopian tube: 21.9 testis: 12.8 TMEM68 FLJ32370 ENSG00000167904 Transmembrane protein 68 8 55696424-55773407 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA018216, HPA019173 Uncertain Approved Vesicles Expressed in all Expressed in all fallopian tube: 36.6 TMEM69 C1orf154, FLJ21029 ENSG00000159596 Transmembrane protein 69 1 45687214-45694443 Predicted membrane proteins Evidence at transcript level HPA026993 Approved Approved Nucleoplasm Liver cancer:3.66e-8 (unfavourable), Breast cancer:2.24e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 21.9 TMEM70 FLJ20533 ENSG00000175606 Transmembrane protein 70 8 73972437-73982783 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA023187, CAB034226 Uncertain Supported Nucleoplasm
Mitochondria Expressed in all Expressed in all skeletal muscle: 30.2 TMEM71 FLJ33069 ENSG00000165071 Transmembrane protein 71 8 132685007-132760712 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA058401, HPA070655 Uncertain Validated Mitochondria Mixed Mixed bone marrow,heart muscle: 24.2 TMEM72 bA285G1.3, C10orf127, KSP37 ENSG00000187783 Transmembrane protein 72 10 44911200-44937002 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039894, HPA062907 Supported Renal cancer:1.01e-4 (favourable) Tissue enriched Tissue enriched 7 kidney: 54.0 rectum: 8.0 TMEM74 FLJ30668, NET36 ENSG00000164841 Transmembrane protein 74 8 108606850-108787615 Predicted membrane proteins Evidence at protein level HPA015672 Uncertain Approved Cytosol Mixed Tissue enhanced cerebral cortex: 6.3 testis: 1.5 TMEM74B C20orf46, FLJ11190 ENSG00000125895 Transmembrane protein 74B 20 1180561-1185415 Predicted membrane proteins Evidence at transcript level HPA045213 Approved Approved Nucleoplasm
Golgi apparatus Renal cancer:2.55e-7 (unfavourable), Pancreatic cancer:3.07e-5 (favourable) Mixed Mixed small intestine: 28.0 TMEM78 FLJ40168 ENSG00000177800 Transmembrane protein 78 1 229249636-229251810 Predicted membrane proteins Evidence at transcript level HPA042351 Uncertain Not detected Not detected epididymis: 0.5 TMEM79 FLJ16057, FLJ32254, MATT, MGC13102 ENSG00000163472 Transmembrane protein 79 1 156282935-156293185 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA055214 Supported Approved Nucleoli fibrillar center Renal cancer:4.31e-7 (unfavourable), Liver cancer:2.61e-5 (unfavourable) Expressed in all Group enriched 5 esophagus: 61.9;prostate: 45.1;skin: 66.9 tonsil: 11.1 TMEM80 FLJ38216 ENSG00000177042 Transmembrane protein 80 11 695428-705028 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA059592, HPA067046 Uncertain Approved Golgi apparatus Renal cancer:2.47e-4 (favourable) Expressed in all Expressed in all thyroid gland: 43.4 TMEM81 HC3107, KVLA2788, MGC75217, UNQ2788 ENSG00000174529 Transmembrane protein 81 1 205083129-205084460 Predicted membrane proteins Evidence at protein level HPA052515 Approved Intermediate filaments Renal cancer:6.65e-9 (unfavourable), Liver cancer:3.25e-6 (unfavourable), Urothelial cancer:2.67e-4 (favourable) Expressed in all Mixed testis: 6.7 TMEM82 ENSG00000162460 Transmembrane protein 82 1 15742422-15747982 Predicted membrane proteins Evidence at protein level HPA060282 Uncertain Renal cancer:3.80e-7 (favourable) Tissue enhanced Tissue enhanced duodenum: 23.7;liver: 9.0;small intestine: 19.8 kidney: 7.6 TMEM86A FLJ90119 ENSG00000151117 Transmembrane protein 86A 11 18693122-18704785 Predicted membrane proteins Evidence at transcript level HPA057119 Uncertain Expressed in all Mixed skin: 13.3 TMEM86B MGC30208 ENSG00000180089 Transmembrane protein 86B 19 55226639-55229264 Enzymes, Predicted membrane proteins Evidence at protein level HPA057689 Uncertain Approved Midbody
Centrosome Pancreatic cancer:9.97e-6 (favourable), Liver cancer:3.13e-4 (favourable) Tissue enriched Mixed gallbladder: 6.6 TMEM87A DKFZP564G2022 ENSG00000103978 Transmembrane protein 87A 15 42210452-42273663 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA018104, HPA018189 Supported Supported Golgi apparatus Expressed in all Expressed in all prostate: 122.4 TMEM87B FLJ14681 ENSG00000153214 Transmembrane protein 87B 2 112055223-112119318 Predicted membrane proteins Evidence at protein level HPA035183 Approved Approved Golgi apparatus
Vesicles Renal cancer:1.52e-7 (unfavourable), Cervical cancer:3.78e-4 (unfavourable), Head and neck cancer:4.28e-4 (unfavourable), Liver cancer:4.72e-4 (unfavourable) Expressed in all Mixed prostate: 43.2 TMEM88 FLJ20025, MGC71744 ENSG00000167874 Transmembrane protein 88 17 7855065-7856099 Predicted membrane proteins Evidence at protein level HPA052991 Approved Liver cancer:4.43e-6 (favourable), Colorectal cancer:1.16e-4 (unfavourable) Expressed in all Mixed placenta: 34.0 TMEM88B ENSG00000205116 Transmembrane protein 88B 1 1426128-1427787 Predicted membrane proteins Evidence at protein level HPA065743 Supported Tissue enhanced Tissue enriched 13 cerebral cortex: 11.9 testis: 0.9 TMEM89 ENSG00000183396 Transmembrane protein 89 3 48620759-48621855 Predicted membrane proteins Evidence at protein level HPA053577 Uncertain Not detected Tissue enriched 10 testis: 9.4 bone marrow: 0.9 TMEM8A M83, TMEM6, TMEM8 ENSG00000129925 Transmembrane protein 8A 16 370773-387113 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051281, HPA064673 Approved Supported Nucleoplasm
Cytokinetic bridge Renal cancer:1.29e-5 (favourable) Expressed in all Expressed in all testis: 57.6 TMEM8B C9orf127, NAG-5, NGX6 ENSG00000137103 Transmembrane protein 8B 9 35814451-35854847 Predicted membrane proteins Evidence at protein level HPA052130, HPA062701 Approved Approved Vesicles Renal cancer:1.89e-15 (favourable), Pancreatic cancer:3.14e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 26.7 TMEM8C TMEM226 ENSG00000187616 Transmembrane protein 8C 9 133514586-133528612 Predicted membrane proteins Evidence at transcript level HPA051846, HPA055785 Uncertain Not detected Not detected cerebral cortex,epididymis: 0.5 TMEM91 FLJ27310, IFITMD6 ENSG00000142046 Transmembrane protein 91 19 41350911-41384083 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA053240 Uncertain Renal cancer:3.52e-7 (unfavourable), Pancreatic cancer:3.54e-5 (favourable) Expressed in all Expressed in all skin: 31.0 TMEM92 FLJ33318 ENSG00000167105 Transmembrane protein 92 17 50271406-50281485 Predicted membrane proteins Evidence at protein level HPA063009, HPA069820 Approved Supported Nucleoplasm Renal cancer:1.14e-6 (unfavourable), Head and neck cancer:8.35e-4 (unfavourable) Mixed Tissue enhanced duodenum: 41.4;small intestine: 51.6 gallbladder: 21.9 TMEM94 KIAA0195 ENSG00000177728 Transmembrane protein 94 17 75441159-75500090 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008423, HPA050660 Approved Supported Nucleoplasm
Nuclear bodies Pancreatic cancer:2.26e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 54.3 TMEM97 MAC30 ENSG00000109084 Transmembrane protein 97 17 28319095-28328685 Predicted membrane proteins Evidence at protein level HPA044795 Approved Approved Nuclear membrane
Plasma membrane
Cytosol Renal cancer:1.24e-4 (unfavourable) Expressed in all Expressed in all testis: 109.7 TMEM98 DKFZP564K1964 ENSG00000006042 Transmembrane protein 98 17 32927910-32945106 Disease related genes, Predicted membrane proteins Evidence at protein level HPA040473, HPA053385 Uncertain Supported Nucleoplasm Renal cancer:3.85e-4 (favourable), Lung cancer:7.10e-4 (favourable), Liver cancer:8.14e-4 (unfavourable) Expressed in all Expressed in all ovary: 237.4 TMEM99 MGC21518 ENSG00000167920 Transmembrane protein 99 17 40819106-40836274 Predicted membrane proteins Evidence at transcript level HPA076359 Approved Cytosol Expressed in all Tissue enhanced testis: 175.7 epididymis: 52.1 TMEM9B C11orf15 ENSG00000175348 TMEM9 domain family, member B 11 8947294-8965011 Predicted membrane proteins Evidence at protein level HPA037784 Uncertain Renal cancer:4.26e-5 (favourable) Expressed in all Expressed in all thyroid gland: 129.2 TMIE DFNB6 ENSG00000181585 Transmembrane inner ear 3 46701333-46710886 Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA038298 Uncertain Uncertain Vesicles
Cytosol Tissue enriched Tissue enhanced adrenal gland: 7.5;cerebral cortex: 5.3 testis: 1.7 TMIGD1 TMIGD, UNQ9372 ENSG00000182271 Transmembrane and immunoglobulin domain containing 1 17 30316333-30334059 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA021946 Approved Mitochondria Tissue enhanced Group enriched 24 colon: 83.2;rectum: 111.5;small intestine: 165.6 kidney: 5.0 TMIGD2 CD28H, IGPR-1, MGC23244 ENSG00000167664 Transmembrane and immunoglobulin domain containing 2 19 4292232-4302431 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011081 Approved Mixed Tissue enhanced lymph node: 7.5 appendix: 5.7 TMPO LAP2, LEMD4, TP ENSG00000120802 Thymopoietin 12 98515512-98550379 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA008150, CAB009847 Supported Validated Nuclear membrane Renal cancer:9.34e-4 (unfavourable) Expressed in all Expressed in all lymph node: 92.4 TMPPE FLJ45032 ENSG00000188167 Transmembrane protein with metallophosphoesterase domain 3 33090421-33096801 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027019 Uncertain Approved Nucleoplasm
Mitochondria Mixed Mixed parathyroid gland: 4.0 TMPRSS11D ENSG00000153802 Transmembrane protease, serine 11D 4 67820876-67884032 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA052834 Uncertain Group enriched Group enriched 39 esophagus: 70.8;tonsil: 31.7 cervix, uterine: 1.3 TMPRSS11E DESC1, TMPRSS11E2 ENSG00000087128 Transmembrane protease, serine 11E 4 68447449-68497604 Enzymes, Predicted membrane proteins Evidence at protein level HPA051062 Uncertain Lung cancer:6.73e-4 (unfavourable) Group enriched Tissue enriched 5 esophagus: 128.6 epididymis: 24.6 TMPRSS11F FLJ16046 ENSG00000198092 Transmembrane protease, serine 11F 4 68053198-68129880 Enzymes, Predicted membrane proteins Evidence at transcript level HPA026911 Uncertain Group enriched Group enriched 7 esophagus: 16.8;skin: 11.0;tonsil: 3.8 breast: 1.5 TMPRSS15 ENTK, MGC133046, PRSS7 ENSG00000154646 Transmembrane protease, serine 15 21 18269116-18485879 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA015611 Supported Group enriched Tissue enriched 44 duodenum: 1039.0 small intestine: 23.3 TMPRSS2 PRSS10 ENSG00000184012 Transmembrane protease, serine 2 21 41464551-41531116 Cancer-related genes, Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034493, HPA035787 Supported Supported Nucleoplasm
Cell Junctions Renal cancer:7.86e-6 (favourable), Endometrial cancer:2.56e-4 (favourable) Tissue enriched Tissue enhanced prostate: 495.7 stomach: 142.5 TMPRSS4 MT-SP2, TMPRSS3 ENSG00000137648 Transmembrane protease, serine 4 11 118077012-118121890 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA006238 Uncertain Approved Nucleoplasm
Cytosol Pancreatic cancer:3.14e-4 (unfavourable) Mixed Tissue enhanced rectum: 78.4;urinary bladder: 80.0 esophagus: 74.1 TMPRSS5 MGC141886, MGC148044 ENSG00000166682 Transmembrane protease, serine 5 11 113687550-113706373 Disease related genes, Enzymes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010992 Approved Nucleoplasm Tissue enhanced Tissue enhanced cerebral cortex: 10.1 salivary gland: 3.0 TMPRSS7 ENSG00000176040 Transmembrane protease, serine 7 3 112034843-112081269 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA040630 Uncertain Not detected Tissue enhanced testis: 2.5 fallopian tube: 0.5 TMPRSS9 ENSG00000178297 Transmembrane protease, serine 9 19 2389771-2426239 Enzymes, Predicted membrane proteins Evidence at protein level HPA051483 Uncertain Mixed Tissue enhanced spleen: 2.3 testis: 1.7 TMTC1 ARG99, FLJ31400, FLJ41625, OLF ENSG00000133687 Transmembrane and tetratricopeptide repeat containing 1 12 29500840-29784759 Predicted membrane proteins Evidence at protein level HPA016720 Approved Approved Nucleoplasm
Cytosol Endometrial cancer:1.90e-4 (unfavourable), Renal cancer:5.49e-4 (unfavourable) Mixed Tissue enhanced spleen: 61.6 adipose tissue: 41.5 TMTC2 DKFZp762A217 ENSG00000179104 Transmembrane and tetratricopeptide repeat containing 2 12 82686880-83134870 Predicted membrane proteins Evidence at protein level HPA026954, HPA026955 Uncertain Approved Actin filaments
Cytosol Renal cancer:2.84e-5 (favourable) Mixed Mixed cerebral cortex: 16.4 TMTC3 FLJ90492, SMILE ENSG00000139324 Transmembrane and tetratricopeptide repeat containing 3 12 88142296-88199887 Predicted membrane proteins Evidence at protein level HPA038550 Approved Approved Microtubules Expressed in all Mixed skin: 14.9 TMTC4 FLJ14624, FLJ22153 ENSG00000125247 Transmembrane and tetratricopeptide repeat containing 4 13 100603927-100675093 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016489 Uncertain Approved Vesicles Expressed in all Expressed in all cerebral cortex: 26.5 TMUB1 C7orf21, SB144 ENSG00000164897 Transmembrane and ubiquitin-like domain containing 1 7 151081080-151083546 Predicted membrane proteins, Predicted secreted proteins, Transporters Evidence at protein level HPA029429 Approved Supported Nucleoplasm
Cytosol Expressed in all Expressed in all small intestine: 53.3 TMUB2 MGC3123 ENSG00000168591 Transmembrane and ubiquitin-like domain containing 2 17 44186970-44191731 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043137 Approved Approved Vesicles
Cytosol Expressed in all Expressed in all testis: 48.5 TMX1 PDIA11, TMX, TXNDC, TXNDC1 ENSG00000139921 Thioredoxin-related transmembrane protein 1 14 51240162-51257546 Predicted membrane proteins Evidence at protein level HPA003085 Approved Supported Nucleoli
Endoplasmic reticulum Liver cancer:1.29e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 19.8 TMX2 PDIA12, TXNDC14 ENSG00000213593 Thioredoxin-related transmembrane protein 2 11 57712600-57740973 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA040282, HPA063763 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.55e-5 (favourable), Urothelial cancer:3.37e-4 (unfavourable), Head and neck cancer:3.64e-4 (unfavourable), Liver cancer:4.11e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 129.2 TMX3 FLJ20793, KIAA1830, PDIA13, TXNDC10 ENSG00000166479 Thioredoxin-related transmembrane protein 3 18 68673688-68715298 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014157 Uncertain Renal cancer:2.87e-4 (unfavourable) Expressed in all Expressed in all appendix: 32.3 TMX4 DJ971N18.2, KIAA1162, PDIA14, TXNDC13 ENSG00000125827 Thioredoxin-related transmembrane protein 4 20 7977348-8019829 Predicted membrane proteins Evidence at protein level HPA000399, HPA015752 Supported Supported Nuclear membrane Renal cancer:2.60e-5 (favourable) Expressed in all Expressed in all testis: 117.9 TNFRSF10A Apo2, CD261, DR4, TRAILR-1 ENSG00000104689 Tumor necrosis factor receptor superfamily, member 10a 8 23190452-23225126 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA050958, HPA054475 Approved Supported Nucleoplasm Pancreatic cancer:1.00e-4 (unfavourable) Expressed in all Mixed lymph node: 16.1 TNFRSF10B CD262, DR5, KILLER, TRAIL-R2, TRICK2A, TRICKB ENSG00000120889 Tumor necrosis factor receptor superfamily, member 10b 8 23020133-23069179 Cancer-related genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023625 Approved Renal cancer:1.76e-4 (unfavourable) Expressed in all Expressed in all gallbladder: 33.4 TNFRSF10C CD263, DcR1, LIT, TRAILR3, TRID ENSG00000173535 Tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain 8 23084355-23117437 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB025635 Supported Mixed Tissue enhanced appendix: 22.4 spleen: 18.5 TNFRSF10D CD264, DcR2, TRAILR4, TRUNDD ENSG00000173530 Tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain 8 23135588-23164030 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA070971 Approved Plasma membrane
Actin filaments Cervical cancer:1.70e-4 (unfavourable) Expressed in all Mixed gallbladder: 12.7 TNFRSF11A CD265, FEO, LOH18CR1, PDB2, RANK ENSG00000141655 Tumor necrosis factor receptor superfamily, member 11a, NFKB activator 18 62325287-62391292 CD markers, Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB010391, HPA027728, HPA047976 Uncertain Supported Plasma membrane
Cytosol Mixed Tissue enhanced duodenum: 31.2 small intestine: 20.9 TNFRSF12A CD266, FN14, TweakR ENSG00000006327 Tumor necrosis factor receptor superfamily, member 12A 16 3018445-3022383 Cancer-related genes, CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007853 Approved Approved Plasma membrane
Cytosol Head and neck cancer:5.50e-4 (unfavourable), Renal cancer:8.78e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 195.6 TNFRSF13B CD267, IGAD2, TACI ENSG00000240505 Tumor necrosis factor receptor superfamily, member 13B 17 16929816-16972118 CD markers, Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030453 Uncertain Not detected Tissue enhanced lymph node: 20.7;skeletal muscle: 22.1;spleen: 28.0;tonsil: 22.5 appendix: 12.5 TNFRSF13C BAFFR, CD268 ENSG00000159958 Tumor necrosis factor receptor superfamily, member 13C 22 41922023-41926818 CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level HPA003246, CAB008380 Supported Uncertain Nucleus Cervical cancer:4.44e-7 (favourable) Mixed Group enriched 10 appendix: 23.8;lymph node: 46.7;spleen: 44.4;tonsil: 51.9 bone marrow: 4.0 TNFRSF14 ATAR, CD270, HVEA, HVEM, LIGHTR, TR2 ENSG00000157873 Tumor necrosis factor receptor superfamily, member 14 1 2555639-2565382 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA006404, CAB026150, CAB030007 Approved Approved Cytosol
Rods & Rings Urothelial cancer:7.79e-6 (favourable), Endometrial cancer:8.01e-6 (favourable), Breast cancer:4.39e-5 (favourable) Expressed in all Expressed in all duodenum: 46.7 TNFRSF18 AITR, CD357, GITR ENSG00000186891 Tumor necrosis factor receptor superfamily, member 18 1 1203508-1206691 CD markers, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA008025 Approved Renal cancer:4.40e-11 (unfavourable), Endometrial cancer:7.72e-6 (favourable), Head and neck cancer:4.12e-4 (favourable) Expressed in all Tissue enhanced skin: 43.3 parathyroid gland: 17.6 TNFRSF19 TAJ, TAJ-alpha, TRADE, TROY ENSG00000127863 Tumor necrosis factor receptor superfamily, member 19 13 23570370-23676104 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA010135 Approved Nucleoplasm
Mitochondria Renal cancer:9.13e-7 (favourable), Lung cancer:3.87e-4 (favourable) Expressed in all Tissue enhanced skin: 129.2 fallopian tube: 49.9 TNFRSF1A CD120a, TNF-R, TNF-R-I, TNF-R55, TNFAR, TNFR1, TNFR60 ENSG00000067182 Tumor necrosis factor receptor superfamily, member 1A 12 6328757-6342114 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Disease related genes, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004102, CAB010309 Approved Renal cancer:2.70e-7 (unfavourable), Head and neck cancer:3.68e-4 (unfavourable), Endometrial cancer:8.22e-4 (favourable) Expressed in all Expressed in all gallbladder: 140.8 TNFRSF1B CD120b, p75, TNF-R-II, TNF-R75, TNFBR, TNFR2, TNFR80 ENSG00000028137 Tumor necrosis factor receptor superfamily, member 1B 1 12167003-12209228 Cancer-related genes, Candidate cardiovascular disease genes, CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA004796 Approved Renal cancer:8.35e-5 (unfavourable), Testis cancer:8.68e-4 (unfavourable) Expressed in all Tissue enhanced appendix: 103.0 spleen: 79.2 TNFRSF21 CD358, DR6 ENSG00000146072 Tumor necrosis factor receptor superfamily, member 21 6 47231532-47309905 CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA006746, CAB009805 Approved Renal cancer:7.23e-6 (favourable) Expressed in all Expressed in all parathyroid gland: 103.4 TNFRSF25 APO-3, DDR3, DR3, LARD, TNFRSF12, TR3, TRAMP, WSL-1, WSL-LR ENSG00000215788 Tumor necrosis factor receptor superfamily, member 25 1 6461151-6466195 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA077620 Approved Cell Junctions Renal cancer:1.65e-7 (unfavourable), Head and neck cancer:3.09e-4 (favourable), Colorectal cancer:4.46e-4 (unfavourable) Expressed in all Tissue enhanced skin: 29.7 spleen: 12.3 TNFRSF4 ACT35, CD134, OX40, TXGP1L ENSG00000186827 Tumor necrosis factor receptor superfamily, member 4 1 1211326-1214138 Cancer-related genes, CD markers, Disease related genes, Predicted membrane proteins Evidence at protein level CAB016128 Supported Head and neck cancer:3.50e-6 (favourable), Renal cancer:4.52e-6 (unfavourable), Liver cancer:6.03e-4 (unfavourable) Expressed in all Tissue enhanced adipose tissue: 9.7;appendix: 8.6 lymph node: 7.2 TNFRSF8 CD30, D1S166E, KI-1 ENSG00000120949 Tumor necrosis factor receptor superfamily, member 8 1 12063377-12144207 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB000016, HPA032081, HPA032082 Approved Tissue enriched Tissue enhanced appendix: 4.3 adipose tissue: 3.1 TNFRSF9 4-1BB, CD137, ILA ENSG00000049249 Tumor necrosis factor receptor superfamily, member 9 1 7915894-7943165 Cancer-related genes, CD markers, Predicted membrane proteins Evidence at protein level HPA071425 Approved Nucleoli
Plasma membrane Renal cancer:2.69e-8 (unfavourable) Mixed Tissue enhanced lymph node: 11.2;tonsil: 7.4 appendix: 5.3 TNFSF10 Apo-2L, CD253, TL2, TRAIL ENSG00000121858 Tumor necrosis factor (ligand) superfamily, member 10 3 172505508-172523507 Cancer-related genes, CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054938 Uncertain Approved Microtubules Pancreatic cancer:9.43e-4 (unfavourable) Expressed in all Expressed in all lung: 260.2 TNFSF11 CD254, ODF, OPGL, RANKL, TRANCE ENSG00000120659 Tumor necrosis factor (ligand) superfamily, member 11 13 42562736-42608013 Cancer-related genes, CD markers, Disease related genes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009193, HPA045142 Supported Mixed Tissue enhanced lymph node: 17.6 appendix: 6.5 TNFSF13 APRIL, CD256 ENSG00000161955 Tumor necrosis factor (ligand) superfamily, member 13 17 7558292-7561608 Cancer-related genes, CD markers, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA004863 Uncertain Renal cancer:1.30e-9 (favourable), Glioma:8.28e-4 (unfavourable) Expressed in all Expressed in all lung: 150.0 TNFSF13B BAFF, BLYS, CD257, TALL-1, TALL1, THANK, TNFSF20 ENSG00000102524 Tumor necrosis factor (ligand) superfamily, member 13b 13 108251240-108308484 Cancer-related genes, CD markers, FDA approved drug targets, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009188 Approved Renal cancer:2.53e-11 (unfavourable) Expressed in all Mixed appendix: 36.2 TNFSF14 CD258, HVEM-L, LIGHT, LTg ENSG00000125735 Tumor necrosis factor (ligand) superfamily, member 14 19 6661253-6670588 CD markers, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA012700 Approved Renal cancer:6.07e-13 (unfavourable) Tissue enhanced Mixed adipose tissue: 6.8 TNFSF15 MGC129934, MGC129935, TL1, TL1A, VEGI, VEGI192A ENSG00000181634 Tumor necrosis factor (ligand) superfamily, member 15 9 114784635-114806126 Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA012948, HPA046522 Approved Approved Nucleus
Nuclear membrane
Cytosol Mixed Mixed duodenum: 9.7 TNFSF18 AITRL, hGITRL, TL6 ENSG00000120337 Tumor necrosis factor (ligand) superfamily, member 18 1 173039960-173050963 Predicted membrane proteins Evidence at protein level HPA012699 Uncertain Mixed Tissue enhanced cerebral cortex: 2.9;gallbladder: 3.1 parathyroid gland: 1.4 TNFSF4 CD252, gp34, OX-40L, TXGP1 ENSG00000117586 Tumor necrosis factor (ligand) superfamily, member 4 1 173183734-173207313 Cancer-related genes, CD markers, Disease related genes, Predicted intracellular proteins Evidence at protein level HPA059579 Approved Approved Nucleus
Vesicles Expressed in all Tissue enhanced testis: 7.5 appendix: 3.2 TNFSF9 4-1BB-L ENSG00000125657 Tumor necrosis factor (ligand) superfamily, member 9 19 6530999-6535928 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA059857 Approved Golgi apparatus Renal cancer:1.04e-4 (unfavourable) Mixed Mixed cerebral cortex: 3.5 TNMD BRICD4, ChM1L, myodulin, TEM, tendin ENSG00000000005 Tenomodulin X 100584802-100599885 Predicted membrane proteins Evidence at protein level HPA034961, HPA055634 Uncertain Mixed Tissue enhanced adipose tissue: 10.1;seminal vesicle: 32.9 breast: 4.3 TOMM20 KIAA0016, MAS20, MOM19, TOM20 ENSG00000173726 Translocase of outer mitochondrial membrane 20 homolog (yeast) 1 235109336-235128936 Predicted membrane proteins Evidence at protein level CAB005585, HPA011562 Supported Validated Mitochondria Expressed in all Expressed in all cerebral cortex,thyroid gland: 230.5 TOMM20L UNQ9438 ENSG00000196860 Translocase of outer mitochondrial membrane 20 homolog (yeast)-like 14 58395916-58408701 Predicted membrane proteins Evidence at transcript level HPA044997 Uncertain Mixed Tissue enriched 10 testis: 13.1 parathyroid gland: 1.3 TOMM22 TOM22 ENSG00000100216 Translocase of outer mitochondrial membrane 22 homolog (yeast) 22 38681948-38685421 Predicted membrane proteins Evidence at protein level HPA003037 Supported Validated Mitochondria Liver cancer:2.90e-5 (unfavourable) Expressed in all Expressed in all fallopian tube: 32.4 TOMM5 bA613M10.3, C9orf105 ENSG00000175768 Translocase of outer mitochondrial membrane 5 homolog (yeast) 9 37582646-37592642 Predicted intracellular proteins Evidence at protein level HPA048712 Approved Supported Mitochondria Liver cancer:2.09e-4 (unfavourable), Ovarian cancer:2.37e-4 (favourable), Melanoma:5.49e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 98.1 TOMM70A KIAA0719 ENSG00000154174 Translocase of outer mitochondrial membrane 70 homolog A (S. cerevisiae) 3 100363431-100401398 Predicted membrane proteins Evidence at protein level HPA014589, CAB017156, HPA048020 Supported Validated Mitochondria Expressed in all Expressed in all cerebral cortex: 52.9 TOR1AIP1 FLJ13142, LAP1B ENSG00000143337 Torsin A interacting protein 1 1 179882042-179925000 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA047151, HPA050546 Supported Validated Nuclear membrane Expressed in all Expressed in all thyroid gland: 78.9 TOR1AIP2 IFRG15, LULL1, NET9 ENSG00000169905 Torsin A interacting protein 2 1 179839967-179877803 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA051849, HPA058348, HPA070542 Uncertain Validated Endoplasmic reticulum Renal cancer:2.29e-4 (unfavourable) Expressed in all Expressed in all placenta: 33.9 TOR4A C9orf167, FLJ20245 ENSG00000198113 Torsin family 4, member A 9 137277749-137282641 Predicted intracellular proteins Evidence at protein level HPA044913 Approved Approved Nucleoplasm Liver cancer:3.44e-4 (unfavourable), Colorectal cancer:6.48e-4 (unfavourable) Expressed in all Mixed stomach: 11.7 TP53I11 PIG11 ENSG00000175274 Tumor protein p53 inducible protein 11 11 44885903-44951306 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA059727, HPA061276 Uncertain Supported Endoplasmic reticulum
Golgi apparatus Breast cancer:7.33e-5 (unfavourable), Renal cancer:4.65e-4 (unfavourable), Melanoma:6.12e-4 (unfavourable) Expressed in all Expressed in all adipose tissue: 58.0 TPBG 5T4, 5T4-AG ENSG00000146242 Trophoblast glycoprotein 6 82363206-82370828 Predicted membrane proteins Evidence at protein level HPA010554 Supported Approved Nucleoplasm Colorectal cancer:6.68e-4 (unfavourable) Expressed in all Mixed cervix, uterine: 17.4 TPCN1 FLJ20612, KIAA1169, TPC1 ENSG00000186815 Two pore segment channel 1 12 113221050-113298585 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA039757 Approved Expressed in all Expressed in all thyroid gland: 53.3 TPCN2 TPC2 ENSG00000162341 Two pore segment channel 2 11 69048897-69090604 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA016561, HPA027080 Supported Approved Nucleoli Ovarian cancer:1.49e-4 (unfavourable), Head and neck cancer:2.96e-4 (unfavourable) Expressed in all Mixed endometrium: 11.7 TPM1 C15orf13, CMH3 ENSG00000140416 Tropomyosin 1 (alpha) 15 63042632-63071915 Cancer-related genes, Candidate cardiovascular disease genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000261, HPA009066, CAB017698, HPA047089, HPA053624 Supported Approved Actin filaments
Cytosol Urothelial cancer:7.30e-4 (unfavourable) Expressed in all Expressed in all heart muscle: 6465.2 TPO TPX ENSG00000115705 Thyroid peroxidase 2 1374223-1543711 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA007987, CAB009587 Supported Tissue enriched Tissue enriched 101 thyroid gland: 1811.8 spleen: 17.9 TPRA1 FLJ32197, GPR175, TMEM227, TPRA40 ENSG00000163870 Transmembrane protein, adipocyte asscociated 1 3 127573069-127598251 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019784 Approved Approved Vesicles Liver cancer:6.46e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 38.1 TPSG1 PRSS31, TMT ENSG00000116176 Tryptase gamma 1 16 1221651-1225257 Enzymes, Predicted membrane proteins Evidence at transcript level HPA060458 Approved Renal cancer:1.76e-8 (unfavourable) Tissue enhanced Tissue enhanced colon: 15.2;duodenum: 14.7;small intestine: 10.7 rectum: 9.8 TPTE CT44, PTEN2 ENSG00000274391 Transmembrane phosphatase with tensin homology 21 10521553-10606140 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA049690, HPA068342 Supported Approved Endoplasmic reticulum
Cytosol Tissue enriched Tissue enriched 225 testis: 198.9 epididymis,placenta: 0.8 TPTE2 TPIP ENSG00000132958 Transmembrane phosphoinositide 3-phosphatase and tensin homolog 2 13 19422877-19536762 Enzymes, Plasma proteins, Predicted membrane proteins Evidence at protein level HPA068342 Approved Endoplasmic reticulum
Cytosol Tissue enriched Tissue enriched 33 testis: 11.9 lymph node,tonsil: 0.3 TRABD PP2447 ENSG00000170638 TraB domain containing 22 50185915-50199598 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA000822 Approved Approved Nucleus
Mitochondria Endometrial cancer:1.19e-5 (favourable), Renal cancer:1.85e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 38.6 TRABD2A C2orf89, TIKI1 ENSG00000186854 TraB domain containing 2A 2 84821650-84907008 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA045817 Approved Group enriched Tissue enhanced colon: 35.8;ovary: 30.5;rectum: 43.4 lymph node: 11.8 TRABD2B TIKI2 ENSG00000269113 TraB domain containing 2B 1 47760528-47996895 Predicted secreted proteins Evidence at protein level HPA045817 Approved Tissue enriched Tissue enhanced kidney: 7.7 seminal vesicle: 4.8 TRAF3IP3 T3JAM ENSG00000009790 TRAF3 interacting protein 3 1 209756032-209782320 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040796 Approved Approved Vesicles Breast cancer:4.11e-4 (favourable), Lung cancer:8.15e-4 (favourable) Mixed Tissue enhanced lymph node: 116.4;spleen: 83.8;tonsil: 86.0 appendix: 70.3 TRAM1 TRAM, TRAMP ENSG00000067167 Translocation associated membrane protein 1 8 70573442-70608387 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA023929 Approved Cervical cancer:2.06e-4 (unfavourable), Renal cancer:7.79e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 316.6 TRAM1L1 MGC26568 ENSG00000174599 Translocation associated membrane protein 1-like 1 4 117083554-117085576 Predicted membrane proteins Evidence at transcript level HPA044560 Uncertain Approved Mitochondria Mixed Mixed cerebral cortex: 14.2 TRAM2 KIAA0057 ENSG00000065308 Translocation associated membrane protein 2 6 52497402-52576915 Predicted membrane proteins Evidence at protein level HPA035092, HPA057925 Approved Approved Cytosol Renal cancer:1.41e-9 (unfavourable), Endometrial cancer:1.88e-4 (unfavourable) Expressed in all Expressed in all placenta: 51.8 TRAT1 HSPC062, TCRIM, TRIM ENSG00000163519 T cell receptor associated transmembrane adaptor 1 3 108822698-108855005 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002356, CAB026130 Supported Mixed Tissue enhanced appendix: 14.6;lymph node: 26.8 spleen: 11.7 TRDN ENSG00000186439 Triadin 6 123216339-123637093 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038226, HPA058226 Supported Approved Plasma membrane
Cytosol Tissue enhanced Group enriched 25 heart muscle: 254.8;skeletal muscle: 650.4 prostate: 18.2 TREM1 CD354, TREM-1 ENSG00000124731 Triggering receptor expressed on myeloid cells 1 6 41267926-41286719 CD markers, Plasma proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA005563 Uncertain Tissue enhanced Tissue enhanced appendix: 68.9;bone marrow: 63.1;lung: 103.1 adipose tissue: 26.7 TREM2 TREM-2, Trem2a, Trem2b, Trem2c ENSG00000095970 Triggering receptor expressed on myeloid cells 2 6 41158506-41163186 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010917, HPA012571 Approved Supported Vesicles Liver cancer:4.24e-4 (unfavourable) Expressed in all Tissue enhanced cerebral cortex: 37.1;lung: 40.5 adrenal gland: 16.2 TREML1 dJ238O23.3, TLT1 ENSG00000161911 Triggering receptor expressed on myeloid cells-like 1 6 41149342-41154337 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA016700, HPA017860 Supported Mixed Tissue enhanced lymph node: 6.6 bone marrow: 5.0 TREML4 TLT4 ENSG00000188056 Triggering receptor expressed on myeloid cells-like 4 6 41228324-41238882 Predicted membrane proteins Evidence at transcript level HPA065044 Uncertain Not detected Not detected spleen: 0.5 TREX1 AGS1, DRN3 ENSG00000213689 Three prime repair exonuclease 1 3 48465811-48467645 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA035437 Supported Not detected Expressed in all spleen: 28.4 TRIB2 GS3955, TRB2 ENSG00000071575 Tribbles pseudokinase 2 2 12716889-12742734 Enzymes, Predicted membrane proteins Evidence at protein level HPA001305 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all ovary: 116.8 TRIM13 DLEU5, Leu5, RFP2, RNF77 ENSG00000204977 Tripartite motif containing 13 13 49995888-50020481 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000367 Approved Expressed in all Expressed in all testis: 140.9 TRIM5 RNF88, TRIM5alpha ENSG00000132256 Tripartite motif containing 5 11 5663557-5938619 Predicted intracellular proteins Evidence at protein level CAB013497, HPA023420, HPA023422 Approved Supported Cytosol Expressed in all Mixed breast: 39.9 TRIM55 MURF-2, RNF29 ENSG00000147573 Tripartite motif containing 55 8 66126896-66175487 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038793, HPA053691 Approved Approved Golgi apparatus
Cytosol Group enriched Tissue enhanced heart muscle: 41.4;liver: 19.8 testis: 13.1 TRIM59 Mrf1, RNF104, TRIM57, TSBF1 ENSG00000213186 Tripartite motif containing 59 3 160432445-160485773 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017750 Uncertain Approved Rods & Rings Pancreatic cancer:1.15e-5 (unfavourable), Cervical cancer:4.36e-4 (favourable) Mixed Mixed cerebral cortex: 18.4 TRIP12 KIAA0045 ENSG00000153827 Thyroid hormone receptor interactor 12 2 229763838-229923239 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA036835, HPA045893 Supported Approved Nuclear speckles Liver cancer:3.60e-4 (unfavourable) Expressed in all Expressed in all testis: 271.5 TRMT2B CXorf34, FLJ12687 ENSG00000188917 TRNA methyltransferase 2 homolog B X 101009346-101052116 Enzymes, Predicted intracellular proteins Evidence at protein level HPA003745, HPA035120, HPA040814 Uncertain Approved Nucleoplasm
Nuclear bodies Renal cancer:2.30e-7 (favourable), Breast cancer:1.58e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 21.0 TRPA1 ANKTM1 ENSG00000104321 Transient receptor potential cation channel, subfamily A, member 1 8 72019917-72075617 Disease related genes, FDA approved drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA026630 Uncertain Colorectal cancer:6.57e-4 (favourable) Mixed Tissue enhanced urinary bladder: 30.5 gallbladder: 11.4 TRPC1 HTRP-1 ENSG00000144935 Transient receptor potential cation channel, subfamily C, member 1 3 142724074-142807888 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level CAB009387, HPA021130 Supported Approved Vesicles Renal cancer:2.72e-5 (unfavourable) Mixed Mixed endometrium: 18.5 TRPC3 ENSG00000138741 Transient receptor potential cation channel, subfamily C, member 3 4 121879027-121951754 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA037969 Uncertain Not detected Tissue enhanced smooth muscle: 4.1 cerebral cortex: 2.1 TRPC4AP C20orf188, dJ756N5.2, DKFZp586C1223, DKFZP727M231, PPP1R158, TRRP4AP ENSG00000100991 Transient receptor potential cation channel, subfamily C, member 4 associated protein 20 35002404-35092871 Predicted intracellular proteins Evidence at protein level HPA051197, HPA065061 Uncertain Approved Cytosol Liver cancer:6.25e-8 (unfavourable), Renal cancer:1.17e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 71.2 TRPC6 FSGS2, TRP6 ENSG00000137672 Transient receptor potential cation channel, subfamily C, member 6 11 101451564-101872562 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA045098, HPA062164 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced placenta: 29.8 lung: 20.0 TRPC7 ENSG00000069018 Transient receptor potential cation channel, subfamily C, member 7 5 136213320-136365537 Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level CAB022592, HPA031126 Uncertain Uncertain Actin filaments
Focal adhesion sites Not detected Not detected testis: 0.7 TRPM1 CSNB1C, LTRPC1, MLSN1 ENSG00000134160 Transient receptor potential cation channel, subfamily M, member 1 15 31001061-31161273 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA014779, HPA014785 Approved Uncertain Nucleoplasm
Cytosol Tissue enriched Group enriched 27 skin: 4.8;testis: 2.5 kidney: 0.1 TRPM2 EREG1, KNP3, LTRPC2, NUDT9H, NUDT9L1, TRPC7 ENSG00000142185 Transient receptor potential cation channel, subfamily M, member 2 21 44350163-44443081 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA030976, HPA035260 Approved Approved Nuclear membrane Renal cancer:4.39e-6 (unfavourable), Urothelial cancer:7.59e-4 (favourable), Endometrial cancer:9.28e-4 (favourable) Expressed in all Mixed bone marrow: 18.9 TRPM4 FLJ20041 ENSG00000130529 Transient receptor potential cation channel, subfamily M, member 4 19 49157741-49211836 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA041169 Supported Supported Nucleoplasm
Plasma membrane Renal cancer:2.53e-7 (favourable), Endometrial cancer:2.88e-7 (favourable) Expressed in all Mixed colon: 27.5 TRPM5 LTRPC5, MTR1 ENSG00000070985 Transient receptor potential cation channel, subfamily M, member 5 11 2404515-2423045 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA042115, HPA043315 Approved Tissue enhanced Group enriched 5 colon: 1.0;duodenum: 3.0;epididymis: 2.2;seminal vesicle: 2.5;small intestine: 2.9 testis,thyroid gland: 0.4 TRPM7 CHAK1, LTRPC7, TRP-PLIK ENSG00000092439 Transient receptor potential cation channel, subfamily M, member 7 15 50552473-50686815 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA035523, HPA052173 Uncertain Approved Nucleoplasm Expressed in all Tissue enriched 7 parathyroid gland: 212.8 thyroid gland: 29.0 TRPV2 VRL, VRL-1, VRL1 ENSG00000187688 Transient receptor potential cation channel, subfamily V, member 2 17 16415542-16437003 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA044993 Uncertain Supported Plasma membrane Renal cancer:1.19e-6 (unfavourable), Testis cancer:5.53e-4 (unfavourable) Tissue enriched Mixed lung: 44.1 TRPV3 VRL3 ENSG00000167723 Transient receptor potential cation channel, subfamily V, member 3 17 3510502-3557995 Disease related genes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA069550 Approved Plasma membrane
Centrosome
Cytosol Mixed Tissue enhanced skin: 5.2;small intestine: 4.6 duodenum: 1.7 TRPV4 CMT2C, OTRPC4, TRP12, VR-OAC, VRL-2, VROAC ENSG00000111199 Transient receptor potential cation channel, subfamily V, member 4 12 109783085-109833401 Disease related genes, Potential drug targets, Predicted membrane proteins, Voltage-gated ion channels Evidence at protein level HPA007150 Uncertain Renal cancer:4.12e-5 (favourable), Ovarian cancer:8.10e-4 (unfavourable) Expressed in all Mixed kidney: 11.8 TRPV5 CaT2, ECAC1 ENSG00000127412 Transient receptor potential cation channel, subfamily V, member 5 7 142908101-142933808 Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA063175 Approved Not detected Not detected kidney: 0.5 TRPV6 CaT1, ECAC2 ENSG00000165125 Transient receptor potential cation channel, subfamily V, member 6 7 142871203-142885762 Predicted intracellular proteins, Predicted membrane proteins, Transporters, Voltage-gated ion channels Evidence at protein level HPA062864 Approved Tissue enriched Tissue enhanced prostate: 38.7;salivary gland: 29.3 placenta: 17.4 TRRAP PAF400, TR-AP, Tra1 ENSG00000196367 Transformation/transcription domain-associated protein 7 98877933-99013243 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054376 Supported Nucleoplasm
Golgi apparatus Liver cancer:8.77e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 22.2 TSC1 hamartin, KIAA0243, LAM, TSC ENSG00000165699 Tuberous sclerosis 1 9 132891348-132944633 Cancer-related genes, Disease related genes, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB011568, CAB012481, HPA074132 Supported Validated Cytosol Liver cancer:6.03e-6 (unfavourable), Renal cancer:7.91e-4 (favourable), Pancreatic cancer:8.01e-4 (favourable) Expressed in all Expressed in all testis: 34.3 TSC2 LAM, PPP1R160, TSC4, tuberin ENSG00000103197 Tuberous sclerosis 2 16 2047465-2088720 Cancer-related genes, Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB002225, HPA030409, HPA049679 Approved Validated Cytosol Pancreatic cancer:5.06e-4 (favourable) Expressed in all Expressed in all seminal vesicle: 35.7 TSHR LGR3 ENSG00000165409 Thyroid stimulating hormone receptor 14 80954989-81146302 Cancer-related genes, Disease related genes, FDA approved drug targets, G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB000473 Approved Tissue enriched Tissue enriched 277 thyroid gland: 443.8 lymph node: 1.6 TSNARE1 FLJ31164 ENSG00000171045 T-SNARE domain containing 1 8 142212080-142403240 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA015890 Approved Nucleus Urothelial cancer:7.33e-4 (favourable) Expressed in all Expressed in all skin: 29.2 TSPAN1 NET-1, TSPAN-1 ENSG00000117472 Tetraspanin 1 1 46175073-46185958 Predicted membrane proteins Evidence at protein level HPA011909 Approved Approved Nucleoplasm
Vesicles Renal cancer:9.28e-6 (favourable) Expressed in all Tissue enhanced colon: 534.2;rectum: 660.3 prostate: 315.2 TSPAN11 ENSG00000110900 Tetraspanin 11 12 30926428-30996599 Predicted membrane proteins Evidence at protein level HPA066789 Approved Vesicles Lung cancer:3.43e-4 (favourable), Head and neck cancer:5.28e-4 (favourable) Mixed Mixed cerebral cortex: 18.0 TSPAN12 NET-2, TM4SF12 ENSG00000106025 Tetraspanin 12 7 120787320-120858402 Disease related genes, Predicted membrane proteins Evidence at protein level HPA051570, HPA058244 Uncertain Approved Vesicles
Microtubules Expressed in all Mixed kidney: 90.9 TSPAN13 NET-6, TM4SF13 ENSG00000106537 Tetraspanin 13 7 16753535-16784536 Predicted membrane proteins Evidence at protein level HPA007426 Uncertain Approved Nucleus Glioma:5.27e-5 (unfavourable), Ovarian cancer:2.20e-4 (favourable), Renal cancer:2.43e-4 (unfavourable), Liver cancer:2.94e-4 (unfavourable) Expressed in all Expressed in all lung: 246.3 TSPAN14 DC-TM4F2, MGC11352, TM4SF14 ENSG00000108219 Tetraspanin 14 10 80454166-80533123 Predicted membrane proteins Evidence at protein level HPA014773, HPA057174 Uncertain Supported Vesicles Cervical cancer:3.56e-4 (favourable), Renal cancer:4.20e-4 (favourable) Expressed in all Expressed in all placenta: 128.3 TSPAN15 NET-7, TM4SF15 ENSG00000099282 Tetraspanin 15 10 69451473-69507669 Predicted membrane proteins Evidence at protein level HPA044657 Approved Approved Nucleoplasm
Cytosol Renal cancer:1.25e-4 (unfavourable), Liver cancer:8.00e-4 (unfavourable) Expressed in all Mixed stomach: 73.0 TSPAN16 TM-8, TM4-B, TM4SF16 ENSG00000130167 Tetraspanin 16 19 11296139-11326996 Predicted membrane proteins Evidence at protein level HPA041579 Approved Not detected Tissue enriched 32 testis: 153.1 bone marrow: 4.8 TSPAN17 FBX23, FBXO23, TM4SF17 ENSG00000048140 Tetraspanin 17 5 176647387-176659054 Predicted membrane proteins Evidence at transcript level HPA030447 Approved Nucleoplasm Expressed in all Expressed in all bone marrow: 34.8 TSPAN19 ENSG00000231738 Tetraspanin 19 12 85014311-85036277 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA057066 Uncertain Not detected Tissue enhanced testis: 8.3 lung: 4.6 TSPAN2 FLJ12082, TSN2, TSPAN-2 ENSG00000134198 Tetraspanin 2 1 115048011-115089500 Predicted membrane proteins Evidence at protein level HPA015640 Uncertain Approved Nucleoplasm Renal cancer:8.48e-7 (unfavourable), Endometrial cancer:8.89e-4 (unfavourable) Mixed Tissue enhanced endometrium: 71.2;smooth muscle: 64.0 seminal vesicle: 40.1 TSPAN3 TM4-A, TM4SF8, TSPAN-3 ENSG00000140391 Tetraspanin 3 15 77041404-77083984 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015996 Uncertain Approved Nucleoplasm
Golgi apparatus Expressed in all Expressed in all epididymis: 519.8 TSPAN31 SAS ENSG00000135452 Tetraspanin 31 12 57738013-57750211 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA057489 Approved Renal cancer:9.91e-5 (favourable), Head and neck cancer:1.09e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 73.1 TSPAN32 PHEMX, TSSC6 ENSG00000064201 Tetraspanin 32 11 2301997-2318200 Predicted membrane proteins Evidence at protein level HPA024135 Uncertain Mixed Tissue enhanced bone marrow: 12.0 heart muscle: 6.8 TSPAN33 MGC50844, Penumbra ENSG00000158457 Tetraspanin 33 7 129144892-129169697 Predicted membrane proteins, Transporters Evidence at protein level HPA020357 Approved Approved Microtubules Renal cancer:8.74e-5 (favourable), Pancreatic cancer:8.88e-4 (favourable) Expressed in all Expressed in all kidney: 126.4 TSPAN6 T245, TM4SF6, TSPAN-6 ENSG00000000003 Tetraspanin 6 X 100627109-100639991 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004109 Approved Approved Cytosol Expressed in all Mixed fallopian tube: 101.0 TSPAN7 A15, CD231, DXS1692E, MRX58, MXS1, TALLA-1, TM4SF2 ENSG00000156298 Tetraspanin 7 X 38561370-38688920 CD markers, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA003140, CAB062566, CAB068245 Supported Renal cancer:5.48e-7 (favourable), Pancreatic cancer:1.70e-4 (favourable), Endometrial cancer:3.40e-4 (unfavourable) Expressed in all Tissue enriched 6 cerebral cortex: 576.3 adrenal gland: 99.7 TSPAN8 CO-029, TM4SF3 ENSG00000127324 Tetraspanin 8 12 71125085-71441898 Cancer-related genes, Predicted membrane proteins Evidence at protein level CAB026009, HPA044337 Supported Approved Nucleoplasm Urothelial cancer:7.36e-5 (favourable), Renal cancer:9.66e-5 (unfavourable) Tissue enhanced Tissue enhanced colon: 926.1;duodenum: 931.2;rectum: 922.7;small intestine: 928.3 stomach: 574.1 TSPAN9 NET-5 ENSG00000011105 Tetraspanin 9 12 3077355-3286564 Predicted membrane proteins Evidence at protein level HPA014002 Uncertain Approved Nucleoplasm
Golgi apparatus
Cytosol Melanoma:4.67e-4 (unfavourable) Expressed in all Mixed heart muscle: 81.6 TSPO BZRP, DBI, IBP, MBR, mDRC, PBR, pk18, PKBS ENSG00000100300 Translocator protein (18kDa) 22 43151514-43163242 Cancer-related genes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB011232, HPA046260 Uncertain Approved Vesicles
Mitochondria
Cytosol Liver cancer:1.61e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 301.2 TSPO2 BZRPL1, dJ34B21.2 ENSG00000112212 Translocator protein 2 6 41042554-41044337 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA066996 Uncertain Mixed Tissue enriched 16 bone marrow: 30.9 placenta: 1.8 TSR3 C16orf42, MGC24381 ENSG00000007520 TSR3, 20S rRNA accumulation, homolog (S. cerevisiae) 16 1349240-1351911 Predicted intracellular proteins Evidence at protein level HPA040760, HPA046265 Uncertain Approved Golgi apparatus
Cytosol Expressed in all Expressed in all cerebral cortex: 36.8 TSSK1B FKSG81, SPOGA4, STK22D, TSSK1 ENSG00000212122 Testis-specific serine kinase 1B 5 113432554-113435031 Enzymes, Predicted membrane proteins Evidence at protein level HPA027827 Supported Not detected Tissue enriched 222 testis: 62.0 ovary,parathyroid gland,skin: 0.2 TSSK4 C14orf20, STK22E ENSG00000139908 Testis-specific serine kinase 4 14 24205697-24208362 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060660 Approved Cell Junctions Mixed Tissue enhanced testis: 42.8 parathyroid gland: 10.8 TTC3 DCRR1, RNF105, TPRD, TPRDI, TPRDII, TPRDIII ENSG00000182670 Tetratricopeptide repeat domain 3 21 37073226-37203112 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016810, HPA023964, HPA036304 Uncertain Approved Nucleus
Nucleoli
Cytosol Expressed in all Expressed in all thyroid gland: 107.0 TTC37 KIAA0372, THES ENSG00000198677 Tetratricopeptide repeat domain 37 5 95463895-95555007 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA037905 Approved Supported Nucleoplasm
Cytosol Colorectal cancer:2.62e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 80.8 TTC39A C1orf34, DEME-6, KIAA0452 ENSG00000085831 Tetratricopeptide repeat domain 39A 1 51287258-51345116 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA028098, HPA043440 Uncertain Approved Centrosome Liver cancer:5.05e-5 (unfavourable) Mixed Tissue enhanced testis: 87.2 breast: 58.0 TTC8 BBS8, RP51 ENSG00000165533 Tetratricopeptide repeat domain 8 14 88824153-88881078 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA003310 Uncertain Endometrial cancer:1.69e-5 (favourable), Renal cancer:4.89e-4 (favourable), Ovarian cancer:7.77e-4 (favourable) Expressed in all Expressed in all ovary: 90.7 TTI2 C8orf41, FLJ23263 ENSG00000129696 TELO2 interacting protein 2 8 33473386-33513601 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023523, HPA029823 Approved Validated Centrosome Expressed in all Mixed testis: 21.9 TTYH1 ENSG00000167614 Tweety family member 1 19 54415219-54436900 Predicted membrane proteins, Transporters Evidence at protein level HPA023617, HPA050655 Approved Breast cancer:3.64e-4 (favourable) Tissue enriched Tissue enriched 27 cerebral cortex: 57.9 testis: 2.1 TTYH3 KIAA1691 ENSG00000136295 Tweety family member 3 7 2631951-2664802 Predicted membrane proteins Evidence at protein level HPA053520 Uncertain Liver cancer:2.53e-5 (unfavourable), Renal cancer:2.58e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 62.4 TUBA8 TUBAL2 ENSG00000183785 Tubulin, alpha 8 22 18110331-18146554 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA043684, CAB046031, HPA063394 Approved Supported Microtubules Not detected Group enriched 6 cerebral cortex: 28.7;heart muscle: 85.0;skeletal muscle: 121.8;testis: 47.4 thyroid gland: 11.2 TUBD1 FLJ12709, TUBD ENSG00000108423 Tubulin, delta 1 17 59859482-59892945 FDA approved drug targets, Predicted intracellular proteins Evidence at protein level CAB004609, HPA023980, HPA027090 Approved Validated Nucleoplasm
Cytosol Liver cancer:1.00e-5 (unfavourable), Colorectal cancer:2.04e-4 (favourable), Renal cancer:6.06e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 12.7 TUBGCP6 DJ402G11.6, GCP6, KIAA1669 ENSG00000128159 Tubulin, gamma complex associated protein 6 22 50217689-50244992 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA043928 Approved Urothelial cancer:3.18e-5 (favourable), Pancreatic cancer:5.75e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 27.6 TUSC3 MGC13453, MRT7, N33, OST3A ENSG00000104723 Tumor suppressor candidate 3 8 15417215-15766649 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA049851, HPA049974 Approved Thyroid cancer:7.86e-4 (favourable) Expressed in all Mixed epididymis: 140.7 TUSC5 IFITMD3, LOST1 ENSG00000184811 Tumor suppressor candidate 5 17 1279663-1300987 Predicted membrane proteins Evidence at protein level HPA050825 Approved Tissue enhanced Tissue enriched 18 adipose tissue: 109.9 breast: 6.0 TVP23A FAM18A, YDR084C ENSG00000166676 Trans-golgi network vesicle protein 23 homolog A (S. cerevisiae) 16 10760919-10818794 Predicted membrane proteins Evidence at transcript level HPA060582 Uncertain Approved Vesicles Tissue enhanced Tissue enhanced cerebral cortex: 6.3 ovary: 3.2 TVP23B CGI-148, FAM18B, FAM18B1, YDR084C ENSG00000171928 Trans-golgi network vesicle protein 23 homolog B (S. cerevisiae) 17 18780995-18806714 Predicted membrane proteins Evidence at protein level HPA019585, HPA065603 Uncertain Approved Golgi apparatus Expressed in all Expressed in all thyroid gland: 78.3 TVP23C FAM18B2, MGC8763 ENSG00000175106 Trans-golgi network vesicle protein 23 homolog C (S. cerevisiae) 17 15502264-15563595 Predicted membrane proteins Evidence at protein level HPA019585, HPA065603 Uncertain Validated Golgi apparatus Mixed Mixed thyroid gland: 10.3 TVP23C-CDRT4 FAM18B2-CDRT4 ENSG00000259024 TVP23C-CDRT4 readthrough 17 15436021-15563561 Predicted membrane proteins Evidence at transcript level HPA065603 Approved Golgi apparatus Not detected Mixed parathyroid gland: 11.6 TXNDC11 EFP1 ENSG00000153066 Thioredoxin domain containing 11 16 11679080-11742878 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA041174, HPA041390 Supported Supported Plasma membrane
Cytosol Endometrial cancer:2.12e-5 (favourable), Glioma:8.01e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 83.0 TXNDC15 2310047H23Rik, C5orf14, FLJ22625 ENSG00000113621 Thioredoxin domain containing 15 5 134873803-134901525 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA015483 Approved Approved Golgi apparatus Renal cancer:1.44e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 83.7 TXNDC16 KIAA1344 ENSG00000087301 Thioredoxin domain containing 16 14 52430590-52552522 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA002543 Approved Approved Mitochondria Renal cancer:6.79e-4 (favourable) Expressed in all Tissue enhanced prostate: 41.9 seminal vesicle: 18.2 TXNL4A DIB1, DIM1, HsT161, SNRNP15, TXNL4, U5-15kD ENSG00000141759 Thioredoxin-like 4A 18 79970811-80033949 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA041324 Approved Nucleus
Nuclear membrane
Cytosol Liver cancer:3.38e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 82.7 TYR OCA1, OCA1A, OCAIA ENSG00000077498 Tyrosinase 11 89177452-89295759 Disease related genes, Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level CAB000079, HPA043241, HPA050889 Supported Validated Vesicles Tissue enriched Tissue enriched 33 skin: 29.9 breast: 0.9 TYRO3 Brt, Dtk, Etk-2, Rek, RSE, Sky, Tif ENSG00000092445 TYRO3 protein tyrosine kinase 15 41557675-41583586 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA071245 Approved Expressed in all Tissue enhanced cerebral cortex: 67.6;ovary: 61.4 testis: 36.9 TYROBP DAP12, KARAP, PLO-SL, PLOSL ENSG00000011600 TYRO protein tyrosine kinase binding protein 19 35904401-35908295 Disease related genes, Predicted membrane proteins Evidence at protein level CAB009493, HPA041899 Supported Renal cancer:1.05e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 387.8 TYRP1 b-PROTEIN, CAS2, CATB, GP75, OCA3, TRP, TYRP ENSG00000107165 Tyrosinase-related protein 1 9 12685439-12710290 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA000937, CAB002520 Supported Supported Vesicles Tissue enriched Group enriched 6 heart muscle: 35.6;skin: 169.5 kidney: 16.9 TYW1 FLJ10900, MGC23001, MGC60291, RSAFD1, TYW1A, YPL207W ENSG00000198874 TRNA-yW synthesizing protein 1 homolog (S. cerevisiae) 7 66995173-67239519 Enzymes, Predicted membrane proteins Evidence at protein level HPA013568, HPA014118, HPA015535, HPA043136, HPA047029, HPA047052, HPA052097 Approved Approved Nucleus
Nucleoli Ovarian cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 22.9 TYW1B LINC00069, MGC87315, NCRNA00069, RSAFD2 ENSG00000277149 TRNA-yW synthesizing protein 1 homolog B (S. cerevisiae) 7 72558744-72828198 Predicted membrane proteins Evidence at protein level HPA013568, HPA014118, HPA043136, HPA047029, HPA047052, HPA052097 Approved Approved Nucleus
Nucleoli Expressed in all Mixed ovary: 6.7 UBA1 A1S9T, CFAP124, GXP1, POC20, UBE1, UBE1X ENSG00000130985 Ubiquitin-like modifier activating enzyme 1 X 47190861-47215128 Cancer-related genes, Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000289, HPA001506, CAB019435, CAB073410 Approved Validated Nucleoplasm Liver cancer:6.10e-5 (unfavourable), Thyroid cancer:1.78e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 235.0 UBA7 D8, UBA1B, UBE1L, UBE2 ENSG00000182179 Ubiquitin-like modifier activating enzyme 7 3 49805207-49813946 Plasma proteins, Predicted membrane proteins Evidence at protein level CAB015444, HPA058182 Approved Approved Nucleoplasm
Vesicles
Cytosol Renal cancer:1.04e-5 (unfavourable), Urothelial cancer:1.48e-4 (favourable), Breast cancer:1.55e-4 (favourable) Expressed in all Expressed in all spleen: 66.5 UBAC2 FLJ30548, PHGDHL1, RP11-178C10.1 ENSG00000134882 UBA domain containing 2 13 99200774-99386434 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA013448 Approved Approved Cytosol Pancreatic cancer:1.73e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 35.6 UBE2J1 CGI-76, HSPC153, NCUBE1, UBC6 ENSG00000198833 Ubiquitin-conjugating enzyme E2, J1 6 89326625-89352848 Enzymes, Predicted membrane proteins Evidence at protein level HPA003509, CAB073419 Supported Liver cancer:6.90e-5 (unfavourable), Renal cancer:1.11e-4 (unfavourable), Endometrial cancer:2.87e-4 (favourable), Ovarian cancer:7.43e-4 (favourable) Expressed in all Expressed in all lymph node: 103.6 UBE2N MGC8489, UBC13, UbcH-ben ENSG00000177889 Ubiquitin-conjugating enzyme E2N 12 93405673-93442262 Cancer-related genes, Enzymes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA044976 Approved Supported Nucleus
Nucleoli fibrillar center Liver cancer:2.41e-4 (unfavourable) Expressed in all Expressed in all testis: 252.8 UBE3A ANCR, AS, E6-AP, EPVE6AP, FLJ26981, HPVE6A ENSG00000114062 Ubiquitin protein ligase E3A 15 25333728-25439056 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009723, HPA039410, HPA040380 Approved Approved Nucleoplasm
Cytosol Expressed in all Expressed in all testis: 88.7 UBIAD1 SCCD, TERE1 ENSG00000120942 UbiA prenyltransferase domain containing 1 1 11273206-11296049 Disease related genes, Predicted membrane proteins Evidence at protein level HPA044862 Approved Vesicles Renal cancer:6.80e-5 (favourable) Expressed in all Expressed in all fallopian tube: 15.7 UBR1 ENSG00000159459 Ubiquitin protein ligase E3 component n-recognin 1 15 42942897-43106113 Disease related genes, Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA038838 Approved Approved Nucleoplasm
Vesicles Expressed in all Expressed in all parathyroid gland: 26.9 UBR3 DKFZp434P117, FLJ37422, KIAA2024, ZNF650 ENSG00000144357 Ubiquitin protein ligase E3 component n-recognin 3 (putative) 2 169827458-170084131 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA035390 Approved Approved Nucleus
Nucleoli Expressed in all Expressed in all parathyroid gland: 38.9 UBR4 KIAA0462, KIAA1307, RBAF600, ZUBR1 ENSG00000127481 Ubiquitin protein ligase E3 component n-recognin 4 1 19074506-19210276 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013394, HPA021046 Approved Supported Nucleoplasm
Centrosome
Cytosol Expressed in all Expressed in all skin: 90.6 UBXN4 KIAA0242, UBXD2, UBXDC1 ENSG00000144224 UBX domain protein 4 2 135741619-135785055 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036325 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all thyroid gland: 104.6 UBXN8 D8S2298E, REP8, UBXD6 ENSG00000104691 UBX domain protein 8 8 30732247-30767006 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017725, HPA077538 Approved Supported Nucleoli
Endoplasmic reticulum Renal cancer:5.25e-5 (unfavourable), Colorectal cancer:6.13e-4 (favourable) Expressed in all Expressed in all ovary: 109.4 UGCG GCS ENSG00000148154 UDP-glucose ceramide glucosyltransferase 9 111896766-111935369 Enzymes, FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA024124 Approved Endometrial cancer:4.44e-5 (favourable), Cervical cancer:6.62e-4 (favourable) Expressed in all Expressed in all adrenal gland: 84.4 UGGT1 HUGT1, UGCGL1 ENSG00000136731 UDP-glucose glycoprotein glucosyltransferase 1 2 128091200-128195677 Plasma proteins, Predicted intracellular proteins Evidence at protein level HPA012761, HPA015127 Supported Uncertain Cytosol Renal cancer:6.37e-4 (unfavourable) Expressed in all Expressed in all epididymis: 23.8 UGT1A6 GNT1, HLUGP, UGT1F ENSG00000167165 UDP glucuronosyltransferase 1 family, polypeptide A6 2 233691607-233773300 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB009819, HPA054065 Supported Liver cancer:2.89e-6 (unfavourable) Tissue enhanced Group enriched 6 kidney: 74.7;liver: 71.9;urinary bladder: 112.0 esophagus: 15.2 UGT2A1 ENSG00000173610 UDP glucuronosyltransferase 2 family, polypeptide A1, complex locus 4 69588417-69653249 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA017261, HPA045108 Uncertain Tissue enhanced Group enriched 7 kidney: 8.1;liver: 5.5 skin: 0.9 UGT2A2 ENSG00000271271 UDP glucuronosyltransferase 2 family, polypeptide A2 4 69589309-69639642 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Uncertain Not detected Not detected cervix, uterine,skin: 0.2 UGT2A3 FLJ21934 ENSG00000135220 UDP glucuronosyltransferase 2 family, polypeptide A3 4 68928463-68951791 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Supported Renal cancer:6.07e-7 (favourable), Colorectal cancer:3.31e-4 (favourable) Tissue enriched Tissue enhanced duodenum: 84.3;gallbladder: 46.5;kidney: 46.4;small intestine: 87.8 rectum: 24.3 UGT2B10 ENSG00000109181 UDP glucuronosyltransferase 2 family, polypeptide B10 4 68815993-68831196 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Uncertain Tissue enriched Tissue enriched 87 liver: 303.2 gallbladder: 3.4 UGT2B11 ENSG00000213759 UDP glucuronosyltransferase 2 family, polypeptide B11 4 69004618-69214731 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA045108 Uncertain Group enriched Tissue enriched 16 breast: 314.2 gallbladder: 19.0 UGT2B15 UGT2B8 ENSG00000196620 UDP glucuronosyltransferase 2 family, polypeptide B15 4 68537413-68670628 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Approved Urothelial cancer:4.50e-4 (favourable), Liver cancer:9.82e-4 (favourable) Tissue enriched Group enriched 6 colon: 23.8;duodenum: 30.6;gallbladder: 114.5;liver: 108.6;small intestine: 33.9 stomach: 10.2 UGT2B17 ENSG00000197888 UDP glucuronosyltransferase 2 family, polypeptide B17 4 68537184-68568527 Enzymes, Predicted membrane proteins Evidence at protein level HPA045108 Supported Group enriched Tissue enhanced colon: 378.9;duodenum: 381.0;small intestine: 532.1 rectum: 153.4 UGT2B28 ENSG00000135226 UDP glucuronosyltransferase 2 family, polypeptide B28 4 69280487-69423402 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045108 Uncertain Tissue enriched Tissue enriched 12 breast: 268.9 gallbladder: 21.7 UGT2B4 UGT2B11 ENSG00000156096 UDP glucuronosyltransferase 2 family, polypeptide B4 4 69480165-69526014 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB033260, HPA045108 Supported Tissue enriched Tissue enriched 71 liver: 652.2 heart muscle: 9.2 UGT2B7 UGT2B9 ENSG00000171234 UDP glucuronosyltransferase 2 family, polypeptide B7 4 69051363-69112987 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA045108 Uncertain Colorectal cancer:7.65e-5 (favourable), Renal cancer:3.79e-4 (favourable), Urothelial cancer:5.38e-4 (favourable) Group enriched Group enriched 14 kidney: 1315.4;liver: 823.8 fallopian tube: 79.1 UGT3A1 FLJ34658 ENSG00000145626 UDP glycosyltransferase 3 family, polypeptide A1 5 35951010-36001028 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA047697, HPA056290 Uncertain Approved Vesicles
Cytosol Group enriched Tissue enhanced kidney: 52.9;liver: 29.1 duodenum: 9.7 UGT3A2 ENSG00000168671 UDP glycosyltransferase 3 family, polypeptide A2 5 36035017-36071358 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA059475 Uncertain Approved Nucleus
Cytosol Tissue enriched Tissue enhanced skin: 11.9;testis: 4.6 bone marrow: 3.3 UGT8 CGT ENSG00000174607 UDP glycosyltransferase 8 4 114598455-114678224 Enzymes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014405, HPA065785 Approved Approved Mitochondria Renal cancer:8.55e-5 (favourable) Mixed Tissue enhanced cerebral cortex: 101.6 kidney: 29.8 ULBP1 RAET1I ENSG00000111981 UL16 binding protein 1 6 149964007-149973710 Predicted membrane proteins Evidence at protein level HPA007547, HPA071005 Supported Approved Plasma membrane
Actin filaments
Cytosol Mixed Tissue enhanced testis: 11.0 thyroid gland: 3.5 ULBP2 RAET1H ENSG00000131015 UL16 binding protein 2 6 149942000-149949235 Predicted membrane proteins Evidence at protein level CAB018974 Approved Supported Vesicles
Plasma membrane Glioma:3.69e-4 (unfavourable), Cervical cancer:8.07e-4 (unfavourable) Expressed in all Mixed cerebral cortex,esophagus: 3.0 ULK4 FAM7C1, FLJ20574, REC01035 ENSG00000168038 Unc-51 like kinase 4 3 41246599-41962430 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017930 Uncertain Approved Nucleoplasm
Mitochondria
Cytosol Mixed Tissue enhanced testis: 37.9 parathyroid gland: 14.2 UMOD ENSG00000169344 Uromodulin 16 20333052-20356301 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB009446, HPA043420, HPA054721 Supported Tissue enriched Tissue enriched 718 kidney: 2377.1 cerebral cortex: 3.3 UMODL1 ENSG00000177398 Uromodulin-like 1 21 42062959-42143453 Predicted membrane proteins Evidence at protein level HPA067245 Uncertain Group enriched Group enriched 7 fallopian tube: 1.9;testis: 1.7 small intestine: 0.2 UNC50 GMH1, UNCL, URP ENSG00000115446 Unc-50 homolog (C. elegans) 2 98608579-98618515 Predicted membrane proteins Evidence at protein level HPA027009 Approved Liver cancer:4.89e-5 (unfavourable), Breast cancer:4.79e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 105.7 UNC5A KIAA1976, UNC5H1 ENSG00000113763 Unc-5 netrin receptor A 5 176810477-176880895 Predicted membrane proteins Evidence at protein level HPA071450 Approved Plasma membrane
Cytosol Endometrial cancer:2.23e-4 (unfavourable) Tissue enhanced Group enriched 22 adrenal gland: 10.4;cerebral cortex: 35.5 lymph node: 1.0 UNC5CL MGC34763, ZUD ENSG00000124602 Unc-5 family C-terminal like 6 41026911-41039217 Predicted intracellular proteins Evidence at protein level HPA015725 Supported Approved Centrosome Mixed Tissue enhanced duodenum: 38.3;small intestine: 33.1;stomach: 24.0 kidney: 14.9 UNC5D KIAA1777, Unc5h4 ENSG00000156687 Unc-5 netrin receptor D 8 35235457-35796550 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA042940 Uncertain Tissue enhanced Tissue enhanced cerebral cortex: 9.2;duodenum: 6.2;prostate: 9.0 cervix, uterine: 3.4 UNC93A dJ366N23.1, dJ366N23.2 ENSG00000112494 Unc-93 homolog A (C. elegans) 6 167271169-167316019 Predicted membrane proteins Evidence at protein level HPA035729 Uncertain Tissue enhanced Tissue enhanced duodenum: 9.9;skin: 17.9 liver: 7.1 UNC93B1 UNC93 ENSG00000110057 Unc-93 homolog B1 (C. elegans) 11 67991104-68004982 Disease related genes, Predicted membrane proteins Evidence at protein level HPA038716, HPA038717, HPA042803 Approved Approved Nucleoplasm Pancreatic cancer:1.73e-4 (unfavourable), Renal cancer:7.38e-4 (unfavourable) Expressed in all Mixed spleen: 56.6 UPK1A TSPAN21 ENSG00000105668 Uroplakin 1A 19 35666516-35678483 Predicted membrane proteins Evidence at protein level HPA049879 Supported Tissue enriched Tissue enhanced esophagus: 27.0;urinary bladder: 112.9 skin: 15.6 UPK1B TSPAN20, UPK1 ENSG00000114638 Uroplakin 1B 3 119173517-119205153 Predicted membrane proteins Evidence at protein level HPA031799, HPA031800 Supported Endometrial cancer:3.87e-5 (favourable), Stomach cancer:7.76e-4 (unfavourable) Tissue enhanced Tissue enhanced stomach: 33.2;urinary bladder: 37.5 tonsil: 16.0 UPK2 MGC138598, UP2, UPII ENSG00000110375 Uroplakin 2 11 118925164-118958559 Predicted membrane proteins Evidence at protein level HPA043312, HPA061106 Supported Renal cancer:7.30e-7 (unfavourable), Lung cancer:9.57e-4 (unfavourable) Tissue enriched Tissue enriched 46 urinary bladder: 71.3 adipose tissue: 1.5 UPK3A UPK3 ENSG00000100373 Uroplakin 3A 22 45284982-45295874 Disease related genes, Predicted membrane proteins Evidence at protein level HPA018407, HPA018415 Supported Uncertain Nuclear membrane
Nuclear bodies Group enriched Group enriched 7 parathyroid gland: 12.8;prostate: 33.5;skeletal muscle: 12.6;urinary bladder: 16.0 thyroid gland: 2.6 UPK3B FLJ32198, MGC10902, p35, UPIIIb ENSG00000243566 Uroplakin 3B 7 76510428-76516521 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA010506 Approved Approved Nucleus
Vesicles
Cytosol Group enriched Group enriched 10 esophagus: 12.4;lung: 29.9;urinary bladder: 11.4 tonsil: 1.7 UPK3BL UPLP ENSG00000267368 Uroplakin 3B-like 7 102637025-102642791 Predicted membrane proteins Evidence at protein level HPA011403 Supported Mixed Expressed in all esophagus: 139.3 UQCC1 BFZB, C20orf44, CBP3, FLJ10850, UQCC ENSG00000101019 Ubiquinol-cytochrome c reductase complex assembly factor 1 20 35302566-35412141 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA034875 Approved Approved Nucleoplasm
Plasma membrane
Actin filaments Expressed in all Expressed in all parathyroid gland: 42.6 UQCC3 C11orf83, UNQ655 ENSG00000204922 Ubiquinol-cytochrome c reductase complex assembly factor 3 11 62670273-62673687 Disease related genes, Predicted membrane proteins Evidence at protein level HPA046851 Approved Approved Nucleoplasm
Mitochondria
Cytosol Liver cancer:2.55e-4 (unfavourable) Expressed in all Expressed in all duodenum,small intestine: 8.2 UQCRQ QCR8, QP-C, UQCR7 ENSG00000164405 Ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5kDa 5 132866560-132868031 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA046693, HPA053323 Approved Validated Mitochondria Endometrial cancer:4.23e-4 (favourable) Expressed in all Expressed in all skeletal muscle: 376.1 URGCP DKFZp666G166, DKFZp686O0457, FLJ20654, KIAA1507, URG4 ENSG00000106608 Upregulator of cell proliferation 7 43875894-43926411 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019879, HPA020134, HPA029468 Approved Supported Cytosol Renal cancer:1.90e-4 (favourable) Expressed in all Expressed in all parathyroid gland: 33.8 USE1 D12, MDS032, p31, SLT1 ENSG00000053501 Unconventional SNARE in the ER 1 homolog (S. cerevisiae) 19 17215346-17219829 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026851, HPA047562 Approved Renal cancer:3.59e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 42.1 USMG5 bA792D24.4, DAPIT, MGC14697 ENSG00000173915 Up-regulated during skeletal muscle growth 5 homolog (mouse) 10 103389041-103396466 Predicted membrane proteins Evidence at protein level HPA044798 Supported Mitochondria Expressed in all Expressed in all heart muscle: 547.4 USP30 FLJ40511, MGC10702 ENSG00000135093 Ubiquitin specific peptidase 30 12 109023089-109088026 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016952 Approved Renal cancer:5.23e-6 (favourable) Expressed in all Expressed in all testis: 25.5 UST 2OST ENSG00000111962 Uronyl-2-sulfotransferase 6 148747328-149076990 Predicted membrane proteins Evidence at protein level HPA032022 Approved Approved Mitochondria Expressed in all Tissue enhanced thyroid gland: 49.6 adrenal gland: 17.0 UTP23 C8orf53, MGC14595 ENSG00000147679 UTP23, small subunit (SSU) processome component, homolog (yeast) 8 116766503-116849463 Predicted intracellular proteins Evidence at protein level HPA044418 Uncertain Approved Nucleoli Breast cancer:5.18e-5 (unfavourable) Expressed in all Expressed in all bone marrow: 21.3 VAMP1 SYB1, VAMP-1 ENSG00000139190 Vesicle-associated membrane protein 1 (synaptobrevin 1) 12 6462237-6470987 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB002779, CAB016119 Approved Renal cancer:1.04e-11 (unfavourable), Colorectal cancer:6.37e-5 (unfavourable), Liver cancer:6.97e-4 (unfavourable) Expressed in all Mixed cerebral cortex: 43.6 VAMP2 SYB2, VAMP-2 ENSG00000220205 Vesicle-associated membrane protein 2 (synaptobrevin 2) 17 8159149-8163546 FDA approved drug targets, Predicted membrane proteins, Transporters Evidence at protein level CAB078785 Supported Renal cancer:9.76e-8 (favourable), Pancreatic cancer:3.83e-6 (favourable), Endometrial cancer:1.08e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 485.0 VAMP4 ENSG00000117533 Vesicle-associated membrane protein 4 1 171700160-171742247 Predicted membrane proteins Evidence at protein level HPA050418 Supported Approved Golgi apparatus Renal cancer:5.43e-6 (unfavourable) Expressed in all Expressed in all cerebral cortex: 22.4 VAMP5 ENSG00000168899 Vesicle-associated membrane protein 5 2 85584408-85593412 Predicted membrane proteins Evidence at protein level HPA035082 Supported Approved Nucleoplasm
Plasma membrane Renal cancer:1.28e-5 (unfavourable) Expressed in all Expressed in all lung: 120.0 VAMP7 SYBL1, TI-VAMP, VAMP-7 ENSG00000124333 Vesicle-associated membrane protein 7 X 155881293-155943769 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036733 Approved Supported Vesicles Renal cancer:2.83e-4 (favourable) Expressed in all Expressed in all placenta: 56.8 VAMP8 EDB ENSG00000118640 Vesicle-associated membrane protein 8 2 85561562-85582031 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA006882, CAB037132, CAB037147 Supported Thyroid cancer:8.07e-9 (favourable), Urothelial cancer:1.59e-6 (favourable) Expressed in all Expressed in all lung: 328.4 VANGL1 STB2 ENSG00000173218 VANGL planar cell polarity protein 1 1 115641953-115698224 Disease related genes, Predicted membrane proteins Evidence at protein level HPA025235, CAB076375 Approved Approved Plasma membrane Colorectal cancer:7.53e-4 (favourable), Pancreatic cancer:7.89e-4 (unfavourable) Expressed in all Mixed fallopian tube: 19.2 VANGL2 KIAA1215, LPP1, LTAP, MGC119403, MGC119404, STB1, STBM, STBM1 ENSG00000162738 VANGL planar cell polarity protein 2 1 160400586-160428678 Disease related genes, Predicted membrane proteins Evidence at protein level HPA027043 Uncertain Expressed in all Tissue enhanced skin: 44.8 cerebral cortex: 18.2 VAPA hVAP-33, VAP-A ENSG00000101558 VAMP (vesicle-associated membrane protein)-associated protein A, 33kDa 18 9914002-9960021 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA009174 Approved Validated Endoplasmic reticulum Renal cancer:5.72e-7 (favourable) Expressed in all Expressed in all adrenal gland: 61.6 VAPB ALS8, VAP-B, VAP-C ENSG00000124164 VAMP (vesicle-associated membrane protein)-associated protein B and C 20 58389122-58451101 Disease related genes, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA013144, CAB013722 Supported Validated Endoplasmic reticulum Renal cancer:1.08e-8 (favourable) Expressed in all Expressed in all cerebral cortex: 42.5 VASN SLITL2 ENSG00000168140 Vasorin 16 4371848-4383528 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA011246 Uncertain Endometrial cancer:6.24e-5 (unfavourable) Expressed in all Mixed placenta: 16.0 VCAM1 CD106 ENSG00000162692 Vascular cell adhesion molecule 1 1 100719742-100739045 Cancer-related genes, CD markers, Plasma proteins, Predicted membrane proteins Evidence at protein level CAB000154, HPA034796, HPA069867 Supported Approved Cell Junctions Head and neck cancer:7.19e-5 (favourable), Cervical cancer:3.82e-4 (favourable) Tissue enriched Tissue enriched 5 spleen: 557.0 lymph node: 111.2 VEZT DKFZP761C241 ENSG00000028203 Vezatin, adherens junctions transmembrane protein 12 95217746-95302790 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA004811, HPA017066 Approved Supported Nucleoplasm
Cytosol Renal cancer:1.93e-5 (unfavourable), Liver cancer:1.71e-4 (unfavourable), Stomach cancer:3.68e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 31.2 VIMP AD-015, MGC2553, SBBI8, SELS, SEPS1 ENSG00000131871 VCP-interacting membrane selenoprotein 15 101270817-101277500 Predicted membrane proteins Evidence at protein level HPA010025 Approved Validated Endoplasmic reticulum Endometrial cancer:1.33e-4 (favourable), Ovarian cancer:5.19e-4 (favourable) Expressed in all Expressed in all testis: 141.3 VIPR1 HVR1, RDC1, VPAC1, VPAC1R ENSG00000114812 Vasoactive intestinal peptide receptor 1 3 42489299-42537573 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at protein level HPA026777 Approved Tissue enhanced Tissue enhanced lung: 60.0 duodenum: 35.4 VIPR2 VPAC2, VPAC2R ENSG00000106018 Vasoactive intestinal peptide receptor 2 7 159028175-159144957 G-protein coupled receptors, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA062707 Approved Tissue enhanced Tissue enhanced seminal vesicle: 28.2 epididymis: 14.8 VKORC1 VKCFD2 ENSG00000167397 Vitamin K epoxide reductase complex, subunit 1 16 31090842-31095980 Disease related genes, Enzymes, FDA approved drug targets, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA042720 Approved Renal cancer:2.09e-10 (unfavourable) Expressed in all Expressed in all liver: 141.1 VKORC1L1 ENSG00000196715 Vitamin K epoxide reductase complex, subunit 1-like 1 7 65873267-65959563 Enzymes, FDA approved drug targets, Predicted membrane proteins Evidence at protein level HPA053954 Approved Supported Endoplasmic reticulum Expressed in all Expressed in all adipose tissue: 57.3 VLDLR CARMQ1, CHRMQ1, VLDLRCH ENSG00000147852 Very low density lipoprotein receptor 9 2621834-2660053 Disease related genes, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level CAB032462, HPA051312 Uncertain Approved Vesicles
Cytokinetic bridge
Microtubule organizing center Endometrial cancer:5.95e-4 (favourable) Expressed in all Tissue enhanced ovary: 109.9;parathyroid gland: 123.5 heart muscle: 44.5 VMA21 MEAX, XMEA ENSG00000160131 VMA21 vacuolar H+-ATPase homolog (S. cerevisiae) X 151396515-151409364 Disease related genes, Predicted membrane proteins Evidence at protein level HPA010972 Uncertain Cervical cancer:2.30e-5 (favourable) Expressed in all Expressed in all cerebral cortex: 30.1 VMP1 EPG3, TANGO5, TMEM49 ENSG00000062716 Vacuole membrane protein 1 17 59707192-59842255 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA030773, HPA064780 Uncertain Approved Nucleoli
Endoplasmic reticulum Renal cancer:2.77e-8 (unfavourable), Endometrial cancer:1.56e-5 (unfavourable), Liver cancer:8.02e-4 (unfavourable) Expressed in all Expressed in all spleen: 64.7 VN1R1 V1RL1, VNR19I1, ZVNH1, ZVNR1 ENSG00000178201 Vomeronasal 1 receptor 1 19 57454790-57457142 G-protein coupled receptors, Predicted membrane proteins, Transporters Evidence at transcript level HPA062209 Uncertain Nucleus
Vesicles Mixed Mixed epididymis: 2.8 VN1R2 V1RL2 ENSG00000196131 Vomeronasal 1 receptor 2 19 53258292-53261837 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA044551 Uncertain Not detected Mixed small intestine: 2.5 VN1R4 V1RL4 ENSG00000228567 Vomeronasal 1 receptor 4 19 53266676-53267723 G-protein coupled receptors, Predicted membrane proteins Evidence at transcript level HPA027018 Uncertain Not detected Not detected testis: 0.5 VPS33A ENSG00000139719 Vacuolar protein sorting 33 homolog A (S. cerevisiae) 12 122229564-122266521 Predicted intracellular proteins Evidence at protein level HPA038701 Approved Nucleoplasm Liver cancer:9.11e-5 (unfavourable), Thyroid cancer:2.41e-4 (favourable), Renal cancer:5.29e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 13.7 VPS33B FLJ14848 ENSG00000184056 Vacuolar protein sorting 33 homolog B (yeast) 15 90998416-91022603 Disease related genes, Predicted intracellular proteins Evidence at protein level HPA040415 Approved Expressed in all Expressed in all cerebral cortex: 16.2 VRK1 ENSG00000100749 Vaccinia related kinase 1 14 96797304-96931722 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA000660, HPA017929 Approved Supported Nucleus
Cytosol Liver cancer:4.15e-4 (unfavourable) Expressed in all Mixed testis: 59.5 VRK2 ENSG00000028116 Vaccinia related kinase 2 2 57907651-58159920 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB046459, HPA047503 Approved Supported Endoplasmic reticulum Liver cancer:6.32e-6 (unfavourable), Renal cancer:4.66e-5 (unfavourable), Pancreatic cancer:4.65e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 29.2 VSIG1 MGC44287 ENSG00000101842 V-set and immunoglobulin domain containing 1 X 108044970-108079184 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA001445, HPA036310, HPA036311 Supported Approved Vesicles
Cytosol Group enriched Group enriched 10 stomach: 187.2;testis: 90.9 gallbladder: 14.3 VSIG10 ENSG00000176834 V-set and immunoglobulin domain containing 10 12 118063593-118136026 Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA014526 Approved Cytosol Liver cancer:1.76e-4 (unfavourable), Melanoma:7.53e-4 (unfavourable) Expressed in all Mixed small intestine: 28.3 VSIG10L ENSG00000186806 V-set and immunoglobulin domain containing 10 like 19 51331536-51342124 Predicted membrane proteins Evidence at protein level HPA060453, HPA066745 Uncertain Validated Nucleus Liver cancer:8.75e-4 (unfavourable) Expressed in all Tissue enhanced esophagus: 31.5;salivary gland: 9.3 tonsil: 6.0 VSIG2 CTH, CTXL ENSG00000019102 V-set and immunoglobulin domain containing 2 11 124747472-124752238 Predicted membrane proteins Evidence at protein level HPA035919, HPA050147 Supported Approved Nucleoplasm Mixed Tissue enhanced stomach: 582.1 rectum: 153.8 VSIG4 Z39IG ENSG00000155659 V-set and immunoglobulin domain containing 4 X 66021738-66040125 Plasma proteins, Predicted membrane proteins Evidence at protein level HPA003903, CAB026000 Approved Uncertain Nucleoli
Plasma membrane
Cytosol Renal cancer:1.95e-6 (unfavourable), Colorectal cancer:1.34e-4 (unfavourable) Expressed in all Expressed in all lung: 243.3 VSIG8 ENSG00000243284 V-set and immunoglobulin domain containing 8 1 159854316-159862657 Predicted membrane proteins Evidence at protein level HPA023219 Uncertain Group enriched Tissue enhanced skin: 13.6;tonsil: 6.1 fallopian tube: 2.1 VSTM1 UNQ3033 ENSG00000189068 V-set and transmembrane domain containing 1 19 54040825-54063953 Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins Evidence at protein level HPA059365 Approved Vesicles Mixed Tissue enriched 37 bone marrow: 35.4 urinary bladder: 0.9 VSTM4 C10orf72, FLJ31737 ENSG00000165633 V-set and transmembrane domain containing 4 10 49014245-49115509 Predicted membrane proteins, Predicted secreted proteins Evidence at transcript level HPA017279 Uncertain Approved Nucleus
Vesicles Urothelial cancer:4.25e-4 (unfavourable) Tissue enriched Mixed adrenal gland: 55.1 VSTM5 C11orf90, LOC387804 ENSG00000214376 V-set and transmembrane domain containing 5 11 93818232-93850531 Predicted membrane proteins Evidence at transcript level HPA029525 Uncertain Uncertain Endoplasmic reticulum Mixed Tissue enhanced placenta: 6.5 cerebral cortex: 2.8 VTCN1 B7-H4, B7H4, B7S1, B7X, FLJ22418 ENSG00000134258 V-set domain containing T cell activation inhibitor 1 1 117143587-117210960 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054200 Approved Approved Plasma membrane
Cell Junctions
Focal adhesion sites Group enriched Tissue enhanced breast: 127.6;fallopian tube: 50.8 cervix, uterine: 21.9 VTI1A MVti1, Vti1-rp2, Vti1a ENSG00000151532 Vesicle transport through interaction with t-SNAREs 1A 10 112446998-112818744 Cancer-related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA054108 Supported Supported Golgi apparatus
Vesicles Liver cancer:6.50e-5 (unfavourable), Renal cancer:7.27e-5 (favourable) Expressed in all Mixed parathyroid gland: 12.1 VTI1B VTI2 ENSG00000100568 Vesicle transport through interaction with t-SNAREs 1B 14 67647075-67674831 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA044121, HPA048150, HPA060118 Approved Validated Golgi apparatus
Vesicles Renal cancer:3.53e-12 (favourable) Expressed in all Expressed in all epididymis: 62.3 VWA9 C15orf44, DKFZP564O1664 ENSG00000138614 Von Willebrand factor A domain containing 9 15 65578753-65611289 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040255, HPA040651 Approved Approved Nucleoplasm
Nuclear membrane
Nuclear bodies
Mitochondria Expressed in all Expressed in all fallopian tube: 38.7 WAC BM-016, FLJ31290, MGC10753, PRO1741, Wwp4 ENSG00000095787 WW domain containing adaptor with coiled-coil 10 28532493-28623112 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA036528, HPA042609 Approved Supported Nucleoplasm Liver cancer:9.27e-6 (unfavourable) Expressed in all Expressed in all parathyroid gland: 129.7 WBP1 WBP-1 ENSG00000239779 WW domain binding protein 1 2 74458329-74460891 Predicted membrane proteins Evidence at protein level HPA057067 Approved Approved Cytosol Colorectal cancer:1.04e-4 (unfavourable), Urothelial cancer:6.36e-4 (favourable), Pancreatic cancer:6.83e-4 (favourable) Expressed in all Expressed in all thyroid gland: 91.2 WBP1L C10orf26, FLJ20154, OPAL1 ENSG00000166272 WW domain binding protein 1-like 10 102743970-102816267 Predicted membrane proteins Evidence at protein level HPA037635, HPA038371 Uncertain Approved Nucleoplasm
Microtubules Renal cancer:1.56e-6 (favourable), Endometrial cancer:4.03e-4 (favourable) Expressed in all Expressed in all thyroid gland: 69.6 WBSCR22 MERM1, MGC19709, MGC2022, MGC5140, PP3381, WBMT ENSG00000071462 Williams Beuren syndrome chromosome region 22 7 73683025-73705161 Predicted intracellular proteins Evidence at protein level HPA052185 Approved Supported Nucleus
Nucleoli Renal cancer:1.46e-4 (unfavourable), Liver cancer:9.92e-4 (unfavourable) Expressed in all Expressed in all testis: 207.5 WDFY3 ALFY, KIAA0993, ZFYVE25 ENSG00000163625 WD repeat and FYVE domain containing 3 4 84669610-84966391 Predicted intracellular proteins Evidence at protein level HPA042734, HPA048572 Approved Approved Nucleoli
Plasma membrane
Cytosol Renal cancer:3.64e-5 (favourable), Stomach cancer:9.35e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 35.6 WDFY4 C10orf64, Em:AC060234.3, FLJ45748, KIAA1607 ENSG00000128815 WDFY family member 4 10 48684876-48982956 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA040634 Approved Approved Nucleoplasm
Cytosol Mixed Tissue enhanced lymph node: 47.7;spleen: 34.4;tonsil: 33.0 appendix: 23.7 WDR11 BRWD2, DR11, FLJ10506, HH14, KIAA1351, WDR15 ENSG00000120008 WD repeat domain 11 10 120851175-120909524 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA038980 Approved Approved Microtubules
Cytosol Renal cancer:5.04e-4 (favourable) Expressed in all Mixed parathyroid gland: 45.7 WDR33 FLJ11294, NET14, WDC146 ENSG00000136709 WD repeat domain 33 2 127701022-127811187 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA026897, HPA046527 Supported Supported Nucleoplasm
Nucleoli fibrillar center Liver cancer:2.13e-4 (unfavourable) Expressed in all Expressed in all testis: 38.5 WDR43 KIAA0007, NET12, UTP5 ENSG00000163811 WD repeat domain 43 2 28894643-28948222 Predicted intracellular proteins Evidence at protein level HPA044733 Uncertain Liver cancer:3.66e-5 (unfavourable), Endometrial cancer:5.70e-4 (unfavourable) Expressed in all Expressed in all testis: 36.3 WDR45 JM5, NBIA5, WDRX1, WIPI4 ENSG00000196998 WD repeat domain 45 X 49071470-49101170 Disease related genes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA027562 Uncertain Approved Nucleoli Cervical cancer:1.21e-4 (favourable), Head and neck cancer:1.61e-4 (favourable) Expressed in all Expressed in all epididymis: 133.5 WDR83OS C19orf56, PTD008 ENSG00000105583 WD repeat domain 83 opposite strand 19 12668071-12671356 Predicted membrane proteins Evidence at protein level HPA065685 Approved Endoplasmic reticulum Lung cancer:2.09e-4 (favourable), Ovarian cancer:8.84e-4 (favourable) Expressed in all Expressed in all fallopian tube: 315.6 WFS1 DFNA14, DFNA38, DFNA6, DIDMOAD, WFS ENSG00000109501 Wolfram syndrome 1 (wolframin) 4 6269849-6303265 Disease related genes, Plasma proteins, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA029128 Approved Endometrial cancer:1.13e-6 (favourable), Thyroid cancer:3.13e-4 (unfavourable) Expressed in all Mixed ovary: 61.4 WLS C1orf139, EVI, FLJ23091, GPR177, mig-14, MRP, wls ENSG00000116729 Wntless Wnt ligand secretion mediator 1 68098473-68233120 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA069520 Approved Supported Endoplasmic reticulum Renal cancer:3.67e-7 (favourable), Urothelial cancer:3.51e-4 (unfavourable), Breast cancer:4.03e-4 (favourable), Ovarian cancer:9.43e-4 (favourable) Expressed in all Expressed in all epididymis: 160.7 WNK1 HSAN2, HSN2, PPP1R167, PRKWNK1 ENSG00000060237 WNK lysine deficient protein kinase 1 12 752593-911452 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA046541, HPA059157 Supported Supported Cytosol Ovarian cancer:9.67e-4 (unfavourable) Expressed in all Expressed in all esophagus: 92.7 WNK4 PRKWNK4 ENSG00000126562 WNK lysine deficient protein kinase 4 17 42780678-42796936 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted intracellular proteins Evidence at protein level HPA016500 Approved Mixed Tissue enhanced kidney: 18.9;prostate: 14.3;rectum: 12.1 colon: 8.9 WNT2B WNT13, XWNT2 ENSG00000134245 Wingless-type MMTV integration site family, member 2B 1 112466541-112530165 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA060696, HPA066368 Uncertain Approved Vesicles Tissue enhanced Mixed seminal vesicle: 20.0 WRB CHD5, GET1 ENSG00000182093 Tryptophan rich basic protein 21 39380244-39428528 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA018527 Approved Expressed in all Expressed in all fallopian tube: 107.8 WWP1 AIP5, DKFZP434D2111 ENSG00000123124 WW domain containing E3 ubiquitin protein ligase 1 8 86342738-86478420 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023180 Approved Approved Golgi apparatus
Plasma membrane
Cytosol Renal cancer:5.45e-5 (favourable) Expressed in all Expressed in all parathyroid gland: 185.9 XCR1 CCXCR1, GPR5 ENSG00000173578 Chemokine (C motif) receptor 1 3 46017024-46027742 G-protein coupled receptors, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA013169 Uncertain Mixed Tissue enhanced lymph node: 11.0 spleen: 9.3 XK Kx, NA, NAC, X1k, XKR1 ENSG00000047597 X-linked Kx blood group X 37685759-37732130 Blood group antigen proteins, Disease related genes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA019036 Approved Approved Nucleoplasm
Vesicles
Mitochondria Mixed Mixed rectum: 12.3 XKR3 MGC57211, XTES ENSG00000172967 XK, Kell blood group complex subunit-related family, member 3 22 16783412-16821699 Predicted membrane proteins, Transporters Evidence at transcript level HPA003379, HPA035081 Uncertain Not detected Tissue enriched 80 testis: 14.3 cerebral cortex: 0.1 XKR4 KIAA1889 ENSG00000206579 XK, Kell blood group complex subunit-related family, member 4 8 55102389-55542054 Predicted membrane proteins, Transporters Evidence at protein level HPA025072, HPA028083 Uncertain Not detected Tissue enriched 6 cerebral cortex: 4.7 seminal vesicle: 0.8 XKR6 C8orf21, C8orf5, C8orf7 ENSG00000171044 XK, Kell blood group complex subunit-related family, member 6 8 10896045-11201366 Predicted membrane proteins Evidence at transcript level HPA024828 Uncertain Mixed Mixed testis: 1.8 XKR7 C20orf159, dJ310O13.4 ENSG00000260903 XK, Kell blood group complex subunit-related family, member 7 20 31968002-32003387 Predicted membrane proteins Evidence at protein level HPA040854 Uncertain Not detected Tissue enriched 10 cerebral cortex: 3.6 adrenal gland,testis: 0.3 XKR8 FLJ10307 ENSG00000158156 XK, Kell blood group complex subunit-related family, member 8 1 27959462-27968096 Predicted membrane proteins, Transporters Evidence at protein level HPA049984, HPA053529 Uncertain Approved Golgi apparatus Breast cancer:8.63e-4 (favourable) Expressed in all Expressed in all placenta: 13.6 XKR9 ENSG00000221947 XK, Kell blood group complex subunit-related family, member 9 8 70669365-70790371 Predicted membrane proteins, Transporters Evidence at transcript level HPA044430 Uncertain Approved Mitochondria Pancreatic cancer:7.20e-4 (unfavourable) Mixed Tissue enhanced testis: 14.1 small intestine: 6.2 XPO6 FLJ22519, KIAA0370, RANBP20 ENSG00000169180 Exportin 6 16 28097979-28211920 Predicted intracellular proteins Evidence at protein level HPA038246 Uncertain Approved Nucleus
Nucleoli
Plasma membrane
Cytosol Liver cancer:3.68e-4 (unfavourable), Urothelial cancer:8.80e-4 (unfavourable) Expressed in all Expressed in all testis: 94.0 XPR1 SYG1, X3 ENSG00000143324 Xenotropic and polytropic retrovirus receptor 1 1 180632004-180890251 Disease related genes, Predicted membrane proteins Evidence at protein level HPA016557 Supported Approved Endoplasmic reticulum
Golgi apparatus Liver cancer:3.04e-4 (unfavourable) Expressed in all Expressed in all testis: 31.1 XXbac-BPG246D15.9 ENSG00000250264 6 32813767-32838822 Predicted membrane proteins Evidence at transcript level HPA001312 Approved Approved Nuclear speckles
Endoplasmic reticulum Not detected Tissue enhanced appendix: 16.0;spleen: 9.7 lymph node: 6.6 XXbac-BPG32J3.19 ENSG00000250641 6 31706904-31717918 Predicted membrane proteins No evidence HPA008053 Uncertain Tissue enriched Not detected testis: 0.5 XXcos-LUCA11.5 ENSG00000272104 3 50350892-50367923 Predicted intracellular proteins Evidence at protein level HPA042817 Uncertain Not detected Mixed small intestine: 7.1 YIF1A 54TM, FinGER7, YIF1, YIF1P ENSG00000174851 Yip1 interacting factor homolog A (S. cerevisiae) 11 66284580-66289170 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014840 Approved Supported Golgi apparatus
Vesicles
Microtubule organizing center Urothelial cancer:8.70e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 61.2 YIF1B FinGER8 ENSG00000167645 Yip1 interacting factor homolog B (S. cerevisiae) 19 38305104-38317273 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA039328, HPA055257, HPA062675 Approved Approved Golgi apparatus
Vesicles Liver cancer:4.53e-5 (unfavourable), Pancreatic cancer:1.88e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 49.6 YIPF1 DJ167A19.1, FinGER1 ENSG00000058799 Yip1 domain family, member 1 1 53851719-53889834 Predicted membrane proteins Evidence at protein level HPA014716 Approved Approved Nucleoplasm Liver cancer:1.34e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 42.1 YIPF2 FinGER2, MGC3262 ENSG00000130733 Yip1 domain family, member 2 19 10922185-10928681 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA019902 Approved Approved Golgi apparatus
Mitochondria Expressed in all Expressed in all testis: 73.3 YIPF3 C6orf109, dJ337H4.3, DKFZp566C243, FinGER3, KLIP1 ENSG00000137207 Yip1 domain family, member 3 6 43511827-43516990 Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA014859, HPA063699 Supported Validated Nucleoplasm
Golgi apparatus Expressed in all Expressed in all parathyroid gland: 140.3 YIPF4 FinGER4, MGC11061 ENSG00000119820 Yip1 domain family, member 4 2 32277910-32316594 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA017884 Supported Supported Golgi apparatus
Vesicles
Plasma membrane Expressed in all Expressed in all cerebral cortex: 19.0 YIPF5 FinGER5, SMAP-5 ENSG00000145817 Yip1 domain family, member 5 5 144158159-144170714 Predicted membrane proteins Evidence at protein level HPA042338, HPA073622 Supported Supported Nucleoplasm
Endoplasmic reticulum
Golgi apparatus
Vesicles Head and neck cancer:1.12e-5 (unfavourable), Liver cancer:3.26e-5 (unfavourable), Breast cancer:7.83e-5 (unfavourable) Expressed in all Expressed in all placenta: 42.9 YIPF6 FinGER6, MGC21416 ENSG00000181704 Yip1 domain family, member 6 X 68498323-68537285 Predicted membrane proteins Evidence at protein level HPA003720 Uncertain Approved Vesicles Expressed in all Expressed in all thyroid gland: 32.7 YIPF7 FinGER9, FLJ39576 ENSG00000177752 Yip1 domain family, member 7 4 44622065-44678556 Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA030642 Uncertain Not detected Tissue enriched 42 skeletal muscle: 29.6 esophagus: 0.7 YME1L1 ENSG00000136758 YME1-like 1 ATPase 10 27110112-27155266 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA066953 Approved Supported Nuclear bodies
Mitochondria Liver cancer:8.25e-6 (unfavourable) Expressed in all Expressed in all thyroid gland: 105.3 ZBTB11 ZNF-U69274, ZNF913 ENSG00000066422 Zinc finger and BTB domain containing 11 3 101648889-101677495 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA015328, HPA024138 Approved Validated Nucleoplasm Endometrial cancer:7.49e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 23.5 ZBTB8B DKFZp547H154, RP1-27O5.1, ZNF916B ENSG00000273274 Zinc finger and BTB domain containing 8B 1 32465069-32496686 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA027818, HPA028690, HPA055553 Approved Tissue enhanced Not detected cerebral cortex: 0.6 ZDHHC1 C16orf1, HSU90653, ZNF377 ENSG00000159714 Zinc finger, DHHC-type containing 1 16 67394419-67416833 Enzymes, Predicted membrane proteins Evidence at transcript level HPA042531, HPA048659 Uncertain Approved Cytosol Endometrial cancer:1.25e-6 (favourable), Renal cancer:1.55e-6 (favourable), Pancreatic cancer:5.99e-4 (favourable) Expressed in all Mixed fallopian tube: 31.4 ZDHHC11 FLJ13153, ZNF399 ENSG00000188818 Zinc finger, DHHC-type containing 11 5 795606-850986 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at transcript level HPA057886, HPA069008 Uncertain Approved Lipid droplets Mixed Mixed fallopian tube: 10.7 ZDHHC11B ENSG00000206077 Zinc finger, DHHC-type containing 11B 5 710360-766952 Enzymes, Predicted membrane proteins Evidence at transcript level HPA057886, HPA069008 Uncertain Approved Lipid droplets Lung cancer:3.98e-4 (favourable) Mixed Mixed cerebral cortex: 6.2 ZDHHC12 FLJ14524, ZNF400 ENSG00000160446 Zinc finger, DHHC-type containing 12 9 128720869-128724127 Enzymes, Predicted membrane proteins Evidence at transcript level HPA059339 Uncertain Approved Nucleoplasm Expressed in all Expressed in all small intestine: 36.5 ZDHHC13 FLJ10852, FLJ10941, HIP14L ENSG00000177054 Zinc finger, DHHC-type containing 13 11 19117099-19176422 Enzymes, Predicted membrane proteins, Transporters Evidence at protein level HPA016759, HPA018791 Uncertain Validated Vesicles Expressed in all Mixed esophagus: 40.5 ZDHHC14 FLJ20984, NEW1CP ENSG00000175048 Zinc finger, DHHC-type containing 14 6 157381133-157678146 Enzymes, Predicted membrane proteins Evidence at protein level HPA046033, HPA063754 Uncertain Approved Nucleoli
Mitochondria Pancreatic cancer:6.93e-4 (favourable) Expressed in all Mixed endometrium: 12.3 ZDHHC15 FLJ31812, MRX91 ENSG00000102383 Zinc finger, DHHC-type containing 15 X 75368427-75523502 Disease related genes, Enzymes, Plasma proteins, Potential drug targets, Predicted membrane proteins Evidence at transcript level HPA003618 Uncertain Approved Nuclear speckles
Cytosol Tissue enhanced Mixed cerebral cortex: 4.8 ZDHHC16 APH2 ENSG00000171307 Zinc finger, DHHC-type containing 16 10 97446131-97457370 Enzymes, Predicted membrane proteins Evidence at protein level HPA039893, HPA040214 Uncertain Supported Nucleus
Nuclear membrane
Cytosol Expressed in all Expressed in all placenta: 31.3 ZDHHC17 HIP14, HYPH, KIAA0946 ENSG00000186908 Zinc finger, DHHC-type containing 17 12 76763588-76853696 Enzymes, Predicted intracellular proteins, Predicted membrane proteins, Transporters Evidence at protein level HPA016807 Approved Supported Golgi apparatus
Vesicles
Cytosol Renal cancer:7.11e-5 (unfavourable) Expressed in all Expressed in all cerebral cortex: 45.4 ZDHHC18 DKFZp667O2416 ENSG00000204160 Zinc finger, DHHC-type containing 18 1 26826710-26857602 Enzymes, Predicted membrane proteins Evidence at protein level HPA040234 Approved Approved Microtubules Renal cancer:1.36e-10 (unfavourable), Liver cancer:7.42e-7 (unfavourable), Glioma:9.53e-4 (unfavourable) Expressed in all Expressed in all bone marrow: 75.3 ZDHHC2 ZNF372 ENSG00000104219 Zinc finger, DHHC-type containing 2 8 17156029-17224799 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA023331 Uncertain Renal cancer:3.24e-4 (favourable) Expressed in all Expressed in all thyroid gland: 53.5 ZDHHC20 FLJ25952 ENSG00000180776 Zinc finger, DHHC-type containing 20 13 21372573-21459370 Enzymes, Predicted membrane proteins Evidence at protein level HPA014483, HPA014702 Approved Uncertain Vesicles
Plasma membrane
Mitochondria Renal cancer:1.01e-4 (unfavourable), Pancreatic cancer:6.55e-4 (unfavourable) Expressed in all Expressed in all testis: 60.4 ZDHHC21 DNZ1, HSPC097 ENSG00000175893 Zinc finger, DHHC-type containing 21 9 14611071-14693471 Enzymes, Predicted membrane proteins Evidence at protein level HPA065254 Approved Approved Golgi apparatus
Cytosol Urothelial cancer:9.28e-6 (favourable), Renal cancer:1.29e-4 (favourable) Expressed in all Mixed cerebral cortex: 16.0 ZDHHC22 C14orf59 ENSG00000177108 Zinc finger, DHHC-type containing 22 14 77131270-77142734 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA072213 Approved Plasma membrane Tissue enriched Tissue enriched 57 cerebral cortex: 64.4 epididymis: 1.1 ZDHHC23 MGC42530 ENSG00000184307 Zinc finger, DHHC-type containing 23 3 113947901-113965401 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA016808 Uncertain Approved Nucleus Renal cancer:1.48e-7 (favourable), Endometrial cancer:2.85e-4 (unfavourable), Thyroid cancer:5.90e-4 (unfavourable) Expressed in all Tissue enhanced testis: 15.3 cerebral cortex: 6.2 ZDHHC24 ENSG00000174165 Zinc finger, DHHC-type containing 24 11 66520637-66546238 Enzymes, Predicted membrane proteins Evidence at protein level HPA016619 Approved Approved Vesicles
Cytosol Glioma:2.39e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 10.9 ZDHHC3 GODZ, ZNF373 ENSG00000163812 Zinc finger, DHHC-type containing 3 3 44915257-44976185 Enzymes, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level CAB012465, HPA016616 Approved Approved Golgi apparatus Renal cancer:1.81e-8 (favourable), Liver cancer:1.37e-4 (unfavourable), Colorectal cancer:3.43e-4 (favourable) Expressed in all Expressed in all skin: 65.4 ZDHHC4 FLJ10479, ZNF374 ENSG00000136247 Zinc finger, DHHC-type containing 4 7 6577434-6589374 Enzymes, Predicted membrane proteins Evidence at protein level HPA032124, HPA064358 Approved Approved Nuclear bodies Renal cancer:1.18e-7 (favourable), Head and neck cancer:3.95e-6 (unfavourable), Urothelial cancer:8.94e-4 (unfavourable), Cervical cancer:9.35e-4 (unfavourable) Expressed in all Expressed in all thyroid gland: 77.5 ZDHHC5 KIAA1748, ZNF375 ENSG00000156599 Zinc finger, DHHC-type containing 5 11 57667747-57701187 Enzymes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014670 Approved Approved Nucleoplasm
Plasma membrane
Cell Junctions
Cytosol Pancreatic cancer:6.74e-5 (unfavourable) Expressed in all Expressed in all parathyroid gland: 86.1 ZDHHC6 FLJ21952, ZNF376 ENSG00000023041 Zinc finger, DHHC-type containing 6 10 112424428-112446917 Enzymes, Predicted membrane proteins Evidence at protein level HPA014357 Approved Expressed in all Expressed in all small intestine: 51.7 ZDHHC7 FLJ10792, FLJ20279, SERZ-B, SERZ1, ZNF370 ENSG00000153786 Zinc finger, DHHC-type containing 7 16 84974181-85011535 Enzymes, Predicted membrane proteins Evidence at protein level HPA019215, HPA059054, HPA059642 Uncertain Validated Golgi apparatus Renal cancer:1.12e-5 (favourable), Liver cancer:4.20e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 63.6 ZDHHC8 KIAA1292, ZNF378 ENSG00000099904 Zinc finger, DHHC-type containing 8 22 20129456-20148007 Enzymes, Predicted membrane proteins Evidence at protein level HPA003422 Uncertain Approved Nucleoplasm
Cytosol Renal cancer:4.04e-4 (unfavourable), Cervical cancer:9.68e-4 (unfavourable) Expressed in all Expressed in all spleen: 30.2 ZDHHC9 CGI-89, CXorf11, ZDHHC10, ZNF379, ZNF380 ENSG00000188706 Zinc finger, DHHC-type containing 9 X 129803288-129843909 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins Evidence at protein level HPA031814 Uncertain Supported Golgi apparatus
Cytosol Cervical cancer:4.64e-5 (unfavourable), Breast cancer:9.77e-5 (unfavourable), Head and neck cancer:2.45e-4 (unfavourable) Expressed in all Expressed in all cerebral cortex: 71.2 ZFPL1 D11S750, MCG4 ENSG00000162300 Zinc finger protein-like 1 11 65084223-65088400 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA014909, HPA017347 Supported Validated Golgi apparatus Liver cancer:9.12e-6 (unfavourable), Renal cancer:2.73e-5 (favourable) Expressed in all Expressed in all fallopian tube: 31.5 ZFYVE27 FLJ32919, SPG33 ENSG00000155256 Zinc finger, FYVE domain containing 27 10 97737121-97760907 Disease related genes, Predicted membrane proteins Evidence at protein level HPA037523, HPA069876 Approved Approved Nucleoplasm
Cytosol Colorectal cancer:6.91e-4 (unfavourable), Stomach cancer:7.54e-4 (favourable), Urothelial cancer:7.80e-4 (favourable) Expressed in all Expressed in all cerebral cortex: 33.4 ZG16B HRPE773, JCLN2, PRO1567 ENSG00000162078 Zymogen granule protein 16B 16 2830169-2839585 Plasma proteins, Predicted intracellular proteins, Predicted secreted proteins Evidence at protein level HPA041125, HPA053549 Supported Approved Nucleoplasm
Vesicles Endometrial cancer:3.48e-6 (favourable) Tissue enhanced Tissue enriched 210 salivary gland: 19669.3 prostate: 93.6 ZGRF1 C4orf21, FLJ11331 ENSG00000138658 Zinc finger, GRF-type containing 1 4 112539333-112636995 Predicted intracellular proteins Evidence at protein level HPA030704, HPA030706 Uncertain Approved Cytosol Mixed Mixed testis: 6.7 ZMPSTE24 FACE-1, HGPS, PRO1, STE24, Ste24p ENSG00000084073 Zinc metallopeptidase STE24 1 40258107-40294184 Disease related genes, Enzymes, Potential drug targets, Predicted membrane proteins, Transporters Evidence at protein level HPA006988 Approved Approved Golgi apparatus
Cytosol Liver cancer:5.73e-6 (unfavourable), Thyroid cancer:6.34e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 89.0 ZMYM5 MYM, ZNF198L1, ZNF237 ENSG00000132950 Zinc finger, MYM-type 5 13 19823482-19863636 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA020879 Uncertain Expressed in all Expressed in all testis: 44.2 ZMYM6 Buster2, MYM, ZBED7, ZNF198L4, ZNF258 ENSG00000163867 Zinc finger, MYM-type 6 1 34986165-35031968 Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA011004, HPA071865 Approved Supported Nucleoplasm Breast cancer:1.30e-5 (favourable) Expressed in all Mixed testis: 18.9 ZMYM6NB ENSG00000243749 ZMYM6 neighbor 1 34981535-34985353 Predicted membrane proteins Evidence at protein level HPA051024 Uncertain Approved Nucleus
Nucleoli Expressed in all Expressed in all placenta: 90.9 ZMYND11 BS69 ENSG00000015171 Zinc finger, MYND-type containing 11 10 134465-254637 Disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins Evidence at protein level HPA015816 Supported Nucleoplasm Renal cancer:4.76e-7 (favourable) Expressed in all Expressed in all parathyroid gland: 196.6 ZNF138 pHZ-32 ENSG00000197008 Zinc finger protein 138 7 64794388-64833681 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA077435 Uncertain Cytosol Expressed in all Mixed cerebral cortex: 9.2 ZNF286A KIAA1874, ZNF286 ENSG00000187607 Zinc finger protein 286A 17 15699577-15720787 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA021594 Approved Nucleoli Mixed Mixed ovary: 21.8 ZNF333 KIAA1806 ENSG00000160961 Zinc finger protein 333 19 14689801-14733746 Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA043973, HPA054680 Uncertain Approved Nucleoplasm Mixed Mixed endometrium: 11.2 ZNF358 FLJ10390, ZFEND ENSG00000198816 Zinc finger protein 358 19 7515292-7521026 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030887, HPA063624 Approved Approved Nucleus Pancreatic cancer:2.50e-4 (favourable) Expressed in all Expressed in all ovary: 85.4 ZNF419 ZAPHIR, ZNF419A ENSG00000105136 Zinc finger protein 419 19 57487711-57496097 Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA003152, HPA003274 Uncertain Supported Nucleus
Nucleoli fibrillar center Urothelial cancer:2.53e-5 (favourable), Prostate cancer:6.47e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 15.7 ZNF511 MGC30006 ENSG00000198546 Zinc finger protein 511 10 133308475-133313162 Predicted membrane proteins, Predicted secreted proteins, Transcription factors Evidence at protein level HPA035360 Uncertain Renal cancer:1.13e-4 (unfavourable) Expressed in all Expressed in all ovary: 11.4 ZNF525 KIAA1979 ENSG00000203326 Zinc finger protein 525 19 53330675-53392217 Predicted intracellular proteins Evidence at transcript level HPA047105 Uncertain Mixed Mixed parathyroid gland: 20.6 ZNF546 MGC43537, ZNF49 ENSG00000187187 Zinc finger protein 546 19 39984134-40021041 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030838 Approved Nucleus
Cytosol Mixed Tissue enhanced testis: 14.4 parathyroid gland: 3.3 ZNF566 FLJ14779, MGC12515 ENSG00000186017 Zinc finger protein 566 19 36445119-36489902 Plasma proteins, Predicted intracellular proteins, Transcription factors Evidence at protein level HPA023456 Uncertain Approved Nucleus Endometrial cancer:1.86e-4 (unfavourable) Expressed in all Mixed thyroid gland: 8.0 ZNF570 FLJ30791 ENSG00000171827 Zinc finger protein 570 19 37467585-37488652 Predicted intracellular proteins, Predicted secreted proteins, Transcription factors Evidence at transcript level HPA028881 Uncertain Approved Nucleoplasm Renal cancer:4.06e-5 (favourable) Expressed in all Mixed testis: 10.7 ZNF610 FLJ36040 ENSG00000167554 Zinc finger protein 610 19 52336245-52367778 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA055771 Approved Renal cancer:1.05e-7 (favourable), Ovarian cancer:3.38e-4 (favourable) Mixed Tissue enhanced testis: 22.1 ovary: 10.4 ZNF618 KIAA1952, NEDD10 ENSG00000157657 Zinc finger protein 618 9 113876282-114056591 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA023116, HPA061732 Uncertain Approved Nucleoplasm Renal cancer:5.22e-7 (favourable), Glioma:8.34e-4 (unfavourable) Expressed in all Mixed parathyroid gland: 16.2 ZNF7 HF.16, KOX4 ENSG00000147789 Zinc finger protein 7 8 144827464-144847509 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA030296, HPA059090 Uncertain Approved Mitochondria Renal cancer:8.46e-8 (unfavourable) Expressed in all Expressed in all testis: 31.4 ZNF816 ZNF816A ENSG00000180257 Zinc finger protein 816 19 52949379-52962911 Predicted intracellular proteins, Predicted membrane proteins, Transcription factors Evidence at protein level HPA042466 Uncertain Uncertain Nucleoli Expressed in all Mixed prostate: 20.4 ZNF85 HPF4, HTF1 ENSG00000105750 Zinc finger protein 85 19 20923222-20950697 Predicted intracellular proteins, Transcription factors Evidence at protein level HPA044760 Uncertain Supported Nucleus Ovarian cancer:6.45e-6 (favourable), Endometrial cancer:5.20e-5 (unfavourable) Mixed Tissue enhanced testis: 27.8 thyroid gland: 12.0 ZNF880 ENSG00000221923 Zinc finger protein 880 19 52369917-52385795 Predicted intracellular proteins, Transcription factors Evidence at transcript level HPA077316 Approved Intermediate filaments Renal cancer:4.33e-8 (favourable) Expressed in all Expressed in all thyroid gland: 31.2 ZNRF3 BK747E2.3, FLJ22057, KIAA1133, RNF203 ENSG00000183579 Zinc and ring finger 3 22 28883592-29057487 Predicted membrane proteins Evidence at protein level HPA036702, HPA036703 Uncertain Uncertain Golgi apparatus Not detected Mixed epididymis: 16.2 ZP2 ZPA ENSG00000103310 Zona pellucida glycoprotein 2 (sperm receptor) 16 21197450-21214510 Predicted membrane proteins Evidence at protein level HPA011296 Approved Not detected Not detected placenta: 0.7 ZP3 ZP3-372, ZP3-424, ZP3A, ZP3B, ZPC ENSG00000188372 Zona pellucida glycoprotein 3 (sperm receptor) 7 76397518-76442071 Predicted membrane proteins Evidence at protein level HPA054061 Supported Renal cancer:1.02e-6 (unfavourable) Expressed in all Mixed fallopian tube: 6.2 ZP4 ZPB ENSG00000116996 Zona pellucida glycoprotein 4 1 237877864-237890922 Predicted membrane proteins Evidence at protein level HPA008547 Supported Not detected Not detected tonsil: 0.2 ZSWIM1 C20orf162, dJ337O18.5 ENSG00000168612 Zinc finger, SWIM-type containing 1 20 45881227-45885266 Predicted intracellular proteins Evidence at protein level HPA041147, HPA046751 Uncertain Approved Plasma membrane
Cytosol Pancreatic cancer:1.77e-4 (favourable), Liver cancer:5.47e-4 (unfavourable) Expressed in all Expressed in all parathyroid gland: 10.6